"biotid","substrate_name","substrate_cid","substrate_inchikey","substrate_inchi","enzyme","reaction_type","biotransformation_type","biosystem","prod_name","prod_cid","prod_inchikey","prod_inchi","reference"
"BIOTID00001","acetaminophen","1983","RZVAJINKPMORJF-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)","CYP1A2; CYP2E1; CYP3A4; CYP2A6; CYP2C9; CYP2D6; CYP1A1","Oxidation of p-substituted anilides","Human Phase I","Human","N-Acetyl-p-benzoquinone","39763","URNSECGXFRDEDC-UHFFFAOYSA-N","InChI=1S/C8H7NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5H,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00002","acetaminophen","1983","RZVAJINKPMORJF-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)","CYP2A6 (major); CYP2E1; CYP1A2; CYP2C8; CYP2C9; CYP3A4","Hydroxylation of benzene on carbon orhto to a strongly electron donating group","Human Phase I","Human","3-Hydroxyacetaminophen","161950","IPFBMHOMTSBTSU-UHFFFAOYSA-N","InChI=1S/C8H9NO3/c1-5(10)9-6-2-3-7(11)8(12)4-6/h2-4,11-12H,1H3,(H,9,10)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00003","pinoline","1868","QYMDEOQLJUUNOF-UHFFFAOYSA-N","InChI=1S/C12H14N2O/c1-15-8-2-3-11-10(6-8)9-4-5-13-7-12(9)14-11/h2-3,6,13-14H,4-5,7H2,1H3","CYP2D6","O-aryl demethylation","Human Phase I","Human","1H,2H,3H,4H,9H‐pyrido[3,4‐b]indol‐6‐ol","159959","HASNCBJLQYTILW-UHFFFAOYSA-N","InChI=1S/C11H12N2O/c14-7-1-2-10-9(5-7)8-3-4-12-6-11(8)13-10/h1-2,5,12-14H,3-4,6H2","Yu, A. (2003) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase; Pharmacogenetics 2003, Vol 13 No 6"
"BIOTID00004","1-(3-Trifluoromethylphenyl)piperazine","4296","KKIMDKMETPPURN-UHFFFAOYSA-N","InChI=1S/C11H13F3N2/c12-11(13,14)9-2-1-3-10(8-9)16-6-4-15-5-7-16/h1-3,8,15H,4-7H2","CYP2D6; CYP1A2; CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","HO-TFMPP","NULL","IJBCBVIOADJKJZ-UHFFFAOYSA-N","InChI=1S/C11H13F3N2O/c12-11(13,14)9-7-8(1-2-10(9)17)16-5-3-15-4-6-16/h1-2,7,15,17H,3-6H2","PMID:14505325;PMID:14698036;PMID:15833296"
"BIOTID00005","2-Amino-3-methylimidazo(4,5-F)quinoline","53462","ARZWATDYIYAUTA-UHFFFAOYSA-N","InChI=1S/C11H10N4/c1-15-9-5-4-8-7(3-2-6-13-8)10(9)14-11(15)12/h2-6H,1H3,(H2,12,14)","CYP1A2; CYP1A1","N-Hydroxylation","Human Phase I","Human","N-OH-2-amino-3-methylimidazo[4,5-f]quinoline (N-OH-IQ)","105079","QYFQSQCBYZOECM-UHFFFAOYSA-N","InChI=1S/C11H10N4O/c1-15-9-5-4-8-7(3-2-6-12-8)10(9)13-11(15)14-16/h2-6,16H,1H3,(H,13,14)","PMID:9111224"
"BIOTID00006","5-Methoxy-N,N-diisopropyltryptamine","151182","DNBPMBJFRRVTSJ-UHFFFAOYSA-N","InChI=1S/C17H26N2O/c1-12(2)19(13(3)4)9-8-14-11-18-17-7-6-15(20-5)10-16(14)17/h6-7,10-13,18H,8-9H2,1-5H3","CYP2D6","O-Demethylation","Human Phase I","Human","5-OH-DIPT","71360804","HWOLNTJLIUHEOG-UHFFFAOYSA-N","InChI=1S/C16H24N2O/c1-11(2)18(12(3)4)8-7-13-10-17-16-6-5-14(19)9-15(13)16/h5-6,9-12,17,19H,7-8H2,1-4H3","PMID:17980859;PMID:20942780"
"BIOTID00007","5-Methoxy-N,N-diisopropyltryptamine","151182","DNBPMBJFRRVTSJ-UHFFFAOYSA-N","InChI=1S/C17H26N2O/c1-12(2)19(13(3)4)9-8-14-11-18-17-7-6-15(20-5)10-16(14)17/h6-7,10-13,18H,8-9H2,1-5H3","CYP1A2;CYP3A4;CYP2C9;CYP2C19","N-deisopropylation","Human Phase I","Human","5-MeO-IPT","707167","QQZJNZJNPDORBO-UHFFFAOYSA-N","InChI=1S/C14H20N2O/c1-10(2)15-7-6-11-9-16-14-5-4-12(17-3)8-13(11)14/h4-5,8-10,15-16H,6-7H2,1-3H3","PMID:17980859;PMID:20942780"
"BIOTID00008","(R)-halothane","445258","BCQZXOMGPXTTIC-SFOWXEAESA-N","InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H/t1-/m0/s1","CYP2E1","Oxidation of halotrifluoroethane","Human Phase I","Human","trifluoroacetic acid","23138861","DTQVDTLACAAQTR-UHFFFAOYSA-N","InChI=1S/C2HF3O2/c3-2(4,5)1(6)7/h(H,6,7)","Spracklin, D.K. et al (1996); Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4; Drug Metab Dispos. 1996 Sep;24(9):976-83.|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00009","(R)-halothane","445258","BCQZXOMGPXTTIC-SFOWXEAESA-N","InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H/t1-/m0/s1","CYP2A6; CYP3A4; CYP2B6; CYP2C9; CYP2D6","Reduction of halotrifluoroethane","Human Phase I","Human","2-chloro-1,1-difluoroethene","9664","HTHNTJCVPNKCPZ-UHFFFAOYSA-N","InChI=1S/C2HClF2/c3-1-2(4)5/h1H","Spracklin, D.K. et al (1996); Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4; Drug Metab Dispos. 1996 Sep;24(9):976-83.|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00010","(R)-halothane","445258","BCQZXOMGPXTTIC-SFOWXEAESA-N","InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H/t1-/m0/s1","CYP2A6; CYP3A4; CYP2B6; CYP2C9; CYP2D6","Reduction of terminal aliphatic trihalide","Human Phase I","Human","1-chloro-2,2,2-trifluoroethanide","NULL","JUKWCHLDFKRDHO-UHFFFAOYSA-N","InChI=1S/C2HClF3/c3-1-2(4,5)6/h1H/q-1","Spracklin, D.K. et al (1996); Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4; Drug Metab Dispos. 1996 Sep;24(9):976-83.|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00011","(R)-3,4-Methylenedioxymethamphetamine","667458","SHXWCVYOXRDMCX-MRVPVSSYSA-N","InChI=1S/C11H15NO2/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10/h3-4,6,8,12H,5,7H2,1-2H3/t8-/m1/s1","CYP1A2; CYP2D6","Methylenedioxy ring opening","Human Phase I","Human","N-Methyl-3,4- dihydroxyamphetamine","67851484","NTCPGTZTPGFNOM-SSDOTTSWSA-N","InChI=1S/C10H15NO2/c1-7(11-2)5-8-3-4-9(12)10(13)6-8/h3-4,6-7,11-13H,5H2,1-2H3/t7-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00012","(R)-3,4-Methylenedioxymethamphetamine","667458","SHXWCVYOXRDMCX-MRVPVSSYSA-N","InChI=1S/C11H15NO2/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10/h3-4,6,8,12H,5,7H2,1-2H3/t8-/m1/s1","CYP2D6 (major); CYP1A2; CYP2B6; CYP3A4","N-dealkylation of acyclic secondary amine","Human Phase I","Human","3,4-Methylenedioxymethamphetamine","3046161","NGBBVGZWCFBOGO-SSDOTTSWSA-N","InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3/t7-/m1/s1","Zanger, U.M. and Klein, K. (2013); Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance; Front Genet. 2013; 4: 24.; DOI:10.3389/fgene.2013.00024|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00013","(4R)-5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid","748472","JPXPPUOCSLMCHK-CQSZACIVSA-N","InChI=1S/C16H16N2O6/c1-8-12(15(19)20)14(13(9(2)17-8)16(21)24-3)10-5-4-6-11(7-10)18(22)23/h4-7,14,17H,1-3H3,(H,19,20)/t14-/m1/s1","CYP2C19;CYP2D6;CYP2E1;CYP3A4","Dehydrogenation","Human Phase I","Human","OPC-13463","9996712","BXLPPWLKFWCWOY-UHFFFAOYSA-N","InChI=1S/C16H14N2O6/c1-8-12(15(19)20)14(13(9(2)17-8)16(21)24-3)10-5-4-6-11(7-10)18(22)23/h4-7H,1-3H3,(H,19,20)","PMID:9929520"
"BIOTID00014","Homo-Tienilic Alcohol","3282572","UGJUNCJBZLALDV-UHFFFAOYSA-N","InChI=1S/C14H12Cl2O3S/c15-12-9(14(18)11-3-1-8-20-11)4-5-10(13(12)16)19-7-2-6-17/h1,3-5,8,17H,2,6-7H2","CYP2C8;CYP2C9;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","AQKYWBULJQYLJP-UHFFFAOYSA-N","InChI=1S/C14H12Cl2O4S/c15-12-8(14(19)10-4-5-11(18)21-10)2-3-9(13(12)16)20-7-1-6-17/h2-5,17-18H,1,6-7H2","PMID:10387023"
"BIOTID00015","Homo-Tienilic Alcohol","3282572","UGJUNCJBZLALDV-UHFFFAOYSA-N","InChI=1S/C14H12Cl2O3S/c15-12-9(14(18)11-3-1-8-20-11)4-5-10(13(12)16)19-7-2-6-17/h1,3-5,8,17H,2,6-7H2","CYP2C8;CYP2C9;CYP2C19","O-Demethylation","Human Phase I","Human","NULL","9970501","PPDIALCNVFLTST-UHFFFAOYSA-N","InChI=1S/C11H6Cl2O2S/c12-9-6(3-4-7(14)10(9)13)11(15)8-2-1-5-16-8/h1-5,14H","PMID:10387023"
"BIOTID00016","(R)-1-(4-Methoxyphenyl)propan-2-amine","6951129","NEGYEDYHPHMHGK-MRVPVSSYSA-N","InChI=1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3/t8-/m1/s1","CYP2D6","O-Demethylation","Human Phase I","Human","NULL","12234986","GIKNHHRFLCDOEU-SSDOTTSWSA-N","InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3/t7-/m1/s1","PMID:10456690"
"BIOTID00017","1-Methyl-10-alpha-methoxy-9,10-dihydrolysergol","9796365","LVXVIPZBNJSUKL-NJAPINKUSA-N","InChI=1S/C18H24N2O2/c1-19-10-13-7-16-18(22-3,8-12(11-21)9-20(16)2)14-5-4-6-15(19)17(13)14/h4-6,10,12,16,21H,7-9,11H2,1-3H3/t12-,16-,18+/m1/s1","CYP2D6","N-Demethylation","Human Phase I","Human","MDL","597497","JGQZSBLQHCTAJF-UHFFFAOYSA-N","InChI=1S/C17H22N2O2/c1-19-9-11(10-20)7-17(21-2)13-4-3-5-14-16(13)12(8-18-14)6-15(17)19/h3-5,8,11,15,18,20H,6-7,9-10H2,1-2H3","PMID:8971425"
"BIOTID00018","(S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid","9912743","DRSJLVGDSNWQBI-SFHVURJKSA-N","InChI=1S/C24H21Cl2NO5/c1-31-19-7-4-8-20(32-2)21(19)15-11-9-14(10-12-15)13-18(24(29)30)27-23(28)22-16(25)5-3-6-17(22)26/h3-12,18H,13H2,1-2H3,(H,27,28)(H,29,30)/t18-/m0/s1","CYP2C9","O-Desmethylation","Human Phase I","Human","NULL","NULL","PHONWYGCWSCOCC-UHFFFAOYSA-N","InChI=1S/C23H19Cl2NO5/c1-31-19-7-3-6-18(27)20(19)14-10-8-13(9-11-14)12-17(23(29)30)26-22(28)21-15(24)4-2-5-16(21)25/h2-11,17,27H,12H2,1H3,(H,26,28)(H,29,30)","PMID:15855725"
"BIOTID00019","Rabeprazole (rabeprazole_thioether)","9949996","BSXAHDOWMOSVAP-UHFFFAOYSA-N","InChI=1S/C18H21N3O2S/c1-13-16(19-9-8-17(13)23-11-5-10-22-2)12-24-18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)","CYP1A2;CYP2A6;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","S-OXIDATION","Human Phase I","Human","Rabeprazole","5029","YREYEVIYCVEVJK-UHFFFAOYSA-N","InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)","PMID:16389533"
"BIOTID00020","Rabeprazole (rabeprazole_thioether)","9949996","BSXAHDOWMOSVAP-UHFFFAOYSA-N","InChI=1S/C18H21N3O2S/c1-13-16(19-9-8-17(13)23-11-5-10-22-2)12-24-18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)","CYP1A2;CYP2A6;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","O-Desmethylation","Human Phase I","Human","Desmethylrabeprazole-thioether","15166260","WKTPBAPTLLDMKZ-UHFFFAOYSA-N","InChI=1S/C17H19N3O2S/c1-12-15(18-8-7-16(12)22-10-4-9-21)11-23-17-19-13-5-2-3-6-14(13)20-17/h2-3,5-8,21H,4,9-11H2,1H3,(H,19,20)","PMID:16389533"
"BIOTID00021","Dehydroxyzyleuton","10104880","CKVDCQYUEYONIA-ZETCQYMHSA-N","InChI=1S/C11H12N2OS/c1-7(13-11(12)14)10-6-8-4-2-3-5-9(8)15-10/h2-7H,1H3,(H3,12,13,14)/t7-/m0/s1","CYP3A4","Thiohene S-oxidation","Human Phase I","Human","Dehydroxyzyleuton sulfoxide","NULL","KGUIRZVMBWMQQZ-RWNHWRGESA-N","InChI=1S/C11H12N2O2S/c1-7(13-11(12)14)10-6-8-4-2-3-5-9(8)16(10)15/h2-7H,1H3,(H3,12,13,14)/t7-,16?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00022","Dehydroxyzyleuton","10104880","CKVDCQYUEYONIA-ZETCQYMHSA-N","InChI=1S/C11H12N2OS/c1-7(13-11(12)14)10-6-8-4-2-3-5-9(8)15-10/h2-7H,1H3,(H3,12,13,14)/t7-/m0/s1","CYP1A2; CYP2C9","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","(1S)â€1â€(6â€hydroxyâ€1â€benzothiophenâ€2â€yl)ethylurea","NULL","QAVLMIJBDWRSOJ-LURJTMIESA-N","InChI=1S/C11H12N2O2S/c1-6(13-11(12)15)9-4-7-2-3-8(14)5-10(7)16-9/h2-6,14H,1H3,(H3,12,13,15)/t6-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00023","(2R,3S)-2-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholine","10113945","AFBDSAJOMZYQAI-CNOZUTPLSA-N","InChI=1S/C20H18F7NO2/c1-11(13-8-14(19(22,23)24)10-15(9-13)20(25,26)27)30-18-17(28-6-7-29-18)12-2-4-16(21)5-3-12/h2-5,8-11,17-18,28H,6-7H2,1H3/t11-,17+,18-/m1/s1","CYP3A4","Dehydrogenation","Human Phase I","Human","aprepitant_M2","NULL","LAWNGOQIFZBYOQ-UHFFFAOYSA-N","InChI=1S/C20H16F7NO2/c1-11(13-8-14(19(22,23)24)10-15(9-13)20(25,26)27)30-18-17(28-6-7-29-18)12-2-4-16(21)5-3-12/h2-6,8-11,17-18H,7H2,1H3","PMID:15304427"
"BIOTID00024","2-Methoxy-5-trifluoromethoxybenzylamine","23192118","JGFONUZHXXBGTF-UHFFFAOYSA-N","InChI=1S/C9H10F3NO2/c1-14-8-3-2-7(4-6(8)5-13)15-9(10,11)12/h2-4H,5,13H2,1H3","CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","O-Demethylation","Human Phase I","Human","CP-919,230","11694142","NIJPYMIFXMKSQQ-UHFFFAOYSA-N","InChI=1S/C8H8F3NO2/c9-8(10,11)14-6-1-2-7(13)5(3-6)4-12/h1-3,13H,4,12H2","PMID:17965517"
"BIOTID00025","3-(furan-2-ylmethyl)-1,7,8-trimethylpurine-2,6-dione","102123094","VACPENDPPYPFPY-UHFFFAOYSA-N","InChI=1S/C13H14N4O3/c1-8-14-11-10(15(8)2)12(18)16(3)13(19)17(11)7-9-5-4-6-20-9/h4-6H,7H2,1-3H3","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","VQJXXSJFJDVJED-UHFFFAOYSA-N","InChI=1S/C13H14N4O4/c1-7-14-11-10(15(7)2)12(19)16(3)13(20)17(11)5-9-4-8(18)6-21-9/h4,6,18H,5H2,1-3H3","PMID:9585555"
"BIOTID00026","3-(furan-2-ylmethyl)-1,7,8-trimethylpurine-2,6-dione","102123094","VACPENDPPYPFPY-UHFFFAOYSA-N","InChI=1S/C13H14N4O3/c1-8-14-11-10(15(8)2)12(18)16(3)13(19)17(11)7-9-5-4-6-20-9/h4-6H,7H2,1-3H3","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","GDDPKUCTHHNKKK-UHFFFAOYSA-N","InChI=1S/C13H14N4O4/c1-7-14-11-10(15(7)2)12(19)16(3)13(20)17(11)6-9-8(18)4-5-21-9/h4-5,18H,6H2,1-3H3","PMID:9585555"
"BIOTID00027","3-(furan-2-ylmethyl)-1,7,8-trimethylpurine-2,6-dione","102123094","VACPENDPPYPFPY-UHFFFAOYSA-N","InChI=1S/C13H14N4O3/c1-8-14-11-10(15(8)2)12(18)16(3)13(19)17(11)7-9-5-4-6-20-9/h4-6H,7H2,1-3H3","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","BKDFYXRQPYHFRL-UHFFFAOYSA-N","InChI=1S/C13H14N4O4/c1-7-14-11-10(15(7)2)12(19)16(3)13(20)17(11)6-8-4-5-9(18)21-8/h4-5,18H,6H2,1-3H3","PMID:9585555"
"BIOTID00028","3-(furan-2-ylmethyl)-1,7,8-trimethylpurine-2,6-dione","102123094","VACPENDPPYPFPY-UHFFFAOYSA-N","InChI=1S/C13H14N4O3/c1-8-14-11-10(15(8)2)12(18)16(3)13(19)17(11)7-9-5-4-6-20-9/h4-6H,7H2,1-3H3","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","XEQINVKPXLRNDE-UHFFFAOYSA-N","InChI=1S/C13H14N4O4/c1-15-9(7-18)14-11-10(15)12(19)16(2)13(20)17(11)6-8-4-3-5-21-8/h3-5,18H,6-7H2,1-2H3","PMID:9585555"
"BIOTID00029","3-(cyclohexylmethyl)-1,7,8-trimethylpurine-2,6-dione","102123104","ARGFHYICTJBMFD-UHFFFAOYSA-N","InChI=1S/C15H22N4O2/c1-10-16-13-12(17(10)2)14(20)18(3)15(21)19(13)9-11-7-5-4-6-8-11/h11H,4-9H2,1-3H3","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","QJYDMSYDZAXBOV-UHFFFAOYSA-N","InChI=1S/C15H22N4O3/c1-9-16-13-12(17(9)2)14(21)18(3)15(22)19(13)8-10-5-4-6-11(20)7-10/h10-11,20H,4-8H2,1-3H3","PMID:9585555"
"BIOTID00030","3-(cyclohexylmethyl)-1,7,8-trimethylpurine-2,6-dione","102123104","ARGFHYICTJBMFD-UHFFFAOYSA-N","InChI=1S/C15H22N4O2/c1-10-16-13-12(17(10)2)14(20)18(3)15(21)19(13)9-11-7-5-4-6-8-11/h11H,4-9H2,1-3H3","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","GGSFCOBRZLNYNO-UHFFFAOYSA-N","InChI=1S/C15H22N4O3/c1-10-16-13-12(19(10)9-20)14(21)17(2)15(22)18(13)8-11-6-4-3-5-7-11/h11,20H,3-9H2,1-2H3","PMID:9585555"
"BIOTID00031","3-(cyclohexylmethyl)-1,7,8-trimethylpurine-2,6-dione","102123104","ARGFHYICTJBMFD-UHFFFAOYSA-N","InChI=1S/C15H22N4O2/c1-10-16-13-12(17(10)2)14(20)18(3)15(21)19(13)9-11-7-5-4-6-8-11/h11H,4-9H2,1-3H3","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","PCPMKBBRSWHCAD-UHFFFAOYSA-N","InChI=1S/C15H22N4O3/c1-17-11(9-20)16-13-12(17)14(21)18(2)15(22)19(13)8-10-6-4-3-5-7-10/h10,20H,3-9H2,1-2H3","PMID:9585555"
"BIOTID00032","(-)-ethosuximide","6603844","HAPOVYFOVVWLRS-SSDOTTSWSA-N","InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)/t7-/m1/s1","CYP2E1;CYP3A4","Alphatic Hydroxylation","Human Phase I","Human","NULL","54520268","YPHULFCUFXXVGD-UHFFFAOYSA-N","InChI=1S/C7H11NO3/c1-4(9)7(2)3-5(10)8-6(7)11/h4,9H,3H2,1-2H3,(H,8,10,11)","PMID:12637244"
"BIOTID00033","(-)-etodolac","667528","NNYBQONXHNTVIJ-QGZVFWFLSA-N","InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)/t17-/m1/s1","CYP2C9","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-Hydroxyetodolac","14146232","GQHWDDBALZVXBU-UHFFFAOYSA-N","InChI=1S/C17H21NO4/c1-3-10-7-11(19)8-13-12-5-6-22-17(4-2,9-14(20)21)16(12)18-15(10)13/h7-8,18-19H,3-6,9H2,1-2H3,(H,20,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00034","(-)-etodolac","667528","NNYBQONXHNTVIJ-QGZVFWFLSA-N","InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)/t17-/m1/s1","CYP2C9","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","7-Hydroxyetodolac","14112821","LOALFJPXZIHKNH-UHFFFAOYSA-N","InChI=1S/C17H21NO4/c1-3-10-13(19)6-5-11-12-7-8-22-17(4-2,9-14(20)21)16(12)18-15(10)11/h5-6,18-19H,3-4,7-9H2,1-2H3,(H,20,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00035","(-)-limonene","439250","XMGQYMWWDOXHJM-SNVBAGLBSA-N","InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,10H,1,5-7H2,2-3H3/t10-/m1/s1","CYP2C9; CYP2C19","Allylic hydroxylation","Human Phase I","Human","Carveol","7438","BAVONGHXFVOKBV-UHFFFAOYSA-N","InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h4,9-11H,1,5-6H2,2-3H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00036","(-)-limonene","439250","XMGQYMWWDOXHJM-SNVBAGLBSA-N","InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,10H,1,5-7H2,2-3H3/t10-/m1/s1","CYP2C9; CYP2C19; CYP3A4","Allylic hydroxylation","Human Phase I","Human","Perillyl alcohol","369312","NDTYTMIUWGWIMO-SNVBAGLBSA-N","InChI=1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3/t10-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00037","(-)-pseudococaine","644018","ZPUCINDJVBIVPJ-LXTVHRRPSA-N","InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15-/m1/s1","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","Norcocaine","NULL","AYDBLCSLKNTEJL-XJFOESAGSA-N","InChI=1S/C16H19NO4/c1-20-16(19)14-12-8-7-11(17-12)9-13(14)21-15(18)10-5-3-2-4-6-10/h2-6,11-14,17H,7-9H2,1H3/t11-,12+,13-,14-/m1/s1","Rendic, S. et al. (1997); Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors; Drug Metabolism reviews 1997, 29, 413-580|Brone, R.F. et al. (1977); Biological Effects of Cocaine Derivatives I: Improved Systhesis and Pharmacological Evaluation of Norcocaine; J. Pharm. Sci. 1977, 66, 119-120."
"BIOTID00038","(-)-thalidomide","92142","UEJJHQNACJXSKW-VIFPVBQESA-N","InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/t9-/m0/s1","CYP2C19","Alpha hydroxylation of carbonyl group","Human Phase I","Human","cis, trans-5'-OH-thalidomide","NULL","HHTOWVWIVBSOKC-IENPIDJESA-N","InChI=1S/C13H10N2O5/c16-9-5-8(10(17)14-11(9)18)15-12(19)6-3-1-2-4-7(6)13(15)20/h1-4,8-9,16H,5H2,(H,14,17,18)/t8-,9?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00039","(-)-thalidomide","92142","UEJJHQNACJXSKW-VIFPVBQESA-N","InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/t9-/m0/s1","CYP2C19","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","5-OH-thalidomide","44250311","LJBQRRQTZUJWRC-VIFPVBQESA-N","InChI=1S/C13H10N2O5/c16-6-1-2-7-8(5-6)13(20)15(12(7)19)9-3-4-10(17)14-11(9)18/h1-2,5,9,16H,3-4H2,(H,14,17,18)/t9-/m0/s1","R1) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00040","(-)-thalidomide","92142","UEJJHQNACJXSKW-VIFPVBQESA-N","InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/t9-/m0/s1","CYP1A1; CYP1A2; CYP2C19; CYP2E1","ARENE_EPOXIDATION","Human Phase I","Human","(-)-thalidomide arene oxide","NULL","MNALUCRLHVMELD-UEJVZZJDSA-N","InChI=1S/C13H10N2O5/c16-10-2-1-7(11(17)14-10)15-12(18)5-3-8-9(20-8)4-6(5)13(15)19/h3-4,7-9H,1-2H2,(H,14,16,17)/t7-,8?,9?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00041","(-)-zileuton","10220327","MWLSOWXNZPKENC-ZETCQYMHSA-N","InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)/t7-/m0/s1","CYP3A4","Thiohene S-oxidation","Human Phase I","Human","Zileuton sulfoxide","95162932","KWEAXQJUQDQMNY-ISJKBYAMSA-N","InChI=1S/C11H12N2O3S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)17(10)16/h2-7,15H,1H3,(H2,12,14)/t7-,17?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00042","(-)-zileuton","10220327","MWLSOWXNZPKENC-ZETCQYMHSA-N","InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)/t7-/m0/s1","CYP1A2; CYP2C9","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","Hydroxyzileuton","NULL","ZQQVPNNYZLDMMO-LURJTMIESA-N","InChI=1S/C11H12N2O3S/c1-6(13(16)11(12)15)9-4-7-2-3-8(14)5-10(7)17-9/h2-6,14,16H,1H3,(H2,12,15)/t6-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00043","Perhexiline","38988177","CYXKNKQEMFBLER-GOSISDBHSA-N","InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2/t18-/m1/s1","CYP2D6","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","cis-hydroxyperhexilline","NULL","DZFRYNPJLZCKSC-BTRQGYIVSA-N","InChI=1S/C19H35NO/c21-18-11-9-16(10-12-18)19(15-6-2-1-3-7-15)14-17-8-4-5-13-20-17/h15-21H,1-14H2/t16?,17?,18-,19-/m0/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID00044","Perhexiline","38988177","CYXKNKQEMFBLER-GOSISDBHSA-N","InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2/t18-/m1/s1","CYP2D6","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","trans-hydroxyperhexilline","NULL","DZFRYNPJLZCKSC-CRIGQSRLSA-N","InChI=1S/C19H35NO/c21-18-11-9-16(10-12-18)19(15-6-2-1-3-7-15)14-17-8-4-5-13-20-17/h15-21H,1-14H2/t16-,17?,18+,19?","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID00045","(+)-3-carene","443156","BQOFWKZOCNGFEC-BDAKNGLRSA-N","InChI=1S/C10H16/c1-7-4-5-8-9(6-7)10(8,2)3/h4,8-9H,5-6H2,1-3H3/t8-,9+/m1/s1","CYP2B6; CYP2C19; CYP2D6","Hydroxlation of methyl carbon adjacent to an aliphatic ring","Human Phase I","Human","3-Caren-10-ol","129775894","BLWHTASVUYWISZ-BDAKNGLRSA-N","InChI=1S/C10H16O/c1-10(2)8-4-3-7(6-11)5-9(8)10/h3,8-9,11H,4-6H2,1-2H3/t8-,9+/m1/s1","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID00046","(+)-3-carene","443156","BQOFWKZOCNGFEC-BDAKNGLRSA-N","InChI=1S/C10H16/c1-7-4-5-8-9(6-7)10(8,2)3/h4,8-9H,5-6H2,1-3H3/t8-,9+/m1/s1","CYP1A2","EPOXIDATION_OF_112_TRISUBSTITUTED_ALKLENE","Human Phase I","Human","Carene epoxide","59057784","AGHSZSJVJPSERC-CCSIGSMKSA-N","InChI=1S/C10H16O/c1-9(2)6-4-8-10(3,11-8)5-7(6)9/h6-8H,4-5H2,1-3H3/t6-,7+,8?,10?/m1/s1","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID00047","(+)-bisoprolol","NULL","VHYCDWMUTMEGQY-QGZVFWFLSA-N","InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3/t17-/m1/s1","CYP2D6; CYP3A4","O-deisopropylation","Human Phase I","Human","(+)-bisoprolol, O-deisopropyl","NULL","AIGGWEPYIOOYLI-CQSZACIVSA-N","InChI=1S/C15H25NO4/c1-12(2)16-9-14(18)11-20-15-5-3-13(4-6-15)10-19-8-7-17/h3-6,12,14,16-18H,7-11H2,1-2H3/t14-/m1/s1","Horikiri, Y. (1998); Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans; Journal of Pharmaceutical Sciences; Vol. 87, No. 3"
"BIOTID00048","(+)-fipronil","15278225","ZOCSXAVNDGMNBV-SANMLTNESA-N","InChI=1S/C12H4Cl2F6N4OS/c13-5-1-4(11(15,16)17)2-6(14)8(5)24-10(22)9(7(3-21)23-24)26(25)12(18,19)20/h1-2H,22H2/t26-/m0/s1","CYP3A4","S-oxidation of sulfoxide to sulfone","Human Phase I","Human","f ipronil sulfone","3078139","LGHZJDKSVUTELU-UHFFFAOYSA-N","InChI=1S/C12H4Cl2F6N4O2S/c13-5-1-4(11(15,16)17)2-6(14)8(5)24-10(22)9(7(3-21)23-24)27(25,26)12(18,19)20/h1-2H,22H2","Tang, J. et al. (2004); In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam; Chem Biol Interact. 2004 Apr 15;147(3):319-29"
"BIOTID00049","(+)-halofantrine","36688213","FOHHNHSLJDZUGQ-RUZDIDTESA-N","InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3/t25-/m1/s1","CYP3A4","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","(+)-halofantrine, N-desbutyl","76971137","FYHCHSNOXWVJJT-OAQYLSRUSA-N","InChI=1S/C22H22Cl2F3NO/c1-2-3-7-28-8-6-21(29)19-12-18-17(10-14(23)11-20(18)24)16-9-13(22(25,26)27)4-5-15(16)19/h4-5,9-12,21,28-29H,2-3,6-8H2,1H3/t21-/m1/s1","Halliday, R.C. et al. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Phar- macol 1995; 40: 369-78."
"BIOTID00050","(+)-isothujone","91456","USMNOWBWPHYOEA-XKSSXDPKSA-N","InChI=1S/C10H16O/c1-6(2)10-4-8(10)7(3)9(11)5-10/h6-8H,4-5H2,1-3H3/t7-,8+,10-/m0/s1","CYP2A6; CYP2B6; CYP2D6; CYP3A4","Hydroxylation of penultimate aliphatic tertiary carbon","Human Phase I","Human","4-hydroxy-isothujone","45096397","QCIUNUUHBWFYTD-QNSHHTMESA-N","InChI=1S/C10H16O2/c1-6(2)10-4-7(10)9(3,12)8(11)5-10/h6-7,12H,4-5H2,1-3H3/t7-,9-,10+/m1/s1","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID00051","(+)-isothujone","91456","USMNOWBWPHYOEA-XKSSXDPKSA-N","InChI=1S/C10H16O/c1-6(2)10-4-8(10)7(3)9(11)5-10/h6-8H,4-5H2,1-3H3/t7-,8+,10-/m0/s1","CYP2A6; CYP2B6; CYP2D6; CYP3A4","Hydroxylation of penultimate aliphatic tertiary carbon","Human Phase I","Human","7-hydroxy-isothujone","NULL","BWIMEHVFTVSHCC-NYNCVSEMSA-N","InChI=1S/C10H16O2/c1-6-7-4-10(7,5-8(6)11)9(2,3)12/h6-7,12H,4-5H2,1-3H3/t6-,7+,10+/m0/s1","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID00052","(13alpha)-3-methoxy-estra-1,3,5(10)-triene-17alpha-ol","101235253","ULAADVBNYHGIBP-UJWQCDCRSA-N","InChI=1S/C19H26O2/c1-19-10-9-15-14-6-4-13(21-2)11-12(14)3-5-16(15)17(19)7-8-18(19)20/h4,6,11,15-18,20H,3,5,7-10H2,1-2H3/t15-,16-,17+,18-,19-/m1/s1","CYP2C19(major);CYP2C9;CYP1A2;CYP3A4","O-Demethylation","Human Phase I","Human","Estradiol","5757","VOXZDWNPVJITMN-UYTYNIKBSA-N","InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17-,18-/m1/s1","PMID:9714305"
"BIOTID00053","(2r)-1-(2-methoxyphenyl)propan-2-amine","7432381","VBAHFEPKESUPDE-MRVPVSSYSA-N","InChI=1S/C10H15NO/c1-8(11)7-9-5-3-4-6-10(9)12-2/h3-6,8H,7,11H2,1-2H3/t8-/m1/s1","CYP2D6","O-Demethylation","Human Phase I","Human","NULL","541960","BCYNCBWCTHFJIU-UHFFFAOYSA-N","InChI=1S/C9H13NO/c1-7(10)6-8-4-2-3-5-9(8)11/h2-5,7,11H,6,10H2,1H3","PMID:10456690"
"BIOTID00054","(2r)-1-(2-methoxyphenyl)propan-2-amine","7432381","VBAHFEPKESUPDE-MRVPVSSYSA-N","InChI=1S/C10H15NO/c1-8(11)7-9-5-3-4-6-10(9)12-2/h3-6,8H,7,11H2,1-2H3/t8-/m1/s1","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","84732347","PKIJOVMSOHJKHU-UHFFFAOYSA-N","InChI=1S/C10H15NO2/c1-7(11)6-8-4-3-5-9(12)10(8)13-2/h3-5,7,12H,6,11H2,1-2H3","PMID:10456690"
"BIOTID00055","(2r)-1-(2-methoxyphenyl)propan-2-amine","7432381","VBAHFEPKESUPDE-MRVPVSSYSA-N","InChI=1S/C10H15NO/c1-8(11)7-9-5-3-4-6-10(9)12-2/h3-6,8H,7,11H2,1-2H3/t8-/m1/s1","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","IPNIOEZCSLMIQL-UHFFFAOYSA-N","InChI=1S/C10H21NO2/c1-7(11)5-8-6-9(12)3-4-10(8)13-2/h7-10,12H,3-6,11H2,1-2H3","PMID:10456690"
"BIOTID00056","(2r)-2-[4-(3-methylthiophen-2-yl)phenyl]propanoic acid","127523","DTOPKPBTCXKNFF-SNVBAGLBSA-N","InChI=1S/C14H14O2S/c1-9-7-8-17-13(9)12-5-3-11(4-6-12)10(2)14(15)16/h3-8,10H,1-2H3,(H,15,16)/t10-/m1/s1","CYP2C9","C-Oxidation","Human Phase I","Human","NULL","NULL","UCLJEKUGFLLCDU-SECBINFHSA-N","InChI=1S/C14H14O3S/c1-8-7-12(15)18-13(8)11-5-3-10(4-6-11)9(2)14(16)17/h3-6,9H,7H2,1-2H3,(H,16,17)/t9-/m1/s1","PMID:10548450"
"BIOTID00058","(2s,5s)-troglitazone","6518172","GXPHKUHSUJUWKP-CYFREDJKSA-N","InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)/t19-,24-/m0/s1","CYP3A4","2,4-thiazolidinedione ring opening","Human Phase I","Human","(2S)â€3â€(4â€{[(2S)â€6â€hydroxyâ€2,5,7,8â€tetramethylâ€3,4â€dihydroâ€1â€benzopyranâ€2â€yl]methoxy}phenyl)â€2â€(hydroxysulfanyl)propanecarbonyl isocyanate","NULL","HMEBITABBUPZPK-RDPSFJRHSA-N","InChI=1S/C24H27NO6S/c1-14-15(2)22-19(16(3)21(14)27)9-10-24(4,31-22)12-30-18-7-5-17(6-8-18)11-20(32-29)23(28)25-13-26/h5-8,20,27,29H,9-12H2,1-4H3/t20-,24-/m0/s1","He, K. et al. (2001); Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction; Biochem Pharmacol.; 62(2):191-8|Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322|SÃƒÂ¡nchez, A. ET AL. (2006); Thiazolidinedione Bioactivation: A Comparison of the Bioactivation Potentials of Troglitazone, Rosiglitazone, and Pioglitazone Using Stable Isotope-Labeled Analogues and Liquid Chromatography Tandem Mass Spectrometry; Current Medicinal Chemistry, 2009 Vol. 16, No. 27"
"BIOTID00059","(2s,5s)-troglitazone","6518172","GXPHKUHSUJUWKP-CYFREDJKSA-N","InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)/t19-,24-/m0/s1","CYP3A4","2,4-thiazolidinedione ring opening","Human Phase I","Human","(1S)-1-(formylcarbamoyl)-2-(4-{[(2S)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl]methoxy}phenyl)ethane-1-sulfinic acid","NULL","XIINUBVMVMENJH-RDPSFJRHSA-N","InChI=1S/C24H29NO7S/c1-14-15(2)22-19(16(3)21(14)27)9-10-24(4,32-22)12-31-18-7-5-17(6-8-18)11-20(33(29)30)23(28)25-13-26/h5-8,13,20,27H,9-12H2,1-4H3,(H,29,30)(H,25,26,28)/t20-,24-/m0/s1","He, K. et al. (2001); Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction; Biochem Pharmacol.; 62(2):191-8|Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322|SÃƒÂ¡nchez, A. ET AL. (2006); Thiazolidinedione Bioactivation: A Comparison of the Bioactivation Potentials of Troglitazone, Rosiglitazone, and Pioglitazone Using Stable Isotope-Labeled Analogues and Liquid Chromatography Tandem Mass Spectrometry; Current Medicinal Chemistry, 2009 Vol. 16, No. 27"
"BIOTID00060","Saquinavir","441243","QWAXKHKRTORLEM-UGJKXSETSA-N","InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1","CYP3A4","Hydroxylation of terminal methyl","Human Phase I","Human","(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide","122197282","SQCJGICLIMLWFB-UGJKXSETSA-N","InChI=1S/C38H50N6O6/c1-38(2,23-45)43-37(50)32-19-26-13-6-7-14-27(26)21-44(32)22-33(46)30(18-24-10-4-3-5-11-24)41-36(49)31(20-34(39)47)42-35(48)29-17-16-25-12-8-9-15-28(25)40-29/h3-5,8-12,15-17,26-27,30-33,45-46H,6-7,13-14,18-23H2,1-2H3,(H2,39,47)(H,41,49)(H,42,48)(H,43,50)/t26-,27+,30-,31-,32-,33+/m0/s1","Fitzsimmons, M.E. and Collins, J.M. (1997); Selective Biotransformation of the HIV Protease Inhibitor Saquinavir by Human Small Intestinal Cytochrome P450 3A4: Potential Contribution to High First-Pass Metabolism. Drug Metab. Dispos.; 25; pp. 256Ã¢â‚¬â€œ266"
"BIOTID00061","Saquinavir","441243","QWAXKHKRTORLEM-UGJKXSETSA-N","InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","(2S)-N-[(2S,3R)-4-[(3S,4aR,8aS)-3-(tert-butylcarbamoyl)-6-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide","NULL","VEVTYHWFAKZKCL-VICGCSEUSA-N","InChI=1S/C38H50N6O6/c1-38(2,3)43-37(50)32-19-26-18-27(45)15-13-25(26)21-44(32)22-33(46)30(17-23-9-5-4-6-10-23)41-36(49)31(20-34(39)47)42-35(48)29-16-14-24-11-7-8-12-28(24)40-29/h4-12,14,16,25-27,30-33,45-46H,13,15,17-22H2,1-3H3,(H2,39,47)(H,41,49)(H,42,48)(H,43,50)/t25-,26+,27?,30+,31+,32+,33-/m1/s1","Fitzsimmons, M.E. and Collins, J.M. (1997); Selective Biotransformation of the HIV Protease Inhibitor Saquinavir by Human Small Intestinal Cytochrome P450 3A4: Potential Contribution to High First-Pass Metabolism. Drug Metab. Dispos.; 25; pp. 256Ã¢â‚¬â€œ266"
"BIOTID00062","Saquinavir","441243","QWAXKHKRTORLEM-UGJKXSETSA-N","InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-7-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide","NULL","YHJGQHOJUFVUIN-XFHLUWSMSA-N","InChI=1S/C38H50N6O6/c1-38(2,3)43-37(50)32-19-25-13-15-27(45)18-26(25)21-44(32)22-33(46)30(17-23-9-5-4-6-10-23)41-36(49)31(20-34(39)47)42-35(48)29-16-14-24-11-7-8-12-28(24)40-29/h4-12,14,16,25-27,30-33,45-46H,13,15,17-22H2,1-3H3,(H2,39,47)(H,41,49)(H,42,48)(H,43,50)/t25-,26+,27?,30-,31-,32-,33+/m0/s1","Fitzsimmons, M.E. and Collins, J.M. (1997); Selective Biotransformation of the HIV Protease Inhibitor Saquinavir by Human Small Intestinal Cytochrome P450 3A4: Potential Contribution to High First-Pass Metabolism. Drug Metab. Dispos.; 25; pp. 256Ã¢â‚¬â€œ266"
"BIOTID00063","(3z)-5-[(1alpha,4alpha)-3beta-[(phenylsulfonyl)amino]bicyclo[2.2.1]heptan-2alpha-yl]-3-pentenoic acid","101619702","IBHYMKYJWOYNMU-KHECKTLASA-N","InChI=1S/C18H23NO4S/c20-17(21)9-5-4-8-16-13-10-11-14(12-13)18(16)19-24(22,23)15-6-2-1-3-7-15/h1-7,13-14,16,18-19H,8-12H2,(H,20,21)/b5-4-/t13-,14+,16+,18+/m1/s1","CYP2C9;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","(3Z)â€5â€{3â€benzenesulfonamidoâ€6â€hydroxybicyclo[2.2.1]heptanâ€2â€yl}pentâ€3â€enoic acid","NULL","JJKBBLIIFRKQPZ-PLNGDYQASA-N","InChI=1S/C18H23NO5S/c20-16-11-12-10-15(16)14(8-4-5-9-17(21)22)18(12)19-25(23,24)13-6-2-1-3-7-13/h1-7,12,14-16,18-20H,8-11H2,(H,21,22)/b5-4-","PMID:9010633"
"BIOTID00064","(3z)-5-[(1alpha,4alpha)-3beta-[(phenylsulfonyl)amino]bicyclo[2.2.1]heptan-2alpha-yl]-3-pentenoic acid","101619702","IBHYMKYJWOYNMU-KHECKTLASA-N","InChI=1S/C18H23NO4S/c20-17(21)9-5-4-8-16-13-10-11-14(12-13)18(16)19-24(22,23)15-6-2-1-3-7-15/h1-7,13-14,16,18-19H,8-12H2,(H,20,21)/b5-4-/t13-,14+,16+,18+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","(3Z)â€5â€{3â€benzenesulfonamidoâ€5â€hydroxybicyclo[2.2.1]heptanâ€2â€yl}pentâ€3â€enoic acid","NULL","AXYCZOBHLHHYRD-PLNGDYQASA-N","InChI=1S/C18H23NO5S/c20-16-11-12-10-15(16)18(14(12)8-4-5-9-17(21)22)19-25(23,24)13-6-2-1-3-7-13/h1-7,12,14-16,18-20H,8-11H2,(H,21,22)/b5-4-","PMID:9010633"
"BIOTID00065","(r)-(+)-felodipine","941699","RZTAMFZIAATZDJ-HNNXBMFYSA-N","InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3/t15-/m0/s1","CYP3A4","Dehydrogenation of 4-aryl substituted 1,4-dihydropyridine","Human Phase I","Human","Dehydrofelodipine","62970","REQRUBNOOIAHMG-UHFFFAOYSA-N","InChI=1S/C18H17Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8H,5H2,1-4H3","Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322"
"BIOTID00066","(R)-(-)-Mexiletine","180621","VLPIATFUUWWMKC-SNVBAGLBSA-N","InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m1/s1","CYP1A2 (minor); CYP2D6 (major)","HYDROXYLATION_OF_AROMATIC_CARBON; HYDROXYLATION_OF_BENZENE_PARA_TO_EDG","Human Phase I","Human","(R)-(-)-Mexiletine, p-hydroxyl","71351213","YWOSWRCXWBDSRQ-SECBINFHSA-N","InChI=1S/C11H17NO2/c1-7-4-10(13)5-8(2)11(7)14-6-9(3)12/h4-5,9,13H,6,12H2,1-3H3/t9-/m1/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Zhou, S.F. and Wang, B. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218; PMID:19754423"
"BIOTID00067","(R)-(-)-Mexiletine","180621","VLPIATFUUWWMKC-SNVBAGLBSA-N","InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m1/s1","CYP1A2 (minor); CYP2D6 (major)","HYDROXYLATION_OF_AROMATIC_CARBON; HYDROXYLATION_OF_BENZENE_ORTHO_TO_EDG","Human Phase I","Human","(R)-(-)-Mexiletine, m-hydroxyl","73211883","LBHCZYGJQAXJSW-MRVPVSSYSA-N","InChI=1S/C11H17NO2/c1-7-4-5-10(13)9(3)11(7)14-6-8(2)12/h4-5,8,13H,6,12H2,1-3H3/t8-/m1/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Zhou, S.F. and Wang, B. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218; PMID:19754423"
"BIOTID00068","(R)-(-)-Mexiletine","180621","VLPIATFUUWWMKC-SNVBAGLBSA-N","InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m1/s1","CYP1A2 (minor); CYP2D6 (major)","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","(R)-(-)-Mexiletine, 2-OH-hydroxymethyl","92288928","XMJYSMLLWRQQAE-SECBINFHSA-N","InChI=1S/C11H17NO2/c1-8-4-3-5-10(6-13)11(8)14-7-9(2)12/h3-5,9,13H,6-7,12H2,1-2H3/t9-/m1/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Zhou, S.F. and Wang, B. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218; PMID:19754423"
"BIOTID00069","(R)-(-)-Mexiletine","180621","VLPIATFUUWWMKC-SNVBAGLBSA-N","InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m1/s1","CYP1A2 (major); CYP2B6; CYP2E1","N-hydroxylation of primary or secondary aliphatic amine","Human Phase I","Human","(R)-(-)-Mexiletine, N-hydroxy","92288929","ABMUWCMGKRQAIK-SNVBAGLBSA-N","InChI=1S/C11H17NO2/c1-8-5-4-6-9(2)11(8)14-7-10(3)12-13/h4-6,10,12-13H,7H2,1-3H3/t10-/m1/s1","Abolfathi, Z. et al. (1995); CYP1A2 is the Major Enzyme Involved in the N-Oxidation of Mexiletine (MEX) in Man. Clin. Pharmacol. Ther.; 57; 221 (OIII- A33).|Labbe, L. et al.; (2003). Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobi- otica 33:13Ã¢â‚¬â€œ25."
"BIOTID00070","(r)-azelastine","12831280","MBUVEWMHONZEQD-GOSISDBHSA-N","InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3/t18-/m1/s1","CYP3A4; CYP2D6; CYP1A2 (minor)","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","(r)-azelastine, N-desmethyl","40584683","WRYCMIFVXDQIKN-QGZVFWFLSA-N","InChI=1S/C21H22ClN3O/c22-16-9-7-15(8-10-16)14-20-18-5-1-2-6-19(18)21(26)25(24-20)17-4-3-12-23-13-11-17/h1-2,5-10,17,23H,3-4,11-14H2/t17-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00071","(r)-bupropion","688387","SNPPWIUOZRMYNY-SECBINFHSA-N","InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3/t9-/m1/s1","CYP2B6; CYP3A4","Hydroxylation of terminal methyl","Human Phase I","Human","(2R)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one","9879135","AKOAEVOSDHIVFX-SECBINFHSA-N","InChI=1S/C13H18ClNO2/c1-9(15-13(2,3)8-16)12(17)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3/t9-/m1/s1","Chen, Y. et al. (2010); The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40:8, 536-546, DOI:10.3109/00498254.2010.492880"
"BIOTID00072","(r)-bupropion","688387","SNPPWIUOZRMYNY-SECBINFHSA-N","InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3/t9-/m1/s1","CYP2C19","Hydroxylation of terminal methyl","Human Phase I","Human","(2R)-2-(tert-butylamino)-1-(3-chlorophenyl)-3-hydroxypropan-1-one","22943248","MYCARDPPKMGEQK-LLVKDONJSA-N","InChI=1S/C13H18ClNO2/c1-13(2,3)15-11(8-16)12(17)9-5-4-6-10(14)7-9/h4-7,11,15-16H,8H2,1-3H3/t11-/m1/s1","Chen, Y. et al. (2010); The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40:8, 536-546, DOI:10.3109/00498254.2010.492880"
"BIOTID00073","(r)-bupropion","688387","SNPPWIUOZRMYNY-SECBINFHSA-N","InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3/t9-/m1/s1","CYP2B6;CYP2C19; CYP2E1","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","(2R)-2-(tert-butylamino)-1-(3-chloro-4-hydroxyphenyl)propan-1-one","NULL","LSZBTGUSYVNVLH-MRVPVSSYSA-N","InChI=1S/C13H18ClNO2/c1-8(15-13(2,3)4)12(17)9-5-6-11(16)10(14)7-9/h5-8,15-16H,1-4H3/t8-/m1/s1","Chen, Y. et al. (2010); The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40:8, 536-546, DOI:10.3109/00498254.2010.492880|Faucette, S.R. et al. (2000); Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity. Drug Metab. Dispos. 2000, 28, 1222 Ã¢â‚¬â€œ 1230."
"BIOTID00074","(r)-bupropion","688387","SNPPWIUOZRMYNY-SECBINFHSA-N","InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3/t9-/m1/s1","CYP2B6;CYP2C19; CYP2E1","Hydroxylation of aromatic carbon meta to halide group","Human Phase I","Human","(2R)â€2â€(tertâ€butylamino)â€1â€(3â€chloroâ€5â€hydroxyphenyl)propanâ€1â€one","NULL","MKUMNNVIQOBJFK-MRVPVSSYSA-N","InChI=1S/C13H18ClNO2/c1-8(15-13(2,3)4)12(17)9-5-10(14)7-11(16)6-9/h5-8,15-16H,1-4H3/t8-/m1/s1","Chen, Y. et al. (2010); The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40:8, 536-546, DOI:10.3109/00498254.2010.492880|Faucette, S.R. et al. (2000); Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity. Drug Metab. Dispos. 2000, 28, 1222 Ã¢â‚¬â€œ 1230."
"BIOTID00075","(r)-chloroquine","444810","WHTVZRBIWZFKQO-CQSZACIVSA-N","InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)/t14-/m1/s1","CYP2C8; CYP2D6; CYP3A4; CYP3A5","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES","Human Phase I","Human","(r)-chloroquine, N-desethyl","38989112","MCYUUUTUAAGOOT-GFCCVEGCSA-N","InChI=1S/C16H22ClN3/c1-3-18-9-4-5-12(2)20-15-8-10-19-16-11-13(17)6-7-14(15)16/h6-8,10-12,18H,3-5,9H2,1-2H3,(H,19,20)/t12-/m1/s1","Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00076","(r)-enflurane","11052326","JPGQOUSTVILISH-SFOWXEAESA-N","InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H/t1-/m0/s1","CYP2E1","Oxidation of halotrifluoroethane","Human Phase I","Human","2-(difluoromethoxy)-2,2-difluoroacetyl fluoride","NULL","TVUMCYGRGFDDJV-UHFFFAOYSA-N","InChI=1S/C3HF5O2/c4-1(9)3(7,8)10-2(5)6/h2H","Kenna, J.G. et Al. (2013); Drug-induced Disease (3rd Edition) (2013), Chapter 23 - Mechanisim, Pathology, and Clinical Presentation of Hepatoxicity of Anesthetic Agents 2013, 403-422 http://dx.doi.org/10.1016/B978-0-12-387817-5.00023-6|Chris, D.D. et al. (1988); Potential Metabolic basis for enflurane hepatitis and the appaarent cross-sensutuzation between enflurane and halothane; Drug Metab Dispos 1988, 16, 135-140"
"BIOTID00077","(r)-ketamine","644025","YQEZLKZALYSWHR-CYBMUJFWSA-N","InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3/t13-/m1/s1","CYP2C9; CYP2B6; CYP3A4 ","N-dealkylation of acyclic secondary amine","Human Phase I","Human","Norketamine","10105008","BEQZHFIKTBVCAU-GFCCVEGCSA-N","InChI=1S/C12H14ClNO/c13-10-6-2-1-5-9(10)12(14)8-4-3-7-11(12)15/h1-2,5-6H,3-4,7-8,14H2/t12-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00078","(r)-mda","3046161","NGBBVGZWCFBOGO-SSDOTTSWSA-N","InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3/t7-/m1/s1","CYP2D6;CYP3A4","O-Demethylation","Human Phase I","Human","Alpha-methyldopamine","17005","KSRGADMGIRTXAF-UHFFFAOYSA-N","InChI=1S/C9H13NO2/c1-6(10)4-7-2-3-8(11)9(12)5-7/h2-3,5-6,11-12H,4,10H2,1H3","PMID:10720722"
"BIOTID00079","(r)-metoprolol","157717","IUBSYMUCCVWXPE-CQSZACIVSA-N","InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3/t14-/m1/s1","CYP2D6","Hydroxylation of non-terminal aliphatic carbon adjacent to aromatic ring","Human Phase I","Human","alpha-Hydroxymetoprolol","3082567","OFRYBPCSEMMZHR-AFYYWNPRSA-N","InChI=1S/C15H25NO4/c1-11(2)16-8-13(17)9-20-14-6-4-12(5-7-14)15(18)10-19-3/h4-7,11,13,15-18H,8-10H2,1-3H3/t13-,15?/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985; PMID:18259985"
"BIOTID00080","(r)-metoprolol","157717","IUBSYMUCCVWXPE-CQSZACIVSA-N","InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3/t14-/m1/s1","CYP2D6; CYP3A4","O-dealkylation of dialkylether","Human Phase I","Human","O-Demethylmetoprolol","40561637","CUKXSBOAIJILRY-CYBMUJFWSA-N","InChI=1S/C14H23NO3/c1-11(2)15-9-13(17)10-18-14-5-3-12(4-6-14)7-8-16/h3-6,11,13,15-17H,7-10H2,1-2H3/t13-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693."
"BIOTID00081","(r)-metoprolol","157717","IUBSYMUCCVWXPE-CQSZACIVSA-N","InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3/t14-/m1/s1","CYP2C19","N-deisopropylation","Human Phase I","Human","N_DEISOPROPYLATION","92978216","XJWXVDJGNOHFLR-LLVKDONJSA-N","InChI=1S/C12H19NO3/c1-15-7-6-10-2-4-12(5-3-10)16-9-11(14)8-13/h2-5,11,14H,6-9,13H2,1H3/t11-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00082","(r)-trimipramine","5282594","ZSCDBOWYZJWBIY-MRXNPFEDSA-N","InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3/t16-/m1/s1","CYP2C19","N-demethylation","Human Phase I","Human","NULL","160632","FUEUKSCRQNPXKS-UHFFFAOYSA-N","InChI=1S/C19H24N2/c1-15(13-20-2)14-21-18-9-5-3-7-16(18)11-12-17-8-4-6-10-19(17)21/h3-10,15,20H,11-14H2,1-2H3","PMID:19902987"
"BIOTID00083","(r)-trimipramine","5282594","ZSCDBOWYZJWBIY-MRXNPFEDSA-N","InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3/t16-/m1/s1","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","PBUTZRBWGXMKPS-UHFFFAOYSA-N","InChI=1S/C20H26N2O/c1-15(13-21(2)3)14-22-18-10-6-4-8-16(18)12-20(23)17-9-5-7-11-19(17)22/h4-11,15,20,23H,12-14H2,1-3H3","PMID:19902987"
"BIOTID00084","(r)-trimipramine","5282594","ZSCDBOWYZJWBIY-MRXNPFEDSA-N","InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3/t16-/m1/s1","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","160610","FQJSSUOYVSEYPF-UHFFFAOYSA-N","InChI=1S/C20H26N2O/c1-15(13-21(2)3)14-22-19-7-5-4-6-16(19)8-9-17-12-18(23)10-11-20(17)22/h4-7,10-12,15,23H,8-9,13-14H2,1-3H3","PMID:19902987"
"BIOTID00085","(s)-(-)-carvedilol","185395","OGHNVEJMJSYVRP-KRWDZBQOSA-N","InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3/t17-/m0/s1","CYP2D6 (major); CYP2E1 (minor); CYP2C9 (minor); CYP3A4 (minor)","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","4'-OH-carvedilol","40425351","ZCJHEORDHXCJNB-KRWDZBQOSA-N","InChI=1S/C24H26N2O5/c1-29-23-13-16(27)9-10-21(23)30-12-11-25-14-17(28)15-31-22-8-4-7-20-24(22)18-5-2-3-6-19(18)26-20/h2-10,13,17,25-28H,11-12,14-15H2,1H3/t17-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00086","(s)-(-)-carvedilol","185395","OGHNVEJMJSYVRP-KRWDZBQOSA-N","InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3/t17-/m0/s1","CYP2C9 (major); CYP2D6 (minor); CYP1A2 (minor); CYP2E1 (minor)","O-aryl demethylation","Human Phase I","Human","O-Desmethylcarvedilol","40425346","XAUKPPPYYOKVQJ-INIZCTEOSA-N","InChI=1S/C23H24N2O4/c26-16(14-24-12-13-28-21-10-4-3-9-20(21)27)15-29-22-11-5-8-19-23(22)17-6-1-2-7-18(17)25-19/h1-11,16,24-27H,12-15H2/t16-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00087","(s)-(-)-carvedilol","185395","OGHNVEJMJSYVRP-KRWDZBQOSA-N","InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3/t17-/m0/s1","CYP2D6 (major); CYP2E1 (minor); CYP2C9 (minor); CYP3A4 (minor)","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","5'-OH-carvedilol","40425353","PVUVZUBTCLBJMT-KRWDZBQOSA-N","InChI=1S/C24H26N2O5/c1-29-21-10-9-16(27)13-23(21)30-12-11-25-14-17(28)15-31-22-8-4-7-20-24(22)18-5-2-3-6-19(18)26-20/h2-10,13,17,25-28H,11-12,14-15H2,1H3/t17-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00088","(s)-(-)-carvedilol","185395","OGHNVEJMJSYVRP-KRWDZBQOSA-N","InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3/t17-/m0/s1","CYP1A2 (major); CYP3A4 (minor); CYP1A1 (minor)","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","8-OH-carvedilol","90478462","GPPVNZVFGNMPNR-INIZCTEOSA-N","InChI=1S/C24H26N2O5/c1-29-20-9-2-3-10-21(20)30-13-12-25-14-16(27)15-31-22-11-5-7-18-23(22)17-6-4-8-19(28)24(17)26-18/h2-11,16,25-28H,12-15H2,1H3/t16-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00089","(s)-(+)-ibuprofen","39912","HEFNNWSXXWATRW-JTQLQIEISA-N","InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1","CYP2C9; CYP2C8","Hydroxylation of penultimate aliphatic tertiary carbon","Human Phase I","Human","2-Hydroxyibuprofen","12617415","UJHKVYPPCJBOSG-VIFPVBQESA-N","InChI=1S/C13H18O3/c1-9(12(14)15)11-6-4-10(5-7-11)8-13(2,3)16/h4-7,9,16H,8H2,1-3H3,(H,14,15)/t9-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00090","(s)-(+)-ibuprofen","39912","HEFNNWSXXWATRW-JTQLQIEISA-N","InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1","CYP2C9; CYP2C8","Hydroxylation of terminal methyl","Human Phase I","Human","3-Hydroxyibuprofen","NULL","HFAIHLSDLUYLQA-AXDSSHIGSA-N","InChI=1S/C13H18O3/c1-9(8-14)7-11-3-5-12(6-4-11)10(2)13(15)16/h3-6,9-10,14H,7-8H2,1-2H3,(H,15,16)/t9?,10-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00091","(s)-fluoxetine","1548968","RTHCYVBBDHJXIQ-INIZCTEOSA-N","InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3/t16-/m0/s1","CYP2C9 (major); CYP2D6; CYP2C19; CYP3A4; CYP3A5","N-dealkylation of acyclic secondary amine","Human Phase I","Human","(s)-Norfluoxetine","3058751","WIQRCHMSJFFONW-HNNXBMFYSA-N","InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ring, B.J. et al. (2001); Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine; J Pharmacol Exp Ther. 2001 Jun;297(3):1044-50.|Margolis J.M.; (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes; Drug Metab Dispos. 2000 Oct;28(10):1187-91; PMID:10997938; Drug Metab Dispos. 2000 Oct;28(10):1187-91."
"BIOTID00092","(s)-fluoxetine","1548968","RTHCYVBBDHJXIQ-INIZCTEOSA-N","InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3/t16-/m0/s1","CYP2C19; CYP3A4","O-dealkylation","Human Phase I","Human","p-Trifluoromethyl phenol","67874","BAYGVMXZJBFEMB-UHFFFAOYSA-N","InChI=1S/C7H5F3O/c8-7(9,10)5-1-3-6(11)4-2-5/h1-4,11H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ring, B.J. et al. (2001); Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine; J Pharmacol Exp Ther. 2001 Jun;297(3):1044-50.|Margolis J.M.; (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes; Drug Metab Dispos. 2000 Oct;28(10):1187-91; PMID:10997938; Drug Metab Dispos. 2000 Oct;28(10):1187-91."
"BIOTID00093","(s)-fluoxetine","1548968","RTHCYVBBDHJXIQ-INIZCTEOSA-N","InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3/t16-/m0/s1","CYP2C19; CYP3A4","O-dealkylation","Human Phase I","Human","3-(methylamino)-1-phenylpropan-1-one","407877","CAIKBWLFBLRPJU-UHFFFAOYSA-N","InChI=1S/C10H13NO/c1-11-8-7-10(12)9-5-3-2-4-6-9/h2-6,11H,7-8H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ring, B.J. et al. (2001); Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine; J Pharmacol Exp Ther. 2001 Jun;297(3):1044-50.|Margolis J.M.; (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes; Drug Metab Dispos. 2000 Oct;28(10):1187-91; PMID:10997938; Drug Metab Dispos. 2000 Oct;28(10):1187-91."
"BIOTID00094","(s)-flurbiprofen","72099","SYTBZMRGLBWNTM-JTQLQIEISA-N","InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m0/s1","CYP2C9","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4-OH-S-flurbiprofen","40578888","GTSMMBJBNJDFRA-VIFPVBQESA-N","InChI=1S/C15H13FO3/c1-9(15(18)19)11-4-7-13(14(16)8-11)10-2-5-12(17)6-3-10/h2-9,17H,1H3,(H,18,19)/t9-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00095","(s)-hexobarbital","7036944","UYXAWHWODHRRMR-LBPRGKRZSA-N","InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)/t12-/m0/s1","CYP2C9; CYP2C19","Allylic hydroxylation","Human Phase I","Human","3'-OH-(S)-hexobarbital","NULL","YHCGILGEMWNROZ-MYIOLCAUSA-N","InChI=1S/C12H16N2O4/c1-12(7-4-3-5-8(15)6-7)9(16)13-11(18)14(2)10(12)17/h6,8,15H,3-5H2,1-2H3,(H,13,16,18)/t8?,12-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00096","(s)-mephobarbital","6451435","ALARQZQTBTVLJV-ZDUSSCGKSA-N","InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)/t13-/m0/s1","CYP2C19","Aromatic Hydroxylation","Human Phase I","Human","4-hydroxymephobarbital","133152","ARGUVULFWSAUDV-UHFFFAOYSA-N","InChI=1S/C13H14N2O4/c1-3-13(8-4-6-9(16)7-5-8)10(17)14-12(19)15(2)11(13)18/h4-7,16H,3H2,1-2H3,(H,14,17,19)","PMID:11124227"
"BIOTID00097","(s)-mephobarbital","6451435","ALARQZQTBTVLJV-ZDUSSCGKSA-N","InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)/t13-/m0/s1","CYP2B6","N-demethylation","Human Phase I","Human","phenobarbital","4763","DDBREPKUVSBGFI-UHFFFAOYSA-N","InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)","PMID:11124227"
"BIOTID00098","(s)-norfenfluramine","9815618","MLBHFBKZUPLWBD-ZETCQYMHSA-N","InChI=1S/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3/t7-/m0/s1","CYP1A2","C-DEALKLYATION","Human Phase I","Human","NULL","104223","BPVYCXMGJPKOTQ-UHFFFAOYSA-N","InChI=1S/C9H10F3N/c10-9(11,12)8-3-1-2-7(6-8)4-5-13/h1-3,6H,4-5,13H2","PMID:9825834"
"BIOTID00099","(s)-oxybutynin","206530","XIQVNETUBQGFHX-JOCHJYFZSA-N","InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1","CYP3A4","HYDROLYSIS_OF_CARBOXYLIC_ESTER","Human Phase I","Human","2-cyclohexyl-2-phenylglycolic acid","777375","YTRNSQPXEDGWMR-CQSZACIVSA-N","InChI=1S/C14H18O3/c15-13(16)14(17,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1,3-4,7-8,12,17H,2,5-6,9-10H2,(H,15,16)/t14-/m1/s1","Sato, Y. et al. (2012); Conclusive Identification of the Oxybutynin-Hydrolyzing Enzyme in Human Liver; DRUGMETABOLISM ANDDISPOSITION 2012, 40, 902-906|MIZUSHIMA, H. et al. (2007); Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo; Xenobiotica, 2007, 37, 59-73|Abramov, Y. et al. (2004); Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review; Expert Opin. Pharmacother., 2004, 5, 2351-2359"
"BIOTID00099","(s)-oxybutynin","206530","XIQVNETUBQGFHX-JOCHJYFZSA-N","InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1","CYP3A4","HYDROLYSIS_OF_CARBOXYLIC_ESTER","Human Phase I","Human","4-(diethylamino)but-2-yn-1-ol","82735","ACGZBRWTWOZSFU-UHFFFAOYSA-N","InChI=1S/C8H15NO/c1-3-9(4-2)7-5-6-8-10/h10H,3-4,7-8H2,1-2H3","Sato, Y. et al. (2012); Conclusive Identification of the Oxybutynin-Hydrolyzing Enzyme in Human Liver; DRUGMETABOLISM ANDDISPOSITION 2012, 40, 902-906|MIZUSHIMA, H. et al. (2007); Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo; Xenobiotica, 2007, 37, 59-73|Abramov, Y. et al. (2004); Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review; Expert Opin. Pharmacother., 2004, 5, 2351-2359"
"BIOTID00100","(s)-oxybutynin","206530","XIQVNETUBQGFHX-JOCHJYFZSA-N","InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1","CYP3A4","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-desethyloxybutynin","133577","SNIBJKHIKIIGPR-HXUWFJFHSA-N","InChI=1S/C20H27NO3/c1-2-21-15-9-10-16-24-19(22)20(23,17-11-5-3-6-12-17)18-13-7-4-8-14-18/h3,5-6,11-12,18,21,23H,2,4,7-8,13-16H2,1H3/t20-/m1/s1","Sato, Y. et al. (2012); Conclusive Identification of the Oxybutynin-Hydrolyzing Enzyme in Human Liver; DRUGMETABOLISM ANDDISPOSITION 2012, 40, 902-906|MIZUSHIMA, H. et al. (2007); Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo; Xenobiotica, 2007, 37, 59-73|Abramov, Y. et al. (2004); Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review; Expert Opin. Pharmacother., 2004, 5, 2351-2359"
"BIOTID00101","(s)-propafenone","184820","JWHAUXFOSRPERK-SFHVURJKSA-N","InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3/t18-/m0/s1","CYP2D6","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","(S)-5-Hydroxypropafenone","40565857","LUTWDNUXHDYZRA-SFHVURJKSA-N","InChI=1S/C21H27NO4/c1-2-12-22-14-18(24)15-26-21-11-9-17(23)13-19(21)20(25)10-8-16-6-4-3-5-7-16/h3-7,9,11,13,18,22-24H,2,8,10,12,14-15H2,1H3/t18-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00102","(s)-propafenone","184820","JWHAUXFOSRPERK-SFHVURJKSA-N","InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3/t18-/m0/s1","CYP1A2; CYP3A4","N-dealkylation of acyclic secondary amine","Human Phase I","Human","(S)-N-Despropylpropafenone","40582745","HIGKMVIPYOFHBP-HNNXBMFYSA-N","InChI=1S/C18H21NO3/c19-12-15(20)13-22-18-9-5-4-8-16(18)17(21)11-10-14-6-2-1-3-7-14/h1-9,15,20H,10-13,19H2/t15-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00103","(s)-propafenone","184820","JWHAUXFOSRPERK-SFHVURJKSA-N","InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3/t18-/m0/s1","CYP2D6 (implied)","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","(S)-4'-Hydroxypropafenone","NULL","OKWVLRWZWPULGI-SFHVURJKSA-N","InChI=1S/C21H27NO4/c1-2-13-22-14-18(24)15-26-21-6-4-3-5-19(21)20(25)12-9-16-7-10-17(23)11-8-16/h3-8,10-11,18,22-24H,2,9,12-15H2,1H3/t18-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00104","(s)-tomoxetine","6093336","VHGCDTVCOLNTBX-KRWDZBQOSA-N","InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m0/s1","CYP2D6; CYP2A6; CYP2B6; CYP2C9; CYP2C19; CYP2E1; CYP3A4","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","4-Hydroxy-(s)-tomoxetine","9816910","PPXQPRLGNSJNJM-QGZVFWFLSA-N","InChI=1S/C17H21NO2/c1-13-12-15(19)8-9-16(13)20-17(10-11-18-2)14-6-4-3-5-7-14/h3-9,12,17-19H,10-11H2,1-2H3/t17-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00105","(s)-tomoxetine","6093336","VHGCDTVCOLNTBX-KRWDZBQOSA-N","InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m0/s1","CYP2D6; CYP2C19 (major)","N-dealkylation of acyclic secondary amine","Human Phase I","Human","N-Desmethyl-(s)-tomoxetine","9881925","FYSYNTKLUNOCQR-QGZVFWFLSA-N","InChI=1S/C17H21NO2/c1-18-12-11-17(14-7-3-2-4-8-14)20-16-10-6-5-9-15(16)13-19/h2-10,17-19H,11-13H2,1H3/t17-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Sauer, J-M. et al. (2005); Clinical Pharmacokinetics of Atomoxetine; Clinical Pharmacokinetics; Volume 44, Issue 6, pp 571Ã¢â‚¬â€œ590"
"BIOTID00106","(s)-tomoxetine","6093336","VHGCDTVCOLNTBX-KRWDZBQOSA-N","InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m0/s1","CYP2D6; CYP2B6; CYP2C19","Aliphatic hydroxylation of carbon alpha to secondary or tertiary alkyl-N","Human Phase I","Human","2-Hydroxy-(s)-tomoxetine","NULL","JQNRSAPXUBOGPP-QGZVFWFLSA-N","InChI=1S/C17H21NO2/c1-14-7-5-6-10-16(14)20-17(11-12-18-13-19)15-8-3-2-4-9-15/h2-10,17-19H,11-13H2,1H3/t17-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00107","(s)-venlafaxine","11846746","PNVNVHUZROJLTJ-MRXNPFEDSA-N","InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3/t16-/m1/s1","CYP2C19 (major); CYP3A4 (minor); CYP2C9 (minor)","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-Desmethylvenlafaxine","9860056","MKAFOJAJJMUXLW-OAHLLOKOSA-N","InChI=1S/C16H25NO2/c1-17-12-15(16(18)10-4-3-5-11-16)13-6-8-14(19-2)9-7-13/h6-9,15,17-18H,3-5,10-12H2,1-2H3/t15-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00108","(s)-venlafaxine","11846746","PNVNVHUZROJLTJ-MRXNPFEDSA-N","InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3/t16-/m1/s1","CYP2D6","O-aryl demethylation","Human Phase I","Human","O-Desmethylvenlafaxine","9816723","KYYIDSXMWOZKMP-OAHLLOKOSA-N","InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3/t15-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00109","[2-methyl-4-(o-tolylazo)phenyl]amine","NULL","PFRYFZZSECNQOL-WUKNDPDISA-N","InChI=1S/C14H15N3/c1-10-5-3-4-6-14(10)17-16-12-7-8-13(15)11(2)9-12/h3-9H,15H2,1-2H3/b17-16+","CYP1A2","AROMATIC HYDROXYLATION","Human Phase I","Human","4'-hydroxy-o-aminoazotoJuene","NULL","ZPIIWWHBQDZLEA-WUKNDPDISA-N","InChI=1S/C14H15N3O/c1-9-7-11(3-5-13(9)15)16-17-14-6-4-12(18)8-10(14)2/h3-8,18H,15H2,1-2H3/b17-16+","PMID:6756667"
"BIOTID00110","[2-methyl-4-(o-tolylazo)phenyl]amine","NULL","PFRYFZZSECNQOL-WUKNDPDISA-N","InChI=1S/C14H15N3/c1-10-5-3-4-6-14(10)17-16-12-7-8-13(15)11(2)9-12/h3-9H,15H2,1-2H3/b17-16+","CYP1A2","ALIPHATIC HYDROXYLATION","Human Phase I","Human","2'-hydroxymethyl-3-raethyl-4-aminoazoberizene","NULL","IMGUGWPUMUYXKT-WUKNDPDISA-N","InChI=1S/C14H15N3O/c1-10-8-12(6-7-13(10)15)16-17-14-5-3-2-4-11(14)9-18/h2-8,18H,9,15H2,1H3/b17-16+","PMID:6756667"
"BIOTID00111","[2-methyl-4-(o-tolylazo)phenyl]amine","NULL","PFRYFZZSECNQOL-WUKNDPDISA-N","InChI=1S/C14H15N3/c1-10-5-3-4-6-14(10)17-16-12-7-8-13(15)11(2)9-12/h3-9H,15H2,1-2H3/b17-16+","CYP1A2","N-HYDROXYLATION","Human Phase I","Human","N-hydroxy-oaminoazotohiene","NULL","GBPILLZVLVJCGK-FOCLMDBBSA-N","InChI=1S/C14H15N3O/c1-10-5-3-4-6-13(10)16-15-12-7-8-14(17-18)11(2)9-12/h3-9,17-18H,1-2H3/b16-15+","PMID:6756667"
"BIOTID00112","1_4_cineole","10106","RFFOTVCVTJUTAD-AOOOYVTPSA-N","InChI=1S/C10H18O/c1-8(2)10-6-4-9(3,11-10)5-7-10/h8H,4-7H2,1-3H3","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","NULL","113623","IFQZADDJTDGGCP-UHFFFAOYSA-N","InChI=1S/C10H18O2/c1-7(2)10-5-4-9(3,12-10)8(11)6-10/h7-8,11H,4-6H2,1-3H3","PMID:11695850"
"BIOTID00113","1_8_cineole","2758","WEEGYLXZBRQIMU-WAAGHKOSSA-N","InChI=1S/C10H18O/c1-9(2)8-4-6-10(3,11-9)7-5-8/h8H,4-7H2,1-3H3","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","2alpha-hydroxy-1,8-cineole","529885","YVCUGZBVCHODNB-UHFFFAOYSA-N","InChI=1S/C10H18O2/c1-9(2)7-4-5-10(3,12-9)8(11)6-7/h7-8,11H,4-6H2,1-3H3","Duisken, M. et al. (2005); Metabolism of 1,8-cineole by human cytochrome P450 enzymes: identification of a new hydroxylated metabolite; / Biochimica et Biophysica Acta 1722; 304Ã¢â‚¬â€œ31."
"BIOTID00114","1_8_cineole","2758","WEEGYLXZBRQIMU-WAAGHKOSSA-N","InChI=1S/C10H18O/c1-9(2)8-4-6-10(3,11-9)7-5-8/h8H,4-7H2,1-3H3","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","3alpha-hydroxy-1,8-cineole","439906","WHIKIYRWRMRQNK-UHFFFAOYSA-N","InChI=1S/C10H18O2/c1-9(2)7-4-5-10(3,12-9)6-8(7)11/h7-8,11H,4-6H2,1-3H3","Duisken, M. et al. (2005); Metabolism of 1,8-cineole by human cytochrome P450 enzymes: identification of a new hydroxylated metabolite; / Biochimica et Biophysica Acta 1722; 304Ã¢â‚¬â€œ31."
"BIOTID00115","1-(3-chlorophenyl)piperazine","1355","VHFVKMTVMIZMIK-UHFFFAOYSA-N","InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2","CYP2D6","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","2‐chloro‐4‐(piperazin‐1‐yl)phenol","10420741","FXECOYYRPDGOQB-UHFFFAOYSA-N","InChI=1S/C10H13ClN2O/c11-9-7-8(1-2-10(9)14)13-5-3-12-4-6-13/h1-2,7,12,14H,3-6H2","J. Bolleddula et al.; Drug Metab Rev, 2014; 46(3): 379Ã¢â‚¬â€œ419"
"BIOTID00116","1-(4-methoxyphenyl)piperazine","269722","MRDGZSKYFPGAKP-UHFFFAOYSA-N","InChI=1S/C11H16N2O/c1-14-11-4-2-10(3-5-11)13-8-6-12-7-9-13/h2-5,12H,6-9H2,1H3","CYP2D6","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","1-(4-hydroxyphenyl)piperazine","92467","GPEOAEVZTOQXLG-UHFFFAOYSA-N","InChI=1S/C10H14N2O/c13-10-3-1-9(2-4-10)12-7-5-11-6-8-12/h1-4,11,13H,5-8H2","STAACK, R.F. et al. (2004); In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step; xenobiotica, 2004, 34, 179Ã¢â‚¬â€œ192"
"BIOTID00117","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1388","PLRACCBDVIHHLZ-UHFFFAOYSA-N","InChI=1S/C12H15N/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11/h2-7H,8-10H2,1H3","CYP2D6","N_DEHYDROGENATION_OF_ALICYCLIC_TERTIARY_AMINES_PATTERN1","Human Phase I","Human","1-methyl-4-phenylpyridin-1-ium","39484","FMGYKKMPNATWHP-UHFFFAOYSA-N","InChI=1S/C12H12N/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11/h2-10H,1H3/q+1","Bajpai, P. et al. (2013); Metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine by Mitochondrion-targeted Cytochrome P450 2D6 IMPLICATIONS IN PARKINSON DISEASE; THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288, 4436Ã¢â‚¬â€œ4451|Coleman, T. et al. (1996); 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease; Journal of Pharmacology and Experimental Therapeutics, 1996, 277, 685-690"
"BIOTID00118","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1388","PLRACCBDVIHHLZ-UHFFFAOYSA-N","InChI=1S/C12H15N/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11/h2-7H,8-10H2,1H3","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","pOH-MPTP","95056","GIGCUVKCMPXMAZ-UHFFFAOYSA-N","InChI=1S/C12H15NO/c1-13-8-6-11(7-9-13)10-2-4-12(14)5-3-10/h2-6,14H,7-9H2,1H3","Bajpai, P. et al. (2013); Metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine by Mitochondrion-targeted Cytochrome P450 2D6 IMPLICATIONS IN PARKINSON DISEASE; THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288, 4436Ã¢â‚¬â€œ4451|Coleman, T. et al. (1996); 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease; Journal of Pharmacology and Experimental Therapeutics, 1996, 277, 685-690"
"BIOTID00119","1-nitropyrene","21694","ALRLPDGCPYIVHP-UHFFFAOYSA-N","InChI=1S/C16H9NO2/c18-17(19)14-9-7-12-5-4-10-2-1-3-11-6-8-13(14)16(12)15(10)11/h1-9H","CYP3A4","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","3-OH-1-nitropyrene","104936","BOQCPFGCIYLAGN-UHFFFAOYSA-N","InChI=1S/C16H9NO3/c18-14-8-13(17(19)20)11-6-4-9-2-1-3-10-5-7-12(14)16(11)15(9)10/h1-8,18H","PMID:11525925"
"BIOTID00120","1-nitropyrene","21694","ALRLPDGCPYIVHP-UHFFFAOYSA-N","InChI=1S/C16H9NO2/c18-17(19)14-9-7-12-5-4-10-2-1-3-11-6-8-13(14)16(12)15(10)11/h1-9H","CYP3A4","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","trans-4,5- Dihydrodiol- 1-nitropyrene","107705","HSGLBAJOUBFGPZ-UHFFFAOYSA-N","InChI=1S/C16H9NO3/c18-17(19)12-7-6-11-14-9(12)5-4-8-2-1-3-10(13(8)14)15-16(11)20-15/h1-7,15-16H","PMID:11525925"
"BIOTID00121","1-nitropyrene","21694","ALRLPDGCPYIVHP-UHFFFAOYSA-N","InChI=1S/C16H9NO2/c18-17(19)14-9-7-12-5-4-10-2-1-3-11-6-8-13(14)16(12)15(10)11/h1-9H","CYP3A4; CYP1A2","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","6-OH-1- nitropyrene","104988","MAVZUIFIVMZYMX-UHFFFAOYSA-N","InChI=1S/C16H9NO3/c18-14-8-4-10-1-5-11-13(17(19)20)7-3-9-2-6-12(14)16(10)15(9)11/h1-8,18H","PMID:11525925"
"BIOTID00122","1-nitropyrene","21694","ALRLPDGCPYIVHP-UHFFFAOYSA-N","InChI=1S/C16H9NO2/c18-17(19)14-9-7-12-5-4-10-2-1-3-11-6-8-13(14)16(12)15(10)11/h1-9H","CYP1A2","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","8-OH-1-nitropyrene","105022","RHXGKMNLLUKFLG-UHFFFAOYSA-N","InChI=1S/C16H9NO3/c18-14-8-4-10-2-1-9-3-7-13(17(19)20)11-5-6-12(14)16(10)15(9)11/h1-8,18H","PMID:11525925"
"BIOTID00123","1-propanol, 3-[3-(1-piperidinylmethyl)phenoxy]-","10444765","JACPUZOKPSTMTK-UHFFFAOYSA-N","InChI=1S/C15H23NO2/c17-10-5-11-18-15-7-4-6-14(12-15)13-16-8-2-1-3-9-16/h4,6-7,12,17H,1-3,5,8-11,13H2","CYP2D6","O-dealkylation","Human Phase I","Human","NULL","826974","ORGBERFQYFWYGX-UHFFFAOYSA-N","InChI=1S/C12H17NO/c14-12-6-4-5-11(9-12)10-13-7-2-1-3-8-13/h4-6,9,14H,1-3,7-8,10H2","PMID:11556126"
"BIOTID00124","1-propanol, 3-[3-(1-piperidinylmethyl)phenoxy]-","10444765","JACPUZOKPSTMTK-UHFFFAOYSA-N","InChI=1S/C15H23NO2/c17-10-5-11-18-15-7-4-6-14(12-15)13-16-8-2-1-3-9-16/h4,6-7,12,17H,1-3,5,8-11,13H2","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","JOBXIACVHWADOM-UHFFFAOYSA-N","InChI=1S/C15H23NO3/c17-9-4-10-19-14-6-3-5-13(11-14)12-16-8-2-1-7-15(16)18/h3,5-6,11,15,17-18H,1-2,4,7-10,12H2","PMID:11556126"
"BIOTID00125","1,2-dichlorobenzene","7239","RFFLAFLAYFXFSW-UHFFFAOYSA-N","InChI=1S/C6H4Cl2/c7-5-3-1-2-4-6(5)8/h1-4H","CYP1A1; CYP1A2; CYP2E1 (major); CYP3A4","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","2,3-dichlorophenol","11334","UMPSXRYVXUPCOS-UHFFFAOYSA-N","InChI=1S/C6H4Cl2O/c7-4-2-1-3-5(9)6(4)8/h1-3,9H","bogaards, JJP et al. (1995); Human Cytochrome P450 Enzyme Selectivities in the Oxidation of Chlorinated Benzenes; Toxicol Appl Pharmacol. 1995 May;132(1):44-52; PMID:7747284|Nedelcheva, V. et al. (1998); Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse, and human liver microsomes; Chemico-Biological Interactions 115 (1998) 53Ã¢â‚¬â€œ70"
"BIOTID00126","1,2-dichlorobenzene","7239","RFFLAFLAYFXFSW-UHFFFAOYSA-N","InChI=1S/C6H4Cl2/c7-5-3-1-2-4-6(5)8/h1-4H","CYP1A1; CYP1A2; CYP2E1 (major); CYP3A4","Hydroxylation of aromatic carbon para to halide group","Human Phase I","Human","3,4-dichlorophenol","7258","WDNBURPWRNALGP-UHFFFAOYSA-N","InChI=1S/C6H4Cl2O/c7-5-2-1-4(9)3-6(5)8/h1-3,9H","bogaards, JJP et al. (1995); Human Cytochrome P450 Enzyme Selectivities in the Oxidation of Chlorinated Benzenes; Toxicol Appl Pharmacol. 1995 May;132(1):44-52; PMID:7747284|Nedelcheva, V. et al. (1998); Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse, and human liver microsomes; Chemico-Biological Interactions 115 (1998) 53Ã¢â‚¬â€œ70"
"BIOTID00127","1,2,4-trichlorobenzene","13","PBKONEOXTCPAFI-UHFFFAOYSA-N","InChI=1S/C6H3Cl3/c7-4-1-2-5(8)6(9)3-4/h1-3H","CYP2E1 (major)","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","2,3,5-trichlorophenol","13619","WWGQHTJIFOQAOC-UHFFFAOYSA-N","InChI=1S/C6H3Cl3O/c7-3-1-4(8)6(9)5(10)2-3/h1-2,10H","bogaards, JJP et al. (1995); Human Cytochrome P450 Enzyme Selectivities in the Oxidation of Chlorinated Benzenes; Toxicol Appl Pharmacol. 1995 May;132(1):44-52; PMID:7747284|Nedelcheva, V. et al. (1998); Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse, and human liver microsomes; Chemico-Biological Interactions 115 (1998) 53Ã¢â‚¬â€œ70"
"BIOTID00128","1,2,4-trichlorobenzene","13","PBKONEOXTCPAFI-UHFFFAOYSA-N","InChI=1S/C6H3Cl3/c7-4-1-2-5(8)6(9)3-4/h1-3H","CYP3A4 (major)","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","2,3,6-trichlorophenol","13618","XGCHAIDDPMFRLJ-UHFFFAOYSA-N","InChI=1S/C6H3Cl3O/c7-3-1-2-4(8)6(10)5(3)9/h1-2,10H","bogaards, JJP et al. (1995); Human Cytochrome P450 Enzyme Selectivities in the Oxidation of Chlorinated Benzenes; Toxicol Appl Pharmacol. 1995 May;132(1):44-52; PMID:7747284|Nedelcheva, V. et al. (1998); Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse, and human liver microsomes; Chemico-Biological Interactions 115 (1998) 53Ã¢â‚¬â€œ70"
"BIOTID00129","1,2,4-trichlorobenzene","13","PBKONEOXTCPAFI-UHFFFAOYSA-N","InChI=1S/C6H3Cl3/c7-4-1-2-5(8)6(9)3-4/h1-3H","CYP2E1 (major); CYP1A1","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","2,4,5-trichlorophenol","7271","LHJGJYXLEPZJPM-UHFFFAOYSA-N","InChI=1S/C6H3Cl3O/c7-3-1-5(9)6(10)2-4(3)8/h1-2,10H","bogaards, JJP et al. (1995); Human Cytochrome P450 Enzyme Selectivities in the Oxidation of Chlorinated Benzenes; Toxicol Appl Pharmacol. 1995 May;132(1):44-52; PMID:7747284|Nedelcheva, V. et al. (1998); Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse, and human liver microsomes; Chemico-Biological Interactions 115 (1998) 53Ã¢â‚¬â€œ70"
"BIOTID00130","1'-nitrosonornicotine","12613538","XKABJYQDMJTNGQ-VIFPVBQESA-N","InChI=1S/C9H11N3O/c13-11-12-6-2-4-9(12)8-3-1-5-10-7-8/h1,3,5,7,9H,2,4,6H2/t9-/m0/s1","CYP2A6;CYP2D6;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","188075","OPIMKKJZZFWGRJ-UHFFFAOYSA-N","InChI=1S/C9H11N3O2/c13-9-4-3-8(12(9)11-14)7-2-1-5-10-6-7/h1-2,5-6,8-9,13H,3-4H2","PMID:9276639"
"BIOTID00131","1'-nitrosonornicotine","12613538","XKABJYQDMJTNGQ-VIFPVBQESA-N","InChI=1S/C9H11N3O/c13-11-12-6-2-4-9(12)8-3-1-5-10-7-8/h1,3,5,7,9H,2,4,6H2/t9-/m0/s1","CYP2A6;CYP2D6;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","3017881","XSFLWWFLOHDYKM-UHFFFAOYSA-N","InChI=1S/C9H11N3O2/c13-9(4-2-6-12(9)11-14)8-3-1-5-10-7-8/h1,3,5,7,13H,2,4,6H2","PMID:9276639"
"BIOTID00132","11_oxo_delta8_tetrahydrocannabinol","NULL","BGIBNWZALWRTHR-IRXDYDNUSA-N","InChI=1S/C21H28O3/c1-4-5-6-7-14-11-18(23)20-16-10-15(13-22)8-9-17(16)21(2,3)24-19(20)12-14/h8,11-13,16-17,23H,4-7,9-10H2,1-3H3/t16-,17-/m0/s1","CYP2C8;CYP2C9;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","1411","OGXXAQFMAFTSRU-UHFFFAOYSA-N","InChI=1S/C21H28O4/c1-4-5-6-7-13-10-17(22)19-15-12-14(20(23)24)8-9-16(15)21(2,3)25-18(19)11-13/h8,10-11,15-16,22H,4-7,9,12H2,1-3H3,(H,23,24)","PMID:15618706"
"BIOTID00133","2-(1-piperazinyl)pyrimidine","88747","MRBFGEHILMYPTF-UHFFFAOYSA-N","InChI=1S/C8H12N4/c1-2-10-8(11-3-1)12-6-4-9-5-7-12/h1-3,9H,4-7H2","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","34180809","QLKRAKYZQCJDSA-UHFFFAOYSA-N","InChI=1S/C8H12N4O/c13-7-5-10-8(11-6-7)12-3-1-9-2-4-12/h5-6,9,13H,1-4H2","PMID:15507542"
"BIOTID00134","2-acetamidofluorene","5897","CZIHNRWJTSTCEX-UHFFFAOYSA-N","InChI=1S/C15H13NO/c1-10(17)16-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9H,8H2,1H3,(H,16,17)","CYP1A2","N-hydroxylation of secondary arylamide","Human Phase I","Human","N-Hydroxy-2-acetamidofluorene","5896","SOKUIEGXJHVFDV-UHFFFAOYSA-N","InChI=1S/C15H13NO2/c1-10(17)16(18)13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9,18H,8H2,1H3","McManus, M. E. et al (1990), Metablism of 2-acetylaminofluorene and Benzo(a)pyrene activation of food-derived heterocyclic amine mutagens by human cytochromes P-450; Cancer research, 50 (11); 3367-3376, PMID:2334931"
"BIOTID00135","2-acetamidofluorene","5897","CZIHNRWJTSTCEX-UHFFFAOYSA-N","InChI=1S/C15H13NO/c1-10(17)16-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9H,8H2,1H3,(H,16,17)","CYP1A2","Aromatic Hydroxylation","Human Phase I","Human","1-OH-AFF","5896","LAMHNIXDQRUHBE-UHFFFAOYSA-N","InChI=1S/C15H13NO2/c1-9(17)16-12-5-6-13-11(8-12)7-10-3-2-4-14(18)15(10)13/h2-6,8,18H,7H2,1H3,(H,16,17)","McManus, M. E. et al (1990), Metablism of 2-acetylaminofluorene and Benzo(a)pyrene activation of food-derived heterocyclic amine mutagens by human cytochromes P-450; Cancer research, 50 (11); 3367-3376, PMID:2334931"
"BIOTID00136","2-acetamidofluorene","5897","CZIHNRWJTSTCEX-UHFFFAOYSA-N","InChI=1S/C15H13NO/c1-10(17)16-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9H,8H2,1H3,(H,16,17)","CYP1A2","Aromatic Hydroxylation","Human Phase I","Human","5-OH-AFF","5896","YWJAUYPOERJZNB-UHFFFAOYSA-N","InChI=1S/C15H15NO2/c1-10(17)16-12-5-6-13-11(8-12)9-15(18)7-3-2-4-14(13)15/h2-6,8,18H,7,9H2,1H3,(H,16,17)","McManus, M. E. et al (1990), Metablism of 2-acetylaminofluorene and Benzo(a)pyrene activation of food-derived heterocyclic amine mutagens by human cytochromes P-450; Cancer research, 50 (11); 3367-3376, PMID:2334931"
"BIOTID00137","2-acetamidofluorene","5897","CZIHNRWJTSTCEX-UHFFFAOYSA-N","InChI=1S/C15H13NO/c1-10(17)16-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9H,8H2,1H3,(H,16,17)","CYP1A2","Aromatic Hydroxylation","Human Phase I","Human","N-Hydroxy-2-acetamidofluorene","5896","SOKUIEGXJHVFDV-UHFFFAOYSA-N","InChI=1S/C15H13NO2/c1-10(17)16(18)13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9,18H,8H2,1H3","McManus, M. E. et al (1990), Metablism of 2-acetylaminofluorene and Benzo(a)pyrene activation of food-derived heterocyclic amine mutagens by human cytochromes P-450; Cancer research, 50 (11); 3367-3376, PMID:2334931"
"BIOTID00138","2-acetylbenzothiophene","89805","SGSGCQGCVKWRNM-UHFFFAOYSA-N","InChI=1S/C10H8OS/c1-7(11)10-6-8-4-2-3-5-9(8)12-10/h2-6H,1H3","CYP1A2;CYP2B6;CYP2E1;CYP3A4","S-Oxidation","Human Phase I","Human","NULL","NULL","IWTQTBVQUABYQV-UHFFFAOYSA-N","InChI=1S/C10H18O2S/c1-7(11)10-6-8-4-2-3-5-9(8)13(10)12/h7-11H,2-6H2,1H3","PMID:14967000"
"BIOTID00139","2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide","489128","KNGXENHWYNLKBU-UHFFFAOYSA-N","InChI=1S/C14H14ClN3O/c15-12-11(14(16)19)10-5-1-2-7-18(10)13(12)9-4-3-6-17-8-9/h3-4,6,8H,1-2,5,7H2,(H2,16,19)","CYP1A2;CYP2C8;CYP2C9;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","rac-RPR 127025","9817505","YHMQXWQYGOPVLE-UHFFFAOYSA-N","InChI=1S/C14H14ClN3O2/c15-11-10(14(16)20)13-9(19)4-2-6-18(13)12(11)8-3-1-5-17-7-8/h1,3,5,7,9,19H,2,4,6H2,(H2,16,20)","PMID:11453890"
"BIOTID00140","2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide","489128","KNGXENHWYNLKBU-UHFFFAOYSA-N","InChI=1S/C14H14ClN3O/c15-12-11(14(16)19)10-5-1-2-7-18(10)13(12)9-4-3-6-17-8-9/h3-4,6,8H,1-2,5,7H2,(H2,16,19)","CYP2C8","N-Oxidation","Human Phase I","Human","RPR 122701","70240244","BYPUGCWAOMUKTI-UHFFFAOYSA-N","InChI=1S/C14H14ClN3O2/c15-12-11(14(16)19)10-5-1-2-7-18(10)13(12)9-4-3-6-17(20)8-9/h3-4,6,8H,1-2,5,7H2,(H2,16,19)","PMID:11453890"
"BIOTID00141","2-naphthylamine","7057","JBIJLHTVPXGSAM-UHFFFAOYSA-N","InChI=1S/C10H9N/c11-10-6-5-8-3-1-2-4-9(8)7-10/h1-7H,11H2","CYP1A2","N-hydroxylation of primary arylamine","Human Phase I","Human","N-Hydroxy-2-naphthalenamine","69176","JGXYZXHJZJYHPW-UHFFFAOYSA-N","InChI=1S/C10H9NO/c12-11-10-6-5-8-3-1-2-4-9(8)7-10/h1-7,11-12H","Rendic, S., Di Carlo, F. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors; Drug Metabolism Reviews, 29:1-2, 413-580; DOI:10.3109/03602539709037591; PMID:9187528"
"BIOTID00142","2-nitropyrene","13090","MAZCGYFIOOIVHE-UHFFFAOYSA-N","InChI=1S/C16H9NO2/c18-17(19)14-8-12-6-4-10-2-1-3-11-5-7-13(9-14)16(12)15(10)11/h1-9H","CYP1A1; CYP1A2","REDUCTION_OF_NITRO_TO_AMINE","Human Phase I","Human","2-aminopyrene","107762","MFUFBSLEAGDECJ-UHFFFAOYSA-N","InChI=1S/C16H11N/c17-14-8-12-6-4-10-2-1-3-11-5-7-13(9-14)16(12)15(10)11/h1-9H,17H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID00143","2-oxoquazepam","93250","YFSXBSRGIRSXAD-UHFFFAOYSA-N","InChI=1S/C17H11ClF4N2O/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2","CYP3A4; CYP2C9","3-Hydroxylation of 5-aryl-1,4-benzodiazepine","Human Phase I","Human","3-Hydroxy-2-oxoquazepam","135860","UUODKRKSEPDUBO-UHFFFAOYSA-N","InChI=1S/C17H11ClF4N2O2/c18-9-5-6-13-11(7-9)14(10-3-1-2-4-12(10)19)23-15(25)16(26)24(13)8-17(20,21)22/h1-7,15,25H,8H2","Miura, M and Ohkubo, T (2004); In vitrometabolism of quazepam in human liver and intestine and assessment of drug interactions; Xenobiotica; 34(11-12):1001-11; PMID:15801544; DOI:10.1080/02772240400015214"
"BIOTID00144","2-oxoquazepam","93250","YFSXBSRGIRSXAD-UHFFFAOYSA-N","InChI=1S/C17H11ClF4N2O/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2","CYP3A4; CYP2C9","N-dealkylation of tertiary carboxamide","Human Phase I","Human","N-Desalkyl-2-oxoquazepam","4540","UVCOILFBWYKHHB-UHFFFAOYSA-N","InChI=1S/C15H10ClFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)","Miura, M and Ohkubo, T (2004); In vitrometabolism of quazepam in human liver and intestine and assessment of drug interactions; Xenobiotica; 34(11-12):1001-11; PMID:15801544; DOI:10.1080/02772240400015214"
"BIOTID00145","2-phenylphenol","7017","LLEMOWNGBBNAJR-UHFFFAOYSA-N","InChI=1S/C12H10O/c13-12-9-5-4-8-11(12)10-6-2-1-3-7-10/h1-9,13H","CYP1A2; CYP2B6; CYP2D6; CYP2E1; CYP3A4","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","2,5-dihydroxybiphenyl","14116","XCZKKZXWDBOGPA-UHFFFAOYSA-N","InChI=1S/C12H10O2/c13-10-6-7-12(14)11(8-10)9-4-2-1-3-5-9/h1-8,13-14H","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00146","2-propylquinoline","74166","IZXJPGLOYYDHRM-UHFFFAOYSA-N","InChI=1S/C12H13N/c1-2-5-11-9-8-10-6-3-4-7-12(10)13-11/h3-4,6-9H,2,5H2,1H3","CYP2C9;CYP2E1;CYP3A4","Epoxidation","Human Phase I","Human","NULL","NULL","DZTXKZYGPUGPOX-UHFFFAOYSA-N","InChI=1S/C12H13NO/c1-2-3-8-4-5-9-10(13-8)6-7-11-12(9)14-11/h4-7,11-12H,2-3H2,1H3","PMID:12745870"
"BIOTID00147","2-propylquinoline","74166","IZXJPGLOYYDHRM-UHFFFAOYSA-N","InChI=1S/C12H13N/c1-2-5-11-9-8-10-6-3-4-7-12(10)13-11/h3-4,6-9H,2,5H2,1H3","CYP2C9;CYP2E1;CYP3A4","Epoxidation","Human Phase I","Human","NULL","NULL","BDFVUGCETZCMBD-UHFFFAOYSA-N","InChI=1S/C12H13NO/c1-2-3-9-6-4-8-5-7-10-12(14-10)11(8)13-9/h4-7,10,12H,2-3H2,1H3","PMID:12745870"
"BIOTID00148","2-propylquinoline","74166","IZXJPGLOYYDHRM-UHFFFAOYSA-N","InChI=1S/C12H13N/c1-2-5-11-9-8-10-6-3-4-7-12(10)13-11/h3-4,6-9H,2,5H2,1H3","CYP2A6;CYP2C9;CYP2C19;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","21806134","SZMLTFOLQWEQFJ-UHFFFAOYSA-N","InChI=1S/C12H13NO/c14-9-3-5-11-8-7-10-4-1-2-6-12(10)13-11/h1-2,4,6-8,14H,3,5,9H2","PMID:12745870"
"BIOTID00149","2-propylquinoline","74166","IZXJPGLOYYDHRM-UHFFFAOYSA-N","InChI=1S/C12H13N/c1-2-5-11-9-8-10-6-3-4-7-12(10)13-11/h3-4,6-9H,2,5H2,1H3","CYP2A6;CYP2C9;CYP2C19;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","19432906","NZUSIRTZUGQDDG-UHFFFAOYSA-N","InChI=1S/C12H13NO/c1-2-12(14)11-8-7-9-5-3-4-6-10(9)13-11/h3-8,12,14H,2H2,1H3","PMID:12745870"
"BIOTID00150","2,2-dichloro-1,1,1-trifluoroethane","9385","OHMHBGPWCHTMQE-UHFFFAOYSA-N","InChI=1S/C2HCl2F3/c3-1(4)2(5,6)7/h1H","CYP2E1","Oxidation of halotrifluoroethane","Human Phase I","Human","Trifluoroacetyl chloride","65564","JVTSHOJDBRTPHD-UHFFFAOYSA-N","InChI=1S/C2HF3O/c3-2(4,5)1-6/h1H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00151","2,2',4,5,5'-pentachlorobiphenyl","37807","LAHWLEDBADHJGA-UHFFFAOYSA-N","InChI=1S/C12H5Cl5/c13-6-1-2-9(14)7(3-6)8-4-11(16)12(17)5-10(8)15/h1-5H","CYP2A6; CYP3A4; CYP2C18","Hydroxylation of aromatic carbon meta to halide group","Human Phase I","Human","2,2',4',5,5'-pentachloro-[1,1'-biphenyl]-4-ol","6453821","AVHHNFHLLZCWFH-UHFFFAOYSA-N","InChI=1S/C12H5Cl5O/c13-7-3-10(16)9(15)1-5(7)6-2-11(17)12(18)4-8(6)14/h1-4,18H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00152","2,2',4,5,5'-pentachlorobiphenyl","37807","LAHWLEDBADHJGA-UHFFFAOYSA-N","InChI=1S/C12H5Cl5/c13-6-1-2-9(14)7(3-6)8-4-11(16)12(17)5-10(8)15/h1-5H","CYP2A6; CYP3A4; CYP2C18","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","2,2',4',5,5'-pentachloro-[1,1'-biphenyl]-4-ol","6453821","AVHHNFHLLZCWFH-UHFFFAOYSA-N","InChI=1S/C12H5Cl5O/c13-7-3-10(16)9(15)1-5(7)6-2-11(17)12(18)4-8(6)14/h1-4,18H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00153","2,6-dichlorobenzonitrile","3031","YOYAIZYFCNQIRF-UHFFFAOYSA-N","InChI=1S/C7H3Cl2N/c8-6-2-1-3-7(9)5(6)4-10/h1-3H","CYP2A6","Epoxidation","Human Phase I","Human","NULL","NULL","DJGJOWHCUWYCBV-UHFFFAOYSA-N","InChI=1S/C7H3Cl2NO/c8-4-1-5-7(11-5)6(9)3(4)2-10/h1,5,7H","PMID:8649351"
"BIOTID00154","2,6-dichlorobenzonitrile","3031","YOYAIZYFCNQIRF-UHFFFAOYSA-N","InChI=1S/C7H3Cl2N/c8-6-2-1-3-7(9)5(6)4-10/h1-3H","CYP2A6","Epoxidation","Human Phase I","Human","NULL","NULL","IFPXJNRREXKNOF-UHFFFAOYSA-N","InChI=1S/C7H3Cl2NO/c8-5-1-2-6-7(9,11-6)4(5)3-10/h1-2,4H","PMID:8649351"
"BIOTID00155","2'-methoxyacetophenone","68481","DWPLEOPKBWNPQV-UHFFFAOYSA-N","InChI=1S/C9H10O2/c1-7(10)8-5-3-4-6-9(8)11-2/h3-6H,1-2H3","CYP2A6","O-Demethylation","Human Phase I","Human","2'-Hydroxyacetophenone","8375","JECYUBVRTQDVAT-UHFFFAOYSA-N","InChI=1S/C8H8O2/c1-6(9)7-4-2-3-5-8(7)10/h2-5,10H,1H3","PMID:11016631"
"BIOTID00156","2h-1-benzopyran-2-one, 4-(chloromethyl)-7-ethoxy-","71339287","RWMRBNNWQLUEFX-UHFFFAOYSA-N","InChI=1S/C12H11ClO3/c1-2-15-9-3-4-10-8(7-13)5-12(14)16-11(10)6-9/h3-6H,2,7H2,1H3","CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C19;CYP2D6;CYP2E1;CYP3A4","O-Deethylation","Human Phase I","Human","4-(Chloromethyl)-7-hydroxychromen-2-one","5398846","TXSLBPGPBNGHRW-UHFFFAOYSA-N","InChI=1S/C10H7ClO3/c11-5-6-3-10(13)14-9-4-7(12)1-2-8(6)9/h1-4,12H,5H2","PMID:9732386"
"BIOTID00157","2h-1-benzopyran-2-one, 7-(pentyloxy)-","23274496","AUCNGVTWAHBDRJ-UHFFFAOYSA-N","InChI=1S/C14H16O3/c1-2-3-4-9-16-12-7-5-11-6-8-14(15)17-13(11)10-12/h5-8,10H,2-4,9H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","PDIHZXAOHSNFDO-UHFFFAOYSA-N","InChI=1S/C14H16O4/c1-2-11(15)7-8-17-12-5-3-10-4-6-14(16)18-13(10)9-12/h3-6,9,11,15H,2,7-8H2,1H3","PMID:10620357"
"BIOTID00158","2h-1-benzopyran-2-one, 7-(pentyloxy)-","23274496","AUCNGVTWAHBDRJ-UHFFFAOYSA-N","InChI=1S/C14H16O3/c1-2-3-4-9-16-12-7-5-11-6-8-14(15)17-13(11)10-12/h5-8,10H,2-4,9H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","YFNQBQOIGGOKIQ-UHFFFAOYSA-N","InChI=1S/C14H16O4/c1-10(15)3-2-8-17-12-6-4-11-5-7-14(16)18-13(11)9-12/h4-7,9-10,15H,2-3,8H2,1H3","PMID:10620357"
"BIOTID00159","2h-1-benzopyran-2-one, 7-(pentyloxy)-","23274496","AUCNGVTWAHBDRJ-UHFFFAOYSA-N","InChI=1S/C14H16O3/c1-2-3-4-9-16-12-7-5-11-6-8-14(15)17-13(11)10-12/h5-8,10H,2-4,9H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","AMPSKTOYFFQMLR-UHFFFAOYSA-N","InChI=1S/C14H16O4/c1-2-3-4-13(15)17-11-7-5-10-6-8-14(16)18-12(10)9-11/h5-9,13,15H,2-4H2,1H3","PMID:10620357"
"BIOTID00160","3-cyano-7-ethoxycoumarin","164045","YAFGHMIAFYQSCF-UHFFFAOYSA-N","InChI=1S/C12H9NO3/c1-2-15-10-4-3-8-5-9(7-13)12(14)16-11(8)6-10/h3-6H,2H2,1H3","CYP1A2;CYP2A6;CYP2B6;CYP2C9;CYP2C19,CYP2D6;CYP2E1","O-Demethylation","Human Phase I","Human","3-Cyano-7-hydroxycoumarin","5393173","IJQYTHQDUDCJEQ-UHFFFAOYSA-N","InChI=1S/C10H5NO3/c11-5-7-3-6-1-2-8(12)4-9(6)14-10(7)13/h1-4,12H","PMID:15205384;PMID:9732386;PMID:14689466"
"BIOTID00161","3-cyano-7-methoxycoumarin","688917","GGAFPIBJPYCFGR-UHFFFAOYSA-N","InChI=1S/C11H7NO3/c1-14-9-3-2-7-4-8(6-12)11(13)15-10(7)5-9/h2-5H,1H3","CYP1A2;CYP2B6;CYP2C19;CYP2E1","O-Demethylation","Human Phase I","Human","3-Cyano-7-hydroxycoumarin","5393173","IJQYTHQDUDCJEQ-UHFFFAOYSA-N","InChI=1S/C10H5NO3/c11-5-7-3-6-1-2-8(12)4-9(6)14-10(7)13/h1-4,12H","PMID:12065444"
"BIOTID00162","3-methylindole","6736","ZFRKQXVRDFCRJG-UHFFFAOYSA-N","InChI=1S/C9H9N/c1-7-6-10-9-5-3-2-4-8(7)9/h2-6,10H,1H3","CYP2F1","Terminal desaturation","Human Phase I","Human","3-methyleneindolenine","NULL","BCNUXXXHEIUHJB-UHFFFAOYSA-O","InChI=1S/C9H7N/c1-7-6-10-9-5-3-2-4-8(7)9/h2-6H,1H2/p+1","Kalgutkar, A.S. et al. (2002); On the Diversity of Oxidative Bioactivation Reactions on Nitrogen-Containing Xenobiotics; Current Drug Metabolism, 3, 379-424; PMID:12093357"
"BIOTID00163","3-methylindole","6736","ZFRKQXVRDFCRJG-UHFFFAOYSA-N","InChI=1S/C9H9N/c1-7-6-10-9-5-3-2-4-8(7)9/h2-6,10H,1H3","CYP2F1; CYP2A6; CYP3A4; CYP2C8","PYRROLE_EPOXIDATION","Human Phase I","Human","3-methylindole-2,3-epoxide","18427220","WHTZCVZCHNDLHB-UHFFFAOYSA-N","InChI=1S/C9H9NO/c1-9-6-4-2-3-5-7(6)10-8(9)11-9/h2-5,8,10H,1H3","Kalgutkar, A.S. et al. (2002); On the Diversity of Oxidative Bioactivation Reactions on Nitrogen-Containing Xenobiotics; Current Drug Metabolism, 3, 379-424; PMID:12093357"
"BIOTID00164","3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (4r)-","157704","PVHUJELLJLJGLN-MRXNPFEDSA-N","InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3/t16-/m1/s1","CYP3A4 ","Dehydrogenation","Human Phase I","Human","NULL","146012","YEHVABIPGJLMET-UHFFFAOYSA-N","InChI=1S/C18H18N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9H,5H2,1-4H3","PMID:2061924"
"BIOTID00165","3alpha,12beta-dihydroxy-5alpha-cholan-24-oic acid","5283834","KXGVEGMKQFWNSR-DNZDVJRKSA-N","InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17+,18-,19+,20+,21-,23+,24-/m1/s1","CYP3A4 ","Aliphatic Hydroxylation","Human Phase I","Human","hyocholic acid (HCA)","14298688","COCMFMBNEAMQMA-UHFFFAOYSA-N","InChI=1S/C24H40O6/c1-12(4-7-19(27)28)14-5-6-15-20-16(11-18(26)24(14,15)3)23(2)9-8-13(25)10-17(23)21(29)22(20)30/h12-18,20-22,25-26,29-30H,4-11H2,1-3H3,(H,27,28)","PMID:19130183"
"BIOTID00166","3alpha,7beta,12beta-trihydroxy-5alpha-cholan-24-oic acid","NULL","BHQCQFFYRZLCQQ-JWQTVRMOSA-N","InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14-,15-,16-,17+,18+,19+,20-,22+,23+,24-/m1/s1","CYP3A4","Dehydrogenation","Human Phase I","Human","NULL","4046638","OEKUSRBIIZNLHZ-UHFFFAOYSA-N","InChI=1S/C24H38O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-20,22,26-27H,4-12H2,1-3H3,(H,28,29)","PMID:18583509"
"BIOTID00167","3s14s-ochratoxin a","NULL","RWQKHEORZBHNRI-BONVTDFDSA-N","InChI=1S/C20H18ClNO6/c1-10-7-12-14(21)9-13(17(23)16(12)20(27)28-10)18(24)22-15(19(25)26)8-11-5-3-2-4-6-11/h2-6,9-10,15,23H,7-8H2,1H3,(H,22,24)(H,25,26)/t10-,15-/m0/s1","CYP1A2;CYP2C9;CYP3A4","ALIPHATIC HYDROXYLATION","Human Phase I","Human","NULL","14550626","BCZIFDALJWPHTK-UHFFFAOYSA-N","InChI=1S/C20H18ClNO7/c1-9-16(23)14-12(21)8-11(17(24)15(14)20(28)29-9)18(25)22-13(19(26)27)7-10-5-3-2-4-6-10/h2-6,8-9,13,16,23-24H,7H2,1H3,(H,22,25)(H,26,27)","PMID:11134544"
"BIOTID00168","4_demethyl_olanzapine","NULL","FHPIXVHJEIZKJW-UHFFFAOYSA-N","InChI=1S/C16H18N4S/c1-11-10-12-15(20-8-6-17-7-9-20)18-13-4-2-3-5-14(13)19-16(12)21-11/h2-5,10,17,19H,6-9H2,1H3","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","JSXLNAYXPFDCKT-UHFFFAOYSA-N","InChI=1S/C16H18N4OS/c1-10-8-11-15(20-7-6-17-9-14(20)21)18-12-4-2-3-5-13(12)19-16(11)22-10/h2-5,8,14,17,19,21H,6-7,9H2,1H3","PMID:8632334"
"BIOTID00169","4-(butylaminomethyl)-7-methoxycoumarin","85782015","AHKHKMDMRHPLNJ-UHFFFAOYSA-N","InChI=1S/C15H19NO3/c1-3-4-7-16-10-11-8-15(17)19-14-9-12(18-2)5-6-13(11)14/h5-6,8-9,16H,3-4,7,10H2,1-2H3","CYP1A2;CYP2C9;CYP2C19;CYP2D6","O-Demethylation","Human Phase I","Human","BHAMC","NULL","WLMCNDYSKYNNLU-UHFFFAOYSA-N","InChI=1S/C14H17NO3/c1-2-3-6-15-9-10-7-14(17)18-13-8-11(16)4-5-12(10)13/h4-5,7-8,15-16H,2-3,6,9H2,1H3","PMID:11095593"
"BIOTID00170","4-(butylaminomethyl)-7-methoxycoumarin","85782015","AHKHKMDMRHPLNJ-UHFFFAOYSA-N","InChI=1S/C15H19NO3/c1-3-4-7-16-10-11-8-15(17)19-14-9-12(18-2)5-6-13(11)14/h5-6,8-9,16H,3-4,7,10H2,1-2H3","CYP1A2","N-Demethylation","Human Phase I","Human","NULL","8758226","JTWMBPZRYBLNNG-UHFFFAOYSA-N","InChI=1S/C11H11NO3/c1-14-8-2-3-9-7(6-12)4-11(13)15-10(9)5-8/h2-5H,6,12H2,1H3","PMID:11095593"
"BIOTID00171","4-(ethylaminomethyl)-7-methoxycoumarin","85782009","WPZFUQQBKHILMS-UHFFFAOYSA-N","InChI=1S/C13H15NO3/c1-3-14-8-9-6-13(15)17-12-7-10(16-2)4-5-11(9)12/h4-7,14H,3,8H2,1-2H3","CYP1A2;CYP2C19;CYP2D6","O-Demethylation","Human Phase I","Human","EHAMC","NULL","VMNKFSGMVYPKAC-UHFFFAOYSA-N","InChI=1S/C12H13NO3/c1-2-13-7-8-5-12(15)16-11-6-9(14)3-4-10(8)11/h3-6,13-14H,2,7H2,1H3","PMID:11095593"
"BIOTID00172","4-(ethylaminomethyl)-7-methoxycoumarin","85782009","WPZFUQQBKHILMS-UHFFFAOYSA-N","InChI=1S/C13H15NO3/c1-3-14-8-9-6-13(15)17-12-7-10(16-2)4-5-11(9)12/h4-7,14H,3,8H2,1-2H3","CYP1A2","N-Dealkylation","Human Phase I","Human","MAMC","8758226","JTWMBPZRYBLNNG-UHFFFAOYSA-N","InChI=1S/C11H11NO3/c1-14-8-2-3-9-7(6-12)4-11(13)15-10(9)5-8/h2-5H,6,12H2,1H3","PMID:11095593"
"BIOTID00173","4-(trifluoromethyl)-7-[2,5-bis(trifluoromethyl)benzyloxy]coumarin","101149749","PCBGILKQGDYJAY-UHFFFAOYSA-N","InChI=1S/C19H9F9O3/c20-17(21,22)10-1-4-13(18(23,24)25)9(5-10)8-30-11-2-3-12-14(19(26,27)28)7-16(29)31-15(12)6-11/h1-7H,8H2","CYP3A4","O-Dealklyation","Human Phase I","Human","HFC","5375667","CCKWMCUOHJAVOL-UHFFFAOYSA-N","InChI=1S/C10H5F3O3/c11-10(12,13)7-4-9(15)16-8-3-5(14)1-2-6(7)8/h1-4,14H","PMID:11465405"
"BIOTID00174","4-[(s)-alpha-(trichloromethyl)-4-methoxybenzyl]-1,2-benzenediol","101363929","CFAVOGVJXCIQLR-AWEZNQCLSA-N","InChI=1S/C15H13Cl3O3/c1-21-11-5-2-9(3-6-11)14(15(16,17)18)10-4-7-12(19)13(20)8-10/h2-8,14,19-20H,1H3/t14-/m0/s1","CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP3A4","O-demethylation","Human Phase I","Human","Tris-OH-M methoxychlor","183678","TUYRXLVIBHDPDA-UHFFFAOYSA-N","InChI=1S/C14H11Cl3O3/c15-14(16,17)13(8-1-4-10(18)5-2-8)9-3-6-11(19)12(20)7-9/h1-7,13,18-20H","PMID:12167570"
"BIOTID00175","4-aminobiphenyl","7102","DMVOXQPQNTYEKQ-UHFFFAOYSA-N","InChI=1S/C12H11N/c13-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9H,13H2","CYP1A2","N-hydroxylation of primary arylamine","Human Phase I","Human","4-aminobiphenyl, N-oxide","81261","MYVLYOJYVMLSFA-UHFFFAOYSA-N","InChI=1S/C12H11NO/c14-13-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9,13-14H","Butler, M.A. et al. (1989); Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines; Proc Natl Acad Sci U S A. 1989 Oct;86(20):7696-700; PMID:2813353; PMCID:PMC298137"
"BIOTID00177","4-Hydroxytamoxifen","449459","TXUZVZSFRXZGTL-QPLCGJKRSA-N","InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-","CYP3A4; CYP3A5","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","Endoxifen","10090750","MHJBZVSGOZTKRH-IZHYLOQSSA-N","InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00178","4-Hydroxytamoxifen","449459","TXUZVZSFRXZGTL-QPLCGJKRSA-N","InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","3,4-Dihydroxy-Tamoxifen","10386463","XFIRLPDGPAOZML-WNAAXNPUSA-N","InChI=1S/C26H29NO3/c1-4-23(19-8-6-5-7-9-19)26(21-12-15-24(28)25(29)18-21)20-10-13-22(14-11-20)30-17-16-27(2)3/h5-15,18,28-29H,4,16-17H2,1-3H3/b26-23+","PMID:10348797"
"BIOTID00179","4-methylaminomethyl-7-methoxycoumarin","8931837","GWMGUFTYUOYYQV-UHFFFAOYSA-N","InChI=1S/C12H13NO3/c1-13-7-8-5-12(14)16-11-6-9(15-2)3-4-10(8)11/h3-6,13H,7H2,1-2H3","CYP1A2;CYP2D6","N-Dealkylation","Human Phase I","Human","N-methyl 7-hydroxy-4-(aminomethyl)-coumarin","15896064","JQLGMEHNJJQLNB-UHFFFAOYSA-N","InChI=1S/C11H11NO3/c1-12-6-7-4-11(14)15-10-5-8(13)2-3-9(7)10/h2-5,12-13H,6H2,1H3","PMID:11095593"
"BIOTID00180","4-nitro-3-(trifluoromethyl)aniline","94955","UTKUVRNVYFTEHF-UHFFFAOYSA-N","InChI=1S/C7H5F3N2O2/c8-7(9,10)5-3-4(11)1-2-6(5)12(13)14/h1-3H,11H2","CYP1A2;CYP2A6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","2-amino5-nitro-4-(trifluoromethyl)phenol","46780317","FKHIQXACMFXULG-UHFFFAOYSA-N","InChI=1S/C7H5F3N2O3/c8-7(9,10)3-1-4(11)6(13)2-5(3)12(14)15/h1-2,13H,11H2","PMID:16507648"
"BIOTID00181","4-nitro-3-(trifluoromethyl)aniline","94955","UTKUVRNVYFTEHF-UHFFFAOYSA-N","InChI=1S/C7H5F3N2O2/c8-7(9,10)5-3-4(11)1-2-6(5)12(13)14/h1-3H,11H2","CYP1A2;CYP2A6;CYP2C9;CYP3A4","N-Hydroxylation; N-Oxidation","Human Phase I","Human","N-[4-nitro-3-(trifluoromethyl)phenyl]-acetamide","NULL","HLQLJFDIWUJMJK-UHFFFAOYSA-N","InChI=1S/C8H7F3N2O3/c1-12(14)5-2-3-7(13(15)16)6(4-5)8(9,10)11/h2-4,12H,1H3","PMID:16507648"
"BIOTID00182","4-nitroanisole","7485","BNUHAJGCKIQFGE-UHFFFAOYSA-N","InChI=1S/C7H7NO3/c1-11-7-4-2-6(3-5-7)8(9)10/h2-5H,1H3","CYP1A2;CYP2A6;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","O-Demethylation","Human Phase I","Human","P-Nitrophenol","980","BTJIUGUIPKRLHP-UHFFFAOYSA-N","InChI=1S/C6H5NO3/c8-6-3-1-5(2-4-6)7(9)10/h1-4,8H","PMID:9364740"
"BIOTID00183","4-nitropyrene","62134","UISKIUIWPSPSAV-UHFFFAOYSA-N","InChI=1S/C16H9NO2/c18-17(19)14-9-12-5-1-3-10-7-8-11-4-2-6-13(14)16(11)15(10)12/h1-9H","CYP1A2; CYP3A4","REDUCTION_OF_NITRO_TO_AMINE","Human Phase I","Human","4-aminopyrene","119443","AYBSKADMMKVOIV-UHFFFAOYSA-N","InChI=1S/C16H11N/c17-14-9-12-5-1-3-10-7-8-11-4-2-6-13(14)16(11)15(10)12/h1-9H,17H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID00184","4-nitropyrene","62134","UISKIUIWPSPSAV-UHFFFAOYSA-N","InChI=1S/C16H9NO2/c18-17(19)14-9-12-5-1-3-10-7-8-11-4-2-6-13(14)16(11)15(10)12/h1-9H","CYP1A2","Epoxidation of arene","Human Phase I","Human","NULL","NULL","ZIOVZZBAVUSART-HZPDHXFCSA-N","InChI=1S/C16H11NO4/c18-15-10-5-1-3-8-7-12(17(20)21)9-4-2-6-11(16(15)19)14(9)13(8)10/h1-7,15-16,18-19H/t15-,16-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID00185","4,4'-methylenebis(2-chloroaniline)","7543","IBOFVQJTBBUKMU-UHFFFAOYSA-N","InChI=1S/C13H12Cl2N2/c14-10-6-8(1-3-12(10)16)5-9-2-4-13(17)11(15)7-9/h1-4,6-7H,5,16-17H2","CYP2A6;CYP3A4","N-Oxidation","Human Phase I","Human","NULL","NULL","BGIRCXVPTMCPMU-UHFFFAOYSA-N","InChI=1S/C13H11Cl2N2O/c14-10-6-8(1-3-12(10)16)5-9-2-4-13(17-18)11(15)7-9/h1-4,6-7,17H,5,16H2/q-1","PMID:1740010"
"BIOTID00186","4'-hydroxy-5,6,7,8-tetramethoxyflavone (tangeretin_T27)","3010100","IECRXMSGDFIOEY-UHFFFAOYSA-N","InChI=1S/C19H18O7/c1-22-15-14-12(21)9-13(10-5-7-11(20)8-6-10)26-16(14)18(24-3)19(25-4)17(15)23-2/h5-9,20H,1-4H3","CYP1A2;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","OROBOL","5318041","ZDLYNMZEAFURQY-UHFFFAOYSA-N","InChI=1S/C19H18O8/c1-23-15-14-12(22)8-13(9-5-6-10(20)11(21)7-9)27-16(14)18(25-3)19(26-4)17(15)24-2/h5-8,20-21H,1-4H3","PMID:12828569"
"BIOTID00187","5-hydroxydiclofenac","3052566","VNQURRWYKFZKJZ-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c15-10-2-1-3-11(16)14(10)17-12-5-4-9(18)6-8(12)7-13(19)20/h1-6,17-18H,7H2,(H,19,20)","CYP2C9","Aromatic Hydroxylation","Human Phase I","Human","4',5-Dihydroxydiclofenac","3052567","DRZFITWJHHNHAD-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO4/c15-10-5-9(19)6-11(16)14(10)17-12-2-1-8(18)3-7(12)4-13(20)21/h1-3,5-6,17-19H,4H2,(H,20,21)","PMID:10449188"
"BIOTID00188","5-methoxytryptamine","1833","JTEJPPKMYBDEMY-UHFFFAOYSA-N","InChI=1S/C11H14N2O/c1-14-9-2-3-11-10(6-9)8(4-5-12)7-13-11/h2-3,6-7,13H,4-5,12H2,1H3","CYP2D6","O-demethylation","Human Phase I","Human","Serotonin","5202","QZAYGJVTTNCVMB-UHFFFAOYSA-N","InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2","PMID:12777961"
"BIOTID00189","5-methylchrysene","19427","GOHBXWHNJHENRX-UHFFFAOYSA-N","InChI=1S/C19H14/c1-13-12-15-7-3-4-8-16(15)18-11-10-14-6-2-5-9-17(14)19(13)18/h2-12H,1H3","CYP1A2;CYP2D6;CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","5-Methyl-1,2-dihydrochrysene-1,2-diol","49838","ZUQHOPBWKPIZSS-UHFFFAOYSA-N","InChI=1S/C19H16O2/c1-11-10-12-4-2-3-5-13(12)14-6-7-16-15(18(11)14)8-9-17(20)19(16)21/h2-10,17,19-21H,1H3","PMID:8542586"
"BIOTID00190","58c80","NULL","NWCVRXADYNRXCT-JOCQHMNTSA-N","InChI=1S/C20H24O3/c1-20(2,3)13-10-8-12(9-11-13)16-17(21)14-6-4-5-7-15(14)18(22)19(16)23/h4-7,12-13,23H,8-11H2,1-3H3/t12-,13-","CYP2C9","Hydroxylation of terminal methyl","Human Phase I","Human","298C84","NULL","QSVGNDZSYQMMEG-JOCQHMNTSA-N","InChI=1S/C20H24O4/c1-20(2,11-21)13-9-7-12(8-10-13)16-17(22)14-5-3-4-6-15(14)18(23)19(16)24/h3-6,12-13,21,24H,7-11H2,1-2H3/t12-,13-","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00191","6-chrysenamine","17534","KIVUHCNVDWYUNP-UHFFFAOYSA-N","InChI=1S/C18H13N/c19-18-11-17-13-6-2-1-5-12(13)9-10-15(17)14-7-3-4-8-16(14)18/h1-11H,19H2","CYP1A2;CYP2A6;CYP2B6;CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","6-MeC-1,2-diol","3025891","BDQUGJCOXDENQA-UHFFFAOYSA-N","InChI=1S/C18H15NO2/c19-16-9-15-11(10-3-1-2-4-13(10)16)5-6-14-12(15)7-8-17(20)18(14)21/h1-9,17-18,20-21H,19H2","PMID:8542586"
"BIOTID00192","6-methylchrysene","15564","ASVDRLYVNFOSCI-UHFFFAOYSA-N","InChI=1S/C19H14/c1-13-12-19-16-8-3-2-6-14(16)10-11-18(19)17-9-5-4-7-15(13)17/h2-12H,1H3","CYP1A2;CYP2D6;CYP2E1;CYP3A4","Epoxidation","Human Phase I","Human","6-MeC-1,2-diol","NULL","FBTQOHSCSMDZOV-UHFFFAOYSA-N","InChI=1S/C19H16O2/c1-11-10-17-14(13-5-3-2-4-12(11)13)6-7-16-15(17)8-9-18(20)19(16)21/h2-10,18-21H,1H3","PMID:8542586"
"BIOTID00193","6-nitrochrysene","24121","UAWLTQJFZUYROA-UHFFFAOYSA-N","InChI=1S/C18H11NO2/c20-19(21)18-11-17-13-6-2-1-5-12(13)9-10-15(17)14-7-3-4-8-16(14)18/h1-11H","CYP1A2;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","N-hydroxy-6-AC","NULL","DDEXKYQWZJEPRX-UHFFFAOYSA-O","InChI=1S/C18H13NO/c20-19-18-11-17-13-6-2-1-5-12(13)9-10-15(17)14-7-3-4-8-16(14)18/h1-11,19-20H/p+1","PMID:8481905"
"BIOTID00194","6-nitrochrysene","24121","UAWLTQJFZUYROA-UHFFFAOYSA-N","InChI=1S/C18H11NO2/c20-19(21)18-11-17-13-6-2-1-5-12(13)9-10-15(17)14-7-3-4-8-16(14)18/h1-11H","CYP2E1;CYP3A4","Reduction","Human Phase I","Human","1,2-DHD-6-NC ","21119321","LZFRXTYVXJWZHG-UHFFFAOYSA-N","InChI=1S/C18H13NO4/c20-17-8-7-12-14(18(17)21)6-5-11-10-3-1-2-4-13(10)16(19(22)23)9-15(11)12/h1-9,17-18,20-21H","PMID:8481905"
"BIOTID00195","7-benzyloxy-4-trifluoromethylcoumarin","848780","WVKLERKKJXUPIK-UHFFFAOYSA-N","InChI=1S/C17H11F3O3/c18-17(19,20)14-9-16(21)23-15-8-12(6-7-13(14)15)22-10-11-4-2-1-3-5-11/h1-9H,10H2","CYP2A6;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP2E1","O-Deethylation","Human Phase I","Human","7-hydroxy-4-triuoromethylcoumarin (HFC)","5375667","CCKWMCUOHJAVOL-UHFFFAOYSA-N","InChI=1S/C10H5F3O3/c11-10(12,13)7-4-9(15)16-8-3-5(14)1-2-6(7)8/h1-4,14H","PMID:11315104"
"BIOTID00196","7-benzyloxyquinoline","3035604","SIDLHXXVIBTSJZ-UHFFFAOYSA-N","InChI=1S/C16H13NO/c1-2-5-13(6-3-1)12-18-15-9-8-14-7-4-10-17-16(14)11-15/h1-11H,12H2","CYP1A2;CYP3A4","O-dealkylation","Human Phase I","Human","7-Hydroxyquinoline","57515736","MDFPCFIBVKKSJU-UHFFFAOYSA-N","InChI=1S/C9H7NO/c11-8-4-3-7-2-1-5-10-9(7)6-8/h1-5H,6H2","PMID:12065444"
"BIOTID00197","7-butoxy-2h-chromen-2-one","156219","BDOGTORASJEUBW-UHFFFAOYSA-N","InChI=1S/C13H14O3/c1-2-3-8-15-11-6-4-10-5-7-13(14)16-12(10)9-11/h4-7,9H,2-3,8H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","GCOXHNLTYHXVNY-UHFFFAOYSA-N","InChI=1S/C13H24O4/c1-2-3-12(14)16-10-6-4-9-5-7-13(15)17-11(9)8-10/h9-15H,2-8H2,1H3","PMID:10620357"
"BIOTID00198","7-butoxy-2h-chromen-2-one","156219","BDOGTORASJEUBW-UHFFFAOYSA-N","InChI=1S/C13H14O3/c1-2-3-8-15-11-6-4-10-5-7-13(14)16-12(10)9-11/h4-7,9H,2-3,8H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","QFEYWSNHHNNZCP-UHFFFAOYSA-N","InChI=1S/C13H24O4/c1-9(14)6-7-16-11-4-2-10-3-5-13(15)17-12(10)8-11/h9-15H,2-8H2,1H3","PMID:10620357"
"BIOTID00199","7-butoxy-2h-chromen-2-one","156219","BDOGTORASJEUBW-UHFFFAOYSA-N","InChI=1S/C13H14O3/c1-2-3-8-15-11-6-4-10-5-7-13(14)16-12(10)9-11/h4-7,9H,2-3,8H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","DUMLRPFNBDKIFM-UHFFFAOYSA-N","InChI=1S/C13H24O4/c14-7-1-2-8-16-11-5-3-10-4-6-13(15)17-12(10)9-11/h10-15H,1-9H2","PMID:10620357"
"BIOTID00200","7-ethoxycoumarin","35703","LIFAQMGORKPVDH-UHFFFAOYSA-N","InChI=1S/C11H10O3/c1-2-13-9-5-3-8-4-6-11(12)14-10(8)7-9/h3-7H,2H2,1H3","CYP1A1 (major); CYP2B6; CYP2E1; CYP1A2; CYP2A6; CYP3A7; CYP2C9; CYP2C19","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Umbelliferone","5281426","ORHBXUUXSCNDEV-UHFFFAOYSA-N","InChI=1S/C9H6O3/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5,10H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015;|PMID:16649998"
"BIOTID00201","7-ethoxycoumarin","35703","LIFAQMGORKPVDH-UHFFFAOYSA-N","InChI=1S/C11H10O3/c1-2-13-9-5-3-8-4-6-11(12)14-10(8)7-9/h3-7H,2H2,1H3","CYP1A1 (major); CYP2B6; CYP2E1; CYP1A2; CYP2A6; CYP3A7; CYP2C9; CYP2C19","Aromatic Hydroxylation","Human Phase I","Human","NULL","54716827","BPWIJZQVCZRWTJ-UHFFFAOYSA-N","InChI=1S/C11H10O4/c1-2-14-7-3-4-8-9(12)6-11(13)15-10(8)5-7/h3-6,12H,2H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015;|PMID:16649998"
"BIOTID00202","7-ethoxyresorufin","3294","CRCWUBLTFGOMDD-UHFFFAOYSA-N","InChI=1S/C14H11NO3/c1-2-17-10-4-6-12-14(8-10)18-13-7-9(16)3-5-11(13)15-12/h3-8H,2H2,1H3","CYP1A2; CYP1A1","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Resorufin","69462","HSSLDCABUXLXKM-UHFFFAOYSA-N","InChI=1S/C12H7NO3/c14-7-1-3-9-11(5-7)16-12-6-8(15)2-4-10(12)13-9/h1-6,14H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00203","7-methoxycoumarin","10748","LIIALPBMIOVAHH-UHFFFAOYSA-N","InChI=1S/C10H8O3/c1-12-8-4-2-7-3-5-10(11)13-9(7)6-8/h2-6H,1H3","CYP1A2;CYP2A6","O-dealkylation","Human Phase I","Human","Umbelliferone","5281426","ORHBXUUXSCNDEV-UHFFFAOYSA-N","InChI=1S/C9H6O3/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5,10H","PMID:16649998"
"BIOTID00204","7-methoxycoumarin","10748","LIIALPBMIOVAHH-UHFFFAOYSA-N","InChI=1S/C10H8O3/c1-12-8-4-2-7-3-5-10(11)13-9(7)6-8/h2-6H,1H3","CYP1A2;CYP2A6","Aromatic Hydroxylation","Human Phase I","Human","4-Hydroxy-7-methoxycoumarin","54691408","MJBHLQMPKBMZSF-UHFFFAOYSA-N","InChI=1S/C10H8O4/c1-13-6-2-3-7-8(11)5-10(12)14-9(7)4-6/h2-5,11H,1H3","PMID:16649998"
"BIOTID00205","7-methylbenz(c)acridine","76861","LZUFUDJVBHLHFC-UHFFFAOYSA-N","InChI=1S/C18H13N/c1-12-14-7-4-5-9-17(14)19-18-15(12)11-10-13-6-2-3-8-16(13)18/h2-11H,1H3","CYP1A2;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","13332617","PIMRBXVJGSKTOZ-UHFFFAOYSA-N","InChI=1S/C18H15NO2/c1-10-12-7-6-11-4-2-3-5-13(11)17(12)19-14-8-9-15(20)18(21)16(10)14/h2-9,15,18,20-21H,1H3","PMID:7866988"
"BIOTID00206","7-methylbenz(c)acridine","76861","LZUFUDJVBHLHFC-UHFFFAOYSA-N","InChI=1S/C18H13N/c1-12-14-7-4-5-9-17(14)19-18-15(12)11-10-13-6-2-3-8-16(13)18/h2-11H,1H3","CYP1A2;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","INGRZFICWPSFBH-UHFFFAOYSA-N","InChI=1S/C18H13NO2/c1-10-11-6-4-5-9-14(11)19-16-12-7-2-3-8-13(12)17(20)18(21)15(10)16/h2-9,20-21H,1H3","PMID:7866988"
"BIOTID00207","7-methylbenz(c)acridine","76861","LZUFUDJVBHLHFC-UHFFFAOYSA-N","InChI=1S/C18H13N/c1-12-14-7-4-5-9-17(14)19-18-15(12)11-10-13-6-2-3-8-16(13)18/h2-11H,1H3","CYP1A2;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","SOLQDOXZTZCSGW-UHFFFAOYSA-N","InChI=1S/C18H13NO2/c1-10-11-4-2-3-5-15(11)19-17-12(10)6-7-14-13(17)8-9-16(20)18(14)21/h2-9,20-21H,1H3","PMID:7866988"
"BIOTID00208","7-methylbenz(c)acridine","76861","LZUFUDJVBHLHFC-UHFFFAOYSA-N","InChI=1S/C18H13N/c1-12-14-7-4-5-9-17(14)19-18-15(12)11-10-13-6-2-3-8-16(13)18/h2-11H,1H3","CYP1A2;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","51818","HEDQVRLHVBZVLF-UHFFFAOYSA-N","InChI=1S/C18H13NO/c20-11-16-14-7-3-4-8-17(14)19-18-13-6-2-1-5-12(13)9-10-15(16)18/h1-10,20H,11H2","PMID:7866988"
"BIOTID00209","8-hydroxyefavirenz","487643","OOVOMPCQLMFEDT-ZDUSSCGKSA-N","InChI=1S/C14H9ClF3NO3/c15-8-5-9-11(10(20)6-8)19-12(21)22-13(9,14(16,17)18)4-3-7-1-2-7/h5-7,20H,1-2H2,(H,19,21)/t13-/m0/s1","CYP2B6","HYDROXYLATION_OF_ALICYCLIC_SECONDARY_CARBON; HYDROXYLATION_OF_ALICYCLIC_SECONDARY_CARBON_PATTERN1","Human Phase I","Human","8,14-diOH-efavirenz","16725849","WILFXLMJFSKQRP-ZDUSSCGKSA-N","InChI=1S/C14H9ClF3NO4/c15-7-5-8-10(9(20)6-7)19-11(21)23-13(8,14(16,17)18)4-3-12(22)1-2-12/h5-6,20,22H,1-2H2,(H,19,21)/t13-/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00210","9-anthraldehyde","69504","YMNKUHIVVMFOFO-UHFFFAOYSA-N","InChI=1S/C15H10O/c16-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)15/h1-10H","CYP2A6;CYP2B6;CYP2C19;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","2201","XGWFJBFNAQHLEF-UHFFFAOYSA-N","InChI=1S/C15H10O2/c16-15(17)14-12-7-3-1-5-10(12)9-11-6-2-4-8-13(11)14/h1-9H,(H,16,17)","PMID:15618706"
"BIOTID00211","9-cis-retinal","6436082","NCYCYZXNIZJOKI-MKOSUFFBSA-N","InChI=1S/C20H28O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,15H,7,10,14H2,1-5H3/b9-6+,12-11+,16-8-,17-13+","CYP1A2;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","4-hydroxy-9-cis-retinals","449171","SHGAZHPCJJPHSC-ZVCIMWCZSA-N","InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+","PMID:10681373"
"BIOTID00212","Lopinavir, D-valine diastereomer-","6850809","KJHKTHWMRKYKJE-UQJYGFKOSA-N","InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34+/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","75213007","HECSHMHYHYDFLR-UHFFFAOYSA-N","InChI=1S/C37H48N4O6/c1-24(2)34(41-19-18-32(43)40-37(41)46)36(45)38-29(20-27-14-7-5-8-15-27)22-31(42)30(21-28-16-9-6-10-17-28)39-33(44)23-47-35-25(3)12-11-13-26(35)4/h5-17,24,29-32,34,42-43H,18-23H2,1-4H3,(H,38,45)(H,39,44)(H,40,46)","PMID:10421617"
"BIOTID00213","abt_378","6850809","KJHKTHWMRKYKJE-UQJYGFKOSA-N","InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34+/m0/s1","CYP3A4","C-Oxidation","Human Phase I","Human","NULL","73729739","PSUMJBRVYHIASB-UHFFFAOYSA-N","InChI=1S/C37H46N4O6/c1-24(2)34(41-19-18-32(43)40-37(41)46)36(45)38-29(20-27-14-7-5-8-15-27)22-31(42)30(21-28-16-9-6-10-17-28)39-33(44)23-47-35-25(3)12-11-13-26(35)4/h5-17,24,29-31,34,42H,18-23H2,1-4H3,(H,38,45)(H,39,44)(H,40,43,46)","PMID:10421617"
"BIOTID00214","1â€[(2S)â€4â€(5â€benzylthiophenâ€2â€yl)butâ€3â€ynâ€2â€yl]â€1â€hydroxyurea","NULL","JONJCOZHGBDTBN-LBPRGKRZSA-N","InChI=1S/C16H16N2O2S/c1-12(18(20)16(17)19)7-8-14-9-10-15(21-14)11-13-5-3-2-4-6-13/h2-6,9-10,12,20H,11H2,1H3,(H2,17,19)/t12-/m0/s1","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","ABT-515","NULL","LWZNUUHYKJKYDV-UHFFFAOYSA-N","InChI=1S/C16H16N2O3S/c1-11(18(21)16(17)20)7-8-13-9-10-14(22-13)15(19)12-5-3-2-4-6-12/h2-6,9-11,15,19,21H,1H3,(H2,17,20)","PMID:9763401"
"BIOTID00215","1-[Amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine","22323","ISZNZKHCRKXXAU-UHFFFAOYSA-N","InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)","CYP2C19;","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","GXIYYKFEFVBTAX-UHFFFAOYSA-N","InChI=1S/C11H15Cl2N5O/c1-11(2,19)18-10(15)17-9(14)16-6-3-4-7(12)8(13)5-6/h3-5,19H,1-2H3,(H5,14,15,16,17,18)","PMID:7640152"
"BIOTID00216","ac1ldic9","667556","GKTWGGQPFAXNFI-OAHLLOKOSA-N","InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m1/s1","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2D6;CYP2C1;CYP3A4","C-Oxidation","Human Phase I","Human","2-oxo-clopidogrel","15097010","AZRUDPJZBRJPHU-UHFFFAOYSA-N","InChI=1S/C16H16ClNO3S/c1-21-16(20)15(11-4-2-3-5-12(11)17)18-7-6-13-10(9-18)8-14(19)22-13/h2-5,15H,6-9H2,1H3","PMID:19812348;PMID:19170597"
"BIOTID00217","ac1mip3e","3075626","DMEPDNFRHUGNPT-XMMPIXPASA-N","InChI=1S/C24H35NO3/c1-5-25(6-2)19-13-18-23(3,4)28-22(26)24(27,20-14-9-7-10-15-20)21-16-11-8-12-17-21/h7,9-10,14-15,21,27H,5-6,8,11-12,16-17,19H2,1-4H3/t24-/m1/s1","CYP3A4","N-deethylation","Human Phase I","Human","N-deethylated  ac1mip3e","154340","BWTHWMSRTKTAFC-UHFFFAOYSA-N","InChI=1S/C22H31NO3/c1-4-23-17-11-16-21(2,3)26-20(24)22(25,18-12-7-5-8-13-18)19-14-9-6-10-15-19/h5,7-8,12-13,19,23,25H,4,6,9-10,14-15,17H2,1-3H3","PMID:10219965"
"BIOTID00218","[5-(Diethylamino)-2-methylpent-3-yn-2-yl] (2S)-2-cyclohexyl-2-hydroxy-2-phenylacetate","3075626","DMEPDNFRHUGNPT-XMMPIXPASA-N","InChI=1S/C24H35NO3/c1-5-25(6-2)19-13-18-23(3,4)28-22(26)24(27,20-14-9-7-10-15-20)21-16-11-8-12-17-21/h7,9-10,14-15,21,27H,5-6,8,11-12,16-17,19H2,1-4H3/t24-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","4-cis-OH ac1mip3e","NULL","AFFNDINOYQEJPP-UHFFFAOYSA-N","InChI=1S/C24H35NO4/c1-5-25(6-2)18-10-17-23(3,4)29-22(27)24(28,19-11-8-7-9-12-19)20-13-15-21(26)16-14-20/h7-9,11-12,20-21,26,28H,5-6,13-16,18H2,1-4H3","PMID:10219965"
"BIOTID00219","ac1ocg1j","6918906","OEHAYUOVELTAPG-VIFPVBQESA-N","InChI=1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3/t9-/m0/s1","CYP2D6","O-demethylation","Human Phase I","Human","NULL","11405","SAHBITMBCTXQOR-UHFFFAOYSA-N","InChI=1S/C10H15NO/c1-8(11-2)7-9-5-3-4-6-10(9)12/h3-6,8,11-12H,7H2,1-2H3","PMID:7835228"
"BIOTID00220","ac1ocg1j","6918906","OEHAYUOVELTAPG-VIFPVBQESA-N","InChI=1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3/t9-/m0/s1","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","179091","MJHSFKIGFVIAFL-UHFFFAOYSA-N","InChI=1S/C11H17NO2/c1-8(12-2)6-9-7-10(13)4-5-11(9)14-3/h4-5,7-8,12-13H,6H2,1-3H3","PMID:7835228"
"BIOTID00221","pimobendan","6918916","GLBJJMFZWDBELO-NSHDSACASA-N","InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)/t11-/m0/s1","CYP1A2;CYP3A4","N-demethylation","Human Phase I","Human","NULL","NULL","QOAXSEARPHDXFC-UHFFFAOYSA-N","InChI=1S/C18H16N4O2/c1-10-8-16(24)21-22-17(10)12-4-7-14-15(9-12)20-18(19-14)11-2-5-13(23)6-3-11/h2-7,9-10,23H,8H2,1H3,(H,19,20)(H,21,24)","PMID:10611143"
"BIOTID00222","aceclofenac","71771","MNIPYSSQXLZQLJ-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)","CYP2C9","Hydroxylation of aromatic carbon meta to halide group","Human Phase I","Human","4'-OH-aceclofenac","9842299","BTDFYMBLEDMWOK-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO5/c17-11-6-10(20)7-12(18)16(11)19-13-4-2-1-3-9(13)5-15(23)24-8-14(21)22/h1-4,6-7,19-20H,5,8H2,(H,21,22)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00223","aceclofenac","71771","MNIPYSSQXLZQLJ-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)","CYP2C9","HYDROXYLATION_OF_AROMATIC_CARBON; HYDROXYLATION_OF_BENZENE_PARA_TO_EDG","Human Phase I","Human","5-OH-aceclofenac","101998321","IUSFDHLZHGPYRJ-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO5/c17-11-2-1-3-12(18)16(11)19-13-5-4-10(20)6-9(13)7-15(23)24-8-14(21)22/h1-6,19-20H,7-8H2,(H,21,22)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00224","aceclofenac","71771","MNIPYSSQXLZQLJ-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)","CYP2C9","HYDROLYSIS_OF_CARBOXYLIC_ESTER","Human Phase I","Human","Diclofenac","3033","DCOPUUMXTXDBNB-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00225","acetaldehyde","177","IKHGUXGNUITLKF-UHFFFAOYSA-N","InChI=1S/C2H4O/c1-2-3/h2H,1H3","CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","Acetic Acid","176","QTBSBXVTEAMEQO-UHFFFAOYSA-N","InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)","PMID:10446146"
"BIOTID00227","acetanilide","904","FZERHIULMFGESH-UHFFFAOYSA-N","InChI=1S/C8H9NO/c1-7(10)9-8-5-3-2-4-6-8/h2-6H,1H3,(H,9,10)","CYP1A2; CYP2E1","p-Hydroxylation of anilide","Human Phase I","Human","Acetaminophen","1983","RZVAJINKPMORJF-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00228","acetanilide","904","FZERHIULMFGESH-UHFFFAOYSA-N","InChI=1S/C8H9NO/c1-7(10)9-8-5-3-2-4-6-8/h2-6H,1H3,(H,9,10)","CYP2E1","N-hydroxylation of anilide","Human Phase I","Human","N-Hydroxy-N-phenylacetamide","115251","GMJUGPZVHVVVCG-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-7(10)9(11)8-5-3-2-4-6-8/h2-6,11H,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00229","acrylonitrile","7855","NLHHRLWOUZZQLW-UHFFFAOYSA-N","InChI=1S/C3H3N/c1-2-3-4/h2H,1H2","CYP2E1","EPOXIDATION_OF_MONOSUBSTITUTED_ALKENE","Human Phase I","Human","Cyanoethylene oxide","20662","RSHIVZARDAPEDE-UHFFFAOYSA-N","InChI=1S/C3H3NO/c4-1-3-2-5-3/h3H,2H2","Wang, H. et al, (2002) Cytochrome p450 2E1 is essential for acrylonitrile metabolism to cyanide: comparative studies using CYP2E1-null and wild-type mice, DMD: 30:911-917, 2002"
"BIOTID00230","adinazolam","37632","GJSLOMWRLALDCT-UHFFFAOYSA-N","InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3","CYP2C19;CYP3A4","N-demethylation","Human Phase I","Human","N-demethyladinazolam","119094","XPMACCNVZKHGPT-UHFFFAOYSA-N","InChI=1S/C18H16ClN5/c1-20-10-16-22-23-17-11-21-18(12-5-3-2-4-6-12)14-9-13(19)7-8-15(14)24(16)17/h2-9,20H,10-11H2,1H3","PMID:9600717"
"BIOTID00231","aflatoxin b1","186907","OQIQSTLJSLGHID-WNWIJWBNSA-N","InChI=1S/C17H12O6/c1-20-10-6-11-14(8-4-5-21-17(8)22-11)15-13(10)7-2-3-9(18)12(7)16(19)23-15/h4-6,8,17H,2-3H2,1H3/t8-,17+/m0/s1","CYP1A2; CYP3A5; CYP3A4; CYP2A13 ","Epoxidation of vinyl ether","Human Phase I","Human"," Aflatoxin B1- exo-8,9-oxide ","NULL","KHBXRZGALJGBPA-LMEGTBPZSA-N","InChI=1S/C17H12O7/c1-20-7-4-8-11(12-14-17(23-14)24-16(12)21-8)13-10(7)5-2-3-6(18)9(5)15(19)22-13/h4,12,14,16-17H,2-3H2,1H3/t12-,14?,16+,17?/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00232","aflatoxin b1","186907","OQIQSTLJSLGHID-WNWIJWBNSA-N","InChI=1S/C17H12O6/c1-20-10-6-11-14(8-4-5-21-17(8)22-11)15-13(10)7-2-3-9(18)12(7)16(19)23-15/h4-6,8,17H,2-3H2,1H3/t8-,17+/m0/s1","CYP1A2 ","Allylic hydroxylation","Human Phase I","Human","Aflatoxin M1 ","NULL","MJBWDEQAUQTVKK-IAGOWNOFSA-N","InChI=1S/C17H12O7/c1-21-9-6-10-13(17(20)4-5-22-16(17)23-10)14-12(9)7-2-3-8(18)11(7)15(19)24-14/h4-6,16,20H,2-3H2,1H3/t16-,17-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00233","aflatoxin b1","186907","OQIQSTLJSLGHID-WNWIJWBNSA-N","InChI=1S/C17H12O6/c1-20-10-6-11-14(8-4-5-21-17(8)22-11)15-13(10)7-2-3-9(18)12(7)16(19)23-15/h4-6,8,17H,2-3H2,1H3/t8-,17+/m0/s1","CYP3A4 ","Allylic hydroxylation","Human Phase I","Human","Aflatoxin Q1 ","NULL","GYNOTJLCULOEIM-VYNLQGFGSA-N","InChI=1S/C17H12O7/c1-21-9-5-10-11(6-2-3-22-17(6)23-10)15-14(9)12-7(18)4-8(19)13(12)16(20)24-15/h2-3,5-7,17-18H,4H2,1H3/t6-,7?,17+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00234","albendazole","2082","HXHWSAZORRCQMX-UHFFFAOYSA-N","InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)","CYP1A2;CYP3A4","S-Oxidation","Human Phase I","Human","NULL","NULL","VXTGHWHFYNYFFV-UHFFFAOYSA-N","InChI=1S/C12H15N3O3S/c1-3-6-19(17)8-4-5-9-10(7-8)14-11(13-9)15-12(16)18-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)","PMID:10759686"
"BIOTID00235","alfentanil","51263","IDBPHNDTYPBSNI-UHFFFAOYSA-N","InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3","CYP3A4","N-dealkylation of tertiary carboxamide","Human Phase I","Human","N-phenylpropionamide","NULL","ZTHRQJQJODGZHV-UHFFFAOYSA-N","InChI=1S/C9H11NO/c1-2-9(11)10-8-6-4-3-5-7-8/h3-7H,2H2,1H3,(H,10,11)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00236","alfentanil","51263","IDBPHNDTYPBSNI-UHFFFAOYSA-N","InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","Noralfentanil","NULL","ULOZGJWEIWAWML-UHFFFAOYSA-N","InChI=1S/C16H24N2O2/c1-3-15(19)18(14-7-5-4-6-8-14)16(13-20-2)9-11-17-12-10-16/h4-8,17H,3,9-13H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00236","alfentanil","51263","IDBPHNDTYPBSNI-UHFFFAOYSA-N","InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","2‐(4‐ethyl‐5‐oxo‐1,2,3,4‐tetrazol‐1‐yl)acetaldehyde","NULL","RWVLUTFSOYZBDA-UHFFFAOYSA-N","InChI=1S/C5H8N4O2/c1-2-8-5(11)9(3-4-10)7-6-8/h4H,2-3H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00237","alilusem","6338015","QQCSUWGQBREWRO-XDJHFCHBSA-N","InChI=1S/C17H15ClN2O5S/c1-11-4-2-3-5-13(11)17(21)20-9-8-15(19-25-26(22,23)24)14-7-6-12(18)10-16(14)20/h2-7,10H,8-9H2,1H3,(H,22,23,24)/b19-15+","CYP2C9;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","UWLKENAFCQWAPV-XDJHFCHBSA-N","InChI=1S/C17H15ClN2O6S/c18-12-5-6-14-15(19-26-27(23,24)25)7-8-20(16(14)9-12)17(22)13-4-2-1-3-11(13)10-21/h1-6,9,21H,7-8,10H2,(H,23,24,25)/b19-15+","PMID:15618654"
"BIOTID00238","almotriptan","123606","WKEMJKQOLOHJLZ-UHFFFAOYSA-N","InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3","CYP2D6; CYP3A4","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","2-OH-almotriptan","NULL","UYQQYVHESFAATL-UHFFFAOYSA-N","InChI=1S/C17H25N3O3S/c1-19(2)9-7-14-11-18-16-6-5-13(10-15(14)16)12-24(22,23)20-8-3-4-17(20)21/h5-6,10-11,17-18,21H,3-4,7-9,12H2,1-2H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00239","almotriptan","123606","WKEMJKQOLOHJLZ-UHFFFAOYSA-N","InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3","CYP1A2; CYP2C8; CYP2E1; CYP2D6; CYP3A4","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","methyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine","NULL","IREINZNGILEJRP-UHFFFAOYSA-N","InChI=1S/C16H23N3O2S/c1-17-7-6-14-11-18-16-5-4-13(10-15(14)16)12-22(20,21)19-8-2-3-9-19/h4-5,10-11,17-18H,2-3,6-9,12H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00240","alpha_dihydroergocryptine","114948","YJUGYRAWLRIQHU-JJCPZVKWSA-N","InChI=1S/C28H35N5O5/c1-15(2)27(26(36)33-14-23(34)32-9-5-8-22(32)28(33,37)38-27)30-25(35)17-10-19-18-6-4-7-20-24(18)16(12-29-20)11-21(19)31(3)13-17/h4,6-7,12,15,17,19,21-22,29,37H,5,8-11,13-14H2,1-3H3,(H,30,35)/t17-,19+,21+,22+,27-,28+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","HOCPALPQPRWWDP-UHFFFAOYSA-N","InChI=1S/C28H35N5O6/c1-14(2)27(26(37)32-13-23(35)33-21(7-8-22(33)34)28(32,38)39-27)30-25(36)16-9-18-17-5-4-6-19-24(17)15(11-29-19)10-20(18)31(3)12-16/h4-6,11,14,16,18,20-22,29,34,38H,7-10,12-13H2,1-3H3,(H,30,36)","PMID:11197065"
"BIOTID00241","alpha-thujone","261491","USMNOWBWPHYOEA-MRTMQBJTSA-N","InChI=1S/C10H16O/c1-6(2)10-4-8(10)7(3)9(11)5-10/h6-8H,4-5H2,1-3H3/t7-,8-,10+/m1/s1","CYP2A6; CYP2B6; CYP2D6; CYP3A4","Hydroxylation of penultimate aliphatic tertiary carbon","Human Phase I","Human","4-hydroxy-alpha-thujone","NULL","QCIUNUUHBWFYTD-JEZHCXPESA-N","InChI=1S/C10H16O2/c1-6(2)10-4-7(10)9(3,12)8(11)5-10/h6-7,12H,4-5H2,1-3H3/t7-,9+,10+/m1/s1","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID00242","alpha-thujone","261491","USMNOWBWPHYOEA-MRTMQBJTSA-N","InChI=1S/C10H16O/c1-6(2)10-4-8(10)7(3)9(11)5-10/h6-8H,4-5H2,1-3H3/t7-,8-,10+/m1/s1","CYP2A6; CYP2B6; CYP2D6; CYP3A4","Hydroxylation of penultimate aliphatic tertiary carbon","Human Phase I","Human","7-hydroxy-alpha-thujone","11041106","BWIMEHVFTVSHCC-BRDIYROLSA-N","InChI=1S/C10H16O2/c1-6-7-4-10(7,5-8(6)11)9(2,3)12/h6-7,12H,4-5H2,1-3H3/t6-,7-,10-/m1/s1","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID00243","alphacetylmethadol","22308","XBMIVRRWGCYBTQ-XMSQKQJNSA-N","InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m1/s1","CYP2B6;CYP2C8;CYP2C19;CYP3A4","N-DEMETHYLATION","Human Phase I","Human","norLAAM","NULL","VWCUGCYZZGRKEE-UHFFFAOYSA-N","InChI=1S/C22H29NO2/c1-5-21(25-18(3)24)22(16-17(2)23-4,19-12-8-6-9-13-19)20-14-10-7-11-15-20/h6-15,17,21,23H,5,16H2,1-4H3","PMID:9394023"
"BIOTID00244","alprazolam","2118","VREFGVBLTWBCJP-UHFFFAOYSA-N","InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3","CYP3A4 (major); CYP2C9 (minor)","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","4-Hydroxyalprazolam","NULL","CEYGCFLPQFNPST-UHFFFAOYSA-N","InChI=1S/C17H13ClN4O/c1-10-20-21-16-17(23)19-15(11-5-3-2-4-6-11)13-9-12(18)7-8-14(13)22(10)16/h2-9,17,23H,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00245","alprazolam","2118","VREFGVBLTWBCJP-UHFFFAOYSA-N","InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3","CYP2C9 (minor); CYP2C19 (minor); CYP3A4 (minor)","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","Beta-Hydroxyalprazolam","NULL","MTACNNZEKCJJGY-UHFFFAOYSA-N","InChI=1S/C17H14N4O2/c22-10-14-19-20-16-17(23)18-15(11-6-2-1-3-7-11)12-8-4-5-9-13(12)21(14)16/h1-9,17,22-23H,10H2","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00247","ambroxol","2132","JBDGDEWWOUBZPM-PHIMTYICSA-N","InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2/t10-,11+","CYP3A4","N-dealkylation of acyclic secondary amine","Human Phase I","Human","4-Aminocyclohexanol, cis-","81293","IMLXLGZJLAOKJN-OLQVQODUSA-N","InChI=1S/C6H13NO/c7-5-1-3-6(8)4-2-5/h5-6,8H,1-4,7H2/t5-,6+","PMID:10659952"
"BIOTID00247","ambroxol","2132","JBDGDEWWOUBZPM-PHIMTYICSA-N","InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2/t10-,11+","CYP3A4","N-dealkylation of acyclic secondary amine","Human Phase I","Human","2-Amino-3,5-dibromobenzaldehyde","688305","RCPAZWISSAVDEA-UHFFFAOYSA-N","InChI=1S/C7H5Br2NO/c8-5-1-4(3-11)7(10)6(9)2-5/h1-3H,10H2","PMID:10659952"
"BIOTID00248","Ametryn","13263","RQVYBGPQFYCBGX-UHFFFAOYSA-N","InChI=1S/C9H17N5S/c1-5-10-7-12-8(11-6(2)3)14-9(13-7)15-4/h6H,5H2,1-4H3,(H2,10,11,12,13,14)","CYP1A1; CYP1A2; CYP2C19; CYP3A4","N-dealkylation of secondary arylalkylamine","Human Phase I","Human","NULL","NULL","PWERJYSEXWGFLB-UHFFFAOYSA-N","InChI=1S/C7H13N5S/c1-4(2)9-6-10-5(8)11-7(12-6)13-3/h4H,1-3H3,(H3,8,9,10,11,12)","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|Lang, D.H.et al. (1997). Identification of enzymes involved in the metabolism of atrazine, terbuthylazine, ametryne, and terbutryne in human liver microsomes. Chem. Res. Toxicol., Vol. 10, No. 9, (1037-1044"
"BIOTID00249","Ametryn","13263","RQVYBGPQFYCBGX-UHFFFAOYSA-N","InChI=1S/C9H17N5S/c1-5-10-7-12-8(11-6(2)3)14-9(13-7)15-4/h6H,5H2,1-4H3,(H2,10,11,12,13,14)","CYP1A1; CYP1A2; CYP2C8; CYP2C9; CYP2C19; CYP3A4","N-deisopropylation","Human Phase I","Human","NULL","NULL","CMKCJDAIKRRBDY-UHFFFAOYSA-N","InChI=1S/C6H11N5S/c1-3-8-5-9-4(7)10-6(11-5)12-2/h3H2,1-2H3,(H3,7,8,9,10,11)","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|Lang, D.H.et al. (1997). Identification of enzymes involved in the metabolism of atrazine, terbuthylazine, ametryne, and terbutryne in human liver microsomes. Chem. Res. Toxicol., Vol. 10, No. 9, (1037-1044"
"BIOTID00250","aminopyrine","NULL","WOEUPEKLVDSCQN-UHFFFAOYSA-N","InChI=1S/C12H15N3O/c1-13(2)11-9-14(3)15(12(11)16)10-7-5-4-6-8-10/h4-9H,1-3H3","CYP2C19; CYP2C8; CYP2D6; CYP2C18; CYP1A2","N-dealkylation of hydrazide","Human Phase I","Human","4-(Dimethylamino)-5-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one","NULL","URECXYGMECJQLI-UHFFFAOYSA-N","InChI=1S/C11H13N3O/c1-13(2)10-8-12-14(11(10)15)9-6-4-3-5-7-9/h3-8,12H,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00251","aminopyrine","NULL","WOEUPEKLVDSCQN-UHFFFAOYSA-N","InChI=1S/C12H15N3O/c1-13(2)11-9-14(3)15(12(11)16)10-7-5-4-6-8-10/h4-9H,1-3H3","CYP1A2; CYP3A4; CYP2C18; CYP2C19; CYP2C8; CYP2C9; CYP2D6","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-Desmethylaminopyrine","NULL","DAQMTRAJUJQXCT-UHFFFAOYSA-N","InChI=1S/C11H13N3O/c1-12-10-8-13(2)14(11(10)15)9-6-4-3-5-7-9/h3-8,12H,1-2H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00252","amiodarone","2157","IYIKLHRQXLHMJQ-UHFFFAOYSA-N","InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3","CYP3A4; CYP2C8; CYP2C9; CYP1A2; CYP2D6","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES","Human Phase I","Human","N-Desethylamiodarone","NULL","VXOKDLACQICQFA-UHFFFAOYSA-N","InChI=1S/C23H25I2NO3/c1-3-5-9-20-21(16-8-6-7-10-19(16)29-20)22(27)15-13-17(24)23(18(25)14-15)28-12-11-26-4-2/h6-8,10,13-14,26H,3-5,9,11-12H2,1-2H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00253","amitriptyline","2160","KRMDCWKBEZIMAB-UHFFFAOYSA-N","InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3","CYP2C19; CYP3A4; CYP2C9; CYP1A2","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","Nortriptyline","NULL","PHVGLTMQBUFIQQ-UHFFFAOYSA-N","InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3","R1) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00254","amitriptyline","2160","KRMDCWKBEZIMAB-UHFFFAOYSA-N","InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3","CYP2D6","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","E-10-OH-amitriptyline","NULL","GHWBJXOKAFHZAI-ATVHPVEESA-N","InChI=1S/C20H23NO/c1-21(2)13-7-12-17-16-9-4-3-8-15(16)14-20(22)19-11-6-5-10-18(17)19/h3-6,8-12,20,22H,7,13-14H2,1-2H3/b17-12-","R1) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3676"
"BIOTID00256","androstenedione","6128","AEMFNILZOJDQLW-LHHMMCJZSA-N","InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15+,16-,18+,19+/m1/s1","CYP3A4","Hydroxylation of carbon gamma to conjugated carbonyl","Human Phase I","Human","6beta-hydroxy-androstenedione","YZXBAPSDXZZRGB","WVAMBAWFDOYFOD-HAMDJXSXSA-N","InChI=1S/C19H26O3/c1-18-7-5-11(20)9-15(18)16(21)10-12-13-3-4-17(22)19(13,2)8-6-14(12)18/h9,12-14,16,21H,3-8,10H2,1-2H3/t12-,13+,14-,16?,18-,19+/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00257","aniline","6115","PAYRUJLWNCNPSJ-UHFFFAOYSA-N","InChI=1S/C6H7N/c7-6-4-2-1-3-5-6/h1-5H,7H2","CYP2E1","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","4-aminophenol","NULL","PLIKAWJENQZMHA-UHFFFAOYSA-N","InChI=1S/C6H7NO/c7-5-1-3-6(8)4-2-5/h1-4,8H,7H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00258","aniline","6115","PAYRUJLWNCNPSJ-UHFFFAOYSA-N","InChI=1S/C6H7N/c7-6-4-2-1-3-5-6/h1-5H,7H2","CYP2E1","N-hydroxylation of primary arylamine","Human Phase I","Human","N-Hydroxyaniline","NULL","CKRZKMFTZCFYGB-UHFFFAOYSA-N","InChI=1S/C6H7NO/c8-7-6-4-2-1-3-5-6/h1-5,7-8H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00259","antipyrine","2206","VEQOALNAAJBPNY-UHFFFAOYSA-N","InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3","CYP2C8; CYP2C19; CYP2C9; CYP1A2","N-dealkylation of hydrazine","Human Phase I","Human","Norantipyrine","NULL","KZQYIMCESJLPQH-UHFFFAOYSA-N","InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-7,11H,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00260","antipyrine","2206","VEQOALNAAJBPNY-UHFFFAOYSA-N","InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3","CYP1A2 ; CYP2C9","Hydroxylation of carbon gamma to conjugated carbonyl","Human Phase I","Human","3-OH-methylantipyrine","NULL","JBJKAGOWIZGVTR-UHFFFAOYSA-N","InChI=1S/C11H12N2O2/c1-12-10(8-14)7-11(15)13(12)9-5-3-2-4-6-9/h2-7,14H,8H2,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00261","antipyrine","2206","VEQOALNAAJBPNY-UHFFFAOYSA-N","InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3","CYP3A4 (major); CYP1A2 (minor)","Hydroxylation of carbon alpha to conjugated carbonyl","Human Phase I","Human","4-OH-antipyrine","98889","SKVPTPMWXJSBTF-UHFFFAOYSA-N","InChI=1S/C11H12N2O2/c1-8-10(14)11(15)13(12(8)2)9-6-4-3-5-7-9/h3-7,14H,1-2H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00262","aprepitant","6918365","ATALOFNDEOCMKK-OITMNORJSA-N","InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1","CYP3A4; CYP3A5; CYP1A2; CYP2C19","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","5‐oxo‐1,4‐dihydro‐1,2,4‐triazole‐3‐carbaldehyde","NULL","YLAKZWGIZJMOJV-UHFFFAOYSA-N","InChI=1S/C3H3N3O2/c7-1-2-4-3(8)6-5-2/h1H,(H2,4,5,6,8)","Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322"
"BIOTID00262","aprepitant","6918365","ATALOFNDEOCMKK-OITMNORJSA-N","InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1","CYP3A4; CYP3A5; CYP1A2; CYP2C19","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","(2R,3S)‐2‐[(1R)‐1‐[3,5‐bis(trifluoromethyl)phenyl]ethoxy]‐3‐(4‐fluorophenyl)morpholine","10113945","AFBDSAJOMZYQAI-CNOZUTPLSA-N","InChI=1S/C20H18F7NO2/c1-11(13-8-14(19(22,23)24)10-15(9-13)20(25,26)27)30-18-17(28-6-7-29-18)12-2-4-16(21)5-3-12/h2-5,8-11,17-18,28H,6-7H2,1H3/t11-,17+,18-/m1/s1","Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322"
"BIOTID00263","aprepitant","6918365","ATALOFNDEOCMKK-OITMNORJSA-N","InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1","CYP3A4; CYP3A5; CYP1A2; CYP2C19","O-dealkylation of dialkylether","Human Phase I","Human","1‐[3,5‐bis(trifluoromethyl)phenyl]ethanone","NULL","MCYCSIKSZLARBD-UHFFFAOYSA-N","InChI=1S/C10H6F6O/c1-5(17)6-2-7(9(11,12)13)4-8(3-6)10(14,15)16/h2-4H,1H3","Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322"
"BIOTID00263","aprepitant","6918365","ATALOFNDEOCMKK-OITMNORJSA-N","InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1","CYP3A4; CYP3A5; CYP1A2; CYP2C19","O-dealkylation of dialkylether","Human Phase I","Human","5‐{[(2S,3S)‐3‐(4‐fluorophenyl)‐2‐hydroxymorpholin‐4‐yl]methyl}‐2,4‐dihydro‐1,2,4‐triazol‐3‐one","NULL","CDZWBDBZNZTSAL-RYUDHWBXSA-N","InChI=1S/C13H15FN4O3/c14-9-3-1-8(2-4-9)11-12(19)21-6-5-18(11)7-10-15-13(20)17-16-10/h1-4,11-12,19H,5-7H2,(H2,15,16,17,20)/t11-,12-/m0/s1","Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322"
"BIOTID00264","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2C8; CYP2C9","Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene","Human Phase I","Human","5-HETE","NULL","KGIJOOYOSFUGPC-XTDASVJISA-N","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h6-7,9-10,12-14,16,19,21H,2-5,8,11,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,13-12-,16-14+","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00265","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A2; CYP3A4","Bisallylic hydroxylation","Human Phase I","Human","7-HETE","NULL","RXLAEFPIBOZBTL-UNXCDKAXSA-N","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-13-16-19(21)17-14-12-15-18-20(22)23/h6-7,9-10,13-14,16-17,19,21H,2-5,8,11-12,15,18H2,1H3,(H,22,23)/b7-6-,10-9-,16-13-,17-14-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00266","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A2; CYP2C8; CYP3A4","Bisallylic hydroxylation","Human Phase I","Human","10-HETE","NULL","ZUOCVLADVGGUGH-OVMCANAPSA-N","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-10-13-16-19(21)17-14-11-8-9-12-15-18-20(22)23/h6-9,13-14,16-17,19,21H,2-5,10-12,15,18H2,1H3,(H,22,23)/b7-6-,9-8-,16-13-,17-14-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00267","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A2; CYP2C8; CYP2C9; CYP3A4","Bisallylic hydroxylation","Human Phase I","Human","13-HETE","NULL","SAKQICHVWOJSNI-BWWNDVLWSA-N","InChI=1S/C20H32O3/c1-2-3-4-10-13-16-19(21)17-14-11-8-6-5-7-9-12-15-18-20(22)23/h6-9,13-14,16-17,19,21H,2-5,10-12,15,18H2,1H3,(H,22,23)/b8-6-,9-7-,16-13-,17-14-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00268","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2A6","Hydroxylation of terminal methyl","Human Phase I","Human","20-HETE","NULL","NNDIXBJHNLFJJP-DTLRTWKJSA-N","InChI=1S/C20H32O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6-7,9-10,12,21H,2,5,8,11,13-19H2,(H,22,23)/b3-1-,6-4-,9-7-,12-10-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00269","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2C8; CYP2C9; CYP2C19; CYP2E1","Hydroxylation of penultimate aliphatic secondary carbon","Human Phase I","Human","19-HETE","NULL","XFUXZHQUWPFWPR-TWVHMNNTSA-N","InChI=1S/C20H32O3/c1-19(21)17-15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18-20(22)23/h3-6,9-12,19,21H,2,7-8,13-18H2,1H3,(H,22,23)/b5-3-,6-4-,11-9-,12-10-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00270","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2E1","Hydroxylation of acyclic aliphatic secondary carbon","Human Phase I","Human","18-HETE","NULL","PPCHNRUZQWLEMF-XBOCNYGYSA-N","InChI=1S/C20H32O3/c1-2-19(21)17-15-13-11-9-7-5-3-4-6-8-10-12-14-16-18-20(22)23/h4-7,10-13,19,21H,2-3,8-9,14-18H2,1H3,(H,22,23)/b6-4-,7-5-,12-10-,13-11-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00271","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2","Hydroxylation of acyclic aliphatic secondary carbon","Human Phase I","Human","17-HETE","NULL","OPPIPPRXLIDJKN-JPURVOHMSA-N","InChI=1S/C20H32O3/c1-2-16-19(21)17-14-12-10-8-6-4-3-5-7-9-11-13-15-18-20(22)23/h3,5-6,8-9,11-12,14,19,21H,2,4,7,10,13,15-18H2,1H3,(H,22,23)/b5-3-,8-6-,11-9-,14-12-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00272","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2","Allylic hydroxylation","Human Phase I","Human","16-HETE","NULL","JEKNPVYFNMZRJG-UFINWASNSA-N","InChI=1S/C20H32O3/c1-2-3-16-19(21)17-14-12-10-8-6-4-5-7-9-11-13-15-18-20(22)23/h4-5,8-11,14,17,19,21H,2-3,6-7,12-13,15-16,18H2,1H3,(H,22,23)/b5-4-,10-8-,11-9-,17-14-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00273","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2B6 (minor); CYP2D6","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","14,15-EET","NULL","JBSCUHKPLGKXKH-ILYOTBPNSA-N","InChI=1S/C20H32O3/c1-2-3-12-15-18-19(23-18)16-13-10-8-6-4-5-7-9-11-14-17-20(21)22/h4,6-7,9-10,13,18-19H,2-3,5,8,11-12,14-17H2,1H3,(H,21,22)/b6-4-,9-7-,13-10-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00274","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2B6 (minor); CYP2D6","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","11,12-EET","NULL","DXOYQVHGIODESM-KROJNAHFSA-N","InChI=1S/C20H32O3/c1-2-3-4-5-9-12-15-18-19(23-18)16-13-10-7-6-8-11-14-17-20(21)22/h6,8-10,12-13,18-19H,2-5,7,11,14-17H2,1H3,(H,21,22)/b8-6-,12-9-,13-10-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00275","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2B6 (minor); CYP2D6","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","8,9-EET","NULL","DBWQSCSXHFNTMO-TYAUOURKSA-N","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-12-15-18-19(23-18)16-13-10-11-14-17-20(21)22/h6-7,9-10,12-13,18-19H,2-5,8,11,14-17H2,1H3,(H,21,22)/b7-6-,12-9-,13-10-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00276","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2B6 (minor); CYP2D6","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","5,6-EET","NULL","VBQNSZQZRAGRIX-QNEBEIHSSA-N","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-19(23-18)16-14-17-20(21)22/h6-7,9-10,12-13,18-19H,2-5,8,11,14-17H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00277","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2C8","Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene","Human Phase I","Human","15-HETE","NULL","JSFATNQSLKRBCI-USWFWKISSA-N","InChI=1S/C20H32O3/c1-2-3-13-16-19(21)17-14-11-9-7-5-4-6-8-10-12-15-18-20(22)23/h4-5,8-11,14,17,19,21H,2-3,6-7,12-13,15-16,18H2,1H3,(H,22,23)/b5-4-,10-8-,11-9-,17-14+","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00278","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2C9","Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene","Human Phase I","Human","12-HETE","NULL","ZNHVWPKMFKADKW-VXBMJZGYSA-N","InChI=1S/C20H32O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h7-11,13-14,17,19,21H,2-6,12,15-16,18H2,1H3,(H,22,23)/b9-7-,11-8-,13-10-,17-14+","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00279","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2C8","Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene","Human Phase I","Human","11-HETE","NULL","GCZRCCHPLVMMJE-RLZWZWKOSA-N","InChI=1S/C20H32O3/c1-2-3-4-5-7-10-13-16-19(21)17-14-11-8-6-9-12-15-18-20(22)23/h6-7,9-11,13-14,16,19,21H,2-5,8,12,15,17-18H2,1H3,(H,22,23)/b9-6-,10-7-,14-11-,16-13+","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00280","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A2; CYP2C8; CYP2C9","Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene","Human Phase I","Human","9-HETE","NULL","KATOYYZUTNAWSA-ZMTMACIGSA-N","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-10-13-16-19(21)17-14-11-9-12-15-18-20(22)23/h6-7,9-11,13-14,17,19,21H,2-5,8,12,15-16,18H2,1H3,(H,22,23)/b7-6-,11-9-,13-10-,17-14-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00281","arachidonic acid","444899","YZXBAPSDXZZRGB-DOFZRALJSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-","CYP1A1; CYP1A2; CYP2C8; CYP2C9","Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene","Human Phase I","Human","8-HETE","NULL","NLUNAYAEIJYXRB-HEJOTXCHSA-N","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-13-16-19(21)17-14-11-12-15-18-20(22)23/h6-7,9-11,13-14,16,19,21H,2-5,8,12,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,14-11-,16-13+","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00282","aripiprazole","60795","CEUORZQYGODEFX-UHFFFAOYSA-N","InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)","CYP3A4","Dehydrogenation of alpha,beta-unsaturated amide","Human Phase I","Human","dehydro-aripiprazole","NULL","CDONPRYEWWPREK-UHFFFAOYSA-N","InChI=1S/C23H25Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-9,16H,1-2,10-15H2,(H,26,29)","Bauman, N. et al (2008), Comparison of the Bioactivation Potential of the Antidepressant and Hepatotaxin Nefazodone with Aripiprazole, a Structural Analog and Marketed Drug, DMD 36:1016-1029, 2008"
"BIOTID00283","aripiprazole","60795","CEUORZQYGODEFX-UHFFFAOYSA-N","InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)","CYP2D6","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","4-Hydroxyaripiprazole","NULL","YZIVLADPQQPFLO-UHFFFAOYSA-N","InChI=1S/C23H27Cl2N3O3/c24-22-19(6-7-20(29)23(22)25)28-12-10-27(11-13-28)9-1-2-14-31-17-5-3-16-4-8-21(30)26-18(16)15-17/h3,5-7,15,29H,1-2,4,8-14H2,(H,26,30)","Shi, R. et al, (2003), Catalytic mechanism of Cytochrome P450 2D6 for 4-hyroxylation of aripirazole: A QM/MM study; DOI:10.1002/ejoc.201300427"
"BIOTID00284","aripiprazole","60795","CEUORZQYGODEFX-UHFFFAOYSA-N","InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","2,3‐dichlorophenylpiperazine","NULL","UDQMXYJSNNCRAS-UHFFFAOYSA-N","InChI=1S/C10H12Cl2N2/c11-8-2-1-3-9(10(8)12)14-6-4-13-5-7-14/h1-3,13H,4-7H2","Caccia, S. (2007); N-Delakylation of arylpiprazine derivatives: Disposition and metabolism of 1-arylpiperazines formed, Curr Drug Metab 8: 612-622."
"BIOTID00284","aripiprazole","60795","CEUORZQYGODEFX-UHFFFAOYSA-N","InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","4‐[(2‐oxo‐3,4‐dihydro‐1H‐quinolin‐7‐yl)oxy]butanal","NULL","UEXWWBPDALYPLF-UHFFFAOYSA-N","InChI=1S/C13H15NO3/c15-7-1-2-8-17-11-5-3-10-4-6-13(16)14-12(10)9-11/h3,5,7,9H,1-2,4,6,8H2,(H,14,16)","Caccia, S. (2007); N-Delakylation of arylpiprazine derivatives: Disposition and metabolism of 1-arylpiperazines formed, Curr Drug Metab 8: 612-622."
"BIOTID00285","arverapamil","15593907","UPKQNCPKPOLASS-AREMUKBSSA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1","CYP2C8; CYP3A4; CYP2D6","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","(2R)-5-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-(3-methoxyphenyl)-2-(propan-2-yl)pentanenitrile","NULL","IQVLXQZAOGCLEE-RUZDIDTESA-N","InChI=1S/C25H34N2O3/c1-19(2)25(18-26,21-8-6-9-22(17-21)28-3)13-7-14-27-15-12-20-10-11-23(29-4)24(16-20)30-5/h6,8-11,16-17,19,27H,7,12-15H2,1-5H3/t25-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00286","arverapamil","15593907","UPKQNCPKPOLASS-AREMUKBSSA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1","CYP2C8; CYP3A4; CYP2D6","N-dealkylation of acyclic secondary amine","Human Phase I","Human","(2R)-5-amino-2-(3-methoxyphenyl)-2-(propan-2-yl)pentanenitrile","NULL","BQGFPUBUNKYGEY-OAHLLOKOSA-N","InChI=1S/C15H22N2O/c1-12(2)15(11-17,8-5-9-16)13-6-4-7-14(10-13)18-3/h4,6-7,10,12H,5,8-9,16H2,1-3H3/t15-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00287","arverapamil","15593907","UPKQNCPKPOLASS-AREMUKBSSA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1","CYP2C8; CYP3A4; CYP2D6","N-dealkylation of acyclic secondary amine","Human Phase I","Human","2-(3,4-dimethoxyphenyl)acetaldehyde","NULL","RIVVYJWUHXMGSK-UHFFFAOYSA-N","InChI=1S/C10H12O3/c1-12-9-4-3-8(5-6-11)7-10(9)13-2/h3-4,6-7H,5H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00288","astemizole","2247","GXDALQBWZGODGZ-UHFFFAOYSA-N","InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)","CYP2D6; CYP3A4 (minor)","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-Hydroxyastemizole","NULL","GJJYAIIDIMCSIM-UHFFFAOYSA-N","InChI=1S/C28H31FN4O2/c1-35-25-9-4-20(5-10-25)12-15-32-16-13-23(14-17-32)30-28-31-26-11-8-24(34)18-27(26)33(28)19-21-2-6-22(29)7-3-21/h2-11,18,23,34H,12-17,19H2,1H3,(H,30,31)","Matsumoto, S.and Yamazoe, Y. (2001); Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine; Br J Clin Pharmacol.; 51(2):133-42; PMID:11259984; PMCID:PMC2014443"
"BIOTID00289","astemizole","2247","GXDALQBWZGODGZ-UHFFFAOYSA-N","InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)","CYP2D6","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","6-desmethylastermizole","NULL","LAGYWHSFHIMTPE-UHFFFAOYSA-N","InChI=1S/C27H29FN4O/c28-22-9-5-21(6-10-22)19-32-26-4-2-1-3-25(26)30-27(32)29-23-14-17-31(18-15-23)16-13-20-7-11-24(33)12-8-20/h1-12,23,33H,13-19H2,(H,29,30)","Matsumoto, S.and Yamazoe, Y. (2001); Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine; Br J Clin Pharmacol.; 51(2):133-42; PMID:11259984; PMCID:PMC2014443"
"BIOTID00290","astemizole","2247","GXDALQBWZGODGZ-UHFFFAOYSA-N","InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)","CYP3A4 (minor)","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","norastemizole","NULL","SFOVDSLXFUGAIV-UHFFFAOYSA-N","InChI=1S/C19H21FN4/c20-15-7-5-14(6-8-15)13-24-18-4-2-1-3-17(18)23-19(24)22-16-9-11-21-12-10-16/h1-8,16,21H,9-13H2,(H,22,23)","Matsumoto, S.and Yamazoe, Y. (2001); Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine; Br J Clin Pharmacol.; 51(2):133-42; PMID:11259984; PMCID:PMC2014443"
"BIOTID00290","astemizole","2247","GXDALQBWZGODGZ-UHFFFAOYSA-N","InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)","CYP3A4 (minor)","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","2-(4-hydroxyphenyl)acetaldehyde","NULL","IPRPPFIAVHPVJH-UHFFFAOYSA-N","InChI=1S/C8H8O2/c9-6-5-7-1-3-8(10)4-2-7/h1-4,6,10H,5H2","Matsumoto, S.and Yamazoe, Y. (2001); Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine; Br J Clin Pharmacol.; 51(2):133-42; PMID:11259984; PMCID:PMC2014443"
"BIOTID00291","atorvastatin","60823","XUKUURHRXDUEBC-KAYWLYCHSA-N","InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","CZBPKFICAYVHHM-UHFFFAOYSA-N","InChI=1S/C33H35FN2O6/c1-20(2)31-30(33(42)35-26-10-6-7-11-27(26)39)29(21-8-4-3-5-9-21)32(22-12-14-23(34)15-13-22)36(31)17-16-24(37)18-25(38)19-28(40)41/h3-15,20,24-25,37-39H,16-19H2,1-2H3,(H,35,42)(H,40,41)","PMID:11038166"
"BIOTID00292","atorvastatin","60823","XUKUURHRXDUEBC-KAYWLYCHSA-N","InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","SOZOATLLFFVAPM-UHFFFAOYSA-N","InChI=1S/C33H35FN2O6/c1-20(2)31-30(33(42)35-24-12-14-25(37)15-13-24)29(21-6-4-3-5-7-21)32(22-8-10-23(34)11-9-22)36(31)17-16-26(38)18-27(39)19-28(40)41/h3-15,20,26-27,37-39H,16-19H2,1-2H3,(H,35,42)(H,40,41)","PMID:11038166"
"BIOTID00293","barnidipine","443869","VXMOONUMYLCFJD-DHLKQENFSA-N","InChI=1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1","CYP2A6;CYP2D6;CYP3A4","N-dealkylation","Human Phase I","Human","NULL","NULL","HTLZEIXVGBRHFZ-UHFFFAOYSA-N","InChI=1S/C20H23N3O6/c1-11-16(19(24)28-3)18(13-5-4-6-14(9-13)23(26)27)17(12(2)22-11)20(25)29-15-7-8-21-10-15/h4-6,9,15,18,21-22H,7-8,10H2,1-3H3","PMID:9381730"
"BIOTID00294","barnidipine","443869","VXMOONUMYLCFJD-DHLKQENFSA-N","InChI=1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1","CYP2A6;CYP2D6;CYP3A4","O-dealkylation","Human Phase I","Human","NULL","NULL","JPXPPUOCSLMCHK-UHFFFAOYSA-N","InChI=1S/C16H16N2O6/c1-8-12(15(19)20)14(13(9(2)17-8)16(21)24-3)10-5-4-6-11(7-10)18(22)23/h4-7,14,17H,1-3H3,(H,19,20)","PMID:9381730"
"BIOTID00295","barnidipine","443869","VXMOONUMYLCFJD-DHLKQENFSA-N","InChI=1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1","CYP2A6;CYP2D6;CYP3A4","Dehydrogenation","Human Phase I","Human","NULL","NULL","DFWOMDUVXAUTRY-UHFFFAOYSA-N","InChI=1S/C27H27N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22H,12-13,15-16H2,1-3H3","PMID:9381730"
"BIOTID00296","benzene","241","UHOVQNZJYSORNB-UHFFFAOYSA-N","InChI=1S/C6H6/c1-2-4-6-5-3-1/h1-6H","CYP2E1","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","Phenol","NULL","ISWSIDIOOBJBQZ-UHFFFAOYSA-N","InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00297","benzeneethanol, 2-[(2,6-dichlorophenyl)amino]- (reduced_diclofenac)","22294737","NFWJEEBVQAMWHK-UHFFFAOYSA-N","InChI=1S/C14H13Cl2NO/c15-11-5-3-6-12(16)14(11)17-13-7-2-1-4-10(13)8-9-18/h1-7,17-18H,8-9H2","CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","QXCJJTXPLFSTFY-UHFFFAOYSA-N","InChI=1S/C14H13Cl2NO2/c15-11-2-1-3-12(16)14(11)17-13-5-4-10(19)8-9(13)6-7-18/h1-5,8,17-19H,6-7H2","PMID:10572000"
"BIOTID00298","benzo(a)pyrene-7,8-diol","42267","FWKXMJCJEOUXDE-UHFFFAOYSA-N","InChI=1S/C20H12O2/c21-17-9-8-14-15-7-6-12-3-1-2-11-4-5-13(19(15)18(11)12)10-16(14)20(17)22/h1-10,21-22H","CYP1A2","Epoxidation","Human Phase I","Human","NULL","NULL","DDBQMRHLXNECKQ-UHFFFAOYSA-N","InChI=1S/C20H10O3/c21-17-13-8-11-5-4-9-2-1-3-10-6-7-12(15(11)14(9)10)16(13)19-20(23-19)18(17)22/h1-8,21-22H","PMID:9806168"
"BIOTID00299","bergapten","2355","BGEBZHIAGXMEMV-UHFFFAOYSA-N","InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3","CYP2D6","Epoxidation","Human Phase I","Human","NULL","NULL","RFWVPDXUEAKCDE-UHFFFAOYSA-N","InChI=1S/C12H8O5/c1-14-10-5-2-3-8(13)15-6(5)4-7-9(10)11-12(16-7)17-11/h2-4,11-12H,1H3","PMID:9665710"
"BIOTID00300","beta_arteether","NULL","AGXLQRPCBKYRSR-JWETUGRJSA-N","InChI=1S/C18H30O5/c1-5-19-15-12(3)14-9-8-11(2)13-7-6-10-17(4)21-16(20-15)18(13,14)23-22-17/h11-16H,5-10H2,1-4H3/t11-,12-,13+,14+,15+,16-,17+,18+/m1/s1","CYP2B6;CYP3A4","O-dealkylation","Human Phase I","Human","DIHYDROQINGHAOSU","NULL","IZUFEMLWLHVKQB-UHFFFAOYSA-N","InChI=1S/C16H26O5/c1-9-6-7-12-10(2)13(17)18-14-16(12)11(9)5-4-8-15(3,19-14)20-21-16/h9-14,17H,4-8H2,1-3H3","PMID:9531517"
"BIOTID00301","beta-artelinic acid","10341948","UVNHKOOJXSALHN-ILQPJIFQSA-N","InChI=1S/C23H30O7/c1-13-4-9-18-14(2)20(26-12-15-5-7-16(8-6-15)19(24)25)27-21-23(18)17(13)10-11-22(3,28-21)29-30-23/h5-8,13-14,17-18,20-21H,4,9-12H2,1-3H3,(H,24,25)/t13-,14-,17+,18+,20+,21-,22-,23-/m1/s1","CYP3A4","O-Debenzylation","Human Phase I","Human","Dihydroqinghaosu (DQHS)","540327","BJDCWCLMFKKGEE-UHFFFAOYSA-N","InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3","PMID:10456689"
"BIOTID00302","beta-methylstyrene","252325","QROGIFZRVHSFLM-QHHAFSJGSA-N","InChI=1S/C9H10/c1-2-6-9-7-4-3-5-8-9/h2-8H,1H3/b6-2+","CYP1A2;CYP2E1;CYP3A4","Epoxidation","Human Phase I","Human","2-methyl-3-phenyloxirane","123339","YVCOJTATJWDGEU-UHFFFAOYSA-N","InChI=1S/C9H10O/c1-7-9(10-7)8-5-3-2-4-6-8/h2-7,9H,1H3","PMID:16038959"
"BIOTID00303","beta-methylstyrene","252325","QROGIFZRVHSFLM-QHHAFSJGSA-N","InChI=1S/C9H10/c1-2-6-9-7-4-3-5-8-9/h2-8H,1H3/b6-2+","CYP1A2;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","5315892","OOCCDEMITAIZTP-QPJJXVBHSA-N","InChI=1S/C9H10O/c10-8-4-7-9-5-2-1-3-6-9/h1-7,10H,8H2/b7-4+","PMID:16038959"
"BIOTID00304","bifendate","108213","JMZOMFYRADAWOG-UHFFFAOYSA-N","InChI=1S/C20H18O10/c1-23-11-5-9(19(21)25-3)13(17-15(11)27-7-29-17)14-10(20(22)26-4)6-12(24-2)16-18(14)30-8-28-16/h5-6H,7-8H2,1-4H3","CYP2C9;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","NULL","YVOKQKHMISVOBZ-UHFFFAOYSA-N","InChI=1S/C19H18O10/c1-24-10-5-8(18(22)26-3)12(15(21)14(10)20)13-9(19(23)27-4)6-11(25-2)16-17(13)29-7-28-16/h5-6,20-21H,7H2,1-4H3","PMID:11259320"
"BIOTID00305","bifendate","108213","JMZOMFYRADAWOG-UHFFFAOYSA-N","InChI=1S/C20H18O10/c1-23-11-5-9(19(21)25-3)13(17-15(11)27-7-29-17)14-10(20(22)26-4)6-12(24-2)16-18(14)30-8-28-16/h5-6H,7-8H2,1-4H3","CYP1A2","O-Demethylation","Human Phase I","Human","NULL","124746","PGORXRYYHHQBMW-UHFFFAOYSA-N","InChI=1S/C19H16O10/c1-23-11-5-9(19(22)25-3)13(17-15(11)27-7-29-17)12-8(18(21)24-2)4-10(20)14-16(12)28-6-26-14/h4-5,20H,6-7H2,1-3H3","PMID:11259320"
"BIOTID00306","biochanin a","5280373","WUADCCWRTIWANL-UHFFFAOYSA-N","InChI=1S/C16H12O5/c1-20-11-4-2-9(3-5-11)12-8-21-14-7-10(17)6-13(18)15(14)16(12)19/h2-8,17-18H,1H3","CYP1A2;CYP2C9;CYP2C19; CYP2D6; CYP2E1","O-Demethylation","Human Phase I","Human","NULL","5280961","TZBJGXHYKVUXJN-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H","PMID:12166960"
"BIOTID00307","bms_275183","6918594","AHXICHPPXIGCBN-AQYLXIGCSA-N","InChI=1S/C43H59NO16/c1-21-24(57-35(50)28(47)31(38(3,4)5)44-36(51)59-39(6,7)8)19-43(53)33(58-34(49)23-16-14-13-15-17-23)30-41(11,32(48)29(56-22(2)45)27(21)40(43,9)10)25(46)18-26-42(30,20-55-26)60-37(52)54-12/h13-17,24-26,28-31,33,46-47,53H,18-20H2,1-12H3,(H,44,51)/t24-,25-,26+,28+,29+,30-,31+,33-,41+,42-,43+/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","FJXCOVGJBIFUNA-UHFFFAOYSA-N","InChI=1S/C43H59NO17/c1-21-24(58-35(51)28(48)31(39(6,7)19-45)44-36(52)60-38(3,4)5)18-43(54)33(59-34(50)23-15-13-12-14-16-23)30-41(10,32(49)29(57-22(2)46)27(21)40(43,8)9)25(47)17-26-42(30,20-56-26)61-37(53)55-11/h12-16,24-26,28-31,33,45,47-48,54H,17-20H2,1-11H3,(H,44,52)","PMID:19158314"
"BIOTID00308","bosentan","104865","GJPICJJJRGTNOD-UHFFFAOYSA-N","InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)","CYP3A4 (major); CYP2C9 (minor)","Hydroxylation of terminal methyl","Human Phase I","Human","4-(2-hydroxy-1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2Ã¢â‚¬â„¢]bipyrimidinyl-4-yl]-benzenesulfonamide","6426755","FAJQMBCLPZWTQJ-UHFFFAOYSA-N","InChI=1S/C27H29N5O7S/c1-27(2,17-34)18-9-11-19(12-10-18)40(35,36)32-23-22(39-21-8-5-4-7-20(21)37-3)26(38-16-15-33)31-25(30-23)24-28-13-6-14-29-24/h4-14,33-34H,15-17H2,1-3H3,(H,30,31,32)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00309","bosentan","104865","GJPICJJJRGTNOD-UHFFFAOYSA-N","InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)","CYP3A4 (major); CYP2C9 (minor)","O-aryl demethylation","Human Phase I","Human","4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-[2,2Ã¢â‚¬â„¢]bipyrimidinyl-4-yl]-benzenesulfonamide","6426756","STTLKJGYAWXIPP-UHFFFAOYSA-N","InChI=1S/C26H27N5O6S/c1-26(2,3)17-9-11-18(12-10-17)38(34,35)31-22-21(37-20-8-5-4-7-19(20)33)25(36-16-15-32)30-24(29-22)23-27-13-6-14-28-23/h4-14,32-33H,15-16H2,1-3H3,(H,29,30,31)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00310","brn 4201400","3076831","GZDFOOAFMQSYOV-UHFFFAOYSA-N","InChI=1S/C14H20N4O2/c1-9-15-11-12(16-9)18(14(20)17(2)13(11)19)8-10-6-4-3-5-7-10/h10H,3-8H2,1-2H3,(H,15,16)","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","ZAHWULQALWTXHA-UHFFFAOYSA-N","InChI=1S/C14H20N4O3/c1-17-13(20)11-12(16-10(8-19)15-11)18(14(17)21)7-9-5-3-2-4-6-9/h9,19H,2-8H2,1H3,(H,15,16)","PMID:9585555"
"BIOTID00311","brofaromine","44571","WZXHSWVDAYOFPE-UHFFFAOYSA-N","InChI=1S/C14H16BrNO2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16H,2-5H2,1H3","CYP2D6","O-aryl demethylation","Human Phase I","Human","O-desmethyl-brofaromine","129154","ROFOHNHESMVUGP-UHFFFAOYSA-N","InChI=1S/C13H14BrNO2/c14-11-7-10(16)5-9-6-12(17-13(9)11)8-1-3-15-4-2-8/h5-8,15-16H,1-4H2","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00312","bromocriptine","31101","OZVBMTJYIDMWIL-AYFBDAFISA-N","InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","NZGWOMCNZDKBSR-UHFFFAOYSA-N","InChI=1S/C32H40BrN5O6/c1-15(2)11-23-29(41)37-24(9-10-25(37)39)32(43)38(23)30(42)31(44-32,16(3)4)35-28(40)17-12-19-18-7-6-8-21-26(18)20(27(33)34-21)13-22(19)36(5)14-17/h6-8,12,15-17,22-25,34,39,43H,9-11,13-14H2,1-5H3,(H,35,40)","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|PMID:11197065"
"BIOTID00313","bromocriptine","31101","OZVBMTJYIDMWIL-AYFBDAFISA-N","InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","XNJNYHSBPHWTQL-UHFFFAOYSA-N","InChI=1S/C32H40BrN5O6/c1-15(2)9-24-29(41)37-14-18(39)11-25(37)32(43)38(24)30(42)31(44-32,16(3)4)35-28(40)17-10-20-19-7-6-8-22-26(19)21(27(33)34-22)12-23(20)36(5)13-17/h6-8,10,15-18,23-25,34,39,43H,9,11-14H2,1-5H3,(H,35,40)","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|PMID:11197065"
"BIOTID00315","bropirimine","65457","CIUUIPMOFZIWIZ-UHFFFAOYSA-N","InChI=1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)","CYP1A2","m-Hydroxylation of monosubstituted benzene","Human Phase I","Human","m-hydroxybropirimine","6320148","CUDNQOMFBZIEEA-UHFFFAOYSA-N","InChI=1S/C10H8BrN3O2/c11-7-8(13-10(12)14-9(7)16)5-2-1-3-6(15)4-5/h1-4,15H,(H3,12,13,14,16)","Wynalda, M.A. et al. (1998); Human biotransformation of bropirimine. Characterization of the major bropirimine oxidative metabolites formed in vitro; Drug Metab Dispos; 26(10):1048-51; PMID:9763414"
"BIOTID00316","bropirimine","65457","CIUUIPMOFZIWIZ-UHFFFAOYSA-N","InChI=1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)","CYP1A2","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","p-hydroxybropirimine","6320168","BPQDHWHENINUML-UHFFFAOYSA-N","InChI=1S/C10H8BrN3O2/c11-7-8(13-10(12)14-9(7)16)5-1-3-6(15)4-2-5/h1-4,15H,(H3,12,13,14,16)","Wynalda, M.A. et al. (1998); Human biotransformation of bropirimine. Characterization of the major bropirimine oxidative metabolites formed in vitro; Drug Metab Dispos; 26(10):1048-51; PMID:9763414"
"BIOTID00317","brotizolam","2451","UMSGKTJDUHERQW-UHFFFAOYSA-N","InChI=1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","alpha-OH-BRT","173861","SCENUYIFDLIXIB-UHFFFAOYSA-N","InChI=1S/C15H10BrClN4OS/c16-11-5-9-14(8-3-1-2-4-10(8)17)18-6-12-19-20-13(7-22)21(12)15(9)23-11/h1-5,22H,6-7H2","PMID:9381732"
"BIOTID00318","brotizolam","2451","UMSGKTJDUHERQW-UHFFFAOYSA-N","InChI=1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","6-OH-BRT","174711","FNHJIEIZAKAUAN-UHFFFAOYSA-N","InChI=1S/C15H10BrClN4OS/c1-7-19-20-13-14(22)18-12(8-4-2-3-5-10(8)17)9-6-11(16)23-15(9)21(7)13/h2-6,14,22H,1H3","PMID:9381732"
"BIOTID00319","butadiene_monoxide","NULL","GXBYFVGCMPJVJX-UHFFFAOYSA-N","InChI=1S/C4H6O/c1-2-4-3-5-4/h2,4H,1,3H2","CYP2A6;CYP2C9;CYP2E1","Epoxidation","Human Phase I","Human","diepoxybutane (DEB)","11254","ZFIVKAOQEXOYFY-UHFFFAOYSA-N","InChI=1S/C4H6O2/c1-3(5-1)4-2-6-4/h3-4H,1-2H2","PMID:9016811"
"BIOTID00320","caffeine","2519","RYYVLZVUVIJVGH-UHFFFAOYSA-N","InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3","CYP1A2","N-dealkylation of N-acylurea","Human Phase I","Human","Paraxanthine","4687","QUNWUDVFRNGTCO-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)11(2)7(13)9-5/h3H,1-2H3,(H,9,13)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00321","caffeine","2519","RYYVLZVUVIJVGH-UHFFFAOYSA-N","InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3","CYP1A2 (major); CYP2E1 (minor)","N-dealkylation of N-acylurea","Human Phase I","Human","Theobromine","5429","CGHOLCBXEQQSQJ-UHFFFAOYSA-N","InChI=1S/C8H9N3O2/c1-4-5-6(11(2)3-9-5)8(13)10-7(4)12/h3-4H,1-2H3,(H,10,12,13)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00322","caffeine","2519","RYYVLZVUVIJVGH-UHFFFAOYSA-N","InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3","CYP1A2 (major); CYP2C8 (minor); CYP2C9 (minor); CYP3A4 (minor); CYP2E1 (minor)","N-dealkylation of mixed tertiary amine","Human Phase I","Human","Theophylline","2153","ZFXYFBGIUFBOJW-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00323","caffeine","2519","RYYVLZVUVIJVGH-UHFFFAOYSA-N","InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3","CYP1A2 (major); CYP2C8 (minor); CYP2C9 (minor); CYP3A4 (minor); CYP2E1 (minor)","HYDROXYLATION_OF_AROMATIC_CARBON_ADJACENT_TO_N","Human Phase I","Human","1,3,7-Trimethyluric acid","79437","BYXCFUMGEBZDDI-UHFFFAOYSA-N","InChI=1S/C8H10N4O3/c1-10-4-5(9-7(10)14)11(2)8(15)12(3)6(4)13/h1-3H3,(H,9,14)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00329","carbamazepine","2554","FFGPTBGBLSHEPO-UHFFFAOYSA-N","InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)","CYP3A4; CYP2C8 ","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human"," Carbamazepine 10,11-epoxide ","2555","ZRWWEEVEIOGMMT-UHFFFAOYSA-N","InChI=1S/C15H12N2O2/c16-15(18)17-11-7-3-1-5-9(11)13-14(19-13)10-6-2-4-8-12(10)17/h1-8,13-14H,(H2,16,18)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00330","carbamazepine","2554","FFGPTBGBLSHEPO-UHFFFAOYSA-N","InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)","CYP3A4; CYP2C8","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2-Hydroxycarbamazepine ","129274","VPZIYMMSJFWLSP-UHFFFAOYSA-N","InChI=1S/C15H12N2O2/c16-15(19)17-13-4-2-1-3-10(13)5-6-11-9-12(18)7-8-14(11)17/h1-9,18H,(H2,16,19)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Panesar, S. K., Bandiera, S. M., Abbott, F. S. (1996). Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat. Drug Metab. Dispos. 24:619Ã¢â‚¬â€œ627"
"BIOTID00331","carbamazepine","2554","FFGPTBGBLSHEPO-UHFFFAOYSA-N","InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)","CYP3A4; CYP2C8 ","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","3-Hydroxycarbamazepine ","135290","QQCFBZCATDIWTH-UHFFFAOYSA-N","InChI=1S/C15H12N2O2/c16-15(19)17-13-4-2-1-3-10(13)5-6-11-7-8-12(18)9-14(11)17/h1-9,18H,(H2,16,19)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Panesar, S. K., Bandiera, S. M., Abbott, F. S. (1996). Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat. Drug Metab. Dispos. 24:619Ã¢â‚¬â€œ628"
"BIOTID00332","carbamazepine","2554","FFGPTBGBLSHEPO-UHFFFAOYSA-N","InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)","CYP3A4; CYP2C8 ","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","9-Hydroxycarbamazepine ","NULL","YKHJWQHRLUVWBR-UHFFFAOYSA-N","InChI=1S/C15H12N2O2/c16-15(19)17-12-5-2-1-4-10(12)8-9-11-13(17)6-3-7-14(11)18/h1-9,18H,(H2,16,19)","Panesar, S. K. et al. (1996). Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat. Drug Metab. Dispos. 24:619Ã¢â‚¬â€œ628"
"BIOTID00333","carbaryl","6129","CVXBEEMKQHEXEN-UHFFFAOYSA-N","InChI=1S/C12H11NO2/c1-13-12(14)15-11-8-4-6-9-5-2-3-7-10(9)11/h2-8H,1H3,(H,13,14)","CYP1A2;CYP2B6;CYP2C19;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","4-hydroxycarbaryl","21956","MDIMSJGGKSUKJZ-UHFFFAOYSA-N","InChI=1S/C12H11NO3/c1-13-12(15)16-11-7-3-4-8-9(11)5-2-6-10(8)14/h2-7,14H,1H3,(H,13,15)","PMID:12385721"
"BIOTID00334","carbaryl","6129","CVXBEEMKQHEXEN-UHFFFAOYSA-N","InChI=1S/C12H11NO2/c1-13-12(14)15-11-8-4-6-9-5-2-3-7-10(9)11/h2-8H,1H3,(H,13,14)","CYP1A2;CYP2B6;CYP2C19;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","5-hydroxycarbaryl","21342","AXMHCYHGQSQUDN-UHFFFAOYSA-N","InChI=1S/C12H11NO3/c1-13-12(15)16-11-7-6-10(14)8-4-2-3-5-9(8)11/h2-7,14H,1H3,(H,13,15)","PMID:12385721"
"BIOTID00335","carbaryl","6129","CVXBEEMKQHEXEN-UHFFFAOYSA-N","InChI=1S/C12H11NO2/c1-13-12(14)15-11-8-4-6-9-5-2-3-7-10(9)11/h2-8H,1H3,(H,13,14)","CYP1A2;CYP2B6;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","carbaryl methylol","21341","OBFZZQGUNWTREB-UHFFFAOYSA-N","InChI=1S/C12H11NO3/c14-8-13-12(15)16-11-7-3-5-9-4-1-2-6-10(9)11/h1-7,14H,8H2,(H,13,15)","PMID:12385721"
"BIOTID00336","Carbofuran","2566","DUEPRVBVGDRKAG-UHFFFAOYSA-N","InChI=1S/C12H15NO3/c1-12(2)7-8-5-4-6-9(10(8)16-12)15-11(14)13-3/h4-6H,7H2,1-3H3,(H,13,14)","CYP1A2; CYP2C19; CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","e-hydroxy-carbofuran","27975","RHSUJRQZTQNSLL-UHFFFAOYSA-N","InChI=1S/C12H15NO4/c1-12(2)10(14)7-5-4-6-8(9(7)17-12)16-11(15)13-3/h4-6,10,14H,1-3H3,(H,13,15)","Abass, K. et al. (2010). Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem. Biol. Interact., Vol. 185, No. 3, (163-173).|Usmani et al.,Chem. Biol. Inter.,150,221,2004 PMID:15560889"
"BIOTID00337","celecoxib","2662","RZEKVGVHFLEQIL-UHFFFAOYSA-N","InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)","CYP2C9 (major); CYP3A4 (minor); CYP2C19 (minor)","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","Hydroxy celecoxib","9908776","ICRSYPPLGADZKA-UHFFFAOYSA-N","InChI=1S/C17H14F3N3O3S/c18-17(19,20)16-9-15(12-3-1-11(10-24)2-4-12)23(22-16)13-5-7-14(8-6-13)27(21,25)26/h1-9,24H,10H2,(H2,21,25,26)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Karjalainen, M. (2008), Blackwell Publishing Ltd In vitro Inhibition of CYP1A2 by Model Inhibitors, Anti-Inflammatory Analgesics and Female Sex Steroids: Predictability of in vivo Interactions; DOI:10.1111/j.1742-7843.2008.00252.x|Werner, U. ( 2003);Celecoxib inhibits metabolism ofcytochrome P450 2D6 substratemetoprolol in humans; (2003), DOI:10.1016/S0009-9236(03)00120-6"
"BIOTID00338","cerivastatin","446156","SEERZIQQUAZTOL-ANMDKAQQSA-N","InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1","CYP2C8;CYP3A4","O-Demethylation ","Human Phase I","Human","NULL","NULL","KUWDGQVSBKGOIJ-MDZDMXLPSA-N","InChI=1S/C25H32FNO5/c1-14(2)24-20(10-9-18(29)11-19(30)12-22(31)32)23(16-5-7-17(26)8-6-16)21(13-28)25(27-24)15(3)4/h5-10,14-15,18-19,28-30H,11-13H2,1-4H3,(H,31,32)/b10-9+","PMID:10976657"
"BIOTID00339","cerivastatin","446156","SEERZIQQUAZTOL-ANMDKAQQSA-N","InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1","CYP2C8","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","RLSAPOCPFJPPQD-MDZDMXLPSA-N","InChI=1S/C26H34FNO6/c1-15(2)25-21(10-9-19(30)11-20(31)12-23(32)33)24(17-5-7-18(27)8-6-17)22(14-34-4)26(28-25)16(3)13-29/h5-10,15-16,19-20,29-31H,11-14H2,1-4H3,(H,32,33)/b10-9+","PMID:10976657"
"BIOTID00340","cevimeline","83898","WUTYZMFRCNBCHQ-PSASIEDQSA-N","InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1","CYP2C19;CYP2D6;CYP3A4;CYP1A2;CYP2A6;CYP2E1","S-Oxidation","Human Phase I","Human","NULL","14716289","CFUGNFXJXCPICM-UHFFFAOYSA-N","InChI=1S/C10H17NO2S/c1-8-13-10(7-14(8)12)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3","PMID:11725960"
"BIOTID00341","(R)-colchicine","53278","IAKHMKGGTNLKSZ-MRXNPFEDSA-N","InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m1/s1","CYP3A4","O-demethylation ","Human Phase I","Human","3-demethylcolchicine","494161","JRRUSQGIRBEMRN-UHFFFAOYSA-N","InChI=1S/C21H23NO6/c1-11(23)22-15-7-5-12-9-17(25)20(27-3)21(28-4)19(12)13-6-8-18(26-2)16(24)10-14(13)15/h6,8-10,15,25H,5,7H2,1-4H3,(H,22,23)","PMID:8960070"
"BIOTID00342","(R)-colchicine","53278","IAKHMKGGTNLKSZ-MRXNPFEDSA-N","InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m1/s1","CYP3A4","O-demethylation ","Human Phase I","Human","2-demethyicolchicine","541033","DPOVAJCRYIUTBD-UHFFFAOYSA-N","InChI=1S/C21H23NO6/c1-11(23)22-15-7-5-12-9-18(27-3)20(25)21(28-4)19(12)13-6-8-17(26-2)16(24)10-14(13)15/h6,8-10,15,25H,5,7H2,1-4H3,(H,22,23)","PMID:8960070"
"BIOTID00343","(R)-colchicine","53278","IAKHMKGGTNLKSZ-MRXNPFEDSA-N","InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m1/s1","CYP3A4","O-demethylation ","Human Phase I","Human","Colchiceine","10156","PRGILOMAMBLWNG-UHFFFAOYSA-N","InChI=1S/C21H23NO6/c1-11(23)22-15-7-5-12-9-18(26-2)20(27-3)21(28-4)19(12)13-6-8-16(24)17(25)10-14(13)15/h6,8-10,15H,5,7H2,1-4H3,(H,22,23)(H,24,25)","PMID:8960070"
"BIOTID00344","{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine","10862355","VXPWQNBKEIVYIS-OAHLLOKOSA-N","InChI=1S/C23H21FN4S/c1-15(16-6-4-3-5-7-16)26-20-14-18(12-13-25-20)22-21(27-23(28-22)29-2)17-8-10-19(24)11-9-17/h3-15H,1-2H3,(H,25,26)(H,27,28)/t15-/m1/s1","CYP1A2;CYP2C19;CYP2D6;CYP3A4","S-OXIDATION","Human Phase I","Human","NULL","NULL","JXAHDPSVNVHDEW-UHFFFAOYSA-N","InChI=1S/C23H21FN4O2S/c1-15(16-6-4-3-5-7-16)26-20-14-18(12-13-25-20)22-21(17-8-10-19(24)11-9-17)27-23(28-22)31(2,29)30/h3-15H,1-2H3,(H,25,26)(H,27,28)","PMID:17344341"
"BIOTID00345","{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine","10862355","VXPWQNBKEIVYIS-OAHLLOKOSA-N","InChI=1S/C23H21FN4S/c1-15(16-6-4-3-5-7-16)26-20-14-18(12-13-25-20)22-21(27-23(28-22)29-2)17-8-10-19(24)11-9-17/h3-15H,1-2H3,(H,25,26)(H,27,28)/t15-/m1/s1","CYP3A4","N-dealkylation","Human Phase I","Human","NULL","NULL","DEVKGTPEZICAAL-UHFFFAOYSA-N","InChI=1S/C15H13FN4OS/c1-22(21)15-19-13(9-2-4-11(16)5-3-9)14(20-15)10-6-7-18-12(17)8-10/h2-8H,1H3,(H2,17,18)(H,19,20)","PMID:17344341"
"BIOTID00346","{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine","10862355","VXPWQNBKEIVYIS-OAHLLOKOSA-N","InChI=1S/C23H21FN4S/c1-15(16-6-4-3-5-7-16)26-20-14-18(12-13-25-20)22-21(27-23(28-22)29-2)17-8-10-19(24)11-9-17/h3-15H,1-2H3,(H,25,26)(H,27,28)/t15-/m1/s1","CYP3A4","N-oxidation","Human Phase I","Human","NULL","NULL","XCXUHCXNRURMFV-UHFFFAOYSA-O","InChI=1S/C23H21FN4O2S/c1-15(16-6-4-3-5-7-16)25-20-14-18(12-13-28(20)29)22-21(26-23(27-22)31(2)30)17-8-10-19(24)11-9-17/h3-15,29H,1-2H3,(H,25,26,27)/p+1","PMID:17344341"
"BIOTID00348","reduced_haloperidol","16048564","WNZBBTJFOIOEMP-FQEVSTJZSA-N","InChI=1S/C21H25ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,20,25-26H,1-2,11-15H2/t20-/m0/s1","CYP3A4","N-Demethylation","Human Phase I","Human","CPHP","38282","LZAYOZUFUAMFLD-UHFFFAOYSA-N","InChI=1S/C11H14ClNO/c12-10-3-1-9(2-4-10)11(14)5-7-13-8-6-11/h1-4,13-14H,5-8H2","PMID:11717183"
"BIOTID00349","reduced_haloperidol","16048564","WNZBBTJFOIOEMP-FQEVSTJZSA-N","InChI=1S/C21H25ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,20,25-26H,1-2,11-15H2/t20-/m0/s1","CYP3A4","Dehydrogenation","Human Phase I","Human","haloperidol","3559","LNEPOXFFQSENCJ-UHFFFAOYSA-N","InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2","PMID:11717183"
"BIOTID00350","DRF_4367","9802596","MVZNVBXATDCMMJ-UHFFFAOYSA-N","InChI=1S/C18H16F3N3O4S/c1-28-14-5-2-11(3-6-14)15-9-17(18(19,20)21)23-24(15)13-4-7-16(29(22,26)27)12(8-13)10-25/h2-9,25H,10H2,1H3,(H2,22,26,27)","CYP2C19;CYP2D6","O-demethylation","Human Phase I","Human","NULL","NULL","PFHJJNLRTMUCBE-UHFFFAOYSA-N","InChI=1S/C17H14F3N3O4S/c18-17(19,20)16-8-14(10-1-4-13(25)5-2-10)23(22-16)12-3-6-15(28(21,26)27)11(7-12)9-24/h1-8,24-25H,9H2,(H2,21,26,27)","PMID:17315542"
"BIOTID00351","benzodioxolyl-butanamine (BDB)","54579998","VHMRXGAIDDCGDU-VIFPVBQESA-N","InChI=1S/C11H15NO2/c1-2-9(12)5-8-3-4-10-11(6-8)14-7-13-10/h3-4,6,9H,2,5,7,12H2,1H3/t9-/m0/s1","CYP2C19;CYP2D6;CYP3A4","O-demethylenation","Human Phase I","Human","DHABB","20329954","ZVTVIPHSXNUZQH-UHFFFAOYSA-N","InChI=1S/C10H15NO2/c1-2-8(11)5-7-3-4-9(12)10(13)6-7/h3-4,6,8,12-13H,2,5,11H2,1H3","PMID:19576971"
"BIOTID00352","itraconazole","24867300","VHVPQPYKVGDNFY-ARROIKNCSA-N","InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25-,31+,35+/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Hydroxy-iteraconazole","108222","ISJVOEOJQLKSJU-UHFFFAOYSA-N","InChI=1S/C35H38Cl2N8O5/c1-24(25(2)46)45-34(47)44(23-40-45)29-6-4-27(5-7-29)41-13-15-42(16-14-41)28-8-10-30(11-9-28)48-18-31-19-49-35(50-31,20-43-22-38-21-39-43)32-12-3-26(36)17-33(32)37/h3-12,17,21-25,31,46H,13-16,18-20H2,1-2H3","PMID:15242978"
"BIOTID00353","itraconazole","24867300","VHVPQPYKVGDNFY-ARROIKNCSA-N","InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25-,31+,35+/m0/s1","CYP3A4","C-Oxidation","Human Phase I","Human","keto-iteraconazole ","21281914","GZEZATDDANETAV-UHFFFAOYSA-N","InChI=1S/C35H36Cl2N8O5/c1-24(25(2)46)45-34(47)44(23-40-45)29-6-4-27(5-7-29)41-13-15-42(16-14-41)28-8-10-30(11-9-28)48-18-31-19-49-35(50-31,20-43-22-38-21-39-43)32-12-3-26(36)17-33(32)37/h3-12,17,21-24,31H,13-16,18-20H2,1-2H3","PMID:15242978"
"BIOTID00354","itraconazole","24867300","VHVPQPYKVGDNFY-ARROIKNCSA-N","InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25-,31+,35+/m0/s1","CYP3A4","N-Desalkylation","Human Phase I","Human","N-Desalkyl-iteraconazole","14349865","FBAPZOQKYAPBHI-UHFFFAOYSA-N","InChI=1S/C31H30Cl2N8O4/c32-22-1-10-28(29(33)15-22)31(18-40-20-34-19-36-40)44-17-27(45-31)16-43-26-8-6-24(7-9-26)39-13-11-38(12-14-39)23-2-4-25(5-3-23)41-21-35-37-30(41)42/h1-10,15,19-21,27H,11-14,16-18H2,(H,37,42)","PMID:15242978"
"BIOTID00355","Mequitazine","15662541","FXKSIMKLXMWGEF-UHFFFAOYSA-N","InChI=1S/C20H22N2S/c1-3-7-18-16(5-1)22(17-6-2-4-8-19(17)23-18)15-20-9-12-21(13-10-20)14-11-20/h1-8H,9-15H2","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","MEVRIBHZYLUYGC-UHFFFAOYSA-N","InChI=1S/C20H22N2OS/c23-15-5-6-17-19(13-15)24-18-4-2-1-3-16(18)22(17)14-20-7-10-21(11-8-20)12-9-20/h1-6,13,23H,7-12,14H2","PMID:9454781"
"BIOTID00356","Mequitazine","15662541","FXKSIMKLXMWGEF-UHFFFAOYSA-N","InChI=1S/C20H22N2S/c1-3-7-18-16(5-1)22(17-6-2-4-8-19(17)23-18)15-20-9-12-21(13-10-20)14-11-20/h1-8H,9-15H2","CYP2D6","S-Oxidation","Human Phase I","Human","NULL","NULL","MWWBJGJQWARQIT-UHFFFAOYSA-N","InChI=1S/C20H22N2OS/c23-24-18-7-3-1-5-16(18)22(17-6-2-4-8-19(17)24)15-20-9-12-21(13-10-20)14-11-20/h1-8H,9-15H2","PMID:9454781"
"BIOTID00357","NE-100","9841596","YBLIQJGXRLZBCZ-UHFFFAOYSA-N","InChI=1S/C23H33NO2/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20/h6-12,19H,4-5,13-18H2,1-3H3","CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","71374942","WPKONAGIRLBFJW-UHFFFAOYSA-N","InChI=1S/C23H33NO3/c1-4-13-24(14-5-2)15-11-20-9-10-22(26-3)23(18-20)27-16-12-19-7-6-8-21(25)17-19/h6-10,17-18,25H,4-5,11-16H2,1-3H3","PMID:15618733"
"BIOTID00358","NE-100","9841596","YBLIQJGXRLZBCZ-UHFFFAOYSA-N","InChI=1S/C23H33NO2/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20/h6-12,19H,4-5,13-18H2,1-3H3","CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","18986923","XGMGOPZOOJNJPJ-UHFFFAOYSA-N","InChI=1S/C23H33NO3/c1-4-14-24(15-5-2)16-12-20-8-11-22(26-3)23(18-20)27-17-13-19-6-9-21(25)10-7-19/h6-11,18,25H,4-5,12-17H2,1-3H3","PMID:15618733"
"BIOTID00359","NE-100","9841596","YBLIQJGXRLZBCZ-UHFFFAOYSA-N","InChI=1S/C23H33NO2/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20/h6-12,19H,4-5,13-18H2,1-3H3","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4","N-DEMETHYLATION","Human Phase I","Human","NULL","10710332","AEQMNSOSQSZZIB-UHFFFAOYSA-N","InChI=1S/C20H27NO2/c1-3-13-21-14-11-18-9-10-19(22-2)20(16-18)23-15-12-17-7-5-4-6-8-17/h4-10,16,21H,3,11-15H2,1-2H3","PMID:15618733"
"BIOTID00360","NE-100","9841596","YBLIQJGXRLZBCZ-UHFFFAOYSA-N","InChI=1S/C23H33NO2/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20/h6-12,19H,4-5,13-18H2,1-3H3","CYP2C9;CYP2C19;CYP2D6","O-DEMETHYLATION","Human Phase I","Human","NULL","10688629","DMVMWWXQRZDRJE-UHFFFAOYSA-N","InChI=1S/C22H31NO2/c1-3-14-23(15-4-2)16-12-20-10-11-21(24)22(18-20)25-17-13-19-8-6-5-7-9-19/h5-11,18,24H,3-4,12-17H2,1-2H3","PMID:15618733"
"BIOTID00361","(R)-m-Methoxyamphetamine","22809970","VEJWNIYARKAHFI-MRVPVSSYSA-N","InChI=1S/C10H15NO/c1-8(11)6-9-4-3-5-10(7-9)12-2/h3-5,7-8H,6,11H2,1-2H3/t8-/m1/s1","CYP2D6","O-DEMETHYLATION","Human Phase I","Human","NULL","102551","WTDGMHYYGNJEKQ-UHFFFAOYSA-N","InChI=1S/C9H13NO/c1-7(10)5-8-3-2-4-9(11)6-8/h2-4,6-7,11H,5,10H2,1H3","PMID:10456690"
"BIOTID00362","(R)-m-Methoxyamphetamine","22809970","VEJWNIYARKAHFI-MRVPVSSYSA-N","InChI=1S/C10H15NO/c1-8(11)6-9-4-3-5-10(7-9)12-2/h3-5,7-8H,6,11H2,1-2H3/t8-/m1/s1","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","197139","GPBOYXOSSQEJBH-UHFFFAOYSA-N","InChI=1S/C10H15NO2/c1-7(11)5-8-3-4-9(12)10(6-8)13-2/h3-4,6-7,12H,5,11H2,1-2H3","PMID:10456690"
"BIOTID00363","(R)-phenprocoumon","54681545","DQDAYGNAKTZFIW-CYBMUJFWSA-N","InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3/t13-/m1/s1","CYP2C8;CYP2C9;CYP2C19;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","54704412","ZPNYHQZRGWFLST-UHFFFAOYSA-N","InChI=1S/C18H16O4/c1-2-13(11-7-9-12(19)10-8-11)16-17(20)14-5-3-4-6-15(14)22-18(16)21/h3-10,13,19-20H,2H2,1H3","PMID:15742978"
"BIOTID00364","(R)-phenprocoumon","54681545","DQDAYGNAKTZFIW-CYBMUJFWSA-N","InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3/t13-/m1/s1","CYP2C9;CYP2C19;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","54681540","BKRXPRMCBOAGQH-UHFFFAOYSA-N","InChI=1S/C18H16O4/c1-2-13(11-6-4-3-5-7-11)16-17(20)14-10-12(19)8-9-15(14)22-18(16)21/h3-10,13,19-20H,2H2,1H3","PMID:15742978"
"BIOTID00365","(R)-phenprocoumon","54681545","DQDAYGNAKTZFIW-CYBMUJFWSA-N","InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3/t13-/m1/s1","CYP2C9;CYP2C19;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","54681539","HBAPGROFUGJSGR-UHFFFAOYSA-N","InChI=1S/C18H16O4/c1-2-13(11-6-4-3-5-7-11)16-17(20)14-9-8-12(19)10-15(14)22-18(16)21/h3-10,13,19-20H,2H2,1H3","PMID:15742978"
"BIOTID00366","pantoprazole","11181988","IQPSEEYGBUAQFF-AREMUKBSSA-N","InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)/t26-/m1/s1","CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","RWTUXUHGTKVBCL-UHFFFAOYSA-N","InChI=1S/C16H15F2N3O5S/c1-24-14-12(19-5-4-13(14)25-8-22)7-27(23)16-20-10-3-2-9(26-15(17)18)6-11(10)21-16/h2-6,15,22H,7-8H2,1H3,(H,20,21)","PMID:9165689"
"BIOTID00367","2Ã¢â‚¬Â[(S)Ã¢â‚¬Â[4Ã¢â‚¬Â(cyclopropylmethoxy)pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl]methanesulfinyl]Ã¢â‚¬Â5Ã¢â‚¬ÂfluoroÃ¢â‚¬Â1HÃ¢â‚¬Â1,3Ã¢â‚¬Âbenzodiazole","70693563","DIUOJMLXZJHNDR-DEOSSOPVSA-N","InChI=1S/C17H16FN3O2S/c18-12-3-4-15-16(7-12)21-17(20-15)24(22)10-13-8-14(5-6-19-13)23-9-11-1-2-11/h3-8,11H,1-2,9-10H2,(H,20,21)/t24-/m0/s1","CYP1A2;CYP2C9;CYP3A4","S-Oxidation","Human Phase I","Human","Sulphone","NULL","FOTFMGNDPAPMPD-UHFFFAOYSA-N","InChI=1S/C17H16FN3O3S/c18-12-3-4-15-16(7-12)21-17(20-15)25(22,23)10-13-8-14(5-6-19-13)24-9-11-1-2-11/h3-8,11H,1-2,9-10H2,(H,20,21)","PMID:10611141"
"BIOTID00368","2Ã¢â‚¬Â[(S)Ã¢â‚¬Â[4Ã¢â‚¬Â(cyclopropylmethoxy)pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl]methanesulfinyl]Ã¢â‚¬Â5Ã¢â‚¬ÂfluoroÃ¢â‚¬Â1HÃ¢â‚¬Â1,3Ã¢â‚¬Âbenzodiazole","70693563","DIUOJMLXZJHNDR-DEOSSOPVSA-N","InChI=1S/C17H16FN3O2S/c18-12-3-4-15-16(7-12)21-17(20-15)24(22)10-13-8-14(5-6-19-13)23-9-11-1-2-11/h3-8,11H,1-2,9-10H2,(H,20,21)/t24-/m0/s1","CYP1A2;CYP2C9;CYP2C19;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","XDFQGBNGMWAJQY-UHFFFAOYSA-N","InChI=1S/C17H16FN3O3S/c18-13-6-14-15(7-16(13)22)21-17(20-14)25(23)9-11-5-12(3-4-19-11)24-8-10-1-2-10/h3-7,10,22H,1-2,8-9H2,(H,20,21)","PMID:10611141"
"BIOTID00369","2Ã¢â‚¬Â[(S)Ã¢â‚¬Â[4Ã¢â‚¬Â(cyclopropylmethoxy)pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl]methanesulfinyl]Ã¢â‚¬Â5Ã¢â‚¬ÂfluoroÃ¢â‚¬Â1HÃ¢â‚¬Â1,3Ã¢â‚¬Âbenzodiazole","70693563","DIUOJMLXZJHNDR-DEOSSOPVSA-N","InChI=1S/C17H16FN3O2S/c18-12-3-4-15-16(7-12)21-17(20-15)24(22)10-13-8-14(5-6-19-13)23-9-11-1-2-11/h3-8,11H,1-2,9-10H2,(H,20,21)/t24-/m0/s1","CYP1A2;CYP2C9;CYP2C19;CYP3A4","O-dealkylation","Human Phase I","Human","Pyridone","NULL","PXUPJAZIXWUXAX-UHFFFAOYSA-N","InChI=1S/C13H10FN3O2S/c14-9-4-10-11(5-12(9)19)17-13(16-10)20-6-7-3-8(18)1-2-15-7/h1-5,19H,6H2,(H,15,18)(H,16,17)","PMID:10611141"
"BIOTID00370","(2S,3R)-3-(4-Hydroxy-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-2,3-dihydro-benzo[1,4]oxathiin-6-ol","448577","TWZNCTCQAGRUGQ-RRPNLBNLSA-N","InChI=1S/C27H29NO4S/c29-21-8-4-20(5-9-21)27-26(32-24-13-10-22(30)18-25(24)33-27)19-6-11-23(12-7-19)31-17-16-28-14-2-1-3-15-28/h4-13,18,26-27,29-30H,1-3,14-17H2/t26-,27+/m0/s1","CYP3A4","S-Oxidation","Human Phase I","Human","NULL","NULL","QFAOUVIEXOWBQC-UHFFFAOYSA-N","InChI=1S/C27H29NO5S/c29-21-8-4-20(5-9-21)27-26(33-24-13-10-22(30)18-25(24)34(27)31)19-6-11-23(12-7-19)32-17-16-28-14-2-1-3-15-28/h4-13,18,26-27,29-30H,1-3,14-17H2","PMID:15833027"
"BIOTID00371","(2S,3R)-3-(4-Hydroxy-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-2,3-dihydro-benzo[1,4]oxathiin-6-ol","448577","TWZNCTCQAGRUGQ-RRPNLBNLSA-N","InChI=1S/C27H29NO4S/c29-21-8-4-20(5-9-21)27-26(32-24-13-10-22(30)18-25(24)33-27)19-6-11-23(12-7-19)31-17-16-28-14-2-1-3-15-28/h4-13,18,26-27,29-30H,1-3,14-17H2/t26-,27+/m0/s1","CYP3A4","S-Dealkylation","Human Phase I","Human","NULL","NULL","FWDUZUKVAMWNDZ-UHFFFAOYSA-N","InChI=1S/C27H31NO4S/c1-2-3-4-15-28-16-17-31-23-12-7-19(8-13-23)26-27(20-5-9-21(29)10-6-20)33-25-18-22(30)11-14-24(25)32-26/h5-14,18,26-30H,2-4,15-17H2,1H3","PMID:15833027"
"BIOTID00372","PNU-96391","9795741","GZVBVBMMNFIXGE-CQSZACIVSA-N","InChI=1S/C15H23NO2S/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3/t14-/m1/s1","CYP1A2;CYP2C19;CYP2D6;CYP3A4","N-dealkylation","Human Phase I","Human","NULL","10890006","KMVLMAUQHRUFDO-UHFFFAOYSA-N","InChI=1S/C12H17NO2S/c1-16(14,15)12-6-2-4-10(8-12)11-5-3-7-13-9-11/h2,4,6,8,11,13H,3,5,7,9H2,1H3","PMID:12433806"
"BIOTID00373","4Ã¢â‚¬Â[(dimethylamino)methyl]Ã¢â‚¬Â7Ã¢â‚¬ÂmethoxychromenÃ¢â‚¬Â2Ã¢â‚¬Âone","8931830","LXMHUJTYIQLCAN-UHFFFAOYSA-N","InChI=1S/C13H15NO3/c1-14(2)8-9-6-13(15)17-12-7-10(16-3)4-5-11(9)12/h4-7H,8H2,1-3H3","CYP1A2","N-dealkylation","Human Phase I","Human","NULL","8931837","GWMGUFTYUOYYQV-UHFFFAOYSA-N","InChI=1S/C12H13NO3/c1-13-7-8-5-12(14)16-11-6-9(15-2)3-4-10(8)11/h3-6,13H,7H2,1-2H3","PMID:11095593"
"BIOTID00374","4Ã¢â‚¬Â[(dimethylamino)methyl]Ã¢â‚¬Â7Ã¢â‚¬ÂmethoxychromenÃ¢â‚¬Â2Ã¢â‚¬Âone","8931830","LXMHUJTYIQLCAN-UHFFFAOYSA-N","InChI=1S/C13H15NO3/c1-14(2)8-9-6-13(15)17-12-7-10(16-3)4-5-11(9)12/h4-7H,8H2,1-3H3","CYP1A2;CYP2C19;CYP2D6","N-dealkylation","Human Phase I","Human","NULL","8481465","KKITYPITUYVFAA-UHFFFAOYSA-N","InChI=1S/C12H13NO3/c1-13(2)7-8-5-12(15)16-11-6-9(14)3-4-10(8)11/h3-6,14H,7H2,1-2H3","PMID:11095593"
"BIOTID00375","bpr-0L075","10359957","UZJVBXKFBQNDTQ-UHFFFAOYSA-N","InChI=1S/C19H19NO5/c1-22-12-5-6-13-14(10-20-15(13)9-12)18(21)11-7-16(23-2)19(25-4)17(8-11)24-3/h5-10,20H,1-4H3","CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","NULL","AWOJHOZYTSBGDR-UHFFFAOYSA-N","InChI=1S/C17H15NO5/c1-22-15-6-9(5-14(20)17(15)23-2)16(21)12-8-18-13-7-10(19)3-4-11(12)13/h3-8,18-20H,1-2H3","PMID:17403915"
"BIOTID00376","bpr-0L075","10359957","UZJVBXKFBQNDTQ-UHFFFAOYSA-N","InChI=1S/C19H19NO5/c1-22-12-5-6-13-14(10-20-15(13)9-12)18(21)11-7-16(23-2)19(25-4)17(8-11)24-3/h5-10,20H,1-4H3","CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","NULL","AWOJHOZYTSBGDR-UHFFFAOYSA-N","InChI=1S/C17H15NO5/c1-22-15-6-9(5-14(20)17(15)23-2)16(21)12-8-18-13-7-10(19)3-4-11(12)13/h3-8,18-20H,1-2H3","PMID:17403915"
"BIOTID00377","bpr-0L075","10359957","UZJVBXKFBQNDTQ-UHFFFAOYSA-N","InChI=1S/C19H19NO5/c1-22-12-5-6-13-14(10-20-15(13)9-12)18(21)11-7-16(23-2)19(25-4)17(8-11)24-3/h5-10,20H,1-4H3","CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","11645570","ZPZUSIUTOXRAIX-UHFFFAOYSA-N","InChI=1S/C18H17NO5/c1-22-11-4-5-12-13(9-19-14(12)8-11)17(20)10-6-15(23-2)18(21)16(7-10)24-3/h4-9,19,21H,1-3H3","PMID:17403915"
"BIOTID00378","bpr-0L075","10359957","UZJVBXKFBQNDTQ-UHFFFAOYSA-N","InChI=1S/C19H19NO5/c1-22-12-5-6-13-14(10-20-15(13)9-12)18(21)11-7-16(23-2)19(25-4)17(8-11)24-3/h5-10,20H,1-4H3","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","10449104","FWYFKYJHENUGSZ-UHFFFAOYSA-N","InChI=1S/C18H17NO5/c1-22-15-6-10(7-16(23-2)18(15)24-3)17(21)13-9-19-14-8-11(20)4-5-12(13)14/h4-9,19-20H,1-3H3","PMID:17403915"
"BIOTID00379","(6-methoxy-1H-indol-3-yl)-(3,4,5-trimethoxyphenyl)methanone","10359957","UZJVBXKFBQNDTQ-UHFFFAOYSA-N","InChI=1S/C19H19NO5/c1-22-12-5-6-13-14(10-20-15(13)9-12)18(21)11-7-16(23-2)19(25-4)17(8-11)24-3/h5-10,20H,1-4H3","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","25211155","FEYUTHKUCJCUAD-UHFFFAOYSA-N","InChI=1S/C19H19NO6/c1-23-13-6-5-11-12(9-20-16(11)18(13)22)17(21)10-7-14(24-2)19(26-4)15(8-10)25-3/h5-9,20,22H,1-4H3","PMID:17403915"
"BIOTID00380","(6-methoxy-1H-indol-3-yl)-(3,4,5-trimethoxyphenyl)methanone","10359957","UZJVBXKFBQNDTQ-UHFFFAOYSA-N","InChI=1S/C19H19NO5/c1-22-12-5-6-13-14(10-20-15(13)9-12)18(21)11-7-16(23-2)19(25-4)17(8-11)24-3/h5-10,20H,1-4H3","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","KJQRQXULEOYSKP-UHFFFAOYSA-N","InChI=1S/C19H19NO6/c1-23-15-8-13-11(7-14(15)21)12(9-20-13)18(22)10-5-16(24-2)19(26-4)17(6-10)25-3/h5-9,20-21H,1-4H3","PMID:17403915"
"BIOTID00381","KR-33028","11515637","WGKIDCRTLNUROQ-UHFFFAOYSA-N","InChI=1S/C11H8N4OS/c12-5-6-2-1-3-8-7(6)4-9(17-8)10(16)15-11(13)14/h1-4H,(H4,13,14,15,16)","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","5-hydroxy-KR-33028","NULL","WMUOGLNRYQAYQF-UHFFFAOYSA-N","InChI=1S/C11H8N4O2S/c12-4-6-5-3-9(10(17)15-11(13)14)18-8(5)2-1-7(6)16/h1-3,16H,(H4,13,14,15,17)","PMID:16857327"
"BIOTID00382","KR-33028","11515637","WGKIDCRTLNUROQ-UHFFFAOYSA-N","InChI=1S/C11H8N4OS/c12-5-6-2-1-3-8-7(6)4-9(17-8)10(16)15-11(13)14/h1-4H,(H4,13,14,15,16)","CYP3A4;CYP1A2","Aromatic Hydroxylation","Human Phase I","Human","7-hydroxy-KR-33028","NULL","RGCBBPXCMGQQDS-UHFFFAOYSA-N","InChI=1S/C11H8N4O2S/c12-4-5-1-2-7(16)9-6(5)3-8(18-9)10(17)15-11(13)14/h1-3,16H,(H4,13,14,15,17)","PMID:16857327"
"BIOTID00383","CTK0G1203","12428581","IVVNZDGDKPTYHK-SNVBAGLBSA-N","InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)/t10-/m1/s1","CYP3A4","N-Oxidation","Human Phase I","Human","NULL","NULL","IJGFZWWPWOGNOQ-UHFFFAOYSA-N","InChI=1S/C13H19N5O/c1-10(13(2,3)4)16-12(15-9-14)17-11-5-7-18(19)8-6-11/h5-8,10H,1-4H3,(H2,15,16,17)","PMID:11851418"
"BIOTID00384","CTK0G1203","12428581","IVVNZDGDKPTYHK-SNVBAGLBSA-N","InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)/t10-/m1/s1","CYP3A4","C-Oxidation","Human Phase I","Human","NULL","NULL","RREAIWVAEAJVOQ-UHFFFAOYSA-N","InChI=1S/C13H21N5O/c1-9(13(2,3)4)16-12(18-11(14)19)17-10-5-7-15-8-6-10/h5-9H,1-4H3,(H4,14,15,16,17,18,19)","PMID:11851418"
"BIOTID00385","N-(1-Phenyl-1H-pyrazole-5-yl)-p-toluenesulfonamide","10245060","VVUQNTKYPPFMID-UHFFFAOYSA-N","InChI=1S/C16H15N3O2S/c1-13-7-9-15(10-8-13)22(20,21)18-16-11-12-17-19(16)14-5-3-2-4-6-14/h2-12,18H,1H3","CYP2C8;CYP2C9;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","QWBFRRFWEZMWIB-UHFFFAOYSA-N","InChI=1S/C16H15N3O3S/c20-12-13-6-8-15(9-7-13)23(21,22)18-16-10-11-17-19(16)14-4-2-1-3-5-14/h1-11,18,20H,12H2","PMID:12767217"
"BIOTID00386","N-(1-Phenyl-1H-pyrazole-5-yl)-p-toluenesulfonamide","10245060","VVUQNTKYPPFMID-UHFFFAOYSA-N","InChI=1S/C16H15N3O2S/c1-13-7-9-15(10-8-13)22(20,21)18-16-11-12-17-19(16)14-5-3-2-4-6-14/h2-12,18H,1H3","CYP2C8;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","VESXFLZNMRMCLI-UHFFFAOYSA-N","InChI=1S/C16H15N3O3S/c1-12-2-8-15(9-3-12)23(21,22)18-16-10-11-17-19(16)13-4-6-14(20)7-5-13/h2-11,18,20H,1H3","PMID:12767217"
"BIOTID00387","terfenadine","6604035","GUGOEEXESWIERI-PMERELPUSA-N","InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3/t30-/m0/s1","CYP2D6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","hydroxyterfenadine","NULL","ZIQKFOOBIMENJF-UHFFFAOYSA-N","InChI=1S/C32H41NO3/c1-31(2,24-34)26-17-15-25(16-18-26)30(35)14-9-21-33-22-19-29(20-23-33)32(36,27-10-5-3-6-11-27)28-12-7-4-8-13-28/h3-8,10-13,15-18,29-30,34-36H,9,14,19-24H2,1-2H3","PMID:9733666"
"BIOTID00388","terfenadine","6604035","GUGOEEXESWIERI-PMERELPUSA-N","InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3/t30-/m0/s1","CYP3A4","N-Dealkylation","Human Phase I","Human","azacyclonol","NULL","ZMISODWVFHHWNR-UHFFFAOYSA-N","InChI=1S/C18H21NO/c20-18(15-7-3-1-4-8-15,16-9-5-2-6-10-16)17-11-13-19-14-12-17/h1-10,17,19-20H,11-14H2","PMID:9733666"
"BIOTID00389","2prime_hydroxy_indomethacin_phenethylamide","44274898","AOIQKSHKQIJFMK-RUZDIDTESA-N","InChI=1S/C27H25ClN2O4/c1-17-22(15-26(32)29-16-25(31)18-6-4-3-5-7-18)23-14-21(34-2)12-13-24(23)30(17)27(33)19-8-10-20(28)11-9-19/h3-14,25,31H,15-16H2,1-2H3,(H,29,32)/t25-/m1/s1","CYP2C19;CYP2D6","O-Demethylation","Human Phase I","Human","NULL","NULL","WTKXBAMDBPYRKN-UHFFFAOYSA-N","InChI=1S/C26H23ClN2O4/c1-16-21(14-25(32)28-15-24(31)17-5-3-2-4-6-17)22-13-20(30)11-12-23(22)29(16)26(33)18-7-9-19(27)10-8-18/h2-13,24,30-31H,14-15H2,1H3,(H,28,32)","PMID:14709628"
"BIOTID00390","2prime_hydroxy_indomethacin_phenethylamide","44274898","AOIQKSHKQIJFMK-RUZDIDTESA-N","InChI=1S/C27H25ClN2O4/c1-17-22(15-26(32)29-16-25(31)18-6-4-3-5-7-18)23-14-21(34-2)12-13-24(23)30(17)27(33)19-8-10-20(28)11-9-19/h3-14,25,31H,15-16H2,1-2H3,(H,29,32)/t25-/m1/s1","CYP3A4","Dehydrogenation","Human Phase I","Human","NULL","NULL","STLPREOBDIPUMI-UHFFFAOYSA-N","InChI=1S/C27H23ClN2O4/c1-17-22(15-26(32)29-16-25(31)18-6-4-3-5-7-18)23-14-21(34-2)12-13-24(23)30(17)27(33)19-8-10-20(28)11-9-19/h3-14H,15-16H2,1-2H3,(H,29,32)","PMID:14709628"
"BIOTID00391","(2S)-1-(1,3-Benzodioxol-5-yl)-N-methyl-2-butanamine","44290645","USWVWJSAJAEEHQ-JTQLQIEISA-N","InChI=1S/C12H17NO2/c1-3-10(13-2)6-9-4-5-11-12(7-9)15-8-14-11/h4-5,7,10,13H,3,6,8H2,1-2H3/t10-/m0/s1","CYP1A2;CYP2B6;CYP2C19;CYP2D6;CYP3A4","N-Demethylation","Human Phase I","Human","NULL","NULL","VHMRXGAIDDCGDU-UHFFFAOYSA-N","InChI=1S/C11H15NO2/c1-2-9(12)5-8-3-4-10-11(6-8)14-7-13-10/h3-4,6,9H,2,5,7,12H2,1H3","PMID:10720722"
"BIOTID00392","(2S)-1-(1,3-Benzodioxol-5-yl)-N-methyl-2-butanamine","44290645","USWVWJSAJAEEHQ-JTQLQIEISA-N","InChI=1S/C12H17NO2/c1-3-10(13-2)6-9-4-5-11-12(7-9)15-8-14-11/h4-5,7,10,13H,3,6,8H2,1-2H3/t10-/m0/s1","CYP1A2;CYP2B6;CYP2C19;CYP2D6;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","NULL","VDJBHSSFCFZNAW-UHFFFAOYSA-N","InChI=1S/C11H17NO2/c1-3-9(12-2)6-8-4-5-10(13)11(14)7-8/h4-5,7,9,12-14H,3,6H2,1-2H3","PMID:10720722"
"BIOTID00393","Seratrodast","73346713","ZBVKEHDGYSLCCC-SFHVURJKSA-N","InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)/t18-/m0/s1","CYP2C19; CYP2C9; CYP2C8; CYP3A4; CYP2B6","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","5-OH-seratrodast","NULL","AQWOADAKGYZHIB-KRWDZBQOSA-N","InChI=1S/C22H26O5/c1-14-18(13-23)21(26)15(2)20(22(14)27)17(16-9-5-3-6-10-16)11-7-4-8-12-19(24)25/h3,5-6,9-10,17,23H,4,7-8,11-13H2,1-2H3,(H,24,25)/t17-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00394","Seratrodast","73346713","ZBVKEHDGYSLCCC-SFHVURJKSA-N","InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)/t18-/m0/s1","CYP2C19; CYP2C9; CYP2C8","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4'-OH-seratrodast","NULL","RCTPAQGTCLHAJU-SFHVURJKSA-N","InChI=1S/C22H26O5/c1-13-14(2)22(27)20(15(3)21(13)26)18(7-5-4-6-8-19(24)25)16-9-11-17(23)12-10-16/h9-12,18,23H,4-8H2,1-3H3,(H,24,25)/t18-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00395","chlorpromazine","2726","ZPEIMTDSQAKGNT-UHFFFAOYSA-N","InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3","CYP2D6; CYP1A2","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","7-Hydroxychlorpromazine","NULL","HICFFJZGXWEIHN-UHFFFAOYSA-N","InChI=1S/C17H19ClN2OS/c1-19(2)8-3-9-20-14-6-5-13(21)11-17(14)22-16-7-4-12(18)10-15(16)20/h4-7,10-11,21H,3,8-9H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID00396","chlorpromazine","2726","ZPEIMTDSQAKGNT-UHFFFAOYSA-N","InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3","CYP3A4","S-oxidation of diarylthioether to sulfoxide","Human Phase I","Human","Chlorpromazine S-oxide","NULL","QEPPAOXKZOTMPM-UHFFFAOYSA-N","InChI=1S/C17H19ClN2OS/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)22(21)17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID00397","chlorpromazine","2726","ZPEIMTDSQAKGNT-UHFFFAOYSA-N","InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3","CYP1A2","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","Chlorpromazine, N-desmethyl","NULL","YHFXGBOUSIKGMZ-UHFFFAOYSA-N","InChI=1S/C16H17ClN2S/c1-18-9-4-10-19-13-5-2-3-6-15(13)20-16-8-7-12(17)11-14(16)19/h2-3,5-8,11,18H,4,9-10H2,1H3","Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322"
"BIOTID00398","chlorpropamide","2727","RKWGIWYCVPQPMF-UHFFFAOYSA-N","InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)","CYP2C9 (major); CYP2C19 (minor); CYP2C8 (minor); CYP1A2 (minor); CYP3A4 (minor)","Hydroxylation of benzene on carbon ortho to an electron donating group","Human Phase I","Human","2-OH-chlorpropamide","NULL","QRXRPQPWKRLTQX-UHFFFAOYSA-N","InChI=1S/C10H13ClN2O4S/c1-2-5-12-10(15)13-18(16,17)9-4-3-7(11)6-8(9)14/h3-4,6,14H,2,5H2,1H3,(H2,12,13,15)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Shon, J. (2004), Chlorpropamide 2 hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism, British Journal of Clinical Pharmacology; DOI:10.1111/j.1365-2125.2005.02364.x"
"BIOTID00399","chlorpropamide","2727","RKWGIWYCVPQPMF-UHFFFAOYSA-N","InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)","CYP2D6","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","3-OH-chlorpropamide","NULL","RXFPYNAVFFDUJE-UHFFFAOYSA-N","InChI=1S/C10H13ClN2O4S/c1-2-5-12-10(15)13-18(16,17)7-3-4-8(11)9(14)6-7/h3-4,6,14H,2,5H2,1H3,(H2,12,13,15)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Shon, J. (2004), Chlorpropamide 2 hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism, British Journal of Clinical Pharmacology; DOI:10.1111/j.1365-2125.2005.02364.x"
"BIOTID00400","chlorpropamide","2727","RKWGIWYCVPQPMF-UHFFFAOYSA-N","InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)","CYP2D6","N-dealkylation of urea","Human Phase I","Human","p-Chlorobenzene sulfonylurea","NULL","AZEPYUPSYWCRBG-UHFFFAOYSA-N","InChI=1S/C7H7ClN2O3S/c8-5-1-3-6(4-2-5)14(12,13)10-7(9)11/h1-4H,(H3,9,10,11)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Shon, J. (2004), Chlorpropamide 2 hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism, British Journal of Clinical Pharmacology; DOI:10.1111/j.1365-2125.2005.02364.x"
"BIOTID00401","Chlorpyrifos","2730","SBPBAQFWLVIOKP-UHFFFAOYSA-N","InChI=1S/C9H11Cl3NO3PS/c1-3-14-17(18,15-4-2)16-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3","CYP2C19; CYP2B6; CYP3A4","Dearylation of organphosphosulfur compound","Human Phase I","Human","3,5,6-Trichloro-2-pyridinol","NULL","WCYYAQFQZQEUEN-UHFFFAOYSA-N","InChI=1S/C5H2Cl3NO/c6-2-1-3(7)5(10)9-4(2)8/h1H,(H,9,10)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00402","Chlorpyrifos","2730","SBPBAQFWLVIOKP-UHFFFAOYSA-N","InChI=1S/C9H11Cl3NO3PS/c1-3-14-17(18,15-4-2)16-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3","CYP2C19; CYP2B6; CYP3A4","Dearylation of organphosphosulfur compound","Human Phase I","Human","Diethyl phosphorothioate","NULL","UCQFCFPECQILOL-UHFFFAOYSA-N","InChI=1S/C4H11O4P/c1-3-7-9(5,6)8-4-2/h3-4H2,1-2H3,(H,5,6)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00403","Chlorpyrifos","2730","SBPBAQFWLVIOKP-UHFFFAOYSA-N","InChI=1S/C9H11Cl3NO3PS/c1-3-14-17(18,15-4-2)16-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3","CYP1A2; CYP2B6; CYP2C8; CYP2C9; CYP2C19; CYP2D6; CYP3A4","Desulfuration of organophosphothioates","Human Phase I","Human","Chlorpyrifos-oxon","NULL","OTMOUPHCTWPNSL-UHFFFAOYSA-N","InChI=1S/C9H11Cl3NO4P/c1-3-15-18(14,16-4-2)17-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00404","chlorzoxazone","2733","TZFWDZFKRBELIQ-UHFFFAOYSA-N","InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)","CYP2E1; CYP1A2; CYP1A1; CYP2A6; CYP2D6; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-Hydroxychlorzoxazone","NULL","AGLXDWOTVQZHIQ-UHFFFAOYSA-N","InChI=1S/C7H4ClNO3/c8-3-1-4-6(2-5(3)10)12-7(11)9-4/h1-2,10H,(H,9,11)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00405","cilostazol","2754","RRGUKTPIGVIEKM-UHFFFAOYSA-N","InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)","CYP1A2;CYP2D6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","OPC-13326","NULL","FCWDVHXHKQJPQA-UHFFFAOYSA-N","InChI=1S/C20H27N5O3/c26-18-13-20(27)21-17-10-9-15(12-16(17)18)28-11-5-4-8-19-22-23-24-25(19)14-6-2-1-3-7-14/h9-10,12,14,18,26H,1-8,11,13H2,(H,21,27)","PMID:10889516"
"BIOTID00406","cilostazol","2754","RRGUKTPIGVIEKM-UHFFFAOYSA-N","InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)","CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","OPC-13217","NULL","KFXNZXLUGHLDBB-UHFFFAOYSA-N","InChI=1S/C20H27N5O3/c26-16-7-5-15(6-8-16)25-19(22-23-24-25)3-1-2-12-28-17-9-10-18-14(13-17)4-11-20(27)21-18/h9-10,13,15-16,26H,1-8,11-12H2,(H,21,27)","PMID:10889516"
"BIOTID00407","cinnarizine","1547484","DERZBLKQOCDDDZ-JLHYYAGUSA-N","InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+","CYP2B6","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4-{phenyl[4-(3-phenylprop-2-en-1-yl)piperazin-1-yl]methyl}phenol","NULL","UQMAKWWGLMGUQQ-JXMROGBWSA-N","InChI=1S/C26H28N2O/c29-25-15-13-24(14-16-25)26(23-11-5-2-6-12-23)28-20-18-27(19-21-28)17-7-10-22-8-3-1-4-9-22/h1-16,26,29H,17-21H2/b10-7+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00408","cinnarizine","1547484","DERZBLKQOCDDDZ-JLHYYAGUSA-N","InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+","CYP2D6","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4-{3-[4-(diphenylmethyl)piperazin-1-yl]prop-1-en-1-yl}phenol","NULL","QFWMZESBHJUDQQ-BQYQJAHWSA-N","InChI=1S/C26H28N2O/c29-25-15-13-22(14-16-25)8-7-17-27-18-20-28(21-19-27)26(23-9-3-1-4-10-23)24-11-5-2-6-12-24/h1-16,26,29H,17-21H2/b8-7+",""
"BIOTID00409","cinnarizine","1547484","DERZBLKQOCDDDZ-JLHYYAGUSA-N","InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+","CYP2C9; CYP1A2; CYP2A6","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1","Human Phase I","Human","1-Benzhydrylpiperazine","70048","NWVNXDKZIQLBNM-UHFFFAOYSA-N","InChI=1S/C17H20N2/c1-3-7-15(8-4-1)17(16-9-5-2-6-10-16)19-13-11-18-12-14-19/h1-10,17-18H,11-14H2","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00409","cinnarizine","1547484","DERZBLKQOCDDDZ-JLHYYAGUSA-N","InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+","CYP2C9; CYP1A2; CYP2A6","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1","Human Phase I","Human","Cinnamaldehyde","70048","KJPRLNWUNMBNBZ-QPJJXVBHSA-N","InChI=1S/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00410","cinnarizine","1547484","DERZBLKQOCDDDZ-JLHYYAGUSA-N","InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+","CYP2C9; CYP1A2; CYP2A6","OXIDATIVE_DEAMINATION_OF_TERTIARY_AMINES; N_DEALKYLATION_OF_ALICYCLIC_TERTIARY_AMINES_PATTERN1","Human Phase I","Human","Benzophenone","3102","RWCCWEUUXYIKHB-UHFFFAOYSA-N","InChI=1S/C13H10O/c14-13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00410","cinnarizine","1547484","DERZBLKQOCDDDZ-JLHYYAGUSA-N","InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+","CYP2C9; CYP1A2; CYP2A6","OXIDATIVE_DEAMINATION_OF_TERTIARY_AMINES; N_DEALKYLATION_OF_ALICYCLIC_TERTIARY_AMINES_PATTERN1","Human Phase I","Human","1-Cinnamylpiperazine","3102","WGEIOMTZIIOUMA-QPJJXVBHSA-N","InChI=1S/C13H18N2/c1-2-5-13(6-3-1)7-4-10-15-11-8-14-9-12-15/h1-7,14H,8-12H2/b7-4+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00411","cisapride","5311047","DCSUBABJRXZOMT-RBBKRZOGSA-N","InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m0/s1","CYP3A4; CYP2C8; CYP2B6","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","Norcisapride","NULL","OMLDMGPCWMBPAN-WCQYABFASA-N","InChI=1S/C14H20ClN3O3/c1-20-12-6-10(16)9(15)5-8(12)14(19)18-11-3-4-17-7-13(11)21-2/h5-6,11,13,17H,3-4,7,16H2,1-2H3,(H,18,19)/t11-,13+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00412","cisapride","5311047","DCSUBABJRXZOMT-RBBKRZOGSA-N","InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m0/s1","CYP3A4; CYP2C8; CYP2B6","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","3-(4-fluorophenoxy)propanal","NULL","JUKZPSFOMPCDJN-UHFFFAOYSA-N","InChI=1S/C9H9FO2/c10-8-2-4-9(5-3-8)12-7-1-6-11/h2-6H,1,7H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00413","cisapride","5311047","DCSUBABJRXZOMT-RBBKRZOGSA-N","InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m0/s1","CYP2C8","Hydroxylation of benzene on carbon para to an electron donating group","Human Phase I","Human","3-Fluoro-4-hydroxycisapride","NULL","JXFYESHHMRUHOT-SIKLNZKXSA-N","InChI=1S/C23H29ClFN3O5/c1-31-21-12-18(26)16(24)11-15(21)23(30)27-19-6-8-28(13-22(19)32-2)7-3-9-33-14-4-5-20(29)17(25)10-14/h4-5,10-12,19,22,29H,3,6-9,13,26H2,1-2H3,(H,27,30)/t19-,22+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00414","cisapride","5311047","DCSUBABJRXZOMT-RBBKRZOGSA-N","InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m0/s1","CYP3A4","Hydroxylation of benzene on carbon ortho to an electron donating group","Human Phase I","Human","4-Fluoro-2- hydroxycisapride","NULL","FNNZAZYOQRBQAC-PGRDOPGGSA-N","InChI=1S/C23H29ClFN3O5/c1-31-21-12-17(26)16(24)11-15(21)23(30)27-18-6-8-28(13-22(18)32-2)7-3-9-33-20-5-4-14(25)10-19(20)29/h4-5,10-12,18,22,29H,3,6-9,13,26H2,1-2H3,(H,27,30)/t18-,22+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00415","(+-)-Cisapride","2769","DCSUBABJRXZOMT-UHFFFAOYNA-N","InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)","CYP3A4; CYP2C8; CYP2B6 ","N-dealkylation of mixed tertiary amine","Human Phase I","Human","Norcisapride","NULL","OMLDMGPCWMBPAN-UHFFFAOYSA-N","InChI=1S/C14H20ClN3O3/c1-20-12-6-10(16)9(15)5-8(12)14(19)18-11-3-4-17-7-13(11)21-2/h5-6,11,13,17H,3-4,7,16H2,1-2H3,(H,18,19)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00416","(+-)-Cisapride","2769","DCSUBABJRXZOMT-UHFFFAOYNA-N","InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)","CYP2C8","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","3-Fluoro-4-hydroxycisapride","NULL","JXFYESHHMRUHOT-UHFFFAOYSA-N","InChI=1S/C23H29ClFN3O5/c1-31-21-12-18(26)16(24)11-15(21)23(30)27-19-6-8-28(13-22(19)32-2)7-3-9-33-14-4-5-20(29)17(25)10-14/h4-5,10-12,19,22,29H,3,6-9,13,26H2,1-2H3,(H,27,30)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00417","(+-)-Cisapride","2769","DCSUBABJRXZOMT-UHFFFAOYNA-N","InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)","CYP3A4","2-Hydroxylation of 1,4-disubstituted benzene","Human Phase I","Human","4-Fluoro-2-hydroxycisapride","NULL","FNNZAZYOQRBQAC-UHFFFAOYSA-N","InChI=1S/C23H29ClFN3O5/c1-31-21-12-17(26)16(24)11-15(21)23(30)27-18-6-8-28(13-22(18)32-2)7-3-9-33-20-5-4-14(25)10-19(20)29/h4-5,10-12,18,22,29H,3,6-9,13,26H2,1-2H3,(H,27,30)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00418","(2R,3S)â€2â€(diphenylmethyl)â€Nâ€{[2â€methoxyâ€5â€(propâ€1â€enâ€2â€yl)phenyl]methyl}â€1â€azabicyclo[2.2.2]octanâ€3â€amine","NULL","CVTMENNEXOZZEZ-IOWSJCHKSA-N","InChI=1S/C31H36N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,25,29-32H,1,16-19,21H2,2-3H3/t30-,31+/m0/s1","CYP2D6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","CP-611,781","NULL","LTBGJXWZYWSBIQ-UHFFFAOYSA-N","InChI=1S/C31H38N2O2/c1-22(21-34)26-13-14-28(35-2)27(19-26)20-32-30-25-15-17-33(18-16-25)31(30)29(23-9-5-3-6-10-23)24-11-7-4-8-12-24/h3-14,19,22,25,29-32,34H,15-18,20-21H2,1-2H3","PMID:11408374"
"BIOTID00419","(2R,3S)â€2â€(diphenylmethyl)â€Nâ€{[2â€methoxyâ€5â€(propâ€1â€enâ€2â€yl)phenyl]methyl}â€1â€azabicyclo[2.2.2]octanâ€3â€amine","NULL","CVTMENNEXOZZEZ-IOWSJCHKSA-N","InChI=1S/C31H36N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,25,29-32H,1,16-19,21H2,2-3H3/t30-,31+/m0/s1","CYP2D6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","CP-616,762","NULL","MVXRTLWIKNHZBT-UHFFFAOYSA-N","InChI=1S/C31H38N2O3/c1-31(35,21-34)26-13-14-27(36-2)25(19-26)20-32-29-24-15-17-33(18-16-24)30(29)28(22-9-5-3-6-10-22)23-11-7-4-8-12-23/h3-14,19,24,28-30,32,34-35H,15-18,20-21H2,1-2H3","PMID:11408374"
"BIOTID00420","clarithromycin","84029","AGOYDEPGAOXOCK-WIQGUNGHSA-N","InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22-,23-,24+,25+,26-,27-,29-,30+,31+,32+,33-,35-,36-,37+,38+/m1/s1","CYP3A4","Aliphatic Hydroxylation (14-(R)-hydroxylation)","Human Phase I","Human","14-(R)-hydroxy-CLAR","NULL","BLPFDXNVUDZBII-UHFFFAOYSA-N","InChI=1S/C38H69NO14/c1-18-16-37(9,48-14)32(53-35-28(42)25(39(11)12)15-19(2)49-35)21(4)29(51-26-17-36(8,47-13)31(44)24(7)50-26)22(5)34(45)52-33(23(6)40)38(10,46)30(43)20(3)27(18)41/h18-26,28-33,35,40,42-44,46H,15-17H2,1-14H3","PMID:9152603"
"BIOTID00421","clarithromycin","84029","AGOYDEPGAOXOCK-WIQGUNGHSA-N","InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22-,23-,24+,25+,26-,27-,29-,30+,31+,32+,33-,35-,36-,37+,38+/m1/s1","CYP3A4","N-demethylation","Human Phase I","Human","N-desmethyl-CLAR","NULL","CIJTVUQEURKBDL-UHFFFAOYSA-N","InChI=1S/C37H67NO13/c1-14-25-37(10,44)30(41)20(4)27(39)18(2)16-36(9,46-13)32(51-34-28(40)24(38-11)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-35(8,45-12)31(42)23(7)48-26/h18-26,28-32,34,38,40-42,44H,14-17H2,1-13H3","PMID:9152603"
"BIOTID00422","clindamycin","446598","KDLRVYVGXIQJDK-AWPVFWJPSA-N","InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1","CYP3A4","N-Dealkylation","Human Phase I","Human","N-desmethyclindamycin","NULL","HDBHHHCDEYATPY-UHFFFAOYSA-N","InChI=1S/C17H31ClN2O5S/c1-4-5-9-6-10(19-7-9)16(24)20-11(8(2)18)15-13(22)12(21)14(23)17(25-15)26-3/h8-15,17,19,21-23H,4-7H2,1-3H3,(H,20,24)","PMID:12814964"
"BIOTID00423","clindamycin","446598","KDLRVYVGXIQJDK-AWPVFWJPSA-N","InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1","CYP3A4","S-Oxidation","Human Phase I","Human","clindamycin sulfoxide","73046007","XSLGFIQRVCXUEU-UHFFFAOYSA-N","InChI=1S/C18H33ClN2O6S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(27-16)28(4)26/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)","PMID:12814964"
"BIOTID00424","clobazam","2789","CXOXHMZGEKVPMT-UHFFFAOYSA-N","InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3","CYP2C9;CYP2C19","N-desmethylation","Human Phase I","Human","N-desmethylclobazam","89657","RRTVVRIFVKKTJK-UHFFFAOYSA-N","InChI=1S/C15H11ClN2O2/c16-10-6-7-12-13(8-10)18(11-4-2-1-3-5-11)15(20)9-14(19)17-12/h1-8H,9H2,(H,17,19)","PMID:15483195"
"BIOTID00425","clobazam","2789","CXOXHMZGEKVPMT-UHFFFAOYSA-N","InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","4-Hydroxyclobazam","14275474","NKSXJAYACJZMBM-UHFFFAOYSA-N","InChI=1S/C16H13ClN2O3/c1-18-13-7-2-10(17)8-14(13)19(16(22)9-15(18)21)11-3-5-12(20)6-4-11/h2-8,20H,9H2,1H3","PMID:15483195"
"BIOTID00426","clomethiazole","10783","PCLITLDOTJTVDJ-UHFFFAOYSA-N","InChI=1S/C6H8ClNS/c1-5-6(2-3-7)9-4-8-5/h4H,2-3H2,1H3","CYP2A6","Aliphatic Hydroxylation","Human Phase I","Human","NLA-715","581759","OOKATFCTRGAPQX-UHFFFAOYSA-N","InChI=1S/C6H8ClNOS/c1-4-6(5(9)2-7)10-3-8-4/h3,5,9H,2H2,1H3","PMID:12734608"
"BIOTID00427","clomipramine","2801","GDLIGKIOYRNHDA-UHFFFAOYSA-N","InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3","CYP2D6","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2-OH-clomipramine","10246110","QXZNSJJZRXNDJQ-UHFFFAOYSA-N","InChI=1S/C19H23ClN2O/c1-21(2)10-5-11-22-17-7-4-3-6-14(17)8-9-15-12-19(23)16(20)13-18(15)22/h3-4,6-7,12-13,23H,5,8-11H2,1-2H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00428","clomipramine","2801","GDLIGKIOYRNHDA-UHFFFAOYSA-N","InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3","CYP2D6","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","8-OH-clomipramine","134222","INPXEQNHQVLPFN-UHFFFAOYSA-N","InChI=1S/C19H23ClN2O/c1-21(2)11-4-12-22-17-5-3-6-19(23)16(17)10-8-14-7-9-15(20)13-18(14)22/h3,5-7,9,13,23H,4,8,10-12H2,1-2H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00429","clomipramine","2801","GDLIGKIOYRNHDA-UHFFFAOYSA-N","InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3","CYP2C19; CYP3A4; CYP1A2","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-Desmethylclomipramine","622606","VPIXQGUBUKFLRF-UHFFFAOYSA-N","InChI=1S/C18H21ClN2/c1-20-11-4-12-21-17-6-3-2-5-14(17)7-8-15-9-10-16(19)13-18(15)21/h2-3,5-6,9-10,13,20H,4,7-8,11-12H2,1H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID00430","clomipramine","2801","GDLIGKIOYRNHDA-UHFFFAOYSA-N","InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3","CYP2D6","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","10-OH-clomipramine","NULL","OVNBDHJPQNLBSY-UHFFFAOYSA-N","InChI=1S/C19H23ClN2O/c1-21(2)10-5-11-22-17-7-4-3-6-16(17)19(23)12-14-8-9-15(20)13-18(14)22/h3-4,6-9,13,19,23H,5,10-12H2,1-2H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID00431","clotiazepam","2811","CHBRHODLKOZEPZ-UHFFFAOYSA-N","InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3","CYP2B6;CYP3A4;CYP2C18;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","Hydroxy-clotiazepam","NULL","PVDJJNSOPTZFFV-UHFFFAOYSA-N","InChI=1S/C16H15ClN2O2S/c1-9(20)13-7-11-15(10-5-3-4-6-12(10)17)18-8-14(21)19(2)16(11)22-13/h3-7,9,20H,8H2,1-2H3","PMID:6133664; PMID:16141545"
"BIOTID00432","clotiazepam","2811","CHBRHODLKOZEPZ-UHFFFAOYSA-N","InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3","CYP2B6;CYP3A4;CYP2C18;CYP2C19","N-desmethylation","Human Phase I","Human","desmethyl-clotiazepam","NULL","NDWDXZCLEWQSMO-UHFFFAOYSA-N","InChI=1S/C15H13ClN2OS/c1-2-9-7-11-14(10-5-3-4-6-12(10)16)17-8-13(19)18-15(11)20-9/h3-7H,2,8H2,1H3,(H,18,19)","PMID:6133664; PMID:16141545"
"BIOTID00433","clozapine","NULL","QZUDBNBUXVUHMW-UHFFFAOYSA-N","InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3","CYP1A2; CYP3A4; CYP2D6; CYP2C19; CYP2C8; CYP3A5; CYP2C9","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","N-Desmethylclozapine","NULL","JNNOSTQEZICQQP-UHFFFAOYSA-N","InChI=1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00434","clozapine","NULL","QZUDBNBUXVUHMW-UHFFFAOYSA-N","InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3","CYP3A4; CYP1A2; CYP2C8; CYP2C19; CYP3A5","N-oxidation of alicyclic tertiary amine","Human Phase I","Human","Clozapine-N-oxide","NULL","OGUCZBIQSYYWEF-UHFFFAOYSA-N","InChI=1S/C18H19ClN4O/c1-23(24)10-8-22(9-11-23)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00435","codeine","5284371","OROGSEYTTFOCAN-DNJOTXNNSA-N","InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1","CYP2D6","O-aryl demethylation","Human Phase I","Human","morphine","5288826","BQJCRHHNABKAKU-KBQPJGBKSA-N","InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1","Caraco, Y et al. (1996); Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity; Drug Metab Dispos. 1996 Jul;24(7):761-4"
"BIOTID00436","codeine","5284371","OROGSEYTTFOCAN-DNJOTXNNSA-N","InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","norcodeine","9925873","HKOIXWVRNLGFOR-KOFBORESSA-N","InChI=1S/C17H19NO3/c1-20-13-5-2-9-8-11-10-3-4-12(19)16-17(10,6-7-18-11)14(9)15(13)21-16/h2-5,10-12,16,18-19H,6-8H2,1H3/t10-,11+,12-,16-,17-/m0/s1","Caraco, Y et al. (1996); Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity; Drug Metab Dispos. 1996 Jul;24(7):761-4"
"BIOTID00437","compound_1","NULL","ODRPZOGBOVWNQM-HKBQPEDESA-N","InChI=1S/C32H29F3N4O3S/c33-32(34,35)26-9-5-23(6-10-26)29-15-16-30(38-29)24-7-13-28(14-8-24)43(41,42)39-27-11-3-22(4-12-27)17-19-37-21-31(40)25-2-1-18-36-20-25/h1-15,18,20,31,37,39-40H,16-17,19,21H2/t31-/m0/s1","CYP3A4","N-Oxidation","Human Phase I","Human","M2","NULL","YLISOGVYLXTXCH-UHFFFAOYSA-N","InChI=1S/C32H29F3N4O4S/c33-32(34,35)26-9-5-23(6-10-26)29-15-16-30(37-29)24-7-13-28(14-8-24)44(42,43)38-27-11-3-22(4-12-27)17-18-36-20-31(40)25-2-1-19-39(41)21-25/h1-15,19,21,31,36,38,40H,16-18,20H2","PMID:12065436"
"BIOTID00438","compound_1","NULL","ODRPZOGBOVWNQM-HKBQPEDESA-N","InChI=1S/C32H29F3N4O3S/c33-32(34,35)26-9-5-23(6-10-26)29-15-16-30(38-29)24-7-13-28(14-8-24)43(41,42)39-27-11-3-22(4-12-27)17-19-37-21-31(40)25-2-1-18-36-20-25/h1-15,18,20,31,37,39-40H,16-17,19,21H2/t31-/m0/s1","CYP3A4","N-Dealkylation","Human Phase I","Human","M4","NULL","AEYKITNYJLCXKL-UHFFFAOYSA-N","InChI=1S/C25H22F3N3O2S/c26-25(27,28)20-7-3-18(4-8-20)23-13-14-24(30-23)19-5-11-22(12-6-19)34(32,33)31-21-9-1-17(2-10-21)15-16-29/h1-13,31H,14-16,29H2","PMID:12065436"
"BIOTID00439","cotinine","854019","UIKROCXWUNQSPJ-VIFPVBQESA-N","InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1","CYP2A6","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","trans-3'-hydroxycotinine","10219774","XOKCJXZZNAUIQN-IENPIDJESA-N","InChI=1S/C10H12N2O2/c1-12-8(5-9(13)10(12)14)7-3-2-4-11-6-7/h2-4,6,8-9,13H,5H2,1H3/t8-,9?/m0/s1","Oscarson, M; (2001); Genetic Polymorphisms in the Cytochrome P450 2A6 (CYP2A6) Gene: Implications for Interindividual Differences in Nicotine Metabolism; Drug Metabolism and Disposition;  February 2001, 29 (2) 91-95; DMD 29:91Ã¢â‚¬â€œ95, 200"
"BIOTID00440","cotinine","854019","UIKROCXWUNQSPJ-VIFPVBQESA-N","InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1","CYP2A6","N-dealkylation of tertiary carboxamide","Human Phase I","Human","Norcotinine","92223","FXFANIORDKRCCA-QMMMGPOBSA-N","InChI=1S/C9H10N2O/c12-9-4-3-8(11-9)7-2-1-5-10-6-7/h1-2,5-6,8H,3-4H2,(H,11,12)/t8-/m0/s1","Oscarson, M; (2001); Genetic Polymorphisms in the Cytochrome P450 2A6 (CYP2A6) Gene: Implications for Interindividual Differences in Nicotine Metabolism; Drug Metabolism and Disposition;  February 2001, 29 (2) 91-95; DMD 29:91Ã¢â‚¬â€œ95, 200"
"BIOTID00441","cotinine","854019","UIKROCXWUNQSPJ-VIFPVBQESA-N","InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1","CYP2A6","Hydroxylation of  carbon next to amide","Human Phase I","Human","5'-hydroxycotinine","9815515","BBNHNZGTKSWIHD-SNVBAGLBSA-N","InChI=1S/C10H12N2O2/c1-12-9(13)4-5-10(12,14)8-3-2-6-11-7-8/h2-3,6-7,14H,4-5H2,1H3/t10-/m1/s1","Oscarson, M; (2001); Genetic Polymorphisms in the Cytochrome P450 2A6 (CYP2A6) Gene: Implications for Interindividual Differences in Nicotine Metabolism; Drug Metabolism and Disposition;  February 2001, 29 (2) 91-95; DMD 29:91Ã¢â‚¬â€œ95, 200"
"BIOTID00442","coumarin","323","ZYGHJZDHTFUPRJ-UHFFFAOYSA-N","InChI=1S/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H","CYP2A6; CYP2B6; CYP1A1; CYP1A2","7-Hydroxylation of coumarin","Human Phase I","Human","7-Hydroxycoumarin","5281426","ORHBXUUXSCNDEV-UHFFFAOYSA-N","InChI=1S/C9H6O3/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5,10H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ekins, S. and Wrighton, S.A. (1999); The role of CYP2B6 in Human Xenobiotic Metabolism; Drug Metabolism Reviews, 31:3, 719-754, DOI:10.1081/ DMR-100101942; PMID:10461547|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00443","coumarin","323","ZYGHJZDHTFUPRJ-UHFFFAOYSA-N","InChI=1S/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H","CYP3A4","7-Hydroxylation of coumarin","Human Phase I","Human","3-Hydroxycoumarin","13650","MJKVTPMWOKAVMS-UHFFFAOYSA-N","InChI=1S/C9H6O3/c10-7-5-6-3-1-2-4-8(6)12-9(7)11/h1-5,10H","Born, S.L. et al. (2002); Identification of the Cytochromes P450 That Catalyze Coumarin 3,4-Epoxidation and 3-Hydroxylation; Drug Metab Dispos; 30(5):483-7; PMID:11950775; DOI:https://doi.org/10.1124/dmd.30.5.483"
"BIOTID00444","coumarin","323","ZYGHJZDHTFUPRJ-UHFFFAOYSA-N","InChI=1S/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H","CYP1A1; CYP1A2; CYP2E1","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","Coumarin 3,4-epoxide","126771","YGDJSRSAEUNWRE-UHFFFAOYSA-N","InChI=1S/C9H6O3/c10-9-8-7(12-8)5-3-1-2-4-6(5)11-9/h1-4,7-8H","Born, S.L. et al. (2002); Identification of the Cytochromes P450 That Catalyze Coumarin 3,4-Epoxidation and 3-Hydroxylation; Drug Metab Dispos; 30(5):483-7; PMID:11950775; DOI:https://doi.org/10.1124/dmd.30.5.483"
"BIOTID00445","cp_122_721","NULL","ZIWFCOIGUNPHPM-MJGOQNOKSA-N","InChI=1S/C20H23F3N2O2/c1-26-18-10-9-16(27-20(21,22)23)12-15(18)13-25-17-8-5-11-24-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,24-25H,5,8,11,13H2,1H3/t17-,19+/m1/s1","CYP2D6","O-Demethylation","Human Phase I","Human","NULL","9929090","IZRHKURJIQCXMT-UHFFFAOYSA-N","InChI=1S/C19H21F3N2O2/c20-19(21,22)26-15-8-9-17(25)14(11-15)12-24-16-7-4-10-23-18(16)13-5-2-1-3-6-13/h1-3,5-6,8-9,11,16,18,23-25H,4,7,10,12H2","PMID:17965517"
"BIOTID00446","cp_122_721","NULL","ZIWFCOIGUNPHPM-MJGOQNOKSA-N","InChI=1S/C20H23F3N2O2/c1-26-18-10-9-16(27-20(21,22)23)12-15(18)13-25-17-8-5-11-24-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,24-25H,5,8,11,13H2,1H3/t17-,19+/m1/s1","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","23192118","JGFONUZHXXBGTF-UHFFFAOYSA-N","InChI=1S/C9H10F3NO2/c1-14-8-3-2-7(4-6(8)5-13)15-9(10,11)12/h2-4H,5,13H2,1H3","PMID:17965517"
"BIOTID00447","cp_125_611","NULL","IZRHKURJIQCXMT-AEFFLSMTSA-N","InChI=1S/C19H21F3N2O2/c20-19(21,22)26-15-8-9-17(25)14(11-15)12-24-16-7-4-10-23-18(16)13-5-2-1-3-6-13/h1-3,5-6,8-9,11,16,18,23-25H,4,7,10,12H2/t16-,18+/m1/s1","CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","N-Dealkylation","Human Phase I","Human","CP-919,230","11694142","NIJPYMIFXMKSQQ-UHFFFAOYSA-N","InChI=1S/C8H8F3NO2/c9-8(10,11)14-6-1-2-7(13)5(3-6)4-12/h1-3,13H,4,12H2","PMID:17965517"
"BIOTID00448","cp_125_611","NULL","IZRHKURJIQCXMT-AEFFLSMTSA-N","InChI=1S/C19H21F3N2O2/c20-19(21,22)26-15-8-9-17(25)14(11-15)12-24-16-7-4-10-23-18(16)13-5-2-1-3-6-13/h1-3,5-6,8-9,11,16,18,23-25H,4,7,10,12H2/t16-,18+/m1/s1","CYP1A2;CYP3A4","O-Detrifluoromethylation","Human Phase I","Human","quinone","NULL","UPDRCHOSPNAMLR-UHFFFAOYSA-N","InChI=1S/C18H22N2O2/c21-15-8-9-17(22)14(11-15)12-20-16-7-4-10-19-18(16)13-5-2-1-3-6-13/h1-3,5-6,8,11,16,18-21H,4,7,9-10,12H2","PMID:17965517"
"BIOTID00449","cp-199331","9895247","OFYJBLBCZNRWLC-DLUDVSRJSA-N","InChI=1S/C26H21F5N2O6S2/c1-37-21-4-2-15(33-41(35,36)26(29,30)31)7-13(21)6-14-11-39-22-5-3-16(8-17(22)25(14)34)38-12-24-32-20-9-18(27)19(28)10-23(20)40-24/h2-5,7-10,14,25,33-34H,6,11-12H2,1H3/t14-,25-/m1/s1","CYP3A4","O-Demethylation","Human Phase I","Human","NULL","NULL","ZEILRBGTCZUBLG-UHFFFAOYSA-N","InChI=1S/C25H19F5N2O6S2/c26-17-8-19-22(9-18(17)27)39-23(31-19)11-37-15-2-4-21-16(7-15)24(34)13(10-38-21)5-12-6-14(1-3-20(12)33)32-40(35,36)25(28,29)30/h1-4,6-9,13,24,32-34H,5,10-11H2","PMID:11602515"
"BIOTID00450","curcumin","969516","VFLDPWHFBUODDF-FCXRPNKRSA-N","InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+","CYP2D6","O-aryl demethylation","Human Phase I","Human","O-demethyl curcumin","5469426","FFRFJIZJLZXEJX-YPCIICBESA-N","InChI=1S/C20H18O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)12-15(21)6-2-13-4-8-17(23)19(25)10-13/h2-11,23-25H,12H2,1H3/b6-2+,7-3+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00451","cyclobenzaprine","2895","JURKNVYFZMSNLP-UHFFFAOYSA-N","InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3","CYP1A2 (major); CYP3A4 (major); CYP2D6 (minor)","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES","Human Phase I","Human","N-Desmethylcyclobenzaprine","9918","XECQQDXTQRYYBH-UHFFFAOYSA-N","InChI=1S/C19H19N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-13,20H,6,14H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00452","cyclohexene, 4-ethenyl-, (s)-","638078","BBDKZWKEPDTENS-MRVPVSSYSA-N","InChI=1S/C8H12/c1-2-8-6-4-3-5-7-8/h2-4,8H,1,5-7H2/t8-/m1/s1","CYP2B6;CYP2E1","Epoxidation","Human Phase I","Human","NULL","114431","OLKHRYQRCJLWLL-UHFFFAOYSA-N","InChI=1S/C8H12O/c1-2-4-7(5-3-1)8-6-9-8/h1-2,7-8H,3-6H2","PMID:11159809"
"BIOTID00453","cyclohexene, 4-ethenyl-, (s)-","638078","BBDKZWKEPDTENS-MRVPVSSYSA-N","InChI=1S/C8H12/c1-2-8-6-4-3-5-7-8/h2-4,8H,1,5-7H2/t8-/m1/s1","CYP2B6;CYP2E1","Epoxidation","Human Phase I","Human","NULL","7832","SLJFKNONPLNAPF-UHFFFAOYSA-N","InChI=1S/C8H12O/c1-2-6-3-4-7-8(5-6)9-7/h2,6-8H,1,3-5H2","PMID:11159809"
"BIOTID00454","cyclosporine_a","5284373","PMATZTZNYRCHOR-UITTWSBISA-N","InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41-,42+,43-,44-,45-,46+,47+,49+,50+,51-,52-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","ZPZHKIOMBYYVRD-OCEACIFDSA-N","InChI=1S/C62H111N11O13/c1-24-43-58(82)67(17)33-48(75)68(18)44(29-34(2)3)55(79)66-49(38(10)11)61(85)69(19)45(30-35(4)5)54(78)63-41(15)53(77)64-42(16)57(81)70(20)46(31-36(6)7)59(83)71(21)47(32-37(8)9)60(84)72(22)50(39(12)13)62(86)73(23)51(56(80)65-43)52(76)40(14)27-25-26-28-74/h25-26,34-47,49-52,74,76H,24,27-33H2,1-23H3,(H,63,78)(H,64,77)(H,65,80)(H,66,79)/b26-25+","PMID:15450954"
"BIOTID00455","cyclosporine_a","5284373","PMATZTZNYRCHOR-UITTWSBISA-N","InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41-,42+,43-,44-,45-,46+,47+,49+,50+,51-,52-/m1/s1","CYP3A4","N-demethylation","Human Phase I","Human","NULL","6436407","MIIRLHRXLLVIMF-SHHOIMCASA-N","InChI=1S/C61H109N11O12/c1-24-26-27-39(15)51(74)50-55(78)65-42(25-2)57(80)67(18)32-47(73)64-43(28-33(3)4)53(76)66-48(37(11)12)60(83)68(19)44(29-34(5)6)54(77)62-40(16)52(75)63-41(17)56(79)69(20)45(30-35(7)8)58(81)70(21)46(31-36(9)10)59(82)71(22)49(38(13)14)61(84)72(50)23/h24,26,33-46,48-51,74H,25,27-32H2,1-23H3,(H,62,77)(H,63,75)(H,64,73)(H,65,78)(H,66,76)/b26-24+","PMID:15450954"
"BIOTID00456","cyclosporine_a","5284373","PMATZTZNYRCHOR-UITTWSBISA-N","InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41-,42+,43-,44-,45-,46+,47+,49+,50+,51-,52-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","ODPRYBDBGFBROY-WMKIRNDFSA-N","InChI=1S/C62H111N11O13/c1-25-27-28-39(13)51(75)50-55(79)65-42(26-2)57(81)67(18)33-47(74)68(19)43(29-34(3)4)54(78)66-48(37(9)10)60(84)69(20)44(30-35(5)6)53(77)63-40(14)52(76)64-41(15)56(80)71(22)46(32-62(16,17)86)59(83)70(21)45(31-36(7)8)58(82)72(23)49(38(11)12)61(85)73(50)24/h25,27,34-46,48-51,75,86H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t39-,40-,41+,42-,43-,44-,45+,46+,48+,49+,50?,51-/m1/s1","PMID:15450954"
"BIOTID00457","dacarbazine","5351166","OMJKFYKNWZZKTK-POHAHGRESA-N","InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3,11H,1-2H3,(H2,7,13)/b10-6-","CYP1A2;CYP2E1","N-demethylation","Human Phase I","Human","MTIC","5381912","KNZAVOVKKCNCEG-YHYXMXQVSA-N","InChI=1S/C5H8N6O/c1-7-11-10-5-3(4(6)12)8-2-9-5/h2,7,11H,1H3,(H2,6,12)/b10-5-","PMID:10473105"
"BIOTID00458","dapsone","2955","MQJKPEGWNLWLTK-UHFFFAOYSA-N","InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2","CYP2E1; CYP3A4; CYP2C9; CYP2C8","N-hydroxylation of aniline to hydroxylamine","Human Phase I","Human","N-Hydroxydapsone","65387","IYDSJDWESCGRKW-UHFFFAOYSA-N","InChI=1S/C12H12N2O3S/c13-9-1-5-11(6-2-9)18(16,17)12-7-3-10(14-15)4-8-12/h1-8,14-15H,13H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Winter HR, Wang Y, Unadkat JD (2000); CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone; Drug Metab Dispos. 2000 Aug;28(8):865-8, PMID:10901692"
"BIOTID00459","debrisoquine","2966","JWPGJSVJDAJRLW-UHFFFAOYSA-N","InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)","CYP2D6","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","4-Hydroxydebrisoquine","107669","AKFURXZANOMQBD-UHFFFAOYSA-N","InChI=1S/C10H13N3O/c11-10(12)13-5-7-3-1-2-4-8(7)9(14)6-13/h1-4,9,14H,5-6H2,(H3,11,12)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00460","decursinol angelate","776123","AGABNGOXUSXQDD-XKGFZTIGSA-N","InChI=1S/C19H20O5/c1-5-11(2)18(21)23-16-9-13-8-12-6-7-17(20)22-14(12)10-15(13)24-19(16,3)4/h5-8,10,16H,9H2,1-4H3/b11-5-/t16-/m0/s1","CYP2A6","Epoxidation","Human Phase I","Human","NULL","NULL","VYFAOJIJWKADAF-UHFFFAOYSA-N","InChI=1S/C19H20O6/c1-10-19(4,24-10)17(21)23-15-8-12-7-11-5-6-16(20)22-13(11)9-14(12)25-18(15,2)3/h5-7,9-10,15H,8H2,1-4H3","PMID:17620343"
"BIOTID00461","dehydroepiandrosterone","5881","FMGSKLZLMKYGDP-USOAJAOKSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","627623","QQIVKFZWLZJXJT-UHFFFAOYSA-N","InChI=1S/C19H28O3/c1-18-7-5-12(20)9-11(18)3-4-13-14(18)6-8-19(2)15(13)10-16(21)17(19)22/h3,12-16,20-21H,4-10H2,1-2H3","PMID:14977864"
"BIOTID00462","dehydroepiandrosterone","5881","FMGSKLZLMKYGDP-USOAJAOKSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","22245198","OLPSAOWBSPXZEA-UHFFFAOYSA-N","InChI=1S/C19H28O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-15,17,20-21H,3-9H2,1-2H3","PMID:14977864"
"BIOTID00463","delavirdine","5625","WHBIGIKBNXZKFE-UHFFFAOYSA-N","InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","XJERELUGQMAAEH-UHFFFAOYSA-N","InChI=1S/C22H28N6O4S/c1-14(2)23-18-6-7-20(29)25-21(18)27-8-10-28(11-9-27)22(30)19-13-15-12-16(26-33(3,31)32)4-5-17(15)24-19/h4-7,12-14,23-24,26H,8-11H2,1-3H3,(H,25,29)","PMID:9660845"
"BIOTID00464","delavirdine","5625","WHBIGIKBNXZKFE-UHFFFAOYSA-N","InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3","CYP2D6;CYP3A4","N-desalkylation","Human Phase I","Human","NULL","468304","MTEFFPTUUPAKOV-UHFFFAOYSA-N","InChI=1S/C19H22N6O3S/c1-29(27,28)23-14-4-5-16-13(11-14)12-17(22-16)19(26)25-9-7-24(8-10-25)18-15(20)3-2-6-21-18/h2-6,11-12,22-23H,7-10,20H2,1H3","PMID:9660845"
"BIOTID00465","deoxypodophyllotoxin","345501","ZGLXUQQMLLIKAN-SVIJTADQSA-N","InChI=1S/C22H22O7/c1-24-17-6-12(7-18(25-2)21(17)26-3)19-14-8-16-15(28-10-29-16)5-11(14)4-13-9-27-22(23)20(13)19/h5-8,13,19-20H,4,9-10H2,1-3H3/t13-,19+,20-/m0/s1","CYP2C19;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","69791988","RINWQCSDWSZGDJ-UHFFFAOYSA-N","InChI=1S/C21H22O7/c1-25-16-6-11(7-17(26-2)20(16)27-3)18-13-8-15(23)14(22)5-10(13)4-12-9-28-21(24)19(12)18/h5-8,12,18-19,22-23H,4,9H2,1-3H3","PMID:18050240"
"BIOTID00466","deoxypodophyllotoxin","345501","ZGLXUQQMLLIKAN-SVIJTADQSA-N","InChI=1S/C22H22O7/c1-24-17-6-12(7-18(25-2)21(17)26-3)19-14-8-16-15(28-10-29-16)5-11(14)4-13-9-27-22(23)20(13)19/h5-8,13,19-20H,4,9-10H2,1-3H3/t13-,19+,20-/m0/s1","CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","4865","YJGVMLPVUAXIQN-UHFFFAOYSA-N","InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3","PMID:18050240"
"BIOTID00467","deoxypodophyllotoxin","345501","ZGLXUQQMLLIKAN-SVIJTADQSA-N","InChI=1S/C22H22O7/c1-24-17-6-12(7-18(25-2)21(17)26-3)19-14-8-16-15(28-10-29-16)5-11(14)4-13-9-27-22(23)20(13)19/h5-8,13,19-20H,4,9-10H2,1-3H3/t13-,19+,20-/m0/s1","CYP3A4","O-Demethylation","Human Phase I","Human","NULL","1689","RFDMNXDDRXVJTM-UHFFFAOYSA-N","InChI=1S/C21H20O7/c1-24-16-5-11(6-17(25-2)20(16)22)18-13-7-15-14(27-9-28-15)4-10(13)3-12-8-26-21(23)19(12)18/h4-7,12,18-19,22H,3,8-9H2,1-2H3","PMID:18050240"
"BIOTID00468","deramciclane","119590","QOBGWWQAMAPULA-RLLQIKCJSA-N","InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1","CYP3A4","N-demethylation","Human Phase I","Human","NULL","9865894","KTVWFUOXICTLAW-UHFFFAOYSA-N","InChI=1S/C19H29NO/c1-17(2)16-10-11-18(17,3)19(14-16,21-13-12-20-4)15-8-6-5-7-9-15/h5-9,16,20H,10-14H2,1-4H3","PMID:14566442"
"BIOTID00469","desmethylcitalopram","162180","DYIZNULSIBGJPJ-UHFFFAOYSA-N","InChI=1S/C19H19FN2O/c1-22-10-2-9-19(16-4-6-17(20)7-5-16)18-8-3-14(12-21)11-15(18)13-23-19/h3-8,11,22H,2,9-10,13H2,1H3","CYP2D6","N-dealkylation of acyclic secondary amine","Human Phase I","Human","N,N-Didesmethylcitalopram","162976","RKUKMUWCRLRPEJ-UHFFFAOYSA-N","InChI=1S/C18H17FN2O/c19-16-5-3-15(4-6-16)18(8-1-9-20)17-7-2-13(11-21)10-14(17)12-22-18/h2-7,10H,1,8-9,12,20H2","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00470","desogestrel","40973","RPLCPCMSCLEKRS-BPIQYHPVSA-N","InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1","CYP2C9; CYP2C19","Allylic hydroxylation","Human Phase I","Human","3-alpha-OH-desogestrel","29981456","ZMLDTNLDYRJTAZ-JASYKLOUSA-N","InChI=1S/C22H30O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,16-20,23-24H,3-4,6-11,13H2,1H3/t16-,17+,18+,19+,20-,21+,22+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00471","desogestrel","40973","RPLCPCMSCLEKRS-BPIQYHPVSA-N","InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1","CYP2C9; CYP2C19","Allylic hydroxylation","Human Phase I","Human","3-beta-OH-desogestrel","9858547","ZMLDTNLDYRJTAZ-GDLCRWSOSA-N","InChI=1S/C22H30O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,16-20,23-24H,3-4,6-11,13H2,1H3/t16-,17-,18-,19-,20+,21-,22-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00472","dexamethasone","5743","UREBDLICKHMUKA-CXSFZGCWSA-N","InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1","CYP3A4","Hydroxylation of carbon gamma to conjugated carbonyl","Human Phase I","Human","6-alpha-OH DEXAMETHASONE","10386732","RVBSTEHLLHXILB-GQKYHHCASA-N","InChI=1S/C22H29FO6/c1-11-6-13-14-8-16(26)15-7-12(25)4-5-19(15,2)21(14,23)17(27)9-20(13,3)22(11,29)18(28)10-24/h4-5,7,11,13-14,16-17,24,26-27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1","Daniela, M. (1995); DexamethasoneMetabolismby Human Liverin Vitro.Metabolite Identificationand Inhibitionof 6-Hydroxylation; Department of Pharmacology & Therapeutics, University of Liverpool; 0022-3565/96/2771-0105$"
"BIOTID00473","dexamethasone","5743","UREBDLICKHMUKA-CXSFZGCWSA-N","InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1","CYP3A4","Hydroxylation of carbon gamma to conjugated carbonyl","Human Phase I","Human","6-beta-OH DEXAMETHASONE","13848411","RVBSTEHLLHXILB-AWKJOQOESA-N","InChI=1S/C22H29FO6/c1-11-6-13-14-8-16(26)15-7-12(25)4-5-19(15,2)21(14,23)17(27)9-20(13,3)22(11,29)18(28)10-24/h4-5,7,11,13-14,16-17,24,26-27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16?,17+,19+,20+,21+,22+/m1/s1","Daniela, M. (1995); DexamethasoneMetabolismby Human Liverin Vitro.Metabolite Identificationand Inhibitionof 6-Hydroxylation; Department of Pharmacology & Therapeutics, University of Liverpool; 0022-3565/96/2771-0105$"
"BIOTID00474","dexfenfluramine","66265","DBGIVFWFUFKIQN-VIFPVBQESA-N","InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3/t9-/m0/s1","CYP1A2;CYP2D6","N-dealkylation","Human Phase I","Human","nordexfenfluramine","15897","MLBHFBKZUPLWBD-UHFFFAOYSA-N","InChI=1S/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3","PMID:9825834"
"BIOTID00475","dexloxiglumide","65937","QNQZBKQEIFTHFZ-GOSISDBHSA-N","InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1","CYP2B6;CYP2C8;CYP2C9;CYP3A4","O-demethylation","Human Phase I","Human","NULL","101235750","JBHQLPRGRQWTME-UHFFFAOYSA-N","InChI=1S/C20H28Cl2N2O5/c1-2-3-4-10-24(11-5-12-25)20(29)17(8-9-18(26)27)23-19(28)14-6-7-15(21)16(22)13-14/h6-7,13,17,25H,2-5,8-12H2,1H3,(H,23,28)(H,26,27)","PMID:15108219"
"BIOTID00476","dexpropranolol (propranolol)","21138","AQHHHDLHHXJYJD-CQSZACIVSA-N","InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3/t14-/m1/s1","CYP1A2;CYP2D6","N-DESISOPROPYLATION","Human Phase I","Human","NULL","159899","ZFMCITCRZXLMDJ-UHFFFAOYSA-N","InChI=1S/C13H15NO2/c14-8-11(15)9-16-13-7-3-5-10-4-1-2-6-12(10)13/h1-7,11,15H,8-9,14H2","PMID:8877032|PMID:8781788|PMID:10460802"
"BIOTID00477","dexpropranolol (propranolol)","21138","AQHHHDLHHXJYJD-CQSZACIVSA-N","InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3/t14-/m1/s1","CYP1A2;CYP2D6","AROMATIC HYDROXYLATION","Human Phase I","Human","NULL","10446087","WMYPGILKDMWISO-UHFFFAOYSA-N","InChI=1S/C16H21NO3/c1-11(2)17-9-12(18)10-20-16-8-4-5-13-14(16)6-3-7-15(13)19/h3-8,11-12,17-19H,9-10H2,1-2H3","PMID:8877032|PMID:8781788|PMID:10460802"
"BIOTID00478","dexpropranolol (propranolol)","21138","AQHHHDLHHXJYJD-CQSZACIVSA-N","InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3/t14-/m1/s1","CYP1A2;CYP2D6","AROMATIC HYDROXYLATION","Human Phase I","Human","NULL","91565","CWEPACWBWIOYID-UHFFFAOYSA-N","InChI=1S/C16H21NO3/c1-11(2)17-9-12(18)10-20-16-8-7-15(19)13-5-3-4-6-14(13)16/h3-8,11-12,17-19H,9-10H2,1-2H3","PMID:8877032|PMID:8781788|PMID:10460802"
"BIOTID00479","dextromethorphan","5360696","MKXZASYAUGDDCJ-NJAFHUGGSA-N","InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1","CYP2D6 (major); CYP2C9 (minor); CYP3A4 (minor)","O-dealkylation","Human Phase I","Human","Dextrorphan","5360697","JAQUASYNZVUNQP-PVAVHDDUSA-N","InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Yu, A. et al; (2001); COMPARATIVE CONTRIBUTION TO DEXTROMETHORPHAN METABOLISM BY CYTOCHROME P450 ISOFORMS IN VITRO: CAN DEXTROMETHORPHAN BE USED AS A DUAL PROBE FOR BOTH CYP2D6 AND CYP3A ACTIVITIES?; Drug metabolism and Disposition, 2001 Vol. 29, No. 11"
"BIOTID00480","dextromethorphan","5360696","MKXZASYAUGDDCJ-NJAFHUGGSA-N","InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1","CYP3A4 (major); CYP2D6 (minor); CYP2C9 (minor); CYP2B6 (minor); CYP2C19 (minor)","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","3-methoxymorphinan","1671","ILNSWVUXAPSPEH-PVAVHDDUSA-N","InChI=1S/C17H23NO/c1-19-13-6-5-12-10-16-14-4-2-3-7-17(14,8-9-18-16)15(12)11-13/h5-6,11,14,16,18H,2-4,7-10H2,1H3/t14-,16+,17+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Yu, A. et al; (2001); COMPARATIVE CONTRIBUTION TO DEXTROMETHORPHAN METABOLISM BY CYTOCHROME P450 ISOFORMS IN VITRO: CAN DEXTROMETHORPHAN BE USED AS A DUAL PROBE FOR BOTH CYP2D6 AND CYP3A ACTIVITIES?; Drug metabolism and Disposition, 2001 Vol. 29, No. 11"
"BIOTID00481","dextropropoxyphene","10100","XLMALTXPSGQGBX-GCJKJVERSA-N","InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1","CYP3A4","N-demethylation","Human Phase I","Human","Nordextropropoxyphene","18804","IKACRWYHQXOSGM-UHFFFAOYSA-N","InChI=1S/C21H27NO2/c1-4-20(23)24-21(17(2)16-22-3,19-13-9-6-10-14-19)15-18-11-7-5-8-12-18/h5-14,17,22H,4,15-16H2,1-3H3","PMID:15764408"
"BIOTID00482","dexverapamil","65808","SGTNSNPWRIOYBX-HHHXNRCGSA-N","InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3/t27-/m1/s1","CYP2C8; CYP1A2; CYP3A4; CYP3A5","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","dexverapamil, N-demethyl","15593907","UPKQNCPKPOLASS-AREMUKBSSA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00483","dexverapamil","65808","SGTNSNPWRIOYBX-HHHXNRCGSA-N","InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3/t27-/m1/s1","CYP2C8","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","(2R)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(4-hydroxy-3-methoxyphenyl)-2-(propan-2-yl)pentanenitrile","91810609","WLKVZSXOMGNZLB-AREMUKBSSA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-10-22(29)24(17-21)31-5)13-7-14-28(3)15-12-20-8-11-23(30-4)25(16-20)32-6/h8-11,16-17,19,29H,7,12-15H2,1-6H3/t26-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00484","dexverapamil","65808","SGTNSNPWRIOYBX-HHHXNRCGSA-N","InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3/t27-/m1/s1","CYP2C8; CYP3A4; CYP1A2","N-dealkylation of acyclic secondary amine","Human Phase I","Human","2-(3,4-dimethoxyphenyl)acetaldehyde","NULL","RIVVYJWUHXMGSK-UHFFFAOYSA-N","InChI=1S/C10H12O3/c1-12-9-4-3-8(5-6-11)7-10(9)13-2/h3-4,6-7H,5H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00485","dexverapamil","65808","SGTNSNPWRIOYBX-HHHXNRCGSA-N","InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3/t27-/m1/s1","CYP2C8; CYP3A4; CYP1A2","N-dealkylation of acyclic secondary amine","Human Phase I","Human","(R)-D-617","13537153","WLOBUUJURNEQCL-QGZVFWFLSA-N","InChI=1S/C17H26N2O2/c1-13(2)17(12-18,9-6-10-19-3)14-7-8-15(20-4)16(11-14)21-5/h7-8,11,13,19H,6,9-10H2,1-5H3/t17-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00486","diallyl disulfide","16590","PFRGXCVKLLPLIP-UHFFFAOYSA-N","InChI=1S/C6H10S2/c1-3-5-7-8-6-4-2/h3-4H,1-2,5-6H2","CYP2A6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1","S-Oxidation","Human Phase I","Human","DADSO","65036","JDLKFOPOAOFWQN-UHFFFAOYSA-N","InChI=1S/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2","PMID:10383929"
"BIOTID00487","diazepam","3016","AAOVKJBEBIDNHE-UHFFFAOYSA-N","InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3","CYP2B6; CYP3A4; CYP3A5; CYP2C19; CYP2C8; CYP2C9; CYP2C18","N-dealkylation of secondary carboxamide","Human Phase I","Human","Nordiazepam","2997","AKPLHCDWDRPJGD-UHFFFAOYSA-N","InChI=1S/C15H11ClN2O/c16-11-6-7-13-12(8-11)15(17-9-14(19)18-13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00488","diazepam","3016","AAOVKJBEBIDNHE-UHFFFAOYSA-N","InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3","CYP3A4; CYP3A5; CYP2C19 (minor)","3-Hydroxylation of 5-aryl-1,4-benzodiazepine","Human Phase I","Human","Temazepam","5391","SEQDDYPDSLOBDC-UHFFFAOYSA-N","InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00489","Diazinon","3017","FHIVAFMUCKRCQO-UHFFFAOYSA-N","InChI=1S/C12H21N2O3PS/c1-6-15-18(19,16-7-2)17-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3","CYP2C19","Dearylation of organphosphosulfur compound","Human Phase I","Human","Pyrimidinol","17777","AJPIUNPJBFBUKK-UHFFFAOYSA-N","InChI=1S/C8H12N2O/c1-5(2)8-9-6(3)4-7(11)10-8/h4-5H,1-3H3,(H,9,10,11)","Kappers, W.A. et al.; (2001). Diazinon Is Activated by CYP2C19 in Human Liver. Toxicol. Appl. Pharmacol., Vol. 177, No. 1, (68-76)|Buratti, F.M. et al.; Toxicology and Applied Pharmacology 186 (2003) 143Ã¢â‚¬â€œ154."
"BIOTID00490","Diazinon","3017","FHIVAFMUCKRCQO-UHFFFAOYSA-N","InChI=1S/C12H21N2O3PS/c1-6-15-18(19,16-7-2)17-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3","CYP2C19","Dearylation of organphosphosulfur compound","Human Phase I","Human","Diethyl thiophosphate","17173","PKUWKAXTAVNIJR-UHFFFAOYSA-N","InChI=1S/C4H11O3PS/c1-3-6-8(5,9)7-4-2/h3-4H2,1-2H3,(H,5,9)","Kappers, W.A. et al.; (2001). Diazinon Is Activated by CYP2C19 in Human Liver. Toxicol. Appl. Pharmacol., Vol. 177, No. 1, (68-76)|Buratti, F.M. et al.; Toxicology and Applied Pharmacology 186 (2003) 143Ã¢â‚¬â€œ154."
"BIOTID00491","Diazinon","3017","FHIVAFMUCKRCQO-UHFFFAOYSA-N","InChI=1S/C12H21N2O3PS/c1-6-15-18(19,16-7-2)17-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3","CYP1A2; CYP2A6; CYP2B6; CYP2C8; CYP2C9; CYP2C19; CYP2D6; CYP3A4","Desulfuration of organophosphothioates","Human Phase I","Human","Diazoxon","13754","VBLJFQYCTRKKKF-UHFFFAOYSA-N","InChI=1S/C12H21N2O4P/c1-6-16-19(15,17-7-2)18-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3","Kappers, W.A. et al.; (2001). Diazinon Is Activated by CYP2C19 in Human Liver. Toxicol. Appl. Pharmacol., Vol. 177, No. 1, (68-76)|Buratti, F.M. et al.; Toxicology and Applied Pharmacology 186 (2003) 143Ã¢â‚¬â€œ154."
"BIOTID00492","dibenzo[a,l]pyrene","9119","JNTHRSHGARDABO-UHFFFAOYSA-N","InChI=1S/C24H14/c1-2-8-18-16(6-1)14-17-13-12-15-7-5-11-20-19-9-3-4-10-21(19)24(18)23(17)22(15)20/h1-14H","CYP1A2;CYP2B6;CYP2C9;CYP3A4","Epoxidation","Human Phase I","Human","NULL","NULL","RNWHENHYLHGYSS-UHFFFAOYSA-N","InChI=1S/C24H12O/c1-2-6-17-15(5-1)16-7-3-4-13-8-9-14-12-19-18(10-11-20-24(19)25-20)23(17)22(14)21(13)16/h1-12H","PMID:8968059"
"BIOTID00493","dibenzylfluorescein","371436","YZJGKSLPSGPFEV-UHFFFAOYSA-N","InChI=1S/C34H24O5/c35-25-15-17-29-31(19-25)39-32-20-26(37-21-23-9-3-1-4-10-23)16-18-30(32)33(29)27-13-7-8-14-28(27)34(36)38-22-24-11-5-2-6-12-24/h1-20H,21-22H2","CYP2C8; CYP2C9; CYP2C19; CYP3A4","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Fluorescein benzyl ester","NULL","YDIMXOIBAHIGQV-UHFFFAOYSA-N","InChI=1S/C27H18O5/c28-18-10-12-22-24(14-18)32-25-15-19(29)11-13-23(25)26(22)20-8-4-5-9-21(20)27(30)31-16-17-6-2-1-3-7-17/h1-15,28H,16H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00494","dibenzylfluorescein","371436","YZJGKSLPSGPFEV-UHFFFAOYSA-N","InChI=1S/C34H24O5/c35-25-15-17-29-31(19-25)39-32-20-26(37-21-23-9-3-1-4-10-23)16-18-30(32)33(29)27-13-7-8-14-28(27)34(36)38-22-24-11-5-2-6-12-24/h1-20H,21-22H2","CYP2C8; CYP2C9; CYP2C19; CYP3A4","HYDROLYSIS_OF_CARBOXYLIC_ESTER","Human Phase I","Human","2-[6-(benzyloxy)-3-oxo-3H-xanthen-9-yl]benzoic acid","NULL","MZBJPNYKPATCQL-UHFFFAOYSA-N","InChI=1S/C27H18O5/c28-18-10-12-22-24(14-18)32-25-15-19(31-16-17-6-2-1-3-7-17)11-13-23(25)26(22)20-8-4-5-9-21(20)27(29)30/h1-15H,16H2,(H,29,30)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00495","diclofenac","3033","DCOPUUMXTXDBNB-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)","CYP2C9","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","4'-OH-diclofenac","116545","KGVXVPRLBMWZLG-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c15-10-6-9(18)7-11(16)14(10)17-12-4-2-1-3-8(12)5-13(19)20/h1-4,6-7,17-18H,5H2,(H,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Bort, R. (1999); Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways; Biochem Pharmacol. 1999 Sep 1;58(5):787-96; PMID:10449188"
"BIOTID00496","diclofenac","3033","DCOPUUMXTXDBNB-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)","CYP2B6; CYP2C8; CYP2C19; CYP3A4","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","5-OH-diclofenac","3052566","VNQURRWYKFZKJZ-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c15-10-2-1-3-11(16)14(10)17-12-5-4-9(18)6-8(12)7-13(19)20/h1-6,17-18H,7H2,(H,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Bort, R. (1999); Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways; Biochem Pharmacol. 1999 Sep 1;58(5):787-96; PMID:10449188"
"BIOTID00497","digitoxin","441207","WDJUZGPOPHTGOT-UWWSFERISA-N","InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34-,35+,36-,37-,38-,39+,40-,41+/m1/s1","CYP3A4","O-dealkylation","Human Phase I","Human","Digoxigenin Bisdigitoxoside","92999","NTSBMKIZRSBFTA-AIDOXSFESA-N","InChI=1S/C35H54O11/c1-17-31(40)25(36)14-30(43-17)46-32-18(2)44-29(15-26(32)37)45-21-7-9-33(3)20(12-21)5-6-23-24(33)13-27(38)34(4)22(8-10-35(23,34)41)19-11-28(39)42-16-19/h11,17-18,20-27,29-32,36-38,40-41H,5-10,12-16H2,1-4H3/t17-,18-,20-,21+,22-,23-,24+,25+,26+,27-,29+,30+,31-,32-,33+,34+,35+/m1/s1","PMID:1944247"
"BIOTID00498","dihydrocodeine","5284543","RBOXVHNMENFORY-DNJOTXNNSA-N","InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1","CYP2D6","O-dementhylation","Human Phase I","Human","NULL","273032","IJVCSMSMFSCRME-UHFFFAOYSA-N","InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3","PMID:19902987"
"BIOTID00499","dihydrocodeine","5284543","RBOXVHNMENFORY-DNJOTXNNSA-N","InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1","CYP3A4","N-dementhylation","Human Phase I","Human","NULL","625501","IKGNKASQBMZRJL-UHFFFAOYSA-N","InChI=1S/C17H21NO3/c1-20-13-5-2-9-8-11-10-3-4-12(19)16-17(10,6-7-18-11)14(9)15(13)21-16/h2,5,10-12,16,18-19H,3-4,6-8H2,1H3","PMID:19902987"
"BIOTID00500","diltiazem","39186","HSUGRBWQSSZJOP-RTWAWAEBSA-N","InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1","CYP3A4 (major); CYP2C8 (minor); CYP2C9 (minor)","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-Demethyldiltiazem","107891","YOMLDISQSWWYOT-UXHICEINSA-N","InChI=1S/C21H24N2O4S/c1-14(24)27-19-20(15-8-10-16(26-3)11-9-15)28-18-7-5-4-6-17(18)23(21(19)25)13-12-22-2/h4-11,19-20,22H,12-13H2,1-3H3/t19-,20+/m1/s1","Kurokawa, T. et al. (2015); Characterization of Species Differences in Tissue Diltiazem Deacetylation Identifies Ces2a as a Rat-Specific Diltiazem Deacetylase; The American Society for Pharmacology and Experimental Therapeutics; 43:1218Ã¢â‚¬â€œ1225, August 2015;"
"BIOTID00501","diltiazem","39186","HSUGRBWQSSZJOP-RTWAWAEBSA-N","InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1","CYP2D6","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","O-Demethyldiltiazem","25834477","ALISTFINEQANJP-UXHICEINSA-N","InChI=1S/C21H24N2O4S/c1-14(24)27-19-20(15-8-10-16(25)11-9-15)28-18-7-5-4-6-17(18)23(21(19)26)13-12-22(2)3/h4-11,19-20,25H,12-13H2,1-3H3/t19-,20+/m1/s1","Kurokawa, T. et al. (2015); Characterization of Species Differences in Tissue Diltiazem Deacetylation Identifies Ces2a as a Rat-Specific Diltiazem Deacetylase; The American Society for Pharmacology and Experimental Therapeutics; 43:1218Ã¢â‚¬â€œ1225, August 2015;"
"BIOTID00502","diphenhydramine","3100","ZZVUWRFHKOJYTH-UHFFFAOYSA-N","InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3","CYP2D6; CYP1A2; CYP2C9; CYP2C19; CYP2B6","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-Desmethyldiphenhydramine","40791","AGSLYHYWLYGAOU-UHFFFAOYSA-N","InChI=1S/C16H19NO/c1-17-12-13-18-16(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-11,16-17H,12-13H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00503","disopiramide","156295","UVTNFZQICZKOEM-NRFANRHFSA-N","InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)/t21-/m0/s1","CYP3A4","N-desalkylation","Human Phase I","Human","mono-N-desalkyldisopyramide","107858","UWNSWIXIVDMCHZ-UHFFFAOYSA-N","InChI=1S/C18H23N3O/c1-14(2)20-13-11-18(17(19)22,15-8-4-3-5-9-15)16-10-6-7-12-21-16/h3-10,12,14,20H,11,13H2,1-2H3,(H2,19,22)","PMID:10901704"
"BIOTID00504","docetaxel","148124","ZDZOTLJHXYCWBA-VCVYQWHSSA-N","InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1","CYP3A4","Hydroxylation of terminal methyl","Human Phase I","Human","Hydroxy-Docetaxel","15765778","HABZZLXXUPZIJD-VCVYQWHSSA-N","InChI=1S/C43H53NO15/c1-22-26(56-37(52)32(49)30(24-14-10-8-11-15-24)44-38(53)59-39(3,4)20-45)19-43(54)35(57-36(51)25-16-12-9-13-17-25)33-41(7,34(50)31(48)29(22)40(43,5)6)27(47)18-28-42(33,21-55-28)58-23(2)46/h8-17,26-28,30-33,35,45,47-49,54H,18-21H2,1-7H3,(H,44,53)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1","Rodriguez-Antona, C. et al. (2006); Cytochrome P450 pharmacogenetics and cancer. Nature publishing group. (2006) 25, 1679-1691; DOI:10.1038/sj.onc.1209377"
"BIOTID00505","domitroban","5312138","PWTCIBWRMQFJBC-ZEMKZVSASA-N","InChI=1S/C20H27NO4S/c22-19(23)11-7-2-1-6-10-18-15-12-13-16(14-15)20(18)21-26(24,25)17-8-4-3-5-9-17/h1,3-6,8-9,15-16,18,20-21H,2,7,10-14H2,(H,22,23)/b6-1-/t15-,16+,18+,20+/m1/s1","CYP2C9","Aliphatic Hydroxylation","Human Phase I","Human","NULL","44210817","IRARGZKQASOPCS-BHQIHCQQSA-N","InChI=1S/C20H27NO5S/c22-18-13-14-12-17(18)16(10-6-1-2-7-11-19(23)24)20(14)21-27(25,26)15-8-4-3-5-9-15/h1,3-6,8-9,14,16-18,20-22H,2,7,10-13H2,(H,23,24)/b6-1-","PMID:9010633"
"BIOTID00506","domitroban","5312138","PWTCIBWRMQFJBC-ZEMKZVSASA-N","InChI=1S/C20H27NO4S/c22-19(23)11-7-2-1-6-10-18-15-12-13-16(14-15)20(18)21-26(24,25)17-8-4-3-5-9-17/h1,3-6,8-9,15-16,18,20-21H,2,7,10-14H2,(H,22,23)/b6-1-/t15-,16+,18+,20+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","44210816","VEADYYAHWFZYLA-BHQIHCQQSA-N","InChI=1S/C20H27NO5S/c22-18-13-14-12-17(18)20(16(14)10-6-1-2-7-11-19(23)24)21-27(25,26)15-8-4-3-5-9-15/h1,3-6,8-9,14,16-18,20-22H,2,7,10-13H2,(H,23,24)/b6-1-","PMID:9010633"
"BIOTID00507","domperidone","3151","FGXWKSZFVQUSTL-UHFFFAOYSA-N","InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)","CYP1A2;CYP2B6;CYP2C8;CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","158069","SWKZXSSZKVNAJG-UHFFFAOYSA-N","InChI=1S/C22H24ClN5O3/c23-14-2-4-20-17(12-14)25-22(31)28(20)15-6-10-26(11-7-15)8-1-9-27-19-5-3-16(29)13-18(19)24-21(27)30/h2-5,12-13,15,29H,1,6-11H2,(H,24,30)(H,25,31)","PMID:15327587"
"BIOTID00508","domperidone","3151","FGXWKSZFVQUSTL-UHFFFAOYSA-N","InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)","CYP3A4","N-dealkylation","Human Phase I","Human","NULL","104607","DOAYWDKFDPSTSV-UHFFFAOYSA-N","InChI=1S/C12H14ClN3O/c13-8-1-2-11-10(7-8)15-12(17)16(11)9-3-5-14-6-4-9/h1-2,7,9,14H,3-6H2,(H,15,17)","PMID:15327587"
"BIOTID00509","domperidone","3151","FGXWKSZFVQUSTL-UHFFFAOYSA-N","InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)","CYP3A4","N-dealkylation","Human Phase I","Human","NULL","1527023","YNFLIDHXMNKSQR-UHFFFAOYSA-N","InChI=1S/C10H12N2O/c1-2-7-12-9-6-4-3-5-8(9)11-10(12)13/h3-6H,2,7H2,1H3,(H,11,13)","PMID:15327587"
"BIOTID00510","doxepin","667468","ODQWQRRAPPTVAG-BOPFTXTBSA-N","InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11-","CYP2C19","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","nordoxepin","5353833","HVKCEFHNSNZIHO-YBEGLDIGSA-N","InChI=1S/C18H19NO/c1-19-12-6-10-16-15-8-3-2-7-14(15)13-20-18-11-5-4-9-17(16)18/h2-5,7-11,19H,6,12-13H2,1H3/b16-10-","Musshoff F. et al. (2010); Pharmacogenetics and forensic toxicology; Forensic Sci Int.; 203, 53-62. DOI:doi:10.1016/j.forsciint.2010.07.011"
"BIOTID00511","doxepin","667468","ODQWQRRAPPTVAG-BOPFTXTBSA-N","InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11-","CYP2D6","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2-OH-doxepin","58600463","JCZHLWUPQBSZCM-FRKPEAEDSA-N","InChI=1S/C19H21NO2/c1-20(2)11-5-7-16-17-6-3-4-8-19(17)22-13-14-9-10-15(21)12-18(14)16/h3-4,6-10,12,21H,5,11,13H2,1-2H3/b16-7+","Musshoff F. et al. (2010); Pharmacogenetics and forensic toxicology; Forensic Sci Int.; 203, 53-62. DOI:doi:10.1016/j.forsciint.2010.07.011"
"BIOTID00512","ebastine","3191","VPIRRYIYIPYTGX-UHFFFAOYSA-N","InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","Deslakylebastine","54343088","UAIVWKRILRHHTB-UHFFFAOYSA-N","InChI=1S/C14H18O2/c1-14(2,3)12-8-6-11(7-9-12)13(16)5-4-10-15/h6-10H,4-5H2,1-3H3","Hashizume, T. et al. (2002); Involvement of CYP2J2 and CYP4F12 in the methabolism of Ebastine in Human Intestinal Microsomes. The journal of pharmacology and exprimental therapeutics. 2002, 300 (1) 2980304; DOI:https://doi.org/10.1124/jpet.300.1.298"
"BIOTID00512","ebastine","3191","VPIRRYIYIPYTGX-UHFFFAOYSA-N","InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","4-(4-tert-butylphenyl)-4-oxobutanal","3017584","OQAOREVBRZVXDS-UHFFFAOYSA-N","InChI=1S/C18H21NO/c1-3-7-15(8-4-1)18(16-9-5-2-6-10-16)20-17-11-13-19-14-12-17/h1-10,17-19H,11-14H2","Hashizume, T. et al. (2002); Involvement of CYP2J2 and CYP4F12 in the methabolism of Ebastine in Human Intestinal Microsomes. The journal of pharmacology and exprimental therapeutics. 2002, 300 (1) 2980304; DOI:https://doi.org/10.1124/jpet.300.1.298"
"BIOTID00513","ecabapide","65885","JTAGHJPZEDNHHA-UHFFFAOYSA-N","InChI=1S/C20H25N3O4/c1-21-20(25)15-5-4-6-16(12-15)23-13-19(24)22-10-9-14-7-8-17(26-2)18(11-14)27-3/h4-8,11-12,23H,9-10,13H2,1-3H3,(H,21,25)(H,22,24)","CYP3A4","Hydroxylation of benzene on carbon orhto to a strongly electron donating group","Human Phase I","Human","6-hydroxy-ecabapide","101013560","HHTJYUYIEQTITM-UHFFFAOYSA-N","InChI=1S/C20H25N3O5/c1-21-20(26)15-11-14(5-6-16(15)24)23-12-19(25)22-9-8-13-4-7-17(27-2)18(10-13)28-3/h4-7,10-11,23-24H,8-9,12H2,1-3H3,(H,21,26)(H,22,25)","Fujimaki, N. et al. (1999); IdentiÃ‚Â®cation of cytochromes P450 involved in human liver microsomal metabolism of ecabapide, a prokinetic agent; xenobiotica; 29:12, 1273-1282; DOI:10.1080/004982599237930"
"BIOTID00514","ecabapide","65885","JTAGHJPZEDNHHA-UHFFFAOYSA-N","InChI=1S/C20H25N3O4/c1-21-20(25)15-5-4-6-16(12-15)23-13-19(24)22-10-9-14-7-8-17(26-2)18(11-14)27-3/h4-8,11-12,23H,9-10,13H2,1-3H3,(H,21,25)(H,22,24)","CYP3A4","N-dealkylation of secondary arylalkylamine","Human Phase I","Human","5-amino-2-hydroxy-N-methylbenzamide","19822904","TZEPFEDEUUHBDU-UHFFFAOYSA-N","InChI=1S/C8H10N2O2/c1-10-8(12)6-4-5(9)2-3-7(6)11/h2-4,11H,9H2,1H3,(H,10,12)","Fujimaki, N. et al. (1999); IdentiÃ‚Â®cation of cytochromes P450 involved in human liver microsomal metabolism of ecabapide, a prokinetic agent; xenobiotica; 29:12, 1273-1282; DOI:10.1080/004982599237930"
"BIOTID00514","ecabapide","65885","JTAGHJPZEDNHHA-UHFFFAOYSA-N","InChI=1S/C20H25N3O4/c1-21-20(25)15-5-4-6-16(12-15)23-13-19(24)22-10-9-14-7-8-17(26-2)18(11-14)27-3/h4-8,11-12,23H,9-10,13H2,1-3H3,(H,21,25)(H,22,24)","CYP3A4","N-dealkylation of secondary arylalkylamine","Human Phase I","Human","N-[2-(3,4-dimethoxyphenyl)ethyl]-2-oxoacetamide","NULL","JKKUHHGGROMBJG-UHFFFAOYSA-N","InChI=1S/C12H15NO4/c1-16-10-4-3-9(7-11(10)17-2)5-6-13-12(15)8-14/h3-4,7-8H,5-6H2,1-2H3,(H,13,15)","Fujimaki, N. et al. (1999); IdentiÃ‚Â®cation of cytochromes P450 involved in human liver microsomal metabolism of ecabapide, a prokinetic agent; xenobiotica; 29:12, 1273-1282; DOI:10.1080/004982599237930"
"BIOTID00515","efavirenz","64139","XPOQHMRABVBWPR-ZDUSSCGKSA-N","InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1","CYP2B6; CYP1A2; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","8-OH-efavirenz","487643","OOVOMPCQLMFEDT-ZDUSSCGKSA-N","InChI=1S/C14H9ClF3NO3/c15-8-5-9-11(10(20)6-8)19-12(21)22-13(9,14(16,17)18)4-3-7-1-2-7/h5-7,20H,1-2H2,(H,19,21)/t13-/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00516","eicosapentaenoic acid","446284","JAZBEHYOTPTENJ-JLNKQSITSA-N","InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-","CYP2C8;CYP2C9;CYP2C11;CYP2C23","Epoxidation","Human Phase I","Human","NULL","5312543","JDKIKEYFSJUYJZ-OUJQXAOTSA-N","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,15-16H,2,5,8,11-14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,16-15-","PMID:15766564"
"BIOTID00517","eletriptan","NULL","BBMOMQCRLMEOQE-RTBURBONSA-N","InChI=1S/C22H28N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,18-19,23H,5-6,11-13,15-16H2,1H3/t18-,19-/m1/s1","CYP2D6 (major); CYP3A4 (major); CYP2C9 (minor); CYP2C19 (minor); CYP1A2 (minor); CYP2C8 (minor)","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-Desmethyleletriptan","NULL","DZPWTXAGCISGJW-QZTJIDSGSA-N","InChI=1S/C21H26N2O2S/c24-26(25,19-6-2-1-3-7-19)12-10-16-8-9-21-20(13-16)17(15-23-21)14-18-5-4-11-22-18/h1-3,6-9,13,17-18,22-23H,4-5,10-12,14-15H2/t17-,18-/m1/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00518","eplerenone","443872","JUKPWJGBANNWMW-VWBFHTRKSA-N","InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1","CYP3A4","Hydroxylation of carbon gamma to conjugated carbonyl","Human Phase I","Human","6beta-hydroxyeplerenone","NULL","DDHQRXOAZNEFKY-YEIJCWOFSA-N","InChI=1S/C24H30O7/c1-21-7-4-12(25)10-14(21)19(27)17(20(28)29-3)18-13-5-8-23(9-6-16(26)31-23)22(13,2)11-15-24(18,21)30-15/h10,13,15,17-19,27H,4-9,11H2,1-3H3/t13-,15+,17-,18+,19?,21-,22-,23+,24+/m0/s1","cook, C, S. et al. (2002); INVOLVEMENT OF CYP3A IN THE METABOLISM OF EPLERENONE IN HUMANS AND DOGS: DIFFERENTIAL METABOLISM BY CYP3A4 AND CYP3A5; The American Society for Pharmacology and Experimental Therapeutics; 30:1344Ã¢â‚¬â€œ1351, 2002; DOI:0090-9556/02/3011"
"BIOTID00519","eplerenone","443872","JUKPWJGBANNWMW-VWBFHTRKSA-N","InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1","CYP3A4","Alpha hydroxylation of carbonyl group","Human Phase I","Human","21-hydroxyeplerenone","91810647","TVCONGKEWSYBKD-NBACNWMZSA-N","InChI=1S/C24H30O7/c1-21-6-4-13(25)8-12(21)9-14(19(27)29-3)18-15-5-7-23(10-16(26)20(28)31-23)22(15,2)11-17-24(18,21)30-17/h8,14-18,26H,4-7,9-11H2,1-3H3/t14-,15+,16?,17-,18+,21+,22+,23-,24-/m1/s1","cook, C, S. et al. (2002); INVOLVEMENT OF CYP3A IN THE METABOLISM OF EPLERENONE IN HUMANS AND DOGS: DIFFERENTIAL METABOLISM BY CYP3A4 AND CYP3A5; The American Society for Pharmacology and Experimental Therapeutics; 30:1344Ã¢â‚¬â€œ1351, 2002; DOI:0090-9556/02/3011"
"BIOTID00520","erythromycin","NULL","PGRWHWPTHNFQEN-LQDUVHJKSA-N","InChI=1S/C37H71NO11/c1-14-27-37(10,43)31(40)21(3)15-20(2)17-35(8,42)33(49-34-29(39)26(38(11)12)16-23(5)46-34)24(6)30(22(4)19-45-27)48-28-18-36(9,44-13)32(41)25(7)47-28/h20-34,39-43H,14-19H2,1-13H3/t20-,21-,22-,23+,24+,25-,26-,27+,28-,29+,30+,31-,32-,33+,34-,35+,36+,37+/m0/s1","CYP3A4; CYP2B6","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1","Human Phase I","Human","N-Desmethylerythromycin","NULL","SXRMKZCUOASAPB-BEUWEJSBSA-N","InChI=1S/C36H69NO11/c1-13-26-36(10,42)30(39)20(3)14-19(2)16-34(8,41)32(48-33-28(38)25(37-11)15-22(5)45-33)23(6)29(21(4)18-44-26)47-27-17-35(9,43-12)31(40)24(7)46-27/h19-33,37-42H,13-18H2,1-12H3/t19-,20+,21-,22+,23-,24-,25-,26+,27-,28+,29-,30+,31-,32+,33-,34+,35+,36+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00521","esomeprazole","NULL","SUBDBMMJDZJVOS-DEOSSOPVSA-N","InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1","CYP2C19 ","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","5-Hydroxyomeprazole ","40507393","CMZHQFXXAAIBKE-VWLOTQADSA-N","InChI=1S/C17H19N3O4S/c1-10-15(18-7-11(8-21)16(10)24-3)9-25(22)17-19-13-5-4-12(23-2)6-14(13)20-17/h4-7,21H,8-9H2,1-3H3,(H,19,20)/t25-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00522","esomeprazole","NULL","SUBDBMMJDZJVOS-DEOSSOPVSA-N","InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1","CYP3A4 ","S-oxidation of sulfoxide to sulfone","Human Phase I","Human","Omeprazole sulfone ","145900","IXEQEYRTSRFZEO-UHFFFAOYSA-N","InChI=1S/C17H19N3O4S/c1-10-8-18-15(11(2)16(10)24-4)9-25(21,22)17-19-13-6-5-12(23-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID00523","esomeprazole","NULL","SUBDBMMJDZJVOS-DEOSSOPVSA-N","InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1","CYP2C19 ","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","5-O-Desmethylomeprazole ","29918914","TWXDTVZNDQKCOS-QHCPKHFHSA-N","InChI=1S/C16H17N3O3S/c1-9-7-17-14(10(2)15(9)22-3)8-23(21)16-18-12-5-4-11(20)6-13(12)19-16/h4-7,20H,8H2,1-3H3,(H,18,19)/t23-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259987"
"BIOTID00524","estazolam","NULL","CDCHDCWJMGXXRH-UHFFFAOYSA-N","InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2","CYP3A4","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","4-hydroxyestazolam","11666741","LJIJJCXFWLORDQ-UHFFFAOYSA-N","InChI=1S/C16H11ClN4O/c17-11-6-7-13-12(8-11)14(10-4-2-1-3-5-10)19-16(22)15-20-18-9-21(13)15/h1-9,16,22H","M. Miura, K. Otani & T. Ohkubo (2005) Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam, Xenobiotica, 35:5, 455-465, DOI:10.1080/00498250500111612"
"BIOTID00525","estradiol","NULL","VOXZDWNPVJITMN-NZKIEYOBSA-N","InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1","CYP1A2; CYP3A4; CYP1A1","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2-Hydroxyestradiol","247304","DILDHNKDVHLEQB-XSSYPUMDSA-N","InChI=1S/C18H24O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,17,19-21H,2-7H2,1H3/t11-,12+,14-,17-,18-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00526","estradiol","NULL","VOXZDWNPVJITMN-NZKIEYOBSA-N","InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1","CYP1B1 ","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","4-Hydroxyestradiol ","5282360","QOZFCKXEVSGWGS-ZHIYBZGJSA-N","InChI=1S/C18H24O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,16,19-21H,2-3,5,7-9H2,1H3/t11-,12-,14+,16+,18+/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID00527","estrone","NULL","DNXHEGUUPJUMQT-QYFVKBAZSA-N","InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1","CYP3A4; CYP3A5; CYP3A7; CYP1A2; CYP2B6; CYP2C8; CYP2C9; CYP2C19; CYP2D6","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2-OH-estrone","440623","SWINWPBPEKHUOD-JPVZDGGYSA-N","InChI=1S/C18H22O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,19-20H,2-7H2,1H3/t11-,12+,14-,18-/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00528","estrone","NULL","DNXHEGUUPJUMQT-QYFVKBAZSA-N","InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1","CYP1A1; CYP1A2; CYP2C9; CYP3A4; CYP3A5; CYP3A7","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","4-OH-estrone","9971251","XQZVQQZZOVBNLU-QDTBLXIISA-N","InChI=1S/C18H22O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,19,21H,2-3,5,7-9H2,1H3/t11-,12-,14+,18+/m1/s1","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID00529","estrone","NULL","DNXHEGUUPJUMQT-QYFVKBAZSA-N","InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1","CYP1A1; CYP3A4; CYP3A5; CYP3A7","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","6alpha-OH-estrone","21122975","HTORTGVWUGQTHQ-WUAUYOTNSA-N","InChI=1S/C18H22O3/c1-18-7-6-12-11-3-2-10(19)8-14(11)16(20)9-13(12)15(18)4-5-17(18)21/h2-3,8,12-13,15-16,19-20H,4-7,9H2,1H3/t12-,13-,15+,16+,18+/m1/s1","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754425"
"BIOTID00530","estrone","NULL","DNXHEGUUPJUMQT-QYFVKBAZSA-N","InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1","CYP3A4; CYP3A5; CYP3A7","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","6beta-estrone","22295472","HTORTGVWUGQTHQ-UHOVARLQSA-N","InChI=1S/C18H22O3/c1-18-7-6-12-11-3-2-10(19)8-14(11)16(20)9-13(12)15(18)4-5-17(18)21/h2-3,8,12-13,15-16,19-20H,4-7,9H2,1H3/t12-,13-,15+,16-,18+/m1/s1","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754426"
"BIOTID00531","estrone","NULL","DNXHEGUUPJUMQT-QYFVKBAZSA-N","InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1","CYP1A1","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","7alpha-OH-estrone","NULL","MXXBVPDRVYYYJY-JIHIFKDMSA-N","InChI=1S/C18H22O3/c1-18-7-6-13-12-3-2-11(19)8-10(12)9-15(20)17(13)14(18)4-5-16(18)21/h2-3,8,13-15,17,19-20H,4-7,9H2,1H3/t13-,14+,15-,17?,18+/m1/s1","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754427"
"BIOTID00532","estrone","NULL","DNXHEGUUPJUMQT-QYFVKBAZSA-N","InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1","CYP1A1; CYP3A7","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","15alpha-OH-estrone","NULL","FDFNTZDUOBCJMD-OYHJSVMOSA-N","InChI=1S/C18H22O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)17(18)15(20)9-16(18)21/h3,5,8,13-15,17,19-20H,2,4,6-7,9H2,1H3/t13-,14?,15+,17-,18-/m1/s1","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754428"
"BIOTID00533","estrone","NULL","DNXHEGUUPJUMQT-QYFVKBAZSA-N","InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1","CYP1A1; CYP2C8; CYP3A4; CYP3A5; CYP3A7","Alpha hydroxylation of carbonyl group","Human Phase I","Human","16alpha-OH-estrone","NULL","WPOCIZJTELRQMF-DIYRONQZSA-N","InChI=1S/C18H22O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-16,19-20H,2,4,6-7,9H2,1H3/t13-,14?,15+,16-,18+/m1/s1","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754429"
"BIOTID00534","estrone","NULL","DNXHEGUUPJUMQT-QYFVKBAZSA-N","InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1","CYP2C8; CYP3A4; CYP3A5","Alpha hydroxylation of carbonyl group","Human Phase I","Human","16beta-OH-estrone","NULL","WPOCIZJTELRQMF-CCIOVHFFSA-N","InChI=1S/C18H22O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-16,19-20H,2,4,6-7,9H2,1H3/t13-,14?,15+,16+,18+/m1/s1","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754430"
"BIOTID00535","eszopiclone","NULL","GBBSUAFBMRNDJC-INIZCTEOSA-N","InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1","CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4","N-desmethylation","Human Phase I","Human","N-desmethyl-zopiclone","162892","CGSFZSTXVVJLIX-UHFFFAOYSA-N","InChI=1S/C16H15ClN6O3/c17-10-1-2-11(21-9-10)23-14(24)12-13(20-4-3-19-12)15(23)26-16(25)22-7-5-18-6-8-22/h1-4,9,15,18H,5-8H2","PMID:10460808"
"BIOTID00536","eszopiclone","NULL","GBBSUAFBMRNDJC-INIZCTEOSA-N","InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1","CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4","N-Oxidation","Human Phase I","Human","N-oxide-zopiclone","162548","IPTIKKTXLHVRKN-UHFFFAOYSA-N","InChI=1S/C17H17ClN6O4/c1-24(27)8-6-22(7-9-24)17(26)28-16-14-13(19-4-5-20-14)15(25)23(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3","PMID:10460808"
"BIOTID00537","ethanol","NULL","LFQSCWFLJHTTHZ-UHFFFAOYSA-N","InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3","CYP2E1","Oxidation of primary alcohol to aldehyde","Human Phase I","Human","Acetaldehyde","177","IKHGUXGNUITLKF-UHFFFAOYSA-N","InChI=1S/C2H4O/c1-2-3/h2H,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00538","ethiprole","9930667","FNELVJVBIYMIMC-UHFFFAOYSA-N","InChI=1S/C13H9Cl2F3N4OS/c1-2-24(23)11-9(5-19)21-22(12(11)20)10-7(14)3-6(4-8(10)15)13(16,17)18/h3-4H,2,20H2,1H3","CYP3A4","S-oxidation of sulfoxide to sulfone","Human Phase I","Human","Ethiprole Sulfone","22618433","SGTQRPFDKIRFIQ-UHFFFAOYSA-N","InChI=1S/C13H9Cl2F3N4O2S/c1-2-25(23,24)11-9(5-19)21-22(12(11)20)10-7(14)3-6(4-8(10)15)13(16,17)18/h3-4H,2,20H2,1H3","Caboni, P. et al. (2003); Phenylpyrazole Insecticide Photochemistry, Metabolism, and GABAergic Action: Ethiprole Compared with Fipronil; J. Agric. Food Chem. 2003, 51, 7055Ã¢Ë†â€™7061; DOI:10.1021/jf030439"
"BIOTID00539","ethylmethylnitrosamine","NULL","RTDCJKARQCRONF-UHFFFAOYSA-N","InChI=1S/C3H8N2O/c1-3-5(2)4-6/h3H2,1-2H3","CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","N-dealkylation","Human Phase I","Human","NULL","149201","SCSKXSBERKMMJG-UHFFFAOYSA-N","InChI=1S/C2H6N2O/c1-2-3-4-5/h2H2,1H3,(H,3,5)","PMID:8824531"
"BIOTID00540","ethylmethylnitrosamine","NULL","RTDCJKARQCRONF-UHFFFAOYSA-N","InChI=1S/C3H8N2O/c1-3-5(2)4-6/h3H2,1-2H3","CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","N-dealkylation","Human Phase I","Human","NULL","NULL","CIJBKNZDKBKMFU-UHFFFAOYSA-N","InChI=1S/CH4N2O/c1-2-3-4/h1H3,(H,2,4)","PMID:8824531"
"BIOTID00541","ethylmorphine","5359271","OGDVEMNWJVYAJL-LEPYJNQMSA-N","InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1","CYP2D6","N-Demethylation","Human Phase I","Human","Norethylmorphine","NULL","YCZKZYXHGKGDNL-UHFFFAOYSA-N","InChI=1S/C18H21NO3/c1-2-21-14-6-3-10-9-12-11-4-5-13(20)17-18(11,7-8-19-12)15(10)16(14)22-17/h3-6,11-13,17,19-20H,2,7-9H2,1H3","PMID:7756104"
"BIOTID00542","ethylmorphine","5359271","OGDVEMNWJVYAJL-LEPYJNQMSA-N","InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1","CYP3A4","O-dealkylation","Human Phase I","Human","Morphine","NULL","BQJCRHHNABKAKU-UHFFFAOYSA-N","InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3","PMID:7756104"
"BIOTID00543","etizolam","NULL","VMZUTJCNQWMAGF-UHFFFAOYSA-N","InChI=1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3","CYP2B6;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","AUGPQGAHOGVIOZ-UHFFFAOYSA-N","InChI=1S/C17H15ClN4OS/c1-3-10-8-12-14(11-6-4-5-7-13(11)18)19-16(23)15-21-20-9(2)22(15)17(12)24-10/h4-8,16,23H,3H2,1-2H3","PMID:16141545|PMID:18855614"
"BIOTID00544","etizolam","NULL","VMZUTJCNQWMAGF-UHFFFAOYSA-N","InChI=1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3","CYP2B6;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","YRJXUAYHZCDGDO-UHFFFAOYSA-N","InChI=1S/C17H15ClN4OS/c1-9(23)14-7-12-16(11-5-3-4-6-13(11)18)19-8-15-21-20-10(2)22(15)17(12)24-14/h3-7,9,23H,8H2,1-2H3","PMID:16141545|PMID:18855614"
"BIOTID00545","etoperidone","NULL","IZBNNCFOBMGTQX-UHFFFAOYSA-N","InChI=1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","NULL","SLLRYCOTOHVHSM-UHFFFAOYSA-N","InChI=1S/C9H17N3O/c1-4-7-12-9(13)11(6-3)8(5-2)10-12/h4-7H2,1-3H3","PMID:12487725"
"BIOTID00546","etoperidone","NULL","IZBNNCFOBMGTQX-UHFFFAOYSA-N","InChI=1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","1355","VHFVKMTVMIZMIK-UHFFFAOYSA-N","InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2","PMID:12487725"
"BIOTID00547","etoperidone","NULL","IZBNNCFOBMGTQX-UHFFFAOYSA-N","InChI=1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","MFCWBBRTSPFCHK-UHFFFAOYSA-N","InChI=1S/C19H28ClN5O2/c1-3-18-21-25(19(27)24(18)4-2)9-5-8-22-10-12-23(13-11-22)15-6-7-17(26)16(20)14-15/h6-7,14,26H,3-5,8-13H2,1-2H3","PMID:12487725"
"BIOTID00548","etoperidone","NULL","IZBNNCFOBMGTQX-UHFFFAOYSA-N","InChI=1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","WLVZLZINXQKTMZ-UHFFFAOYSA-N","InChI=1S/C19H28ClN5O2/c1-3-24-18(15(2)26)21-25(19(24)27)9-5-8-22-10-12-23(13-11-22)17-7-4-6-16(20)14-17/h4,6-7,14-15,26H,3,5,8-13H2,1-2H3","PMID:12487725"
"BIOTID00549","etoposide","NULL","VJJPUSNTGOMMGY-PRPOLQJISA-N","InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20+,21-,22+,24+,25-,26+,27+,29-/m1/s1","CYP1A2;CYP2E1;CYP3A4","O-Demethylation","Human Phase I","Human","Etoposide Catechol","127462","CYOJPLOJEPTJMM-UHFFFAOYSA-N","InChI=1S/C28H30O13/c1-10-35-8-19-26(39-10)23(31)24(32)28(40-19)41-25-13-6-17-16(37-9-38-17)5-12(13)20(21-14(25)7-36-27(21)33)11-3-15(29)22(30)18(4-11)34-2/h3-6,10,14,19-21,23-26,28-32H,7-9H2,1-2H3","PMID:9732391"
"BIOTID00550","etoricoxib","123619","MNJVRJDLRVPLFE-UHFFFAOYSA-N","InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3","CYP3A4 (major); CYP2C9 (minor); CYP2D6 (minor); CYP1A2 (minor)","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","6-Hydroxymethyletoricoxib","NULL","SCVWZQQMIZJGJY-UHFFFAOYSA-N","InChI=1S/C18H15ClN2O3S/c1-25(23,24)16-6-3-12(4-7-16)17-8-14(19)10-21-18(17)13-2-5-15(11-22)20-9-13/h2-10,22H,11H2,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|Chugh, R. et al. (2007); Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma; Cancer. 2007 Jun 1;109(11):2315-22; PMID:17464949; DOI:10.1002/cncr.22669"
"BIOTID00551","etoricoxib","123619","MNJVRJDLRVPLFE-UHFFFAOYSA-N","InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3","CYP3A4 (major); CYP2C9 (minor); CYP2D6 (minor); CYP1A2 (minor)","Pyridine N-oxidation","Human Phase I","Human","Etoricoxib 1'-N'-oxide","NULL","KMLFAHIIJSUUPX-UHFFFAOYSA-N","InChI=1S/C18H15ClN2O3S/c1-12-3-4-14(11-21(12)22)18-17(9-15(19)10-20-18)13-5-7-16(8-6-13)25(2,23)24/h3-11H,1-2H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|Chugh, R. et al. (2007); Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma; Cancer. 2007 Jun 1;109(11):2315-22; PMID:17464949; DOI:10.1002/cncr.22669"
"BIOTID00552","eugenol","3314","RRAFCDWBNXTKKO-UHFFFAOYSA-N","InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3","CYP1A2;CYP2C9;CYP2D6;CYP2E1","O-demethylation","Human Phase I","Human","Hydroxychavicol","70775","FHEHIXJLCWUPCZ-UHFFFAOYSA-N","InChI=1S/C9H10O2/c1-2-3-7-4-5-8(10)9(11)6-7/h2,4-6,10-11H,1,3H2","PMID:15576237"
"BIOTID00553","eupatilin","5273755","DRRWBCNQOKKKOL-UHFFFAOYSA-N","InChI=1S/C18H16O7/c1-22-12-5-4-9(6-14(12)23-2)13-7-10(19)16-15(25-13)8-11(20)18(24-3)17(16)21/h4-8,20-21H,1-3H3","CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1","O-demethylation","Human Phase I","Human","Jaceosidine","NULL","GLAAQZFBFGEBPS-UHFFFAOYSA-N","InChI=1S/C17H14O7/c1-22-13-5-8(3-4-9(13)18)12-6-10(19)15-14(24-12)7-11(20)17(23-2)16(15)21/h3-7,18,20-21H,1-2H3","PMID:17701830"
"BIOTID00554","everolimus","NULL","HKVAMNSJSFKALM-GKUWKFKPSA-N","InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12-,33-17+,37-27-/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44-,45+,46-,48-,49+,53-/m1/s1","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","NULL","QFJCIRLUMZQUOT-VDLOLMHGSA-N","InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25-/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1","PMID:11384247"
"BIOTID00555","everolimus","NULL","HKVAMNSJSFKALM-GKUWKFKPSA-N","InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12-,33-17+,37-27-/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44-,45+,46-,48-,49+,53-/m1/s1","CYP3A4","N-demethylation","Human Phase I","Human","NULL","NULL","RUFNZQDXYVOQPG-SBCOZZKKSA-N","InChI=1S/C52H81NO14/c1-31-15-11-10-12-16-32(2)44(63-8)29-39-20-18-37(7)52(62,67-39)49(59)50(60)53-22-14-13-17-40(53)51(61)66-45(34(4)27-38-19-21-43(42(56)28-38)65-24-23-54)30-41(55)33(3)26-36(6)47(58)48(64-9)46(57)35(5)25-31/h10-12,15-16,26,31,33-35,37-40,42-45,47-48,54,56,58,62H,13-14,17-25,27-30H2,1-9H3/b12-10+,15-11+,32-16+,36-26-/t31-,33-,34-,35-,37-,38+,39+,40+,42-,43-,44+,45+,47-,48+,52-/m1/s1","PMID:11384247"
"BIOTID00556","ezlopitant","188927","XPNMCDYOYIKVGB-CONSDPRKSA-N","InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1","CYP2D6;CYP3A4","Dehydrogenation","Human Phase I","Human","NULL","NULL","CVTMENNEXOZZEZ-UHFFFAOYSA-N","InChI=1S/C31H36N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,25,29-32H,1,16-19,21H2,2-3H3","PMID:10950851"
"BIOTID00557","ezlopitant","188927","XPNMCDYOYIKVGB-CONSDPRKSA-N","InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1","CYP2D6;CYP3A4","Dehydrogenation","Human Phase I","Human","NULL","NULL","FBOIFJGFNUAMIT-UHFFFAOYSA-N","InChI=1S/C31H38N2O2/c1-31(2,34)26-14-15-27(35-3)25(20-26)21-32-29-24-16-18-33(19-17-24)30(29)28(22-10-6-4-7-11-22)23-12-8-5-9-13-23/h4-15,20,24,28-30,32,34H,16-19,21H2,1-3H3","PMID:10950851"
"BIOTID00558","fentanyl","3345","PJMPHNIQZUBGLI-UHFFFAOYSA-N","InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","Norfentanyl","NULL","PMCBDBWCQQBSRJ-UHFFFAOYSA-N","InChI=1S/C14H20N2O/c1-2-14(17)16(12-6-4-3-5-7-12)13-8-10-15-11-9-13/h3-7,13,15H,2,8-11H2,1H3","Feierman, D. et al. (1996); Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes; Drug metabolism and disposition; 0090-9556/96/2409-0932-939$02.OO/O"
"BIOTID00558","fentanyl","3345","PJMPHNIQZUBGLI-UHFFFAOYSA-N","InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","Phenylacetaldehyde","NULL","DTUQWGWMVIHBKE-UHFFFAOYSA-N","InChI=1S/C8H8O/c9-7-6-8-4-2-1-3-5-8/h1-5,7H,6H2","Feierman, D. et al. (1996); Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes; Drug metabolism and disposition; 0090-9556/96/2409-0932-939$02.OO/O"
"BIOTID00559","finasteride","57363","DBEPLOCGEIEOCV-WSBQPABSSA-N","InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1","CYP3A4","Alipathic Hydroxylation","Human Phase I","Human","NULL","NULL","MFUJYZCMHDCXGQ-UHFFFAOYSA-N","InChI=1S/C23H36N2O3/c1-21(2,13-26)25-20(28)17-7-6-15-14-5-8-18-23(4,12-10-19(27)24-18)16(14)9-11-22(15,17)3/h10,12,14-18,26H,5-9,11,13H2,1-4H3,(H,24,27)(H,25,28)","PMID:8654202"
"BIOTID00560","fk_506","445643","QJJXYPPXXYFBGM-LFZNUXCKSA-N","InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19-,27-21+/t26-,28+,29+,30-,31+,32-,33+,34+,36+,37-,38-,39+,40+,44+/m0/s1","CYP3A4; CYP3A5","O-dealkylation of dialkylether","Human Phase I","Human","13-O-Desmethyltacrolimus","NULL","OGJRKILIPRVJFS-MNAQQUBESA-N","InChI=1S/C43H67NO12/c1-9-12-30-18-24(2)17-25(3)19-37(54-8)39-35(48)21-27(5)43(52,56-39)40(49)41(50)44-16-11-10-13-31(44)42(51)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-32(45)36(22-29)53-7/h9,18,20,25,27-33,35-39,45-46,48,52H,1,10-17,19,21-23H2,2-8H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32+,33-,35-,36+,37-,38+,39-,43+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID00561","fk_506","445643","QJJXYPPXXYFBGM-LFZNUXCKSA-N","InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19-,27-21+/t26-,28+,29+,30-,31+,32-,33+,34+,36+,37-,38-,39+,40+,44+/m0/s1","CYP3A4","O-dealkylation of dialkylether","Human Phase I","Human","15-O-Desmethyltacrolimus","NULL","ZQRSWRVAAABQEF-XFIJPYNGSA-N","InChI=1S/C43H67NO12/c1-9-12-30-18-24(2)17-25(3)19-35(48)39-37(54-8)21-27(5)43(52,56-39)40(49)41(50)44-16-11-10-13-31(44)42(51)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-32(45)36(22-29)53-7/h9,18,20,25,27-33,35-39,45-46,48,52H,1,10-17,19,21-23H2,2-8H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32+,33-,35-,36+,37-,38+,39+,43+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00562","fk_506_m1","NULL","OKRZOXIQNKYTBL-ZNPYSLGISA-N","InChI=1S/C43H67NO12/c1-9-12-30-18-24(2)17-25(3)19-36(54-8)38(48)37-21-27(5)43(52,56-37)40(49)41(50)44-16-11-10-13-31(44)42(51)55-39(28(6)33(46)23-34(30)47)26(4)20-29-14-15-32(45)35(22-29)53-7/h9,18,20,25,27-33,35-39,45-46,48,52H,1,10-17,19,21-23H2,2-8H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32+,33-,35+,36-,37+,38+,39-,43+/m0/s1","CYP3A4","O-demethylation","Human Phase I","Human","13-Desmethyl_fk_506","NULL","WDXIEWFELKAMEX-XMKWMFEPSA-N","InChI=1S/C42H65NO12/c1-8-11-29-17-23(2)16-24(3)18-34(47)37(48)36-20-26(5)42(52,55-36)39(49)40(50)43-15-10-9-12-30(43)41(51)54-38(27(6)32(45)22-33(29)46)25(4)19-28-13-14-31(44)35(21-28)53-7/h8,17,19,24,26-32,34-38,44-45,47-48,52H,1,9-16,18,20-22H2,2-7H3/b23-17+,25-19+","PMID:1373595"
"BIOTID00563","flosequinan","4474062","UYGONJYYUKVHDD-UHFFFAOYSA-N","InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3","CYP3A4","S-oxidation of sulfoxide to sulfone","Human Phase I","Human","flosequinan sulfone","NULL","ZUMVHPMHCIKNFT-UHFFFAOYSA-N","InChI=1S/C11H10FNO3S/c1-13-6-10(17(2,15)16)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3","Kashiyama, E. et al, (1997); CYTOCHROME P450 RESPONSIBLE FOR THE STEREOSELECTIVE S-OXIDATION OF FLOSEQUINAN IN HEPATIC MICROSOMES FROM RATS AND HUMANS; The American Society for Pharmacology and Experimental Therapeutics; DOI:0090-9556/97/2506-07"
"BIOTID00564","flucloxacillin","21319","UIOFUWFRIANQPC-JKIFEVAISA-N","InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","ZUBWLMQDPXVIGD-UHFFFAOYSA-N","InChI=1S/C19H17ClFN3O6S/c1-19(2)14(18(28)29)24-16(27)13(17(24)31-19)22-15(26)11-9(6-25)30-23-12(11)10-7(20)4-3-5-8(10)21/h3-5,13-14,17,25H,6H2,1-2H3,(H,22,26)(H,28,29)","PMID:11409940"
"BIOTID00565","flunarizine","941361","SMANXXCATUTDDT-QPJJXVBHSA-N","InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+","CYP1A2; CYP2C9","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","1Ã¢â‚¬Â[bis(4Ã¢â‚¬Âfluorophenyl)methyl]piperazine","NULL","TTXIFFYPVGWLSE-UHFFFAOYSA-N","InChI=1S/C17H18F2N2/c18-15-5-1-13(2-6-15)17(21-11-9-20-10-12-21)14-3-7-16(19)8-4-14/h1-8,17,20H,9-12H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|"
"BIOTID00566","flunarizine","941361","SMANXXCATUTDDT-QPJJXVBHSA-N","InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+","CYP2D6","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","p-Hydroxyflunarizine","NULL","BORXUYRMIOAMIE-OWOJBTEDSA-N","InChI=1S/C26H26F2N2O/c27-23-9-5-21(6-10-23)26(22-7-11-24(28)12-8-22)30-18-16-29(17-19-30)15-1-2-20-3-13-25(31)14-4-20/h1-14,26,31H,15-19H2/b2-1+","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|"
"BIOTID00567","flunarizine","941361","SMANXXCATUTDDT-QPJJXVBHSA-N","InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+","CYP2C9; CYP1A1","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","bis(4Ã¢â‚¬Âfluorophenyl)methanone","NULL","LSQARZALBDFYQZ-UHFFFAOYSA-N","InChI=1S/C13H8F2O/c14-11-5-1-9(2-6-11)13(16)10-3-7-12(15)8-4-10/h1-8H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|"
"BIOTID00568","fluphenazine","3372","PLDUPXSUYLZYBN-UHFFFAOYSA-N","InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2","CYP2D6","S-oxidation of diarylthioether to sulfoxide","Human Phase I","Human","10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-2-(trifluoromethyl)-10H-5ÃŽÂ»Ã¢ÂÂ´-phenothiazin-5-one","NULL","UFPPOFUTIWYLNR-UHFFFAOYSA-N","InChI=1S/C22H26F3N3O2S/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)31(21)30)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2","Smith, D.A. et al. (1992); Speculations on the structure-activity relationship (SAR) of cytochrome P450 enzymes, Biochem. Pharmacol  1992, 44, 2089-2098 (1992).|Li, S-F. et al. (2010); Quantitative analysis of fluphenazine hydrochloride in human urine using excitation-emission matrix fluorescence based on oxidation derivatization and combined with second-order calibration methods; Anal. Methods 2010, 2, 1069-1077, DOI:Ã‚Â 10.1039/B9AY00299E"
"BIOTID00569","flunitrazepam","3380","PPTYJKAXVCCBDU-UHFFFAOYSA-N","InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3","CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4","N-DEMETHYLATION ","Human Phase I","Human","desmethylflunitrazepam","NULL","KNGIGRDYBQPXKQ-UHFFFAOYSA-N","InChI=1S/C15H10FN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)","PMID:11159802"
"BIOTID00570","flunitrazepam","3380","PPTYJKAXVCCBDU-UHFFFAOYSA-N","InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3","CYP2A6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","3-hydroxyflunitrazepam","NULL","KJTUBZKMFRILQD-UHFFFAOYSA-N","InChI=1S/C16H12FN3O4/c1-19-13-7-6-9(20(23)24)8-11(13)14(18-15(21)16(19)22)10-4-2-3-5-12(10)17/h2-8,15,21H,1H3","PMID:11159802"
"BIOTID00571","flutamide","3397","MKXKFYHWDHIYRV-UHFFFAOYSA-N","InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)","CYP1A2; CYP1B1","Alpha hydroxylation of carbonyl group","Human Phase I","Human","2-OH-flutamide","NULL","YPQLFJODEKMJEF-UHFFFAOYSA-N","InChI=1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)","Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID00573","fluvastatin","1548972","FJLGEFLZQAZZCD-JUFISIKESA-N","InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m0/s1","CYP2C9","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-OH-fluvastatin","NULL","WSYBZSUCJJHTIP-CLFQVBOOSA-N","InChI=1S/C24H26FNO5/c1-14(2)26-21(10-8-17(27)11-19(29)13-23(30)31)24(15-3-5-16(25)6-4-15)20-9-7-18(28)12-22(20)26/h3-10,12,14,17,19,27-29H,11,13H2,1-2H3,(H,30,31)/b10-8+/t17-,19-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|Chugh, R. et al. (2007); Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma; Cancer. 2007 Jun 1;109(11):2315-22; PMID:17464949; DOI:10.1002/cncr.22669"
"BIOTID00574","fluvastatin","1548972","FJLGEFLZQAZZCD-JUFISIKESA-N","InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m0/s1","CYP2C9","N-deisopropylation","Human Phase I","Human","N-Deisopropyl-fluvastatin","131750727","POFAWBXODXSMNI-IGXNXKSNSA-N","InChI=1S/C21H20FNO4/c22-14-7-5-13(6-8-14)21-17-3-1-2-4-18(17)23-19(21)10-9-15(24)11-16(25)12-20(26)27/h1-10,15-16,23-25H,11-12H2,(H,26,27)/b10-9+/t15-,16-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|Chugh, R. et al. (2007); Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma; Cancer. 2007 Jun 1;109(11):2315-22; PMID:17464949; DOI:10.1002/cncr.22669"
"BIOTID00575","fluvastatin","1548972","FJLGEFLZQAZZCD-JUFISIKESA-N","InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m0/s1","CYP2C9 (major); CYP2C8 (minor); CYP2D6 (minor); CYP3A4 (minor)","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","5-OH-fluvastatin","124518231","YCXJQQVRCVXLTP-CLFQVBOOSA-N","InChI=1S/C24H26FNO5/c1-14(2)26-21-9-7-18(28)12-20(21)24(15-3-5-16(25)6-4-15)22(26)10-8-17(27)11-19(29)13-23(30)31/h3-10,12,14,17,19,27-29H,11,13H2,1-2H3,(H,30,31)/b10-8+/t17-,19-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|Chugh, R. et al. (2007); Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma; Cancer. 2007 Jun 1;109(11):2315-22; PMID:17464949; DOI:10.1002/cncr.22669"
"BIOTID00576","fluvoxamine","5324346","CJOFXWAVKWHTFT-XSFVSMFZSA-N","InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+","CYP2D6 (major); CYP1A2 (minor)","O-dealkylation of dialkylether","Human Phase I","Human","Fluvoxamino alcohol","46781165","GCSLDHTZSDNYEC-CPNJWEJPSA-N","InChI=1S/C14H19F3N2O2/c15-14(16,17)12-6-4-11(5-7-12)13(3-1-2-9-20)19-21-10-8-18/h4-7,20H,1-3,8-10,18H2/b19-13+","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00577","formononetin","5280378","HKQYGTCOTHHOMP-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3","CYP1A2","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Daidzein","5281708","ZQSIJRDFPHDXIC-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00578","furafylline","3433","KGQZGCIVHYLPBH-UHFFFAOYSA-N","InChI=1S/C12H12N4O3/c1-7-13-9-10(14-7)16(6-8-4-3-5-19-8)12(18)15(2)11(9)17/h3-5H,6H2,1-2H3,(H,13,14)","CYP1A2","ALKYL_HYDROXYLATION","Human Phase I","Human","3-[(furan-2-yl)methyl]-8-hydroxy-1-methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione   ","NULL","NLBADGJGOKIEHT-UHFFFAOYSA-N","InChI=1S/C12H12N4O4/c1-15-11(18)9-10(14-8(6-17)13-9)16(12(15)19)5-7-3-2-4-20-7/h2-4,17H,5-6H2,1H3,(H,13,14)","Kunze, k.l. et al. (1992); Mechanism-based inhibition of human cytochrome P450 1A2 by furafylline, ISSX Proceedings, 5th North American ZSSX Meeting, Bal Harbour, FL, November 2-6, 1992, 2, 16|Clarke, S.E. et al. (1994); Characterization of the inhibition of P450 1A2 by furafylline, Xenobioticu, 1994, 24, 517-526|Racha, J.K. et al. (1996); Mechanistic studies on the inactivation of human cytochrome P450 1A2 by furafylline, ISSX Proceedings, 7th North American ZSSX Meeting, San Diego, CA, October 20-25, 1996, 10, 229|Kunze. K.L. et al. (1996); Novel aspects of the oxidation of 8-ethyl xanthine analogs of furafylline by human P4501A2, ZSSX Proceedings, 7th North Amencan ZSSX Meeting, San Diego, CA, USA, October 20-25, 1996, 10, 230."
"BIOTID00579","furan","8029","YLQBMQCUIZJEEH-UHFFFAOYSA-N","InChI=1S/C4H4O/c1-2-4-5-3-1/h1-4H","CYP2E1","Oxidization ","Human Phase I","Human","(E)-2-Butenedial","5323604","JGEMYUOFGVHXKV-UPHRSURJSA-N","InChI=1S/C4H4O2/c5-3-1-2-4-6/h1-4H/b2-1-","PMID:20043645"
"BIOTID00580","galangin","5281616","VCCRNZQBSJXYJD-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H","CYP1A2 ; CYP2C9","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4'-OH-galangin","5280863","IYRMWMYZSQPJKC-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H","human cytochrome P450 1A2 by furafylline, ISSX Proceedings, 5th"
"BIOTID00581","galantamine","9651","ASUTZQLVASHGKV-JDFRZJQESA-N","InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1","CYP2D6","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","O-Desmethylgalantamine","443722","OYSGWKOGUVOGFQ-RBOXIYTFSA-N","InChI=1S/C16H19NO3/c1-17-7-6-16-5-4-11(18)8-13(16)20-15-12(19)3-2-10(9-17)14(15)16/h2-5,11,13,18-19H,6-9H2,1H3/t11-,13-,16-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID00582","galantamine","9651","ASUTZQLVASHGKV-JDFRZJQESA-N","InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1","CYP3A4","N-oxidation of alicyclic tertiary amine","Human Phase I","Human","Galantamine N-oxide","11748698","LROQBKNDGTWXET-FVWDGWMTSA-N","InChI=1S/C17H21NO4/c1-18(20)8-7-17-6-5-12(19)9-14(17)22-16-13(21-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-,18?/m0/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID00583","galantamine","9651","ASUTZQLVASHGKV-JDFRZJQESA-N","InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1","CYP2D6","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","N-desmethylgalantamine","9838394","AIXQQSTVOSFSMO-RBOXIYTFSA-N","InChI=1S/C16H19NO3/c1-19-12-3-2-10-9-17-7-6-16-5-4-11(18)8-13(16)20-15(12)14(10)16/h2-5,11,13,17-18H,6-9H2,1H3/t11-,13-,16-/m0/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Mannens, G.S.J. et al. (2002). The metabolism and excretion of galantamine in rats, dogs, and humans; Drug Metab Dispos. 2002 May;30(5):553-63.|"
"BIOTID00584","gefitinib","123631","XGALLCVXEZPNRQ-UHFFFAOYSA-N","InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)","CYP2D6","O-dementhylation","Human Phase I","Human","NULL","NULL","IFMMYZUUCFPEHR-UHFFFAOYSA-N","InChI=1S/C21H22ClFN4O3/c22-16-10-14(2-3-17(16)23)26-21-15-11-20(19(28)12-18(15)24-13-25-21)30-7-1-4-27-5-8-29-9-6-27/h2-3,10-13,28H,1,4-9H2,(H,24,25,26)","North American ZSSX Meeting, Bal Harbour, FL, November 2-6,|PMID:15788367"
"BIOTID00585","gefitinib","123631","XGALLCVXEZPNRQ-UHFFFAOYSA-N","InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)","CYP3A4","oxidative defluorination","Human Phase I","Human","NULL","11190016","IQWXTDMHBQBADK-UHFFFAOYSA-N","InChI=1S/C22H25ClN4O4/c1-29-20-13-18-16(12-21(20)31-8-2-5-27-6-9-30-10-7-27)22(25-14-24-18)26-15-3-4-19(28)17(23)11-15/h3-4,11-14,28H,2,5-10H2,1H3,(H,24,25,26)","North American ZSSX Meeting, Bal Harbour, FL, November 2-6,|PMID:15788367"
"BIOTID00586","genistein","5280961","TZBJGXHYKVUXJN-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H","CYP1A2;CYP2E1","Aromatic Hydroxylation","Human Phase I","Human","Orobol","5281801","IOYHCQBYQJQBSK-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-4-12(19)14-13(5-8)21-6-9(15(14)20)7-1-2-10(17)11(18)3-7/h1-6,16-19H","PMID:10409400"
"BIOTID00587","genistein","5280961","TZBJGXHYKVUXJN-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H","CYP1A2","Aromatic Hydroxylation","Human Phase I","Human","NULL","5281801","IOYHCQBYQJQBSK-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-4-12(19)14-13(5-8)21-6-9(15(14)20)7-1-2-10(17)11(18)3-7/h1-6,16-19H","PMID:10409400"
"BIOTID00588","gepirone","55191","QOIGKGMMAGJZNZ-UHFFFAOYSA-N","InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3","CYP3A4","Hydroxylation","Human Phase I","Human","NULL","10222057","QQMVSPAEOUEOLJ-UHFFFAOYSA-N","InChI=1S/C19H29N5O4/c1-19(2)11-15(26)24(17(28)16(19)27)6-4-3-5-22-7-9-23(10-8-22)18-20-12-14(25)13-21-18/h12-13,16,25,27H,3-11H2,1-2H3","PMID:18840371"
"BIOTID00589","gepirone","55191","QOIGKGMMAGJZNZ-UHFFFAOYSA-N","InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","10270833","FPIFDKJZXXMJRK-UHFFFAOYSA-N","InChI=1S/C19H29N5O3/c1-19(2)11-16(26)24(17(27)12-19)6-4-3-5-22-7-9-23(10-8-22)18-20-13-15(25)14-21-18/h13-14,25H,3-12H2,1-2H3","PMID:18840371"
"BIOTID00590","gepirone","55191","QOIGKGMMAGJZNZ-UHFFFAOYSA-N","InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","9842584","BXIVMLSVUJVOQG-UHFFFAOYSA-N","InChI=1S/C19H29N5O3/c1-19(2)14-15(25)24(17(27)16(19)26)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7,16,26H,3-4,8-14H2,1-2H3","PMID:18840371"
"BIOTID00591","gepirone","55191","QOIGKGMMAGJZNZ-UHFFFAOYSA-N","InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3","CYP3A4","N-Dealkylation","Human Phase I","Human","1-(2-pyrimidinyl)-piperazine (1-PP)","88747","MRBFGEHILMYPTF-UHFFFAOYSA-N","InChI=1S/C8H12N4/c1-2-10-8(11-3-1)12-6-4-9-5-7-12/h1-3,9H,4-7H2","PMID:18840371"
"BIOTID00592","granisetron","3510","MFWNKCLOYSRHCJ-BTTYYORXSA-N","InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12?,13-,14+","CYP1A1","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","7-Hydroxygranisetron","NULL","CGNLROWYSDSBMN-YHWZYXNKSA-N","InChI=1S/C18H24N4O2/c1-21-12-5-3-6-13(21)10-11(9-12)19-18(24)17-16-14(22(2)20-17)7-4-8-15(16)23/h4,7-8,11-13,23H,3,5-6,9-10H2,1-2H3,(H,19,24)/t11?,12-,13+","Chenery, Characterization of the inhibition of P450 1A2 by"
"BIOTID00593","granisetron","3510","MFWNKCLOYSRHCJ-BTTYYORXSA-N","InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12?,13-,14+","CYP3A4 (major); CYP1A1; CYP2D6; CYP3A5","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","9'-Desmethylgranisetron","11243474","GHVQAOGYNZNTIA-YHWZYXNKSA-N","InChI=1S/C17H22N4O/c1-21-12-5-4-6-13(21)10-11(9-12)18-17(22)16-14-7-2-3-8-15(14)19-20-16/h2-3,7-8,11-13H,4-6,9-10H2,1H3,(H,18,22)(H,19,20)/t11?,12-,13+",""
"BIOTID00594","gts-21","5310985","RPYWXZCFYPVCNQ-RVDMUPIBSA-N","InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+","CYP1A2;CYP2E1;CYP3A4","O-Demethylation","Human Phase I","Human","4-OH-GTS-21","NULL","KXAAIPFSUGPVMQ-GXDHUFHOSA-N","InChI=1S/C18H18N2O2/c1-22-17-11-16(21)7-6-13(17)10-14-4-3-9-20-18(14)15-5-2-8-19-12-15/h2,5-8,10-12,21H,3-4,9H2,1H3/b14-10+","furafylline, Xenobioticu, 24, 517-526 (1994); J. K. Racha, A. E.;PMID:10456692"
"BIOTID00595","gts-21","5310985","RPYWXZCFYPVCNQ-RVDMUPIBSA-N","InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+","CYP1A2;CYP2E1;CYP3A4","O-Demethylation","Human Phase I","Human","2-OH-GTS-21","NULL","NSXPRBNXDOFFPH-GXDHUFHOSA-N","InChI=1S/C18H18N2O2/c1-22-16-7-6-13(17(21)11-16)10-14-4-3-9-20-18(14)15-5-2-8-19-12-15/h2,5-8,10-12,21H,3-4,9H2,1H3/b14-10+","furafylline, Xenobioticu, 24, 517-526 (1994); J. K. Racha, A. E.;PMID:10456692"
"BIOTID00596","guanabenz","5702063","WDZVGELJXXEGPV-YIXHJXPBSA-N","InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+","CYP1A2","N-hyroxylation of guanidine or aminohydrazone","Human Phase I","Human","Guanoxabenz","10060509","QKIQJNNDIWGVEH-UUILKARUSA-N","InChI=1S/C8H8Cl2N4O/c9-6-2-1-3-7(10)5(6)4-12-13-8(11)14-15/h1-4,15H,(H3,11,13,14)/b12-4+",""
"BIOTID00597","haloperidol","3559","LNEPOXFFQSENCJ-UHFFFAOYSA-N","InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2","CYP3A4; CYP2D6","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","p-Fluorobenzoylpropionic acid and 4-(4-chlorophenyl)-4-hydroxypiperidine","101359","WUYWHIAAQYQKPP-UHFFFAOYSA-N","InChI=1S/C10H9FO3/c11-8-3-1-7(2-4-8)9(12)5-6-10(13)14/h1-4H,5-6H2,(H,13,14)",""
"BIOTID00598","haloperidol","3559","LNEPOXFFQSENCJ-UHFFFAOYSA-N","InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2","CYP3A4","Formation of pyridinium from 4-substituted piperidine","Human Phase I","Human","Haloperidol pyridinium","9975463","KAPIKUHBALFONG-UHFFFAOYSA-N","InChI=1S/C21H18ClFNO/c22-19-7-3-16(4-8-19)17-11-14-24(15-12-17)13-1-2-21(25)18-5-9-20(23)10-6-18/h3-12,14-15H,1-2,13H2/q+1","human cytochrome P450 1A2 by furafylline, ISSX Proceedings, 7th"
"BIOTID00599","harmaline","5280951","RERZNCLIYCABFS-UHFFFAOYSA-N","InChI=1S/C13H14N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-4,7,15H,5-6H2,1-2H3","CYP2D6 (major); CYP1A2 (minor)","O-aryl demethylation","Human Phase I","Human","Harmalol","NULL","RHVPEFQDYMMNSY-UHFFFAOYSA-N","InChI=1S/C12H12N2O/c1-7-12-10(4-5-13-7)9-3-2-8(15)6-11(9)14-12/h2-3,6,14-15H,4-5H2,1H3",""
"BIOTID00600","harmine","5280953","BXNJHAXVSOCGBA-UHFFFAOYSA-N","InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3","CYP2D6 (major); CYP2C9 (minor); CYP2C19 (minor); CYP1A2 (minor)","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","Harmol","NULL","AVGHDEIZJIEIFK-UHFFFAOYSA-N","InChI=1S/C13H12N2O2/c1-7-13-8(3-4-14-7)9-5-11(16)12(17-2)6-10(9)15-13/h3-6,15-16H,1-2H3","North American ZSSX Meeting, San Diego, CA, October 20-25,"
"BIOTID00601","harmine","5280953","BXNJHAXVSOCGBA-UHFFFAOYSA-N","InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3","CYP2D6","O-aryl demethylation","Human Phase I","Human","6-OH-harmaline","NULL","SATMZMMKDDTOSQ-UHFFFAOYSA-N","InChI=1S/C12H10N2O/c1-7-12-10(4-5-13-7)9-3-2-8(15)6-11(9)14-12/h2-6,14-15H,1H3",""
"BIOTID00602","hexamethylphosphoramide","12679","GNOIPBMMFNIUFM-UHFFFAOYSA-N","InChI=1S/C6H18N3OP/c1-7(2)11(10,8(3)4)9(5)6/h1-6H3","CYP2A6","N-Deethylation","Human Phase I","Human","NULL","66283","JSJBYUNWLNWERF-UHFFFAOYSA-N","InChI=1S/C5H16N3OP/c1-6-10(9,7(2)3)8(4)5/h1-5H3,(H,6,9)","1996, Vol. 10, p. 229; K. L. Kunze, J. K. Racha, and J. Calamia,|PMID:11016631"
"BIOTID00603","hexane","8058","VLKZOEOYAKHREP-UHFFFAOYSA-N","InChI=1S/C6H14/c1-3-5-6-4-2/h3-6H2,1-2H3","CYP2B6; CYP2E1","Hydroxylation of penultimate aliphatic secondary carbon","Human Phase I","Human","Hexanol","12297","QNVRIHYSUZMSGM-UHFFFAOYSA-N","InChI=1S/C6H14O/c1-3-4-5-6(2)7/h6-7H,3-5H2,1-2H3",""
"BIOTID00604","hydrocodone","5284569","LLPOLZWFYMWNKH-CMKMFDCUSA-N","InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1","CYP2D6","O-dementhylation","Human Phase I","Human","Hydromorphone","3648","WVLOADHCBXTIJK-UHFFFAOYSA-N","InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3","furafylline by human P4501A2, ZSSX Proceedings, 7th North Amen-|PMID:14998425"
"BIOTID00605","hydrocodone","5284569","LLPOLZWFYMWNKH-CMKMFDCUSA-N","InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1","CYP3A4","N-dementhylation","Human Phase I","Human","Norhydromorphone","13001737","JGORUXKMRLIJSV-UHFFFAOYSA-N","InChI=1S/C17H19NO3/c1-20-13-5-2-9-8-11-10-3-4-12(19)16-17(10,6-7-18-11)14(9)15(13)21-16/h2,5,10-11,16,18H,3-4,6-8H2,1H3","furafylline by human P4501A2, ZSSX Proceedings, 7th North Amen-|PMID:14998425"
"BIOTID00606","ibrolipim","131601","KPRTURMJVWXURQ-UHFFFAOYSA-N","InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)","CYP2C8;CYP3A4","O-DEETHYLATION","Human Phase I","Human","NULL","NULL","MSDJJQRZCRBFCL-UHFFFAOYSA-N","InChI=1S/C17H16BrN2O4P/c1-2-24-25(22,23)11-12-3-5-13(6-4-12)17(21)20-16-8-7-15(18)9-14(16)10-19/h3-9H,2,11H2,1H3,(H,20,21)(H,22,23)","can ZSSX Meeting, San Diego, CA, USA, October 20-25, 1996,|PMID:11854149"
"BIOTID00607","iloperidone","71360","XMXHEBAFVSFQEX-UHFFFAOYSA-N","InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3","CYP1A2;CYP2E1;CYP3A4","Reduction ","Human Phase I","Human","4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-a-methylbenzene methanol","9823904","SBKZGLWZGZQVHA-UHFFFAOYSA-N","InChI=1S/C24H29FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-17,28H,3,8-13H2,1-2H3","PMID:9732390"
"BIOTID00608","iloperidone","71360","XMXHEBAFVSFQEX-UHFFFAOYSA-N","InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3","CYP3A4","O-Demethylation","Human Phase I","Human","1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]- propoxy]-3-hydroxyphenyl]ethanone","11742411","JRAOALKNNYGKLE-UHFFFAOYSA-N","InChI=1S/C23H25FN2O4/c1-15(27)17-3-6-21(20(28)13-17)29-12-2-9-26-10-7-16(8-11-26)23-19-5-4-18(24)14-22(19)30-25-23/h3-6,13-14,16,28H,2,7-12H2,1H3","PMID:9732390"
"BIOTID00609","iloperidone","71360","XMXHEBAFVSFQEX-UHFFFAOYSA-N","InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-2-hydroxyethanone","18467218","BGCPETUXPSZMBH-UHFFFAOYSA-N","InChI=1S/C24H27FN2O5/c1-30-23-13-17(20(29)15-28)3-6-21(23)31-12-2-9-27-10-7-16(8-11-27)24-19-5-4-18(25)14-22(19)32-26-24/h3-6,13-14,16,28H,2,7-12,15H2,1H3","PMID:9732390"
"BIOTID00610","imatinib","5291","KTUFNOKKBVMGRW-UHFFFAOYSA-N","InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)","CYP3A4 (major); CYP2C8","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","N-desmethylimatinib","9869737","BQQYXPHRXIZMDM-UHFFFAOYSA-N","InChI=1S/C28H29N7O/c1-20-4-9-24(17-26(20)34-28-31-12-10-25(33-28)23-3-2-11-30-18-23)32-27(36)22-7-5-21(6-8-22)19-35-15-13-29-14-16-35/h2-12,17-18,29H,13-16,19H2,1H3,(H,32,36)(H,31,33,34)","Vol. 10, p. 230.."
"BIOTID00611","imidacloprid","86418","YWTYJOPNNQFBPC-UHFFFAOYSA-N","InChI=1S/C9H10ClN5O2/c10-8-2-1-7(5-12-8)6-14-4-3-11-9(14)13-15(16)17/h1-2,5H,3-4,6H2,(H,11,13)","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","5-hydroxy-imidacloprid","19417551","MATMQDMQFSFQHB-UHFFFAOYSA-N","InChI=1S/C9H10ClN5O3/c10-7-2-1-6(3-11-7)5-14-8(16)4-12-9(14)13-15(17)18/h1-3,8,16H,4-5H2,(H,12,13)","PMID:12230409"
"BIOTID00612","imidacloprid","86418","YWTYJOPNNQFBPC-UHFFFAOYSA-N","InChI=1S/C9H10ClN5O2/c10-8-2-1-7(5-12-8)6-14-4-3-11-9(14)13-15(16)17/h1-2,5H,3-4,6H2,(H,11,13)","CYP3A4","Dehydrogenation","Human Phase I","Human","olefin","14626249","TYLCDJYHUVCRBH-UHFFFAOYSA-N","InChI=1S/C9H8ClN5O2/c10-8-2-1-7(5-12-8)6-14-4-3-11-9(14)13-15(16)17/h1-5H,6H2,(H,11,13)","PMID:12230409"
"BIOTID00613","imipramine","3696","BCGWQEUPMDMJNV-UHFFFAOYSA-N","InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3","CYP2C19 (major); CYP2D6 ","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2-Hydroxyimipramine ","108051","ROTCPJFWLNDKHU-UHFFFAOYSA-N","InChI=1S/C19H24N2O/c1-20(2)12-5-13-21-18-7-4-3-6-15(18)8-9-16-14-17(22)10-11-19(16)21/h3-4,6-7,10-11,14,22H,5,8-9,12-13H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00614","imipramine","3696","BCGWQEUPMDMJNV-UHFFFAOYSA-N","InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3","CYP2C19; CYP2C18; CYP2D6; CYP1A2 ","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","Desimipramine ","2995","HCYAFALTSJYZDH-UHFFFAOYSA-N","InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00615","indinavir","5362440","CBVCZFGXHXORBI-PXQQMZJSSA-N","InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1","CYP3A4","N-Oxidation","Human Phase I","Human","NULL","NULL","COILGLLTSZXSAH-UHFFFAOYSA-N","InChI=1S/C36H47N5O5/c1-36(2,3)38-35(45)31-24-39(21-26-12-9-15-41(46)22-26)16-17-40(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)37-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,22,28-29,31-33,42-43H,16-21,23-24H2,1-3H3,(H,37,44)(H,38,45)","PMID:9175724"
"BIOTID00616","indinavir","5362440","CBVCZFGXHXORBI-PXQQMZJSSA-N","InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","22899299","MKMGKCALCCOODL-UHFFFAOYSA-N","InChI=1S/C30H42N4O4/c1-30(2,3)33-29(38)25-18-31-13-14-34(25)19-23(35)16-22(15-20-9-5-4-6-10-20)28(37)32-27-24-12-8-7-11-21(24)17-26(27)36/h4-12,22-23,25-27,31,35-36H,13-19H2,1-3H3,(H,32,37)(H,33,38)","PMID:9175724"
"BIOTID00617","indinavir","5362440","CBVCZFGXHXORBI-PXQQMZJSSA-N","InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","VSRLPVFLWVQTHB-UHFFFAOYSA-N","InChI=1S/C36H47N5O5/c1-36(2,3)39-35(46)31-23-40(21-25-7-6-14-37-20-25)15-16-41(31)22-29(43)18-27(17-24-10-12-28(42)13-11-24)34(45)38-33-30-9-5-4-8-26(30)19-32(33)44/h4-14,20,27,29,31-33,42-44H,15-19,21-23H2,1-3H3,(H,38,45)(H,39,46)","PMID:9175724"
"BIOTID00618","indinavir","5362440","CBVCZFGXHXORBI-PXQQMZJSSA-N","InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","QXNGFJFTQLQPEM-UHFFFAOYSA-N","InChI=1S/C36H47N5O5/c1-36(2,3)39-35(46)30-23-40(21-25-12-9-15-37-20-25)16-17-41(30)22-27(42)19-26(18-24-10-5-4-6-11-24)34(45)38-31-28-13-7-8-14-29(28)32(43)33(31)44/h4-15,20,26-27,30-33,42-44H,16-19,21-23H2,1-3H3,(H,38,45)(H,39,46)","PMID:9175724"
"BIOTID00619","indiplon","6450813","CBIAWPMZSFFRGN-UHFFFAOYSA-N","InChI=1S/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3","CYP3A4; CYP1A2","N-dealkylation of tertiary carboxamide","Human Phase I","Human","N-Desmethylindiplon","44390222","KZQWYRRAKXJLDE-UHFFFAOYSA-N","InChI=1S/C19H14N4O2S/c1-12(24)22-14-5-2-4-13(10-14)16-7-8-20-19-15(11-21-23(16)19)18(25)17-6-3-9-26-17/h2-11H,1H3,(H,22,24)","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00620","indole","6450813","SIKJAQJRHWYJAI-UHFFFAOYSA-N","InChI=1S/C8H7N/c1-2-4-8-7(3-1)5-6-9-8/h1-6,9H","CYP2A6;CYP2C19;CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","NULL","50591","PCKPVGOLPKLUHR-UHFFFAOYSA-N","InChI=1S/C8H7NO/c10-8-5-9-7-4-2-1-3-6(7)8/h1-5,9-10H","PMID:11076521"
"BIOTID00621","indole","6450813","SIKJAQJRHWYJAI-UHFFFAOYSA-N","InChI=1S/C8H7N/c1-2-4-8-7(3-1)5-6-9-8/h1-6,9H","CYP2A6;CYP2C19;CYP2E1","C-Oxidation","Human Phase I","Human","NULL","321710","JYGFTBXVXVMTGB-UHFFFAOYSA-N","InChI=1S/C8H7NO/c10-8-5-6-3-1-2-4-7(6)9-8/h1-4H,5H2,(H,9,10)","PMID:11076521"
"BIOTID00622","indole","6450813","SIKJAQJRHWYJAI-UHFFFAOYSA-N","InChI=1S/C8H7N/c1-2-4-8-7(3-1)5-6-9-8/h1-6,9H","CYP2A6;CYP2C19;CYP2E1","Aromatic Hydroxylation","Human Phase I","Human","NULL","524508","XAWPKHNOFIWWNZ-UHFFFAOYSA-N","InChI=1S/C8H7NO/c10-7-2-1-6-3-4-9-8(6)5-7/h1-5,9-10H","PMID:11076521"
"BIOTID00623","indomethacin","3715","CGIGDMFJXJATDK-UHFFFAOYSA-N","InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)","CYP2C9 (major); CYP2C19 (minor); CYP2D6 (minor); CYP1A2 (minor)","O-aryl demethylation","Human Phase I","Human","O-Desmethylindomethacin","159665","KMLNWQPYFBIALN-UHFFFAOYSA-N","InChI=1S/C18H14ClNO4/c1-10-14(9-17(22)23)15-8-13(21)6-7-16(15)20(10)18(24)11-2-4-12(19)5-3-11/h2-8,21H,9H2,1H3,(H,22,23)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00624","invega, invega sustenna, 9-hydroxyrisperidone, paliperidone","9823781","PMXMIIMHBWHSKN-IBGZPJMESA-N","InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3/t19-/m0/s1","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","AVFAVLATFVTKHI-UHFFFAOYSA-N","InChI=1S/C23H27FN4O4/c1-13-17(23(31)28-12-16(29)11-19(30)22(28)25-13)6-9-27-7-4-14(5-8-27)21-18-3-2-15(24)10-20(18)32-26-21/h2-3,10,14,16,19,29-30H,4-9,11-12H2,1H3","PMID:10482125"
"BIOTID00625","ipriflavone","3747","SFBODOKJTYAUCM-UHFFFAOYSA-N","InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3","CYP1A2;CYP2C9;CYP2C19;CYP3A4","O-dealkylation","Human Phase I","Human","NULL","5376891","WMKOZARWBMFKAS-UHFFFAOYSA-N","InChI=1S/C15H10O3/c16-11-6-7-12-14(8-11)18-9-13(15(12)17)10-4-2-1-3-5-10/h1-9,16H","PMID:17624023"
"BIOTID00626","ipriflavone","3747","SFBODOKJTYAUCM-UHFFFAOYSA-N","InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3","CYP1A2;CYP2C9;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","NULL","101159250","MGBMXLMPUFBMPC-UHFFFAOYSA-N","InChI=1S/C18H16O4/c1-12(10-19)22-14-7-8-15-17(9-14)21-11-16(18(15)20)13-5-3-2-4-6-13/h2-9,11-12,19H,10H2,1H3","PMID:17624023"
"BIOTID00627","ipriflavone","3747","SFBODOKJTYAUCM-UHFFFAOYSA-N","InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3","CYP1A2;CYP2C9;CYP2C19","Aromatic Hydroxylation","Human Phase I","Human","NULL","10469827","DEQMUPGWSXUDKV-UHFFFAOYSA-N","InChI=1S/C18H16O4/c1-11(2)22-14-7-8-15-17(9-14)21-10-16(18(15)20)12-3-5-13(19)6-4-12/h3-11,19H,1-2H3","PMID:17624023"
"BIOTID00628","irbesartan","3749","YOSHYTLCDANDAN-UHFFFAOYSA-N","InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)","CYP2C9","Hydroxylation of penultimate aliphatic secondary carbon","Human Phase I","Human","2-(3-hydroxybutyl)-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one","NULL","YASLDPAAWWZGIP-UHFFFAOYSA-N","InChI=1S/C25H28N6O2/c1-17(32)8-13-22-26-25(14-4-5-15-25)24(33)31(22)16-18-9-11-19(12-10-18)20-6-2-3-7-21(20)23-27-29-30-28-23/h2-3,6-7,9-12,17,32H,4-5,8,13-16H2,1H3,(H,27,28,29,30)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00629","irbesartan","3749","YOSHYTLCDANDAN-UHFFFAOYSA-N","InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)","CYP2C9","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","M7","101944494","SGLAKMDXJPVHBY-UHFFFAOYSA-N","InChI=1S/C25H28N6O2/c1-2-3-8-22-26-25(14-13-19(32)15-25)24(33)31(22)16-17-9-11-18(12-10-17)20-6-4-5-7-21(20)23-27-29-30-28-23/h4-7,9-12,19,32H,2-3,8,13-16H2,1H3,(H,27,28,29,30)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00630","irbesartan","3749","YOSHYTLCDANDAN-UHFFFAOYSA-N","InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)","CYP2C9","C-Oxidation","Human Phase I","Human","M3","NULL","SQPSUXCOWHFKKF-UHFFFAOYSA-N","InChI=1S/C25H26N6O3/c32-22(33)9-5-8-21-26-25(14-3-4-15-25)24(34)31(21)16-17-10-12-18(13-11-17)19-6-1-2-7-20(19)23-27-29-30-28-23/h1-2,6-7,10-13H,3-5,8-9,14-16H2,(H,32,33)(H,27,28,29,30)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|PMID:9571222"
"BIOTID00631","irinotecan","60838","UWKQSNNFCGGAFS-XIFFEERXSA-N","InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1","CYP3A4; CYP3A5","Ring opening of N-substituted piperidine","Human Phase I","Human","7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin","10077584","BSVVZICJFYZDJJ-XIFFEERXSA-N","InChI=1S/C33H38N4O8/c1-3-21-22-15-20(45-32(42)36-13-10-19(11-14-36)34-12-6-5-7-28(38)39)8-9-26(22)35-29-23(21)17-37-27(29)16-25-24(30(37)40)18-44-31(41)33(25,43)4-2/h8-9,15-16,19,34,43H,3-7,10-14,17-18H2,1-2H3,(H,38,39)/t33-/m0/s1","Rouits, E. et al (2008); Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients; British Journal of Cancer 99, 1239 Ã¢â‚¬â€œ 1245"
"BIOTID00633","isoquinoline","8405","AWJUIBRHMBBTKR-UHFFFAOYSA-N","InChI=1S/C9H7N/c1-2-4-9-7-10-6-5-8(9)3-1/h1-7H","CYP3A4; CYP2E1","N-Oxidation","Human Phase I","Human","isoquinoline N-oxide","290378","RZIAABRFQASVSW-UHFFFAOYSA-N","InChI=1S/C9H7NO/c11-10-6-5-8-3-1-2-4-9(8)7-10/h1-7H","PMID:14977867"
"BIOTID00634","isotretinoin","5282379","SHGAZHPCJJPHSC-XFYACQKRSA-N","InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-","CYP2B6;CYP2C8;CYP3A4","Hydroxylation","Human Phase I","Human","NULL","NULL","OJFWBVDTZYLKNZ-POPRBKBWSA-N","InChI=1S/C20H28O3/c1-14(13-19(22)23)8-11-18(21)16(3)9-10-17-15(2)7-6-12-20(17,4)5/h8-11,13,21H,6-7,12H2,1-5H3,(H,22,23)/b10-9+,11-8+,14-13-,18-16-","PMID:5282379"
"BIOTID00635","isoursodeoxycholic acid","127601","RUDATBOHQWOJDD-DNMBCGTGSA-N","InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16+,17-,18+,19+,20+,22+,23+,24-/m1/s1","CYP3A4","Dehydrogenation","Human Phase I","Human","NULL","12771428","KNVADAPHVNKTEP-UHFFFAOYSA-N","InChI=1S/C24H38O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-15,17-20,22,26H,4-13H2,1-3H3,(H,27,28)","PMID:18583509"
"BIOTID00636","isoursodeoxycholic acid","127601","RUDATBOHQWOJDD-DNMBCGTGSA-N","InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16+,17-,18+,19+,20+,22+,23+,24-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","495539","DKPMWHFRUGMUKF-UHFFFAOYSA-N","InChI=1S/C24H40O5/c1-13(4-7-19(26)27)15-5-6-16-20-17(9-11-23(15,16)2)24(3)10-8-14(25)12-18(24)21(28)22(20)29/h13-18,20-22,25,28-29H,4-12H2,1-3H3,(H,26,27)","PMID:18583509"
"BIOTID00637","ivermectin","NULL","QSENXEKZWYFFJK-FKLTURBQSA-N","InChI=1S/C48H74O13/c1-26(2)32-19-20-47(55-25-32)24-35-17-16-34(61-47)15-13-28(4)44(27(3)11-10-12-33-14-18-36-42(49)29(5)21-37(46(51)58-35)48(33,36)52)59-41-23-39(54-9)45(31(7)57-41)60-40-22-38(53-8)43(50)30(6)56-40/h10-13,21,26-27,30-32,34-45,49-50,52H,14-20,22-25H2,1-9H3/b11-10-,28-13-,33-12+/t27-,30-,31-,32-,34+,35-,36-,37-,38-,39-,40-,41-,42+,43-,44-,45-,47-,48+/m0/s1","CYP3A4","O-Demethylation","Human Phase I","Human","NULL","NULL","ZETCQFVJKLCYEI-PSFZNSIOSA-N","InChI=1S/C47H72O13/c1-25(2)31-18-19-46(54-24-31)23-34-16-15-33(60-46)14-12-27(4)43(58-40-22-38(53-8)44(30(7)56-40)59-39-21-37(48)42(50)29(6)55-39)26(3)10-9-11-32-13-17-35-41(49)28(5)20-36(45(51)57-34)47(32,35)52/h9-12,20,25-26,29-31,33-44,48-50,52H,13-19,21-24H2,1-8H3/b10-9-,27-12-,32-11+","PMID:9574819"
"BIOTID00638","ivermectin","NULL","QSENXEKZWYFFJK-FKLTURBQSA-N","InChI=1S/C48H74O13/c1-26(2)32-19-20-47(55-25-32)24-35-17-16-34(61-47)15-13-28(4)44(27(3)11-10-12-33-14-18-36-42(49)29(5)21-37(46(51)58-35)48(33,36)52)59-41-23-39(54-9)45(31(7)57-41)60-40-22-38(53-8)43(50)30(6)56-40/h10-13,21,26-27,30-32,34-45,49-50,52H,14-20,22-25H2,1-9H3/b11-10-,28-13-,33-12+/t27-,30-,31-,32-,34+,35-,36-,37-,38-,39-,40-,41-,42+,43-,44-,45-,47-,48+/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","DGCBDVOXAVTHMT-LMTFIRPJSA-N","InChI=1S/C48H74O14/c1-26(2)32-19-20-46(56-25-32)24-35-17-16-34(61-46)15-13-28(4)44(27(3)11-10-12-33-14-18-36-42(49)29(5)21-37(45(51)59-35)47(33,36)52)60-40-23-39(55-9)48(53,31(7)58-40)62-41-22-38(54-8)43(50)30(6)57-41/h10-13,21,26-27,30-32,34-44,49-50,52-53H,14-20,22-25H2,1-9H3/b11-10-,28-13-,33-12+","PMID:9574819"
"BIOTID00639","ivermectin","NULL","QSENXEKZWYFFJK-FKLTURBQSA-N","InChI=1S/C48H74O13/c1-26(2)32-19-20-47(55-25-32)24-35-17-16-34(61-47)15-13-28(4)44(27(3)11-10-12-33-14-18-36-42(49)29(5)21-37(46(51)58-35)48(33,36)52)59-41-23-39(54-9)45(31(7)57-41)60-40-22-38(53-8)43(50)30(6)56-40/h10-13,21,26-27,30-32,34-45,49-50,52H,14-20,22-25H2,1-9H3/b11-10-,28-13-,33-12+/t27-,30-,31-,32-,34+,35-,36-,37-,38-,39-,40-,41-,42+,43-,44-,45-,47-,48+/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","OGQKAZWTJRMDGM-HYVUHECNSA-N","InChI=1S/C48H74O14/c1-26-11-10-12-31-14-18-35-41(49)28(3)21-36(48(31,35)53)45(51)59-34-17-16-33(62-47(24-34)20-19-32(25-56-47)46(6,7)52)15-13-27(2)43(26)60-40-23-38(55-9)44(30(5)58-40)61-39-22-37(54-8)42(50)29(4)57-39/h10-13,21,26,29-30,32-44,49-50,52-53H,14-20,22-25H2,1-9H3/b11-10-,27-13-,31-12+","PMID:9574819"
"BIOTID00640","k-11777","9851116","RHJLQMVZXQKJKB-FPHSVDBKSA-N","InChI=1S/C32H38N4O4S/c1-35-20-22-36(23-21-35)32(38)34-30(25-27-13-7-3-8-14-27)31(37)33-28(18-17-26-11-5-2-6-12-26)19-24-41(39,40)29-15-9-4-10-16-29/h2-16,19,24,28,30H,17-18,20-23,25H2,1H3,(H,33,37)(H,34,38)/b24-19+/t28-,30-/m0/s1","CYP3A4","N-Oxidation","Human Phase I","Human","N-oxide k-11777","NULL","XBXZEIPEIBJHKU-LYBHJNIJSA-N","InChI=1S/C32H38N4O5S/c1-36(39)22-20-35(21-23-36)32(38)34-30(25-27-13-7-3-8-14-27)31(37)33-28(18-17-26-11-5-2-6-12-26)19-24-42(40,41)29-15-9-4-10-16-29/h2-16,19,24,28,30H,17-18,20-23,25H2,1H3,(H,33,37)(H,34,38)/b24-19+","PMID:11038163"
"BIOTID00641","k-11777","9851116","RHJLQMVZXQKJKB-FPHSVDBKSA-N","InChI=1S/C32H38N4O4S/c1-35-20-22-36(23-21-35)32(38)34-30(25-27-13-7-3-8-14-27)31(37)33-28(18-17-26-11-5-2-6-12-26)19-24-41(39,40)29-15-9-4-10-16-29/h2-16,19,24,28,30H,17-18,20-23,25H2,1H3,(H,33,37)(H,34,38)/b24-19+/t28-,30-/m0/s1","CYP3A4;CYP2D6","N-Desmethylation","Human Phase I","Human","N-desmethyl k-11777","NULL","NWGHXYFZUNRWJM-PTGBLXJZSA-N","InChI=1S/C31H36N4O4S/c36-30(29(24-26-12-6-2-7-13-26)34-31(37)35-21-19-32-20-22-35)33-27(17-16-25-10-4-1-5-11-25)18-23-40(38,39)28-14-8-3-9-15-28/h1-15,18,23,27,29,32H,16-17,19-22,24H2,(H,33,36)(H,34,37)/b23-18+","PMID:11038163"
"BIOTID00642","N-[(2S)-1-[[(E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide","9851116","RHJLQMVZXQKJKB-FPHSVDBKSA-N","InChI=1S/C32H38N4O4S/c1-35-20-22-36(23-21-35)32(38)34-30(25-27-13-7-3-8-14-27)31(37)33-28(18-17-26-11-5-2-6-12-26)19-24-41(39,40)29-15-9-4-10-16-29/h2-16,19,24,28,30H,17-18,20-23,25H2,1H3,(H,33,37)(H,34,38)/b24-19+/t28-,30-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","b-hydroxy-homoPhe K11777","NULL","XIKFDWPFDXTACE-OQKWZONESA-N","InChI=1S/C32H38N4O5S/c1-35-18-20-36(21-19-35)32(39)34-29(23-25-11-5-2-6-12-25)31(38)33-28(30(37)24-26-13-7-3-8-14-26)17-22-42(40,41)27-15-9-4-10-16-27/h2-17,22,28-30,37H,18-21,23-24H2,1H3,(H,33,38)(H,34,39)/b22-17+","PMID:11038163"
"BIOTID00643","kaempferide","5281666","SQFSKOYWJBQGKQ-UHFFFAOYSA-N","InChI=1S/C16H12O6/c1-21-10-4-2-8(3-5-10)16-15(20)14(19)13-11(18)6-9(17)7-12(13)22-16/h2-7,17-18,20H,1H3","CYP1A2 ; CYP2C9","O-aryl demethylation","Human Phase I","Human","4'-OH-galangin","5280863","IYRMWMYZSQPJKC-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00644","ketobemidone","10101","ALFGKMXHOUSVAD-UHFFFAOYSA-N","InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3","CYP3A4; CYP2C9","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","Norketobemidone","161154","BJTDPLRIKDSWIS-UHFFFAOYSA-N","InChI=1S/C14H19NO2/c1-2-13(17)14(6-8-15-9-7-14)11-4-3-5-12(16)10-11/h3-5,10,15-16H,2,6-9H2,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00645","kr-60436","10113707","ZFDXQUVDLKGYIL-UHFFFAOYSA-N","InChI=1S/C22H22F3N3O3/c1-13-12-14(30-2)6-7-17(13)28-10-8-16-20(28)15-4-3-5-18(31-22(23,24)25)19(15)27-21(16)26-9-11-29/h3-7,12,29H,8-11H2,1-2H3,(H,26,27)","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4","O-Demethylation","Human Phase I","Human","O-demethyl-KR-60436","19369784","GGMKFKAZYCZEKA-UHFFFAOYSA-N","InChI=1S/C21H20F3N3O3/c1-12-11-13(29)5-6-16(12)27-9-7-15-19(27)14-3-2-4-17(30-21(22,23)24)18(14)26-20(15)25-8-10-28/h2-6,11,28-29H,7-10H2,1H3,(H,25,26)","PMID:15585365"
"BIOTID00646","kr-60436","10113707","ZFDXQUVDLKGYIL-UHFFFAOYSA-N","InChI=1S/C22H22F3N3O3/c1-13-12-14(30-2)6-7-17(13)28-10-8-16-20(28)15-4-3-5-18(31-22(23,24)25)19(15)27-21(16)26-9-11-29/h3-7,12,29H,8-11H2,1-2H3,(H,26,27)","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4","N-dehydroxyethylation","Human Phase I","Human","NULL","NULL","XDTHJXLHKIVHAW-UHFFFAOYSA-N","InChI=1S/C20H18F3N3O2/c1-11-10-12(27-2)6-7-15(11)26-9-8-14-18(26)13-4-3-5-16(28-20(21,22)23)17(13)25-19(14)24/h3-7,10H,8-9H2,1-2H3,(H2,24,25)","PMID:15585365"
"BIOTID00647","kr-60436","10113707","ZFDXQUVDLKGYIL-UHFFFAOYSA-N","InChI=1S/C22H22F3N3O3/c1-13-12-14(30-2)6-7-17(13)28-10-8-16-20(28)15-4-3-5-18(31-22(23,24)25)19(15)27-21(16)26-9-11-29/h3-7,12,29H,8-11H2,1-2H3,(H,26,27)","CYP2D6;CYP3A4","Hydrogenation","Human Phase I","Human","NULL","NULL","DMVYKDGMHJMQBE-UHFFFAOYSA-N","InChI=1S/C22H20F3N3O3/c1-13-12-14(30-2)6-7-17(13)28-10-8-16-20(28)15-4-3-5-18(31-22(23,24)25)19(15)27-21(16)26-9-11-29/h3-8,10,12,29H,9,11H2,1-2H3,(H,26,27)","PMID:15585365"
"BIOTID00648","2â€(3â€{4â€[2â€(3â€fluorophenyl)ethyl]piperazinâ€1â€yl}propyl)â€5â€(1,2,4â€triazolâ€4â€yl)â€1Hâ€indole","NULL","HYDKUVPEVOHALC-UHFFFAOYSA-N","InChI=1S/C25H29FN6/c26-22-4-1-3-20(15-22)8-10-31-13-11-30(12-14-31)9-2-5-23-16-21-17-24(6-7-25(21)29-23)32-18-27-28-19-32/h1,3-4,6-7,15-19,29H,2,5,8-14H2","CYP2C8;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","PNDJGKITSSZBHH-UHFFFAOYSA-N","InChI=1S/C25H29FN6O/c26-21-4-1-3-19(13-21)25(33)16-31-11-9-30(10-12-31)8-2-5-22-14-20-15-23(6-7-24(20)29-22)32-17-27-28-18-32/h1,3-4,6-7,13-15,17-18,25,29,33H,2,5,8-12,16H2","PMID:10659950"
"BIOTID00649","l_775606","NULL","HYDKUVPEVOHALC-UHFFFAOYSA-N","InChI=1S/C25H29FN6/c26-22-4-1-3-20(15-22)8-10-31-13-11-30(12-14-31)9-2-5-23-16-21-17-24(6-7-25(21)29-23)32-18-27-28-19-32/h1,3-4,6-7,15-19,29H,2,5,8-14H2","CYP2C8;CYP3A4","N-dealkylation","Human Phase I","Human","NULL","NULL","CBQOQETVBHUSNL-UHFFFAOYSA-N","InChI=1S/C18H24N6/c1-22-7-9-23(10-8-22)6-2-3-16-11-15-12-17(4-5-18(15)21-16)24-13-19-20-14-24/h4-5,11-14,21H,2-3,6-10H2,1H3","PMID:10659950"
"BIOTID00650","l-cyclophosphamide","9554282","CMSMOCZEIVJLDB-CQSZACIVSA-N","InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)/t14-/m1/s1","CYP2B6; CYP3A4; CYP3A5","N-dechloroethylation","Human Phase I","Human","Dechloroethyl cyclophosphamide","92254917","DZKGMGPLDJOVCX-LLVKDONJSA-N","InChI=1S/C5H12ClN2O2P/c6-2-4-8-11(9)7-3-1-5-10-11/h1-5H2,(H2,7,8,9)/t11-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Whirl-Carrillo, M. et al. (2012); Pharmacogenomics knowledge for personalized medicine; Clin Pharmacol Ther. 2012 Oct;92(4):414-7. DOI:10.1038/clpt.2012.96; PMID:22992668; PMCID:PMC3660037"
"BIOTID00650","l-cyclophosphamide","9554282","CMSMOCZEIVJLDB-CQSZACIVSA-N","InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)/t14-/m1/s1","CYP2B6; CYP3A4; CYP3A5","N-dechloroethylation","Human Phase I","Human","2-chloroacetaldehyde","33","QSKPIOLLBIHNAC-UHFFFAOYSA-N","InChI=1S/C2H3ClO/c3-1-2-4/h2H,1H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Whirl-Carrillo, M. et al. (2012); Pharmacogenomics knowledge for personalized medicine; Clin Pharmacol Ther. 2012 Oct;92(4):414-7. DOI:10.1038/clpt.2012.96; PMID:22992668; PMCID:PMC3660037"
"BIOTID00651","l-ifosfamide","9588020","HOMGKSMUEGBAAB-CQSZACIVSA-N","InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)/t14-/m1/s1","CYP2B6; CYP3A4; CYP3A5","N-dechloroethylation","Human Phase I","Human","3-Dechloroethylifosfamide","91826887","DZKGMGPLDJOVCX-NSHDSACASA-N","InChI=1S/C5H12ClN2O2P/c6-2-4-8-11(9)7-3-1-5-10-11/h1-5H2,(H2,7,8,9)/t11-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|Chugh, R. et al. (2007); Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma; Cancer. 2007 Jun 1;109(11):2315-22; PMID:17464949; DOI:10.1002/cncr.22669"
"BIOTID00651","l-ifosfamide","9588020","HOMGKSMUEGBAAB-CQSZACIVSA-N","InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)/t14-/m1/s1","CYP2B6; CYP3A4; CYP3A5","N-dechloroethylation","Human Phase I","Human","chloroacetaldehyde","33","QSKPIOLLBIHNAC-UHFFFAOYSA-N","InChI=1S/C2H3ClO/c3-1-2-4/h2H,1H2","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|Chugh, R. et al. (2007); Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma; Cancer. 2007 Jun 1;109(11):2315-22; PMID:17464949; DOI:10.1002/cncr.22669"
"BIOTID00652","l-ifosfamide","9588020","HOMGKSMUEGBAAB-CQSZACIVSA-N","InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)/t14-/m1/s1","CYP2B6; CYP3A4; CYP3A5","N-dechloroethylation","Human Phase I","Human","2-Dechloroethylifosfamide","13093129","ROGLJLJCDSTWBN-LLVKDONJSA-N","InChI=1S/C5H12ClN2O2P/c6-2-4-8-3-1-5-10-11(8,7)9/h1-5H2,(H2,7,9)/t11-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|Chugh, R. et al. (2007); Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma; Cancer. 2007 Jun 1;109(11):2315-22; PMID:17464949; DOI:10.1002/cncr.22669"
"BIOTID00653","l-ifosfamide","9588020","HOMGKSMUEGBAAB-CQSZACIVSA-N","InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)/t14-/m1/s1","CYP2B6 (major); CYP3A4 (major); CYP2A6 (minor); CYP2C8 (minor); CYP2C9 (minor); CYP2C19 (minor); CYP3A5 (minor)","4-alkyl hydroxylation of oxoazaphosphorine","Human Phase I","Human","4-Hydroxyifosfamide","NULL","JHUJMHKRHQPBRG-LGTFYCNTSA-N","InChI=1S/C7H15Cl2N2O3P/c8-2-4-10-15(13)11(5-3-9)7(12)1-6-14-15/h7,12H,1-6H2,(H,10,13)/t7?,15-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|Chugh, R. et al. (2007); Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma; Cancer. 2007 Jun 1;109(11):2315-22; PMID:17464949; DOI:10.1002/cncr.22669"
"BIOTID00654","l-trofosfamide","9576167","UMKFEPPTGMDVMI-QGZVFWFLSA-N","InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2/t17-/m1/s1","CYP3A4; CYP2B6; CYP2A6; CYP2C9","4-alkyl hydroxylation of oxoazaphosphorine","Human Phase I","Human","l-ifosfamide","NULL","RAXABQCFPAWRSY-AHMWTOSDSA-N","InChI=1S/C9H18Cl3N2O3P/c10-2-5-13(6-3-11)18(16)14(7-4-12)9(15)1-8-17-18/h9,15H,1-8H2/t9?,18-/m0/s1","Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023"
"BIOTID00655","l-trofosfamide","9576167","UMKFEPPTGMDVMI-QGZVFWFLSA-N","InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2/t17-/m1/s1","CYP3A4; CYP2B6","N-dechloroethylation","Human Phase I","Human","Ifosfamide","9576167","UMKFEPPTGMDVMI-QGZVFWFLSA-N","InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2/t17-/m1/s1","Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|May-Manke, A. et al. (1999); Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N -dechloroethylation of trofosfamide; Cancer Chemother Pharmacol. 1999;44(4):327-34; PMID:10447581; DOI:10.1007/s002800050985"
"BIOTID00656","l-trofosfamide","9576167","UMKFEPPTGMDVMI-QGZVFWFLSA-N","InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2/t17-/m1/s1","CYP3A4; CYP2B6","N-dechloroethylation","Human Phase I","Human","l-cyclophosphamide","9554282","CMSMOCZEIVJLDB-CQSZACIVSA-N","InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)/t14-/m1/s1","Zhang, J. et al. (2005); Metabolism and transport of oxazaphosphorines and the clinical implications; Drug Metab Rev. 2005;37(4):611-703; PMID:16393888; DOI:10.1080/03602530500364023|May-Manke, A. et al. (1999); Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N -dechloroethylation of trofosfamide; Cancer Chemother Pharmacol. 1999;44(4):327-34; PMID:10447581; DOI:10.1007/s002800050985"
"BIOTID00657","laquinimod","54677946","GKWPCEFFIHSJOE-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3","CYP3A4","p-Hydroxylation of anilide","Human Phase I","Human","5-chloro-N-ethyl-4-hydroxy-N-(4-hydroxyphenyl)-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide","NULL","HBMNTNTZJMZXKP-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O4/c1-3-22(11-7-9-12(23)10-8-11)19(26)16-17(24)15-13(20)5-4-6-14(15)21(2)18(16)25/h4-10,23-24H,3H2,1-2H3","Tuvesson,H. et al.(2005); CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THEMETABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR; DRUG METABOLISM AND DISPOSITION, 2005, 33, 866-872"
"BIOTID00658","laquinimod","54677946","GKWPCEFFIHSJOE-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3","CYP3A4","N-dealkylation of secondary carboxamide","Human Phase I","Human","5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","54687473","BZKCTVZVKAXVFH-UHFFFAOYSA-N","InChI=1S/C17H13ClN2O3/c1-20-12-9-5-8-11(18)13(12)15(21)14(17(20)23)16(22)19-10-6-3-2-4-7-10/h2-9,21H,1H3,(H,19,22)","Tuvesson,H. et al.(2005); CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THEMETABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR; DRUG METABOLISM AND DISPOSITION, 2005, 33, 866-872"
"BIOTID00659","laquinimod","54677946","GKWPCEFFIHSJOE-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3","CYP3A4","N-dealkylation of secondary carboxamide","Human Phase I","Human","5-chloro-N-ethyl-4-hydroxy-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","129041023","PRSDPSUTNKQSOJ-UHFFFAOYSA-N","InChI=1S/C18H15ClN2O3/c1-2-21(11-7-4-3-5-8-11)18(24)15-16(22)14-12(19)9-6-10-13(14)20-17(15)23/h3-10H,2H2,1H3,(H2,20,22,23)","Tuvesson,H. et al.(2005); CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THEMETABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR; DRUG METABOLISM AND DISPOSITION, 2005, 33, 866-872"
"BIOTID00660","laquinimod","54677946","GKWPCEFFIHSJOE-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3","CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","5-chloro-N-ethyl-4,8-dihydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","NULL","KBIYOPLLPLGYEU-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O4/c1-3-22(11-7-5-4-6-8-11)19(26)15-17(24)14-12(20)9-10-13(23)16(14)21(2)18(15)25/h4-10,23-24H,3H2,1-2H3","Tuvesson,H. et al.(2005); CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THEMETABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR; DRUG METABOLISM AND DISPOSITION, 2005, 33, 866-872"
"BIOTID00661","laquinimod","54677946","GKWPCEFFIHSJOE-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3","CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","5-chloro-N-ethyl-4,7-dihydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","NULL","JQKWEWTUEMBDKZ-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O4/c1-3-22(11-7-5-4-6-8-11)19(26)16-17(24)15-13(20)9-12(23)10-14(15)21(2)18(16)25/h4-10,23-24H,3H2,1-2H3","Tuvesson,H. et al.(2005); CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THEMETABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR; DRUG METABOLISM AND DISPOSITION, 2005, 33, 866-872"
"BIOTID00662","laquinimod","54677946","GKWPCEFFIHSJOE-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3","CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","5-chloro-N-ethyl-4,6-dihydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","NULL","IYYNHKJIMIURLE-UHFFFAOYSA-N","InChI=1S/C19H17ClN2O4/c1-3-22(11-7-5-4-6-8-11)19(26)15-17(24)14-12(21(2)18(15)25)9-10-13(23)16(14)20/h4-10,23-24H,3H2,1-2H3","Tuvesson,H. et al.(2005); CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THEMETABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR; DRUG METABOLISM AND DISPOSITION, 2005, 33, 866-872"
"BIOTID00663","lauric acid","3893","POULHZVOKOAJMA-UHFFFAOYSA-N","InChI=1S/C12H24O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h2-11H2,1H3,(H,13,14)","CYP2E1 (major); CYP2C8 (minor); CYP2B6 (minor)","Hydroxylation of terminal methyl","Human Phase I","Human","12-Hydroxylauric acid","79034","ZDHCZVWCTKTBRY-UHFFFAOYSA-N","InChI=1S/C12H24O3/c13-11-9-7-5-3-1-2-4-6-8-10-12(14)15/h13H,1-11H2,(H,14,15)",""
"BIOTID00664","levobupivacaine","92253","LEBVLXFERQHONN-INIZCTEOSA-N","InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1","CYP2C19;CYP2D6;CYP3A4","N-demethylation","Human Phase I","Human","NULL","115282","SILRCGDPZGQJOQ-UHFFFAOYSA-N","InChI=1S/C14H20N2O/c1-10-6-5-7-11(2)13(10)16-14(17)12-8-3-4-9-15-12/h5-7,12,15H,3-4,8-9H2,1-2H3,(H,16,17)","PMID:10725304"
"BIOTID00665","licofelone","133021","UAWXGRJVZSAUSZ-UHFFFAOYSA-N","InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)","CYP3A4; CYP2C8; CYP2C19; CYP2D6","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","licofelone M4","22500686","OCECVTMNVSFNIW-UHFFFAOYSA-N","InChI=1S/C23H22ClNO3/c1-23(2)12-19-22(15-5-9-17(26)10-6-15)21(14-3-7-16(24)8-4-14)18(11-20(27)28)25(19)13-23/h3-10,26H,11-13H2,1-2H3,(H,27,28)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00666","licofelone","133021","UAWXGRJVZSAUSZ-UHFFFAOYSA-N","InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)","CYP2C8; CYP2C9","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","licofelone M2","NULL","QUCLYFKWRYCDCG-UHFFFAOYSA-N","InChI=1S/C23H22ClNO3/c1-23(2)12-18-21(14-6-4-3-5-7-14)22(15-8-9-16(24)19(26)10-15)17(11-20(27)28)25(18)13-23/h3-10,26H,11-13H2,1-2H3,(H,27,28)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00667","licofelone_M1","NULL","YXNIWVFDFGNCED-NNVCNDCRSA-N","InChI=1S/C29H32ClNO7/c1-29(2)13-20-24(16-6-4-3-5-7-16)23(17-8-10-18(30)11-9-17)19(31(20)15-29)12-22(32)37-14-21-25(33)26(34)27(35)28(36)38-21/h3-11,21,25-28,33-36H,12-15H2,1-2H3/t21-,25+,26+,27-,28+/m0/s1","CYP2C8;CYP2C9","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","PRKFXPDIUDYFII-UHFFFAOYSA-N","InChI=1S/C29H32ClNO8/c1-29(15-32)12-20-24(16-5-3-2-4-6-16)23(17-7-9-18(30)10-8-17)19(31(20)14-29)11-22(33)38-13-21-25(34)26(35)27(36)28(37)39-21/h2-10,21,25-28,32,34-37H,11-15H2,1H3","PMID:18268076"
"BIOTID00668","lidocaine","3676","NNJVILVZKWQKPM-UHFFFAOYSA-N","InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)","CYP1A2; CYP3A4; CYP3A5; CYP2C8; CYP2C18; CYP2B6; CYP2A6","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","Monoethylglycinexylidide","24415","WRMRXPASUROZGT-UHFFFAOYSA-N","InChI=1S/C12H18N2O/c1-4-13-8-11(15)14-12-9(2)6-5-7-10(12)3/h5-7,13H,4,8H2,1-3H3,(H,14,15)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ekins, S. and Wrighton, S.A. (1999); The role of CYP2B6 in Human Xenobiotic Metabolism; Drug Metabolism Reviews, 31:3, 719-754, DOI:10.1081/ DMR-100101942; PMID:10461547|Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00669","lidocaine","3676","NNJVILVZKWQKPM-UHFFFAOYSA-N","InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)","CYP1A2; CYP2D6; CYP3A4","Hydroxylation of benzene on carbon ortho to an electron donating group","Human Phase I","Human","3-Hydroxylidocaine","161824","PMGUCIDDSCRAMY-UHFFFAOYSA-N","InChI=1S/C14H22N2O2/c1-5-16(6-2)9-13(18)15-14-10(3)7-8-12(17)11(14)4/h7-8,17H,5-6,9H2,1-4H3,(H,15,18)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ekins, S. and Wrighton, S.A. (1999); The role of CYP2B6 in Human Xenobiotic Metabolism; Drug Metabolism Reviews, 31:3, 719-754, DOI:10.1081/ DMR-100101942; PMID:10461547|Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|Thomas, J., Meffin, P. (1972). Aromatic hydroxylation of lidocaine and mepivacaine in rats and humans. J. Med. Chem. 15:1046Ã¢â‚¬â€œ1049."
"BIOTID00670","linomide","54676478","SGOOQMRIPALTEL-UHFFFAOYSA-N","InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3","CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","4,8-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","NULL","AHXNUHLQDWODQB-UHFFFAOYSA-N","InChI=1S/C18H16N2O4/c1-19(11-7-4-3-5-8-11)17(23)14-16(22)12-9-6-10-13(21)15(12)20(2)18(14)24/h3-10,21-22H,1-2H3","Tuvesson, H. et al.(2005); CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THEMETABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR; DRUG METABOLISM AND DISPOSITION, 2005, 33, 866-827"
"BIOTID00671","linomide","54676478","SGOOQMRIPALTEL-UHFFFAOYSA-N","InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3","CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","4,7-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","NULL","NPWHYPYXYXHWLK-UHFFFAOYSA-N","InChI=1S/C18H16N2O4/c1-19(11-6-4-3-5-7-11)17(23)15-16(22)13-9-8-12(21)10-14(13)20(2)18(15)24/h3-10,21-22H,1-2H3","Tuvesson,H. et al.(2000) Identification of cytochrome P4503A as the major subfamily responsible for the metabolismof roquinimex in man, Xenobiotica, 30:9, 905-914, DOI:10.1080/004982500433327"
"BIOTID00672","linomide","54676478","SGOOQMRIPALTEL-UHFFFAOYSA-N","InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3","CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","4,6-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","54717876","TXDLBIHXLIOKOO-UHFFFAOYSA-N","InChI=1S/C18H16N2O4/c1-19(11-6-4-3-5-7-11)17(23)15-16(22)13-10-12(21)8-9-14(13)20(2)18(15)24/h3-10,21-22H,1-2H3","Tuvesson,H. et al.(2000) Identification of cytochrome P4503A as the major subfamily responsible for the metabolismof roquinimex in man, Xenobiotica, 30:9, 905-914, DOI:10.1080/004982500433327"
"BIOTID00673","linomide","54676478","SGOOQMRIPALTEL-UHFFFAOYSA-N","InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3","CYP3A4","N-dealkylation of tertiary carboxamide","Human Phase I","Human","4-hydroxy-N-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","54682853","ZZCUZAQEHJPLGL-UHFFFAOYSA-N","InChI=1S/C17H14N2O3/c1-19(11-7-3-2-4-8-11)17(22)14-15(20)12-9-5-6-10-13(12)18-16(14)21/h2-10H,1H3,(H2,18,20,21)","Tuvesson,H. et al.(2000) Identification of cytochrome P4503A as the major subfamily responsible for the metabolismof roquinimex in man, Xenobiotica, 30:9, 905-914, DOI:10.1080/004982500433327"
"BIOTID00674","linomide","54676478","SGOOQMRIPALTEL-UHFFFAOYSA-N","InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3","CYP3A4","N-dealkylation of tertiary carboxamide","Human Phase I","Human","4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide","54676449","SCIYKTDXFNBCIV-UHFFFAOYSA-N","InChI=1S/C17H14N2O3/c1-19-13-10-6-5-9-12(13)15(20)14(17(19)22)16(21)18-11-7-3-2-4-8-11/h2-10,20H,1H3,(H,18,21)","Tuvesson,H. et al.(2000) Identification of cytochrome P4503A as the major subfamily responsible for the metabolismof roquinimex in man, Xenobiotica, 30:9, 905-914, DOI:10.1080/004982500433327"
"BIOTID00675","linomide","54676478","SGOOQMRIPALTEL-UHFFFAOYSA-N","InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3","CYP3A4","Hydroxylation of benzene on carbon para to an electron donating group","Human Phase I","Human","4-hydroxy-N-(4-hydroxyphenyl)-N,1-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide","54717849","JWKWHXCWAUZAOS-UHFFFAOYSA-N","InChI=1S/C18H16N2O4/c1-19(11-7-9-12(21)10-8-11)17(23)15-16(22)13-5-3-4-6-14(13)20(2)18(15)24/h3-10,21-22H,1-2H3","Tuvesson,H. et al.(2000) Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man, Xenobiotica, 30:9, 905-914, DOI:10.1080/004982500433327"
"BIOTID00676","lisofylline","501254","NSMXQKNUPPXBRG-SECBINFHSA-N","InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1","CYP3A4; CYP2A6","Hydroxylation of acyclic aliphatic secondary carbon","Human Phase I","Human","lisofylline 4,5-diol","NULL","ZJBOLBRXIQZJSF-VEDVMXKPSA-N","InChI=1S/C13H20N4O4/c1-8(18)9(19)5-4-6-17-12(20)10-11(14-7-15(10)2)16(3)13(17)21/h7-9,18-19H,4-6H2,1-3H3/t8-,9?/m1/s1","Shin, H.S. et al. (1998); CYP3A4-mediated Oxidation of Lisofylline to Lisofylline 4,5-diol in Human Liver Microsomes, Journal of Pharmaceutical Sciences, 1998, 87, 390-393"
"BIOTID00677","lisofylline","501254","NSMXQKNUPPXBRG-SECBINFHSA-N","InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1","CYP1A2","Oxidation of secondary alcohol to ketone","Human Phase I","Human","pentoxifylline","4740","BYPFEZZEUUWMEJ-UHFFFAOYSA-N","InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3","Lee, S.H. et al. (1997); Cytochrome P450 Isozymes Involved in Lisofylline Metabolism to Pentoxifylline in Human Liver Microsomes, Drug Metabolism and Disposition, 1997, 25, 1354-1358|Lillibridge. et al. (1996); Metabolism of Lisofylline and Pentoxifylline in Human Liver Microsomes and Cytosol, Drug Metabolism and Disposition, 1996, 24, 1174-1179|Shin, H.S. et al. (1998); CYP3A4-mediated Oxidation of Lisofylline to Lisofylline 4,5-diol in Human Liver Microsomes, Journal of Pharmaceutical Sciences, 1998, 87, 390-393"
"BIOTID00678","loperamide","3955","RDOIQAHITMMDAJ-UHFFFAOYSA-N","InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3","CYP3A4; CYP2D6; CYP2C8; CYP2B6","N-dealkylation of tertiary carboxamide","Human Phase I","Human","N-Desmethyloperamide","9805944","ZMOPTLXEYOVARP-UHFFFAOYSA-N","InChI=1S/C28H31ClN2O2/c1-30-26(32)28(23-8-4-2-5-9-23,24-10-6-3-7-11-24)18-21-31-19-16-27(33,17-20-31)22-12-14-25(29)15-13-22/h2-15,33H,16-21H2,1H3,(H,30,32)","Kalgutkar, A.S. et al. (2004); IDENTIFICATION OF AN N-METHYL-4-PHENYLPYRIDINIUM-LIKE METABOLITE OF THE ANTIDIARRHEAL AGENT LOPERAMIDE IN HUMAN LIVER MICROSOMES: UNDER LYING REASON(S) FOR THE LACK OF NEUROTOXICITY DESPITE THE BIOACTIVATION EVENT,  DRUG METABOLISM  AND DISPOSITION, 2004, 32, 943Ã¢â‚¬â€œ952|Yue, L. et al. (2016); Identification of novel small-molecule inhibitors targeting meninÃ¢â‚¬â€œMLL interaction, repurposing the antidiarrheal loperamide, Organic & Biomolecular Chemistry, 2016, 14, 8503-8519|Niemi, M. et al. (2006); Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide, Eur J Clin Pharmacol 2006, 62: 463Ã¢â‚¬â€œ472, DOI:10.1007/s00228-006-0133-z|Kim, K-A. et al. (2004); Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes,  Eur J Clin Pharmacol, 2004, 60, 575Ã¢â‚¬â€œ581, DOI 10.1007/s00228-004-0815-3"
"BIOTID00679","loratadine","3957","JCCNYMKQOSZNPW-UHFFFAOYSA-N","InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3","CYP1A2;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP3A4","N_DEALKYLATION","Human Phase I","Human","NULL","124087","JAUOIFJMECXRGI-UHFFFAOYSA-N","InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|PMID:19702548"
"BIOTID00680","lornoxicam","54690031","WLHQHAUOOXYABV-UHFFFAOYSA-N","InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)","CYP2C9 ","HYDROXYLATION_OF_HETEROAROMATIC_CARBON","Human Phase I","Human","5'-Hydroxylornoxicam","54691489","NQOMZUZLRFQVLR-UHFFFAOYSA-N","InChI=1S/C13H10ClN3O5S2/c1-17-10(13(20)16-9-3-2-6(18)5-15-9)11(19)12-7(24(17,21)22)4-8(14)23-12/h2-5,18-19H,1H3,(H,15,16,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00681","losartan","3961","PSIFNNKUMBGKDQ-UHFFFAOYSA-N","InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)","CYP2C9; CYP3A4; CYP3A5","OXIDATION_OF_PRIM_ALCOHOL_TO_CARBOXYLIC_ACID","Human Phase I","Human","E-3174","108185","ZEUXAIYYDDCIRX-UHFFFAOYSA-N","InChI=1S/C22H21ClN6O2/c1-2-3-8-18-24-20(23)19(22(30)31)29(18)13-14-9-11-15(12-10-14)16-6-4-5-7-17(16)21-25-27-28-26-21/h4-7,9-12H,2-3,8,13H2,1H3,(H,30,31)(H,25,26,27,28)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ekins, S. and Wrighton, S.A. (1999); The role of CYP2B6 in Human Xenobiotic Metabolism; Drug Metabolism Reviews, 31:3, 719-754, DOI:10.1081/ DMR-100101942; PMID:10461547|Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00682","losartan carboxaldehyde","9802264","FQZSMTSTFMNWQF-UHFFFAOYSA-N","InChI=1S/C22H21ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,14H,2-3,8,13H2,1H3,(H,25,26,27,28)","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","KMCNHKMBFGXFMW-UHFFFAOYSA-N","InChI=1S/C22H21ClN6O2/c1-2-5-19(31)22-24-20(23)18(13-30)29(22)12-14-8-10-15(11-9-14)16-6-3-4-7-17(16)21-25-27-28-26-21/h3-4,6-11,13,19,31H,2,5,12H2,1H3,(H,25,26,27,28)","PMID:7736913"
"BIOTID00683","losartan carboxaldehyde","9802264","FQZSMTSTFMNWQF-UHFFFAOYSA-N","InChI=1S/C22H21ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,14H,2-3,8,13H2,1H3,(H,25,26,27,28)","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","108185","ZEUXAIYYDDCIRX-UHFFFAOYSA-N","InChI=1S/C22H21ClN6O2/c1-2-3-8-18-24-20(23)19(22(30)31)29(18)13-14-9-11-15(12-10-14)16-6-4-5-7-17(16)21-25-27-28-26-21/h4-7,9-12H,2-3,8,13H2,1H3,(H,30,31)(H,25,26,27,28)","PMID:7736913"
"BIOTID00684","lovastatin","53232","PCZOHLXUXFIOCF-BXMDZJJMSA-N","InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1","CYP3A4","Hydroxylation of penultimate aliphatic tertiary carbon","Human Phase I","Human","6'beta-Hydroxylovastatin","68178378","FUCXPWLYQFERRA-QOPMPQMQSA-N","InChI=1S/C24H36O6/c1-5-14(2)23(27)30-20-13-24(4,28)12-16-7-6-15(3)19(22(16)20)9-8-18-10-17(25)11-21(26)29-18/h6-7,12,14-15,17-20,22,25,28H,5,8-11,13H2,1-4H3/t14-,15-,17+,18+,19-,20-,22-,24+/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Jacobsen, W. et al. (1999); Comparison of Cytochrome P-450-Dependent Metabolism and Drug Interactions of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Lovastatin and Pravastatin in the Liver; DRUG METABOLISM  AND DISPOSITION, 1999, 27, 173Ã¢â‚¬â€œ179|Wang, R.W. et al. (1991); Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes; Archives of Biochemistry and Biophysics, 1991, 290, 355-361|Caron, G. et al. (2007); Predicting the Oxidative Metabolism of Statins: An Application of the MetaSite Algorithm; Pharmaceutical Research, 2007, 24, 480-501"
"BIOTID00686","lovastatin","53232","PCZOHLXUXFIOCF-BXMDZJJMSA-N","InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1","CYP3A4","Hydroxylation of acyclic aliphatic secondary carbon","Human Phase I","Human","3-Hydroxylovastatin","NULL","BFOCOHWMHIGTLP-PCXYPTFZSA-N","InChI=1S/C23H34O6/c1-4-19(25)23(27)29-20-10-13(2)9-15-6-5-14(3)18(22(15)20)8-7-17-11-16(24)12-21(26)28-17/h5-6,9,13-14,16-20,22,24-25H,4,7-8,10-12H2,1-3H3/t13-,14-,16+,17+,18-,19-,20-,22-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Jacobsen, W. et al. (1999); Comparison of Cytochrome P-450-Dependent Metabolism and Drug Interactions of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Lovastatin and Pravastatin in the Liver; DRUG METABOLISM  AND DISPOSITION, 1999, 27, 173Ã¢â‚¬â€œ179|Wang, R.W. et al. (1991); Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes; Archives of Biochemistry and Biophysics, 1991, 290, 355-361|Caron, G. et al. (2007); Predicting the Oxidative Metabolism of Statins: An Application of the MetaSite Algorithm; Pharmaceutical Research, 2007, 24, 480-501"
"BIOTID00687","m-xylene","7929","IVSZLXZYQVIEFR-UHFFFAOYSA-N","InChI=1S/C8H10/c1-7-4-3-5-8(2)6-7/h3-6H,1-2H3","CYP1A2","2-Hydroxylation of 1,4-disubstituted benzene","Human Phase I","Human","2,4-Dimethylphenol","7771","KUFFULVDNCHOFZ-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-6-3-4-8(9)7(2)5-6/h3-5,9H,1-2H3","Tassaneeyakul, W. et al. (1996); Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene, The Journal of Pharmacology and Experimental Therapeutics January 1996,  276, 101-108"
"BIOTID00688","m-xylene","7929","IVSZLXZYQVIEFR-UHFFFAOYSA-N","InChI=1S/C8H10/c1-7-4-3-5-8(2)6-7/h3-6H,1-2H3","CYP2E1","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","3-Methylbenzylalcohol","11476","JJCKHVUTVOPLBV-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-7-3-2-4-8(5-7)6-9/h2-5,9H,6H2,1H3","Tassaneeyakul, W. et al. (1996); Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene, The Journal of Pharmacology and Experimental Therapeutics January 1996,  276, 101-108"
"BIOTID00689","maprotiline","4011","QSLMDECMDJKHMQ-GSXCWMCISA-N","InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3","CYP2D6; CYP1A2","N-dealkylation of acyclic secondary amine","Human Phase I","Human","desmethylmaprotiline","119409","IFHUOEQJTQWFGJ-UHFFFAOYSA-N","InChI=1S/C19H21N/c20-13-5-11-19-12-10-14(15-6-1-3-8-17(15)19)16-7-2-4-9-18(16)19/h1-4,6-9,14H,5,10-13,20H2","Regioselective Metabolism of Toluene and o-, m- and p-Xylene1|PMID:12071336"
"BIOTID00690","maprotiline","4011","QSLMDECMDJKHMQ-GSXCWMCISA-N","InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3","CYP2D6; CYP1A2","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","3-OH-maprotiline","NULL","XEIQDMGVTYYHBG-UHFFFAOYSA-N","InChI=1S/C20H23NO/c1-21-12-4-10-20-11-9-15(16-5-2-3-6-18(16)20)17-8-7-14(22)13-19(17)20/h2-3,5-8,13,15,21-22H,4,9-12H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|PMID:12071336"
"BIOTID00691","maprotiline","4011","QSLMDECMDJKHMQ-GSXCWMCISA-N","InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3","CYP2D6; CYP1A2","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2-OH-maprotiline","58600339","RGTALAKWLKCOBO-UHFFFAOYSA-N","InChI=1S/C20H23NO/c1-21-12-4-10-20-11-9-15(16-5-2-3-6-18(16)20)17-13-14(22)7-8-19(17)20/h2-3,5-8,13,15,21-22H,4,9-12H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|PMID:12071336"
"BIOTID00692","mefenamic acid","4044","HYYBABOKPJLUIN-UHFFFAOYSA-N","InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)","CYP2C9 ","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","3-hydroxymethyl mefenamic aci","610738","QBONJEHEDCBRMZ-UHFFFAOYSA-N","InChI=1S/C15H15NO3/c1-10-11(9-17)5-4-8-13(10)16-14-7-3-2-6-12(14)15(18)19/h2-8,16-17H,9H2,1H3,(H,18,19)","Hug, F. (2007); Molecular Modelling Analysis of the Metabolism of Mefenamic Acid. Journal of Pharmacology and Toxicology, 2: 72-79; DOI:10.3923/jpt.2007.72.79"
"BIOTID00693","meiqx","62275","DVCCCQNKIYNAKB-UHFFFAOYSA-N","InChI=1S/C11H11N5/c1-6-5-13-7-3-4-8-10(9(7)14-6)15-11(12)16(8)2/h3-5H,1-2H3,(H2,12,15)","CYP1A2","N-hydroxylation of primary arylamine","Human Phase I","Human","N-OH-MeIQX","NULL","FVNCCTJGBOTWTM-UHFFFAOYSA-N","InChI=1S/C11H11N5O/c1-6-5-12-7-3-4-8-10(9(7)13-6)14-11(15-17)16(8)2/h3-5,17H,1-2H3,(H,14,15)","Fujita, K. et al. (2002). Down-regulation of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)-induced CYP1A2 expression is associated with bovine lactoferrin inhibition of MeIQx-induced liver and colon carcinogenesis in rats. PMID:12079509"
"BIOTID00694","meiqx","62275","DVCCCQNKIYNAKB-UHFFFAOYSA-N","InChI=1S/C11H11N5/c1-6-5-13-7-3-4-8-10(9(7)14-6)15-11(12)16(8)2/h3-5H,1-2H3,(H2,12,15)","CYP1A2","OXIDATION_OF_METHYL_TO_CARBOXYLIC_ACID","Human Phase I","Human","IQx-8-COOH","85785449","NKWBDQYTYVRHRD-UHFFFAOYSA-N","InChI=1S/C11H9N5O2/c1-16-7-3-2-5-8(9(7)15-11(16)12)14-6(4-13-5)10(17)18/h2-4H,1H3,(H2,12,15)(H,17,18)","Fujita, K. et al. (2002). Down-regulation of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)-induced CYP1A2 expression is associated with bovine lactoferrin inhibition of MeIQx-induced liver and colon carcinogenesis in rats. PMID:12079509"
"BIOTID00695","melatonin","896","DRLFMBDRBRZALE-UHFFFAOYSA-N","InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)","CYP1A1; CYP1A2; CYP2C19 (minor); CYP2E1","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-Hydroxymelatonin","1864","OMYMRCXOJJZYKE-UHFFFAOYSA-N","InChI=1S/C13H16N2O3/c1-8(16)14-4-3-9-7-15-11-6-12(17)13(18-2)5-10(9)11/h5-7,15,17H,3-4H2,1-2H3,(H,14,16)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Kazumi, Y.Y. et al. (2011); Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order; Drug Metabolism Reviews; 43:4; 409-439; DOI:10.3109/03602532.2011.624103; PMID:22017508"
"BIOTID00696","melatonin","896","DRLFMBDRBRZALE-UHFFFAOYSA-N","InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)","CYP2C19 (major); CYP1A2; CYP2E1","O-aryl demethylation","Human Phase I","Human","N-Acetyl-5-hydroxytryptamine","903","MVAWJSIDNICKHF-UHFFFAOYSA-N","InChI=1S/C12H14N2O2/c1-8(15)13-5-4-9-7-14-12-3-2-10(16)6-11(9)12/h2-3,6-7,14,16H,4-5H2,1H3,(H,13,15)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Kazumi, Y.Y. et al. (2011); Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order; Drug Metabolism Reviews; 43:4; 409-439; DOI:10.3109/03602532.2011.624103; PMID:22017508"
"BIOTID00697","meloxicam","54677470","ZRVUJXDFFKFLMG-UHFFFAOYSA-N","InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)","CYP2C9;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","54738103","LOOSAJMIEADILV-UHFFFAOYSA-N","InChI=1S/C14H13N3O5S2/c1-17-11(13(20)16-14-15-6-8(7-18)23-14)12(19)9-4-2-3-5-10(9)24(17,21)22/h2-6,18-19H,7H2,1H3,(H,15,16,20)","PMID:9493314"
"BIOTID00698","meperidine","4058","XADCESSVHJOZHK-UHFFFAOYSA-N","InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3","CYP1A2;CYP2B6;CYP2C8;CYP2C19;CYP2D6;CYP3A4","N-DEMETHYLATION","Human Phase I","Human","normeperidine","32414","QKHMFBKXTNQCTM-UHFFFAOYSA-N","InChI=1S/C14H19NO2/c1-2-17-13(16)14(8-10-15-11-9-14)12-6-4-3-5-7-12/h3-7,15H,2,8-11H2,1H3","PMID:15319333"
"BIOTID00699","methaqualone","6292","JEYCTXHKTXCGPB-UHFFFAOYSA-N","InChI=1S/C16H14N2O/c1-11-7-3-6-10-15(11)18-12(2)17-14-9-5-4-8-13(14)16(18)19/h3-10H,1-2H3","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","hydroxy-methaqualone","21143","HIYZKXXSRNPSQJ-UHFFFAOYSA-N","InChI=1S/C16H14N2O2/c1-10-9-12(19)7-8-15(10)18-11(2)17-14-6-4-3-5-13(14)16(18)20/h3-9,19H,1-2H3","PMID:12900872"
"BIOTID00700","methaqualone","6292","JEYCTXHKTXCGPB-UHFFFAOYSA-N","InChI=1S/C16H14N2O/c1-11-7-3-6-10-15(11)18-12(2)17-14-9-5-4-8-13(14)16(18)19/h3-10H,1-2H3","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","hydroxy-methaqualone","619742","GALCYPRSOBYHHW-UHFFFAOYSA-N","InChI=1S/C16H14N2O2/c1-10-14(8-5-9-15(10)19)18-11(2)17-13-7-4-3-6-12(13)16(18)20/h3-9,19H,1-2H3","PMID:12900872"
"BIOTID00701","methaqualone","6292","JEYCTXHKTXCGPB-UHFFFAOYSA-N","InChI=1S/C16H14N2O/c1-11-7-3-6-10-15(11)18-12(2)17-14-9-5-4-8-13(14)16(18)19/h3-10H,1-2H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","hydroxy-methaqualone","63122","VHBSPUXYKQNPJR-UHFFFAOYSA-N","InChI=1S/C16H14N2O2/c1-11-17-14-8-4-3-7-13(14)16(20)18(11)15-9-5-2-6-12(15)10-19/h2-9,19H,10H2,1H3","PMID:12900872"
"BIOTID00702","methoxsalen","4114","QXKHYNVANLEOEG-UHFFFAOYSA-N","InChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3","CYP2A6","Epoxidation","Human Phase I","Human","NULL","NULL","YSTVXEFXPUPSCK-UHFFFAOYSA-N","InChI=1S/C12H8O5/c1-14-11-8-5(2-3-7(13)15-8)4-6-9(11)16-12-10(6)17-12/h2-4,10,12H,1H3","PMID:9665710"
"BIOTID00703","methyleugenol","7127","ZYEMGPIYFIJGTP-UHFFFAOYSA-N","InChI=1S/C11H14O2/c1-4-5-9-6-7-10(12-2)11(8-9)13-3/h4,6-8H,1,5H2,2-3H3","CYP1A2;CYP2C9;CYP2C19;CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","1Ã¢â‚¬Ëœ-hydroxylate methyleugenol","198104","DFQDENBMPURIHD-UHFFFAOYSA-N","InChI=1S/C11H14O3/c1-4-9(12)8-5-6-10(13-2)11(7-8)14-3/h4-7,9,12H,1H2,2-3H3","PMID:16411663"
"BIOTID00704","metoclopramide","4168","TTWJBBZEZQICBI-UHFFFAOYSA-N","InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)","CYP1A2;CYP2C8;CYP2C19;CYP2D6;CYP3A4","N-dealkylation","Human Phase I","Human","monodeethylmetoclopramide","33761","RTQMQUZXBADBGJ-UHFFFAOYSA-N","InChI=1S/C12H18ClN3O2/c1-3-15-4-5-16-12(17)8-6-9(13)10(14)7-11(8)18-2/h6-7,15H,3-5,14H2,1-2H3,(H,16,17)","PMID:11854155"
"BIOTID00705","midazolam","4192","DDLIGBOFAVUZHB-UHFFFAOYSA-N","InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3","CYP3A4; CYP3A5; CYP3A7; CYP2B6","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","1'-Hydroxymidazolam","107917","QHSMEGADRFZVNE-UHFFFAOYSA-N","InChI=1S/C18H13ClFN3O/c19-11-5-6-16-14(7-11)18(13-3-1-2-4-15(13)20)22-9-12-8-21-17(10-24)23(12)16/h1-8,24H,9-10H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Khan, K. K. et al. (2002); Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation; Mol. Pharmacol. 61:495Ã¢â‚¬â€œ506|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00706","midazolam","4192","DDLIGBOFAVUZHB-UHFFFAOYSA-N","InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3","CYP3A4; CYP3A5; CYP3A7","3-Hydroxylation of 5-aryl-1,4-benzodiazepine","Human Phase I","Human","4-Hydroxymidazolam","124449","ZYISITHKPKHPKG-UHFFFAOYSA-N","InChI=1S/C18H13ClFN3O/c1-10-21-9-16-18(24)22-17(12-4-2-3-5-14(12)20)13-8-11(19)6-7-15(13)23(10)16/h2-9,18,24H,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Khan, K. K. et al. (2002); Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation; Mol. Pharmacol. 61:495Ã¢â‚¬â€œ506|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00707","mifepristone","55245","VKHAHZOOUSRJNA-GCNJZUOMSA-N","InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1","CYP3A4","N-dealkylation of mixed tertiary amine","Human Phase I","Human","Monodemethylated mifepristone","10070462","IBLXOBHABOVXDY-WKWWZUSTSA-N","InChI=1S/C28H33NO2/c1-4-14-28(31)15-13-25-23-11-7-19-16-21(30)10-12-22(19)26(23)24(17-27(25,28)2)18-5-8-20(29-3)9-6-18/h5-6,8-9,16,23-25,29,31H,7,10-13,15,17H2,1-3H3/t23-,24+,25-,27-,28-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Khan, K. K. et al. (2002); Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation; Mol. Pharmacol. 61:495Ã¢â‚¬â€œ506|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996016"
"BIOTID00708","mifepristone","55245","VKHAHZOOUSRJNA-GCNJZUOMSA-N","InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1","CYP3A4","Aliphatic hydroxylation of methyl carbon adjacent to alkyne ring","Human Phase I","Human","17alpha-hydroxymifepristone ","13605512","ULLTWLWXPJPTQG-GCNJZUOMSA-N","InChI=1S/C29H35NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,7,10-13,15-16,18H2,1-3H3/t24-,25+,26-,28-,29-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Khan, K. K. et al. (2002); Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation; Mol. Pharmacol. 61:495Ã¢â‚¬â€œ506|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996018"
"BIOTID00709","minaprine","4199","LDMWSLGGVTVJPG-UHFFFAOYSA-N","InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)","CYP2D6","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4-Hydroxyminaprine","NULL","ADRHYFBXMFKHDO-UHFFFAOYSA-N","InChI=1S/C17H22N4O2/c1-13-12-16(14-2-4-15(22)5-3-14)19-20-17(13)18-6-7-21-8-10-23-11-9-21/h2-5,12,22H,6-11H2,1H3,(H,18,20)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00710","miocamycin","5282188","GQNZGCARKRHPOH-QZYHRENMSA-N","InChI=1S/C45H71NO17/c1-13-34(50)59-33-23-36(52)55-26(4)18-16-15-17-19-32(58-29(7)48)25(3)22-31(20-21-47)41(42(33)54-12)62-44-39(53)38(46(10)11)40(27(5)57-44)61-37-24-45(9,63-30(8)49)43(28(6)56-37)60-35(51)14-2/h15-17,19,21,25-28,31-33,37-44,53H,13-14,18,20,22-24H2,1-12H3/b16-15+,19-17+/t25-,26-,27-,28-,31+,32+,33-,37+,38+,39-,40-,41+,42-,43+,44-,45-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","WRCOPPWOVNIXRA-FNIFWQFPSA-N","InChI=1S/C45H71NO18/c1-13-34(50)60-33-23-36(52)56-26(4)18-16-15-17-19-32(59-29(7)48)25(3)22-31(20-21-47)41(42(33)55-12)62-43-39(53)38(46(10)11)40(27(5)57-43)61-37-24-44(9,63-30(8)49)45(54,28(6)58-37)64-35(51)14-2/h15-17,19,21,25-28,31-33,37-43,53-54H,13-14,18,20,22-24H2,1-12H3/b16-15+,19-17+","PMID:10725309"
"BIOTID00711","montelukast","5281040","UCHDWCPVSPXUMX-TZIWLTJVSA-N","InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1","CYP3A4; CYP2A6","S-oxidation of dialkylthioether to sulfoxide","Human Phase I","Human","montelukast sulfoxide","15297728","QFTNWCBEAVHLQA-XNHCCDLUSA-N","InChI=1S/C35H36ClNO4S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(42(41)23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-,42?/m1/s1","R1) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00712","montelukast","5281040","UCHDWCPVSPXUMX-TZIWLTJVSA-N","InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1","CYP3A4","Hydroxylation of acyclic aliphatic secondary carbon","Human Phase I","Human","21-Hydroxymontelukast","11801753","CHRNGXJVKOMERP-FPUIOERCSA-N","InChI=1S/C35H36ClNO4S/c1-34(2,41)29-9-4-3-8-28(29)31(38)20-32(42-22-35(16-17-35)21-33(39)40)25-7-5-6-23(18-25)10-14-27-15-12-24-11-13-26(36)19-30(24)37-27/h3-15,18-19,31-32,38,41H,16-17,20-22H2,1-2H3,(H,39,40)/b14-10+/t31-,32-/m1/s1","R1) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3676"
"BIOTID00713","montelukast","5281040","UCHDWCPVSPXUMX-TZIWLTJVSA-N","InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1","CYP3A4","Hydroxylation of acyclic aliphatic secondary carbon","Human Phase I","Human","[1Ã¢â‚¬Â({[(1R,3S)Ã¢â‚¬Â1Ã¢â‚¬Â{3Ã¢â‚¬Â[(E)Ã¢â‚¬Â2Ã¢â‚¬Â(7Ã¢â‚¬ÂchloroquinolinÃ¢â‚¬Â2Ã¢â‚¬Âyl)ethenyl]phenyl}Ã¢â‚¬Â3Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â3Ã¢â‚¬Â[2Ã¢â‚¬Â(2Ã¢â‚¬ÂhydroxypropanÃ¢â‚¬Â2Ã¢â‚¬Âyl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]aceticacid","10841306","CHRNGXJVKOMERP-SIOAQITRSA-N","InChI=1S/C35H36ClNO4S/c1-34(2,41)29-9-4-3-8-28(29)31(38)20-32(42-22-35(16-17-35)21-33(39)40)25-7-5-6-23(18-25)10-14-27-15-12-24-11-13-26(36)19-30(24)37-27/h3-15,18-19,31-32,38,41H,16-17,20-22H2,1-2H3,(H,39,40)/b14-10+/t31-,32+/m0/s1","R1) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3677"
"BIOTID00714","montelukast","5281040","UCHDWCPVSPXUMX-TZIWLTJVSA-N","InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1","CYP2C9","Hydroxylation of terminal methyl","Human Phase I","Human","[1Ã¢â‚¬Â({[(1R)Ã¢â‚¬Â1Ã¢â‚¬Â{3Ã¢â‚¬Â[(E)Ã¢â‚¬Â2Ã¢â‚¬Â(7Ã¢â‚¬ÂchloroquinolinÃ¢â‚¬Â2Ã¢â‚¬Âyl)ethenyl]phenyl}Ã¢â‚¬Â3Ã¢â‚¬Â[2Ã¢â‚¬Â(1,2Ã¢â‚¬ÂdihydroxypropanÃ¢â‚¬Â2Ã¢â‚¬Âyl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]aceticacid","9960377","UFQIEVSCRCMNLW-SHISVWIYSA-N","InChI=1S/C35H36ClNO4S/c1-34(41,22-38)30-8-3-2-6-25(30)12-16-32(42-23-35(17-18-35)21-33(39)40)27-7-4-5-24(19-27)9-14-29-15-11-26-10-13-28(36)20-31(26)37-29/h2-11,13-15,19-20,32,38,41H,12,16-18,21-23H2,1H3,(H,39,40)/b14-9+/t32-,34?/m1/s1","R1) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3678"
"BIOTID00715","morphine","NULL","ICXVGHUORQNRQF-NOSXKOESSA-N","InChI=1S/C17H19NO3/c1-18-7-10-6-9-2-4-12(19)15-14(9)17(8-18)11(10)3-5-13(20)16(17)21-15/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13+,16-,17-/m0/s1","CYP2C8;CYP3A4","O-Demethylation","Human Phase I","Human","Normorphine","NULL","VTJHNWBFCNJIRW-UHFFFAOYSA-N","InChI=1S/C16H17NO3/c18-11-3-1-8-5-9-6-17-7-16-10(9)2-4-12(19)15(16)20-14(11)13(8)16/h1-4,9-10,12,15,17-19H,5-7H2","PMID:12936704"
"BIOTID00716","muraglitazar","206044","IRLWJILLXJGJTD-UHFFFAOYSA-N","InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)","CYP2C8;CYP2D6","O-Demethylation","Human Phase I","Human","NULL","44448345","IDSGPTAKWHAXDL-UHFFFAOYSA-N","InChI=1S/C28H26N2O7/c1-19-25(29-27(36-19)21-5-3-2-4-6-21)15-16-35-23-11-7-20(8-12-23)17-30(18-26(32)33)28(34)37-24-13-9-22(31)10-14-24/h2-14,31H,15-18H2,1H3,(H,32,33)","PMID:17062778"
"BIOTID00717","muraglitazar","206044","IRLWJILLXJGJTD-UHFFFAOYSA-N","InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)","CYP2C8;CYP2C9;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","44448403","SZQYQVHETQTNHR-UHFFFAOYSA-N","InChI=1S/C29H28N2O8/c1-36-22-11-13-24(14-12-22)38-29(35)31(18-27(33)34)17-20-7-9-23(10-8-20)37-16-15-25-26(19-32)39-28(30-25)21-5-3-2-4-6-21/h2-14,32H,15-19H2,1H3,(H,33,34)","PMID:17062778"
"BIOTID00718","muraglitazar","206044","IRLWJILLXJGJTD-UHFFFAOYSA-N","InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","44448594","UACPJKHKQTVBSZ-UHFFFAOYSA-N","InChI=1S/C29H28N2O8/c1-19-27(30-28(38-19)21-6-4-3-5-7-21)25(32)18-37-23-10-8-20(9-11-23)16-31(17-26(33)34)29(35)39-24-14-12-22(36-2)13-15-24/h3-15,25,32H,16-18H2,1-2H3,(H,33,34)","PMID:17062778"
"BIOTID00719","muraglitazar","206044","IRLWJILLXJGJTD-UHFFFAOYSA-N","InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)","CYP2C19","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","RIPSACORXYUVGG-UHFFFAOYSA-N","InChI=1S/C29H28N2O8/c1-19-26(30-28(38-19)21-5-7-22(32)8-6-21)15-16-37-24-9-3-20(4-10-24)17-31(18-27(33)34)29(35)39-25-13-11-23(36-2)12-14-25/h3-14,32H,15-18H2,1-2H3,(H,33,34)","PMID:17062778"
"BIOTID00720","muraglitazar","206044","IRLWJILLXJGJTD-UHFFFAOYSA-N","InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)","CYP2C8;CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","44448487","GQHGGKPOZFTGOJ-UHFFFAOYSA-N","InChI=1S/C17H17NO6/c1-23-14-6-8-15(9-7-14)24-17(22)18(11-16(20)21)10-12-2-4-13(19)5-3-12/h2-9,19H,10-11H2,1H3,(H,20,21)","PMID:17062778"
"BIOTID00723","mycophenolic acid","446541","HPNSFSBZBAHARI-RUDMXATFSA-N","InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+","CYP3A4","O-Desmethylation","Human Phase I","Human","6-O-desmethyl-MPA (DM-MPA)","25879063","MHSRNZSBNXFMLF-FPYGCLRLSA-N","InChI=1S/C16H18O6/c1-8(4-6-12(17)18)3-5-10-14(19)9(2)11-7-22-16(21)13(11)15(10)20/h3,19-20H,4-7H2,1-2H3,(H,17,18)/b8-3+","PMID:15570183"
"BIOTID00724","myristicin","4276","BNWJOHGLIBDBOB-UHFFFAOYSA-N","InChI=1S/C11H12O3/c1-3-4-8-5-9(12-2)11-10(6-8)13-7-14-11/h3,5-6H,1,4,7H2,2H3","CYP3A4;CYP1A2","Nifedipine Oxidation","Human Phase I","Human","5-allyl-1-methoxy-2,3-dihydroxybenzene","11389746","BHIIRUKUMCZDIB-UHFFFAOYSA-N","InChI=1S/C10H12O3/c1-3-4-7-5-8(11)10(12)9(6-7)13-2/h3,5-6,11-12H,1,4H2,2H3","PMID:12523956"
"BIOTID00725","n_ac_dfec","NULL","ZONTWFMTDBGILI-WDSKDSINSA-N","InChI=1S/C9H12F5NO4S/c1-4(16)15-5(8(17)18)2-20-9(13,14)6(7(11)12)19-3-10/h5-7H,2-3H2,1H3,(H,15,16)(H,17,18)/t5-,6-/m0/s1","CYP3A4","S-Oxidation","Human Phase I","Human","N-Ac-DFEC-SO","NULL","FNTSAOIDRZFDOF-UHFFFAOYSA-N","InChI=1S/C9H12F5NO5S/c1-4(16)15-5(8(17)18)2-21(19)9(13,14)6(7(11)12)20-3-10/h5-7H,2-3H2,1H3,(H,15,16)(H,17,18)","PMID:15025515"
"BIOTID00726","n_ac_ffvc","NULL","JAZJDNUIJLZFSZ-GZNKVARCSA-N","InChI=1S/C9H11F4NO4S/c1-4(15)14-5(9(16)17)2-19-8(13)6(7(11)12)18-3-10/h5,7H,2-3H2,1H3,(H,14,15)(H,16,17)/b8-6+/t5-/m0/s1","CYP3A4","S-Oxidation","Human Phase I","Human","N-Ac-FFVC-SO","NULL","JMSBQPHJPYIRCM-VBWAOCSMSA-N","InChI=1S/C9H11F4NO5S/c1-4(15)14-5(9(16)17)2-20(18)8(13)6(7(11)12)19-3-10/h5,7H,2-3H2,1H3,(H,14,15)(H,16,17)/b8-6+/t5-,20?/m0/s1","PMID:15025515"
"BIOTID00727","n_ac_pcbc","NULL","GEAIQETWXSVTMO-CBABADBVSA-N","InChI=1S/C7H6Cl5NO2S/c8-3(5(10)11)4(9)6(12)16-1-2(13)7(14)15/h2H,1,13H2,(H,14,15)/b6-4+/t2-/m0/s1","CYP3A4","S-Oxidation","Human Phase I","Human","N-Ac-PCBC-SO","NULL","HWPJYCDRWJJGFK-GPCKVJEVSA-N","InChI=1S/C7H6Cl5NO3S/c8-3(5(10)11)4(9)6(12)17(16)1-2(13)7(14)15/h2H,1,13H2,(H,14,15)/b6-4+/t2-,17?/m0/s1","PMID:8555406"
"BIOTID00728","n-({4-[(5-bromopyrimidin-2-yl)oxy]-3-methylphenyl}carbamoyl)-2-(dimethylamino)benzamide","368697","JNGQUJZDVFZPEN-UHFFFAOYSA-N","InChI=1S/C21H20BrN5O3/c1-13-10-15(8-9-18(13)30-21-23-11-14(22)12-24-21)25-20(29)26-19(28)16-6-4-5-7-17(16)27(2)3/h4-12H,1-3H3,(H2,25,26,28,29)","CYP1A1;CYP2D6;CYP2C9;CYP3A4;CYP3A5;CYP3A7","N-Demethylation","Human Phase I","Human","mmBPU","10253524","QPXHZBJIVOTXDI-UHFFFAOYSA-N","InChI=1S/C20H18BrN5O3/c1-12-9-14(7-8-17(12)29-20-23-10-13(21)11-24-20)25-19(28)26-18(27)15-5-3-4-6-16(15)22-2/h3-11,22H,1-2H3,(H2,25,26,27,28)","PMID:16322314"
"BIOTID00729","n-(2-phenylethyl)indomethacin amide","4292","VYDBTNADENXYSN-UHFFFAOYSA-N","InChI=1S/C27H25ClN2O3/c1-18-23(17-26(31)29-15-14-19-6-4-3-5-7-19)24-16-22(33-2)12-13-25(24)30(18)27(32)20-8-10-21(28)11-9-20/h3-13,16H,14-15,17H2,1-2H3,(H,29,31)","CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","AOIQKSHKQIJFMK-UHFFFAOYSA-N","InChI=1S/C27H25ClN2O4/c1-17-22(15-26(32)29-16-25(31)18-6-4-3-5-7-18)23-14-21(34-2)12-13-24(23)30(17)27(33)19-8-10-20(28)11-9-19/h3-14,25,31H,15-16H2,1-2H3,(H,29,32)","PMID:14709628"
"BIOTID00730","n-(2-phenylethyl)indomethacin amide","4292","VYDBTNADENXYSN-UHFFFAOYSA-N","InChI=1S/C27H25ClN2O3/c1-18-23(17-26(31)29-15-14-19-6-4-3-5-7-19)24-16-22(33-2)12-13-25(24)30(18)27(32)20-8-10-21(28)11-9-20/h3-13,16H,14-15,17H2,1-2H3,(H,29,31)","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","AIUSZASLWVMSGU-UHFFFAOYSA-N","InChI=1S/C27H25ClN2O4/c1-17-22(16-26(32)29-25(31)14-18-6-4-3-5-7-18)23-15-21(34-2)12-13-24(23)30(17)27(33)19-8-10-20(28)11-9-19/h3-13,15,25,31H,14,16H2,1-2H3,(H,29,32)","PMID:14709628"
"BIOTID00731","n-(2-phenylethyl)indomethacin amide","4292","VYDBTNADENXYSN-UHFFFAOYSA-N","InChI=1S/C27H25ClN2O3/c1-18-23(17-26(31)29-15-14-19-6-4-3-5-7-19)24-16-22(33-2)12-13-25(24)30(18)27(32)20-8-10-21(28)11-9-20/h3-13,16H,14-15,17H2,1-2H3,(H,29,31)","CYP2C9;CYP2C19;CYP2D6","O-Demethylation","Human Phase I","Human","NULL","NULL","HDTYXEUHBXMELH-UHFFFAOYSA-N","InChI=1S/C26H23ClN2O3/c1-17-22(16-25(31)28-14-13-18-5-3-2-4-6-18)23-15-21(30)11-12-24(23)29(17)26(32)19-7-9-20(27)10-8-19/h2-12,15,30H,13-14,16H2,1H3,(H,28,31)","PMID:14709628"
"BIOTID00732","n-methylformamide","31254","ATHHXGZTWNVVOU-UHFFFAOYSA-N","InChI=1S/C2H5NO/c1-3-2-4/h2H,1H3,(H,3,4)","CYP2E1","Oxidation of alkyl formamide","Human Phase I","Human","Methyl Isocyanate","12228","HAMGRBXTJNITHG-UHFFFAOYSA-N","InChI=1S/C2H3NO/c1-3-2-4/h1H3","J. Bolleddula et al.; Drug Metab Rev, 2014; 46(3): 379Ã¢â‚¬â€œ419"
"BIOTID00733","n-nitroso-n-methylaniline (NMPhA)","11957","MAXCWSIJKVASQC-UHFFFAOYSA-N","InChI=1S/C7H8N2O/c1-9(8-10)7-5-3-2-4-6-7/h2-6H,1H3","CYP2A6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","YDUKDBWXYYKCDO-UHFFFAOYSA-N","InChI=1S/C7H8N2O2/c10-6-9(8-11)7-4-2-1-3-5-7/h1-5,10H,6H2","PMID:10837014"
"BIOTID00734","n-nitrosodibutylamine","13542","YGJHZCLPZAZIHH-UHFFFAOYSA-N","InChI=1S/C8H18N2O/c1-3-5-7-10(9-11)8-6-4-2/h3-8H2,1-2H3","CYP2A6;CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","NULL","186984","QBBVUPNWYMMECP-UHFFFAOYSA-N","InChI=1S/C8H18N2O2/c1-3-5-7-10(9-12)8(11)6-4-2/h8,11H,3-7H2,1-2H3","PMID:10837014"
"BIOTID00735","n,n-diethyl-n'-(1-ethyl-6-methylergolin-8alpha-yl)sulfamide","9953076","ARTRTLXKTHJPRW-ILZDJORESA-N","InChI=1S/C21H32N4O2S/c1-5-24-13-15-11-20-18(17-9-8-10-19(24)21(15)17)12-16(14-23(20)4)22-28(26,27)25(6-2)7-3/h8-10,13,16,18,20,22H,5-7,11-12,14H2,1-4H3/t16-,18+,20+/m0/s1","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","NULL","HIDIWYKAQSOLPW-UHFFFAOYSA-N","InChI=1S/C19H28N4O2S/c1-4-20-26(24,25)21-14-10-16-15-7-6-8-17-19(15)13(11-23(17)5-2)9-18(16)22(3)12-14/h6-8,11,14,16,18,20-21H,4-5,9-10,12H2,1-3H3","PMID:1346997"
"BIOTID00736","n,n-diethylformamide","12051","SUAKHGWARZSWIH-UHFFFAOYSA-N","InChI=1S/C5H11NO/c1-3-6(4-2)5-7/h5H,3-4H2,1-2H3","CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","20086843","IHYALPORFKQQIE-UHFFFAOYSA-N","InChI=1S/C5H11NO2/c1-3-6(4-7)5(2)8/h4-5,8H,3H2,1-2H3","PMID:11684354"
"BIOTID00737","n,n-dimethyl-5-methoxytryptamine","1832","ZSTKHSQDNIGFLM-UHFFFAOYSA-N","InChI=1S/C13H18N2O/c1-15(2)7-6-10-9-14-13-5-4-11(16-3)8-12(10)13/h4-5,8-9,14H,6-7H2,1-3H3","CYP2D6","O-demethylation","Human Phase I","Human","Bufotenine","10257","VTTONGPRPXSUTJ-UHFFFAOYSA-N","InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3","PMID:12777961"
"BIOTID00738","nabumetone","4409","BLXXJMDCKKHMKV-UHFFFAOYSA-N","InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3","CYP1A2","Alpha hydroxylation of carbonyl group","Human Phase I","Human","4Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â4Ã¢â‚¬Â(6Ã¢â‚¬ÂmethoxynaphthalenÃ¢â‚¬Â2Ã¢â‚¬Âyl)butanÃ¢â‚¬Â2Ã¢â‚¬Âone","9816279","HLOFWGGVFLUZMZ-UHFFFAOYSA-N","InChI=1S/C15H16O3/c1-10(16)7-15(17)13-4-3-12-9-14(18-2)6-5-11(12)8-13/h3-6,8-9,15,17H,7H2,1-2H3","Montellano, P. R. O (2013); Cytochrome P450-activated prodrugs; Future Med Chem., 5(2): 213Ã¢â‚¬â€œ228. doi:10.4155/fmc.12.197."
"BIOTID00739","naphthalene","931","UFWIBTONFRDIAS-UHFFFAOYSA-N","InChI=1S/C10H8/c1-2-6-10-8-4-3-7-9(10)5-1/h1-8H","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","2-Naphthol","8663","JWAZRIHNYRIHIV-UHFFFAOYSA-N","InChI=1S/C10H8O/c11-10-6-5-8-3-1-2-4-9(8)7-10/h1-7,11H","PMID:16243959"
"BIOTID00740","naphthalene","931","UFWIBTONFRDIAS-UHFFFAOYSA-N","InChI=1S/C10H8/c1-2-6-10-8-4-3-7-9(10)5-1/h1-8H","CYP1A2","Aromatic Hydroxylation","Human Phase I","Human","1-Naphthol","7005","KJCVRFUGPWSIIH-UHFFFAOYSA-N","InChI=1S/C10H8O/c11-10-7-3-5-8-4-1-2-6-9(8)10/h1-7,11H","PMID:16243959"
"BIOTID00741","naphthalene","931","UFWIBTONFRDIAS-UHFFFAOYSA-N","InChI=1S/C10H8/c1-2-6-10-8-4-3-7-9(10)5-1/h1-8H","CYP1A2","Aromatic Hydroxylation","Human Phase I","Human","dihydrodiol","11318","NXPPAOGUKPJVDI-UHFFFAOYSA-N","InChI=1S/C10H8O2/c11-9-6-5-7-3-1-2-4-8(7)10(9)12/h1-6,11-12H","PMID:16243959"
"BIOTID00742","naphthalene","931","UFWIBTONFRDIAS-UHFFFAOYSA-N","InChI=1S/C10H8/c1-2-6-10-8-4-3-7-9(10)5-1/h1-8H","CYP1A2;CYP3A4","Epoxidation","Human Phase I","Human","naphthalene-1,2 Expodation","108063","XQIJIALOJPIKGX-UHFFFAOYSA-N","InChI=1S/C10H8O/c1-2-4-8-7(3-1)5-6-9-10(8)11-9/h1-6,9-10H","PMID:16243959"
"BIOTID00743","naproxen","156391","CMWTZPSULFXXJA-VIFPVBQESA-N","InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1","CYP2C9 (major); CYP1A2 ","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Desmethylnaproxen ","13393711","XWJUDDGELKXYNO-QMMMGPOBSA-N","InChI=1S/C13H12O3/c1-8(13(15)16)9-2-3-11-7-12(14)5-4-10(11)6-9/h2-8,14H,1H3,(H,15,16)/t8-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00744","nefazodone","4449","VRBKIVRKKCLPHA-UHFFFAOYSA-N","InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","10435492","XGIODORTBODPTQ-UHFFFAOYSA-N","InChI=1S/C25H32ClN5O3/c1-2-24-27-31(25(33)30(24)17-18-34-21-7-4-3-5-8-21)12-6-11-28-13-15-29(16-14-28)20-9-10-23(32)22(26)19-20/h3-5,7-10,19,32H,2,6,11-18H2,1H3","PMID:10445380"
"BIOTID00745","nefazodone","4449","VRBKIVRKKCLPHA-UHFFFAOYSA-N","InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","11755137","VKGQYGXMUUBRBD-UHFFFAOYSA-N","InChI=1S/C25H32ClN5O3/c1-20(32)24-27-31(25(33)30(24)17-18-34-23-9-3-2-4-10-23)12-6-11-28-13-15-29(16-14-28)22-8-5-7-21(26)19-22/h2-5,7-10,19-20,32H,6,11-18H2,1H3","PMID:10445380"
"BIOTID00746","nefazodone","4449","VRBKIVRKKCLPHA-UHFFFAOYSA-N","InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","1355","VHFVKMTVMIZMIK-UHFFFAOYSA-N","InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2","PMID:10445380"
"BIOTID00747","nefazodone","4449","VRBKIVRKKCLPHA-UHFFFAOYSA-N","InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","10379527","CKTZILJMZWVYIO-UHFFFAOYSA-N","InChI=1S/C15H21N3O3/c1-2-14-16-18(9-6-11-19)15(20)17(14)10-12-21-13-7-4-3-5-8-13/h3-5,7-8,19H,2,6,9-12H2,1H3","PMID:10445380"
"BIOTID00748","nevirapine","4463","NQDJXKOVJZTUJA-UHFFFAOYSA-N","InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)","CYP3A4","HYDROXYLATION_OF_HETEROAROMATIC_CARBON","Human Phase I","Human","2-OH-nevirapine","10850461","LFZSOJABLBVGRJ-UHFFFAOYSA-N","InChI=1S/C15H14N4O2/c1-8-7-11(20)17-14-12(8)18-15(21)10-3-2-6-16-13(10)19(14)9-4-5-9/h2-3,6-7,9H,4-5H2,1H3,(H,17,20)(H,18,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00749","nevirapine","4463","NQDJXKOVJZTUJA-UHFFFAOYSA-N","InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)","CYP2D6 (major); CYP2B6 (minor); CYP3A4 (minor)","HYDROXYLATION_OF_HETEROAROMATIC_CARBON","Human Phase I","Human","8-OH-nevirapine","10755325","DZPVEPLRIKDBFC-UHFFFAOYSA-N","InChI=1S/C15H14N4O2/c1-8-4-5-16-14-12(8)18-15(21)11-6-10(20)7-17-13(11)19(14)9-2-3-9/h4-7,9,20H,2-3H2,1H3,(H,18,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00750","nevirapine","4463","NQDJXKOVJZTUJA-UHFFFAOYSA-N","InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)","CYP2B6","HYDROXYLATION_OF_HETEROAROMATIC_CARBON","Human Phase I","Human","3-OH-nevirapine","10978907","DANIONWINZEYME-UHFFFAOYSA-N","InChI=1S/C15H14N4O2/c1-8-11(20)7-17-14-12(8)18-15(21)10-3-2-6-16-13(10)19(14)9-4-5-9/h2-3,6-7,9,20H,4-5H2,1H3,(H,18,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00751","nevirapine","4463","NQDJXKOVJZTUJA-UHFFFAOYSA-N","InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)","CYP3A4 (major); CYP2D6 (minor); CYP2C9 (minor)","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","12-OH-nevirapine","NULL","YCSZLSPYGSAXJE-UHFFFAOYSA-N","InChI=1S/C16H16N4O2/c21-9-6-10-5-8-18-15-13(10)19-16(22)12-2-1-7-17-14(12)20(15)11-3-4-11/h1-2,5,7-8,11,21H,3-4,6,9H2,(H,19,22)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00752","nicotine","89594","SNICXCGAKADSCV-JTQLQIEISA-N","InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1","CYP2A6 (major); CYP2B6; CYP2A13","Formation of iminium from pyrrolidine ring","Human Phase I","Human","(S)-Nicotine ÃŽâ€1Ã¢â‚¬Â²,5Ã¢â‚¬Â²-iminium ion","181139","GTQXYYYOJZZJHL-JTQLQIEISA-N","InChI=1S/C10H13N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6-8,10H,3,5H2,1H3/q+1/t10-/m0/s1",""
"BIOTID00753","nicotine","89594","SNICXCGAKADSCV-JTQLQIEISA-N","InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1","CYP2A6","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","2Ã¢â‚¬Â²-Hydroxynicotine","23615292","BOQRPPFUUSHFGW-SNVBAGLBSA-N","InChI=1S/C10H14N2O/c1-12-7-3-5-10(12,13)9-4-2-6-11-8-9/h2,4,6,8,13H,3,5,7H2,1H3/t10-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00754","nicotine","89594","SNICXCGAKADSCV-JTQLQIEISA-N","InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1","CYP2A6; CYP2B6; CYP2A13","N_DEALKYLATION_OF_CYCLIC_TERTIARY_AMINES; N_DEALKYLATION_OF_ALICYCLIC_TERTIARY_AMINES_PATTERN1","Human Phase I","Human","Nornicotine","91462","MYKUKUCHPMASKF-VIFPVBQESA-N","InChI=1S/C9H12N2/c1-3-8(7-10-5-1)9-4-2-6-11-9/h1,3,5,7,9,11H,2,4,6H2/t9-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID00755","nifedipine","4485","HYIMSNHJOBLJNT-UHFFFAOYSA-N","InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3","CYP3A4","Dehydrogenation of 4-aryl substituted 1,4-dihydropyridine","Human Phase I","Human","Oxidized nifedipine","128753","UMQHJQGNGLQJPF-UHFFFAOYSA-N","InChI=1S/C17H16N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8H,1-4H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00756","nnal","NULL","IJGFYZIMQQPUTE-VIFPVBQESA-N","InChI=1S/C10H13N3O3/c1-13(12-16)6-4-9(14)10(15)8-3-2-5-11-7-8/h2-3,5,7,9,14H,4,6H2,1H3/t9-/m0/s1","CYP3A4","N-Oxidation","Human Phase I","Human","NULL","NULL","JVFIHEHIBULHPA-UHFFFAOYSA-N","InChI=1S/C10H13N3O4/c1-12(11-16)6-4-9(14)10(15)8-3-2-5-13(17)7-8/h2-3,5,7,9,14H,4,6H2,1H3","PMID:9029045"
"BIOTID00757","nnal","NULL","IJGFYZIMQQPUTE-VIFPVBQESA-N","InChI=1S/C10H13N3O3/c1-13(12-16)6-4-9(14)10(15)8-3-2-5-11-7-8/h2-3,5,7,9,14H,4,6H2,1H3/t9-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","ASZSQTMQLBGNKU-UHFFFAOYSA-N","InChI=1S/C10H13N3O4/c1-13(12-17)9(15)5-8(14)10(16)7-3-2-4-11-6-7/h2-4,6,8-9,14-15H,5H2,1H3","PMID:9029045"
"BIOTID00758","nordiazepam","2997","AKPLHCDWDRPJGD-UHFFFAOYSA-N","InChI=1S/C15H11ClN2O/c16-11-6-7-13-12(8-11)15(17-9-14(19)18-13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19)","CYP1A2;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","OXAZEPAM","4616","ADIMAYPTOBDMTL-UHFFFAOYSA-N","InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)","PMID:8948091"
"BIOTID00759","nortriptyline","NULL","PHVGLTMQBUFIQQ-UHFFFAOYSA-N","InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3","CYP2D6","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","E-10-OH-nortriptyline","6420504","VAGXZGJKNUNLHK-WJDWOHSUSA-N","InChI=1S/C19H21NO/c1-20-12-6-11-16-15-8-3-2-7-14(15)13-19(21)18-10-5-4-9-17(16)18/h2-5,7-11,19-21H,6,12-13H2,1H3/b16-11-","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00760","nortriptyline","NULL","PHVGLTMQBUFIQQ-UHFFFAOYSA-N","InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3","CYP2C19","N-dealkylation of acyclic secondary amine","Human Phase I","Human","demethylnortriptyline","160755","PTQFRALDEONNOA-UHFFFAOYSA-N","InChI=1S/C18H19N/c19-13-5-10-18-16-8-3-1-6-14(16)11-12-15-7-2-4-9-17(15)18/h1-4,6-10H,5,11-13,19H2","Musshoff F. et al. (2010); Pharmacogenetics and forensic toxicology; Forensic Sci Int.; 203, 53-62. DOI:doi:10.1016/j.forsciint.2010.07.011"
"BIOTID00761","o-xylene","7237","CTQNGGLPUBDAKN-UHFFFAOYSA-N","InChI=1S/C8H10/c1-7-5-3-4-6-8(7)2/h3-6H,1-2H3","CYP2E1","Aromatic Hydroxylation","Human Phase I","Human","2,3-Dimethylphenol","7249","YCOXTKKNXUZSKD-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-6-3-4-8(9)5-7(6)2/h3-5,9H,1-2H3","PMID:8558417"
"BIOTID00762","o-xylene","7237","CTQNGGLPUBDAKN-UHFFFAOYSA-N","InChI=1S/C8H10/c1-7-5-3-4-6-8(7)2/h3-6H,1-2H3","CYP2E1","Aromatic Hydroxylation","Human Phase I","Human","3,4-Dimethylphenol","10687","QWBBPBRQALCEIZ-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-6-4-3-5-8(9)7(6)2/h3-5,9H,1-2H3","PMID:8558417"
"BIOTID00763","o-xylene","7237","CTQNGGLPUBDAKN-UHFFFAOYSA-N","InChI=1S/C8H10/c1-7-5-3-4-6-8(7)2/h3-6H,1-2H3","CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","2 Methylbenzylalcohol","6994","XPNGNIFUDRPBFJ-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-7-4-2-3-5-8(7)6-9/h2-5,9H,6H2,1H3","PMID:8558417"
"BIOTID00764","olanzapine","NULL","KVWDHTXUZHCGIO-UHFFFAOYSA-N","InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3","CYP1A2;CYP2D6;CYP3A4","ALIPHATIC HYDROXYLATION","Human Phase I","Human","NULL","NULL","FPDIERBPQFAFSI-UHFFFAOYSA-N","InChI=1S/C17H20N4OS/c1-20-6-8-21(9-7-20)16-13-10-12(11-22)23-17(13)19-15-5-3-2-4-14(15)18-16/h2-5,10,19,22H,6-9,11H2,1H3","PMID:8632334"
"BIOTID00765","olanzapine","NULL","KVWDHTXUZHCGIO-UHFFFAOYSA-N","InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3","CYP1A2;CYP2D6;CYP3A4","N-OXIDATION","Human Phase I","Human","NULL","NULL","LJVNYCDXBXGQIK-UHFFFAOYSA-N","InChI=1S/C17H20N4OS/c1-12-11-13-16(20-7-9-21(2,22)10-8-20)18-14-5-3-4-6-15(14)19-17(13)23-12/h3-6,11,19H,7-10H2,1-2H3","PMID:8632334"
"BIOTID00766","olanzapine","NULL","KVWDHTXUZHCGIO-UHFFFAOYSA-N","InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3","CYP1A2;CYP2D6","AROMATIC HYDROXYLATION","Human Phase I","Human","NULL","NULL","SMNUCABXNXAPBY-UHFFFAOYSA-N","InChI=1S/C17H20N4OS/c1-11-9-13-16(21-7-5-20(2)6-8-21)18-15-10-12(22)3-4-14(15)19-17(13)23-11/h3-4,9-10,19,22H,5-8H2,1-2H3","PMID:8632334"
"BIOTID00767","olanzapine","NULL","KVWDHTXUZHCGIO-UHFFFAOYSA-N","InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3","CYP1A2;CYP2D6","N-desmethylation","Human Phase I","Human","NULL","NULL","FHPIXVHJEIZKJW-UHFFFAOYSA-N","InChI=1S/C16H18N4S/c1-11-10-12-15(20-8-6-17-7-9-20)18-13-4-2-3-5-14(13)19-16(12)21-11/h2-5,10,17,19H,6-9H2,1H3","PMID:8632334"
"BIOTID00768","oleic acid","445639","ZQPPMHVWECSIRJ-KTKRTIGZSA-N","InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H,19,20)/b10-9-","CYP2E1;CYP4A11","Aliphatic Hydroxylation","Human Phase I","Human","NULL","5312773","LQUHZVLTTWMBTO-UPHRSURJSA-N","InChI=1S/C18H34O3/c19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18(20)21/h1-2,19H,3-17H2,(H,20,21)/b2-1-","PMID:10553002"
"BIOTID00769","oleic acid","445639","ZQPPMHVWECSIRJ-KTKRTIGZSA-N","InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H,19,20)/b10-9-","CYP2E1;CYP4A11","Aliphatic Hydroxylation","Human Phase I","Human","NULL","5312772","UMIZOHMCQYCZRX-IHWYPQMZSA-N","InChI=1S/C18H34O3/c1-17(19)15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18(20)21/h2-3,17,19H,4-16H2,1H3,(H,20,21)/b3-2-","PMID:10553002"
"BIOTID00770","olopatadine","5281071","JBIMVDZLSHOPLA-LSCVHKIXSA-N","InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-","CYP3A4","N-Dementhylation","Human Phase I","Human","N-monodemethylolopatadine","14127209","VQMJUHOJPCPUAM-IDUWFGFVSA-N","InChI=1S/C20H21NO3/c1-21-10-4-7-17-16-6-3-2-5-15(16)13-24-19-9-8-14(11-18(17)19)12-20(22)23/h2-3,5-9,11,21H,4,10,12-13H2,1H3,(H,22,23)/b17-7-","PMID:12433826"
"BIOTID00771","onapristone","NULL","IEXUMDBQLIVNHZ-MKNNCVFRSA-N","InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26+,28+,29+/m0/s1","CYP3A4","N-Demethylation","Human Phase I","Human","NULL","NULL","WYWIXJQPMTVGKW-UHFFFAOYSA-N","InChI=1S/C28H37NO3/c1-27-17-24(18-4-7-20(29-2)8-5-18)26-22-11-9-21(31)16-19(22)6-10-23(26)25(27)12-14-28(27,32)13-3-15-30/h4-5,7-8,16,23-25,29-30,32H,3,6,9-15,17H2,1-2H3","PMID:9321513"
"BIOTID00772","opc-13448","10003684","UZYMZRZCYLNXQU-DHZHZOJOSA-N","InChI=1S/C25H22N2O6/c1-16-21(24(28)32-3)23(19-12-7-13-20(15-19)27(30)31)22(17(2)26-16)25(29)33-14-8-11-18-9-5-4-6-10-18/h4-13,15H,14H2,1-3H3/b11-8+","CYP1A2;CYP2D6;CYP3A4","N-Demethylation","Human Phase I","Human","OPC-13463","9996712","BXLPPWLKFWCWOY-UHFFFAOYSA-N","InChI=1S/C16H14N2O6/c1-8-12(15(19)20)14(13(9(2)17-8)16(21)24-3)10-5-4-6-11(7-10)18(22)23/h4-7H,1-3H3,(H,19,20)","PMID:9929520"
"BIOTID00774","org_30659","NULL","YJSTYQGZKJHXLN-SSFAQJFESA-N","InChI=1S/C21H24O2/c1-4-21(23)10-9-18-17-7-5-14-11-15(22)6-8-16(14)19(17)13(2)12-20(18,21)3/h1,9-11,16-19,23H,2,5-8,12H2,3H3/t16-,17+,18+,19-,20+,21+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","VHZCGNWEJWYMGP-UHFFFAOYSA-N","InChI=1S/C21H24O3/c1-4-21(24)8-7-16-19-17(23)10-13-9-14(22)5-6-15(13)18(19)12(2)11-20(16,21)3/h1,7-9,15-19,23-24H,2,5-6,10-11H2,3H3","PMID:11871398"
"BIOTID00775","oxycodone","5284603","BRUQQQPBMZOVGD-XFKAJCMBSA-N","InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1","CYP2C19","O-demethylation","Human Phase I","Human","oxymorphone","4639","UQCNKQCJZOAFTQ-UHFFFAOYSA-N","InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3","PMID:15039299"
"BIOTID00776","oxycodone","5284603","BRUQQQPBMZOVGD-XFKAJCMBSA-N","InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1","CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4","N-demethylation","Human Phase I","Human","noroxycodone","627285","RIKMCJUNPCRFMW-UHFFFAOYSA-N","InChI=1S/C17H19NO4/c1-21-11-3-2-9-8-12-17(20)5-4-10(19)15-16(17,6-7-18-12)13(9)14(11)22-15/h2-3,12,15,18,20H,4-8H2,1H3","PMID:15039299"
"BIOTID00777","p-cresol","2879","IWDCLRJOBJJRNH-UHFFFAOYSA-N","InChI=1S/C7H8O/c1-6-2-4-7(8)5-3-6/h2-5,8H,1H3","CYP2E1","Aromatic Hydroxylation","Human Phase I","Human","4-methyl-hydroquinone","9958","ZBCATMYQYDCTIZ-UHFFFAOYSA-N","InChI=1S/C7H8O2/c1-5-2-3-6(8)7(9)4-5/h2-4,8-9H,1H3","PMID:16174805"
"BIOTID00778","p-cresol","2879","IWDCLRJOBJJRNH-UHFFFAOYSA-N","InChI=1S/C7H8O/c1-6-2-4-7(8)5-3-6/h2-5,8H,1H3","CYP1A2;CYP2C19;CYP2D6;CYP2E1","Dehydrogenation","Human Phase I","Human","NULL","15361578","PAXYTJVAGMMBQX-UHFFFAOYSA-N","InChI=1S/C7H8O/c1-6-2-4-7(8)5-3-6/h2-6H,1H3","PMID:16174805"
"BIOTID00779","p-cresol","2879","IWDCLRJOBJJRNH-UHFFFAOYSA-N","InChI=1S/C7H8O/c1-6-2-4-7(8)5-3-6/h2-5,8H,1H3","CYP1A2;CYP2C19;CYP2D6;CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","NULL","125","BVJSUAQZOZWCKN-UHFFFAOYSA-N","InChI=1S/C7H8O2/c8-5-6-1-3-7(9)4-2-6/h1-4,8-9H,5H2","PMID:16174805"
"BIOTID00780","p-xylene","7809","URLKBWYHVLBVBO-UHFFFAOYSA-N","InChI=1S/C8H10/c1-7-3-5-8(2)6-4-7/h3-6H,1-2H3","CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","4-Methylbenzylalcohol","11505","KMTDMTZBNYGUNX-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-7-2-4-8(6-9)5-3-7/h2-5,9H,6H2,1H3","PMID:8558417"
"BIOTID00781","p-xylene","7809","URLKBWYHVLBVBO-UHFFFAOYSA-N","InChI=1S/C8H10/c1-7-3-5-8(2)6-4-7/h3-6H,1-2H3","CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","2,5-dimethylphenol","7267","NKTOLZVEWDHZMU-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-6-3-4-7(2)8(9)5-6/h3-5,9H,1-2H3","PMID:8558417"
"BIOTID00782","palmitic acid","985","IPCSVZSSVZVIGE-UHFFFAOYSA-N","InChI=1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)","CYP2E1;CYP4A11","Aliphatic Hydroxylation","Human Phase I","Human","NULL","5312759","WQPQDBIUAFINBH-UHFFFAOYSA-N","InChI=1S/C16H32O3/c1-15(17)13-11-9-7-5-3-2-4-6-8-10-12-14-16(18)19/h15,17H,2-14H2,1H3,(H,18,19)","PMID:10553002"
"BIOTID00783","parathion","991","LCCNCVORNKJIRZ-UHFFFAOYSA-N","InChI=1S/C10H14NO5PS/c1-3-14-17(18,15-4-2)16-10-7-5-9(6-8-10)11(12)13/h5-8H,3-4H2,1-2H3","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","Desulfation","Human Phase I","Human","Paraoxon","9395","WYMSBXTXOHUIGT-UHFFFAOYSA-N","InChI=1S/C10H14NO6P/c1-3-15-18(14,16-4-2)17-10-7-5-9(6-8-10)11(12)13/h5-8H,3-4H2,1-2H3","PMID:17079358"
"BIOTID00784","pefloxacin","6919009","FHFYDNQZQSQIAI-UHFFFAOYSA-N","InChI=1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24)","CYP1A2","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","pefloxacin, N-desmethyl","6919051","OGJPXUAPXNRGGI-UHFFFAOYSA-N","InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)","Philip Lee et al. (2014) Handbook of Metabolic Pathways of Xenobiotics; DOI:10.1002/9781118541203.xen370"
"BIOTID00785","pentachlorobenzene","11855","CEOCDNVZRAIOQZ-UHFFFAOYSA-N","InChI=1S/C6HCl5/c7-2-1-3(8)5(10)6(11)4(2)9/h1H","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","PCP","992","IZUPBVBPLAPZRR-UHFFFAOYSA-N","InChI=1S/C6HCl5O/c7-1-2(8)4(10)6(12)5(11)3(1)9/h12H","PMID:8759309"
"BIOTID00786","pentoxyresorufin","107683","ZPSOKQFFOYYPKC-UHFFFAOYSA-N","InChI=1S/C17H17NO3/c1-2-3-4-9-20-13-6-8-15-17(11-13)21-16-10-12(19)5-7-14(16)18-15/h5-8,10-11H,2-4,9H2,1H3","CYP1A1; CYP1A2; CYP1B1","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Resorufin","69462","HSSLDCABUXLXKM-UHFFFAOYSA-N","InChI=1S/C12H7NO3/c14-7-1-3-9-11(5-7)16-12-6-8(15)2-4-10(12)13-9/h1-6,14H","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00787","perazine","4744","WEYVCQFUGFRXOM-UHFFFAOYSA-N","InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3","CYP1A2;CYP2A6;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","S-Oxidation","Human Phase I","Human","NULL","159893","QGGFCTLXKUUQAT-UHFFFAOYSA-N","InChI=1S/C20H25N3OS/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)25(24)20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3","PMID:15056479"
"BIOTID00788","perazine","4744","WEYVCQFUGFRXOM-UHFFFAOYSA-N","InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3","CYP1A2;CYP2B6;CYP2C19;CYP2D6","N-demethylation","Human Phase I","Human","NULL","151090","YWSUKAVVJWNXMP-UHFFFAOYSA-N","InChI=1S/C19H23N3S/c1-3-8-18-16(6-1)22(17-7-2-4-9-19(17)23-18)13-5-12-21-14-10-20-11-15-21/h1-4,6-9,20H,5,10-15H2","PMID:15056479"
"BIOTID00789","perphenazine","4748","RGCVKNLCSQQDEP-UHFFFAOYSA-N","InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2","CYP1A2; CYP3A4; CYP2C9; CYP2C19; CYP2D6 ","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","N-Dealkylated perphenazine","10451115","ZWIQAXTYRCAVFE-UHFFFAOYSA-N","InChI=1S/C19H22ClN3S/c20-15-6-7-19-17(14-15)23(16-4-1-2-5-18(16)24-19)11-3-10-22-12-8-21-9-13-22/h1-2,4-7,14,21H,3,8-13H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00790","perphenazine","4748","RGCVKNLCSQQDEP-UHFFFAOYSA-N","InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2","CYP2D6","S-oxidation of diarylthioether to sulfoxide","Human Phase I","Human","Perphenazine sulfoxide","82341","WXJXTMQMAOYROI-UHFFFAOYSA-N","InChI=1S/C21H26ClN3O2S/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)28(21)27)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00791","phenacetin","4754","CPJSUEIXXCENMM-UHFFFAOYSA-N","InChI=1S/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)","CYP1A1; CYP1A2; CYP2E1; CYP2D6; CYP2C19; CYP2C9; CYP2A6","O-dealkylation","Human Phase I","Human","Acetaminophen","1983","RZVAJINKPMORJF-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Venkatakrishnan, K. et al. (1998); Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity; J Pharm Sci. 1998 Dec;87(12):1502-7; PMID:10189256"
"BIOTID00792","phenacetin","4754","CPJSUEIXXCENMM-UHFFFAOYSA-N","InChI=1S/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)","CYP1A1; CYP1A2","N-hydroxylation of secondary arylamide","Human Phase I","Human","N-OH-phenacetin","29539","GPMYDZBSYQUDJZ-UHFFFAOYSA-N","InChI=1S/C10H13NO3/c1-3-14-10-6-4-9(5-7-10)11(13)8(2)12/h4-7,13H,3H2,1-2H3","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Venkatakrishnan, K. et al. (1998); Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity; J Pharm Sci. 1998 Dec;87(12):1502-7; PMID:10189256"
"BIOTID00794","phenanthrene","995","YNPNZTXNASCQKK-UHFFFAOYSA-N","InChI=1S/C14H10/c1-3-7-13-11(5-1)9-10-12-6-2-4-8-14(12)13/h1-10H","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","9543118","HNMUTKMLCMUDSB-UHFFFAOYSA-N","InChI=1S/C14H10O2/c15-13-8-7-11-10-4-2-1-3-9(10)5-6-12(11)14(13)16/h1-8,15-16H","PMID:9152594|PMID:8062229"
"BIOTID00795","phenanthrene","995","YNPNZTXNASCQKK-UHFFFAOYSA-N","InChI=1S/C14H10/c1-3-7-13-11(5-1)9-10-12-6-2-4-8-14(12)13/h1-10H","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","RLZZZVKAURTHCP-UHFFFAOYSA-N","InChI=1S/C14H10O2/c15-12-8-7-10-6-5-9-3-1-2-4-11(9)13(10)14(12)16/h1-8,15-16H","PMID:9152594|PMID:8062229"
"BIOTID00796","phenanthrene","995","YNPNZTXNASCQKK-UHFFFAOYSA-N","InChI=1S/C14H10/c1-3-7-13-11(5-1)9-10-12-6-2-4-8-14(12)13/h1-10H","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","ODUSUXJNDWKJKH-UHFFFAOYSA-N","InChI=1S/C14H10O2/c15-13-11-7-3-1-5-9(11)10-6-2-4-8-12(10)14(13)16/h1-8,15-16H","PMID:9152594|PMID:8062229"
"BIOTID00797","phencyclidine","6468","JTJMJGYZQZDUJJ-UHFFFAOYSA-N","InChI=1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","PCHP","NULL","SLUMSLWGPLFKGY-UHFFFAOYSA-N","InChI=1S/C17H25NO/c19-16-9-13-18(14-10-16)17(11-5-2-6-12-17)15-7-3-1-4-8-15/h1,3-4,7-8,16,19H,2,5-6,9-14H2","PMID:9152594"
"BIOTID00798","phencyclidine","6468","JTJMJGYZQZDUJJ-UHFFFAOYSA-N","InChI=1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","c-PPC/t-PPC","NULL","KPRUAZBLIREHPD-UHFFFAOYSA-N","InChI=1S/C17H25NO/c19-16-9-11-17(12-10-16,15-7-3-1-4-8-15)18-13-5-2-6-14-18/h1,3-4,7-8,16,19H,2,5-6,9-14H2","PMID:9152594"
"BIOTID00799","phenformin","8249","ICFJFFQQTFMIBG-UHFFFAOYSA-N","InChI=1S/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","PQASMWYEXAKHKQ-UHFFFAOYSA-N","InChI=1S/C10H15N5O/c11-9(12)15-10(13)14-6-5-7-1-3-8(16)4-2-7/h1-4,16H,5-6H2,(H6,11,12,13,14,15)","PMID:12502361"
"BIOTID00800","phenol","996","ISWSIDIOOBJBQZ-UHFFFAOYSA-N","InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H","CYP2E1","p-Hydroxylation of phenol","Human Phase I","Human","Hydroquinone","NULL","QIGBRXMKCJKVMJ-UHFFFAOYSA-N","InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00801","phenol","996","ISWSIDIOOBJBQZ-UHFFFAOYSA-N","InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H","CYP2E1","p-Hydroxylation of phenol","Human Phase I","Human","Catechol","289","YCIMNLLNPGFGHC-UHFFFAOYSA-N","InChI=1S/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8H","PMID:7923572"
"BIOTID00802","phenytoin","1775","CXOFVDLJLONNDW-UHFFFAOYSA-N","InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)","CYP2C9; CYP2C19","m-Hydroxylation of monosubstituted benzene","Human Phase I","Human","3'-HPPH","NULL","FSPRLRPJSPWQNC-UHFFFAOYSA-N","InChI=1S/C15H12N2O3/c18-12-8-4-7-11(9-12)15(10-5-2-1-3-6-10)13(19)16-14(20)17-15/h1-9,18H,(H2,16,17,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3679"
"BIOTID00803","phenytoin","1775","CXOFVDLJLONNDW-UHFFFAOYSA-N","InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)","CYP2C9 (major); CYP2C19 (minor)","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4'-HPPH","NULL","XEEDURHPFVXALT-UHFFFAOYSA-N","InChI=1S/C15H12N2O3/c18-12-8-6-11(7-9-12)15(10-4-2-1-3-5-10)13(19)16-14(20)17-15/h1-9,18H,(H2,16,17,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3679"
"BIOTID00804","phenytoin","1775","CXOFVDLJLONNDW-UHFFFAOYSA-N","InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)","CYP2C9; CYP2C19","DIHYDROXYLATION_OF_DOUBLE_BOND","Human Phase I","Human","5Ã¢â‚¬Â(3,4Ã¢â‚¬ÂdihydroxycyclohexaÃ¢â‚¬Â1,5Ã¢â‚¬ÂdienÃ¢â‚¬Â1Ã¢â‚¬Âyl)Ã¢â‚¬Â5Ã¢â‚¬ÂphenylimidazolidineÃ¢â‚¬Â2,4Ã¢â‚¬Âdione","NULL","FEEKFEKCXIDMIS-UHFFFAOYSA-N","InChI=1S/C15H14N2O4/c18-11-7-6-10(8-12(11)19)15(9-4-2-1-3-5-9)13(20)16-14(21)17-15/h1-8,11-12,18-19H,(H2,16,17,20,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3679"
"BIOTID00805","pilocarpine","5910","QCHFTBOMWOSFHM-WPRPVWTQSA-N","InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1","CYP2A6","Aliphatic Hydroxylation","Human Phase I","Human","3-hydroxypilocarpine","NULL","CDYVNDYSMAKHRR-UHFFFAOYSA-N","InChI=1S/C11H16N2O3/c1-3-11(15)8(6-16-10(11)14)4-9-5-12-7-13(9)2/h5,7-8,15H,3-4,6H2,1-2H3","PMID:17178767"
"BIOTID00806","pimozide","16362","YVUQSNJEYSNKRX-UHFFFAOYSA-N","InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)","CYP1A2;CYP3A4","N-dealkylation","Human Phase I","Human","1,3- dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one (DHPBI)","NULL","BYNBAMHAURJNTR-UHFFFAOYSA-N","InChI=1S/C12H15N3O/c16-12-14-10-3-1-2-4-11(10)15(12)9-5-7-13-8-6-9/h1-4,9,13H,5-8H2,(H,14,16)","PMID:9580580"
"BIOTID00807","piroxicam","54676228","QYSPLQLAKJAUJT-UHFFFAOYSA-N","InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)","CYP2C9","HYDROXYLATION_OF_HETEROAROMATIC_CARBON","Human Phase I","Human","5'-Hydroxypiroxicam","NULL","CCKOORANQAQKKV-UHFFFAOYSA-N","InChI=1S/C15H13N3O5S/c1-18-13(15(21)17-12-7-6-9(19)8-16-12)14(20)10-4-2-3-5-11(10)24(18,22)23/h2-8,19-20H,1H3,(H,16,17,21)","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID00808","pradefovir","58823201","GWNHAOBXDGOXRR-POXGOYDTSA-N","InChI=1S/C17H19ClN5O4P/c18-13-3-1-2-12(8-13)14-4-6-26-28(24,27-14)11-25-7-5-23-10-22-15-16(19)20-9-21-17(15)23/h1-3,8-10,14H,4-7,11H2,(H2,19,20,21)/t14-,28-/m0/s1","CYP3A4","Oxidation","Human Phase I","Human","PMEA","NULL","SUPKOOSCJHTBAH-UHFFFAOYSA-N","InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)","PMID:16940083"
"BIOTID00809","pregnenolone","8955","ORNBQBCIOKFOEO-QGVNFLHTSA-N","InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1","CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","ZAKJZPQDUPCXSD-UHFFFAOYSA-N","InChI=1S/C21H32O3/c1-12(22)19-18(24)11-17-15-5-4-13-10-14(23)6-8-20(13,2)16(15)7-9-21(17,19)3/h4,14-19,23-24H,5-11H2,1-3H3","PMID:9667077"
"BIOTID00810","pregnenolone","8955","ORNBQBCIOKFOEO-QGVNFLHTSA-N","InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1","CYP2C19;CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","MOIQRAOBRXUWGN-UHFFFAOYSA-N","InChI=1S/C21H32O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h3,14-18,22-23H,4-12H2,1-2H3","PMID:9667077"
"BIOTID00811","progesterone","5994","RJKFOVLPORLFTN-LEKSSAKUSA-N","InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1","CYP3A4","Alpha hydroxylation of carbonyl group","Human Phase I","Human","2beta-OH-progesterone","NULL","BOZZHCVRWNSXMR-QOJGXCKPSA-N","InChI=1S/C21H30O3/c1-12(22)15-6-7-16-14-5-4-13-10-18(23)19(24)11-21(13,3)17(14)8-9-20(15,16)2/h10,14-17,19,24H,4-9,11H2,1-3H3/t14-,15+,16-,17-,19-,20+,21-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00812","progesterone","5994","RJKFOVLPORLFTN-LEKSSAKUSA-N","InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1","CYP3A4; CYP3A4; CYP4B1","Hydroxylation of carbon gamma to conjugated carbonyl","Human Phase I","Human","6beta-OH-progesterone","NULL","PWCLWZOSAFOXFL-CXICGXRGSA-N","InChI=1S/C21H30O3/c1-12(22)15-4-5-16-14-11-19(24)18-10-13(23)6-8-21(18,3)17(14)7-9-20(15,16)2/h10,14-17,19,24H,4-9,11H2,1-3H3/t14-,15+,16-,17-,19+,20+,21+/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3676"
"BIOTID00815","progesterone","5994","RJKFOVLPORLFTN-LEKSSAKUSA-N","InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1","CYP3A4; CYP1A1; CYP2D6; CYP2C19","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","16beta-OH-progesterone","NULL","LOVNYFVWYTXDRE-MQWPULPWSA-N","InChI=1S/C21H30O3/c1-12(22)19-18(24)11-17-15-5-4-13-10-14(23)6-8-20(13,2)16(15)7-9-21(17,19)3/h10,15-19,24H,4-9,11H2,1-3H3/t15-,16+,17+,18+,19+,20+,21+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3679"
"BIOTID00816","progesterone","5994","RJKFOVLPORLFTN-LEKSSAKUSA-N","InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1","CYP2D4; CYP2D6; CYP2C19 ","Alpha hydroxylation of carbonyl group","Human Phase I","Human","17beta-OH-progesterone","NULL","DBPWSSGDRRHUNT-CEGNMAFCSA-N","InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3680"
"BIOTID00817","progesterone","5994","RJKFOVLPORLFTN-LEKSSAKUSA-N","InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1","CYP2C9","Alpha hydroxylation of carbonyl group","Human Phase I","Human","21-OH-progesterone","6166","ZESRJSPZRDMNHY-YFWFAHHUSA-N","InChI=1S/C21H30O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h11,15-18,22H,3-10,12H2,1-2H3/t15-,16-,17-,18+,20-,21-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3681"
"BIOTID00818","promazine","4926","ZGUGWUXLJSTTMA-UHFFFAOYSA-N","InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3","CYP1A2 (major); CYP3A4 (major); CYP2A6 (minor); CYP2B6 (minor; CYP2D6 (minor); CYP2E1 (minor)","S-oxidation of alkylarylthioether to sulfoxide","Human Phase I","Human","Promazine 5-sulfoxide","547559","KSHDHDWHIWBNHA-UHFFFAOYSA-N","InChI=1S/C17H20N2OS/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)21(20)17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00819","promazine","4926","ZGUGWUXLJSTTMA-UHFFFAOYSA-N","InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3","CYP1A2 (major); CYP2C9 (minor); CYP2C19 (major); CYP2A6 (minor); CYP2B6 (minor); CYP2D6 (minor); CYP2E1 (minor)","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES","Human Phase I","Human","N-Desmethyl promazine","28315","WOCOVPRTRIBGFZ-UHFFFAOYSA-N","InChI=1S/C16H18N2S/c1-17-11-6-12-18-13-7-2-4-9-15(13)19-16-10-5-3-8-14(16)18/h2-5,7-10,17H,6,11-12H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00820","propofol","4943","OLBCVFGFOZPWHH-UHFFFAOYSA-N","InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3","CYP2B6 (major); CYP2C9 (major); CYP1A2 (minor); CYP2A6 (minor); CYP2C8 (minor); CYP2C19 (minor); CYP2D6 (minor)","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","4-OH-propofol","3014064","UFWIJKBKROBWTG-UHFFFAOYSA-N","InChI=1S/C12H18O2/c1-7(2)10-5-9(13)6-11(8(3)4)12(10)14/h5-8,13-14H,1-4H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00822","psoralen","6199","ZCCUUQDIBDJBTK-UHFFFAOYSA-N","InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H","CYP2A6","Epoxidation","Human Phase I","Human","NULL","NULL","WHALJTOJMFKOIS-UHFFFAOYSA-N","InChI=1S/C11H6O4/c12-9-2-1-5-3-6-8(4-7(5)13-9)14-11-10(6)15-11/h1-4,10-11H","PMID:9665710"
"BIOTID00823","pyrazoloacridine","NULL","HZCWPKGYTCJSEB-UHFFFAOYSA-N","InChI=1S/C19H21N5O3/c1-22(2)9-4-10-23-15-7-8-16(24(25)26)19-17(15)18(21-23)13-11-12(27-3)5-6-14(13)20-19/h5-8,11,20H,4,9-10H2,1-3H3","CYP3A4","N-DEMETHYLATION","Human Phase I","Human","N-DEMETHYL Pyrazoloacridine","NULL","XCSGUYWITQFGEK-UHFFFAOYSA-N","InChI=1S/C18H19N5O3/c1-19-8-3-9-22-14-6-7-15(23(24)25)18-16(14)17(21-22)12-10-11(26-2)4-5-13(12)20-18/h4-7,10,19-20H,3,8-9H2,1-2H3","PMID:14977851"
"BIOTID00824","Stearic Acid","5281","QIQXTHQIDYTFRH-UHFFFAOYSA-N","InChI=1S/C18H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-17H2,1H3,(H,19,20)","CYP2E1;CYP4A11","Aliphatic Hydroxylation","Human Phase I","Human","NULL","5282914","CKGPXFKOAGKQDN-UHFFFAOYSA-N","InChI=1S/C18H36O3/c1-17(19)15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18(20)21/h17,19H,2-16H2,1H3,(H,20,21)","PMID:10553002"
"BIOTID00825","qttnoskslatgqb-uhfffaoysa-n","440775","QTTNOSKSLATGQB-UHFFFAOYSA-N","InChI=1S/C40H44N4O16/c45-33(46)5-1-17-21(9-37(53)54)29-14-26-19(3-7-35(49)50)23(11-39(57)58)31(43-26)16-28-20(4-8-36(51)52)24(12-40(59)60)32(44-28)15-27-18(2-6-34(47)48)22(10-38(55)56)30(42-27)13-25(17)41-29/h41-44H,1-16H2,(H,45,46)(H,47,48)(H,49,50)(H,51,52)(H,53,54)(H,55,56)(H,57,58)(H,59,60)","CYP1A2;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","uroporphyrin","101695106","MHLUUZPKDGLLIA-UHFFFAOYSA-N","InChI=1S/C40H44N4O17/c45-30(46)5-1-16-21(10-35(55)56)28-15-26-18(3-7-32(49)50)23(12-37(59)60)39(43-26)40(61)38-19(4-8-33(51)52)22(11-36(57)58)29(44-38)14-25-17(2-6-31(47)48)20(9-34(53)54)27(42-25)13-24(16)41-28/h40-44,61H,1-15H2,(H,45,46)(H,47,48)(H,49,50)(H,51,52)(H,53,54)(H,55,56)(H,57,58)(H,59,60)","PMID:9763408"
"BIOTID00826","quazepam","4999","IKMPWMZBZSAONZ-UHFFFAOYSA-N","InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2","CYP2C9","Desulfurization of thioamide into amide","Human Phase I","Human","2-Oxoquazepam","93250","YFSXBSRGIRSXAD-UHFFFAOYSA-N","InChI=1S/C17H11ClF4N2O/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2","Miura, M and Ohkubo, T (2004); In vitrometabolism of quazepam in human liver and intestine and assessment of drug interactions; Xenobiotica; 34(11-12):1001-11; PMID:15801544; DOI:10.1080/02772240400015214"
"BIOTID00827","quazepam","4999","IKMPWMZBZSAONZ-UHFFFAOYSA-N","InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2","CYP2C19","Desulfurization of thioamide into amide","Human Phase I","Human","2-Oxoquazepam","93250","YFSXBSRGIRSXAD-UHFFFAOYSA-N","InChI=1S/C17H11ClF4N2O/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2","Miura, M and Ohkubo, T (2004); In vitrometabolism of quazepam in human liver and intestine and assessment of drug interactions; Xenobiotica; 34(11-12):1001-11; PMID:15801544; DOI:10.1080/02772240400015214"
"BIOTID00828","quazepam","4999","IKMPWMZBZSAONZ-UHFFFAOYSA-N","InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2","CYP3A4","Desulfurization of thioamide into amide","Human Phase I","Human","2-Oxoquazepam","93250","YFSXBSRGIRSXAD-UHFFFAOYSA-N","InChI=1S/C17H11ClF4N2O/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2","Miura, M and Ohkubo, T (2004); In vitrometabolism of quazepam in human liver and intestine and assessment of drug interactions; Xenobiotica; 34(11-12):1001-11; PMID:15801544; DOI:10.1080/02772240400015214"
"BIOTID00829","quetiapine","5002","URKOMYMAXPYINW-UHFFFAOYSA-N","InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2","CYP3A4","S-Oxidation","Human Phase I","Human","NULL","10431050","FXJNLPUSSHEDON-UHFFFAOYSA-N","InChI=1S/C21H25N3O3S/c25-14-16-27-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)28(26)20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2","PMID:10482125"
"BIOTID00830","quetiapine","5002","URKOMYMAXPYINW-UHFFFAOYSA-N","InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","132203","VEGVCHRFYPFJFO-UHFFFAOYSA-N","InChI=1S/C21H25N3O3S/c25-12-14-27-13-11-23-7-9-24(10-8-23)21-17-3-1-2-4-19(17)28-20-15-16(26)5-6-18(20)22-21/h1-6,15,25-26H,7-14H2","PMID:10482125"
"BIOTID00831","quinidine","441074","LOUPRKONTZGTKE-LHHVKLHASA-N","InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1","CYP3A4","Allylic hydroxylation","Human Phase I","Human","3-Hydroxyquinidine","13217486","BSRUJCFCZKMFMB-LGWHJFRWSA-N","InChI=1S/C20H24N2O3/c1-3-20(24)12-22-9-7-13(20)10-18(22)19(23)15-6-8-21-17-5-4-14(25-2)11-16(15)17/h3-6,8,11,13,18-19,23-24H,1,7,9-10,12H2,2H3/t13-,18+,19-,20+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00832","quinidine","441074","LOUPRKONTZGTKE-LHHVKLHASA-N","InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1","CYP3A4; CYP2C9; CYP2E1","Oxidation of nitrogen in a strained ring system","Human Phase I","Human","Quinidine-N-oxide","14589189","WVDIZKMXQMCCAA-IKJOXUIJSA-N","InChI=1S/C20H24N2O3/c1-3-13-12-22(24)9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(25-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-,22?/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00833","quinine","3034034","LOUPRKONTZGTKE-WZBLMQSHSA-N","InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1","CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","92","BSRUJCFCZKMFMB-UHFFFAOYSA-N","InChI=1S/C20H24N2O3/c1-3-20(24)12-22-9-7-13(20)10-18(22)19(23)15-6-8-21-17-5-4-14(25-2)11-16(15)17/h3-6,8,11,13,18-19,23-24H,1,7,9-10,12H2,2H3","PMID:8968357"
"BIOTID00834","quinoline","7047","SMWDFEZZVXVKRB-UHFFFAOYSA-N","InChI=1S/C9H7N/c1-2-6-9-8(4-1)5-3-7-10-9/h1-7H","CYP1A2;CYP2A6;CYP2D6;CYP2E1;","EPOXIDATION","Human Phase I","Human","Q-8,6-epoxide","148175","DUTMSHWTRSUNIF-UHFFFAOYSA-N","InChI=1S/C9H7NO/c1-2-6-7(10-5-1)3-4-8-9(6)11-8/h1-5,8-9H","PMID:8824525"
"BIOTID00835","quinoline","7047","SMWDFEZZVXVKRB-UHFFFAOYSA-N","InChI=1S/C9H7N/c1-2-6-9-8(4-1)5-3-7-10-9/h1-7H","CYP1A2;CYP2A6;CYP2E1;CYP3A4","N-OXIDATION","Human Phase I","Human","Quinoline 1-oxide","15366","GIIWGCBLYNDKBO-UHFFFAOYSA-N","InChI=1S/C9H7NO/c11-10-7-3-5-8-4-1-2-6-9(8)10/h1-7H","PMID:8824525"
"BIOTID00836","quinoline","7047","SMWDFEZZVXVKRB-UHFFFAOYSA-N","InChI=1S/C9H7N/c1-2-6-9-8(4-1)5-3-7-10-9/h1-7H","CYP1A2;CYP2A6;CYP2E1","AROMATIC HYDROXYLATION","Human Phase I","Human","3OHQ","11376","IQQDNMHUOLMLNJ-UHFFFAOYSA-N","InChI=1S/C9H7NO/c11-8-5-7-3-1-2-4-9(7)10-6-8/h1-6,11H","PMID:8824525"
"BIOTID00837","qun","446536","GPKJTRJOBQGKQK-MRXNPFEDSA-N","InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)/t16-/m1/s1","CYP3A4","N-desethylation","Human Phase I","Human","NULL","45039956","PLRMAPKCAIMEDG-UHFFFAOYSA-N","InChI=1S/C21H26ClN3O/c1-4-23-11-5-6-14(2)24-21-17-9-7-15(22)12-20(17)25-19-10-8-16(26-3)13-18(19)21/h7-10,12-14,23H,4-6,11H2,1-3H3,(H,24,25)","PMID:16581945"
"BIOTID00838","qun","446536","GPKJTRJOBQGKQK-MRXNPFEDSA-N","InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)/t16-/m1/s1","CYP3A4","O-dementhylation","Human Phase I","Human","NULL","416254","YKEDRCDYDREDNL-UHFFFAOYSA-N","InChI=1S/C22H28ClN3O/c1-4-26(5-2)12-6-7-15(3)24-22-18-10-8-16(23)13-21(18)25-20-11-9-17(27)14-19(20)22/h8-11,13-15,27H,4-7,12H2,1-3H3,(H,24,25)","PMID:16581945"
"BIOTID00839","qun","446536","GPKJTRJOBQGKQK-MRXNPFEDSA-N","InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)/t16-/m1/s1","CYP3A4","O-dementhylation","Human Phase I","Human","NULL","19080","IHHSSHCBRVYGJX-UHFFFAOYSA-N","InChI=1S/C14H11ClN2O/c1-18-9-3-5-12-11(7-9)14(16)10-4-2-8(15)6-13(10)17-12/h2-7H,1H3,(H2,16,17)","PMID:16581945"
"BIOTID00840","(R)-mianserin","154412","UEQUQVLFIPOEMF-SFHVURJKSA-N","InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3/t18-/m0/s1","CYP2D6; CYP1A2; CYP3A4; CYP2B6","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","(R)-mianserin, N-Desmethyl","153935","ZBILSSSEXRZGKS-KRWDZBQOSA-N","InChI=1S/C17H18N2/c1-3-7-15-13(5-1)11-14-6-2-4-8-16(14)19-10-9-18-12-17(15)19/h1-8,17-18H,9-12H2/t17-/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Rendic, S., Di Carlo, F. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors; Drug Metabolism Reviews, 29:1-2, 413-580; DOI:10.3109/03602539709037591; PMID:9187528"
"BIOTID00841","(R)-mianserin","154412","UEQUQVLFIPOEMF-SFHVURJKSA-N","InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3/t18-/m0/s1","CYP2D6; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","(R)-mianserin, 8-hydroxy","NULL","IXAPYQICIDTITB-SFHVURJKSA-N","InChI=1S/C18H20N2O/c1-19-8-9-20-17-11-15(21)7-6-14(17)10-13-4-2-3-5-16(13)18(20)12-19/h2-7,11,18,21H,8-10,12H2,1H3/t18-/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Rendic, S., Di Carlo, F. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors; Drug Metabolism Reviews, 29:1-2, 413-580; DOI:10.3109/03602539709037591; PMID:9187528"
"BIOTID00842","(R)-mianserin","154412","UEQUQVLFIPOEMF-SFHVURJKSA-N","InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3/t18-/m0/s1","CYP3A4","N-oxidation of alicyclic tertiary amine","Human Phase I","Human","(R)-mianserin, N-oxide","29984837","VVDXWJOYXVNLLQ-LROBGIAVSA-N","InChI=1S/C18H20N2O/c1-20(21)11-10-19-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(19)13-20/h2-9,18H,10-13H2,1H3/t18-,20?/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423|Rendic, S., Di Carlo, F. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors; Drug Metabolism Reviews, 29:1-2, 413-580; DOI:10.3109/03602539709037591; PMID:9187528"
"BIOTID00843","raloxifene","5035","GZUITABIAKMVPG-UHFFFAOYSA-N","InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","102197542","CKWWJQCMSWDCDG-UHFFFAOYSA-N","InChI=1S/C28H27NO5S/c30-20-8-4-19(5-9-20)27-24(22-12-13-23(31)26(33)28(22)35-27)25(32)18-6-10-21(11-7-18)34-17-16-29-14-2-1-3-15-29/h4-13,30-31,33H,1-3,14-17H2","PMID:12119000"
"BIOTID00844","raloxifene","5035","GZUITABIAKMVPG-UHFFFAOYSA-N","InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","BZOICNYNBOJKPQ-UHFFFAOYSA-N","InChI=1S/C28H27NO5S/c30-20-7-10-22-25(17-20)35-28(19-6-11-23(31)24(32)16-19)26(22)27(33)18-4-8-21(9-5-18)34-15-14-29-12-2-1-3-13-29/h4-11,16-17,30-32H,1-3,12-15H2","PMID:12119000"
"BIOTID00845","ranitidine","3001055","VMXUWOKSQNHOCA-UKTHLTGXSA-N","InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+","CYP2C19; CYP1A2; CYP2D6","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES","Human Phase I","Human","Desmethylranitidine","10380064","WZLBVRXZNDXPPW-XYOKQWHBSA-N","InChI=1S/C12H20N4O3S/c1-13-7-10-3-4-11(19-10)9-20-6-5-15-12(14-2)8-16(17)18/h3-4,8,13-15H,5-7,9H2,1-2H3/b12-8+","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00846","reboxetine","65856","CBQGYUDMJHNJBX-OALUTQOASA-N","InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1","CYP3A4","Desethylation","Human Phase I","Human","O-desethylreboxetine","10469169","PODXMAMDNUUSTL-UHFFFAOYSA-N","InChI=1S/C17H19NO3/c19-14-8-4-5-9-15(14)21-17(13-6-2-1-3-7-13)16-12-18-10-11-20-16/h1-9,16-19H,10-12H2","PMID:10534319"
"BIOTID00847","reboxetine","65856","CBQGYUDMJHNJBX-OALUTQOASA-N","InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","Phenol B","NULL","KWIARTUNLAUWCQ-UHFFFAOYSA-N","InChI=1S/C19H23NO4/c1-2-22-17-12-15(21)8-9-16(17)24-19(14-6-4-3-5-7-14)18-13-20-10-11-23-18/h3-9,12,18-21H,2,10-11,13H2,1H3","PMID:10534319"
"BIOTID00848","reboxetine","65856","CBQGYUDMJHNJBX-OALUTQOASA-N","InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","Phenol A","NULL","SHPSERQFHJFJAW-UHFFFAOYSA-N","InChI=1S/C19H23NO4/c1-2-22-16-9-8-15(21)12-17(16)24-19(14-6-4-3-5-7-14)18-13-20-10-11-23-18/h3-9,12,18-21H,2,10-11,13H2,1H3","PMID:10534319"
"BIOTID00849","reduced_dolasetron","NULL","MLWGAEVSWJXOQJ-XYLOAFBBSA-N","InChI=1S/C19H22N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,18,20,22H,5-8,10H2/t11?,12-,13+,14?,18-/m1/s1","CYP3A4","Oxidation of nitrogen in a strained ring system","Human Phase I","Human","Dolasetron N-oxide","NULL","HISIYQCTEKKZGZ-KXFXSALQSA-N","InChI=1S/C19H22N2O4/c22-18-10-21(24)12-5-11(18)6-13(21)8-14(7-12)25-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,18,20,22H,5-8,10H2/t11?,12-,13+,14?,18-,21?/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00850","reduced_dolasetron","NULL","MLWGAEVSWJXOQJ-XYLOAFBBSA-N","InChI=1S/C19H22N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,18,20,22H,5-8,10H2/t11?,12-,13+,14?,18-/m1/s1","CYP2D6 (major); CYP3A4; CYP2C9","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-Hydroxydolasetron","NULL","ZMHGUJOFLCUYPP-HGBKZWNCSA-N","InChI=1S/C19H22N2O4/c22-13-1-2-15-16(8-20-17(15)7-13)19(24)25-14-5-11-3-10-4-12(6-14)21(11)9-18(10)23/h1-2,7-8,10-12,14,18,20,22-23H,3-6,9H2/t10?,11-,12+,14?,18-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00851","reduced_dolasetron","NULL","MLWGAEVSWJXOQJ-XYLOAFBBSA-N","InChI=1S/C19H22N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,18,20,22H,5-8,10H2/t11?,12-,13+,14?,18-/m1/s1","CYP2D6; CYP2C9","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","5-Hydroxydolasetron","NULL","GQVSIRWNARNIIA-HGBKZWNCSA-N","InChI=1S/C19H22N2O4/c22-13-1-2-17-15(7-13)16(8-20-17)19(24)25-14-5-11-3-10-4-12(6-14)21(11)9-18(10)23/h1-2,7-8,10-12,14,18,20,22-23H,3-6,9H2/t10?,11-,12+,14?,18-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00852","reduced_dolasetron","NULL","MLWGAEVSWJXOQJ-XYLOAFBBSA-N","InChI=1S/C19H22N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,18,20,22H,5-8,10H2/t11?,12-,13+,14?,18-/m1/s1","CYP2D6; CYP2C9","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","7-Hydroxydolasetron","NULL","OBVOORYFKGUOIG-MJRCBCLYSA-N","InChI=1S/C19H22N2O4/c22-16-3-1-2-14-15(8-20-18(14)16)19(24)25-13-6-11-4-10-5-12(7-13)21(11)9-17(10)23/h1-3,8,10-13,17,20,22-23H,4-7,9H2/t10?,11-,12+,13?,17-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00853","repaglinide","65981","FAEKWTJYAYMJKF-QHCPKHFHSA-N","InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1","CYP2C8;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","46781896","OBMAZJVHPAVADF-UHFFFAOYSA-N","InChI=1S/C27H36N2O5/c1-4-34-25-15-19(11-12-22(25)27(32)33)16-26(31)28-23(14-18(2)3)21-9-5-6-10-24(21)29-13-7-8-20(30)17-29/h5-6,9-12,15,18,20,23,30H,4,7-8,13-14,16-17H2,1-3H3,(H,28,31)(H,32,33)","PMID:12919179"
"BIOTID00854","repaglinide","65981","FAEKWTJYAYMJKF-QHCPKHFHSA-N","InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1","CYP2C8;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","UEOAQSOFPSCIAE-UHFFFAOYSA-N","InChI=1S/C27H36N2O5/c1-4-34-24-16-19(12-13-21(24)26(31)32)17-25(30)28-22(18-27(2,3)33)20-10-6-7-11-23(20)29-14-8-5-9-15-29/h6-7,10-13,16,22,33H,4-5,8-9,14-15,17-18H2,1-3H3,(H,28,30)(H,31,32)","PMID:12919179"
"BIOTID00855","repaglinide","65981","FAEKWTJYAYMJKF-QHCPKHFHSA-N","InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1","CYP3A4","O-Demethylation","Human Phase I","Human","NULL","22132924","FTKOIWGNBGHHGC-UHFFFAOYSA-N","InChI=1S/C25H32N2O4/c1-17(2)14-21(19-8-4-5-9-22(19)27-12-6-3-7-13-27)26-24(29)16-18-10-11-20(25(30)31)23(28)15-18/h4-5,8-11,15,17,21,28H,3,6-7,12-14,16H2,1-2H3,(H,26,29)(H,30,31)","PMID:12919179"
"BIOTID00856","repaglinide","65981","FAEKWTJYAYMJKF-QHCPKHFHSA-N","InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1","CYP2C8;CYP3A4","N-dealkylation","Human Phase I","Human","NULL","57826284","OSCVKZCOJUTUFD-UHFFFAOYSA-N","InChI=1S/C22H28N2O4/c1-4-28-20-12-15(9-10-17(20)22(26)27)13-21(25)24-19(11-14(2)3)16-7-5-6-8-18(16)23/h5-10,12,14,19H,4,11,13,23H2,1-3H3,(H,24,25)(H,26,27)","PMID:12919179"
"BIOTID00857","repaglinide","65981","FAEKWTJYAYMJKF-QHCPKHFHSA-N","InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1","CYP2C8;CYP3A4","N-dealkylation","Human Phase I","Human","NULL","NULL","KAVQVMXQUQWQJZ-UHFFFAOYSA-N","InChI=1S/C26H36N2O5/c1-4-33-24-16-19(11-12-21(24)26(31)32)17-25(30)28-23(15-18(2)3)20-9-5-6-10-22(20)27-13-7-8-14-29/h5-6,9-12,16,18,23,27,29H,4,7-8,13-15,17H2,1-3H3,(H,28,30)(H,31,32)","PMID:12919179"
"BIOTID00858","retinal","638015","NCYCYZXNIZJOKI-OVSJKPMPSA-N","InChI=1S/C20H28O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,15H,7,10,14H2,1-5H3/b9-6+,12-11+,16-8+,17-13+","CYP1A2; CYP1A2; CYP1B1","Aldehyde oxidation","Human Phase I","Human","all-trans retinoic acid","444795","SHGAZHPCJJPHSC-YCNIQYBTSA-N","InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00859","retinal","638015","NCYCYZXNIZJOKI-OVSJKPMPSA-N","InChI=1S/C20H28O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,15H,7,10,14H2,1-5H3/b9-6+,12-11+,16-8+,17-13+","CYP1A2; CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Tretinoin","444795","SHGAZHPCJJPHSC-YCNIQYBTSA-N","InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+","PMID:10681373;PMID:10681376"
"BIOTID00860","retinol","445354","FPIPGXGPPPQFEQ-OVSJKPMPSA-N","InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+","CYP1A1; CYP1A2; CYP3A4; CYP1B1","Oxidation of primary alcohol to aldehyde","Human Phase I","Human","All-trans-retinal","638015","NCYCYZXNIZJOKI-OVSJKPMPSA-N","InChI=1S/C20H28O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,15H,7,10,14H2,1-5H3/b9-6+,12-11+,16-8+,17-13+","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00861","retinol","445354","FPIPGXGPPPQFEQ-OVSJKPMPSA-N","InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+","CYP2C8","Aliphatic Hydroxylation","Human Phase I","Human","4-Hydroxyretinol","6080476","IOELQUUUYMBPSA-RMWYGNQTSA-N","InChI=1S/C20H30O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,19,21-22H,11,13-14H2,1-5H3/b8-6+,10-9+,15-7+,16-12+","PMID:2916844;PMID:10681376"
"BIOTID00862","retinol","445354","FPIPGXGPPPQFEQ-OVSJKPMPSA-N","InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+","CYP1A1;CYP2C8; CYP2C9; CYP2C19;CYP2D6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Retinal","638015","NCYCYZXNIZJOKI-OVSJKPMPSA-N","InChI=1S/C20H28O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,15H,7,10,14H2,1-5H3/b9-6+,12-11+,16-8+,17-13+","PMID:2916844;PMID:10681376"
"BIOTID00863","riddelliine","5281744","SVCNNZDUGWLODJ-RAYFHMIRSA-N","InChI=1S/C18H23NO6/c1-3-12-8-11(2)18(23,10-20)17(22)24-9-13-4-6-19-7-5-14(15(13)19)25-16(12)21/h3-4,14-15,20,23H,2,5-10H2,1H3/b12-3-/t14-,15-,18-/m1/s1","CYP3A4","N-Oxidation","Human Phase I","Human","riddelliine N-Oxide","NULL","NPENPMDVCQGSSO-BASWHVEKSA-N","InChI=1S/C18H23NO7/c1-3-12-8-11(2)18(23,10-20)17(22)25-9-13-4-6-19(24)7-5-14(15(13)19)26-16(12)21/h3-4,14-15,20,23H,2,5-10H2,1H3/b12-3-","PMID:12693032"
"BIOTID00864","riddelliine","5281744","SVCNNZDUGWLODJ-RAYFHMIRSA-N","InChI=1S/C18H23NO6/c1-3-12-8-11(2)18(23,10-20)17(22)24-9-13-4-6-19-7-5-14(15(13)19)25-16(12)21/h3-4,14-15,20,23H,2,5-10H2,1H3/b12-3-/t14-,15-,18-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","DXKDPBHFDYKQEW-BASWHVEKSA-N","InChI=1S/C18H23NO7/c1-3-12-8-11(2)17(23,10-20)16(22)25-9-13-4-6-19-7-5-14(18(13,19)24)26-15(12)21/h3-4,14,20,23-24H,2,5-10H2,1H3/b12-3-","PMID:12693032"
"BIOTID00865","riddelliine","5281744","SVCNNZDUGWLODJ-RAYFHMIRSA-N","InChI=1S/C18H23NO6/c1-3-12-8-11(2)18(23,10-20)17(22)24-9-13-4-6-19-7-5-14(15(13)19)25-16(12)21/h3-4,14-15,20,23H,2,5-10H2,1H3/b12-3-/t14-,15-,18-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","QYQIWFZWIVRCDH-JYOAFUTRSA-N","InChI=1S/C18H23NO7/c1-3-11-6-10(2)18(24,9-20)17(23)25-8-12-7-14(21)19-5-4-13(15(12)19)26-16(11)22/h3,7,13-15,20-21,24H,2,4-6,8-9H2,1H3/b11-3-","PMID:12693032"
"BIOTID00866","rifabutin","NULL","CNAZMMBRYQFSBI-AEXANHCBSA-N","InChI=1S/C47H63N3O11/c1-23(2)22-50-18-16-47(17-19-50)48-37-31-21-32(52)24(3)13-12-14-25(4)39(53)27(6)40(54)28(7)43(60-30(9)51)26(5)33(58-11)15-20-59-46(10)45(57)36-34(38(37)49-47)35(42(31)56)41(55)29(8)44(36)61-46/h12-15,20,23,25-28,33,39-40,43,48,53-55H,16-19,21-22H2,1-11H3/b14-12+,20-15-,24-13-/t25-,26-,27-,28-,33-,39+,40+,43+,46-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","KUKGSXLXNCJNIP-FGGLYSIISA-N","InChI=1S/C47H63N3O12/c1-23(2)22-50-18-16-47(17-19-50)48-36-30-21-31(52)24(3)13-12-15-45(9,58)43(56)28(7)38(53)26(5)41(61-29(8)51)25(4)32(59-11)14-20-60-46(10)44(57)35-33(37(36)49-47)34(40(30)55)39(54)27(6)42(35)62-46/h12-15,20,23,25-26,28,32,38,41,43,48,53-54,56,58H,16-19,21-22H2,1-11H3/b15-12?,20-14-,24-13+","PMID:9164417"
"BIOTID00867","rifabutin","NULL","CNAZMMBRYQFSBI-AEXANHCBSA-N","InChI=1S/C47H63N3O11/c1-23(2)22-50-18-16-47(17-19-50)48-37-31-21-32(52)24(3)13-12-14-25(4)39(53)27(6)40(54)28(7)43(60-30(9)51)26(5)33(58-11)15-20-59-46(10)45(57)36-34(38(37)49-47)35(42(31)56)41(55)29(8)44(36)61-46/h12-15,20,23,25-28,33,39-40,43,48,53-55H,16-19,21-22H2,1-11H3/b14-12+,20-15-,24-13-/t25-,26-,27-,28-,33-,39+,40+,43+,46-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","JPVHOBCIXKVRMK-ZCFOXJOFSA-N","InChI=1S/C47H63N3O12/c1-23(2)21-50-17-15-47(16-18-50)48-37-31-20-32(53)24(3)12-11-13-30(22-51)40(55)26(5)39(54)27(6)43(61-29(8)52)25(4)33(59-10)14-19-60-46(9)45(58)36-34(38(37)49-47)35(42(31)57)41(56)28(7)44(36)62-46/h11-14,19,23,25-27,30,33,39-40,43,48,51,54-56H,15-18,20-22H2,1-10H3/b13-11?,19-14-,24-12+","PMID:9164417"
"BIOTID00868","rifabutin","NULL","CNAZMMBRYQFSBI-AEXANHCBSA-N","InChI=1S/C47H63N3O11/c1-23(2)22-50-18-16-47(17-19-50)48-37-31-21-32(52)24(3)13-12-14-25(4)39(53)27(6)40(54)28(7)43(60-30(9)51)26(5)33(58-11)15-20-59-46(10)45(57)36-34(38(37)49-47)35(42(31)56)41(55)29(8)44(36)61-46/h12-15,20,23,25-28,33,39-40,43,48,53-55H,16-19,21-22H2,1-11H3/b14-12+,20-15-,24-13-/t25-,26-,27-,28-,33-,39+,40+,43+,46-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","VFTRXZUWLHALLQ-ZCFOXJOFSA-N","InChI=1S/C47H63N3O12/c1-23(2)21-50-17-15-47(16-18-50)48-37-30-20-32(53)24(3)12-11-13-25(4)39(54)31(22-51)40(55)27(6)43(61-29(8)52)26(5)33(59-10)14-19-60-46(9)45(58)36-34(38(37)49-47)35(42(30)57)41(56)28(7)44(36)62-46/h11-14,19,23,25-27,31,33,39-40,43,48,51,54-56H,15-18,20-22H2,1-10H3/b13-11?,19-14-,24-12+","PMID:9164417"
"BIOTID00869","rifabutin","NULL","CNAZMMBRYQFSBI-AEXANHCBSA-N","InChI=1S/C47H63N3O11/c1-23(2)22-50-18-16-47(17-19-50)48-37-31-21-32(52)24(3)13-12-14-25(4)39(53)27(6)40(54)28(7)43(60-30(9)51)26(5)33(58-11)15-20-59-46(10)45(57)36-34(38(37)49-47)35(42(31)56)41(55)29(8)44(36)61-46/h12-15,20,23,25-28,33,39-40,43,48,53-55H,16-19,21-22H2,1-11H3/b14-12+,20-15-,24-13-/t25-,26-,27-,28-,33-,39+,40+,43+,46-/m0/s1","CYP3A4","O-dementhylation","Human Phase I","Human","NULL","NULL","STVHLBMBJWXIRE-MDQZGSPOSA-N","InChI=1S/C46H61N3O11/c1-22(2)21-49-17-15-46(16-18-49)47-36-30-20-32(52)23(3)12-11-13-24(4)38(53)26(6)39(54)27(7)42(59-29(9)50)25(5)31(51)14-19-58-45(10)44(57)35-33(37(36)48-46)34(41(30)56)40(55)28(8)43(35)60-45/h11-14,19,22,24-27,31,38-39,42,47,51,53-55H,15-18,20-21H2,1-10H3/b13-11-,19-14?,23-12-","PMID:9164417"
"BIOTID00870","rifalazil","NULL","UEFHFKKWYKVLDC-GZBMFKKJSA-N","InChI=1S/C51H64N4O13/c1-24(2)23-54-16-18-55(19-17-54)32-21-33(57)39-35(22-32)67-48-40(52-39)36-37-44(60)30(8)47-38(36)49(62)51(10,68-47)65-20-15-34(64-11)27(5)46(66-31(9)56)29(7)43(59)28(6)42(58)25(3)13-12-14-26(4)50(63)53-41(48)45(37)61/h12-15,20-22,24-25,27-29,34,42-43,46,57-60H,16-19,23H2,1-11H3,(H,53,63)/b13-12+,20-15+,26-14-/t25-,27+,28+,29-,34-,42-,43-,46+,51-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","HOAQIWMJVFVCSC-XHYMALBCSA-N","InChI=1S/C51H64N4O14/c1-24(2)22-54-15-17-55(18-16-54)31-20-33(58)39-35(21-31)68-48-40(52-39)36-37-44(61)29(7)47-38(36)49(63)51(9,69-47)66-19-14-34(65-10)27(5)46(67-30(8)57)28(6)43(60)32(23-56)42(59)25(3)12-11-13-26(4)50(64)53-41(48)45(37)62/h11-14,19-21,24-25,27-28,32,34,42-43,46,56,58-61H,15-18,22-23H2,1-10H3,(H,53,64)/b12-11?,19-14-,26-13+","PMID:10923859"
"BIOTID00871","rifalazil","NULL","UEFHFKKWYKVLDC-GZBMFKKJSA-N","InChI=1S/C51H64N4O13/c1-24(2)23-54-16-18-55(19-17-54)32-21-33(57)39-35(22-32)67-48-40(52-39)36-37-44(60)30(8)47-38(36)49(62)51(10,68-47)65-20-15-34(64-11)27(5)46(66-31(9)56)29(7)43(59)28(6)42(58)25(3)13-12-14-26(4)50(63)53-41(48)45(37)61/h12-15,20-22,24-25,27-29,34,42-43,46,57-60H,16-19,23H2,1-11H3,(H,53,63)/b13-12+,20-15+,26-14-/t25-,27+,28+,29-,34-,42-,43-,46+,51-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","ZWKUNLRPXMGPQY-WLZSAQFMSA-N","InChI=1S/C51H64N4O14/c1-24(2)22-54-15-17-55(18-16-54)32-20-33(58)39-35(21-32)68-48-40(52-39)36-37-44(61)29(7)47-38(36)49(63)51(9,69-47)66-19-14-34(65-10)26(4)46(67-30(8)57)28(6)43(60)27(5)42(59)25(3)12-11-13-31(23-56)50(64)53-41(48)45(37)62/h11-14,19-21,24-28,34,42-43,46,56,58-61H,15-18,22-23H2,1-10H3,(H,53,64)/b12-11?,19-14-,31-13-","PMID:10923859"
"BIOTID00872","rifalazil","NULL","UEFHFKKWYKVLDC-GZBMFKKJSA-N","InChI=1S/C51H64N4O13/c1-24(2)23-54-16-18-55(19-17-54)32-21-33(57)39-35(22-32)67-48-40(52-39)36-37-44(60)30(8)47-38(36)49(62)51(10,68-47)65-20-15-34(64-11)27(5)46(66-31(9)56)29(7)43(59)28(6)42(58)25(3)13-12-14-26(4)50(63)53-41(48)45(37)61/h12-15,20-22,24-25,27-29,34,42-43,46,57-60H,16-19,23H2,1-11H3,(H,53,63)/b13-12+,20-15+,26-14-/t25-,27+,28+,29-,34-,42-,43-,46+,51-/m0/s1","CYP3A4","O-deacetylation","Human Phase I","Human","NULL","NULL","RWEULXPDQXZYGN-GULGPRAJSA-N","InChI=1S/C49H62N4O12/c1-23(2)22-52-15-17-53(18-16-52)30-20-31(54)37-33(21-30)64-46-38(50-37)34-35-43(58)29(8)45-36(34)47(60)49(9,65-45)63-19-14-32(62-10)26(5)41(56)28(7)42(57)27(6)40(55)24(3)12-11-13-25(4)48(61)51-39(46)44(35)59/h11-14,19-21,23-24,26-28,32,40-42,54-58H,15-18,22H2,1-10H3,(H,51,61)/b12-11?,19-14-,25-13+","PMID:10923859"
"BIOTID00873","riluzole","5070","FTALBRSUTCGOEG-UHFFFAOYSA-N","InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)","CYP1A1","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","4-OH-riluzole","85752610","GXFFABIWILZVMT-UHFFFAOYSA-N","InChI=1S/C8H5F3N2O2S/c9-8(10,11)15-3-1-4(14)6-5(2-3)16-7(12)13-6/h1-2,14H,(H2,12,13)","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID00874","riluzole","5070","FTALBRSUTCGOEG-UHFFFAOYSA-N","InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)","CYP1A1","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","5-OH-riluzole","19063893","ABPVPMBDUVEIQV-UHFFFAOYSA-N","InChI=1S/C8H5F3N2O2S/c9-8(10,11)15-5-2-6-3(1-4(5)14)13-7(12)16-6/h1-2,14H,(H2,12,13)","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID00875","riluzole","5070","FTALBRSUTCGOEG-UHFFFAOYSA-N","InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)","CYP1A2; CYP1A1","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","7-OH-riluzole","85752611","ASRHRBKKDHQFAF-UHFFFAOYSA-N","InChI=1S/C8H5F3N2O2S/c9-8(10,11)15-4-2-1-3-6(5(4)14)16-7(12)13-3/h1-2,14H,(H2,12,13)","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754425"
"BIOTID00876","riluzole","5070","FTALBRSUTCGOEG-UHFFFAOYSA-N","InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)","CYP1A1","N-hydroxylation of primary arylamine","Human Phase I","Human","N-OH-riluzole","9859774","MFGRTKLVQQZZIE-UHFFFAOYSA-N","InChI=1S/C8H5F3N2O2S/c9-8(10,11)15-4-1-2-5-6(3-4)16-7(12-5)13-14/h1-3,14H,(H,12,13)","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754426"
"BIOTID00878","risperidone","5073","RAPZEAPATHNIPO-UHFFFAOYSA-N","InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3","CYP2D6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","475100","ABWPQNZPAOAQSG-UHFFFAOYSA-N","InChI=1S/C23H27FN4O3/c1-14-18(23(30)28-13-17(29)3-5-21(28)25-14)8-11-27-9-6-15(7-10-27)22-19-4-2-16(24)12-20(19)31-26-22/h2,4,12,15,17,29H,3,5-11,13H2,1H3","PMID:10482125"
"BIOTID00879","risperidone","5073","RAPZEAPATHNIPO-UHFFFAOYSA-N","InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","115237","PMXMIIMHBWHSKN-UHFFFAOYSA-N","InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3","PMID:10482125"
"BIOTID00880","risperidone","5073","RAPZEAPATHNIPO-UHFFFAOYSA-N","InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3","CYP2D6","N-Hydroxylation","Human Phase I","Human","NULL","NULL","OQVDRRZXNOKBIU-UHFFFAOYSA-N","InChI=1S/C24H30FN4O3/c1-15-4-3-10-28-23(15)26-16(2)19(24(28)30)9-13-27-11-7-17(8-12-27)22-20-6-5-18(25)14-21(20)32-29(22)31/h5-6,14-15,17,31H,3-4,7-13H2,1-2H3/q+1","PMID:10482125"
"BIOTID00881","risperidone","5073","RAPZEAPATHNIPO-UHFFFAOYSA-N","InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","849421","MRMGJMGHPJZSAE-UHFFFAOYSA-N","InChI=1S/C12H13FN2O/c13-9-1-2-10-11(7-9)16-15-12(10)8-3-5-14-6-4-8/h1-2,7-8,14H,3-6H2","PMID:10482125"
"BIOTID00882","risperidone","5073","RAPZEAPATHNIPO-UHFFFAOYSA-N","InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","NULL","RBTHKVQFHNZPHN-UHFFFAOYSA-N","InChI=1S/C12H18N2O/c1-4-10-9(3)13-11-8(2)6-5-7-14(11)12(10)15/h8H,4-7H2,1-3H3","PMID:10482125"
"BIOTID00883","ropinirole","5095","UHSKFQJFRQCDBE-UHFFFAOYSA-N","InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)","CYP1A2;CYP3A4","N-Despropylation","Human Phase I","Human","NULL","10398490","VKDWFHAQOZYATG-UHFFFAOYSA-N","InChI=1S/C13H18N2O/c1-2-7-14-8-6-10-4-3-5-12-11(10)9-13(16)15-12/h3-5,14H,2,6-9H2,1H3,(H,15,16)","PMID:9224778"
"BIOTID00884","ropinirole","5095","UHSKFQJFRQCDBE-UHFFFAOYSA-N","InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)","CYP1A2;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","133741","PVIICBUWKXYFAA-UHFFFAOYSA-N","InChI=1S/C16H24N2O2/c1-3-8-18(9-4-2)10-7-12-5-6-14(19)16-13(12)11-15(20)17-16/h5-6,19H,3-4,7-11H2,1-2H3,(H,17,20)","PMID:9224778"
"BIOTID00885","ropivacaine","175805","ZKMNUMMKYBVTFN-HNNXBMFYSA-N","InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1","CYP1A2","Hydroxylation of benzene on carbon ortho to an electron donating group","Human Phase I","Human","3-OH-ropivacaine","24892799","IXOVDWXTIIYVOJ-AWEZNQCLSA-N","InChI=1S/C17H26N2O2/c1-4-10-19-11-6-5-7-14(19)17(21)18-16-12(2)8-9-15(20)13(16)3/h8-9,14,20H,4-7,10-11H2,1-3H3,(H,18,21)/t14-/m0/s1","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754426"
"BIOTID00886","ropivacaine","175805","ZKMNUMMKYBVTFN-HNNXBMFYSA-N","InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","PPX","10014180","SILRCGDPZGQJOQ-LBPRGKRZSA-N","InChI=1S/C14H20N2O/c1-10-6-5-7-11(2)13(10)16-14(17)12-8-3-4-9-15-12/h5-7,12,15H,3-4,8-9H2,1-2H3,(H,16,17)/t12-/m0/s1","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754426"
"BIOTID00887","roxithromycin","NULL","RXZBMPWDPOLZGW-FZWLNVMRSA-N","InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25-,26-,27-,28-,29-,30-,32-,33+,34+,35-,36-,38+,39-,40+,41-/m1/s1","CYP3A4","N-Dementhylation","Human Phase I","Human","NULL","NULL","HVLDACGFXJHOFG-OJZPPULMSA-N","InChI=1S/C40H74N2O15/c1-14-28-40(10,48)33(44)23(4)30(42-52-20-51-16-15-49-12)21(2)18-38(8,47)35(57-37-31(43)27(41-11)17-22(3)53-37)24(5)32(25(6)36(46)55-28)56-29-19-39(9,50-13)34(45)26(7)54-29/h21-29,31-35,37,41,43-45,47-48H,14-20H2,1-13H3/b42-30+","PMID:9806945"
"BIOTID00888","ruboxistaurin","153999","ZCBUQCWBWNUWSU-SFHVURJKSA-N","InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1","CYP3A4(major);CYP2D6(minor)","N-desmethylation","Human Phase I","Human","N-desmethyl LY333531","NULL","ZEYTZKVCOZMUKL-UHFFFAOYSA-N","InChI=1S/C27H26N4O3/c1-28-14-17-10-11-30-15-20(18-6-2-4-8-22(18)30)24-25(27(33)29-26(24)32)21-16-31(12-13-34-17)23-9-5-3-7-19(21)23/h2-9,15-17,28H,10-14H2,1H3,(H,29,32,33)","PMID:12167559"
"BIOTID00889","rutaecarpine","65752","ACVGWSKVRYFWRP-UHFFFAOYSA-N","InChI=1S/C18H13N3O/c22-18-13-6-2-4-8-15(13)20-17-16-12(9-10-21(17)18)11-5-1-3-7-14(11)19-16/h1-8,19H,9-10H2","CYP1A2;CYP2C9;CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","637395","NDJIQTYBQIKAGG-UHFFFAOYSA-N","InChI=1S/C18H13N3O2/c22-10-5-6-15-13(9-10)18(23)21-8-7-12-11-3-1-2-4-14(11)19-16(12)17(21)20-15/h1-6,9,19,22H,7-8H2","PMID:16318905"
"BIOTID00890","rutaecarpine","65752","ACVGWSKVRYFWRP-UHFFFAOYSA-N","InChI=1S/C18H13N3O/c22-18-13-6-2-4-8-15(13)20-17-16-12(9-10-21(17)18)11-5-1-3-7-14(11)19-16/h1-8,19H,9-10H2","CYP1A2;CYP2C9;CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","HOKAQDWBHPUJBU-UHFFFAOYSA-N","InChI=1S/C18H13N3O2/c22-14-7-3-6-13-15(14)11-8-9-21-17(16(11)19-13)20-12-5-2-1-4-10(12)18(21)23/h1-7,19,22H,8-9H2","PMID:16318905"
"BIOTID00891","rutaecarpine","65752","ACVGWSKVRYFWRP-UHFFFAOYSA-N","InChI=1S/C18H13N3O/c22-18-13-6-2-4-8-15(13)20-17-16-12(9-10-21(17)18)11-5-1-3-7-14(11)19-16/h1-8,19H,9-10H2","CYP1A2;CYP2C9;CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","LZNDAOKPOOIXKH-UHFFFAOYSA-N","InChI=1S/C18H13N3O2/c22-10-5-6-11-12-7-8-21-17(16(12)19-15(11)9-10)20-14-4-2-1-3-13(14)18(21)23/h1-6,9,19,22H,7-8H2","PMID:16318905"
"BIOTID00892","rutaecarpine","65752","ACVGWSKVRYFWRP-UHFFFAOYSA-N","InChI=1S/C18H13N3O/c22-18-13-6-2-4-8-15(13)20-17-16-12(9-10-21(17)18)11-5-1-3-7-14(11)19-16/h1-8,19H,9-10H2","CYP2C9;CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","102351043","OLMHRSLUDJARDO-UHFFFAOYSA-N","InChI=1S/C18H13N3O2/c22-10-5-6-15-13(9-10)11-7-8-21-17(16(11)19-15)20-14-4-2-1-3-12(14)18(21)23/h1-6,9,19,22H,7-8H2","PMID:16318905"
"BIOTID00893","rutaecarpine","65752","ACVGWSKVRYFWRP-UHFFFAOYSA-N","InChI=1S/C18H13N3O/c22-18-13-6-2-4-8-15(13)20-17-16-12(9-10-21(17)18)11-5-1-3-7-14(11)19-16/h1-8,19H,9-10H2","CYP1A2;CYP2C9;CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","ZJQXOYNZSJVQDA-UHFFFAOYSA-N","InChI=1S/C18H13N3O2/c22-14-7-3-5-10-11-8-9-21-17(16(11)20-15(10)14)19-13-6-2-1-4-12(13)18(21)23/h1-7,20,22H,8-9H2","PMID:16318905"
"BIOTID00894","rutaecarpine","65752","ACVGWSKVRYFWRP-UHFFFAOYSA-N","InChI=1S/C18H13N3O/c22-18-13-6-2-4-8-15(13)20-17-16-12(9-10-21(17)18)11-5-1-3-7-14(11)19-16/h1-8,19H,9-10H2","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","XXDHZWIVXIVSEE-UHFFFAOYSA-N","InChI=1S/C18H13N3O2/c22-14-9-21-17(20-13-8-4-2-6-11(13)18(21)23)16-15(14)10-5-1-3-7-12(10)19-16/h1-8,14,19,22H,9H2","PMID:16318905"
"BIOTID00897","s-methyl diethylthiocarbamate","119467","AQTFQQHFHGBCPG-UHFFFAOYSA-N","InChI=1S/C6H13NOS/c1-4-7(5-2)6(8)9-3/h4-5H2,1-3H3","CYP3A4; CYP2A6; CYP2C9; CYP1A2; CYP2B6; CYP2E1; CYP2D6","S-oxidation of thiocarbamate","Human Phase I","Human","MeDTC sulfoxide","3035711","FQSRGOGWCPXJIN-UHFFFAOYSA-N","InChI=1S/C6H13NO2S/c1-4-7(5-2)6(8)10(3)9/h4-5H2,1-3H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754426"
"BIOTID00898","s-metolachlor","11140605","WVQBLGZPHOPPFO-LBPRGKRZSA-N","InChI=1S/C15H22ClNO2/c1-5-13-8-6-7-11(2)15(13)17(14(18)9-16)12(3)10-19-4/h6-8,12H,5,9-10H2,1-4H3/t12-/m0/s1","CYP2B6;CYP3A4","O-demethylation","Human Phase I","Human","NULL","3017607","RNRZTRIOAPZEME-UHFFFAOYSA-N","InChI=1S/C14H20ClNO2/c1-4-12-7-5-6-10(2)14(12)16(11(3)9-17)13(18)8-15/h5-7,11,17H,4,8-9H2,1-3H3","PMID:11133395"
"BIOTID00900","salicylic acid","338","YGSDEFSMJLZEOE-UHFFFAOYSA-N","InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)","CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","5-hydroxylation","3469","WXTMDXOMEHJXQO-UHFFFAOYSA-N","InChI=1S/C7H6O4/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,8-9H,(H,10,11)","PMID:10064561"
"BIOTID00901","salmeterol","9812133","GIIZNNXWQWCKIB-RUZDIDTESA-N","InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2/t25-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","197627","PGRMEHUQIPZHKM-UHFFFAOYSA-N","InChI=1S/C25H37NO5/c27-19-22-17-21(12-13-24(22)29)25(30)18-26-14-6-1-2-7-15-31-16-8-11-23(28)20-9-4-3-5-10-20/h3-5,9-10,12-13,17,23,25-30H,1-2,6-8,11,14-16,18-19H2","PMID:8723736"
"BIOTID00902","schembl12998564","59905401","KWEMUXODTDSRRP-HEHNFIMWSA-N","InChI=1S/C18H18N4O6/c1-11(23)17(18(24)19-13-6-4-5-7-15(13)27-2)21-20-14-9-8-12(22(25)26)10-16(14)28-3/h4-10,20H,1-3H3,(H,19,24)/b21-17+","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","py74-M1","NULL","YACSLWIRYVWLFY-HEHNFIMWSA-N","InChI=1S/C18H18N4O7/c1-10(23)17(18(25)19-13-7-5-12(24)9-16(13)29-3)21-20-14-6-4-11(22(26)27)8-15(14)28-2/h4-9,20,24H,1-3H3,(H,19,25)/b21-17+","PMID:16014769"
"BIOTID00903","schembl14141926","71082648","AZRUDPJZBRJPHU-HNNXBMFYSA-N","InChI=1S/C16H16ClNO3S/c1-21-16(20)15(11-4-2-3-5-12(11)17)18-7-6-13-10(9-18)8-14(19)22-13/h2-5,15H,6-9H2,1H3/t15-/m0/s1","CYP2B6;CYP2C9;CYP2C19;CYP3A4","Unknown reaction","Human Phase I","Human","NULL","NULL","SPCDTEIYDXUKFI-UHFFFAOYSA-N","InChI=1S/C16H18ClNO3S/c1-21-16(20)15(12-4-2-3-5-13(12)17)18-8-6-14(22)11(10-18)7-9-19/h2-5,9,15,22H,6-8,10H2,1H3","PMID:19812348"
"BIOTID00904","schembl14329530","53903022","HYKWMZVCUBUWMM-UHFFFAOYSA-N","InChI=1S/C15H18O3/c1-2-3-4-5-10-17-13-8-6-12-7-9-15(16)18-14(12)11-13/h6-9,11H,2-5,10H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","102005167","MODGDTPZSCZGEO-UHFFFAOYSA-N","InChI=1S/C15H18O4/c1-2-3-12(16)8-9-18-13-6-4-11-5-7-15(17)19-14(11)10-13/h4-7,10,12,16H,2-3,8-9H2,1H3","PMID:10620357"
"BIOTID00905","schembl14329530","53903022","HYKWMZVCUBUWMM-UHFFFAOYSA-N","InChI=1S/C15H18O3/c1-2-3-4-5-10-17-13-8-6-12-7-9-15(16)18-14(12)11-13/h6-9,11H,2-5,10H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","102005166","NOWFXPJMBCMECA-UHFFFAOYSA-N","InChI=1S/C15H18O4/c1-2-12(16)4-3-9-18-13-7-5-11-6-8-15(17)19-14(11)10-13/h5-8,10,12,16H,2-4,9H2,1H3","PMID:10620357"
"BIOTID00906","schembl14329530","53903022","HYKWMZVCUBUWMM-UHFFFAOYSA-N","InChI=1S/C15H18O3/c1-2-3-4-5-10-17-13-8-6-12-7-9-15(16)18-14(12)11-13/h6-9,11H,2-5,10H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","102005165","OVXORBKWNHNDMG-UHFFFAOYSA-N","InChI=1S/C15H18O4/c1-11(16)4-2-3-9-18-13-7-5-12-6-8-15(17)19-14(12)10-13/h5-8,10-11,16H,2-4,9H2,1H3","PMID:10620357"
"BIOTID00907","schembl149458","57146948","SLVMESMUVMCQIY-AKJBCIBTSA-N","InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3/t16-,26-/m1/s1","CYP2D6","S-REDUCTION","Human Phase I","Human","Sulphoridazine","5452","KLBQZWRITKRQQV-UHFFFAOYSA-N","InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3","PMID:16272405"
"BIOTID00908","schembl17043265","96365834","NXNPGAAZKYDOPW-AWEZNQCLSA-N","InChI=1S/C15H21NO/c1-3-14(16-10-4-5-11-16)15(17)13-8-6-12(2)7-9-13/h6-9,14H,3-5,10-11H2,1-2H3/t14-/m0/s1","CYP1A2;CYP2C19;CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","HO-MPBP","66971611","ZBSFZTIXEWEODS-UHFFFAOYSA-N","InChI=1S/C15H21NO2/c1-2-14(16-9-3-4-10-16)15(18)13-7-5-12(11-17)6-8-13/h5-8,14,17H,2-4,9-11H2,1H3","PMID:17962373"
"BIOTID00909","schembl237672","15487106","IWAUXKQGXMTXLR-UHFFFAOYSA-N","InChI=1S/C18H26NO3/c1-6-19(4,7-2)11-10-16-13(3)15-9-8-14(21-5)12-17(15)22-18(16)20/h8-9,12H,6-7,10-11H2,1-5H3/q+1","CYP1A2;CYP2D6;CYP2B6","O-Demethylation","Human Phase I","Human","AMHC (3-[2-(N,N-diethyl-Nmethylammonium)ethyl]-7-hydroxy-4-methylcoumarin)","87489075","JGXGFWUTRXWEJX-UHFFFAOYSA-O","InChI=1S/C17H23NO3/c1-5-18(4,6-2)10-9-15-12(3)14-8-7-13(19)11-16(14)21-17(15)20/h7-8,11H,5-6,9-10H2,1-4H3/p+1","PMID:11502727"
"BIOTID00910","schembl29464","12325869","SEQDDYPDSLOBDC-HNNXBMFYSA-N","InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3/t15-/m0/s1","CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP3A4","N-dementhylation","Human Phase I","Human","Oxazepam","4616","ADIMAYPTOBDMTL-UHFFFAOYSA-N","InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)","PMID:9586962"
"BIOTID00911","schembl3207291","9865776","XZAFZXJXZHRNAQ-CHWSQXEVSA-N","InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m1/s1","CYP1A2;CYP3A4","N-dealkylation","Human Phase I","Human","NULL","25204357","OCFVOHOLUYXSQZ-UHFFFAOYSA-N","InChI=1S/C17H17N5O4S/c1-26-12-8-21(7-11(12)18)13-3-2-9-14(23)10(16(24)25)6-22(15(9)20-13)17-19-4-5-27-17/h2-6,11-12H,7-8,18H2,1H3,(H,24,25)","PMID:19074528"
"BIOTID00912","schembl3207291","9865776","XZAFZXJXZHRNAQ-CHWSQXEVSA-N","InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m1/s1","CYP1A2;CYP3A4","O-dealkylation","Human Phase I","Human","NULL","NULL","NVIZMCCYAUPCAA-UHFFFAOYSA-N","InChI=1S/C17H17N5O4S/c1-18-11-7-21(8-12(11)23)13-3-2-9-14(24)10(16(25)26)6-22(15(9)20-13)17-19-4-5-27-17/h2-6,11-12,18,23H,7-8H2,1H3,(H,25,26)","PMID:19074528"
"BIOTID00913","schembl3207291","9865776","XZAFZXJXZHRNAQ-CHWSQXEVSA-N","InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m1/s1","CYP1A2;CYP2D6;CYP3A4","Hydrogenation","Human Phase I","Human","NULL","NULL","ZPGHZYKVGXRDKF-UHFFFAOYSA-N","InChI=1S/C18H21N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-6,11-13,19H,7-9H2,1-2H3,(H,25,26)","PMID:19074528"
"BIOTID00914","schembl4023988","9891080","URYBOPNIACOOED-VWPQPMDRSA-N","InChI=1S/C22H27ClN6O4/c1-22(21(31-3)32-4)20(30)19(16-11-14(24)7-10-17(16)33-22)29(12-18-25-27-28(2)26-18)15-8-5-13(23)6-9-15/h5-11,19-21,30H,12,24H2,1-4H3/t19-,20+,22-/m0/s1","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","N-Demethylation","Human Phase I","Human","hydroxy-KR-31543","11299037","MTKWOUZCLHJPDW-UHFFFAOYSA-N","InChI=1S/C9H10ClN5/c1-15-13-9(12-14-15)6-11-8-4-2-7(10)3-5-8/h2-5,11H,6H2,1H3","PMID:15022728"
"BIOTID00915","schembl4023988","9891080","URYBOPNIACOOED-VWPQPMDRSA-N","InChI=1S/C22H27ClN6O4/c1-22(21(31-3)32-4)20(30)19(16-11-14(24)7-10-17(16)33-22)29(12-18-25-27-28(2)26-18)15-8-5-13(23)6-9-15/h5-11,19-21,30H,12,24H2,1-4H3/t19-,20+,22-/m0/s1","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amine","NULL","YYXSRZUODWOTLW-UHFFFAOYSA-N","InChI=1S/C22H27ClN6O5/c1-22(21(32-3)33-4)20(31)19(14-9-15(24)16(30)10-17(14)34-22)29(11-18-25-27-28(2)26-18)13-7-5-12(23)6-8-13/h5-10,19-21,30-31H,11,24H2,1-4H3","PMID:15022728"
"BIOTID00916","schembl4081913","9908587","CQEOXWCXSBFJMB-UHFFFAOYSA-N","InChI=1S/C24H28FN3O/c1-26-24(29)17-18-6-7-20-9-15-28(23(20)16-18)21-10-13-27(14-11-21)12-8-19-4-2-3-5-22(19)25/h2-7,9,15-16,21H,8,10-14,17H2,1H3,(H,26,29)","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","UESYPAOIMZYXCC-UHFFFAOYSA-N","InChI=1S/C24H28FN3O2/c1-26-23(29)15-17-6-7-18-8-13-28(22(18)14-17)20-9-11-27(12-10-20)24(30)16-19-4-2-3-5-21(19)25/h2-8,13-14,20,24,30H,9-12,15-16H2,1H3,(H,26,29)","PMID:12065439"
"BIOTID00917","schembl4081913","9908587","CQEOXWCXSBFJMB-UHFFFAOYSA-N","InChI=1S/C24H28FN3O/c1-26-24(29)17-18-6-7-20-9-15-28(23(20)16-18)21-10-13-27(14-11-21)12-8-19-4-2-3-5-22(19)25/h2-7,9,15-16,21H,8,10-14,17H2,1H3,(H,26,29)","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","KUSDQXXHLZTPLH-UHFFFAOYSA-N","InChI=1S/C24H28FN3O2/c1-26-24(30)15-17-6-7-18-8-13-28(22(18)14-17)19-9-11-27(12-10-19)16-23(29)20-4-2-3-5-21(20)25/h2-8,13-14,19,23,29H,9-12,15-16H2,1H3,(H,26,30)","PMID:12065439"
"BIOTID00918","schembl69463","57417237","IYFNEFQTYQPVOC-KRWDZBQOSA-N","InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)/t17-/m0/s1","CYP3A4","N-Dealkylation","Human Phase I","Human","DA-8164","10024249","WQAFYWMRZOZKJD-UHFFFAOYSA-N","InChI=1S/C18H23N5O4S/c1-4-6-13-15-16(23(3)22-13)18(24)21-17(20-15)12-10-11(28(19,25)26)7-8-14(12)27-9-5-2/h7-8,10H,4-6,9H2,1-3H3,(H2,19,25,26)(H,20,21,24)","PMID:15801542"
"BIOTID00919","schembl69463","57417237","IYFNEFQTYQPVOC-KRWDZBQOSA-N","InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)/t17-/m0/s1","CYP3A4","N-Demethylation","Human Phase I","Human","N-Demethyl-DA-8159","NULL","NVYLYDOUWHBMEY-UHFFFAOYSA-N","InChI=1S/C24H34N6O4S/c1-4-7-19-21-22(29-28-19)24(31)27-23(26-21)18-15-17(9-10-20(18)34-14-5-2)35(32,33)25-12-11-16-8-6-13-30(16)3/h9-10,15-16,25H,4-8,11-14H2,1-3H3,(H,28,29)(H,26,27,31)","PMID:15801542"
"BIOTID00920","schembl69463","57417237","IYFNEFQTYQPVOC-KRWDZBQOSA-N","InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)/t17-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Hydroxy-DA-8164","NULL","KSZBTWZMSAEQBI-UHFFFAOYSA-N","InChI=1S/C25H36N6O5S/c1-5-14-36-20-10-9-17(37(34,35)26-12-11-16-8-7-13-30(16)3)15-18(20)24-27-22-21(19(32)6-2)29-31(4)23(22)25(33)28-24/h9-10,15-16,19,26,32H,5-8,11-14H2,1-4H3,(H,27,28,33)","PMID:15801542"
"BIOTID00921","schembl69463","57417237","IYFNEFQTYQPVOC-KRWDZBQOSA-N","InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)/t17-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Hydroxy-DA-8164","NULL","KRWOGNNCCRDBOG-UHFFFAOYSA-N","InChI=1S/C25H36N6O5S/c1-5-13-36-21-9-8-18(37(34,35)26-11-10-17-7-6-12-30(17)3)15-19(21)24-27-22-20(14-16(2)32)29-31(4)23(22)25(33)28-24/h8-9,15-17,26,32H,5-7,10-14H2,1-4H3,(H,27,28,33)","PMID:15801542"
"BIOTID00922","schembl69463","57417237","IYFNEFQTYQPVOC-KRWDZBQOSA-N","InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)/t17-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Hydroxy-DA-8164","NULL","DTGZHVIJUCNAHH-UHFFFAOYSA-N","InChI=1S/C25H36N6O5S/c1-4-15-36-21-10-9-18(37(34,35)26-12-11-17-7-5-13-30(17)2)16-19(21)24-27-22-20(8-6-14-32)29-31(3)23(22)25(33)28-24/h9-10,16-17,26,32H,4-8,11-15H2,1-3H3,(H,27,28,33)","PMID:15801542"
"BIOTID00923","schembl69463","57417237","IYFNEFQTYQPVOC-KRWDZBQOSA-N","InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)/t17-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Hydroxy-DA-8164","NULL","DXPHYLTXNUWGJL-UHFFFAOYSA-N","InChI=1S/C25H36N6O5S/c1-5-8-19-22-23(31(4)29-19)25(33)28-24(27-22)18-15-17(10-11-20(18)36-21(32)6-2)37(34,35)26-13-12-16-9-7-14-30(16)3/h10-11,15-16,21,26,32H,5-9,12-14H2,1-4H3,(H,27,28,33)","PMID:15801542"
"BIOTID00924","schembl69463","57417237","IYFNEFQTYQPVOC-KRWDZBQOSA-N","InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)/t17-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Hydroxy-DA-8164","NULL","RVNYBPJBGREPNU-UHFFFAOYSA-N","InChI=1S/C25H36N6O5S/c1-5-7-20-22-23(31(4)29-20)25(33)28-24(27-22)19-14-18(9-10-21(19)36-15-16(2)32)37(34,35)26-12-11-17-8-6-13-30(17)3/h9-10,14,16-17,26,32H,5-8,11-13,15H2,1-4H3,(H,27,28,33)","PMID:15801542"
"BIOTID00925","schembl69463","57417237","IYFNEFQTYQPVOC-KRWDZBQOSA-N","InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)/t17-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Hydroxy-DA-8164","NULL","UJBLEAFWMWIAOV-UHFFFAOYSA-N","InChI=1S/C25H36N6O5S/c1-4-7-20-22-23(31(3)29-20)25(33)28-24(27-22)19-16-18(9-10-21(19)36-15-6-14-32)37(34,35)26-12-11-17-8-5-13-30(17)2/h9-10,16-17,26,32H,4-8,11-15H2,1-3H3,(H,27,28,33)","PMID:15801542"
"BIOTID00926","schembl7562446","10969297","ILMMRHUILQOQGP-AWEZNQCLSA-N","InChI=1S/C18H27NO2S/c1-17(2,3)12-7-11(9-14-16(21)19-10-22-14)8-13(15(12)20)18(4,5)6/h7-8,14,20H,9-10H2,1-6H3,(H,19,21)/t14-/m0/s1","CYP3A4","S-Oxidation","Human Phase I","Human","NULL","18936387","GFFXGNKATQVCIR-UHFFFAOYSA-N","InChI=1S/C18H27NO3S/c1-17(2,3)12-7-11(8-13(15(12)20)18(4,5)6)9-14-16(21)19-10-23(14)22/h7-8,14,20H,9-10H2,1-6H3,(H,19,21)","PMID:9394028"
"BIOTID00927","schembl7750160","45138909","DVGIHSLYADPMSE-UHFFFAOYSA-N","InChI=1S/C20H23F3N2S/c1-24(2)12-6-3-7-13-25-16-8-4-5-9-18(16)26-19-11-10-15(14-17(19)25)20(21,22)23/h4-5,8-11,14H,3,6-7,12-13H2,1-2H3","CYP2D6","N-Oxidation","Human Phase I","Human","NULL","101650225","NBPRPUCNHGYVEJ-UHFFFAOYSA-N","InChI=1S/C20H23F3N2OS/c1-25(2,26)13-7-3-6-12-24-16-8-4-5-9-18(16)27-19-11-10-15(14-17(19)24)20(21,22)23/h4-5,8-11,14H,3,6-7,12-13H2,1-2H3","PMID:8100507"
"BIOTID00928","schembl7750160","45138909","DVGIHSLYADPMSE-UHFFFAOYSA-N","InChI=1S/C20H23F3N2S/c1-24(2)12-6-3-7-13-25-16-8-4-5-9-18(16)26-19-11-10-15(14-17(19)25)20(21,22)23/h4-5,8-11,14H,3,6-7,12-13H2,1-2H3","CYP2C19;CYP2D6;CYP2E1;CYP3A4","S-Oxidation","Human Phase I","Human","NULL","101650227","GRTMVBFSTRAPKU-UHFFFAOYSA-N","InChI=1S/C20H23F3N2OS/c1-24(2)12-6-3-7-13-25-16-8-4-5-9-18(16)27(26)19-11-10-15(14-17(19)25)20(21,22)23/h4-5,8-11,14H,3,6-7,12-13H2,1-2H3","PMID:8100507"
"BIOTID00929","schembl895799","66833621","XRXFSKOKCIPNGH-LBPRGKRZSA-N","InChI=1S/C16H16N2OS/c1-12(18-16(17)19)7-8-14-9-10-15(20-14)11-13-5-3-2-4-6-13/h2-6,9-10,12H,11H2,1H3,(H3,17,18,19)/t12-/m0/s1","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4;CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","ABT-438 Hydroxy","NULL","HXOAUZPJYPAHKC-UHFFFAOYSA-N","InChI=1S/C16H16N2O2S/c1-11(18-16(17)20)7-8-13-9-10-14(21-13)15(19)12-5-3-2-4-6-12/h2-6,9-11,15,19H,1H3,(H3,17,18,20)","PMID:9763401"
"BIOTID00930","schembl896413","87173364","RXRULMGJKSLDFM-INIZCTEOSA-N","InChI=1S/C20H17F3N2O4S/c1-29-15-8-12(9-16-18(27)25-19(28)30-16)4-7-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)/t16-/m0/s1","CYP2C9;CYP2C19","O-Demethylation","Human Phase I","Human","M28","NULL","XJKSCTMDKCDXOC-UHFFFAOYSA-N","InChI=1S/C19H15F3N2O5S/c20-19(21,22)12-4-1-10(2-5-12)9-23-15(26)13-6-3-11(7-14(13)25)8-18(29)16(27)24-17(28)30-18/h1-7,25,29H,8-9H2,(H,23,26)(H,24,27,28)","PMID:15319345"
"BIOTID00931","schembl896413","87173364","RXRULMGJKSLDFM-INIZCTEOSA-N","InChI=1S/C20H17F3N2O4S/c1-29-15-8-12(9-16-18(27)25-19(28)30-16)4-7-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)/t16-/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","M24","NULL","YKPJDLODJPNMHH-UHFFFAOYSA-N","InChI=1S/C20H17F3N2O5S/c1-30-15-8-12(9-19(29)17(27)25-18(28)31-19)4-7-14(15)16(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,29H,9-10H2,1H3,(H,24,26)(H,25,27,28)","PMID:15319345"
"BIOTID00932","schembl896413","87173364","RXRULMGJKSLDFM-INIZCTEOSA-N","InChI=1S/C20H17F3N2O4S/c1-29-15-8-12(9-16-18(27)25-19(28)30-16)4-7-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)/t16-/m0/s1","CYP3A4","S-Oxidation","Human Phase I","Human","NULL","NULL","KEOXSUOAVNEEMC-UHFFFAOYSA-N","InChI=1S/C20H17F3N2O5S/c1-30-15-8-12(9-16-18(27)25-19(28)31(16)29)4-7-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)","PMID:15319345"
"BIOTID00933","schembl9652240","14649075","FZXAQGVGSAANBR-GMSGAONNSA-N","InChI=1S/C10H12N2OS/c1-7-9(13)12(2)10(14-7)8-4-3-5-11-6-8/h3-7,10H,1-2H3/t7-,10-/m1/s1","CYP2A6","S-Oxidation","Human Phase I","Human","NULL","NULL","XDJNJKFGIISUQK-UHFFFAOYSA-N","InChI=1S/C10H12N2O2S/c1-7-9(13)12(2)10(15(7)14)8-4-3-5-11-6-8/h3-7,10H,1-2H3","PMID:8627557"
"BIOTID00934","sdz_imm_125","6436153","XZDDMPMZGYEESG-VNHFGJPGSA-N","InChI=1S/C64H115N11O14/c1-24-26-27-42(15)54(78)53-58(82)66-44(25-2)59(83)69(17)34-50(77)70(18)46(30-36(3)4)57(81)68-51(40(11)12)63(87)71(19)47(31-37(5)6)56(80)65-43(16)55(79)67-45(35-89-29-28-76)60(84)72(20)48(32-38(7)8)61(85)73(21)49(33-39(9)10)62(86)74(22)52(41(13)14)64(88)75(53)23/h24,26,36-49,51-54,76,78H,25,27-35H2,1-23H3,(H,65,80)(H,66,82)(H,67,79)(H,68,81)/b26-24+/t42-,43+,44+,45-,46+,47+,48+,49+,51+,52+,53+,54-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","JYCRZIQUYSGOPA-OCOZRVBESA-N","InChI=1S/C64H115N11O15/c1-23-44-59(84)69(16)34-50(78)70(17)46(30-36(2)3)57(82)68-51(40(10)11)63(88)71(18)47(31-37(4)5)56(81)65-43(15)55(80)67-45(35-90-29-28-77)60(85)72(19)48(32-38(6)7)61(86)73(20)49(33-39(8)9)62(87)74(21)52(41(12)13)64(89)75(22)53(58(83)66-44)54(79)42(14)26-24-25-27-76/h24-25,36-49,51-54,76-77,79H,23,26-35H2,1-22H3,(H,65,81)(H,66,83)(H,67,80)(H,68,82)/b25-24+","PMID:7628296"
"BIOTID00935","sdz_imm_125","6436153","XZDDMPMZGYEESG-VNHFGJPGSA-N","InChI=1S/C64H115N11O14/c1-24-26-27-42(15)54(78)53-58(82)66-44(25-2)59(83)69(17)34-50(77)70(18)46(30-36(3)4)57(81)68-51(40(11)12)63(87)71(19)47(31-37(5)6)56(80)65-43(16)55(79)67-45(35-89-29-28-76)60(84)72(20)48(32-38(7)8)61(85)73(21)49(33-39(9)10)62(86)74(22)52(41(13)14)64(88)75(53)23/h24,26,36-49,51-54,76,78H,25,27-35H2,1-23H3,(H,65,80)(H,66,82)(H,67,79)(H,68,81)/b26-24+/t42-,43+,44+,45-,46+,47+,48+,49+,51+,52+,53+,54-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","UVCAQZQZHCIPSQ-SHHOIMCASA-N","InChI=1S/C64H115N11O15/c1-24-26-27-41(13)52(78)51-57(82)66-43(25-2)58(83)69(17)34-49(77)70(18)45(30-36(3)4)56(81)68-53(64(15,16)89)63(88)71(19)46(31-37(5)6)55(80)65-42(14)54(79)67-44(35-90-29-28-76)59(84)72(20)47(32-38(7)8)60(85)73(21)48(33-39(9)10)61(86)74(22)50(40(11)12)62(87)75(51)23/h24,26,36-48,50-53,76,78,89H,25,27-35H2,1-23H3,(H,65,80)(H,66,82)(H,67,79)(H,68,81)/b26-24+","PMID:7628296"
"BIOTID00936","sdz_imm_125","6436153","XZDDMPMZGYEESG-VNHFGJPGSA-N","InChI=1S/C64H115N11O14/c1-24-26-27-42(15)54(78)53-58(82)66-44(25-2)59(83)69(17)34-50(77)70(18)46(30-36(3)4)57(81)68-51(40(11)12)63(87)71(19)47(31-37(5)6)56(80)65-43(16)55(79)67-45(35-89-29-28-76)60(84)72(20)48(32-38(7)8)61(85)73(21)49(33-39(9)10)62(86)74(22)52(41(13)14)64(88)75(53)23/h24,26,36-49,51-54,76,78H,25,27-35H2,1-23H3,(H,65,80)(H,66,82)(H,67,79)(H,68,81)/b26-24+/t42-,43+,44+,45-,46+,47+,48+,49+,51+,52+,53+,54-/m1/s1","CYP3A4","N-Dementhylation","Human Phase I","Human","NULL","NULL","WZXLDFUTSRQGBK-WJTDDFOZSA-N","InChI=1S/C63H113N11O14/c1-23-25-26-41(15)53(77)52-58(82)65-43(24-2)59(83)69(17)33-49(76)70(18)46(30-36(5)6)57(81)68-50(39(11)12)62(86)72(20)47(31-37(7)8)55(79)64-42(16)54(78)67-45(34-88-28-27-75)61(85)71(19)48(32-38(9)10)56(80)66-44(29-35(3)4)60(84)73(21)51(40(13)14)63(87)74(52)22/h23,25,35-48,50-53,75,77H,24,26-34H2,1-22H3,(H,64,79)(H,65,82)(H,66,80)(H,67,78)(H,68,81)/b25-23+","PMID:7628296"
"BIOTID00937","selegiline","26757","MEZLKOACVSPNER-GFCCVEGCSA-N","InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1","CYP2B6 (major); CYP2C19; CYP2D6; CYP1A2; CYP2C9; CYP3A4","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","Desmethylselegiline","185859","UUFAJPMQSFXDFR-LLVKDONJSA-N","InChI=1S/C12H15N/c1-3-9-13-11(2)10-12-7-5-4-6-8-12/h1,4-8,11,13H,9-10H2,2H3/t11-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00938","selegiline","26757","MEZLKOACVSPNER-GFCCVEGCSA-N","InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1","CYP2B6; CYP2C19; CYP2D6; CYP1A2; CYP2C9; CYP3A4","N-depropargylation of secondary or tertiary amine","Human Phase I","Human","Methamphetamine","36604","MYWUZJCMWCOHBA-SECBINFHSA-N","InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00939","senecionine","12299899","HKODIGSRFALUTA-RCDLFFMESA-N","InChI=1S/C18H25NO5/c1-4-12-9-11(2)18(3,22)17(21)23-10-13-5-7-19-8-6-14(15(13)19)24-16(12)20/h4-5,11,14-15,22H,6-10H2,1-3H3/b12-4-/t11-,14+,15+,18+/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","(Ã‚Â± )-6,7-dmydn>7-hydroxy-l-hydroxymethyl-5J/-pyrrolizine (DHP)","NULL","STGQXXNYKQCDKN-UUILKARUSA-N","InChI=1S/C18H25NO6/c1-4-12-9-11(2)17(3,22)16(21)24-10-13-5-7-19-8-6-14(18(13,19)23)25-15(12)20/h4-5,11,14,22-23H,6-10H2,1-3H3/b12-4+","PMID:2009596"
"BIOTID00940","senecionine","12299899","HKODIGSRFALUTA-RCDLFFMESA-N","InChI=1S/C18H25NO5/c1-4-12-9-11(2)18(3,22)17(21)23-10-13-5-7-19-8-6-14(15(13)19)24-16(12)20/h4-5,11,14-15,22H,6-10H2,1-3H3/b12-4-/t11-,14+,15+,18+/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","YXLYGHNKJZQMEC-NYYWCZLTSA-N","InChI=1S/C18H25NO6/c1-4-11-7-10(2)18(3,23)17(22)24-9-12-8-14(20)19-6-5-13(15(12)19)25-16(11)21/h4,8,10,13-15,20,23H,5-7,9H2,1-3H3/b11-4+","PMID:2009596"
"BIOTID00941","senecionine","12299899","HKODIGSRFALUTA-RCDLFFMESA-N","InChI=1S/C18H25NO5/c1-4-12-9-11(2)18(3,22)17(21)23-10-13-5-7-19-8-6-14(15(13)19)24-16(12)20/h4-5,11,14-15,22H,6-10H2,1-3H3/b12-4-/t11-,14+,15+,18+/m0/s1","CYP3A4","N-Oxidation","Human Phase I","Human","senecionine N-oxide","NULL","PLGBHVNNYDZWGZ-UUILKARUSA-N","InChI=1S/C18H25NO6/c1-4-12-9-11(2)18(3,22)17(21)24-10-13-5-7-19(23)8-6-14(15(13)19)25-16(12)20/h4-5,11,14-15,22H,6-10H2,1-3H3/b12-4+","PMID:2009596"
"BIOTID00942","serotonin","5202","QZAYGJVTTNCVMB-UHFFFAOYSA-N","InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2","CYP2B6 (major); CYP2C19; CYP2D6; CYP1A2; CYP2C9; CYP3A4","Unknown Reduction","Human Phase I","Human","NULL","15366337","JYVGHERHVBFYJB-UHFFFAOYSA-N","InChI=1S/C10H11NO/c1-2-7-6-11-10-4-3-8(12)5-9(7)10/h3-6,11-12H,2H2,1H3","PMID:14718257"
"BIOTID00943","sertindole","60149","GZKLJWGUPQBVJQ-UHFFFAOYSA-N","InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","21460411","ISUNIKFVOFAUHU-UHFFFAOYSA-N","InChI=1S/C24H26ClFN4O2/c25-17-1-6-22-20(13-17)21(14-30(22)19-4-2-18(26)3-5-19)16-7-9-28(10-8-16)11-12-29-15-23(31)27-24(29)32/h1-6,13-14,16,23,31H,7-12,15H2,(H,27,32)","PMID:10482125"
"BIOTID00944","sertindole","60149","GZKLJWGUPQBVJQ-UHFFFAOYSA-N","InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)","CYP2D6","N-dealkylation","Human Phase I","Human","NULL","9862272","YCXCLZSLZGBCTA-UHFFFAOYSA-N","InChI=1S/C19H18ClFN2/c20-14-1-6-19-17(11-14)18(13-7-9-22-10-8-13)12-23(19)16-4-2-15(21)3-5-16/h1-6,11-13,22H,7-10H2","PMID:10482125"
"BIOTID00945","sertraline","68617","VGKDLMBJGBXTGI-SJCJKPOMSA-N","InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1","CYP1A2;CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","N-desmethylation","Human Phase I","Human","N-desmethylsertraline","577181","SRPXSILJHWNFMK-UHFFFAOYSA-N","InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2","PMID:15547048"
"BIOTID00946","sildenafil","5212","BNRNXUUZRGQAQC-UHFFFAOYSA-N","InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)","CYP3A4; CYP2C9; CYP2C19; CYP2D6","N-dealkylation of sulfonamide","Human Phase I","Human","N-Desmethyl sildenafil","NULL","VACAHCFUDUBDNR-UHFFFAOYSA-N","InChI=1S/C17H20N4O4S/c1-4-6-12-14-15(21(3)20-12)17(22)19-16(18-14)11-9-10(26(23)24)7-8-13(11)25-5-2/h7-9,26H,4-6H2,1-3H3,(H,18,19,22)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00947","simvastatin","54454","RYMZZMVNJRMUDD-HGQWONQESA-N","InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1","CYP3A4; CYP3A5","Allylic hydroxylation","Human Phase I","Human","6'-ÃŽÂ²-Hydroxysimvastatin ","25221209","WJKSTNFUSXHVRJ-ZEUMIXTGSA-N","InChI=1S/C25H38O6/c1-6-24(3,4)23(28)31-20-14-25(5,29)13-16-8-7-15(2)19(22(16)20)10-9-18-11-17(26)12-21(27)30-18/h7-8,13,15,17-20,22,26,29H,6,9-12,14H2,1-5H3/t15-,17+,18+,19-,20-,22-,25+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00948","simvastatin","54454","RYMZZMVNJRMUDD-HGQWONQESA-N","InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1","CYP3A4; CYP3A5","Aliphatic hydroxylation of acyclic 1,2-disubstituted alkene","Human Phase I","Human","3', 5'-Dihydrodiol","102329665","MRCKOKWQDZYFLT-IHHACARCSA-N","InChI=1S/C25H40O7/c1-6-25(4,5)24(30)32-20-9-13(2)23(29)18-12-19(27)14(3)17(22(18)20)8-7-16-10-15(26)11-21(28)31-16/h12-17,19-20,22-23,26-27,29H,6-11H2,1-5H3/t13-,14-,15-,16-,17+,19?,20+,22-,23?/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID00949","simvastatin","54454","RYMZZMVNJRMUDD-HGQWONQESA-N","InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1","CYP3A4; CYP3A5","Terminal desaturation","Human Phase I","Human","6'-exomethylene","15925972","WDTQWJUBUXHODX-BGYTUHEHSA-N","InChI=1S/C25H36O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,16,18-21,23,26H,2,6,9-10,12-14H2,1,3-5H3/t16-,18+,19+,20-,21-,23-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259987"
"BIOTID00950","sirolimus","NULL","QFJCIRLUMZQUOT-HPLJOQBZSA-N","InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,31-17+,35-25-/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42-,43+,44-,46-,47+,51-/m1/s1","CYP3A4","O-dealkylation of dialkylether","Human Phase I","Human","39-O-Desmethylsirolimus","NULL","RGRYVHKBWYXMGM-KPMJGVQNSA-N","InChI=1S/C50H77NO13/c1-29-15-11-10-12-16-30(2)42(61-8)27-37-20-18-35(7)50(60,64-37)47(57)48(58)51-22-14-13-17-38(51)49(59)63-43(32(4)25-36-19-21-39(52)41(54)26-36)28-40(53)31(3)24-34(6)45(56)46(62-9)44(55)33(5)23-29/h10-12,15-16,24,29,31-33,35-39,41-43,45-46,52,54,56,60H,13-14,17-23,25-28H2,1-9H3/b12-10+,15-11-,30-16+,34-24-/t29-,31+,32+,33+,35+,36-,37-,38-,39+,41+,42+,43-,45+,46-,50+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID00951","sirolimus","NULL","QFJCIRLUMZQUOT-HPLJOQBZSA-N","InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,31-17+,35-25-/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42-,43+,44-,46-,47+,51-/m1/s1","CYP3A4","O-dealkylation of dialkylether","Human Phase I","Human","16-O-Desmethylsirolimus","NULL","ZHYGVVKSAGDVDY-YUVJXFDRSA-N","InChI=1S/C50H77NO13/c1-29-15-11-10-12-16-30(2)40(53)27-37-20-18-35(7)50(60,64-37)47(57)48(58)51-22-14-13-17-38(51)49(59)63-42(32(4)25-36-19-21-39(52)43(26-36)61-8)28-41(54)31(3)24-34(6)45(56)46(62-9)44(55)33(5)23-29/h10-12,15-16,24,29,31-33,35-40,42-43,45-46,52-53,56,60H,13-14,17-23,25-28H2,1-9H3/b12-10+,15-11-,30-16+,34-24-/t29-,31-,32-,33-,35-,36+,37+,38+,39-,40+,42+,43-,45-,46+,50-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID00952","sirolimus","NULL","QFJCIRLUMZQUOT-HPLJOQBZSA-N","InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,31-17+,35-25-/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42-,43+,44-,46-,47+,51-/m1/s1","CYP3A4","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","12-OH-sirolimus","NULL","IPSCPJKWFFXCSS-JCJQFHSISA-N","InChI=1S/C51H79NO14/c1-29-16-12-11-13-17-30(2)42(62-8)27-37-26-41(55)35(7)51(61,66-37)48(58)49(59)52-21-15-14-18-38(52)50(60)65-43(32(4)24-36-19-20-39(53)44(25-36)63-9)28-40(54)31(3)23-34(6)46(57)47(64-10)45(56)33(5)22-29/h11-13,16-17,23,29,31-33,35-39,41-44,46-47,53,55,57,61H,14-15,18-22,24-28H2,1-10H3/b13-11+,16-12-,30-17+,34-23-/t29-,31+,32+,33+,35+,36-,37-,38-,39+,41?,42+,43-,44+,46+,47-,51+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259987"
"BIOTID00953","sirolimus","NULL","QFJCIRLUMZQUOT-HPLJOQBZSA-N","InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,31-17+,35-25-/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42-,43+,44-,46-,47+,51-/m1/s1","CYP3A4","Hydroxylation of alkyl methine","Human Phase I","Human","11-OH-sirolimus","NULL","VNPBYTOPCULMPL-DAYGUYCOSA-N","InChI=1S/C51H79NO14/c1-30-16-12-11-13-17-31(2)41(62-8)28-37-21-22-50(7,60)51(61,66-37)47(57)48(58)52-23-15-14-18-38(52)49(59)65-42(33(4)26-36-19-20-39(53)43(27-36)63-9)29-40(54)32(3)25-35(6)45(56)46(64-10)44(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-39,41-43,45-46,53,56,60-61H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,31-17+,35-25-/t30-,32+,33+,34+,36-,37-,38-,39+,41+,42-,43+,45+,46-,50-,51-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259988"
"BIOTID00954","sirolimus","NULL","QFJCIRLUMZQUOT-HPLJOQBZSA-N","InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,31-17+,35-25-/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42-,43+,44-,46-,47+,51-/m1/s1","CYP3A4","Hydroxylation of alkyl methine","Human Phase I","Human","25-OH-sirolimus","NULL","JMPXWMAQDNEFCU-JNMYBDOASA-N","InChI=1S/C51H79NO14/c1-30-16-12-11-13-17-31(2)41(62-8)27-37-21-19-35(6)51(61,66-37)47(57)48(58)52-23-15-14-18-38(52)49(59)65-42(33(4)25-36-20-22-39(53)43(26-36)63-9)28-40(54)32(3)24-34(5)44(55)45(64-10)46(56)50(7,60)29-30/h11-13,16-17,24,30,32-33,35-39,41-45,53,55,60-61H,14-15,18-23,25-29H2,1-10H3/b13-11+,16-12-,31-17+,34-24-/t30-,32+,33+,35+,36-,37-,38-,39+,41+,42-,43+,44+,45+,50-,51+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259989"
"BIOTID00955","sirolimus","NULL","QFJCIRLUMZQUOT-HPLJOQBZSA-N","InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,31-17+,35-25-/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42-,43+,44-,46-,47+,51-/m1/s1","CYP3A4","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","24-OH-sirolimus","NULL","HEOYJBLRGSZZKU-ARAZPPGESA-N","InChI=1S/C51H79NO14/c1-29-16-12-11-13-17-30(2)44(55)35(7)46(57)47(64-10)45(56)33(5)24-31(3)40(54)28-42(32(4)25-36-20-22-39(53)43(26-36)63-9)65-50(60)38-18-14-15-23-52(38)49(59)48(58)51(61)34(6)19-21-37(66-51)27-41(29)62-8/h11-13,16-17,24,30-32,34-39,41-45,47,53,55-56,61H,14-15,18-23,25-28H2,1-10H3/b12-11+,17-13-,29-16+,33-24-/t30-,31+,32+,34+,35+,36-,37-,38-,39+,41+,42-,43+,44?,45+,47+,51+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259990"
"BIOTID00956","sirolimus","NULL","QFJCIRLUMZQUOT-HPLJOQBZSA-N","InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,31-17+,35-25-/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42-,43+,44-,46-,47+,51-/m1/s1","CYP3A4","Hydroxylation of terminal methyl","Human Phase I","Human","46-OH-sirolimus","NULL","OEGQYPSSHFUXKW-JYIPRCQDSA-N","InChI=1S/C51H79NO14/c1-30-15-11-10-12-16-31(2)42(62-7)27-38-20-18-35(6)51(61,66-38)48(58)49(59)52-22-14-13-17-39(52)50(60)65-43(33(4)25-36-19-21-40(54)44(26-36)63-8)28-41(55)32(3)24-34(5)45(56)47(64-9)46(57)37(23-30)29-53/h10-12,15-16,24,30,32-33,35-40,42-45,47,53-54,56,61H,13-14,17-23,25-29H2,1-9H3/b12-10+,15-11-,31-16+,34-24-/t30-,32+,33+,35+,36-,37-,38-,39-,40+,42+,43-,44+,45+,47+,51+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259991"
"BIOTID00957","sparteine","644020","SLRCCWJSBJZJBV-ZQDZILKHSA-N","InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m0/s1","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","91747587","SUMYRMXHXLJUCO-UHFFFAOYSA-N","InChI=1S/C15H26N2O/c18-15-6-2-4-8-17(15)10-12-9-13(15)11-16-7-3-1-5-14(12)16/h12-14,18H,1-11H2","PMID:12392820"
"BIOTID00958","sparteine","644020","SLRCCWJSBJZJBV-ZQDZILKHSA-N","InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m0/s1","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","523576","AFEKUFYCNWZEGZ-UHFFFAOYSA-N","InChI=1S/C15H26N2O/c18-15-6-3-5-14-11-8-12(10-17(14)15)13-4-1-2-7-16(13)9-11/h11-15,18H,1-10H2","PMID:12392820"
"BIOTID00959","sparteine","644020","SLRCCWJSBJZJBV-ZQDZILKHSA-N","InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m0/s1","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","197754","JMXNBIDTNISOTA-UHFFFAOYSA-N","InChI=1S/C15H26N2O/c18-14-5-3-7-17-9-11-8-12(15(14)17)10-16-6-2-1-4-13(11)16/h11-15,18H,1-10H2","PMID:12392820"
"BIOTID00960","styrene","7501","PPBRXRYQALVLMV-UHFFFAOYSA-N","InChI=1S/C8H8/c1-2-8-6-4-3-5-7-8/h2-7H,1H2","CYP2E1","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","Styrene 7,8-oxide","7276","AWMVMTVKBNGEAK-UHFFFAOYSA-N","InChI=1S/C8H8O/c1-2-4-7(5-3-1)8-6-9-8/h1-5,8H,6H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259993"
"BIOTID00961","sulfadiazine","5215","SEEPANYCNGTZFQ-UHFFFAOYSA-N","InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)","CYP2B6;CYP2C8;CYP2C9;CYP2C19","Hydroxylation","Human Phase I","Human","NULL","45028334","BHNNTIGNLIYDOR-UHFFFAOYSA-N","InChI=1S/C10H10N4O3S/c15-13-8-2-4-9(5-3-8)18(16,17)14-10-11-6-1-7-12-10/h1-7,13,15H,(H,11,12,14)","PMID:15843491"
"BIOTID00962","sulfamethoxazole","5329","JLKIGFTWXXRPMT-UHFFFAOYSA-N","InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)","CYP2C9","N-hydroxylation of primary arylamine","Human Phase I","Human","Sulfamethoxazole N4-hydroxylamine","114821","MJAMPGKHIZXVFJ-UHFFFAOYSA-N","InChI=1S/C10H11N3O4S/c1-7-6-10(12-17-7)13-18(15,16)9-4-2-8(11-14)3-5-9/h2-6,11,14H,1H3,(H,12,13)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00963","tacrine","1935","YLJREFDVOIBQDA-UHFFFAOYSA-N","InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)","CYP1A2","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","N4-hydroxylamine","3655","HLVVITIHAZBPKB-UHFFFAOYSA-N","InChI=1S/C13H14N2O/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259993"
"BIOTID00964","tacrine","1935","YLJREFDVOIBQDA-UHFFFAOYSA-N","InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)","CYP1A2","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","4- Hydroxytacrine","179850","BISIFJGUTDFVFR-UHFFFAOYSA-N","InChI=1S/C13H14N2O/c14-12-8-4-1-2-6-10(8)15-13-9(12)5-3-7-11(13)16/h1-2,4,6,11,16H,3,5,7H2,(H2,14,15)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259993"
"BIOTID00965","tacrine","1935","YLJREFDVOIBQDA-UHFFFAOYSA-N","InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)","CYP1A2","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","2-Hydroxytacrine","179849","PYCYYSWVRAEADT-UHFFFAOYSA-N","InChI=1S/C13H14N2O/c14-13-9-3-1-2-4-11(9)15-12-6-5-8(16)7-10(12)13/h1-4,8,16H,5-7H2,(H2,14,15)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259993"
"BIOTID00966","tacrine","1935","YLJREFDVOIBQDA-UHFFFAOYSA-N","InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)","CYP1A2","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","7-Hydroxytacrine","NULL","XEUVIAIVRAPEEH-UHFFFAOYSA-N","InChI=1S/C13H14N2O/c14-12-8-4-1-2-6-10(8)15-13-9(12)5-3-7-11(13)16/h3,5,7,16H,1-2,4,6H2,(H2,14,15)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259993"
"BIOTID00967","tamarixetin","5281699","FPLMIPQZHHQWHN-UHFFFAOYSA-N","InChI=1S/C16H12O7/c1-22-11-3-2-7(4-9(11)18)16-15(21)14(20)13-10(19)5-8(17)6-12(13)23-16/h2-6,17-19,21H,1H3","CYP1A2;CYP2C9;CYP3A4","O-dealkylation","Human Phase I","Human","QUERCETIN","5280343","REFJWTPEDVJJIY-UHFFFAOYSA-N","InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H","PMID:11955666"
"BIOTID00968","tamoxifen","2733526","NKANXQFJJICGDU-QPLCGJKRSA-N","InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-","CYP2D6; CYP1A2; CYP1A1; CYP3A4; CYP1B1 (at a high concentration (250ÃŽÂ¼M)); CYP2C9 (at a high concentration (250ÃŽÂ¼M)); CYP2C19 (at a high concentration (250ÃŽÂ¼M)); CYP3A5 (at a high concentration (250ÃŽÂ¼M)); CYP2E1","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-Desmethyltamoxifen","6378383","NYDCDZSEEAUOHN-IZHYLOQSSA-N","InChI=1S/C25H27NO/c1-3-24(20-10-6-4-7-11-20)25(21-12-8-5-9-13-21)22-14-16-23(17-15-22)27-19-18-26-2/h4-17,26H,3,18-19H2,1-2H3/b25-24-","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00969","tamoxifen","2733526","NKANXQFJJICGDU-QPLCGJKRSA-N","InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-","CYP2D6 (major); CYP2B6; CYP2C9; CYP3A4 (at a high concentration (250ÃŽÂ¼M)); CYP1A1 (at a high concentration (250ÃŽÂ¼M)); CYP1A2 (at a high concentration (250ÃŽÂ¼M)); CYP3A5 (at a high concentration (250ÃŽÂ¼M))","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4-Hydroxytamoxifen","449459","TXUZVZSFRXZGTL-QPLCGJKRSA-N","InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00970","tamoxifen","2733526","NKANXQFJJICGDU-QPLCGJKRSA-N","InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-","CYP2D6; CYP2B6","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4'-Hydroxytamoxifen","5284643","DODQJNMQWMSYGS-QPLCGJKRSA-N","InChI=1S/C26H29NO2/c1-4-25(20-10-14-23(28)15-11-20)26(21-8-6-5-7-9-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00971","tamoxifen","2733526","NKANXQFJJICGDU-QPLCGJKRSA-N","InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-","CYP3A4; CYP2D6; CYP2B6 (give smaller amounts of ÃŽÂ±-hydroxylation); CYP2C9  (give smaller amounts of ÃŽÂ±-hydroxylation); CYP2C19 (give smaller amounts of ÃŽÂ±-hydroxylation); CYP3A5 (give smaller amounts of ÃŽÂ±-hydroxylation)","Hydroxylation of penultimate aliphatic secondary carbon","Human Phase I","Human","alpha-Hydroxytamoxifen","3036580","BPHFBQJMFWCHGH-QPLCGJKRSA-N","InChI=1S/C26H29NO2/c1-20(28)25(21-10-6-4-7-11-21)26(22-12-8-5-9-13-22)23-14-16-24(17-15-23)29-19-18-27(2)3/h4-17,20,28H,18-19H2,1-3H3/b26-25-","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00972","tamoxifen","2733526","NKANXQFJJICGDU-QPLCGJKRSA-N","InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-","CYP3A4; CYP3A5; CYP2B6","m-Hydroxylation of monosubstituted benzene","Human Phase I","Human","3-Hydroxytamoxifen","3033767","ZQZFYGIXNQKOAV-OCEACIFDSA-N","InChI=1S/C26H29NO2/c1-4-25(20-9-6-5-7-10-20)26(22-11-8-12-23(28)19-22)21-13-15-24(16-14-21)29-18-17-27(2)3/h5-16,19,28H,4,17-18H2,1-3H3/b26-25+","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00973","tamsulosin","129211","DRHKJLXJIQTDTD-OAHLLOKOSA-N","InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","VGTTUYQIYLNEKU-UHFFFAOYSA-N","InChI=1S/C20H28N2O6S/c1-4-27-17-8-6-16(23)13-19(17)28-10-9-22-14(2)11-15-5-7-18(26-3)20(12-15)29(21,24)25/h5-8,12-14,22-23H,4,9-11H2,1-3H3,(H2,21,24,25)","PMID:9849639"
"BIOTID00974","tamsulosin","129211","DRHKJLXJIQTDTD-OAHLLOKOSA-N","InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1","CYP2D6","O-Dementhylation","Human Phase I","Human","NULL","11510266","UIDNSBDGPKUJHU-UHFFFAOYSA-N","InChI=1S/C19H26N2O5S/c1-3-25-17-6-4-5-7-18(17)26-11-10-21-14(2)12-15-8-9-16(22)19(13-15)27(20,23)24/h4-9,13-14,21-22H,3,10-12H2,1-2H3,(H2,20,23,24)","PMID:9849639"
"BIOTID00975","tamsulosin","129211","DRHKJLXJIQTDTD-OAHLLOKOSA-N","InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1","CYP3A4","O-dealkylation","Human Phase I","Human","NULL","NULL","CIJUMNQLYUKWIH-UHFFFAOYSA-N","InChI=1S/C18H24N2O5S/c1-13(20-9-10-25-16-6-4-3-5-15(16)21)11-14-7-8-17(24-2)18(12-14)26(19,22)23/h3-8,12-13,20-21H,9-11H2,1-2H3,(H2,19,22,23)","PMID:9849639"
"BIOTID00977","tangeretin","68077","ULSUXBXHSYSGDT-UHFFFAOYSA-N","InChI=1S/C20H20O7/c1-22-12-8-6-11(7-9-12)14-10-13(21)15-16(23-2)18(24-3)20(26-5)19(25-4)17(15)27-14/h6-10H,1-5H3","CYP1A2;CYP2D6;CYP3A4","O-dealkylation","Human Phase I","Human","NULL","3010100","IECRXMSGDFIOEY-UHFFFAOYSA-N","InChI=1S/C19H18O7/c1-22-15-14-12(21)9-13(10-5-7-11(20)8-6-10)26-16(14)18(24-3)19(25-4)17(15)23-2/h5-9,20H,1-4H3","PMID:12828569"
"BIOTID00978","tangeretin","68077","ULSUXBXHSYSGDT-UHFFFAOYSA-N","InChI=1S/C20H20O7/c1-22-12-8-6-11(7-9-12)14-10-13(21)15-16(23-2)18(24-3)20(26-5)19(25-4)17(15)27-14/h6-10H,1-5H3","CYP3A4","O-dealkylation","Human Phase I","Human","NULL","44258635","VPLTZBCCUJNRIE-UHFFFAOYSA-N","InChI=1S/C18H16O7/c1-22-10-6-4-9(5-7-10)12-8-11(19)13-14(20)15(21)17(23-2)18(24-3)16(13)25-12/h4-8,20-21H,1-3H3","PMID:12828569"
"BIOTID00979","tauromustine","55456","RCLLNBVPCJDIPX-UHFFFAOYSA-N","InChI=1S/C7H15ClN4O4S/c1-11(2)17(15,16)6-4-9-7(13)12(10-14)5-3-8/h3-6H2,1-2H3,(H,9,13)","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","3086342","SATDQZURIZSSKI-UHFFFAOYSA-N","InChI=1S/C6H13ClN4O4S/c1-8-16(14,15)5-3-9-6(12)11(10-13)4-2-7/h8H,2-5H2,1H3,(H,9,12)","PMID:10553719"
"BIOTID00980","tauromustine","55456","RCLLNBVPCJDIPX-UHFFFAOYSA-N","InChI=1S/C7H15ClN4O4S/c1-11(2)17(15,16)6-4-9-7(13)12(10-14)5-3-8/h3-6H2,1-2H3,(H,9,13)","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP3A4","Denitrosation","Human Phase I","Human","NULL","3021902","RUIGAHCLEIQCRC-UHFFFAOYSA-N","InChI=1S/C7H16ClN3O3S/c1-11(2)15(13,14)6-5-10-7(12)9-4-3-8/h3-6H2,1-2H3,(H2,9,10,12)","PMID:10553719"
"BIOTID00981","taxol","14060306","RCINICONZNJXQF-YUKVPPSFSA-N","InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38+,40-,45+,46-,47+/m0/s1","CYP2C8","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","6ÃŽÂ±-Hydroxypaclitaxel ","125121557","NDCWHEDPSFRTDA-ZYWDROJESA-N","InChI=1S/C47H51NO15/c1-24-30(61-43(57)33(51)32(27-16-10-7-11-17-27)48-41(55)28-18-12-8-13-19-28)22-47(58)40(62-42(56)29-20-14-9-15-21-29)36-45(6,38(54)35(60-25(2)49)31(24)44(47,4)5)37(53)34(52)39-46(36,23-59-39)63-26(3)50/h7-21,30,32-37,39-40,51-53,58H,22-23H2,1-6H3,(H,48,55)/t30-,32-,33+,34-,35+,36+,37-,39+,40-,45-,46+,47+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00982","taxol","14060306","RCINICONZNJXQF-YUKVPPSFSA-N","InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38+,40-,45+,46-,47+/m0/s1","CYP3A4 ","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","3Ã¢â‚¬Â²-pHydroxypaclitaxel ","90469727","XKSMHFPSILYEIA-YUKVPPSFSA-N","InChI=1S/C47H51NO15/c1-24-31(61-43(57)36(53)35(27-17-19-30(51)20-18-27)48-41(55)28-13-9-7-10-14-28)22-47(58)40(62-42(56)29-15-11-8-12-16-29)38-45(6,32(52)21-33-46(38,23-59-33)63-26(3)50)39(54)37(60-25(2)49)34(24)44(47,4)5/h7-20,31-33,35-38,40,51-53,58H,21-23H2,1-6H3,(H,48,55)/t31-,32-,33+,35-,36+,37+,38+,40-,45+,46-,47+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996016"
"BIOTID00983","tecalcet","158797","ZVQUCWXZCKWZBP-CQSZACIVSA-N","InChI=1S/C18H22ClNO/c1-14(16-8-5-10-17(13-16)21-2)20-12-6-9-15-7-3-4-11-18(15)19/h3-5,7-8,10-11,13-14,20H,6,9,12H2,1-2H3/t14-/m1/s1","CYP2D6","O-Dementhylation","Human Phase I","Human","NULL","NULL","XASQTOWQYHDYHU-UHFFFAOYSA-N","InChI=1S/C17H20ClNO/c1-13(15-7-4-9-16(20)12-15)19-11-5-8-14-6-2-3-10-17(14)18/h2-4,6-7,9-10,12-13,19-20H,5,8,11H2,1H3","PMID:15060507"
"BIOTID00984","tegaserod","NULL","IKBKZGMPCYNSLU-RGVLZGJSSA-N","InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+","CYP1A2;CYP2D6","O-desmethylation","Human Phase I","Human","NULL","NULL","XOIKMYVDZKDZFH-VXLYETTFSA-N","InChI=1S/C15H21N5O/c1-2-3-4-7-17-15(16)20-19-10-11-9-18-14-6-5-12(21)8-13(11)14/h5-6,8-10,18,21H,2-4,7H2,1H3,(H3,16,17,20)/b19-10+","PMID:11560869"
"BIOTID00985","teniposide","452548","NRUKOCRGYNPUPR-QBPJDGROSA-N","InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1","CYP3A4; CYP3A5 ","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","Teniposide catechol ","101670240","HFNGFXBXLSRAKX-KHIFWGIGSA-N","InChI=1S/C31H30O13S/c1-37-19-6-12(5-16(32)24(19)33)22-13-7-17-18(41-11-40-17)8-14(13)27(15-9-38-29(36)23(15)22)43-31-26(35)25(34)28-20(42-31)10-39-30(44-28)21-3-2-4-45-21/h2-8,15,20,22-23,25-28,30-35H,9-11H2,1H3/t15-,20+,22+,23-,25+,26+,27+,28+,30+,31-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID00986","tenoxicam","54677971","WZWYJBNHTWCXIM-JLHYYAGUSA-N","InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,18H,1H3,(H,14,15)/b13-10+","CYP2C9","HYDROXYLATION_OF_HETEROAROMATIC_CARBON","Human Phase I","Human","5'-Hydroxytenoxicam","54692969","INPPRTDYEGRTIU-JLHYYAGUSA-N","InChI=1S/C13H11N3O5S2/c1-16-10(13(19)15-9-3-2-7(17)6-14-9)11(18)12-8(4-5-22-12)23(16,20)21/h2-6,17,19H,1H3,(H,14,15)/b13-10+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00987","tentoxin","6442695","SIIRBDOFKDACOK-YQMBXKBSSA-N","InChI=1S/C22H30N4O4/c1-14(2)11-17-22(30)26(5)18(12-16-9-7-6-8-10-16)21(29)23-13-19(27)25(4)15(3)20(28)24-17/h6-10,12,14-15,17H,11,13H2,1-5H3,(H,23,29)(H,24,28)/b18-12+/t15-,17-/m0/s1","CYP3A4","N-Dementhylation","Human Phase I","Human","NULL","NULL","YVPZVARRXUXCDO-GZTJUZNOSA-N","InChI=1S/C21H28N4O4/c1-13(2)10-16-21(29)24-17(11-15-8-6-5-7-9-15)20(28)22-12-18(26)25(4)14(3)19(27)23-16/h5-9,11,13-14,16H,10,12H2,1-4H3,(H,22,28)(H,23,27)(H,24,29)/b17-11+","PMID:9432003"
"BIOTID00988","terbinafine","1549008","DOMXUEMWDBAQBQ-WEVVVXLNSA-N","InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+","CYP2C8; CYP2C9; CYP1A2","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES","Human Phase I","Human","N-Desmethylterbinafine","6443233","IZJZLXQHMWUCIC-XBXARRHUSA-N","InChI=1S/C20H23N/c1-20(2,3)14-7-4-8-15-21-16-18-12-9-11-17-10-5-6-13-19(17)18/h4-6,8-13,21H,15-16H2,1-3H3/b8-4+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID00989","terbinafine","1549008","DOMXUEMWDBAQBQ-WEVVVXLNSA-N","InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+","CYP1A2; CYP2C8; CYP2C9; CYP2C19","Hydroxylation of terminal methyl","Human Phase I","Human","Hydroxyterbinafine","21917706","GPEJUKJZTGFNKY-XBXARRHUSA-N","InChI=1S/C21H25NO/c1-21(2,17-23)14-7-4-8-15-22(3)16-19-12-9-11-18-10-5-6-13-20(18)19/h4-6,8-13,23H,15-17H2,1-3H3/b8-4+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3676"
"BIOTID00990","terbinafine","1549008","DOMXUEMWDBAQBQ-WEVVVXLNSA-N","InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+","CYP3A4","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1","Human Phase I","Human","1-Naphtaldehyde","6195","SQAINHDHICKHLX-UHFFFAOYSA-N","InChI=1S/C11H8O/c12-8-10-6-3-5-9-4-1-2-7-11(9)10/h1-8H","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3677"
"BIOTID00993","terbuthylazine","22206","FZXISNSWEXTPMF-UHFFFAOYSA-N","InChI=1S/C9H16ClN5/c1-5-11-7-12-6(10)13-8(14-7)15-9(2,3)4/h5H2,1-4H3,(H2,11,12,13,14,15)","CYP1A2;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","NHBGKDZTEJYFPM-UHFFFAOYSA-N","InChI=1S/C9H16ClN5O/c1-5(16)11-7-12-6(10)13-8(14-7)15-9(2,3)4/h5,16H,1-4H3,(H2,11,12,13,14,15)","PMID:9305587"
"BIOTID00994","terbuthylazine","22206","FZXISNSWEXTPMF-UHFFFAOYSA-N","InChI=1S/C9H16ClN5/c1-5-11-7-12-6(10)13-8(14-7)15-9(2,3)4/h5H2,1-4H3,(H2,11,12,13,14,15)","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","779516","QMTYNRYLLIJMHR-UHFFFAOYSA-N","InChI=1S/C9H16ClN5O/c1-4-11-7-12-6(10)13-8(14-7)15-9(2,3)5-16/h16H,4-5H2,1-3H3,(H2,11,12,13,14,15)","PMID:9305587"
"BIOTID00995","territrem a","44559227","LCJHAHVVYAVVPA-JUDWXZBOSA-N","InChI=1S/C28H30O9/c1-24(2)7-6-21(29)26(4)27(24,31)9-8-25(3)28(26,32)13-16-18(37-25)12-17(36-23(16)30)15-10-19(33-5)22-20(11-15)34-14-35-22/h6-7,10-12,31-32H,8-9,13-14H2,1-5H3/t25-,26+,27-,28-/m1/s1","CYP2C9;CYP2D6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","DNMPMGBSBIYLIH-UHFFFAOYSA-N","InChI=1S/C28H30O10/c1-24(13-29)6-5-21(30)26(3)27(24,32)8-7-25(2)28(26,33)12-16-18(38-25)11-17(37-23(16)31)15-9-19(34-4)22-20(10-15)35-14-36-22/h5-6,9-11,29,32-33H,7-8,12-14H2,1-4H3","PMID:12851121"
"BIOTID00996","tert-amyl methyl ether","61247","HVZJRWJGKQPSFL-UHFFFAOYSA-N","InChI=1S/C6H14O/c1-5-6(2,3)7-4/h5H2,1-4H3","CYP2A6;CYP2E1","O-desmethylation","Human Phase I","Human","tert-amyl alcohol","6405","MSXVEPNJUHWQHW-UHFFFAOYSA-N","InChI=1S/C5H12O/c1-4-5(2,3)6/h6H,4H2,1-3H3","PMID:9101044"
"BIOTID00997","tert-butyl ethyl ether (ETBE)","12512","NUMQCACRALPSHD-UHFFFAOYSA-N","InChI=1S/C6H14O/c1-5-7-6(2,3)4/h5H2,1-4H3","CYP2A6;CYP2E1","O-desmethylation","Human Phase I","Human","Tert-butanol","6386","DKGAVHZHDRPRBM-UHFFFAOYSA-N","InChI=1S/C4H10O/c1-4(2,3)5/h5H,1-3H3","PMID:9101044"
"BIOTID00998","tert-butyl methyl ether","15413","BZLVMXJERCGZMT-UHFFFAOYSA-N","InChI=1S/C5H12O/c1-5(2,3)6-4/h1-4H3","CYP2A6;CYP2E1","O-desmethylation","Human Phase I","Human","Tert-butanol","6386","DKGAVHZHDRPRBM-UHFFFAOYSA-N","InChI=1S/C4H10O/c1-4(2,3)5/h5H,1-3H3","PMID:9101044"
"BIOTID00999","testosterone","6013","MUMGGOZAMZWBJJ-DYKIIFRCSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","CYP3A4; CYP3A5;  CYP2C9; CYP1A1; CYP1B1","Hydroxylation of carbon gamma to conjugated carbonyl","Human Phase I","Human","6ÃŽÂ²Hydroxytestosterone ","65543","XSEGWEUVSZRCBC-ZVBLRVHNSA-N","InChI=1S/C19H28O3/c1-18-7-5-11(20)9-15(18)16(21)10-12-13-3-4-17(22)19(13,2)8-6-14(12)18/h9,12-14,16-17,21-22H,3-8,10H2,1-2H3/t12-,13-,14-,16+,17-,18+,19-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01000","testosterone","6013","MUMGGOZAMZWBJJ-DYKIIFRCSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","CYP3A4 ","Alpha hydroxylation of carbonyl group","Human Phase I","Human","2ÃŽÂ±-Hydroxytestosterone ","14311666","ZOIPFFUVGMVQGE-DTQPDNRZSA-N","InChI=1S/C19H28O3/c1-18-8-7-14-12(13(18)5-6-17(18)22)4-3-11-9-15(20)16(21)10-19(11,14)2/h9,12-14,16-17,21-22H,3-8,10H2,1-2H3/t12-,13-,14-,16+,17-,18-,19-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01001","testosterone","6013","MUMGGOZAMZWBJJ-DYKIIFRCSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","CYP3A4 ","Alpha hydroxylation of carbonyl group","Human Phase I","Human","2ÃŽÂ²-Hydroxytestosterone ","14311667","ZOIPFFUVGMVQGE-LXKHFVGGSA-N","InChI=1S/C19H28O3/c1-18-8-7-14-12(13(18)5-6-17(18)22)4-3-11-9-15(20)16(21)10-19(11,14)2/h9,12-14,16-17,21-22H,3-8,10H2,1-2H3/t12-,13-,14-,16-,17-,18-,19-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01002","testosterone","6013","MUMGGOZAMZWBJJ-DYKIIFRCSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","15ÃŽÂ±-Hydroxytestosterone ","247021","KYGUQDTWUBBBSD-MJVYMRHDSA-N","InChI=1S/C19H28O3/c1-18-7-5-12(20)9-11(18)3-4-13-14(18)6-8-19(2)16(22)10-15(21)17(13)19/h9,13-17,21-22H,3-8,10H2,1-2H3/t13-,14+,15+,16+,17-,18+,19-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID01003","testosterone","6013","MUMGGOZAMZWBJJ-DYKIIFRCSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","15ÃŽÂ²-Hydroxytestosterone ","53255472","KYGUQDTWUBBBSD-XJBBOAPUSA-N","InChI=1S/C19H28O3/c1-18-7-5-12(20)9-11(18)3-4-13-14(18)6-8-19(2)16(22)10-15(21)17(13)19/h9,13-17,21-22H,3-8,10H2,1-2H3/t13-,14+,15-,16+,17-,18+,19-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259987"
"BIOTID01004","testosterone","6013","MUMGGOZAMZWBJJ-DYKIIFRCSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","CYP3A4; CYP2B6 ","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","16ÃŽÂ±-Hydroxytestosterone ","65545","YMCWOAZGWMZGQT-FPNLOETNSA-N","InChI=1S/C19H28O3/c1-18-7-5-12(20)9-11(18)3-4-13-14(18)6-8-19(2)15(13)10-16(21)17(19)22/h9,13-17,21-22H,3-8,10H2,1-2H3/t13-,14+,15+,16-,17+,18+,19+/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259987"
"BIOTID01005","testosterone","6013","MUMGGOZAMZWBJJ-DYKIIFRCSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","CYP3A4; CYP2B6 ","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","16ÃŽÂ²-Hydroxytestosterone ","15708880","YMCWOAZGWMZGQT-KYQPOWKGSA-N","InChI=1S/C19H28O3/c1-18-7-5-12(20)9-11(18)3-4-13-14(18)6-8-19(2)15(13)10-16(21)17(19)22/h9,13-17,21-22H,3-8,10H2,1-2H3/t13-,14+,15+,16+,17+,18+,19+/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259988"
"BIOTID01006","testosterone","6013","MUMGGOZAMZWBJJ-DYKIIFRCSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","CYP2C19; CYP2C9 ","Oxidation of secondary alcohol to ketone","Human Phase I","Human","Androstenedione ","6128","AEMFNILZOJDQLW-QAGGRKNESA-N","InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259989"
"BIOTID01007","tetradecanoic acid","11005","TUNFSRHWOTWDNC-UHFFFAOYSA-N","InChI=1S/C14H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H,15,16)","CYP2E1;CYP4A11","Aliphatic Hydroxylation","Human Phase I","Human","NULL","13111890","KNFJWKJXKURGQU-UHFFFAOYSA-N","InChI=1S/C14H28O3/c1-13(15)11-9-7-5-3-2-4-6-8-10-12-14(16)17/h13,15H,2-12H2,1H3,(H,16,17)","PMID:10553002"
"BIOTID01008","tetranor-(+)-s-145","101592321","DYXPIXIKDXPQPD-DSPQJCBJSA-N","InChI=1S/C16H21NO4S/c18-15(19)9-8-14-11-6-7-12(10-11)16(14)17-22(20,21)13-4-2-1-3-5-13/h1-5,11-12,14,16-17H,6-10H2,(H,18,19)/t11-,12+,14+,16+/m1/s1","CYP2C9","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","DGOAQJDQQGMUKW-UHFFFAOYSA-N","InChI=1S/C16H21NO5S/c18-14-9-10-8-13(14)16(12(10)6-7-15(19)20)17-23(21,22)11-4-2-1-3-5-11/h1-5,10,12-14,16-18H,6-9H2,(H,19,20)","PMID:9010633"
"BIOTID01009","tetranor-(+)-s-145","101592321","DYXPIXIKDXPQPD-DSPQJCBJSA-N","InChI=1S/C16H21NO4S/c18-15(19)9-8-14-11-6-7-12(10-11)16(14)17-22(20,21)13-4-2-1-3-5-13/h1-5,11-12,14,16-17H,6-10H2,(H,18,19)/t11-,12+,14+,16+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","SINNEOMVGGONDX-UHFFFAOYSA-N","InChI=1S/C16H21NO5S/c18-14-9-10-8-13(14)12(6-7-15(19)20)16(10)17-23(21,22)11-4-2-1-3-5-11/h1-5,10,12-14,16-18H,6-9H2,(H,19,20)","PMID:9010633"
"BIOTID01010","theobromine","5429","YAPQBXQYLJRXSA-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13)","CYP1A2;CYP2E1","N-demethylation","Human Phase I","Human","NULL","68374","PFWLFWPASULGAN-UHFFFAOYSA-N","InChI=1S/C6H6N4O2/c1-10-2-7-4-3(10)5(11)9-6(12)8-4/h2H,1H3,(H2,8,9,11,12)","PMID:10215755"
"BIOTID01011","theobromine","5429","YAPQBXQYLJRXSA-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13)","CYP2E1","N-demethylation","Human Phase I","Human","NULL","70639","GMSNIKWWOQHZGF-UHFFFAOYSA-N","InChI=1S/C6H6N4O2/c1-10-4-3(7-2-8-4)5(11)9-6(10)12/h2H,1H3,(H,7,8)(H,9,11,12)","PMID:10215755"
"BIOTID01012","theobromine","5429","YAPQBXQYLJRXSA-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13)","CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","NULL","83126","HMLZLHKHNBLLJD-UHFFFAOYSA-N","InChI=1S/C7H8N4O3/c1-10-3-4(8-6(10)13)11(2)7(14)9-5(3)12/h1-2H3,(H,8,13)(H,9,12,14)","PMID:10215755"
"BIOTID01013","theophylline","2153","ZFXYFBGIUFBOJW-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)","CYP1A2; CYP1A1 ","HYDROXYLATION_OF_HETEROAROMATIC_CARBON; HYDROXYLATION_OF_AROMATIC_CARBON_ADJACENT_TO_N","Human Phase I","Human","1,3-Dimethyluric acid","70346","OTSBKHHWSQYEHK-UHFFFAOYSA-N","InChI=1S/C7H8N4O3/c1-10-4-3(8-6(13)9-4)5(12)11(2)7(10)14/h1-2H3,(H2,8,9,13)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01014","theophylline","2153","ZFXYFBGIUFBOJW-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)","CYP1A2","N-dealkylation of N-acylurea","Human Phase I","Human","1-Methylxanthine ","80220","MVOYJPOZRLFTCP-UHFFFAOYSA-N","InChI=1S/C6H6N4O2/c1-10-5(11)3-4(8-2-7-3)9-6(10)12/h2H,1H3,(H,7,8)(H,9,12)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID01015","theophylline","2153","ZFXYFBGIUFBOJW-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)","CYP1A2","N-dealkylation of N-acylurea","Human Phase I","Human","3-Methylxanthine ","70639","GMSNIKWWOQHZGF-UHFFFAOYSA-N","InChI=1S/C6H6N4O2/c1-10-4-3(7-2-8-4)5(11)9-6(10)12/h2H,1H3,(H,7,8)(H,9,11,12)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259987"
"BIOTID01016","thiabendazole","5430","WJCNZQLZVWNLKY-UHFFFAOYSA-N","InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)","CYP1A2","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","5-hydroxythiabendazole ","108227","VNENJHUOPQAPAT-UHFFFAOYSA-N","InChI=1S/C10H7N3OS/c14-6-1-2-7-8(3-6)13-10(12-7)9-4-15-5-11-9/h1-5,14H,(H,12,13)","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754426"
"BIOTID01019","ticlopidine","5472","PHWBOXQYWZNQIN-UHFFFAOYSA-N","InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2","CYP3A4; CYP2C19","Formation of imminium ion from N-substituted piperidine","Human Phase I","Human","Thienodihydropyridinium","71314787","RLTCLQFOWWSHJX-UHFFFAOYSA-N","InChI=1S/C14H13ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8,10H,5,7,9H2/q+1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01020","ticlopidine","5472","PHWBOXQYWZNQIN-UHFFFAOYSA-N","InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2","CYP2C19; CYP2D6","Thiohene S-oxidation","Human Phase I","Human","Ticlopidine S-oxide","131750720","SSVDYGNPKZJQKO-UHFFFAOYSA-N","InChI=1S/C14H14ClNOS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-18(14)17/h1-4,6,8H,5,7,9-10H2","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01021","ticrynafen","38409","AGHANLSBXUWXTB-UHFFFAOYSA-N","InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)","CYP2C8; CYP2C9 (major)","Thiohene S-oxidation","Human Phase I","Human","Tienilic acid-s-oxide","NULL","QEVMJPARVMJGMC-UHFFFAOYSA-N","InChI=1S/C13H8Cl2O5S/c14-11-7(13(18)9-2-1-5-21(9)19)3-4-8(12(11)15)20-6-10(16)17/h1-5H,6H2,(H,16,17)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01022","ticrynafen","38409","AGHANLSBXUWXTB-UHFFFAOYSA-N","InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)","CYP2C8; CYP2C9 (major); CYP2C18; CYP2C19","Epoxidation of thiophene","Human Phase I","Human","Thiophene-4,5-epoxide","NULL","RJEINYXLECHKSU-UHFFFAOYSA-N","InChI=1S/C13H8Cl2O5S/c14-10-5(12(18)8-3-7-13(20-7)21-8)1-2-6(11(10)15)19-4-9(16)17/h1-3,7,13H,4H2,(H,16,17)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01023","timolol","33624","BLJRIMJGRPQVNF-JTQLQIEISA-N","InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1","CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","YAQBXZZIPUGCRU-UHFFFAOYSA-N","InChI=1S/C13H24N4O4S/c1-13(2,3)14-6-9(18)8-21-12-11(15-22-16-12)17-4-5-20-10(19)7-17/h9-10,14,18-19H,4-8H2,1-3H3","PMID:12392820"
"BIOTID01024","tirilazad","104903","RBKASMJPSJDQKY-RBFSKHHSSA-N","InChI=1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","VDRMYIRMMZPUDN-UHFFFAOYSA-N","InChI=1S/C38H52N6O3/c1-25-20-29-27-22-31(46)30-21-26(45)8-10-37(30,2)28(27)9-11-38(29,3)35(25)32(47)24-41-16-18-43(19-17-41)34-23-33(42-12-4-5-13-42)39-36(40-34)44-14-6-7-15-44/h8-10,21,23,25,27,29,31,35,46H,4-7,11-20,22,24H2,1-3H3","PMID:8627581"
"BIOTID01025","tirilazad","104903","RBKASMJPSJDQKY-RBFSKHHSSA-N","InChI=1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","FBPWEMVQZBGIRA-UHFFFAOYSA-N","InChI=1S/C38H52N6O3/c1-25-20-31-29-7-6-26-21-27(45)8-11-37(26,2)30(29)9-12-38(31,3)35(25)32(47)24-41-16-18-43(19-17-41)34-22-33(42-13-4-5-14-42)39-36(40-34)44-15-10-28(46)23-44/h8-9,11,21-22,25,28-29,31,35,46H,4-7,10,12-20,23-24H2,1-3H3","PMID:8627581"
"BIOTID01026","tirilazad","104903","RBKASMJPSJDQKY-RBFSKHHSSA-N","InChI=1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","KPYNFQOGMHAHOB-UHFFFAOYSA-N","InChI=1S/C38H52N6O3/c1-25-20-31-29-7-6-26-21-27(45)8-11-37(26,2)30(29)9-12-38(31,3)35(25)32(47)24-41-16-18-42(19-17-41)33-22-34(44-15-10-28(46)23-44)40-36(39-33)43-13-4-5-14-43/h8-9,11,21-22,25,28-29,31,35,46H,4-7,10,12-20,23-24H2,1-3H3","PMID:8627581"
"BIOTID01027","tolbutamide","5505","JLRGJRBPOGGCBT-UHFFFAOYSA-N","InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)","CYP2C9; CYP2C19","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","4-Hydroxytolbutamide","3656","SJRHYONYKZIRPM-UHFFFAOYSA-N","InChI=1S/C12H18N2O4S/c1-2-3-8-13-12(16)14-19(17,18)11-6-4-10(9-15)5-7-11/h4-7,15H,2-3,8-9H2,1H3,(H2,13,14,16)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01028","tolterodine","443879","OOGJQPCLVADCPB-HXUWFJFHSA-N","InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1","CYP3A4 (major); CYP2C9 (minor); CYP2C19 (minor)","N-deisopropylation","Human Phase I","Human","N-Dealkylated tolterodine","9857016","CPLYUIYTJCFQJD-QGZVFWFLSA-N","InChI=1S/C19H25NO/c1-14(2)20-12-11-17(16-7-5-4-6-8-16)18-13-15(3)9-10-19(18)21/h4-10,13-14,17,20-21H,11-12H2,1-3H3/t17-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01029","tolterodine","443879","OOGJQPCLVADCPB-HXUWFJFHSA-N","InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1","CYP2D6","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","5-Hydroxymethyl tolterodine","9819382","DUXZAXCGJSBGDW-HXUWFJFHSA-N","InChI=1S/C22H31NO2/c1-16(2)23(17(3)4)13-12-20(19-8-6-5-7-9-19)21-14-18(15-24)10-11-22(21)25/h5-11,14,16-17,20,24-25H,12-13,15H2,1-4H3/t20-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01030","toluene","1140","YXFVVABEGXRONW-UHFFFAOYSA-N","InChI=1S/C7H8/c1-7-5-3-2-4-6-7/h2-6H,1H3","CYP2E1 (at low concentrations); CYP2B6 (at hight concentrations); CYP2C8; CYP1A2; CYP1A1","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","Benzyl alcohol","244","WVDDGKGOMKODPV-UHFFFAOYSA-N","InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01031","toluene","1140","YXFVVABEGXRONW-UHFFFAOYSA-N","InChI=1S/C7H8/c1-7-5-3-2-4-6-7/h2-6H,1H3","CYP1A2","o-Hydroxylation of monosubstituted benzene","Human Phase I","Human","o-Cresol","335","QWVGKYWNOKOFNN-UHFFFAOYSA-N","InChI=1S/C7H8O/c1-6-4-2-3-5-7(6)8/h2-5,8H,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01032","toluene","1140","YXFVVABEGXRONW-UHFFFAOYSA-N","InChI=1S/C7H8/c1-7-5-3-2-4-6-7/h2-6H,1H3","CYP2C8; CYP1A2","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","p-Cresol","2879","IWDCLRJOBJJRNH-UHFFFAOYSA-N","InChI=1S/C7H8O/c1-6-2-4-7(8)5-3-6/h2-5,8H,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01033","torasemide","41781","NGBFQHCMQULJNZ-UHFFFAOYSA-N","InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)","CYP2C9","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","N-[(4-{[3-(hydroxymethyl)phenyl]imino}-1,4-dihydropyridin-3-yl)sulfonyl]propane-2-carbamimidic acid","14475217","WCYVLAMJCQZUCR-UHFFFAOYSA-N","InChI=1S/C16H20N4O4S/c1-11(2)18-16(22)20-25(23,24)15-9-17-7-6-14(15)19-13-5-3-4-12(8-13)10-21/h3-9,11,21H,10H2,1-2H3,(H,17,19)(H2,18,20,22)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01034","toremifene","3005573","XFCLJVABOIYOMF-QPLCGJKRSA-N","InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-","CYP1A1; CYP1A2; CYP3A4 (major)","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES","Human Phase I","Human","N-desmethyltoremifene","3035212","WKJKBQYEFAFHCY-IZHYLOQSSA-N","InChI=1S/C25H26ClNO/c1-27-18-19-28-23-14-12-22(13-15-23)25(21-10-6-3-7-11-21)24(16-17-26)20-8-4-2-5-9-20/h2-15,27H,16-19H2,1H3/b25-24-","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01035","toremifene","3005573","XFCLJVABOIYOMF-QPLCGJKRSA-N","InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-","CYP1A1; CYP1A2; CYP3A4 (major)","Deamino","Human Phase I","Human","N-desmethyltoremifene","3035212","WKJKBQYEFAFHCY-IZHYLOQSSA-N","InChI=1S/C25H26ClNO/c1-27-18-19-28-23-14-12-22(13-15-23)25(21-10-6-3-7-11-21)24(16-17-26)20-8-4-2-5-9-20/h2-15,27H,16-19H2,1H3/b25-24-","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01036","tozasertib","5494449","GCIKSSRWRFVXBI-UHFFFAOYSA-N","InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)","CYP3A4","N-Oxidation","Human Phase I","Human","NULL","10028135","CJZYEATYOSBZON-UHFFFAOYSA-N","InChI=1S/C23H28N8O2S/c1-15-13-20(29-28-15)25-19-14-21(30-9-11-31(2,33)12-10-30)27-23(26-19)34-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)","PMID:17537870"
"BIOTID01037","tozasertib","5494449","GCIKSSRWRFVXBI-UHFFFAOYSA-N","InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)","CYP2C8;CYP3A4","N-demethylation","Human Phase I","Human","NULL","10321534","BMPDSCNEIPYGDD-UHFFFAOYSA-N","InChI=1S/C22H26N8OS/c1-14-12-19(29-28-14)25-18-13-20(30-10-8-23-9-11-30)27-22(26-18)32-17-6-4-16(5-7-17)24-21(31)15-2-3-15/h4-7,12-13,15,23H,2-3,8-11H2,1H3,(H,24,31)(H2,25,26,27,28,29)","PMID:17537870"
"BIOTID01038","tpa-023","9908684","QKIWQBLNTSQOLY-UHFFFAOYSA-N","InChI=1S/C20H22FN7O/c1-5-27-17(22-12-23-27)11-29-19-14(20(2,3)4)10-16-24-25-18(28(16)26-19)13-8-6-7-9-15(13)21/h6-10,12H,5,11H2,1-4H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","COBDXNOSUAZQJY-UHFFFAOYSA-N","InChI=1S/C20H22FN7O2/c1-4-27-17(22-12-23-27)10-30-19-14(20(2,3)11-29)9-16-24-25-18(28(16)26-19)13-7-5-6-8-15(13)21/h5-9,12,29H,4,10-11H2,1-3H3","PMID:17460031"
"BIOTID01039","tpa-023","9908684","QKIWQBLNTSQOLY-UHFFFAOYSA-N","InChI=1S/C20H22FN7O/c1-5-27-17(22-12-23-27)11-29-19-14(20(2,3)4)10-16-24-25-18(28(16)26-19)13-8-6-7-9-15(13)21/h6-10,12H,5,11H2,1-4H3","CYP3A4","N-demethylation","Human Phase I","Human","NULL","9969202","GRECTROMILPREZ-UHFFFAOYSA-N","InChI=1S/C18H18FN7O/c1-18(2,3)12-8-15-23-24-16(11-6-4-5-7-13(11)19)26(15)25-17(12)27-9-14-20-10-21-22-14/h4-8,10H,9H2,1-3H3,(H,20,21,22)","PMID:17460031"
"BIOTID01040","tramadol","33741","TVYLLZQTGLZFBW-ZBFHGGJFSA-N","InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1","CYP1A2;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP3A4","N-demethylation","Human Phase I","Human","N-desmethyltramadol","198555","VUMQHLSPUAFKKK-UHFFFAOYSA-N","InChI=1S/C15H23NO2/c1-16-11-13-6-3-4-9-15(13,17)12-7-5-8-14(10-12)18-2/h5,7-8,10,13,16-17H,3-4,6,9,11H2,1-2H3","PMID:19902987"
"BIOTID01041","tramadol","33741","TVYLLZQTGLZFBW-ZBFHGGJFSA-N","InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1","CYP1A2;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP3A4","O-demethylation","Human Phase I","Human","O-desmethyl-tramadol","130829","UWJUQVWARXYRCG-UHFFFAOYSA-N","InChI=1S/C15H23NO2/c1-16(2)11-13-6-3-4-9-15(13,18)12-7-5-8-14(17)10-12/h5,7-8,10,13,17-18H,3-4,6,9,11H2,1-2H3","PMID:19902987"
"BIOTID01042","traxoprodil","219101","QEMSVZNTSXPFJA-HNAYVOBHSA-N","InChI=1S/C20H25NO3/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17/h2-10,15,19,22-24H,11-14H2,1H3/t15-,19+/m0/s1","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","69503224","DBBLAPQLBKZWRF-UHFFFAOYSA-N","InChI=1S/C20H25NO4/c1-14(19(24)15-7-8-17(22)18(23)13-15)21-11-9-20(25,10-12-21)16-5-3-2-4-6-16/h2-8,13-14,19,22-25H,9-12H2,1H3","PMID:12485956"
"BIOTID01043","trazodone","5533","PHLBKPHSAVXXEF-UHFFFAOYSA-N","InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2","CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","m-CPP","1355","VHFVKMTVMIZMIK-UHFFFAOYSA-N","InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754425"
"BIOTID01044","trazodone","5533","PHLBKPHSAVXXEF-UHFFFAOYSA-N","InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2","CYP3A4","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","p-Hydroxytrazodone","46781917","FNUZSRSXQFIOPL-UHFFFAOYSA-N","InChI=1S/C19H22ClN5O2/c20-16-14-15(5-6-17(16)26)23-12-10-22(11-13-23)7-3-9-25-19(27)24-8-2-1-4-18(24)21-25/h1-2,4-6,8,14,26H,3,7,9-13H2","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754425"
"BIOTID01045","trazodone","5533","PHLBKPHSAVXXEF-UHFFFAOYSA-N","InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2","CYP3A4","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","Trazodone epoxide","131770015","QFERKVDPWYTEPE-UHFFFAOYSA-N","InChI=1S/C19H22ClN5O2/c20-14-3-1-4-15(13-14)23-11-9-22(10-12-23)6-2-7-25-19(26)24-8-5-16-17(27-16)18(24)21-25/h1,3-5,8,13,16-17H,2,6-7,9-12H2","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754426"
"BIOTID01046","triazolam","5556","JOFWLTCLBGQGBO-UHFFFAOYSA-N","InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","1963","BHUYWUDMVCLHND-UHFFFAOYSA-N","InChI=1S/C17H12Cl2N4O/c18-10-5-6-14-12(7-10)17(11-3-1-2-4-13(11)19)20-8-15-21-22-16(9-24)23(14)15/h1-7,24H,8-9H2","PMID:10640299"
"BIOTID01047","triazolam","5556","JOFWLTCLBGQGBO-UHFFFAOYSA-N","InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","128260","YUQRFPYHTPARRM-UHFFFAOYSA-N","InChI=1S/C17H12Cl2N4O/c1-9-21-22-16-17(24)20-15(11-4-2-3-5-13(11)19)12-8-10(18)6-7-14(12)23(9)16/h2-8,17,24H,1H3","PMID:10640299"
"BIOTID01048","trihydroxycoprostane","160520","RIVQQZVHIVNQFH-XJZYBRFWSA-N","InChI=1S/C27H48O3/c1-16(2)7-6-8-17(3)20-9-10-21-25-22(15-24(30)27(20,21)5)26(4)12-11-19(28)13-18(26)14-23(25)29/h16-25,28-30H,6-15H2,1-5H3/t17-,18+,19-,20-,21+,22+,23-,24+,25+,26+,27-/m1/s1","CYP2B6;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","3482062","NTIXPPFPXLYJCT-UHFFFAOYSA-N","InChI=1S/C27H48O4/c1-16(7-6-11-25(2,3)31)19-8-9-20-24-21(15-23(30)27(19,20)5)26(4)12-10-18(28)13-17(26)14-22(24)29/h16-24,28-31H,6-15H2,1-5H3","PMID:9931427"
"BIOTID01049","trimethadione","5576","IRYJRGCIQBGHIV-UHFFFAOYSA-N","InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3","CYP2C8;CYP2C9;CYP2E1;CYP3A4","N-demethylation","Human Phase I","Human","NULL","3081","JYJFNDQBESEHJQ-UHFFFAOYSA-N","InChI=1S/C5H7NO3/c1-5(2)3(7)6-4(8)9-5/h1-2H3,(H,6,7,8)","PMID:14651673"
"BIOTID01050","tropisetron","656665","ZNRGQMMCGHDTEI-CLLJXQQHSA-N","InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13?","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","DKXQNOVTLKKEJJ-UHFFFAOYSA-N","InChI=1S/C17H20N2O3/c1-19-10-2-3-11(19)7-13(6-10)22-17(21)15-9-18-16-5-4-12(20)8-14(15)16/h4-5,8-11,13,18,20H,2-3,6-7H2,1H3","PMID:7598739"
"BIOTID01051","tropisetron","656665","ZNRGQMMCGHDTEI-CLLJXQQHSA-N","InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13?","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","DXYYGLSZCCPMDV-UHFFFAOYSA-N","InChI=1S/C17H20N2O3/c1-19-10-2-3-11(19)7-13(6-10)22-17(21)15-9-18-16-8-12(20)4-5-14(15)16/h4-5,8-11,13,18,20H,2-3,6-7H2,1H3","PMID:7598739"
"BIOTID01052","tropisetron","656665","ZNRGQMMCGHDTEI-CLLJXQQHSA-N","InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13?","CYP3A4","N-demethylation","Human Phase I","Human","NULL","10199314","LCAGVMWMARLFPS-UHFFFAOYSA-N","InChI=1S/C16H18N2O2/c19-16(14-9-17-15-4-2-1-3-13(14)15)20-12-7-10-5-6-11(8-12)18-10/h1-4,9-12,17-18H,5-8H2","PMID:7598739"
"BIOTID01053","tyramine","5610","DZGWFCGJZKJUFP-UHFFFAOYSA-N","InChI=1S/C8H11NO/c9-6-5-7-1-3-8(10)4-2-7/h1-4,10H,5-6,9H2","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","681","VYFYYTLLBUKUHU-UHFFFAOYSA-N","InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2","PMID:9731223"
"BIOTID01054","MK-429","9853559","HGFOOLONGOBCMP-IBGZPJMESA-N","InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1","CYP2D6","O-Demethylation","Human Phase I","Human","NULL","10159447","RCBFABQFMUPLIQ-UHFFFAOYSA-N","InChI=1S/C22H27N5O4/c28-19-8-6-16(14-24-19)18(13-20(29)30)27-12-11-26(22(27)31)10-2-4-17-7-5-15-3-1-9-23-21(15)25-17/h5-8,14,18H,1-4,9-13H2,(H,23,25)(H,24,28)(H,29,30)","PMID:15258111"
"BIOTID01055","MK-429","9853559","HGFOOLONGOBCMP-IBGZPJMESA-N","InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1","CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","ZXYRSIGZWPBVIY-UHFFFAOYSA-N","InChI=1S/C22H27N5O5/c28-18-7-5-15(13-23-18)17(12-20(30)31)27-11-10-26(22(27)32)9-1-2-16-6-3-14-4-8-19(29)25-21(14)24-16/h3,5-7,13,17,19,29H,1-2,4,8-12H2,(H,23,28)(H,24,25)(H,30,31)","PMID:15258111"
"BIOTID01056","MK-429","9853559","HGFOOLONGOBCMP-IBGZPJMESA-N","InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1","CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","IKASYDCFWNCNOM-UHFFFAOYSA-N","InChI=1S/C22H27N5O5/c28-18-7-8-23-21-16(18)5-4-15(25-21)2-1-9-26-10-11-27(22(26)32)17(12-20(30)31)14-3-6-19(29)24-13-14/h3-6,13,17-18,28H,1-2,7-12H2,(H,23,25)(H,24,29)(H,30,31)","PMID:15258111"
"BIOTID01057","(R)-(+)-Rebamipide","969464","ALLWOAVDORUJLA-MRXNPFEDSA-N","InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)/t16-/m1/s1","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","8-Hydroxyrebamipide","NULL","FVCVWZVCENZXPG-UHFFFAOYSA-N","InChI=1S/C19H15ClN2O5/c20-12-6-4-10(5-7-12)18(25)21-14(19(26)27)8-11-9-16(24)22-17-13(11)2-1-3-15(17)23/h1-7,9,14,23H,8H2,(H,21,25)(H,22,24)(H,26,27)","PMID:12162853"
"BIOTID01058","(R)-(+)-Rebamipide","969464","ALLWOAVDORUJLA-MRXNPFEDSA-N","InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)/t16-/m1/s1","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","6-Hydroxyrebamipide","NULL","IMRUHDNHNAKMPT-UHFFFAOYSA-N","InChI=1S/C19H15ClN2O5/c20-12-3-1-10(2-4-12)18(25)22-16(19(26)27)7-11-8-17(24)21-15-6-5-13(23)9-14(11)15/h1-6,8-9,16,23H,7H2,(H,21,24)(H,22,25)(H,26,27)","PMID:12162853"
"BIOTID01059","p-Methoxymethamphetamine, R-(-)-","40463419","UGFMBZYKVQSQFX-SECBINFHSA-N","InChI=1S/C11H17NO/c1-9(12-2)8-10-4-6-11(13-3)7-5-10/h4-7,9,12H,8H2,1-3H3/t9-/m1/s1","CYP2D6","O-Demethylation","Human Phase I","Human","HO-MA","4655","SBUQZKJEOOQSBV-UHFFFAOYSA-N","InChI=1S/C10H15NO/c1-8(11-2)7-9-3-5-10(12)6-4-9/h3-6,8,11-12H,7H2,1-2H3","PMID:15039289"
"BIOTID01060","(S)-Methylenedioxyethylamphetamine","13909090","PVXVWWANJIWJOO-VIFPVBQESA-N","InChI=1S/C12H17NO2/c1-3-13-9(2)6-10-4-5-11-12(7-10)15-8-14-11/h4-5,7,9,13H,3,6,8H2,1-2H3/t9-/m0/s1","CYP1A2;CYP2B6;CYP3A4","N-Dealylation","Human Phase I","Human","3,4-methylenedioxyamphetamine","3050061","NGBBVGZWCFBOGO-ZETCQYMHSA-N","InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3/t7-/m0/s1","PMID:10799653"
"BIOTID01061","(S)-Methylenedioxyethylamphetamine","13909090","PVXVWWANJIWJOO-VIFPVBQESA-N","InChI=1S/C12H17NO2/c1-3-13-9(2)6-10-4-5-11-12(7-10)15-8-14-11/h4-5,7,9,13H,3,6,8H2,1-2H3/t9-/m0/s1","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2D6;CYP2E1;CYP3A4","Demethylenation","Human Phase I","Human","N-methyl-3,4-methylenedioxyamphetamine","NULL","CKUGRMSDBDIJRN-QMMMGPOBSA-N","InChI=1S/C11H17NO2/c1-3-12-8(2)6-9-4-5-10(13)11(14)7-9/h4-5,7-8,12-14H,3,6H2,1-2H3/t8-/m0/s1","PMID:10799653"
"BIOTID01062","unii-3es85mm31y","9959619","NIBCDDKWFDEBEP-UHFFFAOYSA-N","InChI=1S/C28H35N7O4S/c1-4-17-39-24-11-10-21(40(37,38)34-15-13-33(6-3)14-16-34)18-22(24)27-30-25-23(5-2)35(32-26(25)28(36)31-27)19-20-9-7-8-12-29-20/h7-12,18H,4-6,13-17,19H2,1-3H3,(H,30,31,36)","CYP3A4","N-dealkylation","Human Phase I","Human","NULL","22382000","JWJCBYZSCDRFEZ-UHFFFAOYSA-N","InChI=1S/C26H31N7O4S/c1-3-15-37-22-9-8-19(38(35,36)32-13-11-27-12-14-32)16-20(22)25-29-23-21(4-2)33(31-24(23)26(34)30-25)17-18-7-5-6-10-28-18/h5-10,16,27H,3-4,11-15,17H2,1-2H3,(H,29,30,34)","PMID:11569532"
"BIOTID01063","Fenproporex","37888393","IQUFSXIQAFPIMR-NSHDSACASA-N","InChI=1S/C12H16N2/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,9-10H2,1H3/t11-/m0/s1","CYP1A2;CYP2B6;CYP2D6;CYP3A4","N-dealkylation","Human Phase I","Human","amphetamine","3007","KWTSXDURSIMDCE-UHFFFAOYSA-N","InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3","PMID:15294457"
"BIOTID01064","Desmethylescitalopram","11255350","PTJADDMMFYXMMG-IBGZPJMESA-N","InChI=1S/C19H19FN2O/c1-22-10-2-9-19(16-4-6-17(20)7-5-16)18-8-3-14(12-21)11-15(18)13-23-19/h3-8,11,22H,2,9-10,13H2,1H3/t19-/m0/s1","CYP2D6","N-Demethylation","Human Phase I","Human","NULL","162976","RKUKMUWCRLRPEJ-UHFFFAOYSA-N","InChI=1S/C18H17FN2O/c19-16-5-3-15(4-6-16)18(8-1-9-20)17-7-2-13(11-21)10-14(17)12-22-18/h2-7,10H,1,8-9,12,20H2","PMID:10575324"
"BIOTID01065","RPR-106541","9846880","QGBIFMJAQARMNQ-QISPFCDLSA-N","InChI=1S/C24H34F2O4S/c1-5-6-20-29-19-11-14-15-10-17(25)16-9-13(27)7-8-21(16,2)23(15,26)18(28)12-22(14,3)24(19,30-20)31-4/h9,14-15,17-20,28H,5-8,10-12H2,1-4H3/t14-,15-,17-,18-,19+,20+,21-,22-,23-,24-/m0/s1","CYP3A4;CYP3A5","S-Oxidation","Human Phase I","Human","NULL","NULL","NRNSNRMSVJBVDG-UHFFFAOYSA-N","InChI=1S/C24H34F2O5S/c1-5-6-20-30-19-11-14-15-10-17(25)16-9-13(27)7-8-21(16,2)23(15,26)18(28)12-22(14,3)24(19,31-20)32(4)29/h9,14-15,17-20,28H,5-8,10-12H2,1-4H3","PMID:10411567"
"BIOTID01066","Desmethylsibutramine, (S)-","9838199","PLXKZKLXYHLWHR-HNNXBMFYSA-N","InChI=1S/C16H24ClN/c1-12(2)11-15(18-3)16(9-4-10-16)13-5-7-14(17)8-6-13/h5-8,12,15,18H,4,9-11H2,1-3H3/t15-/m0/s1","CYP2B6","N-demethylation","Human Phase I","Human","1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine","134772","WQSACWZKKZPCHN-UHFFFAOYSA-N","InChI=1S/C15H22ClN/c1-11(2)10-14(17)15(8-3-9-15)12-4-6-13(16)7-5-12/h4-7,11,14H,3,8-10,17H2,1-2H3","PMID:18474675"
"BIOTID01068","unii-ku5u13xy7j component vwcugcyzzgrkee-dyesrhjhsa-n","6101785","VWCUGCYZZGRKEE-DYESRHJHSA-N","InChI=1S/C22H29NO2/c1-5-21(25-18(3)24)22(16-17(2)23-4,19-12-8-6-9-13-19)20-14-10-7-11-15-20/h6-15,17,21,23H,5,16H2,1-4H3/t17-,21-/m1/s1","CYP2B6","N-demethylation","Human Phase I","Human","NULL","170384","FYQILXMAOLDNOY-UHFFFAOYSA-N","InChI=1S/C21H27NO2/c1-4-20(24-17(3)23)21(15-16(2)22,18-11-7-5-8-12-18)19-13-9-6-10-14-19/h5-14,16,20H,4,15,22H2,1-3H3","PMID:11396966"
"BIOTID01069","4'-Methoxy-alpha-pyrrolidinopropiophenone, (S)-","66833826","QJWOQBGBEFNYKB-NSHDSACASA-N","InChI=1S/C14H19NO2/c1-11(15-9-3-4-10-15)14(16)12-5-7-13(17-2)8-6-12/h5-8,11H,3-4,9-10H2,1-2H3/t11-/m0/s1","CYP2C19;CYP2D6","O-demethylation","Human Phase I","Human","NULL","21186619","BXBVOHKJJYOAGK-UHFFFAOYSA-N","InChI=1S/C13H17NO2/c1-10(14-8-2-3-9-14)13(16)11-4-6-12(15)7-5-11/h4-7,10,15H,2-3,8-9H2,1H3","PMID:14555336"
"BIOTID01070","unii-s5969b6237 component anucdxcticzjrh-zmzpimszsa-n","76961231","ANUCDXCTICZJRH-ZMZPIMSZSA-N","InChI=1S/C18H16Cl2N2O2/c1-11-10-24-18(13-4-2-3-5-15(13)20)14-8-12(19)6-7-16(14)21-17(23)9-22(11)18/h2-8,11H,9-10H2,1H3,(H,21,23)/t11-,18+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","GTJGDTCEGHHUKM-UHFFFAOYSA-N","InChI=1S/C18H16Cl2N2O3/c1-17(24)10-25-18(12-4-2-3-5-14(12)20)13-8-11(19)6-7-15(13)21-16(23)9-22(17)18/h2-8,24H,9-10H2,1H3,(H,21,23)","PMID:11181496"
"BIOTID01071","unii-vg463bm9rl component dtjqbbhyrqydeg-rlhiphhxsa-n","76957258","DTJQBBHYRQYDEG-RLHIPHHXSA-N","InChI=1S/C22H28N2O3/c1-26-10-8-15-11-14-12-22(21(25)27-2)19-17(7-9-24(13-14)20(15)22)16-5-3-4-6-18(16)23-19/h3-6,14-15,20,23H,7-13H2,1-2H3/t14-,15+,20+,22-/m0/s1","CYP2C9;CYP2C19;CYP2D6;CYP3A4","O-demethylation","Human Phase I","Human","NULL","20642901","FRCVRUHRFLXLAI-UHFFFAOYSA-N","InChI=1S/C21H26N2O3/c1-26-20(25)21-11-13-10-14(7-9-24)19(21)23(12-13)8-6-16-15-4-2-3-5-17(15)22-18(16)21/h2-5,13-14,19,22,24H,6-12H2,1H3","PMID:12019193"
"BIOTID01072","(S)-Sibutramine","937011","UNAANXDKBXWMLN-INIZCTEOSA-N","InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3/t16-/m0/s1","CYP2B6;CYP2C19;CYP3A4","N-demethylation","Human Phase I","Human","NULL","10199199","PLXKZKLXYHLWHR-UHFFFAOYSA-N","InChI=1S/C16H24ClN/c1-12(2)11-15(18-3)16(9-4-10-16)13-5-7-14(17)8-6-13/h5-8,12,15,18H,4,9-11H2,1-3H3","PMID:18474675"
"BIOTID01073","R-Tolperisone","688590","FSKFPVLPFLJRQB-CQSZACIVSA-N","InChI=1S/C16H23NO/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17/h6-9,14H,3-5,10-12H2,1-2H3/t14-/m1/s1","CYP1A2;CYP2C19;CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","hydroxymethyl-tolperisone","NULL","MBFHFUBFALKDKH-UHFFFAOYSA-N","InChI=1S/C16H23NO2/c1-13(11-17-9-3-2-4-10-17)16(19)15-7-5-14(12-18)6-8-15/h5-8,13,18H,2-4,9-12H2,1H3","PMID:12695352"
"BIOTID01074","CP-195543","9823886","NZQDWKCNBOELAI-KSFYIVLOSA-N","InChI=1S/C24H19F3O4/c25-24(26,27)17-7-9-18(23(29)30)20(12-17)15-6-8-19-21(11-15)31-13-16(22(19)28)10-14-4-2-1-3-5-14/h1-9,11-12,16,22,28H,10,13H2,(H,29,30)/t16-,22+/m0/s1","CYP3A4 ","Aliphatic Hydroxylation","Human Phase I","Human","M1 and M2","NULL","FMBOBJXSKPSTNI-UHFFFAOYSA-N","InChI=1S/C24H19F3O5/c25-24(26,27)15-7-9-16(23(30)31)18(11-15)14-6-8-17-20(10-14)32-12-19(22(17)29)21(28)13-4-2-1-3-5-13/h1-11,19,21-22,28-29H,12H2,(H,30,31)","PMID:14742142"
"BIOTID01075","CP-195543","9823886","NZQDWKCNBOELAI-KSFYIVLOSA-N","InChI=1S/C24H19F3O4/c25-24(26,27)17-7-9-18(23(29)30)20(12-17)15-6-8-19-21(11-15)31-13-16(22(19)28)10-14-4-2-1-3-5-14/h1-9,11-12,16,22,28H,10,13H2,(H,29,30)/t16-,22+/m0/s1","CYP3A4 ","Aromatic Hydroxylation","Human Phase I","Human","M3","NULL","HGEAEPSXNYOGMF-UHFFFAOYSA-N","InChI=1S/C24H19F3O5/c25-24(26,27)16-6-8-17(23(30)31)19(11-16)13-5-7-18-21(10-13)32-12-15(22(18)29)9-14-3-1-2-4-20(14)28/h1-8,10-11,15,22,28-29H,9,12H2,(H,30,31)","PMID:14742142"
"BIOTID01076","(R)-Bunitrolol","72710712","VCVQSRCYSKKPBA-GFCCVEGCSA-N","InChI=1S/C14H20N2O2/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15/h4-7,12,16-17H,9-10H2,1-3H3/t12-/m1/s1","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","129632","YKEYQHVHOYKQGR-UHFFFAOYSA-N","InChI=1S/C14H20N2O3/c1-14(2,3)16-8-12(18)9-19-13-5-4-11(17)6-10(13)7-15/h4-6,12,16-18H,8-9H2,1-3H3","PMID:9914647"
"BIOTID01077","v11294","9844400","CGFRGBQJWVFTRF-UHFFFAOYSA-N","InChI=1S/C23H31N5O2/c1-5-24-22-20-23(27-21(26-20)15(2)3)28(14-25-22)13-16-10-11-18(29-4)19(12-16)30-17-8-6-7-9-17/h10-12,14-15,17,24H,5-9,13H2,1-4H3","CYP2C9;CYP3A4;","Aliphatic Hydroxylation","Human Phase I","Human","NULL","10159460","FRGJRBMPEUIQQH-UHFFFAOYSA-N","InChI=1S/C23H31N5O3/c1-5-24-22-20-23(27-21(26-20)14(2)3)28(13-25-22)12-15-6-9-18(30-4)19(10-15)31-17-8-7-16(29)11-17/h6,9-10,13-14,16-17,24,29H,5,7-8,11-12H2,1-4H3","PMID:12160484"
"BIOTID01078","v11294","9844400","CGFRGBQJWVFTRF-UHFFFAOYSA-N","InChI=1S/C23H31N5O2/c1-5-24-22-20-23(27-21(26-20)15(2)3)28(14-25-22)13-16-10-11-18(29-4)19(12-16)30-17-8-6-7-9-17/h10-12,14-15,17,24H,5-9,13H2,1-4H3","CYP2C9;CYP3A4;","Aliphatic Hydroxylation","Human Phase I","Human","NULL","10296006","OSTFNEZNNFLHJP-UHFFFAOYSA-N","InChI=1S/C23H31N5O3/c1-5-24-20-19-21(27-22(26-19)23(2,3)29)28(14-25-20)13-15-10-11-17(30-4)18(12-15)31-16-8-6-7-9-16/h10-12,14,16,24,29H,5-9,13H2,1-4H3","PMID:12160484"
"BIOTID01079","v11294","9844400","CGFRGBQJWVFTRF-UHFFFAOYSA-N","InChI=1S/C23H31N5O2/c1-5-24-22-20-23(27-21(26-20)15(2)3)28(14-25-22)13-16-10-11-18(29-4)19(12-16)30-17-8-6-7-9-17/h10-12,14-15,17,24H,5-9,13H2,1-4H3","CYP2C9;CYP2C19;CYP2D6;CYP3A4;","N-desethylation","Human Phase I","Human","NULL","10110393","IYHNJXKCTUQIRU-UHFFFAOYSA-N","InChI=1S/C21H27N5O2/c1-13(2)20-24-18-19(22)23-12-26(21(18)25-20)11-14-8-9-16(27-3)17(10-14)28-15-6-4-5-7-15/h8-10,12-13,15H,4-7,11,22H2,1-3H3","PMID:12160484"
"BIOTID01080","valdecoxib","119607","LNPDTQAFDNKSHK-UHFFFAOYSA-N","InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)","CYP2C9; CYP3A4","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","4Ã¢â‚¬Â[5Ã¢â‚¬Â(hydroxymethyl)Ã¢â‚¬Â3Ã¢â‚¬ÂphenylÃ¢â‚¬Â1,2Ã¢â‚¬ÂoxazolÃ¢â‚¬Â4Ã¢â‚¬Âyl]benzeneÃ¢â‚¬Â1Ã¢â‚¬Âsulfonamide","9818888","UJSFKTUZOASIPA-UHFFFAOYSA-N","InChI=1S/C16H14N2O4S/c17-23(20,21)13-8-6-11(7-9-13)15-14(10-19)22-18-16(15)12-4-2-1-3-5-12/h1-9,19H,10H2,(H2,17,20,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01081","valdecoxib","119607","LNPDTQAFDNKSHK-UHFFFAOYSA-N","InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)","CYP2C9; CYP3A4","m-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4Ã¢â‚¬Â[3Ã¢â‚¬Â(3Ã¢â‚¬Âhydroxyphenyl)Ã¢â‚¬Â5Ã¢â‚¬ÂmethylÃ¢â‚¬Â1,2Ã¢â‚¬ÂoxazolÃ¢â‚¬Â4Ã¢â‚¬Âyl]benzeneÃ¢â‚¬Â1Ã¢â‚¬Âsulfonamide","72710738","IAVWHASLRCBDDK-UHFFFAOYSA-N","InChI=1S/C16H14N2O4S/c1-10-15(11-5-7-14(8-6-11)23(17,20)21)16(18-22-10)12-3-2-4-13(19)9-12/h2-9,19H,1H3,(H2,17,20,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01082","valproic acid","3121","NIJJYAXOARWZEE-UHFFFAOYSA-N","InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)","CYP2C9; CYP2B6; CYP2A6","Hydroxylation of penultimate aliphatic secondary carbon","Human Phase I","Human","4-Hydroxyvalproate","134467","OASKNPCLIHUTTL-UHFFFAOYSA-N","InChI=1S/C8H16O3/c1-3-4-7(8(10)11)5-6(2)9/h6-7,9H,3-5H2,1-2H3,(H,10,11)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01083","valproic acid","3121","NIJJYAXOARWZEE-UHFFFAOYSA-N","InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)","CYP2C9; CYP2B6; CYP2A6","Hydroxylation of terminal methyl","Human Phase I","Human","5-Hydroxyvalproate","135244","ZIWBCJXKYKOLJK-UHFFFAOYSA-N","InChI=1S/C8H16O3/c1-2-4-7(8(10)11)5-3-6-9/h7,9H,2-6H2,1H3,(H,10,11)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01084","valproic acid","3121","NIJJYAXOARWZEE-UHFFFAOYSA-N","InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)","CYP2C9; CYP2B6; CYP2A6","Hydroxylation of acyclic aliphatic secondary carbon","Human Phase I","Human","3-Hydroxyvalproate","134459","LLPFTSMZBSRZDV-UHFFFAOYSA-N","InChI=1S/C8H16O3/c1-3-5-6(8(10)11)7(9)4-2/h6-7,9H,3-5H2,1-2H3,(H,10,11)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01085","valproic acid","3121","NIJJYAXOARWZEE-UHFFFAOYSA-N","InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)","CYP2C9","Terminal desaturation","Human Phase I","Human","4-ene-valproate","104896","UMYDNZXEHYSVFY-UHFFFAOYSA-N","InChI=1S/C8H14O2/c1-3-5-7(6-4-2)8(9)10/h3,7H,1,4-6H2,2H3,(H,9,10)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01086","valsartan","60846","ACWBQPMHZXGDFX-QFIPXVFZSA-N","InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1","CYP2C9","Hydroxylation of acyclic aliphatic secondary carbon","Human Phase I","Human","4-OH-valsartan","9911647","ICSQZMPILLPFKC-XLDIYJRPSA-N","InChI=1S/C24H29N5O4/c1-15(2)22(24(32)33)29(21(31)13-8-16(3)30)14-17-9-11-18(12-10-17)19-6-4-5-7-20(19)23-25-27-28-26-23/h4-7,9-12,15-16,22,30H,8,13-14H2,1-3H3,(H,32,33)(H,25,26,27,28)/t16?,22-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01087","valspodar","5281884","YJDYDFNKCBANTM-QCWCSKBGSA-N","InChI=1S/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)/b27-26+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52+/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","UBVMYFQRUBCNHS-OCEACIFDSA-N","InChI=1S/C63H111N11O13/c1-25-26-27-41(15)53(77)52-57(81)67-49(37(8)9)61(85)68(18)32-48(76)69(19)44(28-34(2)3)56(80)66-50(38(10)11)62(86)70(20)45(29-35(4)5)55(79)64-42(16)54(78)65-43(17)58(82)71(21)47(31-40(14)33-75)59(83)72(22)46(30-36(6)7)60(84)73(23)51(39(12)13)63(87)74(52)24/h25-26,34-47,49-52,75H,27-33H2,1-24H3,(H,64,79)(H,65,78)(H,66,80)(H,67,81)/b26-25+","PMID:9698296"
"BIOTID01088","vanoxerine","3455","NAUWTFJOPJWYOT-UHFFFAOYSA-N","InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","10504397","KEPMHFZSPIKKQX-UHFFFAOYSA-N","InChI=1S/C28H32F2N2O2/c29-25-9-5-23(6-10-25)28(24-7-11-26(30)12-8-24)34-21-20-32-18-16-31(17-19-32)15-1-2-22-3-13-27(33)14-4-22/h3-14,28,33H,1-2,15-21H2","PMID:7587951"
"BIOTID01089","vanoxerine","3455","NAUWTFJOPJWYOT-UHFFFAOYSA-N","InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","401916","FRNMVZXBCHKPGE-UHFFFAOYSA-N","InChI=1S/C28H32F2N2O2/c29-25-10-6-23(7-11-25)28(24-8-12-26(30)13-9-24)34-21-20-32-18-16-31(17-19-32)15-14-27(33)22-4-2-1-3-5-22/h1-13,27-28,33H,14-21H2","PMID:7587951"
"BIOTID01090","vicriviroc","3009355","CNPVJJQCETWNEU-CYFREDJKSA-N","InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1","CYP3A4; CYP3A5","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","N-Desalkylvicriviroc ","11587992","JBIGWLFHMIEHKP-ZDUSSCGKSA-N","InChI=1S/C18H29N5O/c1-13-11-23(10-7-19-13)18(4)5-8-22(9-6-18)17(24)16-14(2)20-12-21-15(16)3/h12-13,19H,5-11H2,1-4H3/t13-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01093","vicriviroc","3009355","CNPVJJQCETWNEU-CYFREDJKSA-N","InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1","CYP2C9; CYP3A4; CYP3A5","O-dealkylation of dialkylether","Human Phase I","Human","O-Desmethylvicriviroc ","11548108","KKISTQPVRGXETN-MBSDFSHPSA-N","InChI=1S/C27H36F3N5O2/c1-18-15-34(13-14-35(18)23(16-36)21-5-7-22(8-6-21)27(28,29)30)26(4)9-11-33(12-10-26)25(37)24-19(2)31-17-32-20(24)3/h5-8,17-18,23,36H,9-16H2,1-4H3/t18-,23-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3678"
"BIOTID01095","vicriviroc","3009355","CNPVJJQCETWNEU-CYFREDJKSA-N","InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1","CYP3A4; CYP3A5","N-oxidation of pyrimidine","Human Phase I","Human","Vicriviroc N-oxide ","11577561","FJGWJMSLTFKZKY-CYFREDJKSA-N","InChI=1S/C28H38F3N5O3/c1-19-16-34(14-15-35(19)24(17-39-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-33(13-11-27)26(37)25-20(2)32-18-36(38)21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3680"
"BIOTID01096","vitamin_d2","NULL","MECHNRXZTMCUDQ-PXQSPDBHSA-N","InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25+,26+,27+,28-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","HVAVRRBYXYEBNC-MHCIVVCXSA-N","InChI=1S/C28H44O2/c1-19(2)28(6,30)17-15-21(4)25-13-14-26-22(8-7-16-27(25,26)5)10-11-23-18-24(29)12-9-20(23)3/h10-11,15,17,19,21,24-26,29-30H,3,7-9,12-14,16,18H2,1-2,4-6H3/b17-15+,22-10+,23-11-","PMID:15546903"
"BIOTID01097","voriconazole","71616","BCEHBSKCWLPMDN-MGPLVRAMSA-N","InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1","CYP3A4","Hydroxylation of terminal methyl","Human Phase I","Human","Hydroxymethyl Voriconazole","125264509","BGPPSFHHAYWTMX-LRDDRELGSA-N","InChI=1S/C16H14F3N5O2/c17-10-1-2-11(13(18)3-10)16(26,6-24-9-21-8-23-24)12(5-25)15-14(19)4-20-7-22-15/h1-4,7-9,12,25-26H,5-6H2/t12-,16-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01098","voriconazole","71616","BCEHBSKCWLPMDN-MGPLVRAMSA-N","InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1","CYP2C9 (major); CYP2C19 (major); CYP3A4 (minor)","N-oxidation of pyrimidine","Human Phase I","Human","Voriconazole N-Oxide","10044355","KPLFPLUCFPRUHU-MGPLVRAMSA-N","InChI=1S/C16H14F3N5O2/c1-10(15-14(19)5-24(26)9-21-15)16(25,6-23-8-20-7-22-23)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01099","warfarin-r","91546","QTXVAVXCBMYBJW-OAHLLOKOSA-N","InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,22H,11H2,1H3/t15-/m1/s1","CYP3A4","Alpha hydroxylation of carbonyl group","Human Phase I","Human","10-Hydroxywarfarin","NULL","KLDFTXZRAPVGLB-LDCVWXEPSA-N","InChI=1S/C19H16O5/c1-11(20)17(21)15(12-7-3-2-4-8-12)16-18(22)13-9-5-6-10-14(13)24-19(16)23/h2-10,15,17,21,23H,1H3/t15-,17?/m1/s1",""
"BIOTID01100","warfarin-r","91546","QTXVAVXCBMYBJW-OAHLLOKOSA-N","InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,22H,11H2,1H3/t15-/m1/s1","CYP1A2; CYP1A1; CYP2C19","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-Hydroxywarfarin","NULL","JFCOGWFGPAUYNK-CQSZACIVSA-N","InChI=1S/C19H16O5/c1-11(20)9-14(12-5-3-2-4-6-12)17-18(22)15-10-13(21)7-8-16(15)24-19(17)23/h2-8,10,14,21,23H,9H2,1H3/t14-/m1/s1",""
"BIOTID01101","warfarin-r","91546","QTXVAVXCBMYBJW-OAHLLOKOSA-N","InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,22H,11H2,1H3/t15-/m1/s1","CYP1A2; CYP1A1; CYP2C19","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","8-Hydroxywarfarin","NULL","RCTGERXIFCOAHF-CQSZACIVSA-N","InChI=1S/C19H16O5/c1-11(20)10-14(12-6-3-2-4-7-12)16-17(22)13-8-5-9-15(21)18(13)24-19(16)23/h2-9,14,21,23H,10H2,1H3/t14-/m1/s1",""
"BIOTID01102","warfarin-r","91546","QTXVAVXCBMYBJW-OAHLLOKOSA-N","InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,22H,11H2,1H3/t15-/m1/s1","CYP1A2; CYP1A1; CYP2C8","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","#NAME?","NULL","BQSUFDMOXLLKQK-OAHLLOKOSA-N","InChI=1S/C19H16O5/c1-11(20)9-15(12-5-3-2-4-6-12)17-18(22)14-8-7-13(21)10-16(14)24-19(17)23/h2-8,10,15,21,23H,9H2,1H3/t15-/m1/s1",""
"BIOTID01103","warfarin-r","91546","QTXVAVXCBMYBJW-OAHLLOKOSA-N","InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,22H,11H2,1H3/t15-/m1/s1","CYP2C9; CYP2C18","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4'- Hydroxywarfarin","NULL","UNTPHJKCRGFOFJ-OAHLLOKOSA-N","InChI=1S/C19H16O5/c1-11(20)10-15(12-6-8-13(21)9-7-12)17-18(22)14-4-2-3-5-16(14)24-19(17)23/h2-9,15,21,23H,10H2,1H3/t15-/m1/s1",""
"BIOTID01104","warfarin-s","447632","QTXVAVXCBMYBJW-HNNXBMFYSA-N","InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,22H,11H2,1H3/t15-/m0/s1","CYP2C9","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","7-Hydroxywarfarin","NULL","BQSUFDMOXLLKQK-HNNXBMFYSA-N","InChI=1S/C19H16O5/c1-11(20)9-15(12-5-3-2-4-6-12)17-18(22)14-8-7-13(21)10-16(14)24-19(17)23/h2-8,10,15,21,23H,9H2,1H3/t15-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01105","warfarin-s","447632","QTXVAVXCBMYBJW-HNNXBMFYSA-N","InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,22H,11H2,1H3/t15-/m0/s1","CYP2C9","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4'-Hydroxywarfarin","NULL","UNTPHJKCRGFOFJ-HNNXBMFYSA-N","InChI=1S/C19H16O5/c1-11(20)10-15(12-6-8-13(21)9-7-12)17-18(22)14-4-2-3-5-16(14)24-19(17)23/h2-9,15,21,23H,10H2,1H3/t15-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01106","warfarin-s","447632","QTXVAVXCBMYBJW-HNNXBMFYSA-N","InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,22H,11H2,1H3/t15-/m0/s1","CYP2C9; CYP2C8; CYP2C18; CYP2C19; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-Hydroxylation","NULL","JFCOGWFGPAUYNK-AWEZNQCLSA-N","InChI=1S/C19H16O5/c1-11(20)9-14(12-5-3-2-4-6-12)17-18(22)15-10-13(21)7-8-16(15)24-19(17)23/h2-8,10,14,21,23H,9H2,1H3/t14-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01107","warfarin-s","447632","QTXVAVXCBMYBJW-HNNXBMFYSA-N","InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,22H,11H2,1H3/t15-/m0/s1","CYP3A4","Alpha hydroxylation of carbonyl group","Human Phase I","Human","10-Hydroxylation","NULL","KLDFTXZRAPVGLB-MYJWUSKBSA-N","InChI=1S/C19H16O5/c1-11(20)17(21)15(12-7-3-2-4-8-12)16-18(22)13-9-5-6-10-14(13)24-19(16)23/h2-10,15,17,21,23H,1H3/t15-,17?/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01108","7-Ethoxy-4-trifluoromethylcoumarin","130779","OLHOIERZAZMHGK-UHFFFAOYSA-N","InChI=1S/C12H9F3O3/c1-2-17-7-3-4-8-9(12(13,14)15)6-11(16)18-10(8)5-7/h3-6H,2H2,1H3","CYP1A2; CYP2B6; CYP2E1; CYP2C9; CYP2C19","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","7-Hydroxy-4-trifluoromethylcourmarin","5375667","CCKWMCUOHJAVOL-UHFFFAOYSA-N","InChI=1S/C10H5F3O3/c11-10(12,13)7-4-9(15)16-8-3-5(14)1-2-6(7)8/h1-4,14H","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01109","7-methoxy-4-trifluoromethylcoumarin","688586","HAZHUELNIGDYQH-UHFFFAOYSA-N","InChI=1S/C11H7F3O3/c1-16-6-2-3-7-8(11(12,13)14)5-10(15)17-9(7)4-6/h2-5H,1H3","CYP1A2;CYP2A6;CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP2E1","O-Demethylation ","Human Phase I","Human","7-Hydroxy-4-(trifluoromethyl)chromen-2-one","5375667","CCKWMCUOHJAVOL-UHFFFAOYSA-N","InChI=1S/C10H5F3O3/c11-10(12,13)7-4-9(15)16-8-3-5(14)1-2-6(7)8/h1-4,14H","PMID:12065444;PMID:14689466"
"BIOTID01110","7-Benzyloxyresorufin","114982","XNZRYTITWLGTJS-UHFFFAOYSA-N","InChI=1S/C19H13NO3/c21-14-6-8-16-18(10-14)23-19-11-15(7-9-17(19)20-16)22-12-13-4-2-1-3-5-13/h1-11H,12H2","CYP1A1; CYP1A2; CYP1B1","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Resorufin","69462","HSSLDCABUXLXKM-UHFFFAOYSA-N","InChI=1S/C12H7NO3/c14-7-1-3-9-11(5-7)16-12-6-8(15)2-4-10(12)13-9/h1-6,14H","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01111","Dibenz[a,j]acridine","9177","ANUCHZVCBDOPOX-UHFFFAOYSA-N","InChI=1S/C21H13N/c1-3-7-16-14(5-1)9-11-20-18(16)13-19-17-8-4-2-6-15(17)10-12-21(19)22-20/h1-13H","CYP1A2;CYP3A4","N-Oxidation","Human Phase I","Human","NULL","NULL","NACFRPLWKWAEHU-UHFFFAOYSA-N","InChI=1S/C21H15NO/c23-22-20-11-9-14-5-1-3-7-16(14)18(20)13-19-17-8-4-2-6-15(17)10-12-21(19)22/h1-13,20,23H","PMID:7866988"
"BIOTID01112","Dibenz[a,j]acridine","9177","ANUCHZVCBDOPOX-UHFFFAOYSA-N","InChI=1S/C21H13N/c1-3-7-16-14(5-1)9-11-20-18(16)13-19-17-8-4-2-6-15(17)10-12-21(19)22-20/h1-13H","CYP1A2;CYP3A4","Aromatic Oxidation ","Human Phase I","Human","NULL","NULL","LPPJCINILYNPDJ-UHFFFAOYSA-N","InChI=1S/C21H13NO/c23-21-19-15-7-3-1-5-13(15)9-11-17(19)22-18-12-10-14-6-2-4-8-16(14)20(18)21/h1-12,19H","PMID:7866988"
"BIOTID01113","Dibenz[a,j]acridine","9177","ANUCHZVCBDOPOX-UHFFFAOYSA-N","InChI=1S/C21H13N/c1-3-7-16-14(5-1)9-11-20-18(16)13-19-17-8-4-2-6-15(17)10-12-21(19)22-20/h1-13H","CYP1A2;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","3,4-DHD","NULL","DOEKQHQJOZIQIV-UHFFFAOYSA-N","InChI=1S/C21H13NO2/c23-20-10-7-14-15(21(20)24)6-9-19-17(14)11-16-13-4-2-1-3-12(13)5-8-18(16)22-19/h1-11,23-24H","PMID:7866988"
"BIOTID01114","Dibenz[a,j]acridine","9177","ANUCHZVCBDOPOX-UHFFFAOYSA-N","InChI=1S/C21H13N/c1-3-7-16-14(5-1)9-11-20-18(16)13-19-17-8-4-2-6-15(17)10-12-21(19)22-20/h1-13H","CYP1A2;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","1,2-DHD","NULL","JFOYASYEGPXNJA-UHFFFAOYSA-N","InChI=1S/C21H13NO2/c23-19-10-7-13-6-9-18-16(20(13)21(19)24)11-15-14-4-2-1-3-12(14)5-8-17(15)22-18/h1-11,23-24H","PMID:7866988"
"BIOTID01115","Dibenz[a,j]acridine","9177","ANUCHZVCBDOPOX-UHFFFAOYSA-N","InChI=1S/C21H13N/c1-3-7-16-14(5-1)9-11-20-18(16)13-19-17-8-4-2-6-15(17)10-12-21(19)22-20/h1-13H","CYP1A2;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","5,6-DHD","NULL","WYGZMFFEZZAYTB-UHFFFAOYSA-N","InChI=1S/C21H13NO2/c23-20-15-8-4-3-7-14(15)17-11-16-13-6-2-1-5-12(13)9-10-18(16)22-19(17)21(20)24/h1-11,23-24H","PMID:7866988"
"BIOTID01116","Methyl N,N-diethyldithiocarbamate","12704","JYRXPFCUABYLPD-UHFFFAOYSA-N","InChI=1S/C6H13NS2/c1-4-7(5-2)6(8)9-3/h4-5H2,1-3H3","CYP1A2; CYP2A6; CYP2B6; CYP2E1; CYP3A4; CYP3A5","S-oxidation of dithiocarbamate","Human Phase I","Human","MeDDC sulfine ","NULL","RSPAUUVFJFPEHQ-UHFFFAOYSA-N","InChI=1S/C6H13NOS2/c1-4-7(5-2)6(9-3)10-8/h4-5H2,1-3H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01117","7,12 Dimethylbenzanthracene","6001","ARSRBNBHOADGJU-UHFFFAOYSA-N","InChI=1S/C20H16/c1-13-16-8-5-6-9-17(16)14(2)20-18(13)12-11-15-7-3-4-10-19(15)20/h3-12H,1-2H3","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","HJPAZBVZYGHHPT-UHFFFAOYSA-N","InChI=1S/C20H16O2/c1-11-13-7-3-4-8-14(13)12(2)18-17(11)15-9-5-6-10-16(15)19(21)20(18)22/h3-10,21-22H,1-2H3","PMID:8989918"
"BIOTID01118","7,12 Dimethylbenzanthracene","6001","ARSRBNBHOADGJU-UHFFFAOYSA-N","InChI=1S/C20H16/c1-13-16-8-5-6-9-17(16)14(2)20-18(13)12-11-15-7-3-4-10-19(15)20/h3-12H,1-2H3","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","ZSPQGXXFUHZQTL-UHFFFAOYSA-N","InChI=1S/C20H16O2/c1-11-15-9-10-17(21)20(22)19(15)12(2)14-8-7-13-5-3-4-6-16(13)18(11)14/h3-10,21-22H,1-2H3","PMID:8989918"
"BIOTID01119","7,12 Dimethylbenzanthracene","6001","ARSRBNBHOADGJU-UHFFFAOYSA-N","InChI=1S/C20H16/c1-13-16-8-5-6-9-17(16)14(2)20-18(13)12-11-15-7-3-4-10-19(15)20/h3-12H,1-2H3","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","UOGIXWFTUIUULQ-UHFFFAOYSA-N","InChI=1S/C20H16O2/c1-11-13-5-3-4-6-14(13)12(2)19-15(11)7-8-17-16(19)9-10-18(21)20(17)22/h3-10,21-22H,1-2H3","PMID:8989918"
"BIOTID01120","7,12 Dimethylbenzanthracene","6001","ARSRBNBHOADGJU-UHFFFAOYSA-N","InChI=1S/C20H16/c1-13-16-8-5-6-9-17(16)14(2)20-18(13)12-11-15-7-3-4-10-19(15)20/h3-12H,1-2H3","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","SOUMNXRWBUATRC-UHFFFAOYSA-N","InChI=1S/C20H16O/c1-12-16-5-3-4-6-17(16)13(2)20-18(12)10-8-14-7-9-15(21)11-19(14)20/h3-11,21H,1-2H3","PMID:8989918"
"BIOTID01121","7,12 Dimethylbenzanthracene","6001","ARSRBNBHOADGJU-UHFFFAOYSA-N","InChI=1S/C20H16/c1-13-16-8-5-6-9-17(16)14(2)20-18(13)12-11-15-7-3-4-10-19(15)20/h3-12H,1-2H3","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","JCBBZYDVQJQMMB-UHFFFAOYSA-N","InChI=1S/C20H16O/c1-13-15-7-4-5-9-17(15)19(12-21)18-11-10-14-6-2-3-8-16(14)20(13)18/h2-11,21H,12H2,1H3","PMID:8989918"
"BIOTID01122","7,12 Dimethylbenzanthracene","6001","ARSRBNBHOADGJU-UHFFFAOYSA-N","InChI=1S/C20H16/c1-13-16-8-5-6-9-17(16)14(2)20-18(13)12-11-15-7-3-4-10-19(15)20/h3-12H,1-2H3","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","JNJPGADWNSQMQP-UHFFFAOYSA-N","InChI=1S/C20H16O/c1-13-15-7-4-5-9-18(15)19(12-21)20-16(13)11-10-14-6-2-3-8-17(14)20/h2-11,21H,12H2,1H3","PMID:8989918"
"BIOTID01123","DMXAA","123964","XGOYIMQSIKSOBS-UHFFFAOYSA-N","InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)","CYP1A2","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","6-Hydroxy-MXAA","NULL","JEPCGWROBIUIMK-UHFFFAOYSA-N","InChI=1S/C17H14O5/c1-9-11(8-18)5-6-13-15(21)12-4-2-3-10(7-14(19)20)17(12)22-16(9)13/h2-6,18H,7-8H2,1H3,(H,19,20)","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01124","4-(Aminomethyl)-7-methoxycoumarin","8758226","JTWMBPZRYBLNNG-UHFFFAOYSA-N","InChI=1S/C11H11NO3/c1-14-8-2-3-9-7(6-12)4-11(13)15-10(9)5-8/h2-5H,6,12H2,1H3","CYP1A2;CYP2C19;CYP2D6","N-Dealkylation","Human Phase I","Human","7-hydroxy-4-(aminomethyl)-coumarin (HAMC)","NULL","HVMBPUABKRKNPU-UHFFFAOYSA-N","InChI=1S/C10H9NO3/c11-5-6-3-10(13)14-9-4-7(12)1-2-8(6)9/h1-4,12H,5,11H2","PMID:11095593"
"BIOTID01125","Nitrosodiethylamine","5921","WBNQDOYYEUMPFS-UHFFFAOYSA-N","InChI=1S/C4H10N2O/c1-3-6(4-2)5-7/h3-4H2,1-2H3","CYP2A6; CYP2B6; CYP2E1","N-dealkylation of nitrosodialkylamine","Human Phase I","Human","N-Nitrosomonoethylamine","149201","SCSKXSBERKMMJG-UHFFFAOYSA-N","InChI=1S/C2H6N2O/c1-2-3-4-5/h2H2,1H3,(H,3,5)","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015|Ekins, S. and Wrighton, S.A. (1999); The role of CYP2B6 in Human Xenobiotic Metabolism; Drug Metabolism Reviews, 31:3, 719-754, DOI:10.1081/ DMR-100101942; PMID:10461547"
"BIOTID01126","N-Nitrosodimethylamine","6124","UMFJAHHVKNCGLG-UHFFFAOYSA-N","InChI=1S/C2H6N2O/c1-4(2)3-5/h1-2H3","CYP2E1; CYP2A6","Hydroxylation of sp3-carbon adjacent to N in nitrosamine","Human Phase I","Human","N-Nitroso-N-methyl-N-hydroxymethylamine","NULL","CDKXZKUBCGJTDG-UHFFFAOYSA-N","InChI=1S/C2H6N2O2/c1-4(2-5)3-6/h5H,2H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01127","N-Nitrosodimethylamine","6124","UMFJAHHVKNCGLG-UHFFFAOYSA-N","InChI=1S/C2H6N2O/c1-4(2)3-5/h1-2H3","CYP1A2; CYP2E1","N-dealkylation of N-alkylnitrosamine","Human Phase I","Human","N-Nitrosomethylamine","NULL","CIJBKNZDKBKMFU-UHFFFAOYSA-N","InChI=1S/CH4N2O/c1-2-3-4/h1H3,(H,2,4)","Kelley, R.W. et al. (2006); Heteromeric Complex Formation between CYP2E1 and CYP1A2: Evidence for the involvement of electrostatic interactions; Biochemistry. 2006 December 26; 45(51): 15807Ã¢â‚¬â€œ15816.; doi:10.1021/bi061803n; PMCID:PMC1994092"
"BIOTID01128","NNK","47289","FLAQQSHRLBFIEZ-UHFFFAOYSA-N","InChI=1S/C10H13N3O2/c1-13(12-15)7-3-5-10(14)9-4-2-6-11-8-9/h2,4,6,8H,3,5,7H2,1H3","CYP1A1; CYP1A2; CYP1B1; CYP2A6; CYP2B6; CYP2D6; CYP2E1","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","NULL","NULL","DADWKWOJOMSGPK-UHFFFAOYSA-N","InChI=1S/C10H13N3O3/c14-8-13(12-16)6-2-4-10(15)9-3-1-5-11-7-9/h1,3,5,7,14H,2,4,6,8H2","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01129","DEET","4284","MMOXZBCLCQITDF-UHFFFAOYSA-N","InChI=1S/C12H17NO/c1-4-13(5-2)12(14)11-8-6-7-10(3)9-11/h6-9H,4-5H2,1-3H3","CYP1A2; CYP2B6; CYP2D6; CYP2E1","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","N,N-diethyl-m-hydroxymethylbenzamide","NULL","FRZJZRVZZNTMAW-UHFFFAOYSA-N","InChI=1S/C12H17NO2/c1-3-13(4-2)12(15)11-7-5-6-10(8-11)9-14/h5-8,14H,3-4,9H2,1-2H3","Usmani, K.A. et al (2002); In vitro human metabolism and interactions of repellent N,N-diethyl-m-toluamide; Drug. Metab. Dispos.;30(3):289-94.; PMID11854147"
"BIOTID01130","DEET","4284","MMOXZBCLCQITDF-UHFFFAOYSA-N","InChI=1S/C12H17NO/c1-4-13(5-2)12(14)11-8-6-7-10(3)9-11/h6-9H,4-5H2,1-3H3","CYP2A6; CYP2C19; CYP3A4; CYP3A5","Hydroxylation of terminal methyl","Human Phase I","Human","NULL","NULL","KVTUZBGZTRABBQ-UHFFFAOYSA-N","InChI=1S/C12H17NO2/c1-3-13(7-8-14)12(15)11-6-4-5-10(2)9-11/h4-6,9,14H,3,7-8H2,1-2H3","Usmani, K.A. et al (2002); In vitro human metabolism and interactions of repellent N,N-diethyl-m-toluamide; Drug. Metab. Dispos.;30(3):289-94.; PMID11854147"
"BIOTID01131","dibenzo(a,h)anthracene","5889","LHRCREOYAASXPZ-UHFFFAOYSA-N","InChI=1S/C22H14/c1-3-7-19-15(5-1)9-11-17-14-22-18(13-21(17)19)12-10-16-6-2-4-8-20(16)22/h1-14H","CYP1A1; CYP1A2","ARENE_EPOXIDATION","Human Phase I","Human","dibenzo(a,h)anthracene 1,2-epoxide","NULL","KRMRQHCFOIRUMJ-UHFFFAOYSA-N","InChI=1S/C22H14O/c1-2-4-17-13(3-1)5-7-15-12-19-16(11-18(15)17)8-6-14-9-10-20-22(23-20)21(14)19/h1-12,20,22H","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01132","dibenzo(a,h)anthracene","5889","LHRCREOYAASXPZ-UHFFFAOYSA-N","InChI=1S/C22H14/c1-3-7-19-15(5-1)9-11-17-14-22-18(13-21(17)19)12-10-16-6-2-4-8-20(16)22/h1-14H","CYP1A2 (major); CYP2B6 (minor); CYP2C9 (major)","ARENE_EPOXIDATION","Human Phase I","Human","dibenzo(a,h)anthracene 3,4-epoxide","NULL","JXNLSXIURKVPSX-UHFFFAOYSA-N","InChI=1S/C22H16O/c1-2-4-16-13(3-1)5-6-14-12-20-15(11-19(14)16)7-8-18-17(20)9-10-21-22(18)23-21/h1,3,5-12,21-22H,2,4H2","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675|Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01134","Alvameline","178030","RNMOMKCRCIRYCZ-UHFFFAOYSA-N","InChI=1S/C9H15N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5H,3-4,6-7H2,1-2H3","CYP1A2;CYP2A6;CYP2C19;CYP3A4","N-demethylation","Human Phase I","Human","NULL","NULL","KWCDFRUNFDIIQT-UHFFFAOYSA-N","InChI=1S/C8H13N5/c1-2-13-11-8(10-12-13)7-4-3-5-9-6-7/h4,9H,2-3,5-6H2,1H3","PMID:9884321"
"BIOTID01135","Alvameline","178030","RNMOMKCRCIRYCZ-UHFFFAOYSA-N","InChI=1S/C9H15N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5H,3-4,6-7H2,1-2H3","CYP1A2;CYP2C19","N-Oxidation","Human Phase I","Human","NULL","NULL","DTAHTIJECGXNNN-UHFFFAOYSA-N","InChI=1S/C9H15N5O/c1-3-13-11-9(10-12-13)8-5-4-6-14(2,15)7-8/h5H,3-4,6-7H2,1-2H3","PMID:9884321"
"BIOTID01136","Alvameline","178030","RNMOMKCRCIRYCZ-UHFFFAOYSA-N","InChI=1S/C9H15N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5H,3-4,6-7H2,1-2H3","CYP2D6","N-demethylation","Human Phase I","Human","NULL","NULL","CILLGJGQRHDRLI-UHFFFAOYSA-N","InChI=1S/C7H11N5/c1-12-4-2-3-6(5-12)7-8-10-11-9-7/h3H,2,4-5H2,1H3,(H,8,9,10,11)","PMID:9884321"
"BIOTID01137","Alvameline","178030","RNMOMKCRCIRYCZ-UHFFFAOYSA-N","InChI=1S/C9H15N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5H,3-4,6-7H2,1-2H3","CYP1A2;CYP2A6;CYP2C19;CYP3A4","Hydrogenation","Human Phase I","Human","NULL","NULL","ZUJAHDQCHDZIDL-UHFFFAOYSA-N","InChI=1S/C9H14N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5-6H,3-4,7H2,1-2H3/q+1","PMID:9884321"
"BIOTID01138","O-isopropyl acetaminophen","95213","QCSNJTIWCIMFFY-UHFFFAOYSA-N","InChI=1S/C11H15NO2/c1-8(2)14-11-6-4-10(5-7-11)12-9(3)13/h4-8H,1-3H3,(H,12,13)","CYP1A2","O-deethylation","Human Phase I","Human","Acetaminophen","1983","RZVAJINKPMORJF-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)","PMID:11139129"
"BIOTID01139","O-isopropyl acetaminophen","95213","QCSNJTIWCIMFFY-UHFFFAOYSA-N","InChI=1S/C11H15NO2/c1-8(2)14-11-6-4-10(5-7-11)12-9(3)13/h4-8H,1-3H3,(H,12,13)","CYP1A2","C-DEALYLATION","Human Phase I","Human","NULL","NULL","SXEVZVMJNXOXIJ-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-11-8-4-2-7(3-5-8)9-6-10/h2-6H,1H3,(H,9,10)","PMID:11139129"
"BIOTID01140","p-Methoxyacetanilide","5827","XVAIDCNLVLTVFM-UHFFFAOYSA-N","InChI=1S/C9H11NO2/c1-7(11)10-8-3-5-9(12-2)6-4-8/h3-6H,1-2H3,(H,10,11)","CYP1A2","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","p-Methoxyacetanilide, O-demethyl-","1983","RZVAJINKPMORJF-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)","Yun, C.H. et al (2001); Oxidations of p-alkoxyacylanilides catalyzed by human cytochrome P450 1A2: structure-activity relationships and simulation of rate constants of individual steps in catalysis.; Biochemistry 2001, 40, 4521-4530; PMID:11284709."
"BIOTID01141","Terbutryn","(R)-3,4-Methylenedioxymethamphetamine","IROINLKCQGIITA-UHFFFAOYSA-N","InChI=1S/C10H19N5S/c1-6-11-7-12-8(15-10(2,3)4)14-9(13-7)16-5/h6H2,1-5H3,(H2,11,12,13,14,15)","CYP1A2;CYP2B6;CYP3A4","S-Oxidation","Human Phase I","Human","NULL","NULL","LMUNBZZRYCNYLJ-UHFFFAOYSA-N","InChI=1S/C10H19N5OS/c1-6-11-7-12-8(15-10(2,3)4)14-9(13-7)17(5)16/h6H2,1-5H3,(H2,11,12,13,14,15)","PMID:9305587"
"BIOTID01142","Terbutryn","(R)-3,4-Methylenedioxymethamphetamine","IROINLKCQGIITA-UHFFFAOYSA-N","InChI=1S/C10H19N5S/c1-6-11-7-12-8(15-10(2,3)4)14-9(13-7)16-5/h6H2,1-5H3,(H2,11,12,13,14,15)","CYP1A2;CYP2B6;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","PVGZWYYCGWPQRV-UHFFFAOYSA-N","InChI=1S/C10H19N5OS/c1-6(16)11-7-12-8(15-10(2,3)4)14-9(13-7)17-5/h6,16H,1-5H3,(H2,11,12,13,14,15)","PMID:9305587"
"BIOTID01143","Terbutryn","(R)-3,4-Methylenedioxymethamphetamine","IROINLKCQGIITA-UHFFFAOYSA-N","InChI=1S/C10H19N5S/c1-6-11-7-12-8(15-10(2,3)4)14-9(13-7)16-5/h6H2,1-5H3,(H2,11,12,13,14,15)","CYP1A2","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","IPQDKPPIYWXHHF-UHFFFAOYSA-N","InChI=1S/C10H19N5OS/c1-5-11-7-12-8(14-9(13-7)17-4)15-10(2,3)6-16/h16H,5-6H2,1-4H3,(H2,11,12,13,14,15)","PMID:9305587"
"BIOTID01144","MNAN","25805","KSFCDINBDBFFSI-UHFFFAOYSA-N","InChI=1S/C6H14N2O/c1-3-4-5-6-8(2)7-9/h3-6H2,1-2H3","CYP2A6;CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","XPHGMIGPAFBTSM-UHFFFAOYSA-N","InChI=1S/C6H14N2O2/c1-2-3-4-5-8(6-9)7-10/h9H,2-6H2,1H3","PMID:9892192"
"BIOTID01145","MNAN","25805","KSFCDINBDBFFSI-UHFFFAOYSA-N","InChI=1S/C6H14N2O/c1-3-4-5-6-8(2)7-9/h3-6H2,1-2H3","CYP2A6;CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","KFEFEGIRBZOFLE-UHFFFAOYSA-N","InChI=1S/C6H14N2O2/c1-6(9)4-3-5-8(2)7-10/h6,9H,3-5H2,1-2H3","PMID:9892192"
"BIOTID01146","NDPA","12130","YLKFDHTUAUWZPQ-UHFFFAOYSA-N","InChI=1S/C6H14N2O/c1-3-5-8(7-9)6-4-2/h3-6H2,1-2H3","CYP2A6;CYP2B6;CYP2C8;CYP2C9;CYP2D6;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Alpha-OH NDPA","NULL","WYYFOPVMKKUFNN-UHFFFAOYSA-N","InChI=1S/C6H14N2O2/c1-3-5-8(7-10)6(9)4-2/h6,9H,3-5H2,1-2H3","PMID:10910959"
"BIOTID01147","NDPA","12130","YLKFDHTUAUWZPQ-UHFFFAOYSA-N","InChI=1S/C6H14N2O/c1-3-5-8(7-9)6-4-2/h3-6H2,1-2H3","CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Dipropylimine","NULL","WEHWNAOGRSTTBQ-UHFFFAOYSA-N","InChI=1S/C6H15N/c1-3-5-7-6-4-2/h7H,3-6H2,1-2H3","PMID:10910959"
"BIOTID01148","NPYR","13591","WNYADZVDBIBLJJ-UHFFFAOYSA-N","InChI=1S/C4H8N2O/c7-5-6-3-1-2-4-6/h1-4H2","CYP2A6;CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","KCYALJYRNPZWCX-UHFFFAOYSA-N","InChI=1S/C4H8N2O2/c7-4-2-1-3-6(4)5-8/h4,7H,1-3H2","PMID:19356087"
"BIOTID01149","butadiene","7845","KAKZBPTYRLMSJV-UHFFFAOYSA-N","InChI=1S/C4H6/c1-3-4-2/h3-4H,1-2H2","CYP2A6;CYP2C9;CYP2E1","Epoxidation","Human Phase I","Human","butadiene_monoxide","NULL","GXBYFVGCMPJVJX-UHFFFAOYSA-N","InChI=1S/C4H6O/c1-2-4-3-5-4/h2,4H,1,3H2","PMID:8203896"
"BIOTID01150","butadiene","7845","KAKZBPTYRLMSJV-UHFFFAOYSA-N","InChI=1S/C4H6/c1-3-4-2/h3-4H,1-2H2","CYP2A6;CYP2C9;CYP2E1","C-Oxidation","Human Phase I","Human","3-buten-2-one","6570","FUSUHKVFWTUUBE-UHFFFAOYSA-N","InChI=1S/C4H6O/c1-3-4(2)5/h3H,1H2,2H3","PMID:8203896"
"BIOTID01151","RP73401","154575","RRRUXBQSQLKHEL-UHFFFAOYSA-N","InChI=1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23)","CYP2B6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","MKCDCGDRVFIIBH-UHFFFAOYSA-N","InChI=1S/C18H18Cl2N2O4/c1-25-15-5-2-10(6-16(15)26-12-4-3-11(23)7-12)18(24)22-17-13(19)8-21-9-14(17)20/h2,5-6,8-9,11-12,23H,3-4,7H2,1H3,(H,21,22,24)","PMID:9316851"
"BIOTID01152","sulfinpyrazone_sulfide","77327","PLGXGMUJUXKCDD-UHFFFAOYSA-N","InChI=1S/C23H20N2O2S/c26-22-21(16-17-28-20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2","CYP2C9;CYP3A4","S-Oxidation","Human Phase I","Human","Sulfinpyrazone","5342","MBGGBVCUIVRRBF-UHFFFAOYSA-N","InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2","PMID:11302937"
"BIOTID01153","sulfinpyrazone_sulfide","77327","PLGXGMUJUXKCDD-UHFFFAOYSA-N","InChI=1S/C23H20N2O2S/c26-22-21(16-17-28-20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2","CYP2C9;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","NZGXIFCGKSHTGS-UHFFFAOYSA-N","InChI=1S/C23H20N2O4S/c26-19-13-11-18(12-14-19)25-23(28)21(15-16-30(29)20-9-5-2-6-10-20)22(27)24(25)17-7-3-1-4-8-17/h1-14,21,26H,15-16H2","PMID:11302937"
"BIOTID01154","sulfinpyrazone_sulfide","77327","PLGXGMUJUXKCDD-UHFFFAOYSA-N","InChI=1S/C23H20N2O2S/c26-22-21(16-17-28-20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2","CYP2C9;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","SAVSPYPVPBCSAE-UHFFFAOYSA-N","InChI=1S/C23H20N2O4S/c26-19-11-13-20(14-12-19)30(29)16-15-21-22(27)24(17-7-3-1-4-8-17)25(23(21)28)18-9-5-2-6-10-18/h1-14,21,26H,15-16H2","PMID:11302937"
"BIOTID01155","Proguanil","6178111","SSOLNOMRVKKSON-UHFFFAOYSA-N","InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)","CYP1A2; CYP2C19; CYP2D6; CYP3A4; CYP2C9 (minor)","Formation of cycloguanide","Human Phase I","Human","Cycloguanil","NULL","QMNFFXRFOJIOKZ-UHFFFAOYSA-N","InChI=1S/C11H14ClN5/c1-11(2)16-9(13)15-10(14)17(11)8-5-3-7(12)4-6-8/h3-6H,1-2H3,(H4,13,14,15,16)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Diaz, D.S. et al. (2008); Role of Specific Cytochrome P450 Isoforms in the Conversion of Phenoxypropoxybiguanide Analogs in Human Liver Microsomes to Potent Antimalarial Dihydrotriazines; Drug Metabolism and Disposition February 2008, 36 (2) 380-385; DOI:https://doi.org/10.1124/dmd.106.013920|Birkett, D.J. et al. (1994); In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase; Br J Clin Pharmacol.; 37(5):413-20."
"BIOTID01156","Proguanil","6178111","SSOLNOMRVKKSON-UHFFFAOYSA-N","InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)","CYP2C19","N-deisopropylation","Human Phase I","Human","4-Chlorophenylbiguanide","NULL","HTYFFCPFVMJTKM-UHFFFAOYSA-N","InChI=1S/C8H10ClN5/c9-5-1-3-6(4-2-5)13-8(12)14-7(10)11/h1-4H,(H6,10,11,12,13,14)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Diaz, D.S. et al. (2008); Role of Specific Cytochrome P450 Isoforms in the Conversion of Phenoxypropoxybiguanide Analogs in Human Liver Microsomes to Potent Antimalarial Dihydrotriazines; Drug Metabolism and Disposition February 2008, 36 (2) 380-385; DOI:https://doi.org/10.1124/dmd.106.013920|Birkett, D.J. et al. (1994); In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase; Br J Clin Pharmacol.; 37(5):413-20."
"BIOTID01157","4_nitro_phenol","980","BTJIUGUIPKRLHP-UHFFFAOYSA-N","InChI=1S/C6H5NO3/c8-6-3-1-5(2-4-6)7(9)10/h1-4,8H","CYP2E1","Aromatic Hydroxylation","Human Phase I","Human","4-nitrocatechol (4NC) ","3505109","XJNPNXSISMKQEX-UHFFFAOYSA-N","InChI=1S/C6H5NO4/c8-5-2-1-4(7(10)11)3-6(5)9/h1-3,8-9H","PMID:8267647"
"BIOTID01158","7,8-Dihydrobenzo[a]pyrene-7,8-diol","25892","YDXRLMMGARHIIC-UHFFFAOYSA-N","InChI=1S/C20H14O2/c21-17-9-8-14-15-7-6-12-3-1-2-11-4-5-13(19(15)18(11)12)10-16(14)20(17)22/h1-10,17,20-22H","CYP1A1;CYP1B1","Epoxidation","Human Phase I","Human","NULL","NULL","DQEPMTIXHXSFOR-UHFFFAOYSA-N","InChI=1S/C20H14O3/c21-17-13-8-11-5-4-9-2-1-3-10-6-7-12(15(11)14(9)10)16(13)19-20(23-19)18(17)22/h1-8,17-22H","PMID:10409402;PMID:1068451"
"BIOTID01159","Furametpyr","3083543","NRTLIYOWLVMQBO-UHFFFAOYSA-N","InChI=1S/C17H20ClN3O2/c1-9-13(15(18)21(5)20-9)16(22)19-12-8-6-7-11-14(12)10(2)23-17(11,3)4/h6-8,10H,1-5H3,(H,19,22)","CYP1A1;CYP1A2;CYP2C19;CYP3A4","N-Demethylation ","Human Phase I","Human","NULL","NULL","ACFDYUIMXVOAJX-UHFFFAOYSA-N","InChI=1S/C16H18ClN3O2/c1-8-12(14(17)20-19-8)15(21)18-11-7-5-6-10-13(11)9(2)22-16(10,3)4/h5-7,9H,1-4H3,(H,18,21)(H,19,20)","DOI:10.5772/28088;PMID:11087551"
"BIOTID01160","Bioresmethrin","162381","VEMKTZHHVJILDY-UXHICEINSA-N","InChI=1S/C22H26O3/c1-15(2)10-19-20(22(19,3)4)21(23)25-14-17-12-18(24-13-17)11-16-8-6-5-7-9-16/h5-10,12-13,19-20H,11,14H2,1-4H3/t19-,20+/m1/s1","CYP2C8;CYP2C9;CYP2C19;CYP3A4","Oxidation","Human Phase I","Human","BFA","NULL","AFEOKIGLYCQHAZ-UHFFFAOYSA-N","InChI=1S/C12H12O2/c13-8-11-7-12(14-9-11)6-10-4-2-1-3-5-10/h1-5,7,9,13H,6,8H2","PMID:18948380"
"BIOTID01161","TRANS-PERMETHRIN","43859","RLLPVAHGXHCWKJ-MJGOQNOKSA-N","InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3/t17-,19+/m1/s1","CYP2C8;CYP2C9;CYP2C19;CYP3A4","Oxidation","Human Phase I","Human","(3-Phenoxyphenyl)methanol","26295","KGANAERDZBAECK-UHFFFAOYSA-N","InChI=1S/C13H12O2/c14-10-11-5-4-8-13(9-11)15-12-6-2-1-3-7-12/h1-9,14H,10H2","PMID:12898643;PMID:18948380"
"BIOTID01162","LOSIGAMONE","60572","ICDNYWJQGWNLFP-UHFFFAOYSA-N","InChI=1S/C12H11ClO4/c1-16-9-6-10(14)17-12(9)11(15)7-4-2-3-5-8(7)13/h2-6,11-12,15H,1H3","CYP2A6","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","VMJWYCJTSQOPBI-UHFFFAOYSA-N","InChI=1S/C12H11ClO5/c1-17-9-5-10(15)18-12(9)11(16)7-3-2-6(14)4-8(7)13/h2-5,11-12,14,16H,1H3","PMID:9625272;PMID:8886611"
"BIOTID01163","LOSIGAMONE","60572","ICDNYWJQGWNLFP-UHFFFAOYSA-N","InChI=1S/C12H11ClO4/c1-16-9-6-10(14)17-12(9)11(15)7-4-2-3-5-8(7)13/h2-6,11-12,15H,1H3","CYP2A6","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","MNRQDBBYFMHYCB-UHFFFAOYSA-N","InChI=1S/C12H11ClO5/c1-17-9-5-10(15)18-12(9)11(16)7-4-6(14)2-3-8(7)13/h2-5,11-12,14,16H,1H3","PMID:9625272;PMID:8886611"
"BIOTID01164","Promethazine","4927","PWWVAXIEGOYWEE-UHFFFAOYSA-N","InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3","CYP2D6","S-Oxidation","Human Phase I","Human","NULL","NULL","OWTCLFIFAFHQIX-UHFFFAOYSA-N","InChI=1S/C17H20N2OS/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)21(20)17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3","PMID:27994650"
"BIOTID01165","Promethazine","4927","PWWVAXIEGOYWEE-UHFFFAOYSA-N","InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3","CYP2D6","N-Demethylation","Human Phase I","Human","NULL","NULL","IJOZCCILCJIHOA-UHFFFAOYSA-N","InChI=1S/C16H18N2S/c1-12(17-2)11-18-13-7-3-5-9-15(13)19-16-10-6-4-8-14(16)18/h3-10,12,17H,11H2,1-2H3","PMID:8946477"
"BIOTID01166","Verapamil","2520","SGTNSNPWRIOYBX-UHFFFAOYSA-N","InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3","CYP2C8; CYP1A2; CYP3A4; CYP3A5","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","Norverapamil","NULL","UPKQNCPKPOLASS-UHFFFAOYSA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID01167","Verapamil","2520","SGTNSNPWRIOYBX-UHFFFAOYSA-N","InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3","CYP2C8; CYP2C18","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","D-702","NULL","CAAKRPRWCVWYAO-UHFFFAOYSA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28(3)15-12-20-8-10-22(29)24(16-20)31-5/h8-11,16-17,19,29H,7,12-15H2,1-6H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID01168","Verapamil","2520","SGTNSNPWRIOYBX-UHFFFAOYSA-N","InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3","CYP2C8","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","M9 (D-703)","NULL","WLKVZSXOMGNZLB-UHFFFAOYSA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-10-22(29)24(17-21)31-5)13-7-14-28(3)15-12-20-8-11-23(30-4)25(16-20)32-6/h8-11,16-17,19,29H,7,12-15H2,1-6H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID01169","Verapamil","2520","SGTNSNPWRIOYBX-UHFFFAOYSA-N","InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3","CYP2C8; CYP3A4; CYP1A2","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","D-617","NULL","WLOBUUJURNEQCL-UHFFFAOYSA-N","InChI=1S/C17H26N2O2/c1-13(2)17(12-18,9-6-10-19-3)14-7-8-15(20-4)16(11-14)21-5/h7-8,11,13,19H,6,9-10H2,1-5H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID01169","Verapamil","2520","SGTNSNPWRIOYBX-UHFFFAOYSA-N","InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3","CYP2C8; CYP3A4; CYP1A2","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","2-(3,4-dimethoxyphenyl)acetaldehyde","NULL","RIVVYJWUHXMGSK-UHFFFAOYSA-N","InChI=1S/C10H12O3/c1-12-9-4-3-8(5-6-11)7-10(9)13-2/h3-4,6-7H,5H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID01170","METALAXYL","42586","ZQEIXNIJLIKNTD-UHFFFAOYSA-N","InChI=1S/C15H21NO4/c1-10-7-6-8-11(2)14(10)16(13(17)9-19-4)12(3)15(18)20-5/h6-8,12H,9H2,1-5H3","CYP2B6;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","NULL","HOOCPOQCHBHJLU-UHFFFAOYSA-N","InChI=1S/C14H19NO4/c1-9-6-5-7-10(2)13(9)15(12(17)8-16)11(3)14(18)19-4/h5-7,11,16H,8H2,1-4H3","PMID:21783735"
"BIOTID01171","METALAXYL","42586","ZQEIXNIJLIKNTD-UHFFFAOYSA-N","InChI=1S/C15H21NO4/c1-10-7-6-8-11(2)14(10)16(13(17)9-19-4)12(3)15(18)20-5/h6-8,12H,9H2,1-5H3","CYP2B6;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","NULL","ZRIKZVLHMGYCIR-UHFFFAOYSA-N","InChI=1S/C14H19NO4/c1-9-6-5-7-10(2)13(9)15(11(3)14(17)18)12(16)8-19-4/h5-7,11H,8H2,1-4H3,(H,17,18)","PMID:21783735"
"BIOTID01172","METALAXYL","42586","ZQEIXNIJLIKNTD-UHFFFAOYSA-N","InChI=1S/C15H21NO4/c1-10-7-6-8-11(2)14(10)16(13(17)9-19-4)12(3)15(18)20-5/h6-8,12H,9H2,1-5H3","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","SKNRMURHENGAJU-UHFFFAOYSA-N","InChI=1S/C15H21NO5/c1-9-6-7-12(17)10(2)14(9)16(13(18)8-20-4)11(3)15(19)21-5/h6-7,11,17H,8H2,1-5H3","PMID:21783735"
"BIOTID01173","METALAXYL","42586","ZQEIXNIJLIKNTD-UHFFFAOYSA-N","InChI=1S/C15H21NO4/c1-10-7-6-8-11(2)14(10)16(13(17)9-19-4)12(3)15(18)20-5/h6-8,12H,9H2,1-5H3","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","JRTUFKUEKGCXQP-UHFFFAOYSA-N","InChI=1S/C15H21NO5/c1-10-6-5-7-12(8-17)14(10)16(13(18)9-20-3)11(2)15(19)21-4/h5-7,11,17H,8-9H2,1-4H3","PMID:21783735"
"BIOTID01174","demethylmetalaxyl","NULL","HOOCPOQCHBHJLU-UHFFFAOYSA-N","InChI=1S/C14H19NO4/c1-9-6-5-7-10(2)13(9)15(12(17)8-16)11(3)14(18)19-4/h5-7,11,16H,8H2,1-4H3","CYP2B6;CYP3A4","O-Demethylation","Human Phase I","Human","NULL","NULL","FLFYKLJZDDSXEI-UHFFFAOYSA-N","InChI=1S/C13H17NO4/c1-8-5-4-6-9(2)12(8)14(11(16)7-15)10(3)13(17)18/h4-6,10,15H,7H2,1-3H3,(H,17,18)","PMID:21783735"
"BIOTID01176","L-775606","6426760","ZUTQCPBDRJBADG-UHFFFAOYSA-N","InChI=1S/C25H29FN6/c26-22-5-1-3-20(15-22)8-10-31-13-11-30(12-14-31)9-2-4-21-17-27-25-7-6-23(16-24(21)25)32-18-28-29-19-32/h1,3,5-7,15-19,27H,2,4,8-14H2","CYP3A4;CYP2C8","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","LSHOIAPVGOLDNC-UHFFFAOYSA-N","InChI=1S/C25H29FN6O/c26-21-5-1-3-19(13-21)25(33)16-31-11-9-30(10-12-31)8-2-4-20-15-27-24-7-6-22(14-23(20)24)32-17-28-29-18-32/h1,3,5-7,13-15,17-18,25,27,33H,2,4,8-12,16H2","PMID:10659950"
"BIOTID01177","L-775606","6426760","ZUTQCPBDRJBADG-UHFFFAOYSA-N","InChI=1S/C25H29FN6/c26-22-5-1-3-20(15-22)8-10-31-13-11-30(12-14-31)9-2-4-21-17-27-25-7-6-23(16-24(21)25)32-18-28-29-19-32/h1,3,5-7,15-19,27H,2,4,8-14H2","CYP3A4;CYP2C8","N-Dealkylation","Human Phase I","Human","NULL","NULL","OOQZMTKUJVKASW-UHFFFAOYSA-N","InChI=1S/C17H22N6/c1(7-22-8-5-18-6-9-22)2-14-11-19-17-4-3-15(10-16(14)17)23-12-20-21-13-23/h3-4,10-13,18-19H,1-2,5-9H2","PMID:10659950"
"BIOTID01178","Bufuralol","71733","SSEBTPPFLLCUMN-UHFFFAOYSA-N","InChI=1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3","CYP1A2; CYP2D6","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","4-Hydroxybufuralol","NULL","VWEQAYFMBKZBLK-UHFFFAOYSA-N","InChI=1S/C16H23NO3/c1-5-10-6-7-12(18)11-8-14(20-15(10)11)13(19)9-17-16(2,3)4/h6-8,13,17-19H,5,9H2,1-4H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Yamazaki, H. et al. (1994); Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes; Molecular Pharmacology September 1994, 46 (3) 568-577"
"BIOTID01179","Bufuralol","71733","SSEBTPPFLLCUMN-UHFFFAOYSA-N","InChI=1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3","CYP1A2; CYP2D6","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-Hydroxubufuralol","NULL","JSCCUEPMAIGYSD-UHFFFAOYSA-N","InChI=1S/C16H23NO3/c1-5-11-12(18)7-6-10-8-14(20-15(10)11)13(19)9-17-16(2,3)4/h6-8,13,17-19H,5,9H2,1-4H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Yamazaki, H. et al. (1994); Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes; Molecular Pharmacology September 1994, 46 (3) 568-577"
"BIOTID01180","Bufuralol","71733","SSEBTPPFLLCUMN-UHFFFAOYSA-N","InChI=1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3","CYP2D6","Terminal desaturation","Human Phase I","Human","1'2'-Ethenylbufuralol","NULL","FVNDVONSLMNGES-UHFFFAOYSA-N","InChI=1S/C16H21NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h5-9,13,17-18H,1,10H2,2-4H3",""
"BIOTID01181","Deltamethrin","40585","OWZREIFADZCYQD-NSHGMRRFSA-N","InChI=1S/C22H19Br2NO3/c1-22(2)17(12-19(23)24)20(22)21(26)28-18(13-25)14-7-6-10-16(11-14)27-15-8-4-3-5-9-15/h3-12,17-18,20H,1-2H3/t17-,18+,20-/m0/s1","CYP2C8; CYP2C19; CYP3A4; CYP3A5","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4'-OH-deltamethrin","NULL","RLMJIYYRLVNAOJ-NSHGMRRFSA-N","InChI=1S/C22H19Br2NO4/c1-22(2)17(11-19(23)24)20(22)21(27)29-18(12-25)13-4-3-5-16(10-13)28-15-8-6-14(26)7-9-15/h3-11,17-18,20,26H,1-2H3/t17-,18+,20-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01182","(1S)-trans-Cyfluthrin","101998811","QQODLKZGRKWIFG-BEHPGTHXSA-N","InChI=1S/C22H18Cl2FNO3/c1-22(2)15(11-19(23)24)20(22)21(27)29-18(12-26)13-8-9-16(25)17(10-13)28-14-6-4-3-5-7-14/h3-11,15,18,20H,1-2H3/t15-,18?,20+/m0/s1","CYP1A1;CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","GGHOICXUOHBFJW-BEHPGTHXSA-N","InChI=1S/C22H18Cl2FNO4/c1-22(2)15(10-19(23)24)20(22)21(28)30-18(11-26)12-3-8-16(25)17(9-12)29-14-6-4-13(27)5-7-14/h3-10,15,18,20,27H,1-2H3/t15-,18?,20+/m0/s1","PMID:27464030;PMID:18948380"
"BIOTID01183","Bexarotene","82146","NAVMQTYZDKMPEU-UHFFFAOYSA-N","InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)","CYP3A;CYP2C9;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","6-hydroxy-bexarotene","NULL","WTWGVKDCAJSUBZ-UHFFFAOYSA-N","InChI=1S/C24H28O3/c1-14-11-20-19(23(3,4)13-21(25)24(20,5)6)12-18(14)15(2)16-7-9-17(10-8-16)22(26)27/h7-12,21,25H,2,13H2,1,3-6H3,(H,26,27)","PMID:11408365"
"BIOTID01184","Bexarotene","82146","NAVMQTYZDKMPEU-UHFFFAOYSA-N","InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)","CYP3A;CYP2C9;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","7-hydroxy-bexarotene","NULL","ZXOXDVMWISJVGJ-UHFFFAOYSA-N","InChI=1S/C24H28O3/c1-14-11-19-20(24(5,6)21(25)13-23(19,3)4)12-18(14)15(2)16-7-9-17(10-8-16)22(26)27/h7-12,21,25H,2,13H2,1,3-6H3,(H,26,27)","PMID:11408365"
"BIOTID01185","Bexarotene","82146","NAVMQTYZDKMPEU-UHFFFAOYSA-N","InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)","CYP3A;CYP2C9;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","7-oxo-bexarotene","NULL","ZODXGLWZRPTBIM-UHFFFAOYSA-N","InChI=1S/C24H26O3/c1-14-11-20-19(23(3,4)13-21(25)24(20,5)6)12-18(14)15(2)16-7-9-17(10-8-16)22(26)27/h7-12H,2,13H2,1,3-6H3,(H,26,27)","PMID:11408365"
"BIOTID01186","Bexarotene","82146","NAVMQTYZDKMPEU-UHFFFAOYSA-N","InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)","CYP3A;CYP2C9;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","7-oxo-bexarotene","NULL","XLMHAABXFLIUNQ-UHFFFAOYSA-N","InChI=1S/C24H26O3/c1-14-11-19-20(24(5,6)21(25)13-23(19,3)4)12-18(14)15(2)16-7-9-17(10-8-16)22(26)27/h7-12H,2,13H2,1,3-6H3,(H,26,27)","PMID:11408365"
"BIOTID01187","Dolasetron","NULL","UKTAZPQNNNJVKR-KPWCQOOUSA-N","InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11-,12+,13-,14+","CYP2D6;CYP3A4","Hydrogenation;Reduction","Human Phase I","Human","Reduced dolasetron","NULL","MLWGAEVSWJXOQJ-SOWKSNBUSA-N","InChI=1S/C19H22N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,18,20,22H,5-8,10H2/t11-,12+,13-,14+,18?","PMID:19902987;PMID:19817501"
"BIOTID01189","Halothane ","3562","BCQZXOMGPXTTIC-UHFFFAOYSA-N","InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H","CYP2E1; CYP2A6","Oxidation of halotrifluoroethane","Human Phase I","Human","Trifluoroacetyl chloride","61106","PNQBEPDZQUOCNY-UHFFFAOYSA-N","InChI=1S/C2ClF3O/c3-1(7)2(4,5)6","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01190","Halothane ","3562","BCQZXOMGPXTTIC-UHFFFAOYSA-N","InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H","CYP2A6; CYP3A4","Reduction of halotrifluoroethane","Human Phase I","Human","chlorotrifluoroethane","6408","CYXIKYKBLDZZNW-UHFFFAOYSA-N","InChI=1S/C2H2ClF3/c3-1-2(4,5)6/h1H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01191","Halothane ","3562","BCQZXOMGPXTTIC-UHFFFAOYSA-N","InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H","CYP2A6; CYP3A4","Reduction of halotrifluoroethane","Human Phase I","Human","chlorodifluoroethene","9664","HTHNTJCVPNKCPZ-UHFFFAOYSA-N","InChI=1S/C2HClF2/c3-1-2(4)5/h1H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01192","delta-9-Tetrahydrocannabinol","16078","CYQFCXCEBYINGO-IAGOWNOFSA-N","InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1","CYP2C9; CYP2C19; CYP3A4","Hydroxlation of methyl carbon adjacent to an aliphatic ring","Human Phase I","Human","11-OH-delata-Tetrahydrocannabinol","644022","YCBKSSAWEUDACY-IAGOWNOFSA-N","InChI=1S/C21H30O3/c1-4-5-6-7-14-11-18(23)20-16-10-15(13-22)8-9-17(16)21(2,3)24-19(20)12-14/h10-12,16-17,22-23H,4-9,13H2,1-3H3/t16-,17-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01193","delta-9-Tetrahydrocannabinol","16078","CYQFCXCEBYINGO-IAGOWNOFSA-N","InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","7-OH-delta-9-Tetrahydrocannabinol","NULL","DJCKLUPKZRLTPE-RQFJBDDASA-N","InChI=1S/C21H30O3/c1-5-6-7-8-14-11-16(22)19-15-9-13(2)10-17(23)20(15)21(3,4)24-18(19)12-14/h9,11-12,15,17,20,22-23H,5-8,10H2,1-4H3/t15-,17-,20?/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01194","delta-9-Tetrahydrocannabinol","16078","CYQFCXCEBYINGO-IAGOWNOFSA-N","InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","7alpha-OH-delta-9-Tetrahydrocannabinol","NULL","DJCKLUPKZRLTPE-VPWXQRGCSA-N","InChI=1S/C21H30O3/c1-5-6-7-8-14-11-16(22)19-15-9-13(2)10-17(23)20(15)21(3,4)24-18(19)12-14/h9,11-12,15,17,20,22-23H,5-8,10H2,1-4H3/t15-,17+,20-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01195","delta-9-Tetrahydrocannabinol","16078","CYQFCXCEBYINGO-IAGOWNOFSA-N","InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","8-OH-delta-9-Tetrahydrocannabinol","NULL","INKUWBOHCFHXTJ-YNPPLXCJSA-N","InChI=1S/C21H30O3/c1-5-6-7-8-14-10-18(23)20-15-9-13(2)17(22)12-16(15)21(3,4)24-19(20)11-14/h9-11,15-17,22-23H,5-8,12H2,1-4H3/t15-,16-,17?/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01196","delta-9-Tetrahydrocannabinol","16078","CYQFCXCEBYINGO-IAGOWNOFSA-N","InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","8alpha-OH-delta-9-Tetrahydrocannabinol","NULL","INKUWBOHCFHXTJ-PWZMFNOBSA-N","InChI=1S/C21H30O3/c1-5-6-7-8-14-10-18(23)20-15-9-13(2)17(22)12-16(15)21(3,4)24-19(20)11-14/h9-11,15-17,22-23H,5-8,12H2,1-4H3/t15-,16?,17-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01197","S-Bioallethrin","62829","ZCVAOQKBXKSDMS-PVAVHDDUSA-N","InChI=1S/C19H26O3/c1-7-8-13-12(4)16(10-15(13)20)22-18(21)17-14(9-11(2)3)19(17,5)6/h7,9,14,16-17H,1,8,10H2,2-6H3/t14-,16+,17+/m1/s1","CYP2C9;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","MNORPVXFVXBESV-ZOIXOLGDSA-N","InChI=1S/C19H26O4/c1-6-7-13-12(3)16(9-15(13)21)23-18(22)17-14(19(17,4)5)8-11(2)10-20/h6,8,14,16-17,20H,1,7,9-10H2,2-5H3/b11-8-/t14-,16+,17+/m1/s1","PMID:18948380; PMID:789062"
"BIOTID01198","Droloxifene","3033767","ZQZFYGIXNQKOAV-OCEACIFDSA-N","InChI=1S/C26H29NO2/c1-4-25(20-9-6-5-7-10-20)26(22-11-8-12-23(28)19-22)21-13-15-24(16-14-21)29-18-17-27(2)3/h5-16,19,28H,4,17-18H2,1-3H3/b26-25+","CYP2D6;CYP3A4","N-Dementhylation","Human Phase I","Human","NULL","3035880","QPHNKIXIKDPNDI-OCOZRVBESA-N","InChI=1S/C25H27NO2/c1-3-24(19-8-5-4-6-9-19)25(21-10-7-11-22(27)18-21)20-12-14-23(15-13-20)28-17-16-26-2/h4-15,18,26-27H,3,16-17H2,1-2H3/b25-24+","PMID:19817501;PMID:19902987"
"BIOTID01201","VINYL CHLORIDE","6338","BZHJMEDXRYGGRV-UHFFFAOYSA-N","InChI=1S/C2H3Cl/c1-2-3/h2H,1H2","CYP2E1","Epoxidation","Human Phase I","Human","NULL","24472","WBNCHVFLFSFIGK-UHFFFAOYSA-N","InChI=1S/C2H3ClO/c3-2-1-4-2/h2H,1H2","PMID:18259985"
"BIOTID01202","Artesunate","6917864","FIHJKUPKCHIPAT-AHIGJZGOSA-N","InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1","CYP2A6","O-dealkylation","Human Phase I","Human","NULL","44573579","BJDCWCLMFKKGEE-RZULFSQCSA-N","InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12-,13-,14+,15-/m1/s1","PMID:12920490"
"BIOTID01203","Rupatadine","133017","WUZYKBABMWJHDL-UHFFFAOYSA-N","InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","124087","JAUOIFJMECXRGI-UHFFFAOYSA-N","InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2","https://www.pharmacorama.com/en/ezine/20100130120151.php; PMID:27632557"
"BIOTID01204","RL-3142","9905049","SBKRBXLJWOKQFX-LFYBBSHMSA-N","InChI=1S/C20H19N3O/c1-22(2)18-8-3-16(4-9-18)5-12-20(24)17-6-10-19(11-7-17)23-14-13-21-15-23/h3-15H,1-2H3/b12-5+","CYP3A","N-Dementhylation","Human Phase I","Human","NULL","NULL","KMDOGQAGZRZRPI-NYYWCZLTSA-N","InChI=1S/C19H17N3O/c1-20-17-7-2-15(3-8-17)4-11-19(23)16-5-9-18(10-6-16)22-13-12-21-14-22/h2-14,20H,1H3/b11-4+","PMID:9925971"
"BIOTID01205","Erlotinib","176870","AAKJLRGGTJKAMG-UHFFFAOYSA-N","InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)","CYP3A4; CYP3A5; CYP1A1; CYP1A2","O-dealkylation of dialkylether","Human Phase I","Human","2Ã¢â‚¬Â({4Ã¢â‚¬Â[(3Ã¢â‚¬Âethynylphenyl)amino]Ã¢â‚¬Â6Ã¢â‚¬Â(2Ã¢â‚¬Âmethoxyethoxy)quinazolinÃ¢â‚¬Â7Ã¢â‚¬Âyl}oxy)ethanÃ¢â‚¬Â1Ã¢â‚¬Âol","16045730","MTLKTHNRZJKPRP-UHFFFAOYSA-N","InChI=1S/C21H21N3O4/c1-3-15-5-4-6-16(11-15)24-21-17-12-19(28-10-9-26-2)20(27-8-7-25)13-18(17)22-14-23-21/h1,4-6,11-14,25H,7-10H2,2H3,(H,22,23,24)","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01206","zafirlukast","5717","YEEZWCHGZNKEEK-UHFFFAOYSA-N","InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)","CYP2C9; CYP3A4","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","cyclopentyl NÃ¢â‚¬Â[1Ã¢â‚¬Â(hydroxymethyl)Ã¢â‚¬Â3Ã¢â‚¬Â({2Ã¢â‚¬ÂmethoxyÃ¢â‚¬Â4Ã¢â‚¬Â[(2Ã¢â‚¬Âmethylbenzenesulfonyl)carbamoyl]phenyl}methyl)indolÃ¢â‚¬Â5Ã¢â‚¬Âyl]carbamate","71549171","HZAQOSFFIGVMDH-UHFFFAOYSA-N","InChI=1S/C31H33N3O7S/c1-20-7-3-6-10-29(20)42(38,39)33-30(36)22-12-11-21(28(16-22)40-2)15-23-18-34(19-35)27-14-13-24(17-26(23)27)32-31(37)41-25-8-4-5-9-25/h3,6-7,10-14,16-18,25,35H,4-5,8-9,15,19H2,1-2H3,(H,32,37)(H,33,36)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01207","zafirlukast","5717","YEEZWCHGZNKEEK-UHFFFAOYSA-N","InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)","CYP2C9; CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","3Ã¢â‚¬Âhydroxycyclopentyl NÃ¢â‚¬Â[3Ã¢â‚¬Â({2Ã¢â‚¬ÂmethoxyÃ¢â‚¬Â4Ã¢â‚¬Â[(2Ã¢â‚¬Âmethylbenzenesulfonyl)carbamoyl]phenyl}methyl)Ã¢â‚¬Â1Ã¢â‚¬ÂmethylindolÃ¢â‚¬Â5Ã¢â‚¬Âyl]carbamate","NULL","OPQKYGDYABHOST-UHFFFAOYSA-N","InChI=1S/C31H33N3O7S/c1-19-6-4-5-7-29(19)42(38,39)33-30(36)21-9-8-20(28(15-21)40-3)14-22-18-34(2)27-13-10-23(16-26(22)27)32-31(37)41-25-12-11-24(35)17-25/h4-10,13,15-16,18,24-25,35H,11-12,14,17H2,1-3H3,(H,32,37)(H,33,36)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3676"
"BIOTID01208","zaleplon","5719","HUNXMJYCHXQEGX-UHFFFAOYSA-N","InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3","CYP3A4","N-Dementhylation","Human Phase I","Human","Dementhylazed-zaleplon","9993635","HGCZTXQJFDPOKK-UHFFFAOYSA-N","InChI=1S/C15H11N5O/c1-10(21)19-13-4-2-3-11(7-13)14-5-6-17-15-12(8-16)9-18-20(14)15/h2-7,9H,1H3,(H,19,21)","PMID:9604298"
"BIOTID01209","zatosetron","6918154","SPKBYQZELVEOLL-QDMKHBRRSA-N","InChI=1S/C19H25ClN2O2/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23)/t13?,14-,15+","CYP3A4","N-Dementhylation","Human Phase I","Human","NULL","14838375","QMOMUISEPCMZDH-UHFFFAOYSA-N","InChI=1S/C18H23ClN2O2/c1-18(2)9-10-5-11(19)6-15(16(10)23-18)17(22)21-14-7-12-3-4-13(8-14)20-12/h5-6,12-14,20H,3-4,7-9H2,1-2H3,(H,21,22)","PMID:8070310"
"BIOTID01210","zatosetron","6918154","SPKBYQZELVEOLL-QDMKHBRRSA-N","InChI=1S/C19H25ClN2O2/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23)/t13?,14-,15+","CYP3A4","N-Oxidation","Human Phase I","Human","NULL","NULL","YVVPNZDUNJQAQQ-UHFFFAOYSA-N","InChI=1S/C19H25ClN2O3/c1-19(2)10-11-6-12(20)7-16(17(11)25-19)18(23)21-13-8-14-4-5-15(9-13)22(14,3)24/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23)","PMID:8070310"
"BIOTID01211","zatosetron","6918154","SPKBYQZELVEOLL-QDMKHBRRSA-N","InChI=1S/C19H25ClN2O2/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23)/t13?,14-,15+","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","NBWGHXIOQAPXMZ-UHFFFAOYSA-N","InChI=1S/C19H25ClN2O3/c1-19(2)17(23)14-6-10(20)7-15(16(14)25-19)18(24)21-11-8-12-4-5-13(9-11)22(12)3/h6-7,11-13,17,23H,4-5,8-9H2,1-3H3,(H,21,24)","PMID:8070310"
"BIOTID01212","zinc02949712","2267955","BXGYIRIVTYGQAU-UHFFFAOYSA-N","InChI=1S/C14H13F3O3/c1-2-3-6-19-9-4-5-10-11(14(15,16)17)8-13(18)20-12(10)7-9/h4-5,7-8H,2-3,6H2,1H3","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19;CYP3A4","O-Demethylation","Human Phase I","Human","HFC(7-hydroxy-4-trifluoromethylcoumarin)","5375667","CCKWMCUOHJAVOL-UHFFFAOYSA-N","InChI=1S/C10H5F3O3/c11-10(12,13)7-4-9(15)16-8-3-5(14)1-2-6(7)8/h1-4,14H","PMID:15205384"
"BIOTID01213","zinc03978059","40469545","JYGXADMDTFJGBT-FFICGRQZSA-N","InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16+,18+,19+,20+,21+/m1/s1","CYP3A4","Alipathic Hydroxylation (6ÃŽÂ²-hydroxylation)","Human Phase I","Human","free cortisol","253325","GNFTWPCIRXSCQF-UHFFFAOYSA-N","InChI=1S/C21H30O6/c1-19-5-3-11(23)7-14(19)15(24)8-12-13-4-6-21(27,17(26)10-22)20(13,2)9-16(25)18(12)19/h7,12-13,15-16,18,22,24-25,27H,3-6,8-10H2,1-2H3","PMID:10234596"
"BIOTID01214","zinc15020070","26369045","KDXNYSZNOWTPLE-OAQYLSRUSA-N","InChI=1S/C21H14O5/c1-24-13-7-9-17-19(11-13)25-18-10-12(22)6-8-16(18)21(17)15-5-3-2-4-14(15)20(23)26-21/h2-11,22H,1H3/t21-/m1/s1","CYP1A2;CYP2B6;CYP2C8;CYP2C9;CYP2C19","O-Demethylation","Human Phase I","Human","NULL","16850","GNBHRKFJIUUOQI-UHFFFAOYSA-N","InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H","PMID:17332142"
"BIOTID01215","zinc1698316","NULL","BLGXFZZNTVWLAY-CCZXDCJGSA-N","InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18+,19-/m0/s1","CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","XKJJSWXADRRQKQ-UHFFFAOYSA-N","InChI=1S/C21H26N2O4/c1-27-21(26)19-14-9-17-20-13(15-8-12(24)3-4-16(15)22-20)6-7-23(17)10-11(14)2-5-18(19)25/h3-4,8,11,14,17-19,22,24-25H,2,5-7,9-10H2,1H3","PMID:15289791"
"BIOTID01216","zinc1698316","NULL","BLGXFZZNTVWLAY-CCZXDCJGSA-N","InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18+,19-/m0/s1","CYP2D6;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","MIUYYRGOYGWVDO-UHFFFAOYSA-N","InChI=1S/C21H26N2O4/c1-27-21(26)19-15-9-17-20-14(13-4-3-12(24)8-16(13)22-20)6-7-23(17)10-11(15)2-5-18(19)25/h3-4,8,11,15,17-19,22,24-25H,2,5-7,9-10H2,1H3","PMID:15289791"
"BIOTID01217","zinc188","14050068","SLFGIOIONGJGRT-CQSZACIVSA-N","InChI=1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3/t14-/m1/s1","CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP2D6;CYP3A4","S-Oxidation","Human Phase I","Human","S-oxide cyamemazine","71315019","KCPHNCFJFKSBMD-UHFFFAOYSA-N","InChI=1S/C19H21N3OS/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)24(23)19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3","PMID:17951033"
"BIOTID01218","zinc188","14050068","SLFGIOIONGJGRT-CQSZACIVSA-N","InChI=1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3/t14-/m1/s1","CYP1A2;CYP2B6;CYP2C8;CYP2C19;CYP3A4","N-demethylations","Human Phase I","Human","N-demethyl-cyamemazine","10403087","RJBGVEFRAZYALY-UHFFFAOYSA-N","InChI=1S/C18H19N3S/c1-13(11-20-2)12-21-15-5-3-4-6-17(15)22-18-8-7-14(10-19)9-16(18)21/h3-9,13,20H,11-12H2,1-2H3","PMID:17951033"
"BIOTID01219","zinc21985223","9868258","RCOWGILQXUPXEW-CEBPFEQASA-N","InChI=1S/C29H37NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h4-6,8-9,14,17,24-26,31,33H,7,10-13,15-16,18H2,1-3H3/b14-4+/t24-,25+,26-,28-,29-/m0/s1","CYP3A4","N-demethylations","Human Phase I","Human","NULL","NULL","BTSSMZMOPXYSID-QLKAYGNNSA-N","InChI=1S/C28H35NO3/c1-27-17-24(18-4-7-20(29-2)8-5-18)26-22-11-9-21(31)16-19(22)6-10-23(26)25(27)12-14-28(27,32)13-3-15-30/h3-5,7-8,13,16,23-25,29-30,32H,6,9-12,14-15,17H2,1-2H3/b13-3+","PMID:9321513"
"BIOTID01220","zinc33952402","92973650","APSJUNFBAXIXLK-GFCCVEGCSA-N","InChI=1S/C14H19NO/c1-11-5-7-13(8-6-11)14(16)12(2)15-9-3-4-10-15/h5-8,12H,3-4,9-10H2,1-2H3/t12-/m1/s1","CYP2C19;CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","HO-MPPP","71379228","MOCYRRGUYQCODZ-UHFFFAOYSA-N","InChI=1S/C14H19NO2/c1-11(15-8-2-3-9-15)14(17)13-6-4-12(10-16)5-7-13/h4-7,11,16H,2-3,8-10H2,1H3","PMID:12867484"
"BIOTID01221","zinc33952517","92973653","NIYQOTCYXGXMPI-SNVBAGLBSA-N","InChI=1S/C14H17NO3/c1-10(15-6-2-3-7-15)14(16)11-4-5-12-13(8-11)18-9-17-12/h4-5,8,10H,2-3,6-7,9H2,1H3/t10-/m1/s1","CYP2C19;CYP2D6","O-Demethylation","Human Phase I","Human","di-HO-MDPPP","71378089","JUUKUKFPMPTCEC-UHFFFAOYSA-N","InChI=1S/C13H17NO3/c1-9(14-6-2-3-7-14)13(17)10-4-5-11(15)12(16)8-10/h4-5,8-9,15-16H,2-3,6-7H2,1H3","PMID:16019948"
"BIOTID01222","zinc36377943","93233157","VOVIALXJUBGFJZ-CMVRJZLVSA-N","InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18+,20+,21+,22+,23-,24-,25+/m0/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","6beta - HYDROXYBUDESONIDE","633586","JBVVDXJXIDYDMF-UHFFFAOYSA-N","InChI=1S/C25H34O7/c1-4-5-21-31-20-10-15-14-9-17(28)16-8-13(27)6-7-23(16,2)22(14)18(29)11-24(15,3)25(20,32-21)19(30)12-26/h6-8,14-15,17-18,20-22,26,28-29H,4-5,9-12H2,1-3H3","PMID:7720517"
"BIOTID01223","zinc36377943","93233157","VOVIALXJUBGFJZ-CMVRJZLVSA-N","InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18+,20+,21+,22+,23-,24-,25+/m0/s1","CYP3A4","O-dealkylation","Human Phase I","Human","6beta - HYDROXYBUDESONIDE","NULL","AHBITDWKGYOVSC-UHFFFAOYSA-N","InChI=1S/C25H36O6/c1-4-5-21(30)31-20-11-17-16-7-6-14-10-15(27)8-9-24(14,2)22(16)18(28)12-25(17,3)23(20)19(29)13-26/h8-10,16-18,20-23,26,28,30H,4-7,11-13H2,1-3H3","PMID:7720517"
"BIOTID01224","zinc38309998","93476683","XWLXKKNPFMNSFA-SRIRLJBESA-N","InChI=1S/C25H40O6/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29/h7-8,11,15-16,18-21,23,26-27H,6,9-10,12-14H2,1-5H3,(H,28,29)/t15-,16-,18-,19+,20-,21-,23-/m0/s1","CYP2C8;CYP3A4;CYP3A5","Dehydrogenation","Human Phase I","Human","NULL","NULL","SQCZTCQYRLPXBU-UHFFFAOYSA-N","InChI=1S/C25H38O6/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29/h7-8,11,16,18-21,23,26-27H,2,6,9-10,12-14H2,1,3-5H3,(H,28,29)","PMID:9321523"
"BIOTID01225","zinc38309998","93476683","XWLXKKNPFMNSFA-SRIRLJBESA-N","InChI=1S/C25H40O6/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29/h7-8,11,15-16,18-21,23,26-27H,6,9-10,12-14H2,1-5H3,(H,28,29)/t15-,16-,18-,19+,20-,21-,23-/m0/s1","CYP2C8;CYP3A4;CYP3A5","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","IOYVNFOBXVZCQG-UHFFFAOYSA-N","InChI=1S/C25H40O8/c1-6-25(4,5)24(32)33-20-9-13(2)23(31)18-12-19(28)14(3)17(22(18)20)8-7-15(26)10-16(27)11-21(29)30/h12-17,20,22,26-28,31H,6-11H2,1-5H3,(H,29,30)","PMID:9321523"
"BIOTID01226","zinc38309998","93476683","XWLXKKNPFMNSFA-SRIRLJBESA-N","InChI=1S/C25H40O6/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29/h7-8,11,15-16,18-21,23,26-27H,6,9-10,12-14H2,1-5H3,(H,28,29)/t15-,16-,18-,19+,20-,21-,23-/m0/s1","CYP2C8;CYP3A4;CYP3A5","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","SPKYOIMYNFJTPO-UHFFFAOYSA-N","InChI=1S/C25H40O7/c1-6-24(3,4)23(30)32-20-14-25(5,31)13-16-8-7-15(2)19(22(16)20)10-9-17(26)11-18(27)12-21(28)29/h7-8,13,15,17-20,22,26-27,31H,6,9-12,14H2,1-5H3,(H,28,29)","PMID:9321523"
"BIOTID01227","zinc40442723","86318464","MJAMUSZUMAHFLH-NVXWUHKLSA-N","InChI=1S/C18H18FNO2S/c19-14-4-2-1-3-13(14)17(18(22)11-5-6-11)20-8-7-15-12(10-20)9-16(21)23-15/h1-4,9,11,15,17H,5-8,10H2/t15-,17-/m1/s1","CYP2B6;CYP2C9;CYP2C19;CYP2D6;CYP3A4","Unknown reaction","Human Phase I","Human","NULL","NULL","PRDQWPILASEJBX-QIXZXHIJSA-N","InChI=1S/C18H20FNO2S/c19-15-4-2-1-3-14(15)17(18(22)12-5-6-12)20-9-7-16(23)13(11-20)8-10-21/h1-4,8,10,12,16-17,23H,5-7,9,11H2/b13-8-/t16-,17-/m1/s1","PMID:16415119"
"BIOTID01228","zinc4556587","92223505","HSIBGVUMFOSJPD-NPPSGXECSA-N","InChI=1S/C20H26N2O/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3/t12-,13+,17+,20+/m0/s1","CYP2C19;CYP2D6;CYP3A4","O-DEMETHYLATION","Human Phase I","Human","12-hydroxyibogamine","457967","RAUCDOKTMDOIPF-UHFFFAOYSA-N","InChI=1S/C19H24N2O/c1-2-12-7-11-8-16-18-14(5-6-21(10-11)19(12)16)15-9-13(22)3-4-17(15)20-18/h3-4,9,11-12,16,19-20,22H,2,5-8,10H2,1H3","PMID:9698290"
"BIOTID01229","zinc8660420","7057975","JUVIOZPCNVVQFO-MAODMQOUSA-N","InChI=1S/C23H22O6/c1-11(2)16-8-14-15(28-16)6-5-12-22(24)21-13-7-18(25-3)19(26-4)9-17(13)27-10-20(21)29-23(12)14/h5-7,9,16,20-21H,1,8,10H2,2-4H3/t16-,20-,21-/m1/s1","CYP3A4;CYP2C19","O-DEMETHYLATION","Human Phase I","Human","NULL","NULL","LHFMQYZGKSJGFH-UHFFFAOYSA-N","InChI=1S/C22H20O6/c1-10(2)16-7-13-15(27-16)5-4-11-21(24)20-12-6-14(23)18(25-3)8-17(12)26-9-19(20)28-22(11)13/h4-6,8,16,19-20,23H,1,7,9H2,2-3H3","PMID:15540952"
"BIOTID01230","zinc8660420","7057975","JUVIOZPCNVVQFO-MAODMQOUSA-N","InChI=1S/C23H22O6/c1-11(2)16-8-14-15(28-16)6-5-12-22(24)21-13-7-18(25-3)19(26-4)9-17(13)27-10-20(21)29-23(12)14/h5-7,9,16,20-21H,1,8,10H2,2-4H3/t16-,20-,21-/m1/s1","CYP3A4;CYP2C19","Aliphatic Hydroxylation","Human Phase I","Human","NULL","303992","JFVKWCYZKMUTLH-UHFFFAOYSA-N","InChI=1S/C23H22O7/c1-11(2)16-7-13-15(29-16)6-5-12-21(13)30-20-10-28-17-9-19(27-4)18(26-3)8-14(17)23(20,25)22(12)24/h5-6,8-9,16,20,25H,1,7,10H2,2-4H3","PMID:15540952"
"BIOTID01231","zinc8660420","7057975","JUVIOZPCNVVQFO-MAODMQOUSA-N","InChI=1S/C23H22O6/c1-11(2)16-8-14-15(28-16)6-5-12-22(24)21-13-7-18(25-3)19(26-4)9-17(13)27-10-20(21)29-23(12)14/h5-7,9,16,20-21H,1,8,10H2,2-4H3/t16-,20-,21-/m1/s1","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","44257412","MYQAATJJIDGOMQ-UHFFFAOYSA-N","InChI=1S/C23H22O8/c1-11(9-24)16-6-13-15(30-16)5-4-12-21(13)31-20-10-29-17-8-19(28-3)18(27-2)7-14(17)23(20,26)22(12)25/h4-5,7-8,16,20,24,26H,1,6,9-10H2,2-3H3","PMID:15540952"
"BIOTID01232","zinc8660420","7057975","JUVIOZPCNVVQFO-MAODMQOUSA-N","InChI=1S/C23H22O6/c1-11(2)16-8-14-15(28-16)6-5-12-22(24)21-13-7-18(25-3)19(26-4)9-17(13)27-10-20(21)29-23(12)14/h5-7,9,16,20-21H,1,8,10H2,2-4H3/t16-,20-,21-/m1/s1","CYP3A4","Epoxidation","Human Phase I","Human","NULL","NULL","AFMUPHIHAGLSEN-UHFFFAOYSA-N","InChI=1S/C23H22O8/c1-22(10-29-22)18-6-12-14(30-18)5-4-11-20(12)31-19-9-28-15-8-17(27-3)16(26-2)7-13(15)23(19,25)21(11)24/h4-5,7-8,18-19,25H,6,9-10H2,1-3H3","PMID:15540952"
"BIOTID01233","zinc968306","29010891","YXKTVDFXDRQTKV-OAHLLOKOSA-N","InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m1/s1","CYP2B6;CYP2C8;CYP3A4","N-Demethylation","Human Phase I","Human","NULL","102554","JLCDKDGHTWGGQM-UHFFFAOYSA-N","InChI=1S/C16H19N/c1-14(12-15-8-4-2-5-9-15)17-13-16-10-6-3-7-11-16/h2-11,14,17H,12-13H2,1H3","PMID:10461547|PMID:8424894"
"BIOTID01234","ziprasidone","60854","MVWVFYHBGMAFLY-UHFFFAOYSA-N","InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)","CYP3A4","S-Oxidation","Human Phase I","Human","NULL","15959407","XYYQWGUKBVTGJQ-UHFFFAOYSA-N","InChI=1S/C21H21ClN4O2S/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)29(28)24-21/h1-4,11,13H,5-10,12H2,(H,23,27)","PMID:10771452"
"BIOTID01235","ziprasidone","60854","MVWVFYHBGMAFLY-UHFFFAOYSA-N","InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)","CYP3A4","N-dealkylation","Human Phase I","Human","NULL","2772144","KRDOFMHJLWKXIU-UHFFFAOYSA-N","InChI=1S/C11H13N3S/c1-2-4-10-9(3-1)11(13-15-10)14-7-5-12-6-8-14/h1-4,12H,5-8H2","PMID:10771452"
"BIOTID01236","ziprasidone","60854","MVWVFYHBGMAFLY-UHFFFAOYSA-N","InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)","CYP3A4","N-dealkylation","Human Phase I","Human","NULL","132263367","LRZAPTDENMVNNW-UHFFFAOYSA-N","InChI=1S/C10H10ClNO/c1-2-6-3-7-4-10(13)12-9(7)5-8(6)11/h3,5H,2,4H2,1H3,(H,12,13)","PMID:10771452"
"BIOTID01237","zolmitriptan","60857","ULSDMUVEXKOYBU-ZDUSSCGKSA-N","InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1","CYP1A2","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-Desmethylzolmitriptan","178536","QGGCHSMZXKNGCK-LBPRGKRZSA-N","InChI=1S/C15H19N3O2/c1-16-5-4-11-8-17-14-3-2-10(7-13(11)14)6-12-9-20-15(19)18-12/h2-3,7-8,12,16-17H,4-6,9H2,1H3,(H,18,19)/t12-/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01238","zolmitriptan","60857","ULSDMUVEXKOYBU-ZDUSSCGKSA-N","InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1","CYP1A2","N-oxdation of aliphatic tertiary amine","Human Phase I","Human","Zolmitriptan N-oxide","25241756","GZYCQRZFJIZOKU-ZDUSSCGKSA-N","InChI=1S/C16H21N3O3/c1-19(2,21)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-22-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01239","zolpidem","5732","ZAFYATHCZYHLPB-UHFFFAOYSA-N","InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3","CYP3A4(major); CYP1A2 (minor); CYP2D6 (minor)","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","methoxyzolpidem","5732","ZAFYATHCZYHLPB-UHFFFAOYSA-N","InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01240","zolpidem","5732","ZAFYATHCZYHLPB-UHFFFAOYSA-N","InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3","CYP3A4(major); CYP1A2 (minor); CYP2D6 (minor); CYP2C9 (minor); CYP2C19 (minor)","Hydroxylation of  carbon next to amide","Human Phase I","Human","methoxyzolpidem","NULL","OQTVDLUCOCICRN-UHFFFAOYSA-N","InChI=1S/C19H21N3O3/c1-12-10-22-15(8-18(25)21(2)3)19(20-17(22)9-16(12)24)14-6-4-13(11-23)5-7-14/h4-7,9-10,23-24H,8,11H2,1-3H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01242","zotepine","5736","HDOZVRUNCMBHFH-UHFFFAOYSA-N","InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3","CYP1A1; CYP1A2; CYP3A4; CYP3A5; CYP2B6; CYP2C19","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","Norzotepine","10041551","OVVBIIBBRZVPAL-UHFFFAOYSA-N","InChI=1S/C17H16ClNOS/c1-19-8-9-20-15-10-12-4-2-3-5-16(12)21-17-7-6-13(18)11-14(15)17/h2-7,10-11,19H,8-9H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01243","zotepine","5736","HDOZVRUNCMBHFH-UHFFFAOYSA-N","InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3","CYP3A4","N-oxdation of aliphatic tertiary amine","Human Phase I","Human","Zotepine N-oxide","13309858","IZIOJMRQCYPVQW-UHFFFAOYSA-N","InChI=1S/C18H18ClNO2S/c1-20(2,21)9-10-22-16-11-13-5-3-4-6-17(13)23-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01244","zotepine","5736","HDOZVRUNCMBHFH-UHFFFAOYSA-N","InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3","CYP1A2","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2-OH-zotepine","12882318","MCQGRTOFLHWZAG-UHFFFAOYSA-N","InChI=1S/C18H18ClNO2S/c1-20(2)7-8-22-16-10-12-9-14(21)4-6-17(12)23-18-5-3-13(19)11-15(16)18/h3-6,9-11,21H,7-8H2,1-2H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01245","zotepine","5736","HDOZVRUNCMBHFH-UHFFFAOYSA-N","InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3","CYP1A1; CYP1A2; CYP3A4; CYP2D6; CYP2C19","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","3-OH-zotepine","12882320","MOEFMTBUTHFFHY-UHFFFAOYSA-N","InChI=1S/C18H18ClNO2S/c1-20(2)7-8-22-16-9-12-3-5-14(21)11-18(12)23-17-6-4-13(19)10-15(16)17/h3-6,9-11,21H,7-8H2,1-2H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01246","zotepine","5736","HDOZVRUNCMBHFH-UHFFFAOYSA-N","InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3","CYP1A1; CYP1A2; CYP2B6; CYP3A4; CYP3A5","S-oxidation of diarylthioether to sulfoxide","Human Phase I","Human","Zotepine -oxide","12882299","GPQLECKPRFIPAC-UHFFFAOYSA-N","InChI=1S/C18H18ClNO2S/c1-20(2)9-10-22-16-11-13-5-3-4-6-17(13)23(21)18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01247","Benzo[a]pyrene","2336","FMMWHPNWAFZXNH-UHFFFAOYSA-N","InChI=1S/C20H12/c1-2-7-17-15(4-1)12-16-9-8-13-5-3-6-14-10-11-18(17)20(16)19(13)14/h1-12H","CYP1A1; CYP1A2; CYP1B1","ARENE_EPOXIDATION","Human Phase I","Human","Benzo[a]pyrene-7,8-epoxide","37455","OLLMQFHYRYHKTD-UHFFFAOYSA-N","InChI=1S/C20H12O/c1-2-11-4-5-13-10-16-14(8-9-17-20(16)21-17)15-7-6-12(3-1)18(11)19(13)15/h1-10,17,20H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01248","Benzo[a]pyrene","2336","FMMWHPNWAFZXNH-UHFFFAOYSA-N","InChI=1S/C20H12/c1-2-7-17-15(4-1)12-16-9-8-13-5-3-6-14-10-11-18(17)20(16)19(13)14/h1-12H","CYP3A4; CYP2C8; CYP2C9;CYP2C19; CYP1A1; CYP1B1","ARENE_EPOXIDATION","Human Phase I","Human","3-Hydroxybenzo[a]pyrene","NULL","HIWUMYIKMBIYMX-UHFFFAOYSA-N","InChI=1S/C20H12O/c1-2-4-14-11(3-1)9-12-6-8-16-19-13(10-17-20(16)21-17)5-7-15(14)18(12)19/h1-10,17,20H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01249","Benzo[a]pyrene","2336","FMMWHPNWAFZXNH-UHFFFAOYSA-N","InChI=1S/C20H12/c1-2-7-17-15(4-1)12-16-9-8-13-5-3-6-14-10-11-18(17)20(16)19(13)14/h1-12H","CYP1A1; CYP1B1","ARENE_EPOXIDATION","Human Phase I","Human","9-Hydroxybenzo[a]pyrene","37456","GOEJUYABKOTLJA-UHFFFAOYSA-N","InChI=1S/C20H12O/c1-2-11-4-5-13-10-14-7-9-16-20(21-16)19(14)15-8-6-12(3-1)17(11)18(13)15/h1-10,16,20H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01250","Benzo[a]pyrene","2336","FMMWHPNWAFZXNH-UHFFFAOYSA-N","InChI=1S/C20H12/c1-2-7-17-15(4-1)12-16-9-8-13-5-3-6-14-10-11-18(17)20(16)19(13)14/h1-12H","CYP1A1","ARENE_EPOXIDATION","Human Phase I","Human","1-Hydroxybenzo[a]pyrene","NULL","SFZMXWGXHHIMNU-UHFFFAOYSA-N","InChI=1S/C20H12O/c1-2-4-14-11(3-1)9-12-5-6-13-10-17-20(21-17)16-8-7-15(14)18(12)19(13)16/h1-10,17,20H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01251","Benzo[a]pyrene","2336","FMMWHPNWAFZXNH-UHFFFAOYSA-N","InChI=1S/C20H12/c1-2-7-17-15(4-1)12-16-9-8-13-5-3-6-14-10-11-18(17)20(16)19(13)14/h1-12H","CYP1A1; CYP1B1","ARENE_EPOXIDATION","Human Phase I","Human","Benzo[a]pyrene-4,5-epoxide","37786","XGZQLNASOQVQTD-UHFFFAOYSA-N","InChI=1S/C20H12O/c1-2-6-13-12(4-1)10-16-18-14(13)9-8-11-5-3-7-15(17(11)18)19-20(16)21-19/h1-10,19-20H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01252","ethinylestradiol","5991","BFPYWIDHMRZLRN-SLHNCBLASA-N","InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1","CYP1A2;CYP2C8;CYP2C9;CYP2C19;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","73743402","KQJCDKMHNQVWDV-UHFFFAOYSA-N","InChI=1S/C20H24O3/c1-3-20(23)9-7-16-14-5-4-12-10-17(21)18(22)11-15(12)13(14)6-8-19(16,20)2/h1,10-11,13-14,16,21-23H,4-9H2,2H3","PMID:15304426"
"BIOTID01253","ethinylestradiol","5991","BFPYWIDHMRZLRN-SLHNCBLASA-N","InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1","CYP3A4;","Aliphatic Hydroxylation","Human Phase I","Human","NULL","53461753","SYFHJXSYRPNSOI-UHFFFAOYSA-N","InChI=1S/C20H24O3/c1-3-20(23)11-9-16-14-4-5-15-12(6-7-17(21)18(15)22)13(14)8-10-19(16,20)2/h1,6-7,13-14,16,21-23H,4-5,8-11H2,2H3","PMID:15304426"
"BIOTID01254","Retinoic acid, all-trans","444795","SHGAZHPCJJPHSC-YCNIQYBTSA-N","InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+","CYP1A2; CYP3A7; CYP2C8 (major); CYP3A4; CYP2C9 (minor); CYP2B6; CYP3A5; CYP2A6","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","4-Hydroxyretinoic acid","6438629","KGUMXGDKXYTTEY-FRCNGJHJSA-N","InChI=1S/C20H28O3/c1-14(7-6-8-15(2)13-19(22)23)9-10-17-16(3)18(21)11-12-20(17,4)5/h6-10,13,18,21H,11-12H2,1-5H3,(H,22,23)/b8-6+,10-9+,14-7+,15-13+","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01255","Retinoic acid, all-trans","444795","SHGAZHPCJJPHSC-YCNIQYBTSA-N","InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+","CYP4A11; CYP3A7; CYP1A1; CYP2C8; CYP2C9; CYP2C18; CYP3A4; CYP3A5","Hydroxlation of methyl carbon adjacent to an aliphatic ring","Human Phase I","Human","18-Hydroxyretinoic acid","6506224","XSJOIRFEYHJNAW-FCKHSPHMSA-N","InChI=1S/C20H28O3/c1-15(7-5-8-16(2)13-19(22)23)10-11-18-17(14-21)9-6-12-20(18,3)4/h5,7-8,10-11,13,21H,6,9,12,14H2,1-4H3,(H,22,23)/b8-5+,11-10+,15-7+,16-13+","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01256","Retinoic acid, all-trans","444795","SHGAZHPCJJPHSC-YCNIQYBTSA-N","InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+","CYP2C8; CYP2C9; CYP1A1; CYP2D6","EPOXIDATION_OF_1122_TETRASUBSTITUTED_ALKLENE","Human Phase I","Human","5,6-Epoxy-retinoic acid","5363137","KEEHJLBAOLGBJZ-WEDZBJJJSA-N","InChI=1S/C20H28O3/c1-15(8-6-9-16(2)14-17(21)22)10-13-20-18(3,4)11-7-12-19(20,5)23-20/h6,8-10,13-14H,7,11-12H2,1-5H3,(H,21,22)/b9-6+,13-10+,15-8+,16-14+","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01258","1_2-dibromoethane","7839","PAAZPARNPHGIKF-UHFFFAOYSA-N","InChI=1S/C2H4Br2/c3-1-2-4/h1-2H2","CYP2A6;CYP2B6;CYP2E1","Oxidation","Human Phase I","Human","2-bromoacetaldehyde ","105131","NMPVEAUIHMEAQP-UHFFFAOYSA-N","InChI=1S/C2H3BrO/c3-1-2-4/h2H,1H2","PMID:8870687"
"BIOTID01259","2_2_4_4_5_5-hexachlorobiphenyl","37034","MVWHGTYKUMDIHL-UHFFFAOYSA-N","InChI=1S/C12H4Cl6/c13-7-3-11(17)9(15)1-5(7)6-2-10(16)12(18)4-8(6)14/h1-4H","CYP2B6","Aromatic Hydroxylation","Human Phase I","Human","NULL","6452977","ZVJPNYXNOYRCIJ-UHFFFAOYSA-N","InChI=1S/C12H4Cl6O/c13-6-3-8(15)7(14)1-4(6)5-2-9(16)11(18)12(19)10(5)17/h1-3,19H","PMID:7626059"
"BIOTID01260","Nelfinavir","64143","QAGYKUNXZHXKMR-HKWSIXNMSA-N","InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1","CYP2C19","Hydroxylation of terminal methyl","Human Phase I","Human","Nelfinavir hydroxyl-t- butylamide","475066","SLEPDNKZXLVSOH-HKWSIXNMSA-N","InChI=1S/C32H45N3O5S/c1-21-25(14-9-15-28(21)37)30(39)33-26(19-41-24-12-5-4-6-13-24)29(38)18-35-17-23-11-8-7-10-22(23)16-27(35)31(40)34-32(2,3)20-36/h4-6,9,12-15,22-23,26-27,29,36-38H,7-8,10-11,16-20H2,1-3H3,(H,33,39)(H,34,40)/t22-,23+,26-,27-,29+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01261","Nelfinavir","64143","QAGYKUNXZHXKMR-HKWSIXNMSA-N","InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1","CYP3A4","Hydroxylation of benzene on carbon orhto to a strongly electron donating group","Human Phase I","Human","3,4-Dihydroxynelfinavir","NULL","QTSSATVFYFFGRH-HPHCTBIGSA-N","InChI=1S/C32H45N3O5S/c1-20-24(14-15-27(36)29(20)38)30(39)33-25(19-41-23-12-6-5-7-13-23)28(37)18-35-17-22-11-9-8-10-21(22)16-26(35)31(40)34-32(2,3)4/h5-7,12-15,21-22,25-26,28,36-38H,8-11,16-19H2,1-4H3,(H,33,39)(H,34,40)/t21-,22+,25-,26-,28+/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01262","Metamphetamine","10836","MYWUZJCMWCOHBA-VIFPVBQESA-N","InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1","CYP2D6","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4-Hydroxymethamphetamine","158815","SBUQZKJEOOQSBV-QMMMGPOBSA-N","InChI=1S/C10H15NO/c1-8(11-2)7-9-3-5-10(12)6-4-9/h3-6,8,11-12H,7H2,1-2H3/t8-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01263","Metamphetamine","10836","MYWUZJCMWCOHBA-VIFPVBQESA-N","InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1","CYP2D6","N-dealkylation of acyclic secondary amine","Human Phase I","Human","Amphetamine","5826","KWTSXDURSIMDCE-QMMMGPOBSA-N","InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01264","desimipramine","2995","HCYAFALTSJYZDH-UHFFFAOYSA-N","InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3","CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","2-hydroxy-desipramine ","121249","NVJBOLMRGMDGLD-UHFFFAOYSA-N","InChI=1S/C18H22N2O/c1-19-11-4-12-20-17-6-3-2-5-14(17)7-8-15-13-16(21)9-10-18(15)20/h2-3,5-6,9-10,13,19,21H,4,7-8,11-12H2,1H3","PMID:10575324"
"BIOTID01265","Methylene chloride","6344","YMWUJEATGCHHMB-UHFFFAOYSA-N","InChI=1S/CH2Cl2/c2-1-3/h1H2","CYP2E1","Hydroxylation of carbon adjacent to halogen","Human Phase I","Human","Dichloromethanol","169730","GJYVZUKSNFSLCL-UHFFFAOYSA-N","InChI=1S/CH2Cl2O/c2-1(3)4/h1,4H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01266","Trichloroethane","6278","UOCLXMDMGBRAIB-UHFFFAOYSA-N","InChI=1S/C2H3Cl3/c1-2(3,4)5/h1H3","CYP2E1","Aliphatic Hydroxylation","Human Phase I","Human","Trichloroethanol","8259","KPWDGTGXUYRARH-UHFFFAOYSA-N","InChI=1S/C2H3Cl3O/c3-2(4,5)1-6/h6H,1H2","PMID:1664256"
"BIOTID01267","Duloxetine","60835","ZEUITGRIYCTCEM-KRWDZBQOSA-N","InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1","CYP1A2;CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","29981497","DRRXQCXSBONKPD-KRWDZBQOSA-N","InChI=1S/C18H19NO2S/c1-19-11-10-17(18-7-4-12-22-18)21-16-9-8-15(20)13-5-2-3-6-14(13)16/h2-9,12,17,19-20H,10-11H2,1H3/t17-/m0/s1","PMID:12920170"
"BIOTID01268","Duloxetine","60835","ZEUITGRIYCTCEM-KRWDZBQOSA-N","InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1","CYP1A2;CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","10086952","LEIFDHLVPBJTIV-KRWDZBQOSA-N","InChI=1S/C18H19NO2S/c1-19-10-9-17(18-6-3-11-22-18)21-16-5-2-4-13-12-14(20)7-8-15(13)16/h2-8,11-12,17,19-20H,9-10H2,1H3/t17-/m0/s1","PMID:12920170"
"BIOTID01269","Duloxetine","60835","ZEUITGRIYCTCEM-KRWDZBQOSA-N","InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1","CYP1A2;CYP2D6","Aromatic Hydroxylation","Human Phase I","Human","NULL","44344235","MBVKPOXXMWDHKB-KRWDZBQOSA-N","InChI=1S/C18H19NO2S/c1-19-11-10-17(18-9-4-12-22-18)21-16-8-3-5-13-14(16)6-2-7-15(13)20/h2-9,12,17,19-20H,10-11H2,1H3/t17-/m0/s1","PMID:12920170"
"BIOTID01270","leflunomide","3899","VHOGYURTWQBHIL-UHFFFAOYSA-N","InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)","CYP1A2;CYP2C9;CYP3A4","N-O bond cleavage","Human Phase I","Human","NULL","NULL","VOMIUKQFIMFXTP-GMTNAYPDSA-N","InChI=1S/C12H11F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-6,16,18H,1H3,(H,17,19)/b10-7+,16-6?","PMID:19754423"
"BIOTID01271","paraxanthine","4687","QUNWUDVFRNGTCO-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)11(2)7(13)9-5/h3H,1-2H3,(H,9,13)","CYP1A2;CYP2A6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","91611","NOFNCLGCUJJPKU-UHFFFAOYSA-N","InChI=1S/C7H8N4O3/c1-10-3-4(8-6(10)13)9-7(14)11(2)5(3)12/h1-2H3,(H,8,13)(H,9,14)","PMID:8162667;PMID:19754423"
"BIOTID01272","paraxanthine","4687","QUNWUDVFRNGTCO-UHFFFAOYSA-N","InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)11(2)7(13)9-5/h3H,1-2H3,(H,9,13)","CYP1A2","N-dementhylation","Human Phase I","Human","NULL","80220","MVOYJPOZRLFTCP-UHFFFAOYSA-N","InChI=1S/C6H6N4O2/c1-10-5(11)3-4(8-2-7-3)9-6(10)12/h2H,1H3,(H,7,8)(H,9,12)","PMID:8162667;PMID:19754423"
"BIOTID01274","N,N-Dimethylaniline","949","JLTDJTHDQAWBAV-UHFFFAOYSA-N","InChI=1S/C8H11N/c1-9(2)8-6-4-3-5-7-8/h3-7H,1-2H3","CYP1A2;CYP2B1;CYP4B1","N-dementhylation","Human Phase I","Human","NULL","7515","AFBPFSWMIHJQDM-UHFFFAOYSA-N","InChI=1S/C7H9N/c1-8-7-5-3-2-4-6-7/h2-6,8H,1H3","Karki, S. B., Dinnocenzo, J. P., Jones, J. P., Korzekwa, K. R. (1995). Mechanism of oxidative amine dealkylation of substituted N,N-dimethylanilines by cytochrome P-450: application of isotope effect profiles. Journal of the American Chemical Society. 117:"
"BIOTID01277","Estradiol","NULL","VOXZDWNPVJITMN-ZBRFXRBCSA-N","InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1","CYP1A1;CYP1A2;CYP3A4;CYP3A5","Aromatic Hydroxylation","Human Phase I","Human","2-hydroxyestradiol","247304","DILDHNKDVHLEQB-XSSYPUMDSA-N","InChI=1S/C18H24O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,17,19-21H,2-7H2,1H3/t11-,12+,14-,17-,18-/m0/s1","PMID:18259985;PMID:23333322"
"BIOTID01278","Estradiol","NULL","VOXZDWNPVJITMN-ZBRFXRBCSA-N","InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1","CYP1B1","Aromatic Hydroxylation","Human Phase I","Human","NULL","5282360","QOZFCKXEVSGWGS-ZHIYBZGJSA-N","InChI=1S/C18H24O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,16,19-21H,2-3,5,7-9H2,1H3/t11-,12-,14+,16+,18+/m1/s1","PMID:18259985"
"BIOTID01279","alosetron","2099","JSWZEAMFRNKZNL-UHFFFAOYSA-N","InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)","CYP1A2","Aromatic Hydroxylation","Human Phase I","Human","NULL","19799269","UUQDYYPVWUOAOE-UHFFFAOYSA-N","InChI=1S/C17H18N4O2/c1-10-12(19-9-18-10)8-21-7-6-13-15(17(21)23)11-4-3-5-14(22)16(11)20(13)2/h3-5,9,22H,6-8H2,1-2H3,(H,18,19)","PMID:16019944;PMID:17701832"
"BIOTID01280","alosetron","2099","JSWZEAMFRNKZNL-UHFFFAOYSA-N","InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)","CYP1A2","Aromatic Hydroxylation","Human Phase I","Human","NULL","NULL","JYPWLTMVUIKYGC-UHFFFAOYSA-N","InChI=1S/C17H18N4O3/c1-9-11(19-17(24)18-9)8-21-7-6-12-14(16(21)23)10-4-3-5-13(22)15(10)20(12)2/h3-5,22H,6-8H2,1-2H3,(H2,18,19,24)","PMID:16019944;PMID:17701832"
"BIOTID01282","Phenobarbital","4763","DDBREPKUVSBGFI-UHFFFAOYSA-N","InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)","CYP2C9; CYP2C19; CYP2E1","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","p-Hydroxyphenobarbital","9785","IEPXMKJNWPXDBP-UHFFFAOYSA-N","InChI=1S/C12H12N2O4/c1-2-12(7-3-5-8(15)6-4-7)9(16)13-11(18)14-10(12)17/h3-6,15H,2H2,1H3,(H2,13,14,16,17,18)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Lee, A.M. et al. (2006); Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism; Eur J Pharmacol. 2006 Dec 15;552(1-3):151-8; PMID:17049344; DOI:10.1016/j.ejphar.2006.09.006"
"BIOTID01283","Paroxetine","43815","AHOUBRCZNHFOSL-YOEHRIQHSA-N","InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1","CYP2D6","O-Demethylenation","Human Phase I","Human","NULL","59215182","VJMXXTJAPJRAQL-BBRMVZONSA-N","InChI=1S/C18H20FNO3/c19-14-3-1-12(2-4-14)16-7-8-20-10-13(16)11-23-15-5-6-17(21)18(22)9-15/h1-6,9,13,16,20-22H,7-8,10-11H2/t13-,16-/m0/s1","PMID:19817501;PMID:19902987"
"BIOTID01284","bromperidol","2448","RKLNONIVDFXQRX-UHFFFAOYSA-N","InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","93911","QNLXJYQUWCNYBH-UHFFFAOYSA-N","InChI=1S/C11H14BrNO/c12-10-3-1-9(2-4-10)11(14)5-7-13-8-6-11/h1-4,13-14H,5-8H2","PMID:11133003"
"BIOTID01285","bromperidol","2448","RKLNONIVDFXQRX-UHFFFAOYSA-N","InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2","CYP3A4","N-Dealkylation","Human Phase I","Human","NULL","68498","QHDXPJMOWRLLRV-UHFFFAOYSA-N","InChI=1S/C10H11FO/c1-2-3-10(12)8-4-6-9(11)7-5-8/h4-7H,2-3H2,1H3","PMID:11133003"
"BIOTID01288","Urethane","5641","JOYRKODLDBILNP-UHFFFAOYSA-N","InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)","CYP2E1","Dehydrogenation","Human Phase I","Human","Vinyl carbamate","27492","LVLANIHJQRZTPY-UHFFFAOYSA-N","InChI=1S/C3H5NO2/c1-2-6-3(4)5/h2H,1H2,(H2,4,5)","PMID:22531028"
"BIOTID01289","Vinyl carbamate","27492","LVLANIHJQRZTPY-UHFFFAOYSA-N","InChI=1S/C3H5NO2/c1-2-6-3(4)5/h2H,1H2,(H2,4,5)","CYP2E1","Epoxidation","Human Phase I","Human","Vinyl carbamate epoxide","108032","PSNIYGKWARCUAN-UHFFFAOYSA-N","InChI=1S/C3H5NO3/c4-3(5)7-2-1-6-2/h2H,1H2,(H2,4,5)","PMID:11181492"
"BIOTID01290","Glyburide","3488","ZNNLBTZKUZBEKO-UHFFFAOYSA-N","InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)","CYP3A4; CYP2C9; CYP2C19","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","2-trans-hydroxycyclohexyl glyburide ","131770000","PASKIAZVROHUGZ-PMACEKPBSA-N","InChI=1S/C23H28ClN3O6S/c1-33-21-11-8-16(24)14-18(21)22(29)25-13-12-15-6-9-17(10-7-15)34(31,32)27-23(30)26-19-4-2-3-5-20(19)28/h6-11,14,19-20,28H,2-5,12-13H2,1H3,(H,25,29)(H2,26,27,30)/t19-,20-/m0/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID01291","Glyburide","3488","ZNNLBTZKUZBEKO-UHFFFAOYSA-N","InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)","CYP3A4; CYP2C9; CYP2C19","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","4-cis-hydroxycyclohexyl glyburide ","NULL","IUWSGCQEWOOQDN-HDICACEKSA-N","InChI=1S/C23H28ClN3O6S/c1-33-21-11-4-16(24)14-20(21)22(29)25-13-12-15-2-9-19(10-3-15)34(31,32)27-23(30)26-17-5-7-18(28)8-6-17/h2-4,9-11,14,17-18,28H,5-8,12-13H2,1H3,(H,25,29)(H2,26,27,30)/t17-,18+","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID01292","Glyburide","3488","ZNNLBTZKUZBEKO-UHFFFAOYSA-N","InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)","CYP3A4; CYP2C9; CYP2C19","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","4-trans-hydroxycyclohexyl glyburide ","NULL","IUWSGCQEWOOQDN-IYARVYRRSA-N","InChI=1S/C23H28ClN3O6S/c1-33-21-11-4-16(24)14-20(21)22(29)25-13-12-15-2-9-19(10-3-15)34(31,32)27-23(30)26-17-5-7-18(28)8-6-17/h2-4,9-11,14,17-18,28H,5-8,12-13H2,1H3,(H,25,29)(H2,26,27,30)/t17-,18-","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID01293","Glyburide","3488","ZNNLBTZKUZBEKO-UHFFFAOYSA-N","InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)","CYP3A4; CYP2C9; CYP2C19","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","3-trans-Hydroxycyclohexyl glyburide","71749057","VFBAJFAMXTVSQA-ROUUACIJSA-N","InChI=1S/C23H28ClN3O6S/c1-33-21-10-7-16(24)13-20(21)22(29)25-12-11-15-5-8-19(9-6-15)34(31,32)27-23(30)26-17-3-2-4-18(28)14-17/h5-10,13,17-18,28H,2-4,11-12,14H2,1H3,(H,25,29)(H2,26,27,30)/t17-,18-/m0/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID01294","Glyburide","3488","ZNNLBTZKUZBEKO-UHFFFAOYSA-N","InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)","CYP3A4; CYP2C9; CYP2C19","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","3-cis-Hydroxycyclohexyl glyburide","29981563","VFBAJFAMXTVSQA-ZWKOTPCHSA-N","InChI=1S/C23H28ClN3O6S/c1-33-21-10-7-16(24)13-20(21)22(29)25-12-11-15-5-8-19(9-6-15)34(31,32)27-23(30)26-17-3-2-4-18(28)14-17/h5-10,13,17-18,28H,2-4,11-12,14H2,1H3,(H,25,29)(H2,26,27,30)/t17-,18+/m0/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987"
"BIOTID01295","Troleandomycin","202225","LQCLVBQBTUVCEQ-QTFUVMRISA-N","InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1","CYP3A4;CYP3A5","N-Dementhylation","Human Phase I","Human","NULL","NULL","INQNSBMQHRJSME-NNLACWEBSA-N","InChI=1S/C40H65NO15/c1-18-16-40(17-48-40)37(45)22(5)33(52-26(9)42)20(3)24(7)51-38(46)23(6)34(55-31-15-30(47-13)35(25(8)50-31)53-27(10)43)21(4)32(18)56-39-36(54-28(11)44)29(41-12)14-19(2)49-39/h18-25,29-36,39,41H,14-17H2,1-13H3/t18-,19+,20-,21+,22+,23+,24+,25-,29-,30-,31-,32-,33-,34-,35-,36+,39-,40+/m0/s1","PMID:23333322;PMID:9187528"
"BIOTID01296","(-)-bisoprolol","10892731","VHYCDWMUTMEGQY-KRWDZBQOSA-N","InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3/t17-/m0/s1","CYP2D6; CYP3A4","O-deisopropylation","Human Phase I","Human","(-)-bisoprolol, O-deisopropyl","NULL","AIGGWEPYIOOYLI-AWEZNQCLSA-N","InChI=1S/C15H25NO4/c1-12(2)16-9-14(18)11-20-15-5-3-13(4-6-15)10-19-8-7-17/h3-6,12,14,16-18H,7-11H2,1-2H3/t14-/m0/s1","Horikiri, Y. (1998); Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans; Journal of Pharmaceutical Sciences; Vol. 87, No. 3"
"BIOTID01297","(r)-chloroquine, N-desethyl","38989112","MCYUUUTUAAGOOT-GFCCVEGCSA-N","InChI=1S/C16H22ClN3/c1-3-18-9-4-5-12(2)20-15-8-10-19-16-11-13(17)6-7-14(15)16/h6-8,10-12,18H,3-5,9H2,1-2H3,(H,19,20)/t12-/m1/s1","CYP2C8; CYP2D6; CYP3A4; CYP3A5","N-dealkylation of acyclic secondary amine","Human Phase I","Human","(r)-chloroquine, N-desethyl","40579070","GYEDIFVVTRKXHP-SNVBAGLBSA-N","InChI=1S/C14H18ClN3/c1-10(3-2-7-16)18-13-6-8-17-14-9-11(15)4-5-12(13)14/h4-6,8-10H,2-3,7,16H2,1H3,(H,17,18)/t10-/m1/s1","Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01298","(r)-fluoxetine","1548970","RTHCYVBBDHJXIQ-MRXNPFEDSA-N","InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3/t16-/m1/s1","CYP2C9 (major); CYP2D6; CYP2C19; CYP3A5 ","N-dealkylation of acyclic secondary amine","Human Phase I","Human","(r)-Norfluoxetine","9797657","WIQRCHMSJFFONW-OAHLLOKOSA-N","InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ring, B.J. et al. (2001); Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine; J Pharmacol Exp Ther. 2001 Jun;297(3):1044-50.|Margolis J.M.; (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes; Drug Metab Dispos. 2000 Oct;28(10):1187-91; PMID:10997938; Drug Metab Dispos. 2000 Oct;28(10):1187-91."
"BIOTID01299","(r)-fluoxetine","1548970","RTHCYVBBDHJXIQ-MRXNPFEDSA-N","InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3/t16-/m1/s1","CYP2D6","O-dealkylation","Human Phase I","Human","p-Trifluoromethyl phenol","67874","BAYGVMXZJBFEMB-UHFFFAOYSA-N","InChI=1S/C7H5F3O/c8-7(9,10)5-1-3-6(11)4-2-5/h1-4,11H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ring, B.J. et al. (2001); Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine; J Pharmacol Exp Ther. 2001 Jun;297(3):1044-50.|Margolis J.M.; (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes; Drug Metab Dispos. 2000 Oct;28(10):1187-91; PMID:10997938; Drug Metab Dispos. 2000 Oct;28(10):1187-91."
"BIOTID01299","(r)-fluoxetine","1548970","RTHCYVBBDHJXIQ-MRXNPFEDSA-N","InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3/t16-/m1/s1","CYP2D6","O-dealkylation","Human Phase I","Human","3-(methylamino)-1-phenylpropan-1-one","407877","CAIKBWLFBLRPJU-UHFFFAOYSA-N","InChI=1S/C10H13NO/c1-11-8-7-10(12)9-5-3-2-4-6-9/h2-6,11H,7-8H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Ring, B.J. et al. (2001); Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine; J Pharmacol Exp Ther. 2001 Jun;297(3):1044-50.|Margolis J.M.; (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes; Drug Metab Dispos. 2000 Oct;28(10):1187-91; PMID:10997938; Drug Metab Dispos. 2000 Oct;28(10):1187-91."
"BIOTID01300","S-Mephenytoin","107921","GMHKMTDVRCWUDX-LBPRGKRZSA-N","InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)/t12-/m0/s1","CYP2D6;  CYP2C19;  CYP1A2;  CYP2C18;  CYP3A4","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4Ã¢â‚¬Â²-Hydroxymephenytoin","40572060","OQPLORUDZLXXPD-LBPRGKRZSA-N","InChI=1S/C12H14N2O3/c1-3-12(8-4-6-9(15)7-5-8)10(16)14(2)11(17)13-12/h4-7,15H,3H2,1-2H3,(H,13,17)/t12-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Koyama, E. et al. (1997); Reappraisal of Human CYP Isoforms Involved in Imipramine N-Demethylation and 2-Hydroxylation: A Study Using Microsomes Obtained from Putative Extensive and Poor Metabolizers of S-Mephenytoin and Eleven Recombinant Human CYPs; Journal of Pharmacology and Experimental Therapeutics; 281 (3) 1199-1210;"
"BIOTID01301","S-Mephenytoin","107921","GMHKMTDVRCWUDX-LBPRGKRZSA-N","InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)/t12-/m0/s1","CYP2C19; CYP2C18; CYP2D6; CYP1A2; CYP3A4; CYP2B6","N-dealkylation of dicarboximide","Human Phase I","Human","Nirvanol","6540813","UDTWZFJEMMUFLC-NSHDSACASA-N","InChI=1S/C11H12N2O2/c1-2-11(8-6-4-3-5-7-8)9(14)12-10(15)13-11/h3-7H,2H2,1H3,(H2,12,13,14,15)/t11-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Koyama, E. et al. (1997); Reappraisal of Human CYP Isoforms Involved in Imipramine N-Demethylation and 2-Hydroxylation: A Study Using Microsomes Obtained from Putative Extensive and Poor Metabolizers of S-Mephenytoin and Eleven Recombinant Human CYPs; Journal of Pharmacology and Experimental Therapeutics; 281 (3) 1199-1210;"
"BIOTID01302","(S)-(-)-Mexiletine","185376","VLPIATFUUWWMKC-JTQLQIEISA-N","InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m0/s1","CYP1A2 (minor); CYP2D6 (major)","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","(S)-(-)-Mexiletine, p-hydroxyl","92288857","YWOSWRCXWBDSRQ-VIFPVBQESA-N","InChI=1S/C11H17NO2/c1-7-4-10(13)5-8(2)11(7)14-6-9(3)12/h4-5,9,13H,6,12H2,1-3H3/t9-/m0/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Zhou, S.F. and Wang, B. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218; PMID:19754423"
"BIOTID01303","(S)-(-)-Mexiletine","185376","VLPIATFUUWWMKC-JTQLQIEISA-N","InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m0/s1","CYP1A2 (minor); CYP2D6 (major)","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","(S)-(-)-Mexiletine, m-hydroxyl","73356610","LBHCZYGJQAXJSW-QMMMGPOBSA-N","InChI=1S/C11H17NO2/c1-7-4-5-10(13)9(3)11(7)14-6-8(2)12/h4-5,8,13H,6,12H2,1-3H3/t8-/m0/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Zhou, S.F. and Wang, B. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218; PMID:19754423"
"BIOTID01304","(S)-(-)-Mexiletine","185376","VLPIATFUUWWMKC-JTQLQIEISA-N","InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m0/s1","CYP1A2 (minor); CYP2D6 (major)","Hydroxylation of non-terminal aliphatic carbon adjacent to aromatic ring","Human Phase I","Human","(S)-(-)-Mexiletine, 2-OH-hydroxymethyl","71349963","XMJYSMLLWRQQAE-VIFPVBQESA-N","InChI=1S/C11H17NO2/c1-8-4-3-5-10(6-13)11(8)14-7-9(2)12/h3-5,9,13H,6-7,12H2,1-2H3/t9-/m0/s1","Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Zhou, S.F. and Wang, B. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218; PMID:19754423"
"BIOTID01305","(S)-(-)-Mexiletine","185376","VLPIATFUUWWMKC-JTQLQIEISA-N","InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m0/s1","CYP1A2 (major); CYP2B6; CYP2E1","N-hydroxylation of primary or secondary aliphatic amine","Human Phase I","Human","(S)-(-)-Mexiletine, N-hydroxy","92288930","ABMUWCMGKRQAIK-JTQLQIEISA-N","InChI=1S/C11H17NO2/c1-8-5-4-6-9(2)11(8)14-7-10(3)12-13/h4-6,10,12-13H,7H2,1-3H3/t10-/m0/s1","Abolfathi, Z. et al. (1995); CYP1A2 is the Major Enzyme Involved in the N-Oxidation of Mexiletine (MEX) in Man. Clin. Pharmacol. Ther.; 57; 221 (OIII- A33)|Labbe, L. et al.; (2003). Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobi- otica 33:13Ã¢â‚¬â€œ25."
"BIOTID01306","(S)-mianserin","154315","UEQUQVLFIPOEMF-GOSISDBHSA-N","InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3/t18-/m1/s1","CYP1A2; CYP2B6; CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","(S)-mianserin, N-Desmethyl","153934","ZBILSSSEXRZGKS-QGZVFWFLSA-N","InChI=1S/C17H18N2/c1-3-7-15-13(5-1)11-14-6-2-4-8-16(14)19-10-9-18-12-17(15)19/h1-8,17-18H,9-12H2/t17-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic, S., Di Carlo, F. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors; Drug Metabolism Reviews, 29:1-2, 413-580; DOI:10.3109/03602539709037591; PMID:9187528"
"BIOTID01307","(S)-mianserin","154315","UEQUQVLFIPOEMF-GOSISDBHSA-N","InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3/t18-/m1/s1","CYP1A2; CYP2D6; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","(S)-mianserin, 8-hydroxy","NULL","IXAPYQICIDTITB-GOSISDBHSA-N","InChI=1S/C18H20N2O/c1-19-8-9-20-17-11-15(21)7-6-14(17)10-13-4-2-3-5-16(13)18(20)12-19/h2-7,11,18,21H,8-10,12H2,1H3/t18-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic, S., Di Carlo, F. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors; Drug Metabolism Reviews, 29:1-2, 413-580; DOI:10.3109/03602539709037591; PMID:9187528"
"BIOTID01308","(S)-mianserin","154315","UEQUQVLFIPOEMF-GOSISDBHSA-N","InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3/t18-/m1/s1","CYP1A2","N-oxidation of alicyclic tertiary amine","Human Phase I","Human","(S)-mianserin, N-oxide","29984842","VVDXWJOYXVNLLQ-QSVWIEALSA-N","InChI=1S/C18H20N2O/c1-20(21)11-10-19-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(19)13-20/h2-9,18H,10-13H2,1H3/t18-,20?/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic, S., Di Carlo, F. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors; Drug Metabolism Reviews, 29:1-2, 413-580; DOI:10.3109/03602539709037591; PMID:9187528"
"BIOTID01309","(s)-azelastine","12831281","MBUVEWMHONZEQD-SFHVURJKSA-N","InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3/t18-/m0/s1","CYP3A4; CYP2D6; CYP1A2 (minor)","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","(s)-azelastine, N-desmethyl","40584685","WRYCMIFVXDQIKN-KRWDZBQOSA-N","InChI=1S/C21H22ClN3O/c22-16-9-7-15(8-10-16)14-20-18-5-1-2-6-19(18)21(26)25(24-20)17-4-3-12-23-13-11-17/h1-2,5-10,17,23H,3-4,11-14H2/t17-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01310","(s)-bupropion","667684","SNPPWIUOZRMYNY-VIFPVBQESA-N","InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3/t9-/m0/s1","CYP2B6; CYP3A4","Hydroxylation of terminal methyl","Human Phase I","Human","(2S)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one","9813763","AKOAEVOSDHIVFX-VIFPVBQESA-N","InChI=1S/C13H18ClNO2/c1-9(15-13(2,3)8-16)12(17)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3/t9-/m0/s1","Chen, Y. et al. (2010); The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40:8, 536-546, DOI:10.3109/00498254.2010.492880"
"BIOTID01311","(s)-bupropion","667684","SNPPWIUOZRMYNY-VIFPVBQESA-N","InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3/t9-/m0/s1","CYP2C19","Hydroxylation of terminal methyl","Human Phase I","Human","(2S)-2-(tert-butylamino)-1-(3-chlorophenyl)-3-hydroxypropan-1-one","22943245","MYCARDPPKMGEQK-NSHDSACASA-N","InChI=1S/C13H18ClNO2/c1-13(2,3)15-11(8-16)12(17)9-5-4-6-10(14)7-9/h4-7,11,15-16H,8H2,1-3H3/t11-/m0/s1","Chen, Y. et al. (2010); The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40:8, 536-546, DOI:10.3109/00498254.2010.492880"
"BIOTID01312","(s)-bupropion","667684","SNPPWIUOZRMYNY-VIFPVBQESA-N","InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3/t9-/m0/s1","CYP2B6;CYP2C19; CYP2E1","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","(2S)-2-(tert-butylamino)-1-(3-chloro-4-hydroxyphenyl)propan-1-one","NULL","LSZBTGUSYVNVLH-QMMMGPOBSA-N","InChI=1S/C13H18ClNO2/c1-8(15-13(2,3)4)12(17)9-5-6-11(16)10(14)7-9/h5-8,15-16H,1-4H3/t8-/m0/s1","Chen, Y. et al. (2010); The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40:8, 536-546, DOI:10.3109/00498254.2010.492880|Faucette, S.R. et al. (2000); Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity. Drug Metab. Dispos. 2000, 28, 1222 Ã¢â‚¬â€œ 1230."
"BIOTID01313","(s)-bupropion","667684","SNPPWIUOZRMYNY-VIFPVBQESA-N","InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3/t9-/m0/s1","CYP2B6;CYP2C19; CYP2E1","Hydroxylation of aromatic carbon meta to halide group","Human Phase I","Human","(2S)-2-(tert-butylamino)-1-(3-chloro-5-hydroxyphenyl)propan-1-one","NULL","MKUMNNVIQOBJFK-QMMMGPOBSA-N","InChI=1S/C13H18ClNO2/c1-8(15-13(2,3)4)12(17)9-5-10(14)7-11(16)6-9/h5-8,15-16H,1-4H3/t8-/m0/s1","Chen, Y. et al. (2010); The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40:8, 536-546, DOI:10.3109/00498254.2010.492880|Faucette, S.R. et al. (2000); Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity. Drug Metab. Dispos. 2000, 28, 1222 Ã¢â‚¬â€œ 1230."
"BIOTID01314","1,4-dichlorobenzene","4685","OCJBOOLMMGQPQU-UHFFFAOYSA-N","InChI=1S/C6H4Cl2/c7-5-1-2-6(8)4-3-5/h1-4H","CYP2E1 (major)","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","2,5-dichlorophenol","66","RANCECPPZPIPNO-UHFFFAOYSA-N","InChI=1S/C6H4Cl2O/c7-4-1-2-5(8)6(9)3-4/h1-3,9H","bogaards, JJP et al. (1995); Human Cytochrome P450 Enzyme Selectivities in the Oxidation of Chlorinated Benzenes; Toxicol Appl Pharmacol. 1995 May;132(1):44-52; PMID:7747284|Nedelcheva, V. et al. (1998); Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse, and human liver microsomes; Chemico-Biological Interactions 115 (1998) 53Ã¢â‚¬â€œ70"
"BIOTID01315","1,8-dinitropyrene","39185","BLYXNIHKOMELAP-UHFFFAOYSA-N","InChI=1S/C16H8N2O4/c19-17(20)13-7-3-9-1-2-10-4-8-14(18(21)22)12-6-5-11(13)15(9)16(10)12/h1-8H","CYP1A1","REDUCTION_OF_NITRO_TO_AMINE","Human Phase I","Human","1-amino-8-nitropyrene","108113","WGVCNGPAJHVJKK-UHFFFAOYSA-N","InChI=1S/C16H10N2O2/c17-13-7-3-9-1-2-10-4-8-14(18(19)20)12-6-5-11(13)15(9)16(10)12/h1-8H,17H2","Rendic, S. and Guengerich, F.P. (2012); Contributions of Human Enzymes in Carcinogen Metabolism; Chem Res Toxicol; 25(7): 1316Ã¢â‚¬â€œ1383; DOI:10.1021/tx300132k; PMID:22531028"
"BIOTID01316","P-Hydroxynefazodone","10435492","XGIODORTBODPTQ-UHFFFAOYSA-N","InChI=1S/C25H32ClN5O3/c1-2-24-27-31(25(33)30(24)17-18-34-21-7-4-3-5-8-21)12-6-11-28-13-15-29(16-14-28)20-9-10-23(32)22(26)19-20/h3-5,7-10,19,32H,2,6,11-18H2,1H3","CYP3A4","_2_ELECTRON_OXIDATION_OF_P_AMINOPHENOLS_TO_QUINONE_IMINES_PATTERN1","Human Phase I","Human","1Ã¢â‚¬Â(3Ã¢â‚¬ÂchloroÃ¢â‚¬Â4Ã¢â‚¬ÂoxocyclohexaÃ¢â‚¬Â2,5Ã¢â‚¬ÂdienÃ¢â‚¬Â1Ã¢â‚¬Âylidene)Ã¢â‚¬Â4Ã¢â‚¬Â{3Ã¢â‚¬Â[3Ã¢â‚¬ÂethylÃ¢â‚¬Â5Ã¢â‚¬ÂoxoÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â1Ã¢â‚¬Âyl]propyl}Ã¢â‚¬Â1lambda5Ã¢â‚¬ÂpiperazinÃ¢â‚¬Â1Ã¢â‚¬Âylium","NULL","UMYTXCCAWDJHPP-UHFFFAOYSA-N","InChI=1S/C25H31ClN5O3/c1-2-24-27-31(25(33)30(24)17-18-34-21-7-4-3-5-8-21)12-6-11-28-13-15-29(16-14-28)20-9-10-23(32)22(26)19-20/h3-5,7-10,19H,2,6,11-18H2,1H3/q+1","Bolleddula, J. et al. (2014); Biotransformation and bioactivation reactions of alicyclic amines in drug molecules, Drug Metabolism Reviews, 46:3, 379-419, DOI:10.3109/03602532.2014.924962."
"BIOTID01317","1Ã¢â‚¬Â{3Ã¢â‚¬Â[4Ã¢â‚¬Â(3Ã¢â‚¬ÂchloroÃ¢â‚¬Â4Ã¢â‚¬Âhydroxyphenyl)piperazinÃ¢â‚¬Â1Ã¢â‚¬Âyl]propyl}Ã¢â‚¬Â3Ã¢â‚¬ÂethylÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â5Ã¢â‚¬Âone","10435492","XGIODORTBODPTQ-UHFFFAOYSA-N","InChI=1S/C25H32ClN5O3/c1-2-24-27-31(25(33)30(24)17-18-34-21-7-4-3-5-8-21)12-6-11-28-13-15-29(16-14-28)20-9-10-23(32)22(26)19-20/h3-5,7-10,19,32H,2,6,11-18H2,1H3","CYP3A4","Oxidation of 4-substituted phenol","Human Phase I","Human","1Ã¢â‚¬Â{3Ã¢â‚¬Â[4Ã¢â‚¬Â(3Ã¢â‚¬ÂchloroÃ¢â‚¬Â1Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â4Ã¢â‚¬ÂoxocyclohexaÃ¢â‚¬Â2,5Ã¢â‚¬ÂdienÃ¢â‚¬Â1Ã¢â‚¬Âyl)piperazinÃ¢â‚¬Â1Ã¢â‚¬Âyl]propyl}Ã¢â‚¬Â3Ã¢â‚¬ÂethylÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â5Ã¢â‚¬Âone","NULL","XAUKQBXYNIMIMU-VWLOTQADSA-N","InChI=1S/C25H32ClN5O4/c1-2-23-27-31(24(33)30(23)17-18-35-20-7-4-3-5-8-20)12-6-11-28-13-15-29(16-14-28)25(34)10-9-22(32)21(26)19-25/h3-5,7-10,19,34H,2,6,11-18H2,1H3/t25-/m0/s1","Bolleddula, J. et al. (2014); Biotransformation and bioactivation reactions of alicyclic amines in drug molecules, Drug Metabolism Reviews, 46:3, 379-419, DOI:10.3109/03602532.2014.924962."
"BIOTID01318","1Ã¢â‚¬Â{3Ã¢â‚¬Â[4Ã¢â‚¬Â(3Ã¢â‚¬ÂchloroÃ¢â‚¬Â4Ã¢â‚¬Âhydroxyphenyl)piperazinÃ¢â‚¬Â1Ã¢â‚¬Âyl]propyl}Ã¢â‚¬Â3Ã¢â‚¬ÂethylÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â5Ã¢â‚¬Âone","10435492","XGIODORTBODPTQ-UHFFFAOYSA-N","InChI=1S/C25H32ClN5O3/c1-2-24-27-31(25(33)30(24)17-18-34-21-7-4-3-5-8-21)12-6-11-28-13-15-29(16-14-28)20-9-10-23(32)22(26)19-20/h3-5,7-10,19,32H,2,6,11-18H2,1H3","CYP3A4","EPOXIDATION","Human Phase I","Human","1Ã¢â‚¬Â[3Ã¢â‚¬Â(4Ã¢â‚¬Â{3Ã¢â‚¬ÂchloroÃ¢â‚¬Â4Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â7Ã¢â‚¬Âoxabicyclo[4.1.0]heptaÃ¢â‚¬Â2,4Ã¢â‚¬ÂdienÃ¢â‚¬Â1Ã¢â‚¬Âyl}piperazinÃ¢â‚¬Â1Ã¢â‚¬Âyl)propyl]Ã¢â‚¬Â3Ã¢â‚¬ÂethylÃ¢â‚¬Â4Ã¢â‚¬Â(2Ã¢â‚¬Âphenoxyethyl)Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬Â1,2,4Ã¢â‚¬ÂtriazolÃ¢â‚¬Â5Ã¢â‚¬Âone","NULL","KOPPHSPBFWSOBD-RDGATRHJSA-N","InChI=1S/C25H32ClN5O4/c1-2-23-27-31(24(33)30(23)15-16-34-19-7-4-3-5-8-19)10-6-9-28-11-13-29(14-12-28)25-18-20(26)21(32)17-22(25)35-25/h3-5,7-8,17-18,22,32H,2,6,9-16H2,1H3/t22-,25+/m1/s1","Bolleddula, J. et al. (2014); Biotransformation and bioactivation reactions of alicyclic amines in drug molecules, Drug Metabolism Reviews, 46:3, 379-419, DOI:10.3109/03602532.2014.924962."
"BIOTID01319","1-aminopyrene","15352","YZVWKHVRBDQPMQ-UHFFFAOYSA-N","InChI=1S/C16H11N/c17-14-9-7-12-5-4-10-2-1-3-11-6-8-13(14)16(12)15(10)11/h1-9H,17H2","CYP1A1; CYP1A2; CYP3A4","N-hydroxylation of primary arylamine","Human Phase I","Human","N-hydroxy-1-aminopyrene","114981","LQWUGNODGKKHOP-UHFFFAOYSA-N","InChI=1S/C16H11NO/c18-17-14-9-7-12-5-4-10-2-1-3-11-6-8-13(14)16(12)15(10)11/h1-9,17-18H","Rendic, S. and Guengerich, F.P. (2012); Contributions of Human Enzymes in Carcinogen Metabolism; Chem Res Toxicol; 25(7): 1316Ã¢â‚¬â€œ1383; DOI:10.1021/tx300132k; PMID:22531028"
"BIOTID01320","17alpha-Ethinylestradiol","NULL","DQHWEKFXUGLNRV-QPJCZJHGNA-N","InChI=1S/C21H26O2/c1-4-21(23)12-9-18-19(2)10-7-14-13-15(22)5-6-16(14)17(19)8-11-20(18,21)3/h1,5-6,13,17-18,22-23H,7-12H2,2-3H3/t17-,18+,19-,20+,21+/m1/s1","CYP2C9; CYP3A4; CYP2C19; CYP1A2","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2beta-OH-17beta-Ethinylestradiol","NULL","SYRDZWUTDZQTTL-PQLHGUBISA-N","InChI=1S/C21H26O3/c1-4-21(24)10-7-18-19(2)8-5-13-11-16(22)17(23)12-14(13)15(19)6-9-20(18,21)3/h1,11-12,15,18,22-24H,5-10H2,2-3H3/t15-,18+,19-,20+,21+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01321","17alpha-Ethinylestradiol","NULL","DQHWEKFXUGLNRV-QPJCZJHGNA-N","InChI=1S/C21H26O2/c1-4-21(23)12-9-18-19(2)10-7-14-13-15(22)5-6-16(14)17(19)8-11-20(18,21)3/h1,5-6,13,17-18,22-23H,7-12H2,2-3H3/t17-,18+,19-,20+,21+/m1/s1","CYP2C9; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","4beta-OH-17beta-Ethinylestradiol","NULL","OFVWXERYXWCPBX-FVJLHALJSA-N","InChI=1S/C21H26O3/c1-4-21(24)12-9-17-19(2)10-7-14-13(5-6-16(22)18(14)23)15(19)8-11-20(17,21)3/h1,5-6,15,17,22-24H,7-12H2,2-3H3/t15-,17+,19-,20+,21+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01322","17alpha-Ethinylestradiol","NULL","DQHWEKFXUGLNRV-QPJCZJHGNA-N","InChI=1S/C21H26O2/c1-4-21(23)12-9-18-19(2)10-7-14-13-15(22)5-6-16(14)17(19)8-11-20(18,21)3/h1,5-6,13,17-18,22-23H,7-12H2,2-3H3/t17-,18+,19-,20+,21+/m1/s1","CYP2C9; CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","6beta-OH-17beta-Ethinylestradiol","NULL","QAPYNJHRINFWAG-YQPXSLGVSA-N","InChI=1S/C21H26O3/c1-4-21(24)10-8-18-19(2)12-17(23)15-11-13(22)5-6-14(15)16(19)7-9-20(18,21)3/h1,5-6,11,16-18,22-24H,7-10,12H2,2-3H3/t16-,17-,18+,19-,20+,21+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01323","17alpha-Ethinylestradiol","NULL","DQHWEKFXUGLNRV-QPJCZJHGNA-N","InChI=1S/C21H26O2/c1-4-21(23)12-9-18-19(2)10-7-14-13-15(22)5-6-16(14)17(19)8-11-20(18,21)3/h1,5-6,13,17-18,22-23H,7-12H2,2-3H3/t17-,18+,19-,20+,21+/m1/s1","CYP2C9; CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","6alpha-OH-17beta-Ethinylestradiol","NULL","QAPYNJHRINFWAG-SSFAQJFESA-N","InChI=1S/C21H26O3/c1-4-21(24)10-8-18-19(2)12-17(23)15-11-13(22)5-6-14(15)16(19)7-9-20(18,21)3/h1,5-6,11,16-18,22-24H,7-10,12H2,2-3H3/t16-,17+,18+,19-,20+,21+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01324","2,6-Xylidine","6896","UFFBMTHBGFGIHF-UHFFFAOYSA-N","InChI=1S/C8H11N/c1-6-4-3-5-7(2)8(6)9/h3-5H,9H2,1-2H3","CYP2A6; CYP2E1","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","4-hydroxy-2,6-dimethylaniline","76543","GCWYXRHXGLFVFE-UHFFFAOYSA-N","InChI=1S/C8H11NO/c1-5-3-7(10)4-6(2)8(5)9/h3-4,10H,9H2,1-2H3","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01325","2,6-Xylidine","6896","UFFBMTHBGFGIHF-UHFFFAOYSA-N","InChI=1S/C8H11N/c1-6-4-3-5-7(2)8(6)9/h3-5H,9H2,1-2H3","CYP2A6; CYP2E1","N-hydroxylation of primary arylamine","Human Phase I","Human","N-(2,6-dimethylphenyl)hydroxylamine","145679","YFVSZHCWKQTSGT-UHFFFAOYSA-N","InChI=1S/C8H11NO/c1-6-4-3-5-7(2)8(6)9-10/h3-5,9-10H,1-2H3","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01326","3-aminobenzanthrone","NULL","HXXLZOYCGAVCRU-UHFFFAOYSA-N","InChI=1S/C17H13NO/c18-15-9-8-11-10-4-1-2-5-12(10)17(19)14-7-3-6-13(15)16(11)14/h1-9,13,15H,18H2","CYP1A1; CYP1A2; CYP1B1; CYP2A6; CYP2B6; ","N-hydroxylation of primary arylamine","Human Phase I","Human","N-hydroxy-3-aminobenzanthrone","NULL","YNTLLJJVUJRBPX-UHFFFAOYSA-N","InChI=1S/C17H13NO2/c19-17-12-5-2-1-4-10(12)11-8-9-15(18-20)13-6-3-7-14(17)16(11)13/h1-9,13,15,18,20H","Murata, M. et al. (2005); Carcinogenic 3-nitrobenzanthrone induces oxidative damage to isolated and cellular DNA; Free Radical Biology & Medicine 40 (2006) 1242Ã¢â‚¬â€œ1249"
"BIOTID01327","3-Hydroxylidocaine","161824","PMGUCIDDSCRAMY-UHFFFAOYSA-N","InChI=1S/C14H22N2O2/c1-5-16(6-2)9-13(18)15-14-10(3)7-8-12(17)11(14)4/h7-8,17H,5-6,9H2,1-4H3,(H,15,18)","CYP1A2; CYP2D6; CYP3A4","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","3-Hydroxymonoethyl glycinexylidide","3015693","YITCMQBVWIHTTA-UHFFFAOYSA-N","InChI=1S/C12H18N2O2/c1-4-13-7-11(16)14-12-8(2)5-6-10(15)9(12)3/h5-6,13,15H,4,7H2,1-3H3,(H,14,16)","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01328","3'-HPPH","NULL","FSPRLRPJSPWQNC-UHFFFAOYNA-N","InChI=1S/C15H12N2O3/c18-12-8-4-7-11(9-12)15(10-5-2-1-3-6-10)13(19)16-14(20)17-15/h1-9,18H,(H2,16,17,19,20)","CYP2C9; CYP2C19","Hydroxylation of benzene on carbon orhto to a strongly electron donating group","Human Phase I","Human","3Ã¢â‚¬â„¢,4Ã¢â‚¬â„¢- diHPPH","169703","WWEKVOUOQUHVHS-UHFFFAOYSA-N","InChI=1S/C15H12N2O4/c18-11-7-6-10(8-12(11)19)15(9-4-2-1-3-5-9)13(20)16-14(21)17-15/h1-8,18-19H,(H2,16,17,20,21)","PMID:11038165"
"BIOTID01329","4'-HPPH","NULL","XEEDURHPFVXALT-UHFFFAOYNA-N","InChI=1S/C15H12N2O3/c18-12-8-6-11(7-9-12)15(10-4-2-1-3-5-10)13(19)16-14(20)17-15/h1-9,18H,(H2,16,17,19,20)","CYP2C9; CYP2C19","Hydroxylation of benzene on carbon orhto to a strongly electron donating group","Human Phase I","Human","3Ã¢â‚¬â„¢,4Ã¢â‚¬â„¢- diHPPH","169703","WWEKVOUOQUHVHS-UHFFFAOYSA-N","InChI=1S/C15H12N2O4/c18-11-7-6-10(8-12(11)19)15(9-4-2-1-3-5-9)13(20)16-14(21)17-15/h1-8,18-19H,(H2,16,17,20,21)","PMID:11038165"
"BIOTID01330","4,4'-Dichlorobiphenyl","16308","YTBRNEUEFCNVHC-UHFFFAOYSA-N","InChI=1S/C12H8Cl2/c13-11-5-1-9(2-6-11)10-3-7-12(14)8-4-10/h1-8H","CYP1A2","Hydroxylation of aromatic carbon ortho to halide group","Human Phase I","Human","4,4Ã¢â‚¬Â²-Dichloro-3-biphenylol","6452830","YIRDONCMEBQOJP-UHFFFAOYSA-N","InChI=1S/C12H8Cl2O/c13-10-4-1-8(2-5-10)9-3-6-11(14)12(15)7-9/h1-7,15H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01332","7-Methoxyresorufin","119220","KNYYMGDYROYBRE-UHFFFAOYSA-N","InChI=1S/C13H9NO3/c1-16-9-3-5-11-13(7-9)17-12-6-8(15)2-4-10(12)14-11/h2-7H,1H3","CYP1A1; CYP1A2","O-aryl demethylation","Human Phase I","Human","Resorufin","69462","HSSLDCABUXLXKM-UHFFFAOYSA-N","InChI=1S/C12H7NO3/c14-7-1-3-9-11(5-7)16-12-6-8(15)2-4-10(12)13-9/h1-6,14H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01333","(R)-mianserin, 8-hydroxy","NULL","IXAPYQICIDTITB-SFHVURJKSA-N","InChI=1S/C18H20N2O/c1-19-8-9-20-17-11-15(21)7-6-14(17)10-13-4-2-3-5-16(13)18(20)12-19/h2-7,11,18,21H,8-10,12H2,1H3/t18-/m0/s1","CYP2D6; CYP1A2; CYP3A4","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","(R)-mianserin, 8-OH-N-desmethyl","NULL","KDLZTAPNHXUVCE-KRWDZBQOSA-N","InChI=1S/C17H18N2O/c20-14-6-5-13-9-12-3-1-2-4-15(12)17-11-18-7-8-19(17)16(13)10-14/h1-6,10,17-18,20H,7-9,11H2/t17-/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01334","Acetachlor","1988","VTNQPKFIQCLBDU-UHFFFAOYSA-N","InChI=1S/C14H20ClNO2/c1-4-12-8-6-7-11(3)14(12)16(10-18-5-2)13(17)9-15/h6-8H,4-5,9-10H2,1-3H3","CYP2B6; CYP3A4","N-dealkoxylation of N-aryl-N-chloroacetamide","Human Phase I","Human","NULL","670477","SMINYPCTNJDYGK-UHFFFAOYSA-N","InChI=1S/C11H14ClNO/c1-3-9-6-4-5-8(2)11(9)13-10(14)7-12/h4-6H,3,7H2,1-2H3,(H,13,14)","Coleman, S. et al.; Comparative metabolism of chloroacetamide herbicides and selected metabolites in human and rat liver microsomes.; Environ Health Perspect. 2000 Dec;108(12):1151-7"
"BIOTID01335","Acetachlor","1988","VTNQPKFIQCLBDU-UHFFFAOYSA-N","InChI=1S/C14H20ClNO2/c1-4-12-8-6-7-11(3)14(12)16(10-18-5-2)13(17)9-15/h6-8H,4-5,9-10H2,1-3H3","CYP2B6; CYP3A4","N-demethoxymethylation","Human Phase I","Human","NULL","89188136","SQWPFHMYQCSKPP-UHFFFAOYSA-N","InChI=1S/C12H19NO/c1-4-11-8-6-7-10(3)12(11)13-9-14-5-2/h6-8,13H,4-5,9H2,1-3H3","Coleman, S. et al.; Comparative metabolism of chloroacetamide herbicides and selected metabolites in human and rat liver microsomes.; Environ Health Perspect. 2000 Dec;108(12):1151-7"
"BIOTID01336","(R)-acenocoumarol","54676537","VABCILAOYCMVPS-OAHLLOKOSA-N","InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3","CYP2C9; CYP1A2; CYP2C19","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-OH-R-acenocoumarol","NULL","RXFXXWMNPIVMHP-UHFFFAOYSA-N","InChI=1S/C19H15NO7/c1-10(21)9-14(11-5-7-12(8-6-11)20(25)26)16-17(23)13-3-2-4-15(22)18(13)27-19(16)24/h2-8,14,22-23H,9H2,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01337","(R)-acenocoumarol","54676537","VABCILAOYCMVPS-OAHLLOKOSA-N","InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3","CYP2C9; CYP2C19","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","7-OH-R-acenocoumarol","57369793","JTCREUDLEYTCAB-UHFFFAOYSA-N","InChI=1S/C19H15NO7/c1-10(21)8-15(11-2-4-12(5-3-11)20(25)26)17-18(23)14-7-6-13(22)9-16(14)27-19(17)24/h2-7,9,15,22-23H,8H2,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3676"
"BIOTID01338","(R)-acenocoumarol","54676537","VABCILAOYCMVPS-OAHLLOKOSA-N","InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3","CYP2C9; CYP2C19","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","8-OH-R-acenocoumarol","57369794","SUHPKJKJROTWOQ-UHFFFAOYSA-N","InChI=1S/C19H15NO7/c1-10(21)8-14(11-2-4-12(5-3-11)20(25)26)17-18(23)15-9-13(22)6-7-16(15)27-19(17)24/h2-7,9,14,22-23H,8H2,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3677"
"BIOTID01339","Bromazepam","2441","VMIYHDSEFNYJSL-UHFFFAOYSA-N","InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)","CYP1A2; CYP2D6","3-Hydroxylation of 5-aryl-1,4-benzodiazepine","Human Phase I","Human","NULL","166774","URRUSNGCYBXNLO-UHFFFAOYSA-N","InChI=1S/C14H10BrN3O2/c15-8-4-5-10-9(7-8)12(11-3-1-2-6-16-11)18-14(20)13(19)17-10/h1-7,14,20H,(H,17,19)","Bolleddula, J. et al. (2014); Biotransformation and bioactivation reactions of alicyclic amines in drug molecules, Drug Metabolism Reviews, 46:3, 379-419, DOI:10.3109/03602532.2014.924962."
"BIOTID01340","Alachlor","2078","XCSGPAVHZFQHGE-UHFFFAOYSA-N","InChI=1S/C14H20ClNO2/c1-4-11-7-6-8-12(5-2)14(11)16(10-18-3)13(17)9-15/h6-8H,4-5,9-10H2,1-3H3","CYP2B6; CYP3A4","N-dealkoxylation of N-aryl-N-chloroacetamide","Human Phase I","Human","NULL","96338","LBJVHMAYBNQJBK-UHFFFAOYSA-N","InChI=1S/C12H16ClNO/c1-3-9-6-5-7-10(4-2)12(9)14-11(15)8-13/h5-7H,3-4,8H2,1-2H3,(H,14,15)","Coleman, S. et al.; Comparative metabolism of chloroacetamide herbicides and selected metabolites in human and rat liver microsomes.; Environ Health Perspect. 2000 Dec;108(12):1151-7|Coleman et al.,Chem. Biol. Inter.,122,27,1999(PMID:10475613)"
"BIOTID01341","Alachlor","2078","XCSGPAVHZFQHGE-UHFFFAOYSA-N","InChI=1S/C14H20ClNO2/c1-4-11-7-6-8-12(5-2)14(11)16(10-18-3)13(17)9-15/h6-8H,4-5,9-10H2,1-3H3","CYP2B6; CYP3A4","N-demethoxymethylation","Human Phase I","Human","NULL","19433721","QLHHMZDLAILAIS-UHFFFAOYSA-N","InChI=1S/C12H19NO/c1-4-10-7-6-8-11(5-2)12(10)13-9-14-3/h6-8,13H,4-5,9H2,1-3H3","Coleman, S. et al.; In vitro metabolism of alachlor by human liver microsomes and human cytochrome P450 isoforms; Chemico-Biological Interactions 122 (1999) 27Ã¢â‚¬â€œ39"
"BIOTID01342","6-Aminochrysene","17534","KIVUHCNVDWYUNP-UHFFFAOYSA-N","InChI=1S/C18H13N/c19-18-11-17-13-6-2-1-5-12(13)9-10-15(17)14-7-3-4-8-16(14)18/h1-11H,19H2","CYP1B1; CYP1A2; CYP1A1; CYP2A6; CYP2B6","N-hydroxylation of primary arylamine","Human Phase I","Human","N-Hydroxychrysene","115225","DDEXKYQWZJEPRX-UHFFFAOYSA-N","InChI=1S/C18H13NO/c20-19-18-11-17-13-6-2-1-5-12(13)9-10-15(17)14-7-3-4-8-16(14)18/h1-11,19-20H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01343","Aminoflavone","389710","RTUZVPPGTJRELI-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O2/c1-6-13(18)15(21)12-10(22)5-11(23-16(12)14(6)19)7-2-3-9(20)8(17)4-7/h2-5H,20-21H2,1H3","CYP1A2; CYP1A1; CYP2C9; CYP2C19","N-hydroxylation of primary arylamine","Human Phase I","Human","Aminoflavone, N4'-Hydroxy","NULL","BUGQDNPBVYMEFE-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O3/c1-6-13(18)15(20)12-10(22)5-11(24-16(12)14(6)19)7-2-3-9(21-23)8(17)4-7/h2-5,21,23H,20H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01344","Aminoflavone","389710","RTUZVPPGTJRELI-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O2/c1-6-13(18)15(21)12-10(22)5-11(23-16(12)14(6)19)7-2-3-9(20)8(17)4-7/h2-5H,20-21H2,1H3","CYP1A2; CYP2C9; CYP2C19","N-hydroxylation of primary arylamine","Human Phase I","Human","NULL","NULL","BGZUIZSBNOBPKP-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O3/c1-6-13(18)15(21-23)12-10(22)5-11(24-16(12)14(6)19)7-2-3-9(20)8(17)4-7/h2-5,21,23H,20H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01345","Aminoflavone","389710","RTUZVPPGTJRELI-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O2/c1-6-13(18)15(21)12-10(22)5-11(23-16(12)14(6)19)7-2-3-9(20)8(17)4-7/h2-5H,20-21H2,1H3","CYP1A2","Hydroxylation of carbon alpha to conjugated carbonyl","Human Phase I","Human","Aminoflavone, C3-hydroxy","NULL","HUSFKTRIHYXGPZ-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O3/c1-5-10(18)12(21)9-13(22)14(23)15(24-16(9)11(5)19)6-2-3-8(20)7(17)4-6/h2-4,23H,20-21H2,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01346","Aminoflavone, N4'-Hydroxyl","NULL","BUGQDNPBVYMEFE-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O3/c1-6-13(18)15(20)12-10(22)5-11(24-16(12)14(6)19)7-2-3-9(21-23)8(17)4-7/h2-5,21,23H,20H2,1H3","CYP1A2; CYP2C9; CYP2C19","N-hydroxylation of primary arylamine","Human Phase I","Human","Aminoflavone, N4', N5-dihydroxy","NULL","GEASYZROZMRJJL-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O4/c1-6-13(18)15(21-24)12-10(22)5-11(25-16(12)14(6)19)7-2-3-9(20-23)8(17)4-7/h2-5,20-21,23-24H,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01347","Aminoflavone, N5-Hydroxyl","NULL","BGZUIZSBNOBPKP-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O3/c1-6-13(18)15(21-23)12-10(22)5-11(24-16(12)14(6)19)7-2-3-9(20)8(17)4-7/h2-5,21,23H,20H2,1H3","CYP1A1; CYP1A2; CYP2C9; CYP2C19","N-hydroxylation of primary arylamine","Human Phase I","Human","Aminoflavone, N4', N5-dihydroxy","NULL","GEASYZROZMRJJL-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O4/c1-6-13(18)15(21-24)12-10(22)5-11(25-16(12)14(6)19)7-2-3-9(20-23)8(17)4-7/h2-5,20-21,23-24H,1H3","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01349","Amphetamine","32893","KWTSXDURSIMDCE-SVGMAFHSNA-N","InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m1/s1","CYP2D6","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4-Hydroxyamphetamine","3651","GIKNHHRFLCDOEU-UHFFFAOYSA-N","InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01350","Aprindine","2218","NZLBHDRPUJLHCE-UHFFFAOYSA-N","InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3","CYP2D6","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","N-[3-(N,NDiethylamino)propyl]-N-phenyl-2-aminoindan-5-ol","NULL","LOCYZRRMXVRONA-UHFFFAOYSA-N","InChI=1S/C22H30N2O/c1-3-23(4-2)13-8-14-24(20-9-6-5-7-10-20)21-15-18-11-12-22(25)17-19(18)16-21/h5-7,9-12,17,21,25H,3-4,8,13-16H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259986"
"BIOTID01351","Aprindine","2218","NZLBHDRPUJLHCE-UHFFFAOYSA-N","InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3","CYP2D6","Hydroxylation of benzene on carbon para to a strongly electron donating group","Human Phase I","Human","p-Hydroxyphenylaprindine","85832321","NDSJVPYEVPNZKX-UHFFFAOYSA-N","InChI=1S/C22H30N2O/c1-3-23(4-2)14-7-15-24(20-10-12-22(25)13-11-20)21-16-18-8-5-6-9-19(18)17-21/h5-6,8-13,21,25H,3-4,7,14-17H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259987"
"BIOTID01352","Aprindine","2218","NZLBHDRPUJLHCE-UHFFFAOYSA-N","InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3","CYP2D6","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES","Human Phase I","Human","Desethylaprindine","162697","JVKNBCGVGGFZLV-UHFFFAOYSA-N","InChI=1S/C20H26N2/c1-2-21-13-8-14-22(19-11-4-3-5-12-19)20-15-17-9-6-7-10-18(17)16-20/h3-7,9-12,20-21H,2,8,13-16H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259988"
"BIOTID01353","Butachlor","31677","HKPHPIREJKHECO-UHFFFAOYSA-N","InChI=1S/C17H26ClNO2/c1-4-7-11-21-13-19(16(20)12-18)17-14(5-2)9-8-10-15(17)6-3/h8-10H,4-7,11-13H2,1-3H3","CYP2B6; CYP3A4","N-dealkoxylation of N-aryl-N-chloroacetamide","Human Phase I","Human","NULL","96338","LBJVHMAYBNQJBK-UHFFFAOYSA-N","InChI=1S/C12H16ClNO/c1-3-9-6-5-7-10(4-2)12(9)14-11(15)8-13/h5-7H,3-4,8H2,1-2H3,(H,14,15)","Coleman, S. et al.; Comparative metabolism of chloroacetamide herbicides and selected metabolites in human and rat liver microsomes.; Environ Health Perspect. 2000 Dec;108(12):1151-7"
"BIOTID01354","Butachlor","31677","HKPHPIREJKHECO-UHFFFAOYSA-N","InChI=1S/C17H26ClNO2/c1-4-7-11-21-13-19(16(20)12-18)17-14(5-2)9-8-10-15(17)6-3/h8-10H,4-7,11-13H2,1-3H3","CYP2B6; CYP3A4","N-demethoxymethylation","Human Phase I","Human","NULL","96338","LBJVHMAYBNQJBK-UHFFFAOYSA-N","InChI=1S/C12H16ClNO/c1-3-9-6-5-7-10(4-2)12(9)14-11(15)8-13/h5-7H,3-4,8H2,1-2H3,(H,14,15)","Coleman, S. et al.; Comparative metabolism of chloroacetamide herbicides and selected metabolites in human and rat liver microsomes.; Environ Health Perspect. 2000 Dec;108(12):1151-7"
"BIOTID01355","Buprenorphine","644073","RMRJXGBAOAMLHD-IHFGGWKQSA-N","InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1","CYP3A4; CYP2C8; CYP2C9; CYP3A5","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","Norbuprenorphine","114976","YOYLLRBMGQRFTN-IOMBULRVSA-N","InChI=1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1","(R) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01358","(+)-Camphor","159055","DSSYKIVIOFKYAU-XCBNKYQSSA-N","InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3/t7-,10+/m1/s1","CYP2D6","Hydroxlation of methyl carbon adjacent to an aliphatic ring","Human Phase I","Human","5-exo-hydroxycamphor","NULL","MANWHKQXMFYQDY-IKZKJGMZSA-N","InChI=1S/C10H16O2/c1-9-4-3-7(5-8(9)12)10(9,2)6-11/h7,11H,3-6H2,1-2H3/t7-,9+,10?/m1/s1","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID01359","(+)-Camphor","159055","DSSYKIVIOFKYAU-XCBNKYQSSA-N","InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3/t7-,10+/m1/s1","CYP2D6","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","8-hydroxycamphor","NULL","DJQYBVLXBVJHMU-ZRJGNOHYSA-N","InChI=1S/C10H16O2/c1-9(2)6-4-8(12)10(9,3)5-7(6)11/h6-7,11H,4-5H2,1-3H3/t6-,7?,10-/m0/s1","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID01360","Carbosulfan","41384","JLQUFIHWVLZVTJ-UHFFFAOYSA-N","InChI=1S/C20H32N2O3S/c1-6-8-13-22(14-9-7-2)26-21(5)19(23)24-17-12-10-11-16-15-20(3,4)25-18(16)17/h10-12H,6-9,13-15H2,1-5H3","CYP1A1; CYP1A2; CYP2A6; CYP2B6; CYP2C8; CYP2C19; CYP3A4","NS-cleavage","Human Phase I","Human","carbofuran","2566","DUEPRVBVGDRKAG-UHFFFAOYSA-N","InChI=1S/C12H15NO3/c1-12(2)7-8-5-4-6-9(10(8)16-12)15-11(14)13-3/h4-6H,7H2,1-3H3,(H,13,14)","Abass, K. et al. (2010). Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem. Biol. Interact., Vol. 185, No. 3, (163-173)."
"BIOTID01360","Carbosulfan","41384","JLQUFIHWVLZVTJ-UHFFFAOYSA-N","InChI=1S/C20H32N2O3S/c1-6-8-13-22(14-9-7-2)26-21(5)19(23)24-17-12-10-11-16-15-20(3,4)25-18(16)17/h10-12H,6-9,13-15H2,1-5H3","CYP1A1; CYP1A2; CYP2A6; CYP2B6; CYP2C8; CYP2C19; CYP3A4","NS-cleavage","Human Phase I","Human","dibutyl(sulfanyl)amine","21163218","WVGQYNKWWPBXTB-UHFFFAOYSA-N","InChI=1S/C8H19NS/c1-3-5-7-9(10)8-6-4-2/h10H,3-8H2,1-2H3","Abass, K. et al. (2010). Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem. Biol. Interact., Vol. 185, No. 3, (163-173)."
"BIOTID01361","Carbosulfan","41384","JLQUFIHWVLZVTJ-UHFFFAOYSA-N","InChI=1S/C20H32N2O3S/c1-6-8-13-22(14-9-7-2)26-21(5)19(23)24-17-12-10-11-16-15-20(3,4)25-18(16)17/h10-12H,6-9,13-15H2,1-5H3","CYP1A1; CYP2B6; CYP2C19; CYP3A4","Oxidation of S adjacent to an aliphatic nitrogen","Human Phase I","Human","NULL","NULL","YNQSDWJJQZKEPB-UHFFFAOYSA-N","InChI=1S/C20H32N2O4S/c1-6-8-13-22(14-9-7-2)27(24)21(5)19(23)25-17-12-10-11-16-15-20(3,4)26-18(16)17/h10-12H,6-9,13-15H2,1-5H3","Abass, K. et al. (2010). Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem. Biol. Interact., Vol. 185, No. 3, (163-173)."
"BIOTID01362","Chlorpyrifos-oxon","NULL","OTMOUPHCTWPNSL-UHFFFAOYSA-N","InChI=1S/C9H11Cl3NO4P/c1-3-15-18(14,16-4-2)17-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3","CYP2C19; CYP2B6; CYP3A4","Dearylation of organphosphosulfur compound","Human Phase I","Human","3,5,6-Trichloro-2-pyridinol","NULL","WCYYAQFQZQEUEN-UHFFFAOYSA-N","InChI=1S/C5H2Cl3NO/c6-2-1-3(7)5(10)9-4(2)8/h1H,(H,9,10)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01362","Chlorpyrifos-oxon","NULL","OTMOUPHCTWPNSL-UHFFFAOYSA-N","InChI=1S/C9H11Cl3NO4P/c1-3-15-18(14,16-4-2)17-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3","CYP2C19; CYP2B6; CYP3A4","Dearylation of organphosphosulfur compound","Human Phase I","Human","Diethyl phosphate","NULL","UCQFCFPECQILOL-UHFFFAOYSA-N","InChI=1S/C4H11O4P/c1-3-7-9(5,6)8-4-2/h3-4H2,1-2H3,(H,5,6)","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01363","Citalopram","2771","WSEQXVZVJXJVFP-UHFFFAOYNA-N","InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3","CYP2D6","N-oxdation of aliphatic tertiary amine","Human Phase I","Human","Citalopram N-oxide","10068142","DIOGFDCEWUUSBQ-UHFFFAOYSA-N","InChI=1S/C20H21FN2O2/c1-23(2,24)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-25-20/h4-9,12H,3,10-11,14H2,1-2H3","(R) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01364","Citalopram","2771","WSEQXVZVJXJVFP-UHFFFAOYNA-N","InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3","CYP2D6; CYP2C19; CYP3A4","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","N-Desmethylcitalopram","162180","PTJADDMMFYXMMG-UHFFFAOYSA-N","InChI=1S/C19H19FN2O/c1-22-10-2-9-19(16-4-6-17(20)7-5-16)18-8-3-14(12-21)11-15(18)13-23-19/h3-8,11,22H,2,9-10,13H2,1H3","(R) Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01365","D-617","13537153","WLOBUUJURNEQCL-UHFFFAOYNA-N","InChI=1S/C17H26N2O2/c1-13(2)17(12-18,9-6-10-19-3)14-7-8-15(20-4)16(11-14)21-5/h7-8,11,13,19H,6,9-10H2,1-5H3/t17-/m1/s1","CYP3A4; CYP3A5","N-dealkylation of acyclic secondary amine","Human Phase I","Human","D-620","161569","UCWOSFAANAZHKR-UHFFFAOYSA-N","InChI=1S/C16H24N2O2/c1-12(2)16(11-18,8-5-9-17)13-6-7-14(19-3)15(10-13)20-4/h6-7,10,12H,5,8-9,17H2,1-4H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID01366","D-702","29977651","CAAKRPRWCVWYAO-UHFFFAOYNA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28(3)15-12-20-8-10-22(29)24(16-20)31-5/h8-11,16-17,19,29H,7,12-15H2,1-6H3/t26-/m1/s1","CYP3A4; CYP3A5","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","NULL","161569","UCWOSFAANAZHKR-UHFFFAOYSA-N","InChI=1S/C16H24N2O2/c1-12(2)16(11-18,8-5-9-17)13-6-7-14(19-3)15(10-13)20-4/h6-7,10,12H,5,8-9,17H2,1-4H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01367","Dimethoate","3082","MCWXGJITAZMZEV-UHFFFAOYSA-N","InChI=1S/C5H12NO3PS2/c1-6-5(7)4-12-10(11,8-2)9-3/h4H2,1-3H3,(H,6,7)","CYP1A1; CYP1A2; CYP2A6; CYP2B6; CYP2C8; CYP2C9; CYP2C19; CYP3A4","Desulfuration of organophosphorodithioate","Human Phase I","Human","Omethoate","14210","PZXOQEXFMJCDPG-UHFFFAOYSA-N","InChI=1S/C5H12NO4PS/c1-6-5(7)4-12-11(8,9-2)10-3/h4H2,1-3H3,(H,6,7)","Buratti, F.M. and Testai, E. (2007). Evidences for CYP3A4 autoactivation in the desulfuration of dimethoate by the human liver. Toxicology, Vol. 241, No. 1-2, (33-46)."
"BIOTID01368","DEET","4284","MMOXZBCLCQITDF-UHFFFAOYSA-N","InChI=1S/C12H17NO/c1-4-13(5-2)12(14)11-8-6-7-10(3)9-11/h6-9H,4-5H2,1-3H3","CYP1A1; CYP2B6; CYP2D6; CYP2E1","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","N,N-diethyl-m-hydroxymethylbenzamide","4284","MMOXZBCLCQITDF-UHFFFAOYSA-N","InChI=1S/C12H17NO/c1-4-13(5-2)12(14)11-8-6-7-10(3)9-11/h6-9H,4-5H2,1-3H3","Usmani, K.A.; (2002). In vitro human metabolism and interactions of repellent N,N-diethyl-m- toluamide. Drug Metab. Dispos., Vol. 30, No. 3, (289-294)."
"BIOTID01369","DEET","4284","MMOXZBCLCQITDF-UHFFFAOYSA-N","InChI=1S/C12H17NO/c1-4-13(5-2)12(14)11-8-6-7-10(3)9-11/h6-9H,4-5H2,1-3H3","CYP2C19; CYP3A4","N-dealkylation of tertiary carboxamide","Human Phase I","Human","N-ethyl-m-toluamide","93103","FPINATACRXASTP-UHFFFAOYSA-N","InChI=1S/C10H13NO/c1-3-11-10(12)9-6-4-5-8(2)7-9/h4-7H,3H2,1-2H3,(H,11,12)","Usmani, K.A.; (2002). In vitro human metabolism and interactions of repellent N,N-diethyl-m- toluamide. Drug Metab. Dispos., Vol. 30, No. 3, (289-294)."
"BIOTID01369","DEET","4284","MMOXZBCLCQITDF-UHFFFAOYSA-N","InChI=1S/C12H17NO/c1-4-13(5-2)12(14)11-8-6-7-10(3)9-11/h6-9H,4-5H2,1-3H3","CYP2C19; CYP3A4","N-dealkylation of tertiary carboxamide","Human Phase I","Human","acetaldehyde","177","IKHGUXGNUITLKF-UHFFFAOYSA-N","InChI=1S/C2H4O/c1-2-3/h2H,1H3","Usmani, K.A.; (2002). In vitro human metabolism and interactions of repellent N,N-diethyl-m- toluamide. Drug Metab. Dispos., Vol. 30, No. 3, (289-294)."
"BIOTID01370","Diazoxon","13754","VBLJFQYCTRKKKF-UHFFFAOYSA-N","InChI=1S/C12H21N2O4P/c1-6-16-19(15,17-7-2)18-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3","CYP2C19","C-DE-ESTERIFICATION","Human Phase I","Human","Pyrimidinol","17777","AJPIUNPJBFBUKK-UHFFFAOYSA-N","InChI=1S/C8H12N2O/c1-5(2)8-9-6(3)4-7(11)10-8/h4-5H,1-3H3,(H,9,10,11)","Kappers, W.A. et al.; (2001). Diazinon Is Activated by CYP2C19 in Human Liver. Toxicol. Appl. Pharmacol., Vol. 177, No. 1, (68-76)|Buratti, F.M. et al.; Toxicology and Applied Pharmacology 186 (2003) 143Ã¢â‚¬â€œ154."
"BIOTID01371","Diazoxon","13754","VBLJFQYCTRKKKF-UHFFFAOYSA-N","InChI=1S/C12H21N2O4P/c1-6-16-19(15,17-7-2)18-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3","CYP2C19","Dearylation of organphosphosulfur compound","Human Phase I","Human","Diethy phosphate","NULL","UCQFCFPECQILOL-UHFFFAOYSA-N","InChI=1S/C4H11O4P/c1-3-7-9(5,6)8-4-2/h3-4H2,1-2H3,(H,5,6)","Kappers, W.A. et al.; (2001). Diazinon Is Activated by CYP2C19 in Human Liver. Toxicol. Appl. Pharmacol., Vol. 177, No. 1, (68-76)|Buratti, F.M. et al.; Toxicology and Applied Pharmacology 186 (2003) 143Ã¢â‚¬â€œ154."
"BIOTID01372","Disulfoton","3118","DOFZAZXDOSGAJZ-UHFFFAOYSA-N","InChI=1S/C8H19O2PS3/c1-4-9-11(12,10-5-2)14-8-7-13-6-3/h4-8H2,1-3H3","CYP1A2; CYP2B6; CYP2C9; CYP2C18; CYP2C19; CYP2D6; CYP3A4","S-oxidation of dialkylthioether to sulfoxide","Human Phase I","Human","Disulfoton sulfoxide","17242","UPUGLJYNCXXUQV-UHFFFAOYSA-N","InChI=1S/C8H19O3PS3/c1-4-10-12(13,11-5-2)14-7-8-15(9)6-3/h4-8H2,1-3H3","Usmani, K.A.; (2004b). In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab. Dispos., Vol. 32, No. 3, (333-339)."
"BIOTID01373","Diuron","3120","XMTQQYYKAHVGBJ-UHFFFAOYSA-N","InChI=1S/C9H10Cl2N2O/c1-13(2)9(14)12-6-3-4-7(10)8(11)5-6/h3-5H,1-2H3,(H,12,14)","CYP1A1; CYP1A2; CYP2C19; CYP3A4","N-dealkylation of urea","Human Phase I","Human","N-demethyldiuron","19113","IDQHRQQSSQDLTR-UHFFFAOYSA-N","InChI=1S/C8H8Cl2N2O/c1-11-8(13)12-5-2-3-6(9)7(10)4-5/h2-4H,1H3,(H2,11,12,13)","Abass, K. et al. (2007c). Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA- expressed human cytochrome P450 enzymes. Drug Metab. Dispos., Vol. 35, No. 9, (1634-1641)."
"BIOTID01374","donepezil","3152","ADEBPBSSDYVVLD-UHFFFAOYNA-N","InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3","CYP3A4; CYP2C9; CYP2D6","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","2Ã¢â‚¬Â[(1Ã¢â‚¬ÂbenzylpiperidinÃ¢â‚¬Â4Ã¢â‚¬Âyl)methyl]Ã¢â‚¬Â5Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â6Ã¢â‚¬ÂmethoxyÃ¢â‚¬Â2,3Ã¢â‚¬ÂdihydroindenÃ¢â‚¬Â1Ã¢â‚¬Âone","11503234","DSMISVLYMKJMLP-UHFFFAOYSA-N","InChI=1S/C23H27NO3/c1-27-22-14-20-18(13-21(22)25)12-19(23(20)26)11-16-7-9-24(10-8-16)15-17-5-3-2-4-6-17/h2-6,13-14,16,19,25H,7-12,15H2,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01375","donepezil","3152","ADEBPBSSDYVVLD-UHFFFAOYNA-N","InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3","CYP3A4; CYP2C9","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","5,6Ã¢â‚¬ÂdimethoxyÃ¢â‚¬Â2Ã¢â‚¬Â(piperidinÃ¢â‚¬Â4Ã¢â‚¬Âylmethyl)Ã¢â‚¬Â2,3Ã¢â‚¬ÂdihydroindenÃ¢â‚¬Â1Ã¢â‚¬Âone","10446897","PGBZORAISITZTF-UHFFFAOYSA-N","InChI=1S/C17H23NO3/c1-20-15-9-12-8-13(7-11-3-5-18-6-4-11)17(19)14(12)10-16(15)21-2/h9-11,13,18H,3-8H2,1-2H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3676"
"BIOTID01376","donepezil","3152","ADEBPBSSDYVVLD-UHFFFAOYNA-N","InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3","CYP3A4; CYP2C9","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","2Ã¢â‚¬Â[(1Ã¢â‚¬ÂbenzylpiperidinÃ¢â‚¬Â4Ã¢â‚¬Âyl)methyl]Ã¢â‚¬Â6Ã¢â‚¬ÂhydroxyÃ¢â‚¬Â5Ã¢â‚¬ÂmethoxyÃ¢â‚¬Â2,3Ã¢â‚¬ÂdihydroindenÃ¢â‚¬Â1Ã¢â‚¬Âone","14553555","DJRBBQJREIMIEU-UHFFFAOYSA-N","InChI=1S/C23H27NO3/c1-27-22-13-18-12-19(23(26)20(18)14-21(22)25)11-16-7-9-24(10-8-16)15-17-5-3-2-4-6-17/h2-6,13-14,16,19,25H,7-12,15H2,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3677"
"BIOTID01377","Encainide","48041","PJWPNDMDCLXCOM-UHFFFAOYNA-N","InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)","CYP2D6","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","N-demethylencainide","55647","QLMVRMLCNYDKJN-UHFFFAOYSA-N","InChI=1S/C21H26N2O2/c1-25-19-13-10-17(11-14-19)21(24)23-20-8-3-2-6-16(20)9-12-18-7-4-5-15-22-18/h2-3,6,8,10-11,13-14,18,22H,4-5,7,9,12,15H2,1H3,(H,23,24)","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01378","Encainide","48041","PJWPNDMDCLXCOM-UHFFFAOYNA-N","InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)","CYP2D6","O-aryl demethylation","Human Phase I","Human","O-demethylencainide","54736","QMHJFCPHRGVEAF-UHFFFAOYSA-N","InChI=1S/C21H26N2O2/c1-23-15-5-4-7-18(23)12-9-16-6-2-3-8-20(16)22-21(25)17-10-13-19(24)14-11-17/h2-3,6,8,10-11,13-14,18,24H,4-5,7,9,12,15H2,1H3,(H,22,25)","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01379","Esfenvalerate","3347","NYPJDWWKZLNGGM-UHFFFAOYNA-N","InChI=1S/C25H22ClNO3/c1-17(2)24(18-11-13-20(26)14-12-18)25(28)30-23(16-27)19-7-6-10-22(15-19)29-21-8-4-3-5-9-21/h3-15,17,23-24H,1-2H3","CYP2C8; CYP2C9; CYP2C19; CYP3A4; CYP3A5","o-Hydroxylation of monosubstituted benzene","Human Phase I","Human","2'-OH-esfenvalerate","188116","DGQZGRIBSTXBJK-UHFFFAOYSA-N","InChI=1S/C25H22ClNO4/c1-16(2)24(17-10-12-19(26)13-11-17)25(29)31-23(15-27)18-6-5-7-20(14-18)30-22-9-4-3-8-21(22)28/h3-14,16,23-24,28H,1-2H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3677"
"BIOTID01380","Esfenvalerate","3347","NYPJDWWKZLNGGM-UHFFFAOYNA-N","InChI=1S/C25H22ClNO3/c1-17(2)24(18-11-13-20(26)14-12-18)25(28)30-23(16-27)19-7-6-10-22(15-19)29-21-8-4-3-5-9-21/h3-15,17,23-24H,1-2H3","CYP2C8; CYP2C9; CYP2C19; CYP3A4; CYP3A5","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","4'-OH-esfenvalerate","188070","DHTRRTYYQFWHPE-UHFFFAOYSA-N","InChI=1S/C25H22ClNO4/c1-16(2)24(17-6-8-19(26)9-7-17)25(29)31-23(15-27)18-4-3-5-22(14-18)30-21-12-10-20(28)11-13-21/h3-14,16,23-24,28H,1-2H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3677"
"BIOTID01381","N-Desmethylclomipramine","622606","VPIXQGUBUKFLRF-UHFFFAOYSA-N","InChI=1S/C18H21ClN2/c1-20-11-4-12-21-17-6-3-2-5-14(17)7-8-15-9-10-16(19)13-18(15)21/h2-3,5-6,9-10,13,20H,4,7-8,11-12H2,1H3","CYP2C19; CYP3A4; CYP1A2","N-dealkylation of acyclic secondary amine","Human Phase I","Human","N-Didesmethylclomipramine","3085253","LHDZEFLZJRLKPT-UHFFFAOYSA-N","InChI=1S/C17H19ClN2/c18-15-9-8-14-7-6-13-4-1-2-5-16(13)20(11-3-10-19)17(14)12-15/h1-2,4-5,8-9,12H,3,6-7,10-11,19H2","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01382","N-Desmethylclomipramine","622606","VPIXQGUBUKFLRF-UHFFFAOYSA-N","InChI=1S/C18H21ClN2/c1-20-11-4-12-21-17-6-3-2-5-14(17)7-8-15-9-10-16(19)13-18(15)21/h2-3,5-6,9-10,13,20H,4,7-8,11-12H2,1H3","CYP2D6","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","8-OH-N-desmethylclomipramine","NULL","HURXSDYLRQSNES-UHFFFAOYSA-N","InChI=1S/C18H21ClN2O/c1-20-10-3-11-21-16-4-2-5-18(22)15(16)9-7-13-6-8-14(19)12-17(13)21/h2,4-6,8,12,20,22H,3,7,9-11H2,1H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01383","N-demethylencainide","101663689","QLMVRMLCNYDKJN-UHFFFAOYNA-N","InChI=1S/C21H26N2O2/c1-25-19-13-10-17(11-14-19)21(24)23-20-8-3-2-6-16(20)9-12-18-7-4-5-15-22-18/h2-3,6,8,10-11,13-14,18,22H,4-5,7,9,12,15H2,1H3,(H,23,24)/t18-/m0/s1","CYP2D6","O-aryl demethylation","Human Phase I","Human","N,O-didemethylencainide","159040","PAXWCICVMPVYNO-UHFFFAOYSA-N","InChI=1S/C20H24N2O2/c23-18-12-9-16(10-13-18)20(24)22-19-7-2-1-5-15(19)8-11-17-6-3-4-14-21-17/h1-2,5,7,9-10,12-13,17,21,23H,3-4,6,8,11,14H2,(H,22,24)","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01384","O-demethylencainide","54736","QMHJFCPHRGVEAF-UHFFFAOYNA-N","InChI=1S/C21H26N2O2/c1-23-15-5-4-7-18(23)12-9-16-6-2-3-8-20(16)22-21(25)17-10-13-19(24)14-11-17/h2-3,6,8,10-11,13-14,18,24H,4-5,7,9,12,15H2,1H3,(H,22,25)","CYP2D6","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","N,O-didemethylencainide","159040","PAXWCICVMPVYNO-UHFFFAOYSA-N","InChI=1S/C20H24N2O2/c23-18-12-9-16(10-13-18)20(24)22-19-7-2-1-5-15(19)8-11-17-6-3-4-14-21-17/h1-2,5,7,9-10,12-13,17,21,23H,3-4,6,8,11,14H2,(H,22,24)","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01385","Endosulfan-alpha","NULL","RDYMFSUJUZBWLH-KUGKFLLMSA-N","InChI=1S/C9H6Cl6O3S/c10-5-6(11)8(13)4-2-18-19(16)17-1-3(4)7(5,12)9(8,14)15/h3-4H,1-2H2/t3-,4-,7-,8+,19-/m0/s1","CYP2C9; CYP2C19; CYP3A4; CYP3A5; CYP3A7","S-oxidation of organosulfurous compounds","Human Phase I","Human","Endosulfan sulfate","13766812","AAPVQEMYVNZIOO-GXZSMAFLSA-N","InChI=1S/C9H6Cl6O4S/c10-5-6(11)8(13)4-2-19-20(16,17)18-1-3(4)7(5,12)9(8,14)15/h3-4H,1-2H2/t3-,4-,7-,8+/m0/s1","Casabar, R.C.T. (2006). Metabolism of endosulfan- {alpha} by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4. Drug Metab. Dispos., Vol. 34, No. 10, (1779-1785)|Lee, H. 2006). Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms. Drug Metab. Dispos., Vol. 34, No. 7, (1090-1095)."
"BIOTID01386","Fenthion","3346","PNVJTZOFSHSLTO-UHFFFAOYSA-N","InChI=1S/C10H15O3PS2/c1-8-7-9(5-6-10(8)16-4)13-14(15,11-2)12-3/h5-7H,1-4H3","CYP1A2; CYP2B6; CYP2C9; CYP2C19; CYP3A4; CYP3A5","Desulfuration of organophosphothioates","Human Phase I","Human","Fenthion oxon","23046","ZNRZGJAHNMGWQN-UHFFFAOYSA-N","InChI=1S/C10H15O4PS/c1-8-7-9(5-6-10(8)16-4)14-15(11,12-2)13-3/h5-7H,1-4H3","Leoni, C. et al. (2008). The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicol. Appl. Pharmacol., Vol. 233, No. 2, (343-352)."
"BIOTID01387","Flecainide","6604414","DJBNUMBKLMJRSA-LDGXTIHJNA-N","InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)/t11-/m0/s1","CYP2D6","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","2-hydroxy-N-[(piperidin-2-yl)methyl]-5-(2,2,2-trifluoroethoxy)benzamide","NULL","FNWQOVVWANCDDT-UHFFFAOYSA-N","InChI=1S/C15H19F3N2O3/c16-15(17,18)9-23-11-4-5-13(21)12(7-11)14(22)20-8-10-3-1-2-6-19-10/h4-5,7,10,19,21H,1-3,6,8-9H2,(H,20,22)","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01388","Fluoxetine ","3386","RTHCYVBBDHJXIQ-UHFFFAOYSA-N","InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3","CYP2C9 (major); CYP2D6","N-dealkylation of acyclic secondary amine","Human Phase I","Human","Norfluoxetine","4541","WIQRCHMSJFFONW-UHFFFAOYSA-N","InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01389","Fluoxetine ","3386","RTHCYVBBDHJXIQ-UHFFFAOYSA-N","InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3","CYP2C19; CYP3A4","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","p-Trifluoromethylphenol","67874","BAYGVMXZJBFEMB-UHFFFAOYSA-N","InChI=1S/C7H5F3O/c8-7(9,10)5-1-3-6(11)4-2-5/h1-4,11H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01390","lansoprazole","3883","MJIHNNLFOKEZEW-RUZDIDTESA-N","InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)","CYP3A4","S-Oxidation","Human Phase I","Human","NULL","10385385","TVMJMCGRSSSSDJ-UHFFFAOYSA-N","InChI=1S/C16H14F3N3O3S/c1-10-13(20-7-6-14(10)25-9-16(17,18)19)8-26(23,24)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)","PMID:12975331"
"BIOTID01391","lansoprazole","3883","MJIHNNLFOKEZEW-RUZDIDTESA-N","InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)","CYP2C9;CYP2C19;CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","NULL","9800271","IDCLTMRSSAXUNY-UHFFFAOYSA-N","InChI=1S/C16H14F3N3O3S/c1-9-13(20-5-4-14(9)25-8-16(17,18)19)7-26(24)15-21-11-3-2-10(23)6-12(11)22-15/h2-6,23H,7-8H2,1H3,(H,21,22)","PMID:12975331"
"BIOTID01392","Gavestinel","6450546","WZBNEZWCNKUOSM-VOTSOKGWSA-N","InChI=1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)/b7-6+","CYP2C9","Hydroxylation of benzene on carbon para to an electron donating group","Human Phase I","Human","p-OH-gavestinel","10548468","KAIGNSIVVAINPQ-AATRIKPKSA-N","InChI=1S/C18H12Cl2N2O4/c19-9-7-13(20)16-12(17(18(25)26)22-14(16)8-9)5-6-15(24)21-10-1-3-11(23)4-2-10/h1-8,22-23H,(H,21,24)(H,25,26)/b6-5+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01393","Gliclazide","3475","BOVGTQGAOIONJV-UHFFFAOYNA-N","InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)","CYP2C9","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","7-OH-gliclazide","131750725","JMHDCYDSYHLATB-UHFFFAOYSA-N","InChI=1S/C15H21N3O4S/c1-10-2-4-14(5-3-10)23(21,22)17-15(20)16-18-8-11-6-13(19)7-12(11)9-18/h2-5,11-13,19H,6-9H2,1H3,(H2,16,17,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01394","Gliclazide","3475","BOVGTQGAOIONJV-UHFFFAOYNA-N","InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)","CYP2C9; CYP2C19","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","Methylhydroxygliclazide","192219","IHCHVBQHVIUSTM-UHFFFAOYSA-N","InChI=1S/C15H21N3O4S/c19-10-11-4-6-14(7-5-11)23(21,22)17-15(20)16-18-8-12-2-1-3-13(12)9-18/h4-7,12-13,19H,1-3,8-10H2,(H2,16,17,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3676"
"BIOTID01395","Gliclazide","3475","BOVGTQGAOIONJV-UHFFFAOYNA-N","InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)","CYP2C9","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","6-OH-gliclazide","75051323","VUUZEWXIRFGRFE-UHFFFAOYSA-N","InChI=1S/C15H21N3O4S/c1-10-2-5-12(6-3-10)23(21,22)17-15(20)16-18-8-11-4-7-14(19)13(11)9-18/h2-3,5-6,11,13-14,19H,4,7-9H2,1H3,(H2,16,17,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3677"
"BIOTID01396","Glimepiride","3476","WIGIZIANZCJQQY-UHFFFAOYSA-N","InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)","CYP2C9","Hydroxylation of terminal methyl","Human Phase I","Human","Cyclohexylhydroymethylglimepiride","130939","YUNQMQLWOOVHKI-UHFFFAOYSA-N","InChI=1S/C24H34N4O6S/c1-3-21-16(2)14-28(22(21)30)24(32)25-13-12-17-6-10-20(11-7-17)35(33,34)27-23(31)26-19-8-4-18(15-29)5-9-19/h6-7,10-11,18-19,29H,3-5,8-9,12-15H2,1-2H3,(H,25,32)(H2,26,27,31)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3678"
"BIOTID01397","Glipizide","3478","ZJJXGWJIGJFDTL-UHFFFAOYSA-N","InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)","CYP2C9","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","4-trans-OH-glipizide","131769999","WPQWQJBFAJEUHS-UHFFFAOYSA-N","InChI=1S/C21H27N5O5S/c1-14-12-24-19(13-23-14)20(28)22-11-10-15-2-8-18(9-3-15)32(30,31)26-21(29)25-16-4-6-17(27)7-5-16/h2-3,8-9,12-13,16-17,27H,4-7,10-11H2,1H3,(H,22,28)(H2,25,26,29)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3679"
"BIOTID01398","Hydromorphone","5284570","WVLOADHCBXTIJK-YNHQPCIGSA-N","InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1","CYP3A4; CYP2C9; CYP2D6","N-dealkylation of mixed tertiary amine","Human Phase I","Human","Norhydromorphone","10355824","SWIRXSKBBSJXGY-UIHHKEIPSA-N","InChI=1S/C16H17NO3/c18-11-3-1-8-7-10-9-2-4-12(19)15-16(9,5-6-17-10)13(8)14(11)20-15/h1,3,9-10,15,17-18H,2,4-7H2/t9-,10+,15-,16-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01399","R-Ibuprofen","114864","HEFNNWSXXWATRW-SNVBAGLBSA-N","InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m1/s1","CYP2C8; CYP2C9","Hydroxylation of terminal methyl","Human Phase I","Human","R,S-3-Hydroxyibuprofen","NULL","HFAIHLSDLUYLQA-QVDQXJPCSA-N","InChI=1S/C13H18O3/c1-9(8-14)7-11-3-5-12(6-4-11)10(2)13(15)16/h3-6,9-10,14H,7-8H2,1-2H3,(H,15,16)/t9?,10-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01400","R-Ibuprofen","114864","HEFNNWSXXWATRW-SNVBAGLBSA-N","InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m1/s1","CYP2C8; CYP2C9","Hydroxylation of alkyl methine","Human Phase I","Human","R-2-Hydroxyibuprofen","29981596","UJHKVYPPCJBOSG-SECBINFHSA-N","InChI=1S/C13H18O3/c1-9(12(14)15)11-6-4-10(5-7-11)8-13(2,3)16/h4-7,9,16H,8H2,1-3H3,(H,14,15)/t9-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3677"
"BIOTID01401","Lansoprazole","NULL","DQJZOUNZNYHEBV-AREMUKBSSA-N","InChI=1S/C17H16F3N3O2S/c1-10-7-15(25-9-17(18,19)20)11(2)14(21-10)8-26(24)16-22-12-5-3-4-6-13(12)23-16/h3-7H,8-9H2,1-2H3,(H,22,23)/t26-/m1/s1","CYP2C19; CYP2C9; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","Hydroxylansoprazole","NULL","GJTJOZQYAJLAKN-HHHXNRCGSA-N","InChI=1S/C17H16F3N3O3S/c1-9-6-14(26-8-17(18,19)20)10(2)12(21-9)7-27(25)16-22-11-4-3-5-13(24)15(11)23-16/h3-6,24H,7-8H2,1-2H3,(H,22,23)/t27-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01402","Lansoprazole","NULL","DQJZOUNZNYHEBV-AREMUKBSSA-N","InChI=1S/C17H16F3N3O2S/c1-10-7-15(25-9-17(18,19)20)11(2)14(21-10)8-26(24)16-22-12-5-3-4-6-13(12)23-16/h3-7H,8-9H2,1-2H3,(H,22,23)/t26-/m1/s1","CYP3A4","S-oxidation of sulfoxide to sulfone","Human Phase I","Human","Lansoprazole sulfone","NULL","PQOKUEVEGVMXIV-UHFFFAOYSA-N","InChI=1S/C17H16F3N3O3S/c1-10-7-15(26-9-17(18,19)20)11(2)14(21-10)8-27(24,25)16-22-12-5-3-4-6-13(12)23-16/h3-7H,8-9H2,1-2H3,(H,22,23)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3676"
"BIOTID01403","Imidacloprid","86418","YWTYJOPNNQFBPC-UHFFFAOYSA-N","InChI=1S/C9H10ClN5O2/c10-8-2-1-7(5-12-8)6-14-4-3-11-9(14)13-15(16)17/h1-2,5H,3-4,6H2,(H,11,13)","CYP2B6; CYP2D6; CYP2E1; CYP3A4","Reduction of nitroimine","Human Phase I","Human","NULL","183033","BGJQJWBDOOIKPP-UHFFFAOYSA-N","InChI=1S/C9H10ClN5O/c10-8-2-1-7(5-12-8)6-15-4-3-11-9(15)13-14-16/h1-2,5H,3-4,6H2,(H,11,13,16)","Schulz-Jander, D.A. and Casida, J.E. (2002). Imidacloprid insecticide metabolism: human cytochrome P450 isozymes differ in selectivity for imidazolidine oxidation versus nitroimine reduction. Toxicol. Lett., Vol. 132, No. 1, (65-70)."
"BIOTID01404","Linoleic acid","5280450","OYHQOLUKZRVURQ-HZJYTTRNSA-N","InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-","CYP2C9; CYP2C19","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","Leukotoxin","6246154","FBUKMFOXMZRGRB-YFHOEESVSA-N","InChI=1S/C18H32O3/c1-2-3-4-5-7-10-13-16-17(21-16)14-11-8-6-9-12-15-18(19)20/h7,10,16-17H,2-6,8-9,11-15H2,1H3,(H,19,20)/b10-7-","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01405","Linoleic acid","5280450","OYHQOLUKZRVURQ-HZJYTTRNSA-N","InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-","CYP2C9; CYP2C19","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","Isoleukotoxin","5356421","CCPPLLJZDQAOHD-FLIBITNWSA-N","InChI=1S/C18H32O3/c1-2-3-10-13-16-17(21-16)14-11-8-6-4-5-7-9-12-15-18(19)20/h8,11,16-17H,2-7,9-10,12-15H2,1H3,(H,19,20)/b11-8-","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01406","Lithocholic Acid","9903","SMEROWZSTRWXGI-ZQMJQECZNA-N","InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1","CYP3A4","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","6ÃŽÂ±-Hydroxylithocholic acid","5283820","DGABKXLVXPYZII-SIBKNCMHSA-N","InChI=1S/C24H40O4/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16+,17-,18+,19+,20+,21+,23-,24-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01407","Lumiracoxib","151166","KHPKQFYUPIUARC-UHFFFAOYSA-N","InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)","CYP2C9; CYP2C19","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","Lumiracoxib metabolite 1","NULL","PREBINJQDJNORC-UHFFFAOYSA-N","InChI=1S/C15H13ClFNO3/c16-11-2-1-3-12(17)15(11)18-13-5-4-9(8-19)6-10(13)7-14(20)21/h1-6,18-19H,7-8H2,(H,20,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01408","Lumiracoxib","151166","KHPKQFYUPIUARC-UHFFFAOYSA-N","InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)","CYP2C9; CYP2C19","Hydroxylation of aromatic carbon meta to halide group","Human Phase I","Human","Lumiracoxib metabolite 2","9904747","LUNFHOZKXHTOLG-UHFFFAOYSA-N","InChI=1S/C15H13ClFNO3/c1-8-2-3-13(9(4-8)5-14(20)21)18-15-11(16)6-10(19)7-12(15)17/h2-4,6-7,18-19H,5H2,1H3,(H,20,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01409","M7","101944494","SGLAKMDXJPVHBY-UHFFFAOYNA-N","InChI=1S/C25H28N6O2/c1-2-3-8-22-26-25(14-13-19(32)15-25)24(33)31(22)16-17-9-11-18(12-10-17)20-6-4-5-7-21(20)23-27-29-30-28-23/h4-7,9-12,19,32H,2-3,8,13-16H2,1H3,(H,27,28,29,30)","CYP2C9","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","M1","101944491","LIDZWACDVHJFLD-UHFFFAOYSA-N","InChI=1S/C25H28N6O3/c1-16(32)6-11-22-26-25(13-12-19(33)14-25)24(34)31(22)15-17-7-9-18(10-8-17)20-4-2-3-5-21(20)23-27-29-30-28-23/h2-5,7-10,16,19,32-33H,6,11-15H2,1H3,(H,27,28,29,30)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675"
"BIOTID01410","Malathion","12358970","JXSJBGJIGXNWCI-SVGMAFHSNA-N","InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3/t8-/m1/s1","CYP1A2; CYP2B6; CYP2C19; CYP3A4","Desulfuration of organophosphorodithioate","Human Phase I","Human","Maloxon","15415","WSORODGWGUUOBO-UHFFFAOYSA-N","InChI=1S/C10H19O7PS/c1-5-16-9(11)7-8(10(12)17-6-2)19-18(13,14-3)15-4/h8H,5-7H2,1-4H3","Buratti, F.M. et al. (2005). Malathion bioactivation in the human liver liver: The contribution of different cytochrome P450 isoform. Drug Metab. Dispos., Vol. 33, No. 3, (295-302)."
"BIOTID01411","Mianserine","4184","UEQUQVLFIPOEMF-UHFFFAOYNA-N","InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3","CYP2D6 (major; (major, RÃ¢â€°Ë†S)); CYP2B6 (R>S); CYP3A4  (S>R) ","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","8-Hydroxymianserin","162817","YTMQIPGEXLWJTN-UHFFFAOYSA-N","InChI=1S/C18H20N2O/c1-19-8-9-20-17-7-6-15(21)11-14(17)10-13-4-2-3-5-16(13)18(20)12-19/h2-7,11,18,21H,8-10,12H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01412","Mianserine","4184","UEQUQVLFIPOEMF-UHFFFAOYNA-N","InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3","CYP2B6 (R>S); CYP3A4 (R>S); CYP2C19 (R>S); CYP1A2 (RÃ¢â€°Ë†S)","N-dealkylation of alicyclic tertiary amine","Human Phase I","Human","Desmethylmianserin","115194","ZBILSSSEXRZGKS-UHFFFAOYSA-N","InChI=1S/C17H18N2/c1-3-7-15-13(5-1)11-14-6-2-4-8-16(14)19-10-9-18-12-17(15)19/h1-8,17-18H,9-12H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01413","Mianserine","4184","UEQUQVLFIPOEMF-UHFFFAOYNA-N","InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3","CYP3A4 (RÃ¢â€°Ë†S); CYP1A2 (S>R)","N-oxidation of alicyclic tertiary amine","Human Phase I","Human","Mianserin N-oxide","3085244","VVDXWJOYXVNLLQ-UHFFFAOYSA-N","InChI=1S/C18H20N2O/c1-20(21)11-10-19-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(19)13-20/h2-9,18H,10-13H2,1H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01414","Mirtazapine","4205","RONZAEMNMFQXRA-UHFFFAOYNA-N","InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3","CYP1A2; CYP2D6; CYP3A4","N-oxidation of alicyclic tertiary amine","Human Phase I","Human","Mirtazapine N-oxide","46782381","GAFCUVMEBFTFQJ-UHFFFAOYSA-N","InChI=1S/C17H19N3O/c1-20(21)10-9-19-16(12-20)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)19/h2-8,16H,9-12H2,1H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01415","Mirtazapine","4205","RONZAEMNMFQXRA-UHFFFAOYNA-N","InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3","CYP1A2; CYP2D6; CYP3A4","N-dealkylation of mixed tertiary amine","Human Phase I","Human","N-Desmethylmirtazapine","10467350","FGLAMNFOHWVQOH-UHFFFAOYSA-N","InChI=1S/C16H17N3/c1-2-6-14-12(4-1)10-13-5-3-7-18-16(13)19-9-8-17-11-15(14)19/h1-7,15,17H,8-11H2","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01416","Mirtazapine","4205","RONZAEMNMFQXRA-UHFFFAOYNA-N","InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3","CYP1A2; CYP2D6; CYP3A4","HYDROXYLATION_OF_HETEROAROMATIC_CARBON","Human Phase I","Human","8-OH-mirtazapine","NULL","WKBHWUSDTGYZBT-UHFFFAOYSA-N","InChI=1S/C17H19N3O/c1-19-8-9-20-15(11-19)14-5-3-2-4-12(14)10-13-6-7-16(21)18-17(13)20/h2-7,15H,8-11H2,1H3,(H,18,21)","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01417","(-)-Menthol","16666","NOOLISFMXDJSKH-KXUCPTDWSA-N","InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1","CYP2A6","Hydroxylation of alkyl methine","Human Phase I","Human","p-Menthane-3,-8-diol","19100","LMXFTMYMHGYJEI-IWSPIJDZSA-N","InChI=1S/C10H20O2/c1-7-4-5-8(9(11)6-7)10(2,3)12/h7-9,11-12H,4-6H2,1-3H3/t7-,8-,9-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01418","Mestranol","6291","IMSSROKUHAOUJS-MJCUULBUSA-N","InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1","CYP2C9","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Ethinylestradiol","5991","BFPYWIDHMRZLRN-SLHNCBLASA-N","InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01419","Methoxychlor","4115","IAKOZHOLGAGEJT-UHFFFAOYSA-N","InChI=1S/C16H15Cl3O2/c1-20-13-7-3-11(4-8-13)15(16(17,18)19)12-5-9-14(21-2)10-6-12/h3-10,15H,1-2H3","CYP1A2; CYP2A6; CYP2B6; CYP2C8; CYP2C9; CYP2D6; CYP2C19; CYP3A4","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Mono-OH-methoxychlor","183679","BUZUQNXGKRJIJT-UHFFFAOYSA-N","InChI=1S/C15H13Cl3O2/c1-20-13-8-4-11(5-9-13)14(15(16,17)18)10-2-6-12(19)7-3-10/h2-9,14,19H,1H3","Hu, Y. and Kupfer, D. (2002); Metabolism of the Endocrine Disruptor Pesticide-Methoxychlor by Human P450s: Pathways Involving a Novel Catechol Metabolite; Drug Metab Dispos. 2002 Sep;30(9):1035-42."
"BIOTID01420","Mono-OH-methoxychlor","13590210","BUZUQNXGKRJIJT-YQTOOIBONA-N","InChI=1S/C15H13Cl3O2/c1-20-13-8-4-11(5-9-13)14(15(16,17)18)10-2-6-12(19)7-3-10/h2-9,14,19H,1H3/t14-/m0/s1","CYP2B6; CYP3A4; CYP3A5","o-Hydroxylation of phenol","Human Phase I","Human","Catechol-methoxychlor","NULL","CFAVOGVJXCIQLR-UHFFFAOYSA-N","InChI=1S/C15H13Cl3O3/c1-21-11-5-2-9(3-6-11)14(15(16,17)18)10-4-7-12(19)13(20)8-10/h2-8,14,19-20H,1H3","Hu, Y. and Kupfer, D. (2002); Metabolism of the Endocrine Disruptor Pesticide-Methoxychlor by Human P450s: Pathways Involving a Novel Catechol Metabolite; Drug Metab Dispos. 2002 Sep;30(9):1035-42."
"BIOTID01421","Mono-OH-methoxychlor","13590210","BUZUQNXGKRJIJT-YQTOOIBONA-N","InChI=1S/C15H13Cl3O2/c1-20-13-8-4-11(5-9-13)14(15(16,17)18)10-2-6-12(19)7-3-10/h2-9,14,19H,1H3/t14-/m0/s1","CYP1A2; CYP2C8; CYP2C19; CYP2D6","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","Bis-OH-methoxychlor","76302","IUGDILGOLSSKNE-UHFFFAOYSA-N","InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Hu, Y. and Kupfer, D. (2002); Metabolism of the Endocrine Disruptor Pesticide-Methoxychlor by Human P450s: Pathways Involving a Novel Catechol Metabolite; Drug Metab Dispos. 2002 Sep;30(9):1035-42."
"BIOTID01422","Monodemethylated mifepristone","10070462","IBLXOBHABOVXDY-WKWWZUSTSA-N","InChI=1S/C28H33NO2/c1-4-14-28(31)15-13-25-23-11-7-19-16-21(30)10-12-22(19)26(23)24(17-27(25,28)2)18-5-8-20(29-3)9-6-18/h5-6,8-9,16,23-25,29,31H,7,10-13,15,17H2,1-3H3/t23-,24+,25-,27-,28-/m0/s1","CYP3A4","N-dealkylation of secondary arylalkylamine","Human Phase I","Human","Didemethylated mifepristone","16654965","MIPBCIAEOBOEKD-YEEPMTPTSA-N","InChI=1S/C27H31NO2/c1-3-13-27(30)14-12-24-22-10-6-18-15-20(29)9-11-21(18)25(22)23(16-26(24,27)2)17-4-7-19(28)8-5-17/h4-5,7-8,15,22-24,30H,6,9-12,14,16,28H2,1-2H3/t22-,23+,24-,26-,27-/m0/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Khan, K. K. et al. (2002); Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation; Mol. Pharmacol. 61:495Ã¢â‚¬â€œ506|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996017"
"BIOTID01423","Bis-OH-methoxychlor","76302","IUGDILGOLSSKNE-UHFFFAOYSA-N","InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","CYP3A4","o-Hydroxylation of phenol","Human Phase I","Human","Tris-OH-methoxychlor","183678","TUYRXLVIBHDPDA-UHFFFAOYSA-N","InChI=1S/C14H11Cl3O3/c15-14(16,17)13(8-1-4-10(18)5-2-8)9-3-6-11(19)12(20)7-9/h1-7,13,18-20H","Hu, Y. and Kupfer, D. (2002); Metabolism of the Endocrine Disruptor Pesticide-Methoxychlor by Human P450s: Pathways Involving a Novel Catechol Metabolite; Drug Metab Dispos. 2002 Sep;30(9):1035-42."
"BIOTID01424","methadone","4095","USSIQXCVUWKGNF-UHFFFAOYNA-N","InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3","CYP2D6; CYP3A4 (major); CYP2B6; CYP2C8; CYP2C19","N-dealkylation of acyclic tertiary amine","Human Phase I","Human","2ethylidene-1,5-dimethyl-3,3-diphenylpyrolidine","NULL","DDUXMJACVBEYOX-UHFFFAOYSA-N","InChI=1S/C20H25N/c1-4-19-16(2)21(3)15-20(19,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,16,19H,4,15H2,1-3H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01426","Monoethylglycinexylidide","24415","WRMRXPASUROZGT-UHFFFAOYSA-N","InChI=1S/C12H18N2O/c1-4-13-8-11(15)14-12-9(2)6-5-7-10(12)3/h5-7,13H,4,8H2,1-3H3,(H,14,15)","CYP1A2; CYP2D6; CYP3A4","HYDROXYLATION_OF_AROMATIC_CARBON","Human Phase I","Human","3-Hydroxymonoethyl glycinexylidide","3015693","YITCMQBVWIHTTA-UHFFFAOYSA-N","InChI=1S/C12H18N2O2/c1-4-13-7-11(16)14-12-8(2)5-6-10(15)9(12)3/h5-6,13,15H,4,7H2,1-3H3,(H,14,16)","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01427","Monoethylglycinexylidide","24415","WRMRXPASUROZGT-UHFFFAOYSA-N","InChI=1S/C12H18N2O/c1-4-13-8-11(15)14-12-9(2)6-5-7-10(12)3/h5-7,13H,4,8H2,1-3H3,(H,14,15)","CYP1A2; CYP3A4","N-dealkylation of acyclic secondary amine","Human Phase I","Human","Glycinexylidide","87833","IXYVBZOSGGJWCW-UHFFFAOYSA-N","InChI=1S/C10H14N2O/c1-7-4-3-5-8(2)10(7)12-9(13)6-11/h3-5H,6,11H2,1-2H3,(H,12,13)","Zhou, S-F.; (2016); Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism; Edited by CRC Press; ISBN 9781466597884 - CAT# KE23693"
"BIOTID01428","N-Desmethyldiphenhydramine","40791","AGSLYHYWLYGAOU-UHFFFAOYSA-N","InChI=1S/C16H19NO/c1-17-12-13-18-16(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-11,16-17H,12-13H2,1H3","CYP2D6; CYP1A2; CYP2C9; CYP2C19","N-dealkylation of acyclic secondary amine","Human Phase I","Human","N,N-Didesmethyldiphenhydramine","36060","NFJFUDGBWGXTHS-UHFFFAOYSA-N","InChI=1S/C15H17NO/c16-11-12-17-15(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10,15H,11-12,16H2","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01429","N-Desmethylmianserin","153935","ZBILSSSEXRZGKS-KRWDZBQOSA-N","InChI=1S/C17H18N2/c1-3-7-15-13(5-1)11-14-6-2-4-8-16(14)19-10-9-18-12-17(15)19/h1-8,17-18H,9-12H2/t17-/m0/s1","CYP2D6; CYP1A2; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","(R)-mianserin, 8-OH-N-desmethyl","NULL","KDLZTAPNHXUVCE-KRWDZBQOSA-N","InChI=1S/C17H18N2O/c20-14-6-5-13-9-12-3-1-2-4-15(12)17-11-18-7-8-19(17)16(13)10-14/h1-6,10,17-18,20H,7-9,11H2/t17-/m0/s1","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01430","N-Desmethyltamoxifen","6378383","NYDCDZSEEAUOHN-IZHYLOQSSA-N","InChI=1S/C25H27NO/c1-3-24(20-10-6-4-7-11-20)25(21-12-8-5-9-13-21)22-14-16-23(17-15-22)27-19-18-26-2/h4-17,26H,3,18-19H2,1-2H3/b25-24-","CYP3A4; CYP3A5","N-dealkylation of acyclic secondary amine","Human Phase I","Human","N-Desdimethyltamoxifen","3036172","MCJKBWHDNUSJLW-VHXPQNKSSA-N","InChI=1S/C24H25NO/c1-2-23(19-9-5-3-6-10-19)24(20-11-7-4-8-12-20)21-13-15-22(16-14-21)26-18-17-25/h3-16H,2,17-18,25H2,1H3/b24-23-","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01431","N-Desmethyltamoxifen","6378383","NYDCDZSEEAUOHN-IZHYLOQSSA-N","InChI=1S/C25H27NO/c1-3-24(20-10-6-4-7-11-20)25(21-12-8-5-9-13-21)22-14-16-23(17-15-22)27-19-18-26-2/h4-17,26H,3,18-19H2,1-2H3/b25-24-","CYP2D6","p-Hydroxylation of monosubstituted benzene","Human Phase I","Human","Endoxifen","10090750","MHJBZVSGOZTKRH-IZHYLOQSSA-N","InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01432","N-Desmethyltamoxifen","6378383","NYDCDZSEEAUOHN-IZHYLOQSSA-N","InChI=1S/C25H27NO/c1-3-24(20-10-6-4-7-11-20)25(21-12-8-5-9-13-21)22-14-16-23(17-15-22)27-19-18-26-2/h4-17,26H,3,18-19H2,1-2H3/b25-24-","CYP3A4; CYP3A5","Hydroxylation of penultimate aliphatic secondary carbon","Human Phase I","Human","alpha-OH-N-desmethyltamoxifen","10474509","GREXPZNIZPCGIV-IZHYLOQSSA-N","InChI=1S/C25H27NO2/c1-19(27)24(20-9-5-3-6-10-20)25(21-11-7-4-8-12-21)22-13-15-23(16-14-22)28-18-17-26-2/h3-16,19,26-27H,17-18H2,1-2H3/b25-24-","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01433","N-methyl-3,4methylenedioxyamphetamine ","1615","SHXWCVYOXRDMCX-UHFFFAOYNA-N","InChI=1S/C11H15NO2/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10/h3-4,6,8,12H,5,7H2,1-2H3","CYP2D6; CYP1A2 ","Methylenedioxy ring opening","Human Phase I","Human","N-Methyl-3,4dihydroxyamphetamine ","161126","NTCPGTZTPGFNOM-UHFFFAOYSA-N","InChI=1S/C10H15NO2/c1-7(11-2)5-8-3-4-9(12)10(13)6-8/h3-4,6-7,11-13H,5H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01434","1-Naphtaldehyde","6195","SQAINHDHICKHLX-UHFFFAOYSA-N","InChI=1S/C11H8O/c12-8-10-6-3-5-9-4-1-2-7-11(9)10/h1-8H","CYP3A4","Reduction of aldehyde to alcohol","Human Phase I","Human","1-Nahthalenethanol","20908","PBLNHHSDYFYZNC-UHFFFAOYSA-N","InChI=1S/C11H10O/c12-8-10-6-3-5-9-4-1-2-7-11(9)10/h1-7,12H,8H2","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01435","1-Naphtaldehyde","6195","SQAINHDHICKHLX-UHFFFAOYSA-N","InChI=1S/C11H8O/c12-8-10-6-3-5-9-4-1-2-7-11(9)10/h1-8H","CYP3A4","Aldehyde oxidation","Human Phase I","Human","1-Naphthoic acid","6847","LNETULKMXZVUST-UHFFFAOYSA-N","InChI=1S/C11H8O2/c12-11(13)10-7-3-5-8-4-1-2-6-9(8)10/h1-7H,(H,12,13)","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01436","Nateglinide","4443","OELFLUMRDSZNSF-UHFFFAOYNA-N","InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)","CYP2C9; CYP3A4","Hydroxylation of terminal methyl","Human Phase I","Human","2Ã¢â‚¬Â{[4Ã¢â‚¬Â(1Ã¢â‚¬ÂhydroxypropanÃ¢â‚¬Â2Ã¢â‚¬Âyl)cyclohexyl]formamido}Ã¢â‚¬Â3Ã¢â‚¬Âphenylpropanoic acid","NULL","GMHTWYIGIMINLF-UHFFFAOYSA-N","InChI=1S/C19H27NO4/c1-13(12-21)15-7-9-16(10-8-15)18(22)20-17(19(23)24)11-14-5-3-2-4-6-14/h2-6,13,15-17,21H,7-12H2,1H3,(H,20,22)(H,23,24)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01437","Nateglinide","4443","OELFLUMRDSZNSF-UHFFFAOYNA-N","InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)","CYP2C9; CYP3A4","Hydroxylation of penultimate aliphatic tertiary carbon","Human Phase I","Human","2Ã¢â‚¬Â{[4Ã¢â‚¬Â(2Ã¢â‚¬ÂhydroxypropanÃ¢â‚¬Â2Ã¢â‚¬Âyl)cyclohexyl]formamido}Ã¢â‚¬Â3Ã¢â‚¬Âphenylpropanoic acid","NULL","IUMHIIXPABZGRF-UHFFFAOYSA-N","InChI=1S/C19H27NO4/c1-19(2,24)15-10-8-14(9-11-15)17(21)20-16(18(22)23)12-13-6-4-3-5-7-13/h3-7,14-16,24H,8-12H2,1-2H3,(H,20,21)(H,22,23)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01438","Nicardipine","4474","ZBBHBTPTTSWHBA-UHFFFAOYNA-N","InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3","CYP2C8; CYP3A4","N_DEALKYLATION_OF_ALIPHATIC_TERTIARY_AMINES_PATTERN1; N_DEALKYLATION_OF_ACYCLIC_TERTIARY_AMINES","Human Phase I","Human","De-benzylated nicardipine","12529164","ZYQSJVQRWNAWHO-UHFFFAOYSA-N","InChI=1S/C19H23N3O6/c1-11-15(18(23)27-4)17(13-6-5-7-14(10-13)22(25)26)16(12(2)21-11)19(24)28-9-8-20-3/h5-7,10,17,20-21H,8-9H2,1-4H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01439","Nicardipine","4474","ZBBHBTPTTSWHBA-UHFFFAOYNA-N","InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3","CYP1A1; CYP1A2; CYP2C8; CYP2D6; CYP2E1; CYP3A4; CYP3A5","Dehydrogenation of 4-aryl substituted 1,4-dihydropyridine","Human Phase I","Human","Dehydronicardipine","3017161","GROZWIBBDLLXKU-UHFFFAOYSA-N","InChI=1S/C26H27N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15H,13-14,16H2,1-4H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01440","Nordoxepin","5353833","HVKCEFHNSNZIHO-YBEGLDIGSA-N","InChI=1S/C18H19NO/c1-19-12-6-10-16-15-8-3-2-7-14(15)13-20-18-11-5-4-9-17(16)18/h2-5,7-11,19H,6,12-13H2,1H3/b16-10-","CYP2D6","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","2-Hydroxynordoxepin","NULL","VOSZEQAEJIINHX-GIDUJCDVSA-N","InChI=1S/C18H19NO2/c1-19-10-4-6-15-16-5-2-3-7-18(16)21-12-13-8-9-14(20)11-17(13)15/h2-3,5-9,11,19-20H,4,10,12H2,1H3/b15-6+","Musshoff F. et al. (2010); Pharmacogenetics and forensic toxicology; Forensic Sci Int.; 203, 53-62. DOI:doi:10.1016/j.forsciint.2010.07.011"
"BIOTID01441","Norverapamil","15593907","UPKQNCPKPOLASS-UHFFFAOYNA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1","CYP2C8; CYP3A4; CYP2D6","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","D-715 (PR-22)","90238777","OGPWXYNEWNCFSU-UHFFFAOYSA-N","InChI=1S/C25H34N2O4/c1-18(2)25(17-26,20-8-10-22(29-3)24(16-20)31-5)12-6-13-27-14-11-19-7-9-21(28)23(15-19)30-4/h7-10,15-16,18,27-28H,6,11-14H2,1-5H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID01442","Norverapamil","15593907","UPKQNCPKPOLASS-UHFFFAOYNA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1","CYP2C8; CYP3A4; CYP2D6","N-dealkylation of acyclic secondary amine","Human Phase I","Human","D-620","161569","UCWOSFAANAZHKR-UHFFFAOYSA-N","InChI=1S/C16H24N2O2/c1-12(2)16(11-18,8-5-9-17)13-6-7-14(19-3)15(10-13)20-4/h6-7,10,12H,5,8-9,17H2,1-4H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID01442","Norverapamil","15593907","UPKQNCPKPOLASS-UHFFFAOYNA-N","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1","CYP2C8; CYP3A4; CYP2D6","N-dealkylation of acyclic secondary amine","Human Phase I","Human","2-(3,4-dimethoxyphenyl)acetaldehyde","NULL","RIVVYJWUHXMGSK-UHFFFAOYSA-N","InChI=1S/C10H12O3/c1-12-9-4-3-8(5-6-11)7-10(9)13-2/h3-4,6-7H,5H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Tracy, T.S. et al. (1999); Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil; Br J Clin Pharmacol. 1999 May; 47(5): 545Ã¢â‚¬â€œ552; DOI:10.1046/j.1365-2125.1999.00923.x|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423"
"BIOTID01443","omeprazole","4594","SUBDBMMJDZJVOS-UHFFFAOYNA-N","InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)","CYP3A4","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","3-Hydroxyomeprazole","71587579","IGVYIWUGJPECAJ-UHFFFAOYSA-N","InChI=1S/C17H19N3O4S/c1-10-7-18-15(12(8-21)16(10)24-3)9-25(22)17-19-13-5-4-11(23-2)6-14(13)20-17/h4-7,21H,8-9H2,1-3H3,(H,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01444","omeprazole","4594","SUBDBMMJDZJVOS-UHFFFAOYNA-N","InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)","CYP2C19; CYP3A4; CYP2C9","Aliphatic hydroxylation of methyl carbon adjacent to aromatic ring","Human Phase I","Human","5-Hydroxyomeprazole","119560","CMZHQFXXAAIBKE-UHFFFAOYSA-N","InChI=1S/C17H19N3O4S/c1-10-15(18-7-11(8-21)16(10)24-3)9-25(22)17-19-13-5-4-12(23-2)6-14(13)20-17/h4-7,21H,8-9H2,1-3H3,(H,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01445","omeprazole","4594","SUBDBMMJDZJVOS-UHFFFAOYNA-N","InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)","CYP2C19","O-aryl dealkylation not adjacent to substituted carbon","Human Phase I","Human","5'-O-Desmethyl omeprazole","10404448","TWXDTVZNDQKCOS-UHFFFAOYSA-N","InChI=1S/C16H17N3O3S/c1-9-7-17-14(10(2)15(9)22-3)8-23(21)16-18-12-5-4-11(20)6-13(12)19-16/h4-7,20H,8H2,1-3H3,(H,18,19)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01446","omeprazole","4594","SUBDBMMJDZJVOS-UHFFFAOYNA-N","InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)","CYP3A4","S-oxidation of sulfoxide to sulfone","Human Phase I","Human","Omeprazole sulfone","145900","IXEQEYRTSRFZEO-UHFFFAOYSA-N","InChI=1S/C17H19N3O4S/c1-10-8-18-15(11(2)16(10)24-4)9-25(21,22)17-19-13-6-5-12(23-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01447","Ondansetron","4595","FELGMEQIXOGIFQ-UHFFFAOYNA-N","InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3","CYP3A4; CYP2D6; CYP1A2","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","6-OH-ondansetron","20152440","LMMFEGYKXLPLFC-UHFFFAOYSA-N","InChI=1S/C18H19N3O2/c1-11-19-7-8-21(11)10-12-3-5-16-17(18(12)23)14-9-13(22)4-6-15(14)20(16)2/h4,6-9,12,22H,3,5,10H2,1-2H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01448","Ondansetron","4595","FELGMEQIXOGIFQ-UHFFFAOYNA-N","InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3","CYP1A2; CYP2D6; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","7-OH-ondansetron","71749264","DTJUCZWBHDEFRB-UHFFFAOYSA-N","InChI=1S/C18H19N3O2/c1-11-19-7-8-21(11)10-12-3-6-15-17(18(12)23)14-5-4-13(22)9-16(14)20(15)2/h4-5,7-9,12,22H,3,6,10H2,1-2H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01449","Ondansetron","4595","FELGMEQIXOGIFQ-UHFFFAOYNA-N","InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3","CYP1A2; CYP2D6; CYP3A4","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","8-OH-ondansetron","19734439","XVDKMEPUFIAQFH-UHFFFAOYSA-N","InChI=1S/C18H19N3O2/c1-11-19-8-9-21(11)10-12-6-7-14-16(18(12)23)13-4-3-5-15(22)17(13)20(14)2/h3-5,8-9,12,22H,6-7,10H2,1-2H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01450","Phorate","4790","BULVZWIRKLYCBC-UHFFFAOYSA-N","InChI=1S/C7H17O2PS3/c1-4-8-10(11,9-5-2)13-7-12-6-3/h4-7H2,1-3H3","CYP1A2; CYP3A4; CYP2B6; CYP2C9; CYP2C18; CYP2C19; CYP2D6","S-oxidation of dialkylthioether to sulfoxide","Human Phase I","Human","Phorate sulfoxide","17424","XRQHTUDGPWMPKX-UHFFFAOYSA-N","InChI=1S/C7H17O3PS3/c1-4-9-11(12,10-5-2)13-7-14(8)6-3/h4-7H2,1-3H3","Usmani, K.A.; (2004b). In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab. Dispos., Vol. 32, No. 3, (333-339)."
"BIOTID01452","Pioglitazone","4829","HYAFETHFCAUJAY-UHFFFAOYNA-N","InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)","CYP2C8; CYP3A4","OXIDATION_OF_PRIM_ALCOHOL_TO_CARBOXYLIC_ACID","Human Phase I","Human","2Ã¢â‚¬Â[6Ã¢â‚¬Â(2Ã¢â‚¬Â{4Ã¢â‚¬Â[(2,4Ã¢â‚¬ÂdioxoÃ¢â‚¬Â1,3Ã¢â‚¬ÂthiazolidinÃ¢â‚¬Â5Ã¢â‚¬Âyl)methyl]phenoxy}ethyl)pyridinÃ¢â‚¬Â3Ã¢â‚¬Âyl]acetic acid","10068721","OIQJTMMAMWFMQR-UHFFFAOYSA-N","InChI=1S/C19H18N2O5S/c22-17(23)10-13-1-4-14(20-11-13)7-8-26-15-5-2-12(3-6-15)9-16-18(24)21-19(25)27-16/h1-6,11,16H,7-10H2,(H,22,23)(H,21,24,25)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01453","Pioglitazone","4829","HYAFETHFCAUJAY-UHFFFAOYNA-N","InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)","CYP2C8; CYP3A4","Hydroxylation of non-terminal aliphatic carbon adjacent to aromatic ring","Human Phase I","Human","5Ã¢â‚¬Â[(4Ã¢â‚¬Â{2Ã¢â‚¬Â[5Ã¢â‚¬Â(1Ã¢â‚¬Âhydroxyethyl)pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl]ethoxy}phenyl)methyl]Ã¢â‚¬Â1,3Ã¢â‚¬ÂthiazolidineÃ¢â‚¬Â2,4Ã¢â‚¬Âdione","4147757","OXVFDZYQLGRLCD-UHFFFAOYSA-N","InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01454","Pioglitazone","4829","HYAFETHFCAUJAY-UHFFFAOYNA-N","InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)","CYP2C8; CYP3A4","HYDROXYLATION_OF_ALIPHATIC_SECONDARY_CARBON","Human Phase I","Human","5Ã¢â‚¬Â({4Ã¢â‚¬Â[2Ã¢â‚¬Â(5Ã¢â‚¬ÂethylpyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl)Ã¢â‚¬Â2Ã¢â‚¬Âhydroxyethoxy]phenyl}methyl)Ã¢â‚¬Â1,3Ã¢â‚¬ÂthiazolidineÃ¢â‚¬Â2,4Ã¢â‚¬Âdione","9864268","RMTFRGFLVHAYCI-UHFFFAOYSA-N","InChI=1S/C19H20N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,16-17,22H,2,9,11H2,1H3,(H,21,23,24)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01455","17ÃŽÂ²-OH-progesterone","NULL","DBPWSSGDRRHUNT-CEGNMAFCSA-N","InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1","CYP2D4; CYP2D6","Alpha hydroxylation of carbonyl group","Human Phase I","Human","17Beta-21-dihydroxyprogesterone","440707","WHBHBVVOGNECLV-OBQKJFGGSA-N","InChI=1S/C21H30O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h11,15-17,22,25H,3-10,12H2,1-2H3/t15-,16+,17+,19+,20+,21+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01456","Pranidipine","6436048","XTFPDGZNWTZCMF-DHZHZOJONA-N","InChI=1S/C25H24N2O6/c1-16-21(24(28)32-3)23(19-12-7-13-20(15-19)27(30)31)22(17(2)26-16)25(29)33-14-8-11-18-9-5-4-6-10-18/h4-13,15,23,26H,14H2,1-3H3/b11-8+","CYP3A4","Dehydrogenation of 4-aryl substituted 1,4-dihydropyridine","Human Phase I","Human","Dehydrogenated pranidipine","10003684","UZYMZRZCYLNXQU-DHZHZOJOSA-N","InChI=1S/C25H22N2O6/c1-16-21(24(28)32-3)23(19-12-7-13-20(15-19)27(30)31)22(17(2)26-16)25(29)33-14-8-11-18-9-5-4-6-10-18/h4-13,15H,14H2,1-3H3/b11-8+","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01457","Pranidipine","6436048","XTFPDGZNWTZCMF-DHZHZOJONA-N","InChI=1S/C25H24N2O6/c1-16-21(24(28)32-3)23(19-12-7-13-20(15-19)27(30)31)22(17(2)26-16)25(29)33-14-8-11-18-9-5-4-6-10-18/h4-13,15,23,26H,14H2,1-3H3/b11-8+","CYP1A2; CYP2D6; CYP3A4","C-DE-ESTERIFICATION","Human Phase I","Human","transÃ¢â‚¬Â1Ã¢â‚¬ÂphenylÃ¢â‚¬Â1Ã¢â‚¬Âpropene","252325","QROGIFZRVHSFLM-QHHAFSJGSA-N","InChI=1S/C9H10/c1-2-6-9-7-4-3-5-8-9/h2-8H,1H3/b6-2+","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01457","Pranidipine","6436048","XTFPDGZNWTZCMF-DHZHZOJONA-N","InChI=1S/C25H24N2O6/c1-16-21(24(28)32-3)23(19-12-7-13-20(15-19)27(30)31)22(17(2)26-16)25(29)33-14-8-11-18-9-5-4-6-10-18/h4-13,15,23,26H,14H2,1-3H3/b11-8+","CYP1A2; CYP2D6; CYP3A4","C-DE-ESTERIFICATION","Human Phase I","Human","5Ã¢â‚¬Â(methoxycarbonyl)Ã¢â‚¬Â2,6Ã¢â‚¬ÂdimethylÃ¢â‚¬Â4Ã¢â‚¬Â(3Ã¢â‚¬Ânitrophenyl)Ã¢â‚¬Â 1,4Ã¢â‚¬ÂdihydropyridineÃ¢â‚¬Â3Ã¢â‚¬Âcarboxylic acid","NULL","JPXPPUOCSLMCHK-UHFFFAOYSA-N","InChI=1S/C16H16N2O6/c1-8-12(15(19)20)14(13(9(2)17-8)16(21)24-3)10-5-4-6-11(7-10)18(22)23/h4-7,14,17H,1-3H3,(H,19,20)","Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01458","Propafenone ","4932","JWHAUXFOSRPERK-UHFFFAOYNA-N","InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3","CYP2D6","Hydroxylation of benzene on carbon para to an electron donating group","Human Phase I","Human","5-Hydroxypropafenone","107927","LUTWDNUXHDYZRA-UHFFFAOYSA-N","InChI=1S/C21H27NO4/c1-2-12-22-14-18(24)15-26-21-11-9-17(23)13-19(21)20(25)10-8-16-6-4-3-5-7-16/h3-7,9,11,13,18,22-24H,2,8,10,12,14-15H2,1H3","R1) Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01459","Propafenone ","4932","JWHAUXFOSRPERK-UHFFFAOYNA-N","InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3","CYP1A2; CYP3A4","N-dealkylation of acyclic secondary amine","Human Phase I","Human","N-Despropylpropafenone","128820","HIGKMVIPYOFHBP-UHFFFAOYSA-N","InChI=1S/C18H21NO3/c19-12-15(20)13-22-18-9-5-4-8-16(18)17(21)11-10-14-6-2-1-3-7-14/h1-9,15,20H,10-13,19H2","R1) Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01460","(+)-limonene","440917","XMGQYMWWDOXHJM-JTQLQIEISA-N","InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,10H,1,5-7H2,2-3H3/t10-/m0/s1","CYP2C9; CYP2C19","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","Carveol","7438","BAVONGHXFVOKBV-UHFFFAOYSA-N","InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h4,9-11H,1,5-6H2,2-3H3","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID01461","(+)-limonene","440917","XMGQYMWWDOXHJM-JTQLQIEISA-N","InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,10H,1,5-7H2,2-3H3/t10-/m0/s1","CYP2C9; CYP2C19; CYP3A4","Hydroxlation of methyl carbon adjacent to an aliphatic ring","Human Phase I","Human","Perillyl alcohol","10819","NDTYTMIUWGWIMO-UHFFFAOYSA-N","InChI=1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID01462","Monodesethylchloroquine","38989112","MCYUUUTUAAGOOT-UHFFFAOYNA-N","InChI=1S/C16H22ClN3/c1-3-18-9-4-5-12(2)20-15-8-10-19-16-11-13(17)6-7-14(15)16/h6-8,10-12,18H,3-5,9H2,1-2H3,(H,19,20)/t12-/m1/s1","CYP2D6","N-dealkylation of acyclic secondary amine","Human Phase I","Human","N,N-didesethylchloroquinone","122672","GYEDIFVVTRKXHP-UHFFFAOYSA-N","InChI=1S/C14H18ClN3/c1-10(3-2-7-16)18-13-6-8-17-14-9-11(15)4-5-12(13)14/h4-6,8-10H,2-3,7,16H2,1H3,(H,17,18)","Zanger, U.M. and Schwab, M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation; Pharmacology & Therapeutics 138 (2013) 103Ã¢â‚¬â€œ141; PMID:23333322|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01463","Rofecoxib","5090","RZJQGNCSTQAWON-UHFFFAOYSA-N","InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3","CYP1A2; CYP3A4","ALIPHATIC_HYDROXYLATION_OF_CARBON_ADJACENT_TO_OXYGEN","Human Phase I","Human","5-OH-rofecoxib","9973893","NCBVUSNBLYMFPP-UHFFFAOYSA-N","InChI=1S/C17H14O5S/c1-23(20,21)13-9-7-12(8-10-13)15-14(16(18)22-17(15)19)11-5-3-2-4-6-11/h2-10,17,19H,1H3","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01464","rosiglitazone","77999","YASAKCUCGLMORW-UHFFFAOYNA-N","InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)","CYP2C8","HYDROXYLATION_OF_HETEROAROMATIC_CARBON","Human Phase I","Human","para-hydroxyrosiglitazone ","9864316","AGQGGZNSVNKGDU-UHFFFAOYSA-N","InChI=1S/C18H19N3O4S/c1-21(16-7-4-13(22)11-19-16)8-9-25-14-5-2-12(3-6-14)10-15-17(23)20-18(24)26-15/h2-7,11,15,22H,8-10H2,1H3,(H,20,23,24)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3683"
"BIOTID01465","rosiglitazone","77999","YASAKCUCGLMORW-UHFFFAOYNA-N","InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)","CYP2C8","N-dealkylation of mixed tertiary amine","Human Phase I","Human","N-Desmethylrosiglitazone ","12000328","ZJQTVMXUIGXRMR-UHFFFAOYSA-N","InChI=1S/C17H17N3O3S/c21-16-14(24-17(22)20-16)11-12-4-6-13(7-5-12)23-10-9-19-15-3-1-2-8-18-15/h1-8,14H,9-11H2,(H,18,19)(H,20,21,22)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3684"
"BIOTID01466","rosiglitazone","77999","YASAKCUCGLMORW-UHFFFAOYNA-N","InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)","CYP2C8","HYDROXYLATION_OF_HETEROAROMATIC_CARBON","Human Phase I","Human","ortho-hydroxyrosiglitazone","100995317","KQXWMUFVDAFGPU-UHFFFAOYSA-N","InChI=1S/C18H19N3O4S/c1-21(16-14(22)3-2-8-19-16)9-10-25-13-6-4-12(5-7-13)11-15-17(23)20-18(24)26-15/h2-8,15,22H,9-11H2,1H3,(H,20,23,24)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3685"
"BIOTID01467","Rosuvastatin","12136803","BPRHUIZQVSMCRT-RJCHQFKYSA-N","InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m0/s1","CYP2C9; CYP2C19 ","N-dealkylation of mixed tertiary amine","Human Phase I","Human","N-Desmethylrosuvastatin","NULL","DJUKMHIJCDJSIJ-FHQWLQQXSA-N","InChI=1S/C21H26FN3O6S/c1-12(2)19-17(9-8-15(26)10-16(27)11-18(28)29)20(13-4-6-14(22)7-5-13)24-21(23-19)25-32(3,30)31/h4-9,12,15-16,26-27H,10-11H2,1-3H3,(H,28,29)(H,23,24,25)/b9-8+/t15-,16-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3686"
"BIOTID01468","Rosuvastatin","12136803","BPRHUIZQVSMCRT-RJCHQFKYSA-N","InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m0/s1","CYP2C9","ESTERIFICATION","Human Phase I","Human","Rosuvastatin 5 S-lactone","NULL","MSHRTLJOXFXLIV-MDZDMXLPSA-N","InChI=1S/C22H22FN3O5S/c1-13(2)20-18(10-9-17-11-16(27)12-19(28)31-17)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)32(4,29)30/h5-13,27H,1-4H3/b10-9+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3686"
"BIOTID01469","silybin ","31553","SEBFKMXJBCUCAI-ATASIELBNA-N","InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1","CYP2C8","O-aryl dealkylation adjacent to substituted carbon","Human Phase I","Human","O-demethylated-silybin","NULL","RAWNDNZPLHPBEN-OYYPCOLYSA-N","InChI=1S/C24H20O10/c25-9-19-23(10-1-3-13(27)14(28)5-10)33-17-6-11(2-4-16(17)32-19)24-22(31)21(30)20-15(29)7-12(26)8-18(20)34-24/h1-8,19,22-29,31H,9H2/t19-,22+,23-,24-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3687"
"BIOTID01470","Simazine","5216","ODCWYMIRDDJXKW-UHFFFAOYSA-N","InChI=1S/C7H12ClN5/c1-3-9-6-11-5(8)12-7(13-6)10-4-2/h3-4H2,1-2H3,(H2,9,10,11,12,13)","CYP1A1; CYP1A2; CYP2A6; CYP2C19; CYP2D6","N-dealkylation of secondary arylalkylamine","Human Phase I","Human","N-Desethylsimazine","13878","IVENSCMCQBJAKW-UHFFFAOYSA-N","InChI=1S/C5H8ClN5/c1-2-8-5-10-3(6)9-4(7)11-5/h2H2,1H3,(H3,7,8,9,10,11)","Ohkawa, H. and Inui, H. (2014); Metabolism of agrochemicals and related environmental chemicals based on cytochrome P450s in mammals and plants; Pest Manag Sci 2015; 71: 824Ã¢â‚¬â€œ828"
"BIOTID01471","Styrene","7501","PPBRXRYQALVLMV-UHFFFAOYSA-N","InChI=1S/C8H8/c1-2-8-6-4-3-5-7-8/h2-7H,1H2","CYP2E1","EPOXIDATION_OF_12_DISUBSTITUTED_ALKLENE","Human Phase I","Human","Styrene 7,8-oxide","7276","AWMVMTVKBNGEAK-UHFFFAOYSA-N","InChI=1S/C8H8O/c1-2-4-7(5-3-1)8-6-9-8/h1-5,8H,6H2","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01472","Sulfinpyrazone","5342","MBGGBVCUIVRRBF-UHFFFAOYNA-N","InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2","CYP3A4; CYP2C9","S-oxidation of sulfoxide to sulfone","Human Phase I","Human","Sulfinpyrazone sulfone","70676","DQUYGWDNTAETLI-UHFFFAOYSA-N","InChI=1S/C23H20N2O4S/c26-22-21(16-17-30(28,29)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01473","Pyributicarb","93486","VTRWMTJQBQJKQH-UHFFFAOYSA-N","InChI=1S/C18H22N2O2S/c1-18(2,3)13-8-6-9-14(12-13)22-17(23)20(4)15-10-7-11-16(19-15)21-5/h6-12H,1-5H3","CYP2C19","O-aryl demethylation","Human Phase I","Human","Pyributicarb metabolite 1","101930793","NXGVDGXPNJOHIJ-UHFFFAOYSA-N","InChI=1S/C17H20N2O2S/c1-17(2,3)12-7-5-8-13(11-12)21-16(22)19(4)14-9-6-10-15(20)18-14/h5-11H,1-4H3,(H,18,20)","Ohkawa, H and Inui, H. (2015); Metabolism of agrochemicals and relatedenvironmental chemicals based on cytochromeP450s in mammals and plants; Pest Manag Sci.; 71: 824Ã¢â‚¬â€œ828"
"BIOTID01474","Sulprofos","38988334","JXHJNEJVUNHLKO-HNNXBMFYSA-N","InChI=1S/C12H19O2PS3/c1-4-10-18-15(16,13-5-2)14-11-6-8-12(17-3)9-7-11/h6-9H,4-5,10H2,1-3H3/t15-/m0/s1","CYP1A1; CYP1A2; CYP3A4; CYP2C9; CYP2C18; CYP2C19; CYP2D6","S-oxidation of dialkylthioether to sulfoxide","Human Phase I","Human","Sulprofos sulfoxide","588272","CBVUFUJJOXRACG-UHFFFAOYSA-N","InChI=1S/C12H19O3PS3/c1-4-10-18-16(17,14-5-2)15-11-6-8-12(9-7-11)19(3)13/h6-9H,4-5,10H2,1-3H3","Usmani, K.A.; (2004b). In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab. Dispos., Vol. 32, No. 3, (333-339)."
"BIOTID01475","suprofen","5359","MDKGKXOCJGEUJW-UHFFFAOYSA-N","InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)","CYP2C9","Thiohene S-oxidation","Human Phase I","Human","Suprofen -sulfoxide","131769993","BBVYLLCHKPXDCK-UHFFFAOYSA-N","InChI=1S/C14H12O4S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-19(12)18/h2-9H,1H3,(H,16,17)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01476","suprofen","5359","MDKGKXOCJGEUJW-UHFFFAOYSA-N","InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)","CYP2C9","Epoxidation of thiophene","Human Phase I","Human","Thiophene-4,5-epoxide","131769994","SDGBIPHZPNRUFG-UHFFFAOYSA-N","InChI=1S/C14H12O4S/c1-7(13(16)17)8-2-4-9(5-3-8)12(15)11-6-10-14(18-10)19-11/h2-7,10,14H,1H3,(H,16,17)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01477","Tamoxifen N-oxide","3033895","YAASNACECBQAFW-QPLCGJKRSA-N","InChI=1S/C26H29NO2/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)29-20-19-27(2,3)28/h5-18H,4,19-20H2,1-3H3/b26-25-","CYP3A4; CYP3A5","Hydroxylation of penultimate aliphatic secondary carbon","Human Phase I","Human","alpha-OH-tamoxifen N-oxide","72201074","UPGHFQMAOIISKB-QPLCGJKRSA-N","InChI=1S/C26H29NO3/c1-20(28)25(21-10-6-4-7-11-21)26(22-12-8-5-9-13-22)23-14-16-24(17-15-23)30-19-18-27(2,3)29/h4-17,20,28H,18-19H2,1-3H3/b26-25-","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985|Wang and Zhou; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754423|Zhou, S.F. (2009); Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance; Clin Pharmacokinet 2009; 48 (11); PMID:19902987|Rendic,S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metabolism Reviews, 34:1-2, 83-448, DOI:10.1081/ DMR-120001392; PMID:11996015"
"BIOTID01478","Tegafur","5386","WFWLQNSHRPWKFK-UHFFFAOYNA-N","InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)","CYP2A6; CYP1A2; CYP2C8","N-dealkylation of mixed tertiary amine","Human Phase I","Human","5-Fluorouracil","3385","GHASVSINZRGABV-UHFFFAOYSA-N","InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754424"
"BIOTID01479","Thioridazine","5452","KLBQZWRITKRQQV-UHFFFAOYNA-N","InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3","CYP2D6; CYP3A4","S-oxidation of alkylarylthioether to sulfoxide","Human Phase I","Human","Thioridazine 2-sulfoxide ","4078","SLVMESMUVMCQIY-UHFFFAOYSA-N","InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754425"
"BIOTID01480","Thioridazine","5452","KLBQZWRITKRQQV-UHFFFAOYNA-N","InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3","CYP1A2; CYP3A4","N-dealkylation of mixed tertiary amine","Human Phase I","Human","N-desmethylthioridazine ","558813","UFDCSHQNNVQXAS-UHFFFAOYSA-N","InChI=1S/C20H24N2S2/c1-23-16-9-10-20-18(14-16)22(13-11-15-6-4-5-12-21-15)17-7-2-3-8-19(17)24-20/h2-3,7-10,14-15,21H,4-6,11-13H2,1H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754425"
"BIOTID01481","Thioridazine","5452","KLBQZWRITKRQQV-UHFFFAOYNA-N","InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3","CYP1A2; CYP3A4","S-oxidation of diarylthioether to sulfoxide","Human Phase I","Human","Thioridazine 5-sulfoxide","24494","XLDFFVBQCMLXIE-UHFFFAOYSA-N","InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)26(24)21-11-10-17(25-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3","Wang and Zhou; Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009 Vol. 16, No. 31; PMID:19754425"
"BIOTID01482","Thymol","6989","MGSRCZKZVOBKFT-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)6-10(9)11/h4-7,11H,1-3H3","CYP1A2; CYP2A6; CYP2D6","o-Hydroxylation of phenol","Human Phase I","Human","p-Cymene-2,3-diol","95873","LYUBXLHGANLIMX-UHFFFAOYSA-N","InChI=1S/C10H14O2/c1-6(2)8-5-4-7(3)9(11)10(8)12/h4-6,11-12H,1-3H3","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID01483","Thymol","6989","MGSRCZKZVOBKFT-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)6-10(9)11/h4-7,11H,1-3H3","CYP1A2; CYP2A6; CYP2D6","p-Hydroxylation of phenol","Human Phase I","Human","Thymoquinol","95779","OQIOHYHRGZNZCW-UHFFFAOYSA-N","InChI=1S/C10H14O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6,11-12H,1-3H3","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID01484","Thymol","6989","MGSRCZKZVOBKFT-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)6-10(9)11/h4-7,11H,1-3H3","CYP1A2; CYP2A6; CYP2D6","Terminal desaturation","Human Phase I","Human","p-Cymen-8-en-3-ol","6429037","IHWFPRKZRRGTTI-UHFFFAOYSA-N","InChI=1S/C10H12O/c1-7(2)9-5-4-8(3)6-10(9)11/h4-6,11H,1H2,2-3H3","Jaeger, W. and Haeferl, M.; Metabolism of Terpenoids in Animal Models and Humans (Chapter 9) in Handbook of Essential Oils - Science, Technology, and Applications, Second Edition; Edited by K. Husnu Can Baser and Gerhard Buchbauer; CRC Press 2015; pp. 253Ã¢â‚¬â€œ279."
"BIOTID01485","Tizanidine","5487","XFYDIVBRZNQMJC-UHFFFAOYSA-N","InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)","CYP1A2","Hydroxylation of heteroalicyclic secondary carbon","Human Phase I","Human","2Ã¢â‚¬Â[(5Ã¢â‚¬ÂchloroÃ¢â‚¬Â2,1,3Ã¢â‚¬ÂbenzothiadiazolÃ¢â‚¬Â4Ã¢â‚¬Âyl)amino]Ã¢â‚¬Â4,5Ã¢â‚¬ÂdihydroÃ¢â‚¬Â1HÃ¢â‚¬ÂimidazolÃ¢â‚¬Â4Ã¢â‚¬Âol","NULL","LURMELDQBVJARZ-UHFFFAOYSA-N","InChI=1S/C9H8ClN5OS/c10-4-1-2-5-8(15-17-14-5)7(4)13-9-11-3-6(16)12-9/h1-2,6,16H,3H2,(H2,11,12,13)","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01486","Trichloroethylene","6575","XSTXAVWGXDQKEL-UHFFFAOYSA-N","InChI=1S/C2HCl3/c3-1-2(4)5/h1H","CYP2E1; CYP1A2; CYP3A4","EPOXIDATION","Human Phase I","Human","Chloral hydrate","2707","RNFNDJAIBTYOQL-UHFFFAOYSA-N","InChI=1S/C2H3Cl3O2/c3-2(4,5)1(6)7/h1,6-7H","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01487","TSU-68","5329099","NHFDRBXTEDBWCZ-ZROIWOOFSA-N","InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-","CYP1A2; CYP1A1; CYP2C8","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","TSU-68 metabolite 1","NULL","APJYZRJDCRLKDI-ZSOIEALJSA-N","InChI=1S/C18H18N2O4/c1-9-12(4-6-17(22)23)10(2)19-16(9)8-14-13-7-11(21)3-5-15(13)20-18(14)24/h3,5,7-8,19,21H,4,6H2,1-2H3,(H,20,24)(H,22,23)/b14-8-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01488","TSU-68","5329099","NHFDRBXTEDBWCZ-ZROIWOOFSA-N","InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-","CYP1A1; CYP1A2; CYP2C8","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","TSU-68 metabolite 2","NULL","NTSFCHHACMZKEA-JYRVWZFOSA-N","InChI=1S/C18H18N2O4/c1-9-11(6-7-16(22)23)10(2)19-14(9)8-13-12-4-3-5-15(21)17(12)20-18(13)24/h3-5,8,19,21H,6-7H2,1-2H3,(H,20,24)(H,22,23)/b13-8-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01489","TSU-68","5329099","NHFDRBXTEDBWCZ-ZROIWOOFSA-N","InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-","CYP1A1; CYP1A2; CYP2C8","Aromatic hydroxylation of fused benzene ring","Human Phase I","Human","TSU-68 metabolite 3","9949238","YEVBDKUJUCJAMN-ZSOIEALJSA-N","InChI=1S/C18H18N2O4/c1-9-12(5-6-17(22)23)10(2)19-15(9)8-14-13-4-3-11(21)7-16(13)20-18(14)24/h3-4,7-8,19,21H,5-6H2,1-2H3,(H,20,24)(H,22,23)/b14-8-","Wang, B. and Zhou, S.F. (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry; Vol. 16, No. 31; PMID:19754423"
"BIOTID01491","YM-64227","9925883","QFBNONLZWZUQCN-UHFFFAOYSA-N","InChI=1S/C17H23N3O/c1-3-13-10-11-14-15(12-8-6-5-7-9-12)19-17(21)20(4-2)16(14)18-13/h10-12H,3-9H2,1-2H3","CYP1A2","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","M-2 (1,3-cis)","NULL","MJELJBCAAHPYTL-UHFFFAOYSA-N","InChI=1S/C17H23N3O2/c1-3-12-8-9-14-15(11-6-5-7-13(21)10-11)19-17(22)20(4-2)16(14)18-12/h8-9,11,13,21H,3-7,10H2,1-2H3","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01492","YM-64227","9925883","QFBNONLZWZUQCN-UHFFFAOYSA-N","InChI=1S/C17H23N3O/c1-3-13-10-11-14-15(12-8-6-5-7-9-12)19-17(21)20(4-2)16(14)18-13/h10-12H,3-9H2,1-2H3","CYP1A2","Hydroxylation of alicyclic secondary carbon","Human Phase I","Human","M-3 (1,3-trans)","NULL","MJELJBCAAHPYTL-GLGOKHISSA-N","InChI=1S/C17H23N3O2/c1-3-12-8-9-14-15(11-6-5-7-13(21)10-11)19-17(22)20(4-2)16(14)18-12/h8-9,11,13,21H,3-7,10H2,1-2H3/t11?,13-/m1/s1","Brown, C.M. et al. (2008); Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates; Drug Metabolism Reviews, 40:1, 1-100, DOI:10.1080/03602530701836662; PMID:18259985"
"BIOTID01493","Zaltoprofen","5720","MUXFZBHBYYYLTH-UHFFFAOYNA-N","InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)","CYP2C9","REDUCTION_OF_KETONES_TO_ALCOHOL","Human Phase I","Human","10-OH-zaltoprofen","69583459","LKGZEJBRWPSWLF-UHFFFAOYSA-N","InChI=1S/C17H16O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10,14,18H,9H2,1H3,(H,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3682"
"BIOTID01494","Zaltoprofen","5720","MUXFZBHBYYYLTH-UHFFFAOYNA-N","InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)","CYP2C9","S-oxidation of dialkylthioether to sulfoxide","Human Phase I","Human","Zaltoprofen S-oxide","NULL","BMXFBJRSBWVAIU-UHFFFAOYSA-N","InChI=1S/C17H14O4S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)22(15)21/h2-8,10H,9H2,1H3,(H,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3683"
"BIOTID01495","Zoplicone","941731","GBBSUAFBMRNDJC-MRXNPFEDSA-N","InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m1/s1","CYP3A4","N_HYDROXYLATION_OF_ALICYCLIC_TERTIARY_AMINE","Human Phase I","Human","4Ã¢â‚¬Â({[6Ã¢â‚¬Â(5Ã¢â‚¬ÂchloropyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl)Ã¢â‚¬Â7Ã¢â‚¬ÂoxoÃ¢â‚¬Â5H,6H,7HÃ¢â‚¬Âpyrrolo[3,4Ã¢â‚¬Âb]pyrazinÃ¢â‚¬Â5Ã¢â‚¬Âyl]oxy}carbonyl)Ã¢â‚¬Â1Ã¢â‚¬ÂmethylpiperazinÃ¢â‚¬Â1Ã¢â‚¬ÂiumÃ¢â‚¬Â1Ã¢â‚¬Âolate","162548","IPTIKKTXLHVRKN-UHFFFAOYSA-N","InChI=1S/C17H17ClN6O4/c1-24(27)8-6-22(7-9-24)17(26)28-16-14-13(19-4-5-20-14)15(25)23(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3","J. Bolleddula et al.; Drug Metab Rev, 2014; 46(3): 379Ã¢â‚¬â€œ419"
"BIOTID01497","4-VINYLCYCLOHEXENE","7499","BBDKZWKEPDTENS-UHFFFAOYSA-N","InChI=1S/C8H12/c1-2-8-6-4-3-5-7-8/h2-4,8H,1,5-7H2","CYP2B6; CYP2E1","ALKENE_EPXODATION","Human Phase I","Human","VCH-7,8-epoxide","114431","OLKHRYQRCJLWLL-UHFFFAOYSA-N","InChI=1S/C8H12O/c1-2-4-7(5-3-1)8-6-9-8/h1-2,7-8H,3-6H2","S. M. FONTAINE et al. (2001); ROLE OF INDUCTION OF SPECIFIC HEPATIC CYTOCHROME P450 ISOFORMS IN EPOXIDATION OF 4-VINYLCYCLOHEXENE; DRUG METABOLISM AND DISPOSITION; Vol. 29, No. 9"
"BIOTID01498","4-VINYLCYCLOHEXENE","7499","BBDKZWKEPDTENS-UHFFFAOYSA-N","InChI=1S/C8H12/c1-2-8-6-4-3-5-7-8/h2-4,8H,1,5-7H2","CYP2B6; CYP2E1","ALKENE_EPXODATION","Human Phase I","Human","VCH-1,2-epoxide","7832","SLJFKNONPLNAPF-UHFFFAOYSA-N","InChI=1S/C8H12O/c1-2-6-3-4-7-8(5-6)9-7/h2,6-8H,1,3-5H2","S. M. FONTAINE et al. (2001); ROLE OF INDUCTION OF SPECIFIC HEPATIC CYTOCHROME P450 ISOFORMS IN EPOXIDATION OF 4-VINYLCYCLOHEXENE; DRUG METABOLISM AND DISPOSITION; Vol. 29, No. 9"
"BIOTID01499","VCH-1,2-epoxide","114431","OLKHRYQRCJLWLL-UHFFFAOYSA-N","InChI=1S/C8H12O/c1-2-4-7(5-3-1)8-6-9-8/h1-2,7-8H,3-6H2","CYP2B6; CYP2E1","ALKENE_EPXODATION","Human Phase I","Human","VCH-diepoxide","7833","OECTYKWYRCHAKR-UHFFFAOYSA-N","InChI=1S/C8H12O2/c1-2-6-7(10-6)3-5(1)8-4-9-8/h5-8H,1-4H2","S. M. FONTAINE et al. (2001); ROLE OF INDUCTION OF SPECIFIC HEPATIC CYTOCHROME P450 ISOFORMS IN EPOXIDATION OF 4-VINYLCYCLOHEXENE; DRUG METABOLISM AND DISPOSITION; Vol. 29, No. 9"
"BIOTID01500","VCH-7,8-epoxide","7832","SLJFKNONPLNAPF-UHFFFAOYSA-N","InChI=1S/C8H12O/c1-2-6-3-4-7-8(5-6)9-7/h2,6-8H,1,3-5H2","CYP2B6; CYP2E1","ALKENE_EPXODATION","Human Phase I","Human","VCH-diepoxide","7833","OECTYKWYRCHAKR-UHFFFAOYSA-N","InChI=1S/C8H12O2/c1-2-6-7(10-6)3-5(1)8-4-9-8/h5-8H,1-4H2","S. M. FONTAINE et al. (2001); ROLE OF INDUCTION OF SPECIFIC HEPATIC CYTOCHROME P450 ISOFORMS IN EPOXIDATION OF 4-VINYLCYCLOHEXENE; DRUG METABOLISM AND DISPOSITION; Vol. 29, No. 9"
"BIOTID01501","Medroxyprogesterone Acetate","6279","PSGAAPLEWMOORI-PEINSRQWSA-N","InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1","CYP3A4;","Aliphatic Hydroxylation","Human Phase I","Human","M-4","NULL","DEGIWINEDRZHEE-IRACIFBNSA-N","InChI=1S/C24H34O5/c1-13-10-16-17(22(4)12-21(28)20(27)11-19(13)22)6-8-23(5)18(16)7-9-24(23,14(2)25)29-15(3)26/h11,13,16-18,21,28H,6-10,12H2,1-5H3/t13-,16+,17-,18-,21?,22+,23-,24-/m0/s1","PMID:18725509"
"BIOTID01502","Medroxyprogesterone Acetate","6279","PSGAAPLEWMOORI-PEINSRQWSA-N","InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1","CYP3A4;","Aliphatic Hydroxylation","Human Phase I","Human","M-2","71749110","BIIFPBLHBAQCTJ-MCLNPTNPSA-N","InChI=1S/C24H34O5/c1-14(25)24(29-15(2)26)11-8-19-17-13-23(5,28)20-12-16(27)6-9-21(20,3)18(17)7-10-22(19,24)4/h12,17-19,28H,6-11,13H2,1-5H3/t17-,18+,19+,21-,22+,23-,24+/m1/s1","PMID:18725509"
"BIOTID01503","Medroxyprogesterone Acetate","6279","PSGAAPLEWMOORI-PEINSRQWSA-N","InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1","CYP3A4;","Aliphatic Hydroxylation","Human Phase I","Human","M-3","NULL","RXMRJLACDJCPSK-CXLZCUPKSA-N","InChI=1S/C24H34O5/c1-13-10-17-18-7-9-24(14(2)25,29-15(3)26)22(18,4)8-6-19(17)23(5)20(13)11-16(27)12-21(23)28/h11,13,17-19,21,28H,6-10,12H2,1-5H3/t13-,17-,18-,19-,21?,22-,23+,24-/m0/s1","PMID:18725509"
"BIOTID01504","Medroxyprogesterone Acetate (M4)","NULL","DEGIWINEDRZHEE-IRACIFBNSA-N","InChI=1S/C24H34O5/c1-13-10-16-17(22(4)12-21(28)20(27)11-19(13)22)6-8-23(5)18(16)7-9-24(23,14(2)25)29-15(3)26/h11,13,16-18,21,28H,6-10,12H2,1-5H3/t13-,16+,17-,18-,21?,22+,23-,24-/m0/s1","CYP3A4;","Aliphatic Hydroxylation","Human Phase I","Human","M-1","NULL","ORFMCUSRHZJDBM-DPSXXVMFSA-N","InChI=1S/C24H34O6/c1-13(25)24(30-14(2)26)9-7-17-15-11-23(5,29)20-10-18(27)19(28)12-21(20,3)16(15)6-8-22(17,24)4/h10,15-17,19,28-29H,6-9,11-12H2,1-5H3/t15-,16+,17+,19?,21-,22+,23-,24+/m1/s1","PMID:18725509"
"BIOTID01505","Methoxymorpholinyldoxorubicin","9939321","CTMCWCONSULRHO-NLRABFGESA-N","InChI=1S/C32H37NO13/c1-14-27(36)17(33-7-8-44-22(12-33)43-3)9-21(45-14)46-19-11-32(41,20(35)13-34)10-16-24(19)31(40)26-25(29(16)38)28(37)15-5-4-6-18(42-2)23(15)30(26)39/h4-6,14,17,19,21-22,27,34,36,38,40-41H,7-13H2,1-3H3/t14-,17-,19-,21-,22?,27+,32-/m0/s1","CYP3A","Dehydroxylation ","Human Phase I","Human","PNU-159682","NULL","WZFKYQVEFUDASY-BXGVMUGRSA-N","InChI=1S/C32H35NO13/c1-13-31-16(33-10-22(42-3)43-12-20(33)46-31)7-21(44-13)45-18-9-32(40,19(35)11-34)8-15-24(18)30(39)26-25(28(15)37)27(36)14-5-4-6-17(41-2)23(14)29(26)38/h4-6,13,16,18,20-22,31,34,37,39-40H,7-12H2,1-3H3/t13-,16-,18-,20?,21-,22?,31+,32-/m0/s1","Broggini M. (2007) Nemorubicin. In: Krohn K. (eds) Anthracycline Chemistry and Biology II. Topics in Current Chemistry, vol 283. Springer, Berlin, Heidelberg; PMID:28068470"
"BIOTID01506","Perospirone","115368","FBVFZWUMDDXLLG-HDICACEKSA-N","InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+","CYP3A4","Dehydrogenation","Human Phase I","Human","NULL","10526361","WPHIJPAZRBKVBU-UHFFFAOYSA-N","InChI=1S/C23H28N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10H,1-2,5-8,11-16H2","PMID:20363276"
"BIOTID01507","Perospirone","115368","FBVFZWUMDDXLLG-HDICACEKSA-N","InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+","CYP1A1;CYP2C8;CYP2D6","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","PUQHDRPYOGVOMS-QIONWKSUSA-N","InChI=1S/C23H30N4O3S/c28-16-7-8-17-19(15-16)23(30)27(22(17)29)10-4-3-9-25-11-13-26(14-12-25)21-18-5-1-2-6-20(18)31-24-21/h1-2,5-6,16-17,19,28H,3-4,7-15H2/t16?,17-,19+/m1/s1","PMID:20363276"
"BIOTID01508","Perospirone","115368","FBVFZWUMDDXLLG-HDICACEKSA-N","InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+","CYP1A1;CYP2C8;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","102254148","HXAWRAUHOFHYIX-JPYJTQIMSA-N","InChI=1S/C23H30N4O3S/c28-21-18-8-3-4-10-23(18,30)22(29)27(21)12-6-5-11-25-13-15-26(16-14-25)20-17-7-1-2-9-19(17)31-24-20/h1-2,7,9,18,30H,3-6,8,10-16H2/t18-,23+/m1/s1","PMID:20363276"
"BIOTID01509","Perospirone","115368","FBVFZWUMDDXLLG-HDICACEKSA-N","InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+","CYP1A1;CYP2C8;CYP3A4","N-Dealkylatiion","Human Phase I","Human","NULL","2772144","KRDOFMHJLWKXIU-UHFFFAOYSA-N","InChI=1S/C11H13N3S/c1-2-4-10-9(3-1)11(13-15-10)14-7-5-12-6-8-14/h1-4,12H,5-8H2","PMID:20363276"
"BIOTID01510","Perospirone","115368","FBVFZWUMDDXLLG-HDICACEKSA-N","InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+","CYP1A1;CYP2C8;CYP3A4","N-Dealkylatiion","Human Phase I","Human","NULL","NULL","XRQUXFQQGBBCTI-AOOOYVTPSA-N","InChI=1S/C12H19NO3/c14-8-4-3-7-13-11(15)9-5-1-2-6-10(9)12(13)16/h9-10,14H,1-8H2/t9-,10+","PMID:20363276"
"BIOTID01511","Azimilide","9571004","MREBEPTUUMTTIA-PCLIKHOPSA-N","InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+","CYP3A4;CYP3A5;CYP2D6","N-Dementhylation","Human Phase I","Human","NULL","10388708","XNIVKBOABXGBLB-MFKUBSTISA-N","InChI=1S/C22H26ClN5O3/c23-18-5-3-17(4-6-18)20-8-7-19(31-20)15-25-28-16-21(29)27(22(28)30)12-2-1-11-26-13-9-24-10-14-26/h3-8,15,24H,1-2,9-14,16H2/b25-15+","PMID:16052551"
"BIOTID01512","Azimilide","9571004","MREBEPTUUMTTIA-PCLIKHOPSA-N","InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+","CYP3A4;CYP3A5","N-Oxidation","Human Phase I","Human","NULL","NULL","MPNDCLYKZVILKH-PCLIKHOPSA-N","InChI=1S/C23H28ClN5O4/c1-29(32)14-12-26(13-15-29)10-2-3-11-27-22(30)17-28(23(27)31)25-16-20-8-9-21(33-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+","PMID:16052551"
"BIOTID01513","Disopyramide","3114","UVTNFZQICZKOEM-UHFFFAOYSA-N","InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)","CYP","N-Dealkylatiion","Human Phase I","Human","N-Desisopropyldisopyramide","107858","UWNSWIXIVDMCHZ-UHFFFAOYSA-N","InChI=1S/C18H23N3O/c1-14(2)20-13-11-18(17(19)22,15-8-4-3-5-9-15)16-10-6-7-12-21-16/h3-10,12,14,20H,11,13H2,1-2H3,(H2,19,22)","PMID:23406671"
"BIOTID01516","Nimodipine","4497","UIAGMCDKSXEBJQ-UHFFFAOYSA-N","InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3","CYP3A4","Dehydrogenation","Human Phase I","Human","NULL","529928","SJJUCKCPGPCJQM-UHFFFAOYSA-N","InChI=1S/C21H24N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12H,9-10H2,1-5H3","PMID:22469047"
"BIOTID01517","Nimodipine","4497","UIAGMCDKSXEBJQ-UHFFFAOYSA-N","InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3","CYP3A4","O-Dementhylation","Human Phase I","Human","NULL","10431202","PWPBMCUBOQNEJD-UHFFFAOYSA-N","InChI=1S/C20H22N2O7/c1-11(2)29-20(25)17-13(4)21-12(3)16(19(24)28-9-8-23)18(17)14-6-5-7-15(10-14)22(26)27/h5-7,10-11,23H,8-9H2,1-4H3","PMID:22469047"
"BIOTID01518","Nimodipine","4497","UIAGMCDKSXEBJQ-UHFFFAOYSA-N","InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3","CYP3A4","O-dealkylation","Human Phase I","Human","NULL","10021411","QQEOWRHUXVDVJC-UHFFFAOYSA-N","InChI=1S/C18H20N2O6/c1-9(2)26-18(23)15-11(4)19-10(3)14(17(21)22)16(15)12-6-5-7-13(8-12)20(24)25/h5-9,16,19H,1-4H3,(H,21,22)","PMID:22469047"
"BIOTID01519","nisoldipine","4499","VKQFCGNPDRICFG-UHFFFAOYSA-N","InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3","CYP1A2;CYP2C9;CYP2C19;CYP2D6;CYP2E1;CYP3A4","Dehydrogenation","Human Phase I","Human","NULL","10385461","PCNPLNDGLOCZGS-UHFFFAOYSA-N","InChI=1S/C20H22N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11H,10H2,1-5H3","PMID:15618694;PMID:24816159"
"BIOTID01520","nisoldipine","4499","VKQFCGNPDRICFG-UHFFFAOYSA-N","InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3","CYP1A2;CYP2C19;CYP2D6;CYP2E1;CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","VFKWLFKJWCAALB-UHFFFAOYSA-N","InChI=1S/C20H24N2O7/c1-10(2)18(23)29-20(25)16-12(4)21-11(3)15(19(24)28-5)17(16)13-8-6-7-9-14(13)22(26)27/h6-10,17-18,21,23H,1-5H3","PMID:15618694;PMID:24816159"
"BIOTID01521","nisoldipine","4499","VKQFCGNPDRICFG-UHFFFAOYSA-N","InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3","CYP2C9;CYP2C19;CYP2E1","O-Dementhylation","Human Phase I","Human","NULL","14900023","DQPHLBVFFWESCR-UHFFFAOYSA-N","InChI=1S/C19H22N2O6/c1-10(2)9-27-19(24)16-12(4)20-11(3)15(18(22)23)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,10,17,20H,9H2,1-4H3,(H,22,23)","PMID:15618694;PMID:24816159"
"BIOTID01522","OXODIPINE","56108","MSOAVHHAZCMHDI-UHFFFAOYSA-N","InChI=1S/C19H21NO6/c1-5-24-19(22)15-11(3)20-10(2)14(18(21)23-4)16(15)12-7-6-8-13-17(12)26-9-25-13/h6-8,16,20H,5,9H2,1-4H3","CYP3A","Dehydrogenation","Human Phase I","Human","OXODIPINE(m1)","101592396","JSUCRNLHBXXKQA-UHFFFAOYSA-N","InChI=1S/C19H19NO6/c1-5-24-19(22)15-11(3)20-10(2)14(18(21)23-4)16(15)12-7-6-8-13-17(12)26-9-25-13/h6-8H,5,9H2,1-4H3","PMID:1560383"
"BIOTID01523","OXODIPINE(m1)","101592396","MSOAVHHAZCMHDI-UHFFFAOYSA-N","InChI=1S/C19H19NO6/c1-5-24-19(22)15-11(3)20-10(2)14(18(21)23-4)16(15)12-7-6-8-13-17(12)26-9-25-13/h6-8H,5,9H2,1-4H3","CYP3A","O-Dementhylation","Human Phase I","Human","OXODIPINE(m2)","101592397","VJQFAXXCTZFDFM-UHFFFAOYSA-N","InChI=1S/C18H17NO6/c1-4-23-18(22)14-10(3)19-9(2)13(17(20)21)15(14)11-6-5-7-12-16(11)25-8-24-12/h5-7H,4,8H2,1-3H3,(H,20,21)","PMID:1560383"
"BIOTID01524","Tasosartan","60919","ADXGNEYLLLSOAR-UHFFFAOYSA-N","InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29)","CYP3A4","Aromatic Hydroxylation","Human Phase I","Human","enoltasosartanÃ¢â‚¬â€°","10741138","WNDWLZHSOQLSBP-UHFFFAOYSA-N","InChI=1S/C23H21N7O2/c1-13-21-19(31)11-20(32)30(23(21)25-14(2)24-13)12-15-7-9-16(10-8-15)17-5-3-4-6-18(17)22-26-28-29-27-22/h3-10,19,31H,11-12H2,1-2H3,(H,26,27,28,29)","PMID:15974591"
"BIOTID01525","Tirilazad Mesylate","NULL","NTRLSGIBUFLYST-VFTWSTDHSA-N","","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","","","PMID:8627581"
"BIOTID01525","Tirilazad Mesylate","NULL","NTRLSGIBUFLYST-VFTWSTDHSA-N","","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","20271438","AFVFQIVMOAPDHO-UHFFFAOYSA-N","InChI=1S/CH4O3S/c1-5(2,3)4/h1H3,(H,2,3,4)","PMID:8627581"
"BIOTID01525","Tirilazad Mesylate","NULL","NTRLSGIBUFLYST-VFTWSTDHSA-N","","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","NULL","NULL","VDRMYIRMMZPUDN-MHQDJAMUSA-N","InChI=1S/C38H52N6O3/c1-25-20-29-27-22-31(46)30-21-26(45)8-10-37(30,2)28(27)9-11-38(29,3)35(25)32(47)24-41-16-18-43(19-17-41)34-23-33(42-12-4-5-13-42)39-36(40-34)44-14-6-7-15-44/h8-10,21,23,25,27,29,31,35,46H,4-7,11-20,22,24H2,1-3H3/t25-,27-,29+,31?,35-,37-,38+/m1/s1","PMID:8627581"
"BIOTID01526","HEXACHLOROBENZENE","8370","CKAPSXZOOQJIBF-UHFFFAOYSA-N","InChI=1S/C6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9","CYP3A4","Aliphatic Hydroxylation","Human Phase I","Human","Pentachlorophenol","992","IZUPBVBPLAPZRR-UHFFFAOYSA-N","InChI=1S/C6HCl5O/c7-1-2(8)4(10)6(12)5(11)3(1)9/h12H","PMID:9074885"
"BIOTID01527","(-)-Epigallocatechin gallate","65064","WMBWREPUVVBILR-WIYYLYMNSA-N","InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","(-)-Epigallocatechin gallate, 3p-OH-glucuronide","NULL","WNLLMSQFYPFJGS-ZCRVWPRHSA-N","InChI=1S/C28H26O17/c29-10-5-12(30)11-7-18(43-27(41)9-2-13(31)19(34)14(32)3-9)24(42-16(11)6-10)8-1-15(33)20(35)17(4-8)44-28-23(38)21(36)22(37)25(45-28)26(39)40/h1-6,18,21-25,28-38H,7H2,(H,39,40)/t18-,21+,22+,23-,24-,25+,28-/m1/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01528","(-)-Epigallocatechin gallate","65064","WMBWREPUVVBILR-WIYYLYMNSA-N","InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","(-)-Epigallocatechin gallate, 4p-OH-glucuronide","NULL","DBWSOVOTCKCPCB-XNLIHRAISA-N","InChI=1S/C28H26O17/c29-10-5-12(30)11-7-18(43-27(41)9-3-13(31)19(35)14(32)4-9)23(42-17(11)6-10)8-1-15(33)24(16(34)2-8)44-28-22(38)20(36)21(37)25(45-28)26(39)40/h1-6,18,20-23,25,28-38H,7H2,(H,39,40)/t18-,20+,21+,22-,23-,25+,28-/m1/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01529","(-)-Epigallocatechin","72277","XMOCLSLCDHWDHP-IUODEOHRSA-N","InChI=1S/C15H14O7/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6/h1-4,12,15-21H,5H2/t12-,15-/m1/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","(-)-Epigallocatechin, 3p-OH-glucuronide","76970196","CQDATFYRGVZXLF-ZVHNUXTDSA-N","InChI=1S/C21H22O13/c22-7-3-9(23)8-5-11(25)18(32-12(8)4-7)6-1-10(24)14(26)13(2-6)33-21-17(29)15(27)16(28)19(34-21)20(30)31/h1-4,11,15-19,21-29H,5H2,(H,30,31)/t11-,15+,16+,17-,18-,19+,21-/m1/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01530","2-Hydroxychalcone","5367146","UDOOPSJCRMKSGL-ZHACJKMWSA-N","InChI=1S/C15H12O2/c16-14-9-5-4-8-13(14)10-11-15(17)12-6-2-1-3-7-12/h1-11,16H/b11-10+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","2-Hydroxychalcone, 2-OH glucuronide","NULL","GPLMRRNNSBFFSU-QLTJWYTESA-N","InChI=1S/C21H20O8/c22-14(12-6-2-1-3-7-12)11-10-13-8-4-5-9-15(13)28-21-18(25)16(23)17(24)19(29-21)20(26)27/h1-11,16-19,21,23-25H,(H,26,27)/b11-10+/t16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01531","4-Hydroxychalcone","5282361","PWWCDTYUYPOAIU-DHZHZOJOSA-N","InChI=1S/C15H12O2/c16-14-9-6-12(7-10-14)8-11-15(17)13-4-2-1-3-5-13/h1-11,16H/b11-8+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","4-Hydroxychalcone, 4-OH-glucuronide","NULL","NFTLYQZAAUCPAS-BDOXZWLLSA-N","InChI=1S/C21H20O8/c22-15(13-4-2-1-3-5-13)11-8-12-6-9-14(10-7-12)28-21-18(25)16(23)17(24)19(29-21)20(26)27/h1-11,16-19,21,23-25H,(H,26,27)/b11-8+/t16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01532","2p-Hydroxychalcone","638276","AETKQQBRKSELEL-ZHACJKMWSA-N","InChI=1S/C15H12O2/c16-14-9-5-4-8-13(14)15(17)11-10-12-6-2-1-3-7-12/h1-11,16H/b11-10+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","2p-Hydroxychalcone, 2p-OH-glucuronide","NULL","IUCWBJDYFOIRIB-QLTJWYTESA-N","InChI=1S/C21H20O8/c22-14(11-10-12-6-2-1-3-7-12)13-8-4-5-9-15(13)28-21-18(25)16(23)17(24)19(29-21)20(26)27/h1-11,16-19,21,23-25H,(H,26,27)/b11-10+/t16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01533","4p-Hydroxychalcone","5282362","UAHGNXFYLAJDIN-IZZDOVSWSA-N","InChI=1S/C15H12O2/c16-14-9-7-13(8-10-14)15(17)11-6-12-4-2-1-3-5-12/h1-11,16H/b11-6+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","4p-Hydroxychalcone, 4p-OH-glucuronide","NULL","MQZCUJOHTHEMJF-BDQQXEQVSA-N","InChI=1S/C21H20O8/c22-15(11-6-12-4-2-1-3-5-12)13-7-9-14(10-8-13)28-21-18(25)16(23)17(24)19(29-21)20(26)27/h1-11,16-19,21,23-25H,(H,26,27)/b11-6+/t16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01534","Phloretin","4788","VGEREEWJJVICBM-UHFFFAOYSA-N","InChI=1S/C15H14O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20H,3,6H2","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Phloretin, 2p-OH-glucuronide","NULL","BQYYEYGIAKEJPL-QNDFHXLGSA-N","InChI=1S/C21H22O10/c22-9-16-18(27)19(28)20(29)21(31-16)30-15-8-12(24)7-14(26)17(15)13(25)6-3-10-1-4-11(23)5-2-10/h1-2,4-5,7-9,16,18-21,23-24,26-29H,3,6H2/t16-,18-,19+,20-,21-/m1/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01535","Phloretin","4788","VGEREEWJJVICBM-UHFFFAOYSA-N","InChI=1S/C15H14O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20H,3,6H2","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Phloretin, 4p-OH-glucuronide","NULL","RJFGKPUMNZYKLG-ZFORQUDYSA-N","InChI=1S/C21H22O11/c22-10-4-1-9(2-5-10)3-6-12(23)15-13(24)7-11(8-14(15)25)31-21-18(28)16(26)17(27)19(32-21)20(29)30/h1-2,4-5,7-8,16-19,21-22,24-28H,3,6H2,(H,29,30)/t16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01536","7-Hydroxychromone","5409279","WVJCRTSTRGRJJT-UHFFFAOYSA-N","InChI=1S/C9H6O3/c10-6-1-2-7-8(11)3-4-12-9(7)5-6/h1-5,10H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","7-Hydroxychromone, 7-OH-glucuronide","NULL","OUHVBXUCPLMBNL-DKBOKBLXSA-N","InChI=1S/C15H14O9/c16-8-3-4-22-9-5-6(1-2-7(8)9)23-15-12(19)10(17)11(18)13(24-15)14(20)21/h1-5,10-13,15,17-19H,(H,20,21)/t10-,11-,12+,13-,15+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01537","3,4-Diphenyl-7-hydroxycoumarin","5393175","AABUKWVVUWBZCS-UHFFFAOYSA-N","InChI=1S/C21H14O3/c22-16-11-12-17-18(13-16)24-21(23)20(15-9-5-2-6-10-15)19(17)14-7-3-1-4-8-14/h1-13,22H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","3,4-Diphenyl-7-hydroxycoumarin, 7-OH-glucuronide","NULL","QHFKYWZGVOSUJH-RTCYWULBSA-N","InChI=1S/C27H22O9/c28-21-22(29)24(25(31)32)36-27(23(21)30)34-16-11-12-17-18(13-16)35-26(33)20(15-9-5-2-6-10-15)19(17)14-7-3-1-4-8-14/h1-13,21-24,27-30H,(H,31,32)/t21-,22-,23+,24-,27+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01538","4-Methylumbelliferone","5280567","HSHNITRMYYLLCV-UHFFFAOYSA-N","InChI=1S/C10H8O3/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9/h2-5,11H,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","4-Methylumbelliferone O-glucuronide","91553","ARQXEQLMMNGFDU-JHZZJYKESA-N","InChI=1S/C16H16O9/c1-6-4-10(17)24-9-5-7(2-3-8(6)9)23-16-13(20)11(18)12(19)14(25-16)15(21)22/h2-5,11-14,16,18-20H,1H3,(H,21,22)/t11-,12-,13+,14-,16+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01539","4-Hydroxy-6-methylcoumarin","54686349","WIRGBZBGYNIZIB-UHFFFAOYSA-N","InChI=1S/C10H8O3/c1-6-2-3-9-7(4-6)8(11)5-10(12)13-9/h2-5,11H,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","6-methylcoumarin, 4-O-glucuronide","NULL","FTVGAEZOOOWWQS-JHZZJYKESA-N","InChI=1S/C16H16O9/c1-6-2-3-8-7(4-6)9(5-10(17)23-8)24-16-13(20)11(18)12(19)14(25-16)15(21)22/h2-5,11-14,16,18-20H,1H3,(H,21,22)/t11-,12-,13+,14-,16+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01540","6-Hydroxy-7-methoxyl-4-phenylcoumarin","442768","AZELSOYQOIUPBZ-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-15-9-14-12(7-13(15)17)11(8-16(18)20-14)10-5-3-2-4-6-10/h2-9,17H,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","7-methoxyl-4-phenylcoumarin, 6-O-glucuronide","NULL","BUAGEPZSSIYTQL-SXFAUFNYSA-N","InChI=1S/C22H20O10/c1-29-14-9-13-12(11(8-16(23)30-13)10-5-3-2-4-6-10)7-15(14)31-22-19(26)17(24)18(25)20(32-22)21(27)28/h2-9,17-20,22,24-26H,1H3,(H,27,28)/t17-,18-,19+,20-,22+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01541","8-Hydroxywarfarin","54697550","BHBOXPNWDGYJNB-UHFFFAOYSA-N","InChI=1S/C19H16O5/c1-11(20)10-14(12-6-3-2-4-7-12)16-17(22)13-8-5-9-15(21)18(13)24-19(16)23/h2-9,14,21-22H,10H2,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Warfarin 8-O-glucuronide","71749423","CFVGBYFDDKYFMF-JAGVPYGBSA-N","InChI=1S/C25H24O11/c1-11(26)10-14(12-6-3-2-4-7-12)16-17(27)13-8-5-9-15(21(13)35-24(16)33)34-25-20(30)18(28)19(29)22(36-25)23(31)32/h2-9,14,18-20,22,25,27-30H,10H2,1H3,(H,31,32)/t14?,18-,19-,20+,22-,25+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01542","7-Hydroxywarfarin","54692246","SKFYEJMLNMTTJA-HNNXBMFYSA-N","InChI=1S/C19H16O5/c1-11(20)9-15(12-5-3-2-4-6-12)17-18(22)14-8-7-13(21)10-16(14)24-19(17)23/h2-8,10,15,21-22H,9H2,1H3/t15-/m0/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Warfarin 7-O-glucuronide","96364756","HGQPQZDYDCOEEI-YOECQAABSA-N","InChI=1S/C25H24O11/c1-11(26)9-15(12-5-3-2-4-6-12)17-18(27)14-8-7-13(10-16(14)35-24(17)33)34-25-21(30)19(28)20(29)22(36-25)23(31)32/h2-8,10,15,19-22,25,27-30H,9H2,1H3,(H,31,32)/t15-,19-,20-,21+,22-,25+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01543","6-Hydroxywarfarin","54731323","IQWPEJBUOJQPDE-AWEZNQCLSA-N","InChI=1S/C19H16O5/c1-11(20)9-14(12-5-3-2-4-6-12)17-18(22)15-10-13(21)7-8-16(15)24-19(17)23/h2-8,10,14,21-22H,9H2,1H3/t14-/m0/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Warfarin 6-O-glucuronide","NULL","WVBVHLXQTOAFHW-AXCBLOFJSA-N","InChI=1S/C25H24O11/c1-11(26)9-14(12-5-3-2-4-6-12)17-18(27)15-10-13(7-8-16(15)35-24(17)33)34-25-21(30)19(28)20(29)22(36-25)23(31)32/h2-8,10,14,19-22,25,27-30H,9H2,1H3,(H,31,32)/t14-,19-,20-,21+,22-,25+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01544","Scopoletin","5280460","RODXRVNMMDRFIK-UHFFFAOYSA-N","InChI=1S/C10H8O4/c1-13-9-4-6-2-3-10(12)14-8(6)5-7(9)11/h2-5,11H,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Scopoletin OH-glucuronide","25791063","UTTLUAQBFYOVMO-JHZZJYKESA-N","InChI=1S/C16H16O10/c1-23-8-4-6-2-3-10(17)24-7(6)5-9(8)25-16-13(20)11(18)12(19)14(26-16)15(21)22/h2-5,11-14,16,18-20H,1H3,(H,21,22)/t11-,12-,13+,14-,16+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01545","Curcumin","969516","VFLDPWHFBUODDF-FCXRPNKRSA-N","InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Curcumin 4-O-glucuronide","71315012","BNSAVBGHRVFVNN-XSCLDSQRSA-N","InChI=1S/C27H28O12/c1-36-20-11-14(5-9-18(20)30)3-7-16(28)13-17(29)8-4-15-6-10-19(21(12-15)37-2)38-27-24(33)22(31)23(32)25(39-27)26(34)35/h3-12,22-25,27,30-33H,13H2,1-2H3,(H,34,35)/b7-3+,8-4+/t22-,23-,24+,25-,27+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01546","Demethoxycurcumin","5469424","HJTVQHVGMGKONQ-LUZURFALSA-N","InChI=1S/C20H18O5/c1-25-20-12-15(6-11-19(20)24)5-10-18(23)13-17(22)9-4-14-2-7-16(21)8-3-14/h2-12,21,24H,13H2,1H3/b9-4+,10-5+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Demethoxycurcumin O-glucuronide","90478404","YWKJMTRJZNWNFX-RMUOXEHGSA-N","InChI=1S/C26H26O11/c1-35-20-12-15(5-10-18(29)13-17(28)9-4-14-2-7-16(27)8-3-14)6-11-19(20)36-26-23(32)21(30)22(31)24(37-26)25(33)34/h2-12,21-24,26-27,30-32H,13H2,1H3,(H,33,34)/b9-4+,10-5+/t21-,22-,23+,24-,26+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01547","Bisdemethoxycurcumin","5315472","PREBVFJICNPEKM-YDWXAUTNSA-N","InChI=1S/C19H16O4/c20-16-7-1-14(2-8-16)5-11-18(22)13-19(23)12-6-15-3-9-17(21)10-4-15/h1-12,20-21H,13H2/b11-5+,12-6+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Bisdemethoxycurcumin, 4-O-glucuronide","NULL","YPAFJYREFRCBIU-QRSXUEDKSA-N","InChI=1S/C25H24O10/c26-16-7-1-14(2-8-16)3-9-17(27)13-18(28)10-4-15-5-11-19(12-6-15)34-25-22(31)20(29)21(30)23(35-25)24(32)33/h1-12,20-23,25-26,29-31H,13H2,(H,32,33)/b9-3+,10-4+/t20-,21-,22+,23-,25+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01548","Emodin","3220","RHMXXJGYXNZAPX-UHFFFAOYSA-N","InChI=1S/C15H10O5/c1-6-2-8-12(10(17)3-6)15(20)13-9(14(8)19)4-7(16)5-11(13)18/h2-5,16-18H,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Emodin 3-OH-glucuronide","NULL","UOVNRYPZHIVMBG-ZFORQUDYSA-N","InChI=1S/C21H18O11/c1-6-2-8-12(10(22)3-6)15(25)13-9(14(8)24)4-7(5-11(13)23)31-21-18(28)16(26)17(27)19(32-21)20(29)30/h2-5,16-19,21-23,26-28H,1H3,(H,29,30)/t16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01549","Endoxifen","10090750","MHJBZVSGOZTKRH-IZHYLOQSSA-N","InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Endoxifen O-glucuronide","71315759","HSQYCNXRYHIGKV-QXBBUDDSSA-N","InChI=1S/C31H35NO8/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(14-10-20)38-18-17-32-2)21-11-15-23(16-12-21)39-31-28(35)26(33)27(34)29(40-31)30(36)37/h4-16,26-29,31-35H,3,17-18H2,1-2H3,(H,36,37)/b25-24+/t26-,27-,28+,29-,31+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01550","Endoxifen","10090750","MHJBZVSGOZTKRH-IZHYLOQSSA-N","InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-","SULT","4-OH sulfonation of phenolic compound","Human Phase II","Human","Endoxifen O-sulfate","131770047","DHSITAIKYQFMGG-OCOZRVBESA-N","InChI=1S/C25H27NO5S/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(14-10-20)30-18-17-26-2)21-11-15-23(16-12-21)31-32(27,28)29/h4-16,26H,3,17-18H2,1-2H3,(H,27,28,29)/b25-24+","http://www.hmdb.ca/metabolites/HMDB0061140"
"BIOTID01551","Enterolactone","10685477","HVDGDHBAMCBBLR-WMLDXEAASA-N","InChI=1S/C18H18O4/c19-15-5-1-3-12(8-15)7-14-11-22-18(21)17(14)10-13-4-2-6-16(20)9-13/h1-6,8-9,14,17,19-20H,7,10-11H2/t14-,17+/m0/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Enterolactone O-glucuronide","NULL","YPASCVZALRQWQG-XARNJOGHSA-N","InChI=1S/C24H26O10/c25-15-5-1-3-13(8-15)10-17-14(11-32-23(17)31)7-12-4-2-6-16(9-12)33-24-20(28)18(26)19(27)21(34-24)22(29)30/h1-6,8-9,14,17-21,24-28H,7,10-11H2,(H,29,30)/t14-,17+,18-,19-,20+,21-,24+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01552","1-Naphthol","7005","KJCVRFUGPWSIIH-UHFFFAOYSA-N","InChI=1S/C10H8O/c11-10-7-3-5-8-4-1-2-6-9(8)10/h1-7,11H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","1-Naphthyl glucuronide","114851","KEQWBZWOGRCILF-JHZZJYKESA-N","InChI=1S/C16H16O7/c17-11-12(18)14(15(20)21)23-16(13(11)19)22-10-7-3-5-8-4-1-2-6-9(8)10/h1-7,11-14,16-19H,(H,20,21)/t11-,12-,13+,14-,16+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01553","Raloxifene","5035","GZUITABIAKMVPG-UHFFFAOYSA-N","InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Raloxifene 6-O-glucuronide","10100752","MZPMSLSINDGEPM-WKRHDJAJSA-N","InChI=1S/C34H35NO10S/c36-21-8-4-20(5-9-21)32-26(27(37)19-6-10-22(11-7-19)43-17-16-35-14-2-1-3-15-35)24-13-12-23(18-25(24)46-32)44-34-30(40)28(38)29(39)31(45-34)33(41)42/h4-13,18,28-31,34,36,38-40H,1-3,14-17H2,(H,41,42)/t28-,29-,30+,31-,34+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01554","Tyrphostin B42","5328779","TUCIOBMMDDOEMM-RIYZIHGNSA-N","InChI=1S/C17H14N2O3/c18-10-14(8-13-6-7-15(20)16(21)9-13)17(22)19-11-12-4-2-1-3-5-12/h1-9,20-21H,11H2,(H,19,22)/b14-8+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Tyrphostin B42, 3-O-glucuronide","NULL","GYLASZALTGFHAR-DLYXBSSTSA-N","InChI=1S/C23H22N2O9/c24-10-14(21(30)25-11-12-4-2-1-3-5-12)8-13-6-7-15(26)16(9-13)33-23-19(29)17(27)18(28)20(34-23)22(31)32/h1-9,17-20,23,26-29H,11H2,(H,25,30)(H,31,32)/b14-8+/t17-,18-,19+,20-,23+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01555","Tyrphostin B42","5328779","TUCIOBMMDDOEMM-RIYZIHGNSA-N","InChI=1S/C17H14N2O3/c18-10-14(8-13-6-7-15(20)16(21)9-13)17(22)19-11-12-4-2-1-3-5-12/h1-9,20-21H,11H2,(H,19,22)/b14-8+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Tyrphostin B42, 4-O-glucuronide","NULL","SSBVDYQLOOVCBF-DLYXBSSTSA-N","InChI=1S/C23H22N2O9/c24-10-14(21(30)25-11-12-4-2-1-3-5-12)8-13-6-7-16(15(26)9-13)33-23-19(29)17(27)18(28)20(34-23)22(31)32/h1-9,17-20,23,26-29H,11H2,(H,25,30)(H,31,32)/b14-8+/t17-,18-,19+,20-,23+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01556","7-Hydroxyflavanone","1890","SWAJPHCXKPCPQZ-UHFFFAOYSA-N","InChI=1S/C15H12O3/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14,16H,9H2","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Flavanone 7-O-glucuronide","NULL","UEJIGELLVFMCDJ-ZURLMRQQSA-N","InChI=1S/C21H20O9/c22-13-9-14(10-4-2-1-3-5-10)29-15-8-11(6-7-12(13)15)28-21-18(25)16(23)17(24)19(30-21)20(26)27/h1-8,14,16-19,21,23-25H,9H2,(H,26,27)/t14?,16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01557","4p-Hydroxy-3-methoxyflavanone","3921635","ARFRWVLNDNZOTL-UHFFFAOYSA-N","InChI=1S/C16H14O4/c1-19-16-14(18)12-4-2-3-5-13(12)20-15(16)10-6-8-11(17)9-7-10/h2-9,15-17H,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","3-methoxyflavanone 4p-O-glucuronide","NULL","WDDSPDYCSXOPOD-DRAIGCMDSA-N","InChI=1S/C22H22O10/c1-29-19-14(23)12-4-2-3-5-13(12)31-18(19)10-6-8-11(9-7-10)30-22-17(26)15(24)16(25)20(32-22)21(27)28/h2-9,15-20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,18?,19?,20-,22+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01558","Hesperetin","72281","AIONOLUJZLIMTK-AWEZNQCLSA-N","InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Hesperetin 7-O-glucuronide","56598869","NEAWXAXVQDDFJL-QBUJOIIVSA-N","InChI=1S/C22H22O12/c1-31-13-3-2-8(4-10(13)23)14-7-12(25)16-11(24)5-9(6-15(16)33-14)32-22-19(28)17(26)18(27)20(34-22)21(29)30/h2-6,14,17-20,22-24,26-28H,7H2,1H3,(H,29,30)/t14-,17-,18-,19+,20-,22+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01559","Hesperetin","72281","AIONOLUJZLIMTK-AWEZNQCLSA-N","InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Hesperetin 3p-O-glucuronide","101644602","PJAUEKWZQWLQSU-ZQUMRXHJSA-N","InChI=1S/C22H22O12/c1-31-12-3-2-8(13-7-11(25)16-10(24)5-9(23)6-15(16)32-13)4-14(12)33-22-19(28)17(26)18(27)20(34-22)21(29)30/h2-6,13,17-20,22-24,26-28H,7H2,1H3,(H,29,30)/t13-,17-,18-,19+,20-,22+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01560","Narigenin","932","FTVWIRXFELQLPI-UHFFFAOYSA-N","InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Narigenin 7-O-glucuronide","51136360","BDCRTIDKZGEVEN-DNPGXZAYSA-N","InChI=1S/C21H20O11/c22-9-3-1-8(2-4-9)13-7-12(24)15-11(23)5-10(6-14(15)31-13)30-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-6,13,16-19,21-23,25-27H,7H2,(H,28,29)/t13?,16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01561","2p-Hydroxyflavone","161860","ZZLQHXCRRMUGQJ-UHFFFAOYSA-N","InChI=1S/C15H10O3/c16-12-7-3-1-5-10(12)15-9-13(17)11-6-2-4-8-14(11)18-15/h1-9,16H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Flavone 2p-O-glucuronide","NULL","FTGGCUZKPXEQLO-ZFORQUDYSA-N","InChI=1S/C21H18O9/c22-12-9-15(28-13-7-3-1-5-10(12)13)11-6-2-4-8-14(11)29-21-18(25)16(23)17(24)19(30-21)20(26)27/h1-9,16-19,21,23-25H,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01562","3,4p-Dimethoxy-5,7,3p-trihydroxyflavone","5380905","ZSPZNFOLWQEVQJ-UHFFFAOYSA-N","InChI=1S/C17H14O7/c1-22-12-4-3-8(5-10(12)19)16-17(23-2)15(21)14-11(20)6-9(18)7-13(14)24-16/h3-7,18-20H,1-2H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","3,4p-Dimethoxy-5,3p-dihydroxyflavone, 7-O-glucuronide","NULL","UKBHRTHHHQNBBM-USFRMQJTSA-N","InChI=1S/C23H22O13/c1-32-12-4-3-8(5-10(12)24)19-20(33-2)15(26)14-11(25)6-9(7-13(14)35-19)34-23-18(29)16(27)17(28)21(36-23)22(30)31/h3-7,16-18,21,23-25,27-29H,1-2H3,(H,30,31)/t16-,17-,18+,21-,23+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01563","3p-Benzyloxy-5,7-dihydroxy-3,4p-dimethoxyflavone","15342836","JPEXDMDZYIHQEF-UHFFFAOYSA-N","InChI=1S/C24H20O7/c1-28-18-9-8-15(10-19(18)30-13-14-6-4-3-5-7-14)23-24(29-2)22(27)21-17(26)11-16(25)12-20(21)31-23/h3-12,25-26H,13H2,1-2H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","3p-Benzyloxy-5-hydroxy-3,4p-dimethoxyflavone, 7-O-glucuronide","NULL","VKLOPIOKVYIWJA-IRODMLLSSA-N","InChI=1S/C30H28O13/c1-38-18-9-8-15(10-19(18)40-13-14-6-4-3-5-7-14)26-27(39-2)22(32)21-17(31)11-16(12-20(21)42-26)41-30-25(35)23(33)24(34)28(43-30)29(36)37/h3-12,23-25,28,30-31,33-35H,13H2,1-2H3,(H,36,37)/t23-,24-,25+,28-,30+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01564","3p-Hydroxyflavone","229015","ISZWRZGKEWQACU-UHFFFAOYSA-N","InChI=1S/C15H10O3/c16-11-5-3-4-10(8-11)15-9-13(17)12-6-1-2-7-14(12)18-15/h1-9,16H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Flavone 3p-O-glucuronide","NULL","DHKTZCRUILGBGI-ZFORQUDYSA-N","InChI=1S/C21H18O9/c22-13-9-15(29-14-7-2-1-6-12(13)14)10-4-3-5-11(8-10)28-21-18(25)16(23)17(24)19(30-21)20(26)27/h1-9,16-19,21,23-25H,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01565","4p-Hydroxyflavone","229016","SHGLJXBLXNNCTE-UHFFFAOYSA-N","InChI=1S/C15H10O3/c16-11-7-5-10(6-8-11)15-9-13(17)12-3-1-2-4-14(12)18-15/h1-9,16H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Flavone 4p-O-glucuronide","NULL","RBIKMLZICCKZKT-ZFORQUDYSA-N","InChI=1S/C21H18O9/c22-13-9-15(29-14-4-2-1-3-12(13)14)10-5-7-11(8-6-10)28-21-18(25)16(23)17(24)19(30-21)20(26)27/h1-9,16-19,21,23-25H,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01566","5,7-Dihydroxy-3p,4p,5p-trimethoxyflavone","5379265","CPCPHNWWTJLXKQ-UHFFFAOYSA-N","InChI=1S/C18H16O7/c1-22-15-4-9(5-16(23-2)18(15)24-3)13-8-12(21)17-11(20)6-10(19)7-14(17)25-13/h4-8,19-20H,1-3H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","5-Hydroxy-3p,4p,5p-trimethoxyflavone, 7-O-glucuronide","NULL","KEMQFZFXWQLCKM-MJRVOHGCSA-N","InChI=1S/C24H24O13/c1-32-15-4-9(5-16(33-2)21(15)34-3)13-8-12(26)17-11(25)6-10(7-14(17)36-13)35-24-20(29)18(27)19(28)22(37-24)23(30)31/h4-8,18-20,22,24-25,27-29H,1-3H3,(H,30,31)/t18-,19-,20+,22-,24+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|R(2) http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01567","2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine","1530","UQVKZNNCIHJZLS-UHFFFAOYSA-N","InChI=1S/C13H12N4/c1-17-11-7-10(9-5-3-2-4-6-9)8-15-12(11)16-13(17)14/h2-8H,1H3,(H2,14,15,16)","UGT1A1; UGT1A3; UGT1A4)","Glucuronidation of primary aromatic amine","Human Phase II","Human","2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, N2-glucuronide","71313317","SQVPGYDPSLNFET-KSXIZUIISA-N","InChI=1S/C19H20N4O6/c1-23-11-7-10(9-5-3-2-4-6-9)8-20-16(11)21-19(23)22-17-14(26)12(24)13(25)15(29-17)18(27)28/h2-8,12-15,17,24-26H,1H3,(H,27,28)(H,20,21,22)/t12-,13-,14+,15-,17+/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k|Walters DG et al. (2004); Carcinogenesis vol.25 no.9 pp.1659-1669; doi:10.1093/carcin/bgh164"
"BIOTID01568","N2-OH-PhIP","104954","DCVWQAGUQFBCTF-UHFFFAOYSA-N","InChI=1S/C13H12N4O/c1-17-11-7-10(9-5-3-2-4-6-9)8-14-12(11)15-13(17)16-18/h2-8,18H,1H3,(H,14,15,16)","UGT","N-Glucuronidation","Human Phase II","Human","N2-OH-PhIP-N3-glucuronide","NULL","DITDTOGZURUPRH-KSXIZUIISA-O","InChI=1S/C19H20N4O7/c1-22-11-7-10(9-5-3-2-4-6-9)8-20-16(11)23(19(22)21-29)17-14(26)12(24)13(25)15(30-17)18(27)28/h2-8,12-15,17,24-26H,1H3,(H2,27,28,29)/p+1/t12-,13-,14+,15-,17+/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k|Walters DG et al. (2004); Carcinogenesis vol.25 no.9 pp.1659-1669; doi:10.1093/carcin/bgh164"
"BIOTID01569","N2-OH-PhIP","104954","DCVWQAGUQFBCTF-UHFFFAOYSA-N","InChI=1S/C13H12N4O/c1-17-11-7-10(9-5-3-2-4-6-9)8-14-12(11)15-13(17)16-18/h2-8,18H,1H3,(H,14,15,16)","UGT","Hydroxylamine O-glucuronidation","Human Phase II","Human","N2-OH-PhIP-N2-glucuronide","121230711","YZOJGZCDCRPMLU-GLRLOKQVSA-N","InChI=1S/C19H20N4O7/c1-23-11-7-10(9-5-3-2-4-6-9)8-20-16(11)21-19(23)22-30-18-14(26)12(24)13(25)15(29-18)17(27)28/h2-8,12-15,18,24-26H,1H3,(H,27,28)(H,20,21,22)/t12-,13-,14+,15-,18-/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k|Walters DG et al. (2004); Carcinogenesis vol.25 no.9 pp.1659-1669; doi:10.1093/carcin/bgh164"
"BIOTID01570","4'-OH-PhIP","15897928","UGJXOCBVCWTJFP-UHFFFAOYSA-N","InChI=1S/C13H12N4O/c1-17-11-6-9(7-15-12(11)16-13(17)14)8-2-4-10(18)5-3-8/h2-7,18H,1H3,(H2,14,15,16)","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","PhIP 4'-O-glucuronide","NULL","UNVUNODRTHJKHH-PYOGLGTISA-N","InChI=1S/C19H20N4O7/c1-23-11-6-9(7-21-16(11)22-19(23)20)8-2-4-10(5-3-8)29-18-14(26)12(24)13(25)15(30-18)17(27)28/h2-7,12-15,18,24-26H,1H3,(H,27,28)(H2,20,21,22)/t12-,13-,14+,15-,18+/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k|Walters DG et al. (2004); Carcinogenesis vol.25 no.9 pp.1659-1669; doi:10.1093/carcin/bgh164"
"BIOTID01571","2-hydroxyestradiol","247304","DILDHNKDVHLEQB-XSSYPUMDSA-N","InChI=1S/C18H24O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,17,19-21H,2-7H2,1H3/t11-,12+,14-,17-,18-/m0/s1","UGT1A1; UGT1A3; UGT1A7; UGT1A8; UGT1A10","Aromatic -OH glucuronidation","Human Phase II","Human","Estradiol 2-O-glucuronide","14016228","JWRIQYSRJXLEHG-OBRRSLBQSA-N","InChI=1S/C24H32O9/c1-24-7-6-11-12(14(24)4-5-17(24)26)3-2-10-8-15(25)16(9-13(10)11)32-23-20(29)18(27)19(28)21(33-23)22(30)31/h8-9,11-12,14,17-21,23,25-29H,2-7H2,1H3,(H,30,31)/t11-,12+,14-,17-,18-,19-,20+,21-,23+,24-/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01572","2-hydroxyestradiol","247304","DILDHNKDVHLEQB-XSSYPUMDSA-N","InChI=1S/C18H24O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,17,19-21H,2-7H2,1H3/t11-,12+,14-,17-,18-/m0/s1","S-COMT","O-methylation","Human Phase II","Human","2-O-methoxyestradiol","66414","CQOQDQWUFQDJMK-SSTWWWIQSA-N","InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01573","2-hydroxyestradiol","247304","DILDHNKDVHLEQB-XSSYPUMDSA-N","InChI=1S/C18H24O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,17,19-21H,2-7H2,1H3/t11-,12+,14-,17-,18-/m0/s1","S-COMT","O-methylation","Human Phase II","Human","3-O-methoxyestradiol","13267935","MMKYSUOJWFKECQ-SSTWWWIQSA-N","InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-17(22-2)16(20)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01574","2-hydroxyestrone","440623","SWINWPBPEKHUOD-JPVZDGGYSA-N","InChI=1S/C18H22O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,19-20H,2-7H2,1H3/t11-,12+,14-,18-/m0/s1","S-COMT","O-methylation","Human Phase II","Human","2-O-methoxyestrone","440624","WHEUWNKSCXYKBU-QPWUGHHJSA-N","InChI=1S/C19H24O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,20H,3-8H2,1-2H3/t12-,13+,15-,19-/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01575","2-hydroxyestrone","440623","SWINWPBPEKHUOD-JPVZDGGYSA-N","InChI=1S/C18H22O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,19-20H,2-7H2,1H3/t11-,12+,14-,18-/m0/s1","S-COMT","O-methylation","Human Phase II","Human","3-O-methoxyestrone","13831793","YBCPNMOFBUWYTP-QPWUGHHJSA-N","InChI=1S/C19H24O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-17(22-2)16(20)10-14(11)12/h9-10,12-13,15,20H,3-8H2,1-2H3/t12-,13+,15-,19-/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01576","2-hydroxyestrone","440623","SWINWPBPEKHUOD-JPVZDGGYSA-N","InChI=1S/C18H22O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,19-20H,2-7H2,1H3/t11-,12+,14-,18-/m0/s1","UGT1A1; UGT1A7; UGT1A8; UGT1A10","Aromatic -OH glucuronidation","Human Phase II","Human","Estrone 2-O-glucuronide","14016224","DQNRWYSYNOPGQY-FKYASPJISA-N","InChI=1S/C24H30O9/c1-24-7-6-11-12(14(24)4-5-17(24)26)3-2-10-8-15(25)16(9-13(10)11)32-23-20(29)18(27)19(28)21(33-23)22(30)31/h8-9,11-12,14,18-21,23,25,27-29H,2-7H2,1H3,(H,30,31)/t11-,12+,14-,18-,19-,20+,21-,23+,24-/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01577","4-hydroxyestrone","9971251","XQZVQQZZOVBNLU-QDTBLXIISA-N","InChI=1S/C18H22O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,19,21H,2-3,5,7-9H2,1H3/t11-,12-,14+,18+/m1/s1","UGT1A1; UGT1A3; UGT1A7; UGT1A8; UGT1A10","Aromatic -OH glucuronidation","Human Phase II","Human","Estrone 4-O-glucuronide","129011097","XSEHSKUBWMKIFT-ATASCAFHSA-N","InChI=1S/C24H30O9/c1-24-9-8-11-10-4-6-15(25)20(13(10)3-2-12(11)14(24)5-7-16(24)26)32-23-19(29)17(27)18(28)21(33-23)22(30)31/h4,6,11-12,14,17-19,21,23,25,27-29H,2-3,5,7-9H2,1H3,(H,30,31)/t11-,12-,14+,17+,18+,19-,21+,23-,24+/m1/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01578","4-hydroxyestrone","9971251","XQZVQQZZOVBNLU-QDTBLXIISA-N","InChI=1S/C18H22O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,19,21H,2-3,5,7-9H2,1H3/t11-,12-,14+,18+/m1/s1","S-COMT","O-methylation","Human Phase II","Human","4-methoxyestrone","194066","PUEXVLNGOBYUEW-BFDPJXHCSA-N","InChI=1S/C19H24O3/c1-19-10-9-12-11-5-7-16(20)18(22-2)14(11)4-3-13(12)15(19)6-8-17(19)21/h5,7,12-13,15,20H,3-4,6,8-10H2,1-2H3/t12-,13-,15+,19+/m1/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01579","dibenzo[a,l]pyrene-11,12- diol","15418687","MIKPSGCFJZJLRS-UHFFFAOYSA-N","InChI=1S/C24H14O2/c25-20-11-10-18-19(24(20)26)12-14-9-8-13-4-3-7-16-15-5-1-2-6-17(15)23(18)22(14)21(13)16/h1-12,25-26H","UGT1A1; UGT1A4","Aromatic -OH glucuronidation","Human Phase II","Human","dibenzo[a,l]pyrene-11-ol, 12-O-glucuronide","NULL","VYNUATGPWOYQRU-NEOPOEGOSA-N","InChI=1S/C30H22O8/c31-24-19-12-14-9-8-13-4-3-7-16-15-5-1-2-6-17(15)23(22(14)21(13)16)18(19)10-11-20(24)37-30-27(34)25(32)26(33)28(38-30)29(35)36/h1-12,25-28,30-34H,(H,35,36)/t25-,26-,27+,28-,30+/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01580","dibenzo[a,l]pyrene-11,12- diol","15418687","MIKPSGCFJZJLRS-UHFFFAOYSA-N","InChI=1S/C24H14O2/c25-20-11-10-18-19(24(20)26)12-14-9-8-13-4-3-7-16-15-5-1-2-6-17(15)23(18)22(14)21(13)16/h1-12,25-26H","UGT1A1; UGT1A4","Aromatic -OH glucuronidation","Human Phase II","Human","dibenzo[a,l]pyrene-12-ol, 11-O-glucuronide","NULL","AQEIIITVYFRNER-ZLBJCVPKSA-N","InChI=1S/C30H22O8/c31-20-11-10-18-19(27(20)37-30-26(34)24(32)25(33)28(38-30)29(35)36)12-14-9-8-13-4-3-7-16-15-5-1-2-6-17(15)23(18)22(14)21(13)16/h1-12,24-26,28,30-34H,(H,35,36)/t24-,25-,26+,28-,30+/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01581","17-beta-estradiol","5757","VOXZDWNPVJITMN-ZBRFXRBCSA-N","InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1","UGT1A1; UGT1A3; UGT1A7; UGT1A8; UGT1A10","17-OH glucuronidation of sterol","Human Phase II","Human","17-beta-Estradiol glucuronide","9955293","MTKNDAQYHASLID-BFXFFQJBSA-N","InChI=1S/C24H32O8/c1-24-9-8-14-13-5-3-12(25)10-11(13)2-4-15(14)16(24)6-7-17(24)31-23-20(28)18(26)19(27)21(32-23)22(29)30/h3,5,10,14-21,23,25-28H,2,4,6-9H2,1H3,(H,29,30)/t14-,15-,16+,17+,18+,19+,20-,21+,23?,24+/m1/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01582","4-hydroxytamoxifen","449459","TXUZVZSFRXZGTL-QPLCGJKRSA-N","InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-","UGT1A1; UGT1A4; UGT1A6; UGT1A7; UGT1A8; UGT1A9; UGT1A10; UGT2B15; UGT2B17; UGT2B7","Aromatic -OH glucuronidation","Human Phase II","Human","Tamoxifen 4-O-glucuronide","71749358","SSRNQFUJUAOPJD-OFKVRPASSA-N","InChI=1S/C32H37NO8/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(15-11-21)39-19-18-33(2)3)22-12-16-24(17-13-22)40-32-29(36)27(34)28(35)30(41-32)31(37)38/h5-17,27-30,32,34-36H,4,18-19H2,1-3H3,(H,37,38)/b26-25+/t27-,28-,29+,30-,32+/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01583","4-hydroxytamoxifen","449459","TXUZVZSFRXZGTL-QPLCGJKRSA-N","InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-","SULT1A1","4-OH sulfonation of phenolic compound","Human Phase II","Human","Tamoxifen 4-O-sulfate","NULL","CFSXIBDXCWVFJR-OCEACIFDSA-N","InChI=1S/C26H29NO5S/c1-4-25(20-8-6-5-7-9-20)26(22-12-16-24(17-13-22)32-33(28,29)30)21-10-14-23(15-11-21)31-19-18-27(2)3/h5-17H,4,18-19H2,1-3H3,(H,28,29,30)/b26-25+","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01584","tamoxifen","2733526","NKANXQFJJICGDU-QPLCGJKRSA-N","InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-","UGT1A4","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Tamoxifen N-glucuronide","NULL","UKFQQYJAYUAYES-VJGYKHGHSA-O","InChI=1S/C32H37NO7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)39-20-19-33(2,3)31-29(36)27(34)28(35)30(40-31)32(37)38/h5-18,27-31,34-36H,4,19-20H2,1-3H3/p+1/b26-25-/t27-,28-,29+,30-,31?/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01585","NÃ¢â‚¬â„¢-nitrosoanabasine","14335","BXYPVKMROLGXJI-UHFFFAOYSA-N","InChI=1S/C10H13N3O/c14-12-13-7-2-1-5-10(13)9-4-3-6-11-8-9/h3-4,6,8,10H,1-2,5,7H2","UGT2B10","N-Glucuronidation","Human Phase II","Human","NÃ¢â‚¬â„¢-nitrosoanabasine, N-glucuronide","NULL","CNFQJGRMFKQFEI-XRPMQRQJSA-O","InChI=1S/C16H21N3O7/c20-11-12(21)14(16(23)24)26-15(13(11)22)18-6-3-4-9(8-18)10-5-1-2-7-19(10)17-25/h3-4,6,8,10-15,20-22H,1-2,5,7H2/p+1/t10?,11-,12-,13+,14-,15?/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k|Chen G et al. (2008); Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10; Drug Metab Dispos. 2008 May;36(5):824-30; PMID:18238858; DOI:10.1124/dmd.107.019406"
"BIOTID01586","Np-nitrosonornicotine","27919","XKABJYQDMJTNGQ-UHFFFAOYSA-N","InChI=1S/C9H11N3O/c13-11-12-6-2-4-9(12)8-3-1-5-10-7-8/h1,3,5,7,9H,2,4,6H2","UGT2B10","N-Glucuronidation","Human Phase II","Human","Np-nitrosonornicotine, N-glucuronide","NULL","PSNAJRIZSDTBSS-GRTDBQQJSA-O","InChI=1S/C15H19N3O7/c19-10-11(20)13(15(22)23)25-14(12(10)21)17-5-1-3-8(7-17)9-4-2-6-18(9)16-24/h1,3,5,7,9-14,19-21H,2,4,6H2/p+1/t9?,10-,11-,12+,13-,14?/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k|Chen G et al. (2008); Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10; Drug Metab Dispos. 2008 May;36(5):824-30; PMID:18238858; DOI:10.1124/dmd.107.019406"
"BIOTID01587","Nicotine","942","SNICXCGAKADSCV-UHFFFAOYSA-N","InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3","UGT1A4; UGT1A9","N-Glucuronidation","Human Phase II","Human","Nicotine N-glucuronide","NULL","SAWAIULJDYFLPD-XRPMQRQJSA-O","InChI=1S/C16H22N2O6/c1-17-6-3-5-10(17)9-4-2-7-18(8-9)15-13(21)11(19)12(20)14(24-15)16(22)23/h2,4,7-8,10-15,19-21H,3,5-6H2,1H3/p+1/t10?,11-,12-,13+,14-,15?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01588","Cotinine","854019","UIKROCXWUNQSPJ-VIFPVBQESA-N","InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1","UGT1A4; UGT1A9","N-Glucuronidation","Human Phase II","Human","Cotinine N-glucuronide","NULL","XWZCZWKUGIQPJD-QGVFRFOYSA-O","InChI=1S/C16H20N2O7/c1-17-9(4-5-10(17)19)8-3-2-6-18(7-8)15-13(22)11(20)12(21)14(25-15)16(23)24/h2-3,6-7,9,11-15,20-22H,4-5H2,1H3/p+1/t9-,11-,12-,13+,14-,15?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01589","3-Phenoxybenozoic acid","19539","NXTDJHZGHOFSQG-UHFFFAOYSA-N","InChI=1S/C13H10O3/c14-13(15)10-5-4-8-12(9-10)16-11-6-2-1-3-7-11/h1-9H,(H,14,15)","UGT","O-glucuronidation of aromatic acid","Human Phase II","Human","3-Phenoxybenzoic acid glucuronide","6453558","AREJRLCRWVGGGN-NAHJCDBISA-N","InChI=1S/C19H18O9/c20-13-14(21)16(17(23)24)27-19(15(13)22)28-18(25)10-5-4-8-12(9-10)26-11-6-2-1-3-7-11/h1-9,13-16,19-22H,(H,23,24)/t13-,14-,15+,16-,19-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01590","3-Phenoxybenozoic acid","19539","NXTDJHZGHOFSQG-UHFFFAOYSA-N","InChI=1S/C13H10O3/c14-13(15)10-5-4-8-12(9-10)16-11-6-2-1-3-7-11/h1-9H,(H,14,15)","GLYAT (EC 2.3.1.13)","Glycination of aromatic acid","Human Phase II","Human","3-Phenoxybenzoylglycine","171625","IHTUCGBIFBJPEK-UHFFFAOYSA-N","InChI=1S/C15H13NO4/c17-14(18)10-16-15(19)11-5-4-8-13(9-11)20-12-6-2-1-3-7-12/h1-9H,10H2,(H,16,19)(H,17,18)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01591","4-hydroxy-2p,3,5-trichlorobiphenyl","15543903","XLRWQPVYQISORN-UHFFFAOYSA-N","InChI=1S/C12H7Cl3O/c13-9-4-2-1-3-8(9)7-5-10(14)12(16)11(15)6-7/h1-6,16H","SULT1A2","4-OH sulfonation of phenolic compound","Human Phase II","Human","2p,3,5-trichlorobiphenyl, 4-sulfate","NULL","XWDRZEQZEVVMAL-UHFFFAOYSA-N","InChI=1S/C12H7Cl3O4S/c13-9-4-2-1-3-8(9)7-5-10(14)12(11(15)6-7)19-20(16,17)18/h1-6H,(H,16,17,18)","Liu Y et al. (2006); Hydroxylated polychlorinated biphenyls are substrates and inhibitors of human hydroxysteroid sulfotransferase SULT2A1; Chem. Res. Toxicol. 19, 1420-1425"
"BIOTID01592","Dopamine","681","VYFYYTLLBUKUHU-UHFFFAOYSA-N","InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2","SULT","3-OH sulfonation of phenolic compound","Human Phase II","Human","dopamine 3-O-sulfate","25201578","NZKRYJGNYPYXJZ-UHFFFAOYSA-N","InChI=1S/C8H11NO5S/c9-4-3-6-1-2-7(10)8(5-6)14-15(11,12)13/h1-2,5,10H,3-4,9H2,(H,11,12,13)","http://www.hmdb.ca/metabolites/HMDB0002028"
"BIOTID01593","Dopamine","681","VYFYYTLLBUKUHU-UHFFFAOYSA-N","InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","Dopamine 4- D-Glucuronide","76064178","CQASRCDNLNMIJY-UHFFFAOYSA-N","InChI=1S/C14H19NO8/c15-4-3-6-1-2-8(7(16)5-6)22-14-11(19)9(17)10(18)12(23-14)13(20)21/h1-2,5,9-12,14,16-19H,3-4,15H2,(H,20,21)","https://www.drugbank.ca/drugs/DB00988"
"BIOTID01594","Gavestinel","6450546","WZBNEZWCNKUOSM-VOTSOKGWSA-N","InChI=1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)/b7-6+","UGT","O-glucuronidation of aromatic acid","Human Phase II","Human","gavestinel 4-O-acyl glucuronide","NULL","ITRQKRDZGOCGMA-COEUMGADSA-N","InChI=1S/C24H20Cl2N2O9/c25-10-8-13(26)16-12(6-7-15(29)27-11-4-2-1-3-5-11)17(28-14(16)9-10)23(35)37-24-20(32)18(30)19(31)21(36-24)22(33)34/h1-9,18-21,24,28,30-32H,(H,27,29)(H,33,34)/b7-6+/t18-,19-,20+,21-,24?/m0/s1","https://www.drugbank.ca/drugs/DB06741"
"BIOTID01596","p-OH-gavestinel","10548468","KAIGNSIVVAINPQ-AATRIKPKSA-N","InChI=1S/C18H12Cl2N2O4/c19-9-7-13(20)16-12(17(18(25)26)22-14(16)8-9)5-6-15(24)21-10-1-3-11(23)4-2-10/h1-8,22-23H,(H,21,24)(H,25,26)/b6-5+","SULT","4-OH sulfonation of phenolic compound","Human Phase II","Human","gavestinel 4-sulfate","NULL","HHDJDYHZOXVMIE-AATRIKPKSA-N","InChI=1S/C18H12Cl2N2O7S/c19-9-7-13(20)16-12(17(18(24)25)22-14(16)8-9)5-6-15(23)21-10-1-3-11(4-2-10)29-30(26,27)28/h1-8,22H,(H,21,23)(H,24,25)(H,26,27,28)/b6-5+","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675.|http://www.hmdb.ca/metabolites/HMDB0061130"
"BIOTID01597","3-hydroxyguanfacine","NULL","SHBGZECCBYCTEJ-UHFFFAOYSA-N","InChI=1S/C9H9Cl2N3O3/c10-7-3(1-6(17)14-9(12)13)8(11)5(16)2-4(7)15/h2,15-16H,1H2,(H4,12,13,14,17)","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","3-hydroxyguanfacine glucuronide","NULL","AUDUMKPECIWTMB-ZAOAHOKWSA-N","InChI=1S/C15H17Cl2N3O9/c16-7-3(1-6(22)20-15(18)19)8(17)5(2-4(7)21)28-14-11(25)9(23)10(24)12(29-14)13(26)27/h2,9-12,14,21,23-25H,1H2,(H,26,27)(H4,18,19,20,22)/t9-,10-,11+,12-,14?/m0/s1","https://www.drugbank.ca/drugs/DB01018"
"BIOTID01598","3-Hydroxymorphinan","5463854","IYNWSQDZXMGGGI-NUEKZKHPSA-N","InChI=1S/C16H21NO/c18-12-5-4-11-9-15-13-3-1-2-6-16(13,7-8-17-15)14(11)10-12/h4-5,10,13,15,17-18H,1-3,6-9H2/t13-,15+,16+/m0/s1","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","3-OH-morphinan -glucuronide","76973589","QYVMECDBFFRIEZ-OYXPUGGQSA-N","InChI=1S/C22H29NO7/c24-16-17(25)19(20(27)28)30-21(18(16)26)29-12-5-4-11-9-15-13-3-1-2-6-22(13,7-8-23-15)14(11)10-12/h4-5,10,13,15-19,21,23-26H,1-3,6-9H2,(H,27,28)/t13-,15+,16-,17-,18+,19-,21+,22+/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675.|http://www.hmdb.ca/metabolites/HMDB0061130"
"BIOTID01599","3-Hydroxymorphinan","5463854","IYNWSQDZXMGGGI-NUEKZKHPSA-N","InChI=1S/C16H21NO/c18-12-5-4-11-9-15-13-3-1-2-6-16(13,7-8-17-15)14(11)10-12/h4-5,10,13,15,17-18H,1-3,6-9H2/t13-,15+,16+/m0/s1","SULT","Aromatic -OH glucuronidation","Human Phase II","Human","3-Hydroxymorphinan sulfate","NULL","KYOWUZONPGRBFN-NUEKZKHPSA-N","InChI=1S/C16H21NO4S/c18-22(19,20)21-12-5-4-11-9-15-13-3-1-2-6-16(13,7-8-17-15)14(11)10-12/h4-5,10,13,15,17H,1-3,6-9H2,(H,18,19,20)/t13-,15+,16+/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675.|http://www.hmdb.ca/metabolites/HMDB0061130"
"BIOTID01600","8-Hydroxynevirapine","10755325","DZPVEPLRIKDBFC-UHFFFAOYSA-N","InChI=1S/C15H14N4O2/c1-8-4-5-16-14-12(8)18-15(21)11-6-10(20)7-17-13(11)19(14)9-2-3-9/h4-7,9,20H,2-3H2,1H3,(H,18,21)","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","8-Hydroxynevirapine O-glucuronide","NULL","IVZWGLRSSHUFTI-IQSUWLOCSA-N","InChI=1S/C21H22N4O8/c1-8-4-5-22-18-12(8)24-19(29)11-6-10(7-23-17(11)25(18)9-2-3-9)32-21-15(28)13(26)14(27)16(33-21)20(30)31/h4-7,9,13-16,21,26-28H,2-3H2,1H3,(H,24,29)(H,30,31)/t13-,14-,15+,16-,21?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675.|http://www.hmdb.ca/metabolites/HMDB0061130"
"BIOTID01601","12-Hydroxynevirapine","NULL","BFLZKCGARMNKLQ-UHFFFAOYSA-N","InChI=1S/C15H14N4O2/c1-8-4-6-17-14-12(8)18-15(21)9-3-2-5-16-13(9)19(14)10-7-11(10)20/h2-6,10-11,20H,7H2,1H3,(H,18,21)","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","12-Hydroxynevirapine O-glucuronide","NULL","KZGVXPVTFDGWPX-RDPCRGLVSA-N","InChI=1S/C21H22N4O8/c1-8-4-6-23-18-12(8)24-19(29)9-3-2-5-22-17(9)25(18)10-7-11(10)32-21-15(28)13(26)14(27)16(33-21)20(30)31/h2-6,10-11,13-16,21,26-28H,7H2,1H3,(H,24,29)(H,30,31)/t10?,11?,13-,14-,15+,16-,21?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675.|http://www.hmdb.ca/metabolites/HMDB0061130"
"BIOTID01602","3-Hydroxynevirapine","10978907","DANIONWINZEYME-UHFFFAOYSA-N","InChI=1S/C15H14N4O2/c1-8-11(20)7-17-14-12(8)18-15(21)10-3-2-6-16-13(10)19(14)9-4-5-9/h2-3,6-7,9,20H,4-5H2,1H3,(H,18,21)","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","3-Hydroxynevirapine O-glucuronide","NULL","NDHKVQJGORCCLP-IQSUWLOCSA-N","InChI=1S/C21H22N4O8/c1-8-11(32-21-15(28)13(26)14(27)16(33-21)20(30)31)7-23-18-12(8)24-19(29)10-3-2-6-22-17(10)25(18)9-4-5-9/h2-3,6-7,9,13-16,21,26-28H,4-5H2,1H3,(H,24,29)(H,30,31)/t13-,14-,15+,16-,21?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675.|http://www.hmdb.ca/metabolites/HMDB0061130"
"BIOTID01603","2-Hydroxynevirapine","10850461","LFZSOJABLBVGRJ-UHFFFAOYSA-N","InChI=1S/C15H14N4O2/c1-8-7-11(20)17-14-12(8)18-15(21)10-3-2-6-16-13(10)19(14)9-4-5-9/h2-3,6-7,9H,4-5H2,1H3,(H,17,20)(H,18,21)","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","2-Hydroxynevirapine glucuronide","131769929","RNMZKTLILDCQOC-KUSYAZKWSA-N","InChI=1S/C21H22N4O8/c1-8-7-11(32-21-15(28)13(26)14(27)16(33-21)20(30)31)23-18-12(8)24-19(29)10-3-2-6-22-17(10)25(18)9-4-5-9/h2-3,6-7,9,13-16,21,26-28H,4-5H2,1H3,(H,24,29)(H,30,31)/t13-,14-,15+,16-,21+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060720"
"BIOTID01604","thymol","6989","MGSRCZKZVOBKFT-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)6-10(9)11/h4-7,11H,1-3H3","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","thymol O-glucuronide","101461902","ADQJSAVCKZSGMK-JHZZJYKESA-N","InChI=1S/C16H22O7/c1-7(2)9-5-4-8(3)6-10(9)22-16-13(19)11(17)12(18)14(23-16)15(20)21/h4-7,11-14,16-19H,1-3H3,(H,20,21)/t11-,12-,13+,14-,16+/m0/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01605","thymol","6989","MGSRCZKZVOBKFT-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)6-10(9)11/h4-7,11H,1-3H3","SULT","3-OH sulfonation of phenolic compound","Human Phase II","Human","thymol sulfate","12456386","NODSEPOUFZPJEQ-UHFFFAOYSA-N","InChI=1S/C10H14O4S/c1-7(2)9-5-4-8(3)6-10(9)14-15(11,12)13/h4-7H,1-3H3,(H,11,12,13)","http://www.hmdb.ca/metabolites/HMDB0062720"
"BIOTID01606","Catechol","289","YCIMNLLNPGFGHC-UHFFFAOYSA-N","InChI=1S/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8H","SULT","O-sulfonation","Human Phase II","Human","catechol sulfate","3083879","MZPWKJZDOCIALD-UHFFFAOYSA-N","InChI=1S/C6H6O5S/c7-5-3-1-2-4-6(5)11-12(8,9)10/h1-4,7H,(H,8,9,10)","http://www.hmdb.ca/metabolites/HMDB0061713"
"BIOTID01607","Catechol","289","YCIMNLLNPGFGHC-UHFFFAOYSA-N","InChI=1S/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8H","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","124202060","ICPYZFZFSLTYID-GPTQDWHKSA-N","InChI=1S/C12H14O8/c13-5-3-1-2-4-6(5)19-12-9(16)7(14)8(15)10(20-12)11(17)18/h1-4,7-10,12-16H,(H,17,18)/t7-,8-,9+,10-,12+/m1/s1","http://www.hmdb.ca/metabolites/HMDB0059998"
"BIOTID01608","3-OH-7-ethoxycourmarin","13031686","OCCRKOWLAVGGOA-UHFFFAOYSA-N","InChI=1S/C11H10O4/c1-2-14-10-6-9-7(5-8(10)12)3-4-11(13)15-9/h3-6,12H,2H2,1H3","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","3-OH-7-ethoxycourmarin O-glucuronide","NULL","HAURMTSHBOQRNH-KSXIZUIISA-N","InChI=1S/C17H18O10/c1-2-24-9-6-8-7(3-4-11(18)25-8)5-10(9)26-17-14(21)12(19)13(20)15(27-17)16(22)23/h3-6,12-15,17,19-21H,2H2,1H3,(H,22,23)/t12-,13-,14+,15-,17+/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01609","Aminoflavone","389710","RTUZVPPGTJRELI-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O2/c1-6-13(18)15(21)12-10(22)5-11(23-16(12)14(6)19)7-2-3-9(20)8(17)4-7/h2-5H,20-21H2,1H3","UGT","Glucuronidation of primary aromatic amine","Human Phase II","Human","Aminoflavone N-glucuronide (MX)","NULL","SDLMJDGDMKNPGY-GCGJSEPQSA-N","InChI=1S/C22H19F3N2O8/c1-6-13(24)15(27-21-18(31)16(29)17(30)20(35-21)22(32)33)12-10(28)5-11(34-19(12)14(6)25)7-2-3-9(26)8(23)4-7/h2-5,16-18,20-21,27,29-31H,26H2,1H3,(H,32,33)/t16-,17-,18+,20-,21+/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01610","Aminoflavone M-II","NULL","BGZUIZSBNOBPKP-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O3/c1-6-13(18)15(21-23)12-10(22)5-11(24-16(12)14(6)19)7-2-3-9(20)8(17)4-7/h2-5,21,23H,20H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","Aminoflavone M-II O-glucuronide","NULL","QEXKIRZJZBQQPU-DCIOMXRHSA-N","InChI=1S/C22H19F3N2O9/c1-6-13(24)15(27-36-22-18(31)16(29)17(30)20(35-22)21(32)33)12-10(28)5-11(34-19(12)14(6)25)7-2-3-9(26)8(23)4-7/h2-5,16-18,20,22,27,29-31H,26H2,1H3,(H,32,33)/t16-,17-,18+,20-,22-/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01611","Aminoflavone M-II","NULL","BGZUIZSBNOBPKP-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O3/c1-6-13(18)15(21-23)12-10(22)5-11(24-16(12)14(6)19)7-2-3-9(20)8(17)4-7/h2-5,21,23H,20H2,1H3","SULT","O-sulfonation","Human Phase II","Human","Aminoflavone M-II O-sulfate","NULL","KIZLKKOSCJAZHD-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O6S/c1-6-13(18)15(21-27-28(23,24)25)12-10(22)5-11(26-16(12)14(6)19)7-2-3-9(20)8(17)4-7/h2-5,21H,20H2,1H3,(H,23,24,25)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01612","Aminoflavone MIII","NULL","BUGQDNPBVYMEFE-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O3/c1-6-13(18)15(20)12-10(22)5-11(24-16(12)14(6)19)7-2-3-9(21-23)8(17)4-7/h2-5,21,23H,20H2,1H3","UGT","Glucuronidation of primary aromatic amine","Human Phase II","Human","Aminoflavone MIII O-glucuronide","NULL","ZAJSZDGJFRTTQZ-DCIOMXRHSA-N","InChI=1S/C22H19F3N2O9/c1-6-13(24)15(26)12-10(28)5-11(34-19(12)14(6)25)7-2-3-9(8(23)4-7)27-36-22-18(31)16(29)17(30)20(35-22)21(32)33/h2-5,16-18,20,22,27,29-31H,26H2,1H3,(H,32,33)/t16-,17-,18+,20-,22-/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01613","Aminoflavone M-IV","NULL","HUSFKTRIHYXGPZ-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O3/c1-5-10(18)12(21)9-13(22)14(23)15(24-16(9)11(5)19)6-2-3-8(20)7(17)4-6/h2-4,23H,20-21H2,1H3","SULT","O-sulfonation","Human Phase II","Human","Aminoflavone M-IV O-sulfate","NULL","SHPUPBLJTYTUDO-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O6S/c1-5-10(18)12(21)9-13(22)16(27-28(23,24)25)14(26-15(9)11(5)19)6-2-3-8(20)7(17)4-6/h2-4H,20-21H2,1H3,(H,23,24,25)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01614","Aminoflavone M-V","NULL","GEASYZROZMRJJL-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O4/c1-6-13(18)15(21-24)12-10(22)5-11(25-16(12)14(6)19)7-2-3-9(20-23)8(17)4-7/h2-5,20-21,23-24H,1H3","SULT","O-sulfonation","Human Phase II","Human","Aminoflavone M-V O-sulfate","NULL","GECZFGWGPXYRIH-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O7S/c1-6-13(18)15(21-28-29(24,25)26)12-10(22)5-11(27-16(12)14(6)19)7-2-3-9(20-23)8(17)4-7/h2-5,20-21,23H,1H3,(H,24,25,26)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01615","8-OH-ondansetron","19734439","XVDKMEPUFIAQFH-UHFFFAOYSA-N","InChI=1S/C18H19N3O2/c1-11-19-8-9-21(11)10-12-6-7-14-16(18(12)23)13-4-3-5-15(22)17(13)20(14)2/h3-5,8-9,12,22H,6-7,10H2,1-2H3","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","ondansetron 8-O-glucuronide","91668158","BLTLDLYCSAWXFJ-DMBZKHIPSA-N","InChI=1S/C24H27N3O8/c1-11-25-8-9-27(11)10-12-6-7-14-16(18(12)28)13-4-3-5-15(17(13)26(14)2)34-24-21(31)19(29)20(30)22(35-24)23(32)33/h3-5,8-9,12,19-22,24,29-31H,6-7,10H2,1-2H3,(H,32,33)/t12?,19-,20-,21+,22-,24+/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01616","8-OH-ondansetron","19734439","XVDKMEPUFIAQFH-UHFFFAOYSA-N","InChI=1S/C18H19N3O2/c1-11-19-8-9-21(11)10-12-6-7-14-16(18(12)23)13-4-3-5-15(22)17(13)20(14)2/h3-5,8-9,12,22H,6-7,10H2,1-2H3","SULT","O-sulfonation","Human Phase II","Human","ondansetron 8-O-sulfate","15700432","FKMUSAHZDJNPJY-UHFFFAOYSA-N","InChI=1S/C18H19N3O5S/c1-11-19-8-9-21(11)10-12-6-7-14-16(18(12)22)13-4-3-5-15(17(13)20(14)2)26-27(23,24)25/h3-5,8-9,12H,6-7,10H2,1-2H3,(H,23,24,25)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01617","7-OH-ondansetron","71749264","DTJUCZWBHDEFRB-UHFFFAOYSA-N","InChI=1S/C18H19N3O2/c1-11-19-7-8-21(11)10-12-3-6-15-17(18(12)23)14-5-4-13(22)9-16(14)20(15)2/h4-5,7-9,12,22H,3,6,10H2,1-2H3","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","ondansetron 7-O-glucuronide","NULL","AYBPIAZKEUHJJR-DMBZKHIPSA-N","InChI=1S/C24H27N3O8/c1-11-25-7-8-27(11)10-12-3-6-15-17(18(12)28)14-5-4-13(9-16(14)26(15)2)34-24-21(31)19(29)20(30)22(35-24)23(32)33/h4-5,7-9,12,19-22,24,29-31H,3,6,10H2,1-2H3,(H,32,33)/t12?,19-,20-,21+,22-,24+/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01618","7-OH-ondansetron","71749264","DTJUCZWBHDEFRB-UHFFFAOYSA-N","InChI=1S/C18H19N3O2/c1-11-19-7-8-21(11)10-12-3-6-15-17(18(12)23)14-5-4-13(22)9-16(14)20(15)2/h4-5,7-9,12,22H,3,6,10H2,1-2H3","SULT","O-sulfonation","Human Phase II","Human","ondansetron 7-O-sulfate","NULL","ZUXDHGQACAQLQR-UHFFFAOYSA-N","InChI=1S/C18H19N3O5S/c1-11-19-7-8-21(11)10-12-3-6-15-17(18(12)22)14-5-4-13(26-27(23,24)25)9-16(14)20(15)2/h4-5,7-9,12H,3,6,10H2,1-2H3,(H,23,24,25)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01619","6-OH-ondansetron","20152440","LMMFEGYKXLPLFC-UHFFFAOYSA-N","InChI=1S/C18H19N3O2/c1-11-19-7-8-21(11)10-12-3-5-16-17(18(12)23)14-9-13(22)4-6-15(14)20(16)2/h4,6-9,12,22H,3,5,10H2,1-2H3","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","ondansetron 6-O-glucuronide","NULL","BQFVWKTVJSIIOJ-DMBZKHIPSA-N","InChI=1S/C24H27N3O8/c1-11-25-7-8-27(11)10-12-3-5-16-17(18(12)28)14-9-13(4-6-15(14)26(16)2)34-24-21(31)19(29)20(30)22(35-24)23(32)33/h4,6-9,12,19-22,24,29-31H,3,5,10H2,1-2H3,(H,32,33)/t12?,19-,20-,21+,22-,24+/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01620","6-OH-ondansetron","20152440","LMMFEGYKXLPLFC-UHFFFAOYSA-N","InChI=1S/C18H19N3O2/c1-11-19-7-8-21(11)10-12-3-5-16-17(18(12)23)14-9-13(22)4-6-15(14)20(16)2/h4,6-9,12,22H,3,5,10H2,1-2H3","SULT","O-sulfonation","Human Phase II","Human","ondansetron 6-O-sulfate","NULL","CCTWXRNCMQAGNC-UHFFFAOYSA-N","InChI=1S/C18H19N3O5S/c1-11-19-7-8-21(11)10-12-3-5-16-17(18(12)22)14-9-13(26-27(23,24)25)4-6-15(14)20(16)2/h4,6-9,12H,3,5,10H2,1-2H3,(H,23,24,25)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01621","linoleyl alcohol","5365682","JXNPEDYJTDQORS-HZJYTTRNSA-N","InChI=1S/C18H34O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h6-7,9-10,19H,2-5,8,11-18H2,1H3/b7-6-,10-9-","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","linoleyl O-glucuronide","101105916","UJWQBQZVFWQUPX-WOIPLQSNSA-N","InChI=1S/C24H42O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-30-24-21(27)19(25)20(26)22(31-24)23(28)29/h6-7,9-10,19-22,24-27H,2-5,8,11-18H2,1H3,(H,28,29)/b7-6-,10-9-/t19-,20-,21+,22-,24+/m0/s1","Jude, R.A. et al. (2001); Glucuronidation of Linoleic Acid Diols by Human Microsomal and Recombinant UDP-Glucuronosyltransferases: Identification of UGT2B7 as the Major Isoform Involved; Archives of Biochemistry and Biophysics; Vol. 389, No. 2, May 15, pp. 176Ã¢â‚¬â€œ186, 2001; doi:10.1006/abbi.2001.2344"
"BIOTID01622","All-trans-retinoic acid","444795","SHGAZHPCJJPHSC-YCNIQYBTSA-N","InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","All-trans-retinoyl glucuronide","5281877","MTGFYEHKPMOVNE-NEFMKCFNSA-N","InChI=1S/C26H36O8/c1-15(11-12-18-17(3)10-7-13-26(18,4)5)8-6-9-16(2)14-19(27)33-25-22(30)20(28)21(29)23(34-25)24(31)32/h6,8-9,11-12,14,20-23,25,28-30H,7,10,13H2,1-5H3,(H,31,32)/b9-6+,12-11+,15-8+,16-14+/t20-,21-,22+,23-,25+/m0/s1","Rune Blomhoff and Heidi Kiil Blomhoff (2005); Overview of Retinoid Metabolism and Function; DOI 10.1002/neu.20242"
"BIOTID01623","Bilirubin","5280352","BPYKTIZUTYGOLE-IFADSCNNSA-N","InChI=1S/C33H36N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h7-8,13-14,34-35H,1-2,9-12,15H2,3-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/b26-13-,27-14-","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","6-[3-[2-[[3-(2-carboxyethyl)-5-[(Z)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid","5280588","ARBDURHEPGRPSR-LCNKTQGVSA-N","InChI=1S/C39H44N4O12/c1-7-20-19(6)36(50)43-27(20)14-25-18(5)23(10-12-31(46)54-39-34(49)32(47)33(48)35(55-39)38(52)53)29(41-25)15-28-22(9-11-30(44)45)17(4)24(40-28)13-26-16(3)21(8-2)37(51)42-26/h7-8,13-14,32-35,39-41,47-49H,1-2,9-12,15H2,3-6H3,(H,42,51)(H,43,50)(H,44,45)(H,52,53)/b26-13-,27-14-/t32-,33-,34+,35-,39+/m0/s1","de Wildt, S.N. et al. (2012); Glucuronidation in Humans; Clinical Pharmacokinetics; June 1999, Volume 36, Issue 6, pp 439Ã¢â‚¬â€œ452"
"BIOTID01624","Bilirubin","5280352","BPYKTIZUTYGOLE-IFADSCNNSA-N","InChI=1S/C33H36N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h7-8,13-14,34-35H,1-2,9-12,15H2,3-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/b26-13-,27-14-","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","(2S,3S,4S,5R,6S)Ã¢â‚¬Â6Ã¢â‚¬Â{[3Ã¢â‚¬Â(2Ã¢â‚¬Â{[3Ã¢â‚¬Â(2Ã¢â‚¬Âcarboxyethyl)Ã¢â‚¬Â5Ã¢â‚¬Â{[(2Z)Ã¢â‚¬Â4Ã¢â‚¬ÂethenylÃ¢â‚¬Â3Ã¢â‚¬ÂmethylÃ¢â‚¬Â5Ã¢â‚¬ÂoxoÃ¢â‚¬Â1HÃ¢â‚¬ÂpyrrolÃ¢â‚¬Â2Ã¢â‚¬Âylidene]methyl}Ã¢â‚¬Â4Ã¢â‚¬ÂmethylÃ¢â‚¬Â1HÃ¢â‚¬ÂpyrrolÃ¢â‚¬Â2Ã¢â‚¬Âyl]methyl}Ã¢â‚¬Â5Ã¢â‚¬Â{[(2Z)Ã¢â‚¬Â3Ã¢â‚¬ÂethenylÃ¢â‚¬Â4Ã¢â‚¬ÂmethylÃ¢â‚¬Â5Ã¢â‚¬ÂoxoÃ¢â‚¬Â1HÃ¢â‚¬ÂpyrrolÃ¢â‚¬Â2Ã¢â‚¬Âylidene]methyl}Ã¢â‚¬Â4Ã¢â‚¬ÂmethylÃ¢â‚¬Â1HÃ¢â‚¬ÂpyrrolÃ¢â‚¬Â3Ã¢â‚¬Âyl)propanoyl]oxy}Ã¢â‚¬Â3,4,5Ã¢â‚¬ÂtrihydroxyoxaneÃ¢â‚¬Â2Ã¢â‚¬Âcarboxylic acid","25245462","MQRFWGRFUKAJAX-LCNKTQGVSA-N","InChI=1S/C39H44N4O12/c1-7-20-19(6)36(50)43-27(20)14-25-17(4)22(9-11-30(44)45)28(41-25)15-29-23(18(5)24(40-29)13-26-16(3)21(8-2)37(51)42-26)10-12-31(46)54-39-34(49)32(47)33(48)35(55-39)38(52)53/h7-8,13-14,32-35,39-41,47-49H,1-2,9-12,15H2,3-6H3,(H,42,51)(H,43,50)(H,44,45)(H,52,53)/b26-13-,27-14-/t32-,33-,34+,35-,39+/m0/s1","de Wildt, S.N. et al. (2012); Glucuronidation in Humans; Clinical Pharmacokinetics; June 1999, Volume 36, Issue 6, pp 439Ã¢â‚¬â€œ452"
"BIOTID01625","Epitestosterone","10204","MUMGGOZAMZWBJJ-KZYORJDKSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17+,18-,19-/m0/s1","UGT","17-OH glucuronidation of sterol","Human Phase II","Human","Epitestosterone O-glucuronide","NULL","NIKZPECGCSUSBV-AUCSGLRSSA-N","InChI=1S/C25H36O8/c1-24-9-7-13(26)11-12(24)3-4-14-15-5-6-17(25(15,2)10-8-16(14)24)32-23-20(29)18(27)19(28)21(33-23)22(30)31/h11,14-21,23,27-29H,3-10H2,1-2H3,(H,30,31)/t14-,15-,16-,17+,18-,19-,20+,21-,23?,24-,25-/m0/s1","de Wildt, S.N. et al. (2012); Glucuronidation in Humans; Clinical Pharmacokinetics; June 1999, Volume 36, Issue 6, pp 439Ã¢â‚¬â€œ452"
"BIOTID01626","hyocholic acid","92805","DKPMWHFRUGMUKF-KWXDGCAGSA-N","InChI=1S/C24H40O5/c1-13(4-7-19(26)27)15-5-6-16-20-17(9-11-23(15,16)2)24(3)10-8-14(25)12-18(24)21(28)22(20)29/h13-18,20-22,25,28-29H,4-12H2,1-3H3,(H,26,27)/t13-,14-,15-,16+,17+,18+,20+,21-,22+,23-,24-/m1/s1","UGT","Bile acid C24 acyl glucuronidation","Human Phase II","Human","hyocholic acid 24-O-glucuronide","126843482","XPBXRQXFXJGCIA-RAJUUOCTSA-N","InChI=1S/C30H48O11/c1-13(4-7-19(32)40-28-25(37)23(35)24(36)26(41-28)27(38)39)15-5-6-16-20-17(9-11-29(15,16)2)30(3)10-8-14(31)12-18(30)21(33)22(20)34/h13-18,20-26,28,31,33-37H,4-12H2,1-3H3,(H,38,39)/t13-,14-,15-,16+,17+,18+,20+,21-,22+,23+,24+,25-,26+,28-,29-,30-/m1/s1","Trottier, J. et al (2013); Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants and response to fenofibrate; Clin Pharmacol Ther. 2013 October ; 94(4): 533Ã¢â‚¬â€œ543. doi:10.1038/clpt.2013.122.|http://www.uniprot.org/uniprot/P22309"
"BIOTID01627","hyocholic acid","92805","DKPMWHFRUGMUKF-KWXDGCAGSA-N","InChI=1S/C24H40O5/c1-13(4-7-19(26)27)15-5-6-16-20-17(9-11-23(15,16)2)24(3)10-8-14(25)12-18(24)21(28)22(20)29/h13-18,20-22,25,28-29H,4-12H2,1-3H3,(H,26,27)/t13-,14-,15-,16+,17+,18+,20+,21-,22+,23-,24-/m1/s1","UGT","6-OH glucuronidation of sterol","Human Phase II","Human","hyocholic acid 6-O-glucuronide","NULL","XVNRNIWARCALGY-AWCVKPOVSA-N","InChI=1S/C30H48O11/c1-13(4-7-19(32)33)15-5-6-16-20-17(9-11-29(15,16)2)30(3)10-8-14(31)12-18(30)25(21(20)34)40-28-24(37)22(35)23(36)26(41-28)27(38)39/h13-18,20-26,28,31,34-37H,4-12H2,1-3H3,(H,32,33)(H,38,39)/t13-,14-,15-,16+,17+,18+,20+,21+,22+,23+,24-,25-,26+,28?,29-,30-/m1/s1","Trottier, J. et al (2013); Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants and response to fenofibrate; Clin Pharmacol Ther. 2013 October ; 94(4): 533Ã¢â‚¬â€œ543. doi:10.1038/clpt.2013.122.|http://www.uniprot.org/uniprot/P22309"
"BIOTID01628","Resveratrol","445154","LUKBXSAWLPMMSZ-OWOJBTEDSA-N","InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","Resveratrol 3-O-glucuronide","5273285","QWSAYEBSTMCFKY-OTPOQTMVSA-N","InChI=1S/C20H20O9/c21-12-5-3-10(4-6-12)1-2-11-7-13(22)9-14(8-11)28-20-17(25)15(23)16(24)18(29-20)19(26)27/h1-9,15-18,20-25H,(H,26,27)/b2-1+/t15-,16-,17+,18-,20+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01629","Entacapone","5281081","JRURYQJSLYLRLN-BJMVGYQFSA-N","InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","29979332","QFIJKZUWSRMQEH-IJKJBMBDSA-N","InChI=1S/C20H23N3O11/c1-3-22(4-2)18(28)10(8-21)5-9-6-11(23(31)32)13(24)12(7-9)33-20-16(27)14(25)15(26)17(34-20)19(29)30/h5-7,14-17,20,24-27H,3-4H2,1-2H3,(H,29,30)/b10-5+/t14-,15-,16+,17-,20+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01630","Ezetimibe","150311","OLNTVTPDXPETLC-XPWALMASSA-N","InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","9894653","UOFYCFMTERCNEW-ADEYADIWSA-N","InChI=1S/C30H29F2NO9/c31-17-5-1-15(2-6-17)22(34)14-13-21-23(33(28(21)38)19-9-7-18(32)8-10-19)16-3-11-20(12-4-16)41-30-26(37)24(35)25(36)27(42-30)29(39)40/h1-12,21-27,30,34-37H,13-14H2,(H,39,40)/t21-,22+,23-,24+,25+,26-,27+,30-/m1/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01631","Mycophenolic Acid","446541","HPNSFSBZBAHARI-RUDMXATFSA-N","InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","6442661","BYFGTSAYQQIUCN-HGIHDBQLSA-N","InChI=1S/C23H28O12/c1-9(5-7-13(24)25)4-6-11-18(32-3)10(2)12-8-33-22(31)14(12)19(11)34-23-17(28)15(26)16(27)20(35-23)21(29)30/h4,15-17,20,23,26-28H,5-8H2,1-3H3,(H,24,25)(H,29,30)/b9-4+/t15-,16-,17+,20-,23+/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01632","2‐(pyren‐1‐yl)ethanol","14980287","SQBQYJJJOFDXCB-UHFFFAOYSA-N","InChI=1S/C18H14O/c19-11-10-12-4-5-15-7-6-13-2-1-3-14-8-9-16(12)18(15)17(13)14/h1-9,19H,10-11H2","SULT1A1; SULT1A2; SULT1C1; SULT1C2; SULT1C3; SULT1E1; SULT2A1","Sulfation of primary alcohol","Human Phase II","Human","NULL","NULL","YPIDVHOTOYRMEZ-UHFFFAOYSA-N","InChI=1S/C18H14O4S/c19-23(20,21)22-11-10-12-4-5-15-7-6-13-2-1-3-14-8-9-16(12)18(15)17(13)14/h1-9H,10-11H2,(H,19,20,21)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01633","1-(1-pyrenyl)ethanol","119118","LFCWFVPSUMBNQM-UHFFFAOYSA-N","InChI=1S/C18H14O/c1-11(19)15-9-7-14-6-5-12-3-2-4-13-8-10-16(15)18(14)17(12)13/h2-11,19H,1H3","SULT1A1; SULT1E1","Sulfation of secondary alcohol","Human Phase II","Human","NULL","179887","RKSXMHNLGDICSW-UHFFFAOYSA-N","InChI=1S/C18H14O4S/c1-11(22-23(19,20)21)15-9-7-14-6-5-12-3-2-4-13-8-10-16(15)18(14)17(12)13/h2-11H,1H3,(H,19,20,21)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01634","1-hydroxymethylpyrene","104977","NGDMLQSGYUCLDC-UHFFFAOYSA-N","InChI=1S/C17H12O/c18-10-14-7-6-13-5-4-11-2-1-3-12-8-9-15(14)17(13)16(11)12/h1-9,18H,10H2","SULT1A1; SULT1B1, SULT2A1","Sulfation of primary alcohol","Human Phase II","Human","NULL","131320","JEHJDOIFMGNIQI-UHFFFAOYSA-N","InChI=1S/C17H12O4S/c18-22(19,20)21-10-14-7-6-13-5-4-11-2-1-3-12-8-9-15(14)17(13)16(11)12/h1-9H,10H2,(H,18,19,20)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01635","1-methoxy-3-indolylmethyl-alcohol","398553","AQEZKEWAYCAHAX-UHFFFAOYSA-N","InChI=1S/C10H11NO2/c1-13-11-6-8(7-12)9-4-2-3-5-10(9)11/h2-6,12H,7H2,1H3","SULT1A1","Sulfation of primary alcohol","Human Phase II","Human","NULL","NULL","YSOOVZCCUFIEJJ-UHFFFAOYSA-N","InChI=1S/C10H11NO5S/c1-15-11-6-8(7-16-17(12,13)14)9-4-2-3-5-10(9)11/h2-6H,7H2,1H3,(H,12,13,14)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01636","2,4-dinitrobenzylalcohol","20974","ZKKOBDGQUYKWFN-UHFFFAOYSA-N","InChI=1S/C7H6N2O5/c10-4-5-1-2-6(8(11)12)3-7(5)9(13)14/h1-3,10H,4H2","SULT1A1","Sulfation of primary alcohol","Human Phase II","Human","NULL","10683971","ZKVQMAQWFWHLEU-UHFFFAOYSA-N","InChI=1S/C7H6N2O8S/c10-8(11)6-2-1-5(4-17-18(14,15)16)7(3-6)9(12)13/h1-3H,4H2,(H,14,15,16)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01637","2-aminobenzylalcohol","21439","VYFOAVADNIHPTR-UHFFFAOYSA-N","InChI=1S/C7H9NO/c8-7-4-2-1-3-6(7)5-9/h1-4,9H,5,8H2","SULT1A1","Sulfation of primary alcohol","Human Phase II","Human","NULL","NULL","XBOBNEOJIDFIIU-UHFFFAOYSA-N","InChI=1S/C7H9NO4S/c8-7-4-2-1-3-6(7)5-12-13(9,10)11/h1-4H,5,8H2,(H,9,10,11)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01638","2-hydroxylamino-3-methyl-9H-pyrido[2,3-b]indole","154859","VQFWOOZJALLVRG-UHFFFAOYSA-N","InChI=1S/C12H11N3O/c1-7-6-9-8-4-2-3-5-10(8)13-12(9)14-11(7)15-16/h2-6,16H,1H3,(H2,13,14,15)","SULT1A1","Hydroxylamine O-sulfonation","Human Phase II","Human","NULL","NULL","SEHPJJKSFDOKGR-UHFFFAOYSA-N","InChI=1S/C12H11N3O4S/c1-7-6-9-8-4-2-3-5-10(8)13-12(9)14-11(7)15-19-20(16,17)18/h2-6H,1H3,(H2,13,14,15)(H,16,17,18)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01639","2-hydroxylamino-5-phenylpyridine","178830","XXBYLOVPPUOSHR-UHFFFAOYSA-N","InChI=1S/C11H10N2O/c14-13-11-7-6-10(8-12-11)9-4-2-1-3-5-9/h1-8,14H,(H,12,13)","SULT1A1","Hydroxylamine O-sulfonation","Human Phase II","Human","NULL","NULL","ADCZAHJFXXSWIV-UHFFFAOYSA-N","InChI=1S/C11H10N2O4S/c14-18(15,16)17-13-11-7-6-10(8-12-11)9-4-2-1-3-5-9/h1-8H,(H,12,13)(H,14,15,16)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01640","5-hydroxymethylfurfural","237332","NOEGNKMFWQHSLB-UHFFFAOYSA-N","InChI=1S/C6H6O3/c7-3-5-1-2-6(4-8)9-5/h1-3,8H,4H2","SULT1A1","Sulfation of primary alcohol","Human Phase II","Human","NULL","154718","WVMJEBICTINBRO-UHFFFAOYSA-N","InChI=1S/C6H6O6S/c7-3-5-1-2-6(12-5)4-11-13(8,9)10/h1-3H,4H2,(H,8,9,10)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01641","7-hydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene","97714","VKUQFYXBPGXTKI-UHFFFAOYSA-N","InChI=1S/C20H16O/c21-18-6-2-5-15-16-10-9-13-4-1-3-12-7-8-14(11-17(15)18)20(16)19(12)13/h1,3-4,7-11,18,21H,2,5-6H2","SULT1A1","Sulfation of secondary alcohol","Human Phase II","Human","NULL","NULL","HUTQGIULASXZMJ-UHFFFAOYSA-N","InChI=1S/C20H16O4S/c21-25(22,23)24-18-6-2-5-15-16-10-9-13-4-1-3-12-7-8-14(11-17(15)18)20(16)19(12)13/h1,3-4,7-11,18H,2,5-6H2,(H,21,22,23)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01642","furfuryl alcohol","7361","XPFVYQJUAUNWIW-UHFFFAOYSA-N","InChI=1S/C5H6O2/c6-4-5-2-1-3-7-5/h1-3,6H,4H2","SULT1A1; SULT1C2","Sulfation of primary alcohol","Human Phase II","Human","NULL","101669210","ARHBKANMCICMIT-UHFFFAOYSA-N","InChI=1S/C5H6O5S/c6-11(7,8)10-4-5-2-1-3-9-5/h1-3H,4H2,(H,6,7,8)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01643","N-acetyl-N-hydroxy-3-aminobenzanthrone","NULL","HKNUZKJRYBXLDZ-UHFFFAOYSA-N","InChI=1S/C19H15NO3/c1-11(21)20(23)17-10-9-13-12-5-2-3-6-14(12)19(22)16-8-4-7-15(17)18(13)16/h2-10,15,17,23H,1H3","SULT1A1","O-sulfonation","Human Phase II","Human","NULL","NULL","NZSGZHDOQBDCEL-UHFFFAOYSA-N","InChI=1S/C19H15NO6S/c1-11(21)20(26-27(23,24)25)17-10-9-13-12-5-2-3-6-14(12)19(22)16-8-4-7-15(17)18(13)16/h2-10,15,17H,1H3,(H,23,24,25)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01644","N-acetyl-N-hydroxy-3-aminobenzanthrone","NULL","HKNUZKJRYBXLDZ-UHFFFAOYSA-N","InChI=1S/C19H15NO3/c1-11(21)20(23)17-10-9-13-12-5-2-3-6-14(12)19(22)16-8-4-7-15(17)18(13)16/h2-10,15,17,23H,1H3","NAT1; NAT2","O-acetylation","Human Phase II","Human","NULL","NULL","BBONYHUTYYCQRI-UHFFFAOYSA-N","InChI=1S/C21H17NO4/c1-12(23)22(26-13(2)24)19-11-10-15-14-6-3-4-7-16(14)21(25)18-9-5-8-17(19)20(15)18/h3-11,17,19H,1-2H3","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01645","6-hydroxymethylanthanthrene","149704","YWJXFEXZVZQIRV-UHFFFAOYSA-N","InChI=1S/C23H14O/c24-12-19-17-6-2-4-14-7-8-16-11-15-5-1-3-13-9-10-18(19)23(20(13)15)22(16)21(14)17/h1-11,24H,12H2","SULT1C3","Sulfation of primary alcohol","Human Phase II","Human","NULL","NULL","NVLCELHVDANZKF-UHFFFAOYSA-N","InChI=1S/C23H14O4S/c24-28(25,26)27-12-19-17-6-2-4-14-7-8-16-11-15-5-1-3-13-9-10-18(19)23(20(13)15)22(16)21(14)17/h1-11H,12H2,(H,24,25,26)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01646","N-hydroxy-aminophenylnorharman","154225","LECLBYWFRKFHIQ-UHFFFAOYSA-N","InChI=1S/C17H13N3O/c21-19-12-5-7-13(8-6-12)20-16-4-2-1-3-14(16)15-9-10-18-11-17(15)20/h1-11,19,21H","NAT1; NAT2","O-acetylation of N-hydroxylarylamine","Human Phase II","Human","NULL","71366829","DJMGXUFTFWIYEZ-UHFFFAOYSA-N","InChI=1S/C19H15N3O2/c1-13(23)24-21-14-6-8-15(9-7-14)22-18-5-3-2-4-16(18)17-10-11-20-12-19(17)22/h2-12,21H,1H3","Oda, Y. et al. (2006); Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymes expressed in Salmonella typhimurium umu tester strains; Mutagenesis, Volume 21, Issue 6, 1 November 2006, Pages 411Ã¢â‚¬â€œ416"
"BIOTID01647","N-hydroxy-aminophenylharman","NULL","HDGKCLSJGPSPQX-UHFFFAOYSA-N","InChI=1S/C18H15N3O/c1-12-18-16(10-11-19-12)15-4-2-3-5-17(15)21(18)14-8-6-13(20-22)7-9-14/h2-11,20,22H,1H3","NAT1; NAT2","O-acetylation of N-hydroxylarylamine","Human Phase II","Human","NULL","NULL","ZHWHGQUDSADOPI-UHFFFAOYSA-N","InChI=1S/C20H17N3O2/c1-13-20-18(11-12-21-13)17-5-3-4-6-19(17)23(20)16-9-7-15(8-10-16)22-25-14(2)24/h3-12,22H,1-2H3","Oda, Y. et al. (2006); Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymes expressed in Salmonella typhimurium umu tester strains; Mutagenesis, Volume 21, Issue 6, 1 November 2006, Pages 411Ã¢â‚¬â€œ416"
"BIOTID01648","N-hydroxy-benzidine","153360","VAINAOKETCVWJD-UHFFFAOYSA-N","InChI=1S/C12H12N2O/c13-11-5-1-9(2-6-11)10-3-7-12(14-15)8-4-10/h1-8,14-15H,13H2","NAT1","O-acetylation of N-hydroxylarylamine","Human Phase II","Human","N-hydroxy-benzidine O-acetyl","129827299","VFVUONTVQXSSGF-UHFFFAOYSA-N","InChI=1S/C14H14N2O2/c1-10(17)18-16-14-8-4-12(5-9-14)11-2-6-13(15)7-3-11/h2-9,16H,15H2,1H3","Murata, M. et al. (2005); Carcinogenic 3-nitrobenzanthrone induces oxidative damage to isolated and cellular DNA; Free Radical Biology & Medicine 40 (2006) 1242Ã¢â‚¬â€œ1249"
"BIOTID01649","N-hydroxy-2-aminofluorene","5895","JJCLXJPUTJMRTM-UHFFFAOYSA-N","InChI=1S/C13H11NO/c15-14-11-5-6-13-10(8-11)7-9-3-1-2-4-12(9)13/h1-6,8,14-15H,7H2","NAT1","O-acetylation of N-hydroxylarylamine","Human Phase II","Human","N-hydroxy-2-aminofluorene, O-acetyl","149047","DAJPHRKDAWYAJZ-UHFFFAOYSA-N","InChI=1S/C15H13NO2/c1-10(17)18-16-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9,16H,8H2,1H3","Murata, M. et al. (2005); Carcinogenic 3-nitrobenzanthrone induces oxidative damage to isolated and cellular DNA; Free Radical Biology & Medicine 40 (2006) 1242Ã¢â‚¬â€œ1249"
"BIOTID01650","N-[4-(2,4-dichlorophenoxy)phenyl]hydroxylamine","3033634","BUJCMVKZULBFON-UHFFFAOYSA-N","InChI=1S/C12H9Cl2NO2/c13-8-1-6-12(11(14)7-8)17-10-4-2-9(15-16)3-5-10/h1-7,15-16H","NAT1","O-acetylation of N-hydroxylarylamine","Human Phase II","Human","N-[4-(2,4-dichlorophenoxy)phenyl]hydroxylamine O-acetyl","NULL","NFMBWIPSPREWBZ-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c1-9(18)20-17-11-3-5-12(6-4-11)19-14-7-2-10(15)8-13(14)16/h2-8,17H,1H3","Murata, M. et al. (2005); Carcinogenic 3-nitrobenzanthrone induces oxidative damage to isolated and cellular DNA; Free Radical Biology & Medicine 40 (2006) 1242Ã¢â‚¬â€œ1249"
"BIOTID01651","N‐(2‐methoxyphenyl)hydroxylamine","13226840","VJZCVIHHXKSOIN-UHFFFAOYSA-N","InChI=1S/C7H9NO2/c1-10-7-5-3-2-4-6(7)8-9/h2-5,8-9H,1H3","NAT1","O-acetylation of N-hydroxylarylamine","Human Phase II","Human","NÃ¢â‚¬Â(2Ã¢â‚¬Âmethoxyphenyl)hydroxylamine, O-acetyl","NULL","BHCWTPPZVHKEHF-UHFFFAOYSA-N","InChI=1S/C9H11NO3/c1-7(11)13-10-8-5-3-4-6-9(8)12-2/h3-6,10H,1-2H3","Murata, M. et al. (2005); Carcinogenic 3-nitrobenzanthrone induces oxidative damage to isolated and cellular DNA; Free Radical Biology & Medicine 40 (2006) 1242Ã¢â‚¬â€œ1249"
"BIOTID01652","isoniazid","3767","QRXWMOHMRWLFEY-UHFFFAOYSA-N","InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)","NAT2","N-acetylation of Hydrazine derivative","Human Phase II","Human","isoniazid N-acetyl","71602","CVBGNAKQQUWBQV-UHFFFAOYSA-N","InChI=1S/C8H9N3O2/c1-6(12)10-11-8(13)7-2-4-9-5-3-7/h2-5H,1H3,(H,10,12)(H,11,13)","https://www.pharmgkb.org/pathway/PA166151813"
"BIOTID01653","hydralazine","3637","RPTUSVTUFVMDQK-UHFFFAOYSA-N","InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)","NAT","N-acetylation of Hydrazine derivative","Human Phase II","Human","hydralazine N-acetyl","31507","YQUVBMKWVZWZED-UHFFFAOYSA-N","InChI=1S/C10H10N4O/c1-7(15)12-14-10-9-5-3-2-4-8(9)6-11-13-10/h2-6H,1H3,(H,12,15)(H,13,14)","Lemke, L.E. and McQueen, C.A. (1995); Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine.; Drug Metab Dispos. 1995 May;23(5):559-65.; PMID:7587931"
"BIOTID01654","mesalazine","4075","KBOPZPXVLCULAV-UHFFFAOYSA-N","InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)","NAT","N-acetylation of arylamine","Human Phase II","Human","mesalazine, N-acetyl","65512","GEFDRROBUCULOD-UHFFFAOYSA-N","InChI=1S/C9H9NO4/c1-5(11)10-6-2-3-8(12)7(4-6)9(13)14/h2-4,12H,1H3,(H,10,11)(H,13,14)","Taggart, A.J. et al. (1992); The Effect of Age and Acetylator Phenotype on the Pharmacokinetics of Sulfasalazine in Patients with Rheumatoid Arthritis; Clinical Pharmacokinetics; October 1992, Volume 23, Issue 4, pp 311Ã¢â‚¬â€œ320"
"BIOTID01655","Sulfapyridine","5336","GECHUMIMRBOMGK-UHFFFAOYSA-N","InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)","NAT","N-acetylation of arylamine","Human Phase II","Human","Sulfapyridine, N-acetyl","58638","CYLYVXPHAQLXFG-UHFFFAOYSA-N","InChI=1S/C13H13N3O3S/c1-10(17)15-11-5-7-12(8-6-11)20(18,19)16-13-4-2-3-9-14-13/h2-9H,1H3,(H,14,16)(H,15,17)","Taggart, A.J. et al. (1992); The Effect of Age and Acetylator Phenotype on the Pharmacokinetics of Sulfasalazine in Patients with Rheumatoid Arthritis; Clinical Pharmacokinetics; October 1992, Volume 23, Issue 4, pp 311Ã¢â‚¬â€œ320"
"BIOTID01656","4-aminobenzoate","4876","ALYNCZNDIQEVRV-UHFFFAOYSA-M","InChI=1S/C7H7NO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,8H2,(H,9,10)/p-1","NAT","N-acetylation of arylamine","Human Phase II","Human","4-acetylaminobenzoate","6918889","QCXJEYYXVJIFCE-UHFFFAOYSA-M","InChI=1S/C9H9NO3/c1-6(11)10-8-4-2-7(3-5-8)9(12)13/h2-5H,1H3,(H,10,11)(H,12,13)/p-1","PMID:735647|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01657","4-amino-3-methylbenzoic acid","75598","NHFKECPTBZZFBC-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-5-4-6(8(10)11)2-3-7(5)9/h2-4H,9H2,1H3,(H,10,11)","NAT1; NAT2","N-acetylation of arylamine","Human Phase II","Human","NULL","3015948","WCQSEJSRAJSUSS-UHFFFAOYSA-N","InChI=1S/C10H11NO3/c1-6-5-8(10(13)14)3-4-9(6)11-7(2)12/h3-5H,1-2H3,(H,11,12)(H,13,14)","PMID:675406|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01658","2,3-dimethylaniline","6893","VVAKEQGKZNKUSU-UHFFFAOYSA-N","InChI=1S/C8H11N/c1-6-4-3-5-8(9)7(6)2/h3-5H,9H2,1-2H3","NAT1; NAT2","N-acetylation of arylamine","Human Phase II","Human"," 2,3Ã¢â‚¬Âdimethylacetanilide","8656","SRSHEJADOPNDDF-UHFFFAOYSA-N","InChI=1S/C10H13NO/c1-7-5-4-6-10(8(7)2)11-9(3)12/h4-6H,1-3H3,(H,11,12)","PMID:686074|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01659","2,4-dimethylaniline","7250","CZZZABOKJQXEBO-UHFFFAOYSA-N","InChI=1S/C8H11N/c1-6-3-4-8(9)7(2)5-6/h3-5H,9H2,1-2H3","NAT1; NAT2","N-acetylation of arylamine","Human Phase II","Human"," 2,4Ã¢â‚¬Âdimethylacetanilide","16303","PJEIIBXJUDOMAN-UHFFFAOYSA-N","InChI=1S/C10H13NO/c1-7-4-5-10(8(2)6-7)11-9(3)12/h4-6H,1-3H3,(H,11,12)","PMID:686074|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01660","2,5-dimethylaniline","7259","VOWZNBNDMFLQGM-UHFFFAOYSA-N","InChI=1S/C8H11N/c1-6-3-4-7(2)8(9)5-6/h3-5H,9H2,1-2H3","NAT1; NAT2","N-acetylation of arylamine","Human Phase II","Human"," 2,5Ã¢â‚¬Âdimethylacetanilide","16304","CXLKSNKWHULUKA-UHFFFAOYSA-N","InChI=1S/C10H13NO/c1-7-4-5-8(2)10(6-7)11-9(3)12/h4-6H,1-3H3,(H,11,12)","PMID:686074|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01661","2-(4-aminobenzamido)pyridine","81976","GBYNWLIJDNPFRH-UHFFFAOYSA-N","InChI=1S/C12H11N3O/c13-10-6-4-9(5-7-10)12(16)15-11-3-1-2-8-14-11/h1-8H,13H2,(H,14,15,16)","GST","N-acetylation of arylamine","Human Phase II","Human","4Ã¢â‚¬ÂacetamidoÃ¢â‚¬ÂNÃ¢â‚¬Â(pyridinÃ¢â‚¬Â2Ã¢â‚¬Âyl)benzamide","215925","GDKVDCDNGVWBCW-UHFFFAOYSA-N","InChI=1S/C14H13N3O2/c1-10(18)16-12-7-5-11(6-8-12)14(19)17-13-4-2-3-9-15-13/h2-9H,1H3,(H,16,18)(H,15,17,19)","PMID:487114|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01662","(+)-2-bromo-3-(4-nitrophenyl)propanoic acid","265266","UOMCKHFTGNAYBX-UHFFFAOYSA-N","InChI=1S/C9H8BrNO4/c10-8(9(12)13)5-6-1-3-7(4-2-6)11(14)15/h1-4,8H,5H2,(H,12,13)","GST","GSH-conjugation of organohalide","Human Phase II","Human","2-(glutathion-S-yl)-3-(4-nitrophenyl)propanoic acid","129847590","TUKINTUYICBBAJ-RFHHWMCGSA-N","InChI=1S/C19H24N4O10S/c20-12(18(28)29)5-6-15(24)22-13(17(27)21-8-16(25)26)9-34-14(19(30)31)7-10-1-3-11(4-2-10)23(32)33/h1-4,12-14H,5-9,20H2,(H,21,27)(H,22,24)(H,25,26)(H,28,29)(H,30,31)/t12-,13-,14?/m0/s1","Board PG et al. (2003); Clarification of the role of key active site residues of glutathione transferase zeta/maleylacetoacetate isomerase by a new spectrophotometric technique; Biochem. J. 374, 731-737"
"BIOTID01663","1,3,5-trinitrobenzene","7434","UATJOMSPNYCXIX-UHFFFAOYSA-N","InChI=1S/C6H3N3O6/c10-7(11)4-1-5(8(12)13)3-6(2-4)9(14)15/h1-3H","GSTA1","GSH-conjugation of benzene substituted with an electron donating group","Human Phase II","Human","S-(2,4,6-trinitrocyclohexa-2,5-dien-1-yl)glutathione","5288478","VQUXYLXGOSJDJJ-SBPVCVGVSA-N","InChI=1S/C16H20N6O12S/c17-8(16(27)28)1-2-12(23)19-9(15(26)18-5-13(24)25)6-35-14-10(21(31)32)3-7(20(29)30)4-11(14)22(33)34/h3-4,7-9,14H,1-2,5-6,17H2,(H,18,26)(H,19,23)(H,24,25)(H,27,28)/t7?,8-,9-,14?/m0/s1","Gildenhuys S et al. (2010); Arginine 15 stabilizes an S(N)Ar reaction transition state and the binding of anionic ligands at the active site of human glutathione transferase A1-1; Biophys. Chem. 146, 118-125"
"BIOTID01664","1-chloro-2,3-dinitrobenzene","33096","KYDXWCHDUCDNGR-UHFFFAOYSA-N","InChI=1S/C6H3ClN2O4/c7-4-2-1-3-5(8(10)11)6(4)9(12)13/h1-3H","GST","GSH-conjugation","Human Phase II","Human","S-(2,3-dinitrophenyl)glutathione","87333628","VZZVSNSQKIKBLC-IUCAKERBSA-N","InChI=1S/C16H19N5O10S/c17-8(16(26)27)4-5-12(22)19-9(15(25)18-6-13(23)24)7-32-11-3-1-2-10(20(28)29)14(11)21(30)31/h1-3,8-9H,4-7,17H2,(H,18,25)(H,19,22)(H,23,24)(H,26,27)/t8-,9-/m0/s1",""
"BIOTID01665","1-chloro-2,4-dinitrobenzene","6","VYZAHLCBVHPDDF-UHFFFAOYSA-N","InChI=1S/C6H3ClN2O4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3H","GST","GSH-conjugation","Human Phase II","Human","S-(2,4-dinitrophenyl)glutathione","97535","FXEUKVKGTKDDIQ-UWVGGRQHSA-N","InChI=1S/C16H19N5O10S/c17-9(16(26)27)2-4-13(22)19-10(15(25)18-6-14(23)24)7-32-12-3-1-8(20(28)29)5-11(12)21(30)31/h1,3,5,9-10H,2,4,6-7,17H2,(H,18,25)(H,19,22)(H,23,24)(H,26,27)/t9-,10-/m0/s1","Gildenhuys S et al. (2010); Arginine 15 stabilizes an S(N)Ar reaction transition state and the binding of anionic ligands at the active site of human glutathione transferase A1-1; Biophys. Chem. 146, 118-125"
"BIOTID01666","1-Chloro-2,4-dinitrobenzene","6","VYZAHLCBVHPDDF-UHFFFAOYSA-N","InChI=1S/C6H3ClN2O4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3H","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","BPDOULKXPOUAPX-UHFFFAOYSA-N","InChI=1S/C16H20ClN5O10S/c17-16(4-3-8(21(29)30)5-11(16)22(31)32)33-7-10(14(26)19-6-13(24)25)20-12(23)2-1-9(18)15(27)28/h3-5,8-10H,1-2,6-7,18H2,(H,19,26)(H,20,23)(H,24,25)(H,27,28)","Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation"
"BIOTID01667","Pefloxacin","51081","FHFYDNQZQSQIAI-UHFFFAOYSA-N","InChI=1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24)","GST","O-glucuronidation of aromatic acid","Human Phase II","Human","Pefloxacin O-glucuronide","NULL","QDEVJYIKQHAKNT-KTQJQPAOSA-N","InChI=1S/C23H28FN3O9/c1-3-26-10-12(22(34)36-23-19(31)17(29)18(30)20(35-23)21(32)33)16(28)11-8-13(24)15(9-14(11)26)27-6-4-25(2)5-7-27/h8-10,17-20,23,29-31H,3-7H2,1-2H3,(H,32,33)/t17-,18-,19+,20-,23?/m0/s1","Philip Lee et al. (2014) Handbook of Metabolic Pathways of Xenobiotics; DOI:10.1002/9781118541203.xen370"
"BIOTID01668","Brodifacoum","54680676","VEUZZDOCACZPRY-UHFFFAOYSA-N","InChI=1S/C31H23BrO3/c32-24-15-13-20(14-16-24)19-9-11-21(12-10-19)23-17-22-5-1-2-6-25(22)27(18-23)29-30(33)26-7-3-4-8-28(26)35-31(29)34/h1-16,23,27,33H,17-18H2","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","Brodifacoum O-glucuronide","NULL","UGNYAZFBDKONOJ-WMNBIHONSA-N","InChI=1S/C37H31BrO9/c38-24-15-13-20(14-16-24)19-9-11-21(12-10-19)23-17-22-5-1-2-6-25(22)27(18-23)29-33(26-7-3-4-8-28(26)45-36(29)44)46-37-32(41)30(39)31(40)34(47-37)35(42)43/h1-16,23,27,30-32,34,37,39-41H,17-18H2,(H,42,43)/t23?,27?,30-,31-,32+,34-,37?/m0/s1","USEPA; Reregistration Eligibility Decision Document - Rodenticide Cluster. Washington, DC: USEPA, Off Pest Prog. USEPA 738-R-98-007 p.36 July 1998. Available from, as of March 17, 2003"
"BIOTID01669","Nornalmefene","9971176","QUXLQAACGCFFEX-ISWURRPUSA-N","InChI=1S/C17H19NO3/c1-9-4-5-17(20)12-8-10-2-3-11(19)14-13(10)16(17,6-7-18-12)15(9)21-14/h2-3,12,15,18-20H,1,4-8H2/t12-,15+,16+,17-/m1/s1","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","Nornalmefene O-glucuronide","10322049","DKWNNQJPZBNSJW-WUDROUKASA-N","InChI=1S/C23H27NO9/c1-9-4-5-23(30)12-8-10-2-3-11(17-13(10)22(23,6-7-24-12)19(9)32-17)31-21-16(27)14(25)15(26)18(33-21)20(28)29/h2-3,12,14-16,18-19,21,24-27,30H,1,4-8H2,(H,28,29)/t12-,14+,15+,16-,18+,19+,21-,22+,23-/m1/s1",""
"BIOTID01670","Prechrysophanol","NULL","FMMRCPMGCDHFFU-LDGXTIHJNA-N","InChI=1S/C15H16O3/c1-8-4-10-6-9-2-3-11(16)7-12(9)15(18)14(10)13(17)5-8/h4-6,11,16-18H,2-3,7H2,1H3/t11-/m1/s1","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","Prechrysophanol O-glucuronide","102517602","ZRZIXMBLBGOIRG-OMJXQOQOSA-N","InChI=1S/C21H24O9/c1-8-4-10-6-9-2-3-11(22)7-12(9)15(23)14(10)13(5-8)29-21-18(26)16(24)17(25)19(30-21)20(27)28/h4-6,11,16-19,21-26H,2-3,7H2,1H3,(H,27,28)/t11-,16+,17+,18-,19+,21-/m1/s1",""
"BIOTID01671","Lumiracoxib","151166","KHPKQFYUPIUARC-UHFFFAOYSA-N","InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","Lumiracoxib O-glucuronide","NULL","GEVZOJTWMGGTTK-DAZJWRSOSA-N","InChI=1S/C21H21ClFNO8/c1-9-5-6-13(24-15-11(22)3-2-4-12(15)23)10(7-9)8-14(25)31-21-18(28)16(26)17(27)19(32-21)20(29)30/h2-7,16-19,21,24,26-28H,8H2,1H3,(H,29,30)/t16-,17-,18+,19-,21?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01672","4-Hydroxy-alpha-thujone","NULL","QCIUNUUHBWFYTD-JEZHCXPESA-N","InChI=1S/C10H16O2/c1-6(2)10-4-7(10)9(3,12)8(11)5-10/h6-7,12H,4-5H2,1-3H3/t7-,9+,10+/m1/s1","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","alpha-thujone, 4-O-glucuronide","NULL","UILIWLYYTHIBJT-BSVWXJLRSA-N","InChI=1S/C16H24O9/c1-5(2)16-4-6(16)15(3,23)11(20)12(16)25-14-9(19)7(17)8(18)10(24-14)13(21)22/h5-10,12,14,17-19,23H,4H2,1-3H3,(H,21,22)/t6-,7+,8+,9-,10+,12-,14?,15+,16+/m1/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01673","Scutellarein","5281697","JVXZRQGOGOXCEC-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)11-5-9(17)13-12(21-11)6-10(18)14(19)15(13)20/h1-6,16,18-20H","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","Scutellarein 7-O-glucuronide","21969382","DJSISFGPUUYILV-DAZJWRSOSA-N","InChI=1S/C21H18O12/c22-8-3-1-7(2-4-8)10-5-9(23)13-11(31-10)6-12(14(24)15(13)25)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-22,24-28H,(H,29,30)/t16-,17-,18+,19-,21?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01674","Desogestrel","40973","RPLCPCMSCLEKRS-BPIQYHPVSA-N","InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","Desogestrel 17-O-glucuronide","NULL","ZUFUEHVHFQAYMH-BCARWAMXSA-N","InChI=1S/C28H38O7/c1-4-27-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(27)12-13-28(27,5-2)35-26-23(31)21(29)22(30)24(34-26)25(32)33/h2,8,17-24,26,29-31H,3-4,6-7,9-14H2,1H3,(H,32,33)/t17-,18-,19-,20+,21-,22-,23+,24-,26?,27-,28-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01675","3-Iodobenzoic acid","12060","KVBWBCRPWVKFQT-UHFFFAOYSA-N","InChI=1S/C7H5IO2/c8-6-3-1-2-5(4-6)7(9)10/h1-4H,(H,9,10)","UGT","O-glucuronidation of aromatic acid","Human Phase II","Human","3-Iodobenzoyl glyucuronide","NULL","IFVFOZXNBDJIJC-XFVPOMSTSA-N","InChI=1S/C13H13IO8/c14-6-3-1-2-5(4-6)12(20)22-13-9(17)7(15)8(16)10(21-13)11(18)19/h1-4,7-10,13,15-17H,(H,18,19)/t7-,8-,9+,10-,13?/m0/s1","Jensen,BP. et al. (2004); Application of inductively coupled plasma mass spectrometry and high-performance liquid chromatography--with parallel electrospray mass spectrometry to the investigation of the disposition and metabolic fate of 2-, 3- and 4-iodobenzoic acids in the rat.; J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 5;809(2):279-85."
"BIOTID01676","4-Iodobenzoic acid","12085","GHICCUXQJBDNRN-UHFFFAOYSA-N","InChI=1S/C7H5IO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,(H,9,10)","UGT","O-glucuronidation of aromatic acid","Human Phase II","Human","4-Iodobenzoyl glyucuronide","NULL","QLHNUPHXNJRFOY-XFVPOMSTSA-N","InChI=1S/C13H13IO8/c14-6-3-1-5(2-4-6)12(20)22-13-9(17)7(15)8(16)10(21-13)11(18)19/h1-4,7-10,13,15-17H,(H,18,19)/t7-,8-,9+,10-,13?/m0/s1","Jensen,BP. et al. (2004); Application of inductively coupled plasma mass spectrometry and high-performance liquid chromatography--with parallel electrospray mass spectrometry to the investigation of the disposition and metabolic fate of 2-, 3- and 4-iodobenzoic acids in the rat.; J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 5;809(2):279-85."
"BIOTID01677","Oxoprenolol","4631","CEMAWMOMDPGJMB-UHFFFAOYNA-N","InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","Oxprenolol glucuronide","162729","CJVSRVDYHNLUAN-DNPGXZAYSA-N","InChI=1S/C21H31NO9/c1-4-9-28-14-7-5-6-8-15(14)29-11-13(10-22-12(2)3)30-21-18(25)16(23)17(24)19(31-21)20(26)27/h4-8,12-13,16-19,21-25H,1,9-11H2,2-3H3,(H,26,27)/t13?,16-,17-,18+,19-,21+/m0/s1","Laethem, ME et al. (1995); Clin Pharmacol Ther. 1995 Apr;57(4):419-24."
"BIOTID01678","Zomepirac","5733","ZXVNMYWKKDOREA-UHFFFAOYSA-N","InChI=1S/C15H14ClNO3/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10/h3-7H,8H2,1-2H3,(H,18,19)","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","Zomepirac O-glucuronide","NULL","FNGKIZYZSHHXJZ-DAZJWRSOSA-N","InChI=1S/C21H22ClNO9/c1-9-7-12(23(2)14(9)15(25)10-3-5-11(22)6-4-10)8-13(24)31-21-18(28)16(26)17(27)19(32-21)20(29)30/h3-7,16-19,21,26-28H,8H2,1-2H3,(H,29,30)/t16-,17-,18+,19-,21?/m0/s1","Langendijk PN et al. (1984); Simultaneous determination of zomepirac and its major metabolite zomepirac glucuronide in human plasma and urine; J Chromatogr. 1984 May 11;307(2):371-9."
"BIOTID01679","Clioquinol","2788","QCDFBFJGMNKBDO-UHFFFAOYSA-N","InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","Clioquinol O-glucuronide","54571499","ZXPACOCAPRBPFP-YLWMSMGXSA-N","InChI=1S/C15H13ClINO7/c16-6-4-7(17)12(8-5(6)2-1-3-18-8)24-15-11(21)9(19)10(20)13(25-15)14(22)23/h1-4,9-11,13,15,19-21H,(H,22,23)/t9-,10-,11+,13-,15?/m0/s1",""
"BIOTID01680","Quinotolast","65871","ZUPLNRDTYQWUHP-UHFFFAOYSA-N","InChI=1S/C17H12N6O3/c24-15(18-17-19-21-22-20-17)12-10-14(26-11-6-2-1-3-7-11)13-8-4-5-9-23(13)16(12)25/h1-10H,(H2,18,19,20,21,22,24)","UGT","N-glucuronidation","Human Phase II","Human","Quinotolast N-glucuronide","101661861","ZRRIOSTWOXCBKN-ARNOYJHMSA-N","InChI=1S/C23H20N6O10/c30-15-16(31)18(21(35)36)38-22(17(15)32)39-29-26-23(25-27-29)24-19(33)12-10-14(37-11-6-2-1-3-7-11)13-8-4-5-9-28(13)20(12)34/h1-10,15-18,22,30-32H,(H,35,36)(H,24,26,33)/t15-,16-,17+,18-,22-/m0/s1","Terakawa M. et al. (1993); Steady-State Pharmacokinetics of Quinotolast Sodium in Man; Drug Metabolism and Pharmacokinetics; Vol. 8 (1993) No. 5 P 1029-1040"
"BIOTID01683","RG12525","22615990","SOMUITKIBMREBL-UHFFFAOYSA-N","InChI=1S/C24H19N5O2/c1-3-7-22(24-26-28-29-27-24)18(6-1)15-30-20-11-13-21(14-12-20)31-16-19-10-9-17-5-2-4-8-23(17)25-19/h1-14H,15-16H2,(H,26,27,28,29)","UGT1A1; UGT2B7","N-glucuronidation of azole","Human Phase II","Human","RG12525 N2-glucuronide","NULL","KXRLQRIPSYPFMG-FENBJSOMSA-O","InChI=1S/C30H27N5O8/c36-24-25(37)27(30(39)40)43-29(26(24)38)35-33-28(32-34-35)22-7-3-1-6-18(22)15-41-20-11-13-21(14-12-20)42-16-19-10-9-17-5-2-4-8-23(17)31-19/h1-14,24-27,29,36-38H,15-16H2,(H,39,40)/p+1/t24-,25-,26+,27-,29?/m0/s1","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01684","JNJ-10198409","9797370","ZDNURMVOKAERHZ-UHFFFAOYSA-N","InChI=1S/C18H16FN3O2/c1-23-15-7-10-6-14-17(13(10)9-16(15)24-2)21-22-18(14)20-12-5-3-4-11(19)8-12/h3-5,7-9H,6H2,1-2H3,(H2,20,21,22)","UGT1A9","N-glucuronidation of azole","Human Phase II","Human","JNJ-10198409 N-glucuronide B","18445703","SAGRGZOVMGNLOV-UHFFFAOYSA-N","InChI=1S/C24H24FN3O8/c1-34-15-7-10-6-14-17(13(10)9-16(15)35-2)28(27-22(14)26-12-5-3-4-11(25)8-12)23-20(31)18(29)19(30)21(36-23)24(32)33/h3-5,7-9,18-21,23,29-31H,6H2,1-2H3,(H,26,27)(H,32,33)","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01685","JNJ-10198409","9797370","ZDNURMVOKAERHZ-UHFFFAOYSA-N","InChI=1S/C18H16FN3O2/c1-23-15-7-10-6-14-17(13(10)9-16(15)24-2)21-22-18(14)20-12-5-3-4-11(19)8-12/h3-5,7-9H,6H2,1-2H3,(H2,20,21,22)","UGT","N-glucuronidation of azole","Human Phase II","Human","JNJ-10198409 N-glucuronide C","NULL","MRWZWFDJHGQBAU-UHFFFAOYSA-O","InChI=1S/C24H24FN3O8/c1-34-15-7-10-6-14-17(13(10)9-16(15)35-2)27-28(22(14)26-12-5-3-4-11(25)8-12)23-20(31)18(29)19(30)21(36-23)24(32)33/h3-5,7-9,18-21,23,29-31H,6H2,1-2H3,(H2,26,27,32,33)/p+1","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01686","JNJ-10198409","9797370","ZDNURMVOKAERHZ-UHFFFAOYSA-N","InChI=1S/C18H16FN3O2/c1-23-15-7-10-6-14-17(13(10)9-16(15)24-2)21-22-18(14)20-12-5-3-4-11(19)8-12/h3-5,7-9H,6H2,1-2H3,(H2,20,21,22)","UGT1A4; UGT1A9","N-glucuronidation of azole","Human Phase II","Human","JNJ-10198409 N-glucuronide C","18445712","SEOXPQXQARYLQL-UHFFFAOYSA-N","InChI=1S/C24H24FN3O8/c1-34-15-7-10-6-14-17(13(10)9-16(15)35-2)26-27-22(14)28(12-5-3-4-11(25)8-12)23-20(31)18(29)19(30)21(36-23)24(32)33/h3-5,7-9,18-21,23,29-31H,6H2,1-2H3,(H,26,27)(H,32,33)","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01687","Midazolam","4192","DDLIGBOFAVUZHB-UHFFFAOYSA-N","InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3","UGT1A4","N-glucuronidation of azole","Human Phase II","Human","Midazolam N-glucuronide","NULL","ULVPQZCKSQYJQR-DRSFHUHJSA-O","InChI=1S/C24H21ClFN3O6/c1-11-28(23-21(32)19(30)20(31)22(35-23)24(33)34)10-13-9-27-18(14-4-2-3-5-16(14)26)15-8-12(25)6-7-17(15)29(11)13/h2-8,10,19-23,30-32H,9H2,1H3/p+1/t19-,20-,21+,22-,23?/m0/s1","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01688","Afloqualone","2040","VDOSWXIDETXFET-UHFFFAOYSA-N","InChI=1S/C16H14FN3O/c1-10-4-2-3-5-14(10)20-15(9-17)19-13-7-6-11(18)8-12(13)16(20)21/h2-8H,9,18H2,1H3","UGT1A4","Glucuronidation of primary aromatic amine","Human Phase II","Human","Afloqualone N-glucuronide","NULL","VYGBGLNICWUQHO-UHFFFAOYSA-N","InChI=1S/C22H22FN3O7/c1-10-4-2-3-5-14(10)26-15(9-23)25-13-7-6-11(8-12(13)21(26)30)24-20-18(29)16(27)17(28)19(33-20)22(31)32/h2-8,16-20,24,27-29H,9H2,1H3,(H,31,32)","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01689","N-Acetylbenzidine","18787","DZQXBXZZSKPMDV-UHFFFAOYSA-N","InChI=1S/C14H14N2O/c1-10(17)16-14-8-4-12(5-9-14)11-2-6-13(15)7-3-11/h2-9H,15H2,1H3,(H,16,17)","UGT1A1; UGT1A4; UGT1A9","Glucuronidation of primary aromatic amine","Human Phase II","Human","N-Acetylbenzidine, N-glucuronide","NULL","FOSFMZROUHWIBO-UHFFFAOYSA-N","InChI=1S/C20H22N2O7/c1-10(23)21-13-6-2-11(3-7-13)12-4-8-14(9-5-12)22-19-17(26)15(24)16(25)18(29-19)20(27)28/h2-9,15-19,22,24-26H,1H3,(H,21,23)(H,27,28)","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01690","retigabine","121892","PCOBBVZJEWWZFR-UHFFFAOYSA-N","InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)","UGT1A1; UGT1A9","Glucuronidation of primary aromatic amine","Human Phase II","Human","retigabine N2-glucuronide","22228602","AVGRGNFEIQMATO-UHFFFAOYSA-N","InChI=1S/C22H26FN3O8/c1-2-33-22(32)26-14-8-7-13(24-10-11-3-5-12(23)6-4-11)9-15(14)25-20-18(29)16(27)17(28)19(34-20)21(30)31/h3-9,16-20,24-25,27-29H,2,10H2,1H3,(H,26,32)(H,30,31)","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01693","Desmethylclozapine","NULL","JNNOSTQEZICQQP-UHFFFAOYSA-N","InChI=1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2","UGT1A3","N-glucuronidation","Human Phase II","Human","Desmethylclozapine N-glucuronide","NULL","LJGGFKKXPBOVDL-UHFFFAOYSA-N","InChI=1S/C23H25ClN4O6/c24-12-5-6-15-16(11-12)26-21(13-3-1-2-4-14(13)25-15)27-7-9-28(10-8-27)22-19(31)17(29)18(30)20(34-22)23(32)33/h1-6,11,17-20,22,25,29-31H,7-10H2,(H,32,33)","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01694","Desipramine","2995","HCYAFALTSJYZDH-UHFFFAOYSA-N","InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3","UGT1A3","N-glucuronidation","Human Phase II","Human","Desipramine N-glucuronide","NULL","USQMVWGMFYLMOY-UHFFFAOYSA-N","InChI=1S/C24H30N2O6/c1-25(23-21(29)19(27)20(28)22(32-23)24(30)31)13-6-14-26-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)26/h2-5,7-10,19-23,27-29H,6,11-14H2,1H3,(H,30,31)","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01695","Diphenylamine","11487","DMBHHRLKUKUOEG-UHFFFAOYSA-N","InChI=1S/C12H11N/c1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h1-10,13H","UGT1A3","N-glucuronidation","Human Phase II","Human","Diphenylamine N-glucuronide","NULL","IJMCZAXZUZCSEO-UHFFFAOYSA-N","InChI=1S/C18H19NO6/c20-13-14(21)16(18(23)24)25-17(15(13)22)19(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13-17,20-22H,(H,23,24)","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01696","Promethazine","4927","PWWVAXIEGOYWEE-UHFFFAOYNA-N","InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Promethazine N-glucuronide","NULL","ABNKYMDJQOWLOF-UHFFFAOYSA-O","InChI=1S/C23H28N2O6S/c1-13(25(2,3)22-20(28)18(26)19(27)21(31-22)23(29)30)12-24-14-8-4-6-10-16(14)32-17-11-7-5-9-15(17)24/h4-11,13,18-22,26-28H,12H2,1-3H3/p+1","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01697","Diphenhydramine","3100","ZZVUWRFHKOJYTH-UHFFFAOYSA-N","InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Diphenhydramine N-glucuronide","NULL","OAIGZXXQYIJBLR-UHFFFAOYSA-O","InChI=1S/C23H29NO7/c1-24(2,22-19(27)17(25)18(26)21(31-22)23(28)29)13-14-30-20(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17-22,25-27H,13-14H2,1-2H3/p+1","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01698","Loxepine","3964","XJGVXQDUIWGIRW-UHFFFAOYSA-N","InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Loxepine N-glucuronide","NULL","LQIYQWUFVYHRTJ-UHFFFAOYSA-O","InChI=1S/C24H26ClN3O7/c1-28(23-20(31)18(29)19(30)21(35-23)24(32)33)10-8-27(9-11-28)22-14-12-13(25)6-7-16(14)34-17-5-3-2-4-15(17)26-22/h2-7,12,18-21,23,29-31H,8-11H2,1H3/p+1","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01699","Clozapine","NULL","QZUDBNBUXVUHMW-UHFFFAOYSA-N","InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Clozapine N-glucuronide","NULL","SJZOZBLWKIWHFH-UHFFFAOYSA-O","InChI=1S/C24H27ClN4O6/c1-29(23-20(32)18(30)19(31)21(35-23)24(33)34)10-8-28(9-11-29)22-14-4-2-3-5-15(14)26-16-7-6-13(25)12-17(16)27-22/h2-7,12,18-21,23,30-32H,8-11H2,1H3,(H-,26,27,33,34)/p+1","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01700","Ketotifen","3827","ZCVMWBYGMWKGHF-UHFFFAOYSA-N","InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Ketotifen N-glucuronide","NULL","WLTPAELNPGRIGG-AQTBWJFISA-O","InChI=1S/C25H27NO7S/c1-26(24-21(30)19(28)20(29)22(33-24)25(31)32)9-6-13(7-10-26)18-15-5-3-2-4-14(15)12-17(27)23-16(18)8-11-34-23/h2-5,8,11,19-22,24,28-30H,6-7,9-10,12H2,1H3/p+1/b18-13-","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01701","Chlorpromazine","2726","ZPEIMTDSQAKGNT-UHFFFAOYSA-N","InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Chlorpromazine N-glucuronide","NULL","WOWWOPLXFLBDAN-UHFFFAOYSA-O","InChI=1S/C23H27ClN2O6S/c1-26(2,22-20(29)18(27)19(28)21(32-22)23(30)31)11-5-10-25-14-6-3-4-7-16(14)33-17-9-8-13(24)12-15(17)25/h3-4,6-9,12,18-22,27-29H,5,10-11H2,1-2H3/p+1","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01702","Doxepin","667477","ODQWQRRAPPTVAG-GZTJUZNOSA-N","InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Doxepin N-glucuronide","NULL","HIWVLLQQFXUDIX-GZTJUZNOSA-O","InChI=1S/C25H29NO7/c1-26(2,24-22(29)20(27)21(28)23(33-24)25(30)31)13-7-11-17-16-9-4-3-8-15(16)14-32-19-12-6-5-10-18(17)19/h3-6,8-12,20-24,27-29H,7,13-14H2,1-2H3/p+1/b17-11+","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01703","Tripelennamine","5587","UFLGIAIHIAPJJC-UHFFFAOYSA-N","InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Tripelennamine N-glucuronide","NULL","PAYFYCLCAWTSBX-UHFFFAOYSA-O","InChI=1S/C22H29N3O6/c1-25(2,21-19(28)17(26)18(27)20(31-21)22(29)30)13-12-24(16-10-6-7-11-23-16)14-15-8-4-3-5-9-15/h3-11,17-21,26-28H,12-14H2,1-2H3/p+1","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01704","Cyproheptadine","2913","JJCFRYNCJDLXIK-UHFFFAOYSA-N","InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Cyproheptadine N-glucuronide","NULL","CQLKKFODLDAYGC-UHFFFAOYSA-O","InChI=1S/C27H29NO6/c1-28(26-24(31)22(29)23(30)25(34-26)27(32)33)14-12-18(13-15-28)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11,22-26,29-31H,12-15H2,1H3/p+1","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01705","Imipramine","3696","BCGWQEUPMDMJNV-UHFFFAOYSA-N","InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3","UGT1A3","N-glucuronidation of tertiary aliphatic amine","Human Phase II","Human","Imipramine N-glucuronide","NULL","CXPKQHSXFUNBMP-UHFFFAOYSA-O","InChI=1S/C25H32N2O6/c1-27(2,24-22(30)20(28)21(29)23(33-24)25(31)32)15-7-14-26-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)26/h3-6,8-11,20-24,28-30H,7,12-15H2,1-2H3/p+1","Green MD et al. (1998); Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3; Drug Metab Dispos.;26(6):507-12; PMID:9616184"
"BIOTID01706","Nirvanol","91480","UDTWZFJEMMUFLC-UHFFFAOYSA-N","InChI=1S/C11H12N2O2/c1-2-11(8-6-4-3-5-7-8)9(14)12-10(15)13-11/h3-7H,2H2,1H3,(H2,12,13,14,15)","UGT","N-glucuronidation","Human Phase II","Human","Nirvanol N-glucuronide","NULL","DODGRIDUNRFYLX-UHFFFAOYSA-N","InChI=1S/C17H20N2O8/c1-2-17(8-6-4-3-5-7-8)15(25)19(16(26)18-17)13-11(22)9(20)10(21)12(27-13)14(23)24/h3-7,9-13,20-22H,2H2,1H3,(H,18,26)(H,23,24)",""
"BIOTID01707","Isonicotinoylhydrazine","3767","QRXWMOHMRWLFEY-UHFFFAOYSA-N","InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)","UGT","O-glucuronidation","Human Phase II","Human","NULL","3768","QVJOLLPKYFYTIH-UHFFFAOYSA-N","InChI=1S/C12H15N3O7/c16-6-7(17)9(12(20)21)22-11(8(6)18)15-14-10(19)5-1-3-13-4-2-5/h1-4,6-9,11,15-18H,(H,14,19)(H,20,21)",""
"BIOTID01708","Ketobemidone","10101","ALFGKMXHOUSVAD-UHFFFAOYSA-N","InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","Ketobemidone O-glucuronide","NULL","DBYXYLOBEILJKX-UHFFFAOYSA-N","InChI=1S/C21H29NO8/c1-3-14(23)21(7-9-22(2)10-8-21)12-5-4-6-13(11-12)29-20-17(26)15(24)16(25)18(30-20)19(27)28/h4-6,11,15-18,20,24-26H,3,7-10H2,1-2H3,(H,27,28)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01709","Ketobemidone","10101","ALFGKMXHOUSVAD-UHFFFAOYSA-N","InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3","SULT","3-OH sulfonation of phenolic compound","Human Phase II","Human","Ketobemidone sulfate","NULL","VXBQULGKHFXBBF-UHFFFAOYSA-N","InChI=1S/C15H21NO5S/c1-3-14(17)15(7-9-16(2)10-8-15)12-5-4-6-13(11-12)21-22(18,19)20/h4-6,11H,3,7-10H2,1-2H3,(H,18,19,20)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01710","chlorofluoroacetic acid","98260","JBIKZDFUXGHTHD-UHFFFAOYSA-N","InChI=1S/C2H2ClFO2/c3-1(4)2(5)6/h1H,(H,5,6)","GST","GSH-conjugation of organohalide","Human Phase II","Human","chloroacetyl-S-glutathione","54244650","QSJWCVDVLJSMFK-UHFFFAOYSA-N","InChI=1S/C12H18ClN3O8S/c13-9(12(23)24)25-4-6(10(20)15-3-8(18)19)16-7(17)2-1-5(14)11(21)22/h5-6,9H,1-4,14H2,(H,15,20)(H,16,17)(H,18,19)(H,21,22)(H,23,24)","Board PG et al. (2003); Clarification of the role of key active site residues of glutathione transferase zeta/maleylacetoacetate isomerase by a new spectrophotometric technique; Biochem. J. 374, 731-737; PMID:12852784; PMCID:PMC1223650; DOI:10.1042/BJ20030625"
"BIOTID01711","4-nitrobenzyl chloride","7482","KGCNHWXDPDPSBV-UHFFFAOYSA-N","InChI=1S/C7H6ClNO2/c8-5-6-1-3-7(4-2-6)9(10)11/h1-4H,5H2","GST","GSH-conjugation of organohalide","Human Phase II","Human","S-(4-Nitrobenzyl)glutathione","5133","OAWORKDPTSAMBZ-UHFFFAOYSA-N","InChI=1S/C17H22N4O8S/c18-12(17(26)27)5-6-14(22)20-13(16(25)19-7-15(23)24)9-30-8-10-1-3-11(4-2-10)21(28)29/h1-4,12-13H,5-9,18H2,(H,19,25)(H,20,22)(H,23,24)(H,26,27)","Shokeer A et al. (2005); Residue 234 in glutathione transferase T1-1 plays a pivotal role in the catalytic activity and the selectivity against alternative substrates; Biochem. J. 388, 387-392; PMID:15683365; DOI:10.1042/BJ20042064"
"BIOTID01712","4-nitrobenzyl chloride","7482","KGCNHWXDPDPSBV-UHFFFAOYSA-N","InChI=1S/C7H6ClNO2/c8-5-6-1-3-7(4-2-6)9(10)11/h1-4H,5H2","GST","GSH-conjugation","Human Phase II","Human","4-nitrobenzyl-glutathione","97538","OAWORKDPTSAMBZ-STQMWFEESA-N","InChI=1S/C17H22N4O8S/c18-12(17(26)27)5-6-14(22)20-13(16(25)19-7-15(23)24)9-30-8-10-1-3-11(4-2-10)21(28)29/h1-4,12-13H,5-9,18H2,(H,19,25)(H,20,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01713","4-nitrobenzyl chloride","7482","KGCNHWXDPDPSBV-UHFFFAOYSA-N","InChI=1S/C7H6ClNO2/c8-5-6-1-3-7(4-2-6)9(10)11/h1-4H,5H2","GST","GSH-conjugation","Human Phase II","Human","S-(2,4-dinitrophenyl)glutathione","97535","FXEUKVKGTKDDIQ-UWVGGRQHSA-N","InChI=1S/C16H19N5O10S/c17-9(16(26)27)2-4-13(22)19-10(15(25)18-6-14(23)24)7-32-12-3-1-8(20(28)29)5-11(12)21(30)31/h1,3,5,9-10H,2,4,6-7,17H2,(H,18,25)(H,19,22)(H,23,24)(H,26,27)/t9-,10-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01714","alachlor","2078","XCSGPAVHZFQHGE-UHFFFAOYSA-N","InChI=1S/C14H20ClNO2/c1-4-11-7-6-8-12(5-2)14(11)16(10-18-3)13(17)9-15/h6-8H,4-5,9-10H2,1-3H3","GST","GSH-conjugation of organohalide","Human Phase II","Human","S-(alachlor)glutathione","NULL","WAAUWKSMOLRUDH-UHFFFAOYSA-N","InChI=1S/C24H36N4O8S/c1-4-15-7-6-8-16(5-2)22(15)28(14-36-3)20(30)13-37-12-18(23(33)26-11-21(31)32)27-19(29)10-9-17(25)24(34)35/h6-8,17-18H,4-5,9-14,25H2,1-3H3,(H,26,33)(H,27,29)(H,31,32)(H,34,35)","Park SG et al. (2009); Detoxification of cytotoxic alachlor by glutathione: characterization of conjugated adducts by electrospray ionization tandem mass spectrometry; J Agric Food Chem.;57(20):9838-47; PMID:19788241; DOI:10.1021/jf902077h"
"BIOTID01715","monochlorobimane","114886","SUIPVTCEECPFIB-UHFFFAOYSA-N","InChI=1S/C10H11ClN2O2/c1-5-7(3)12-8(4-11)6(2)10(15)13(12)9(5)14/h4H2,1-3H3","GST","GSH-conjugation of organohalide","Human Phase II","Human","Bimane-glutathione","NULL","ZTZDOPADIRRVJM-UHFFFAOYSA-N","InChI=1S/C20H27N5O8S/c1-9-11(3)24-14(10(2)18(29)25(24)17(9)28)8-34-7-13(15(26)6-22-20(32)33)23-16(27)5-4-12(21)19(30)31/h12-13,22H,4-8,21H2,1-3H3,(H,23,27)(H,30,31)(H,32,33)","Mukanganyama S et al. (2011); The evaluation of novel natural products as inhibitors of human glutathione transferase P1-1; J. Enzyme Inhib. Med. Chem. 26, 460-467; PMID:21028940; DOI:10.3109/14756366.2010.526769"
"BIOTID01716","aminochrome","170262","XDEURYRPQDIBSL-UHFFFAOYSA-N","InChI=1S/C8H7NO2/c10-7-3-5-1-2-9-6(5)4-8(7)11/h3-4,9H,1-2H2","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","JOVSHRUXLSHZEU-UHFFFAOYSA-N","InChI=1S/C18H24N4O8S/c19-9(18(29)30)1-2-12(24)22-10(17(28)21-6-13(25)26)7-31-16-14-8(3-4-20-14)5-11(23)15(16)27/h5,9-10,20,23,27H,1-4,6-7,19H2,(H,21,28)(H,22,24)(H,25,26)(H,29,30)","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01717","tert-butanol","6386","DKGAVHZHDRPRBM-UHFFFAOYSA-N","InChI=1S/C4H10O/c1-4(2,3)5/h5H,1-3H3","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","53831690","GCXCPPYOGCFUST-UBQDNYDRSA-N","InChI=1S/C10H18O7/c1-10(2,3)17-9-6(13)4(11)5(12)7(16-9)8(14)15/h4-7,9,11-13H,1-3H3,(H,14,15)/t4-,5-,6+,7-,9?/m0/s1","PMID:24887323|https://ofmpub.epa.gov/eims/eimscomm.getfile?p_download_id=528031"
"BIOTID01718","tert-butanol","6386","DKGAVHZHDRPRBM-UHFFFAOYSA-N","InChI=1S/C4H10O/c1-4(2,3)5/h5H,1-3H3","SULT","O-sulfation","Human Phase II","Human","NULL","10005178","FVBHYZVVSXFCOO-UHFFFAOYSA-N","InChI=1S/C4H10O4S/c1-4(2,3)8-9(5,6)7/h1-3H3,(H,5,6,7)","PMID:24887323|https://ofmpub.epa.gov/eims/eimscomm.getfile?p_download_id=528031"
"BIOTID01719","Prunetin","5281804","KQMVAGISDHMXJJ-UHFFFAOYSA-N","InChI=1S/C16H12O5/c1-20-11-6-13(18)15-14(7-11)21-8-12(16(15)19)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","CATNYWBROAUMSP-UHFFFAOYSA-N","InChI=1S/C22H20O11/c1-30-11-6-13-15(16(24)12(8-31-13)9-2-4-10(23)5-3-9)14(7-11)32-22-19(27)17(25)18(26)20(33-22)21(28)29/h2-8,17-20,22-23,25-27H,1H3,(H,28,29)","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01720","Indacaterol","6918554","QZZUEBNBZAPZLX-QFIPXVFZSA-N","InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","HSHFGCOYMJEKRT-RCCTZJQCSA-N","InChI=1S/C30H36N2O9/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)31-13-22(19-5-7-21(33)24-20(19)6-8-23(34)32-24)40-30-27(37)25(35)26(36)28(41-30)29(38)39/h5-10,18,22,25-28,30-31,33,35-37H,3-4,11-13H2,1-2H3,(H,32,34)(H,38,39)/t22-,25-,26-,27+,28-,30?/m0/s1","https://www.drugbank.ca/drugs/DB05039"
"BIOTID01721","Triiodothyronine","5920","AUYYCJSJGJYCDS-LBPRGKRZSA-N","InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","YYFGGGCINNGOLE-UYJXKVRSSA-N","InChI=1S/C21H20I3NO10/c22-9-6-8(33-17-10(23)3-7(4-11(17)24)5-12(25)19(29)30)1-2-13(9)34-21-16(28)14(26)15(27)18(35-21)20(31)32/h1-4,6,12,14-16,18,21,26-28H,5,25H2,(H,29,30)(H,31,32)/t12-,14-,15-,16+,18-,21?/m0/s1","Kester MH et al. (2002); Characterization of iodothyronine sulfatase activities in human and rat liver and placenta.; Endocrinology. 2002 Mar;143(3):814-9."
"BIOTID01722","3-Hydroxy-2p,3p-dimethoxyflavone","688713","KEUIFZDBIBQKJD-UHFFFAOYSA-N","InChI=1S/C17H14O5/c1-20-13-9-5-7-11(16(13)21-2)17-15(19)14(18)10-6-3-4-8-12(10)22-17/h3-9,19H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","YWIFYTGFZNWLSF-UHFFFAOYSA-N","InChI=1S/C23H22O11/c1-30-13-9-5-7-11(18(13)31-2)19-20(14(24)10-6-3-4-8-12(10)32-19)33-23-17(27)15(25)16(26)21(34-23)22(28)29/h3-9,15-17,21,23,25-27H,1-2H3,(H,28,29)","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01723","8-aminoisoindolo (1,2-b)quinazolin-12(10H)-one","71750","SRIOCKJKFXAKHK-UHFFFAOYSA-N","InChI=1S/C15H11N3O/c16-10-5-6-13-9(7-10)8-18-14(17-13)11-3-1-2-4-12(11)15(18)19/h1-7H,8,16H2","NAT","N-acetylation of arylamine","Human Phase II","Human","NULL","356023","GIYORETUPYJWBA-UHFFFAOYSA-N","InChI=1S/C17H13N3O2/c1-10(21)18-12-6-7-15-11(8-12)9-20-16(19-15)13-4-2-3-5-14(13)17(20)22/h2-8H,9H2,1H3,(H,18,21)","PMID:735860|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01724","Irbesartan M8","3749","YOSHYTLCDANDAN-UHFFFAOYSA-N","InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","GQGGVFUQUGQLOH-XVALDCFZSA-O","InChI=1S/C32H38N6O7/c1-2-3-10-22-33-32(15-6-7-16-32)31(45)37(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)29-34-36-38(35-29)24-25(39)23(30(43)44)26(40)28(42)27(24)41/h4-5,8-9,11-14,23-29,39-42H,2-3,6-7,10,15-17H2,1H3/p+1/t23-,24?,25?,26+,27-,28-,29?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01725","Perindopril","107807","IPVQLZZIHOAWMC-QXKUPLGCSA-N","InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","179962","DCYRDAKXQLERQS-FQCHSDBKSA-N","InChI=1S/C23H36N2O11/c1-4-13(20(30)31)24-10(2)19(29)25-14-8-6-5-7-12(14)9-15(25)21(32)36-23(22(33)34)18(28)17(27)16(26)11(3)35-23/h10-18,24,26-28H,4-9H2,1-3H3,(H,30,31)(H,33,34)/t10?,11-,12+,13?,14+,15+,16-,17+,18-,23-/m1/s1","http://www.hmdb.ca/metabolites/HMDB0060863"
"BIOTID01726","Resokaempferol","5281611","OBWHQJYOOCRPST-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)15-14(19)13(18)11-6-5-10(17)7-12(11)20-15/h1-7,16-17,19H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","RKQLEENPCJRZQG-WQUGZTNDSA-N","InChI=1S/C21H18O11/c22-9-3-6-11-12(7-9)31-18(15(25)13(11)23)8-1-4-10(5-2-8)30-21-17(27)14(24)16(26)19(32-21)20(28)29/h1-7,14,16-17,19,21-22,24-27H,(H,28,29)/t14-,16-,17+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01727","Cholic acid","221493","BHQCQFFYRZLCQQ-OELDTZBJSA-N","InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1","UGT","3-OH glucuronidation of sterol","Human Phase II","Human","Cholic acid glucuronide","21252309","RBLDVEUUCHVWMW-SXYQVCRBSA-N","InChI=1S/C30H48O11/c1-13(4-7-21(33)34)16-5-6-17-22-18(12-20(32)30(16,17)3)29(2)9-8-15(10-14(29)11-19(22)31)40-28-25(37)23(35)24(36)26(41-28)27(38)39/h13-20,22-26,28,31-32,35-37H,4-12H2,1-3H3,(H,33,34)(H,38,39)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24+,25-,26+,28-,29+,30-/m1/s1","https://www.drugbank.ca/metabolites/DBMET00553"
"BIOTID01728","7-Hydroxy-beta-thujone","130754407","BWIMEHVFTVSHCC-NYNCVSEMSA-N","InChI=1S/C10H16O2/c1-6-7-4-10(7,5-8(6)11)9(2,3)12/h6-7,12H,4-5H2,1-3H3/t6-,7+,10+/m0/s1","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","NULL","WHRPFNIQYJHGRX-RZLXBWJHSA-N","InChI=1S/C16H24O8/c1-6-7-4-16(7,5-8(6)17)15(2,3)24-14-11(20)9(18)10(19)12(23-14)13(21)22/h6-7,9-12,14,18-20H,4-5H2,1-3H3,(H,21,22)/t6-,7+,9-,10-,11+,12-,14?,16+/m0/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01729","4-Hydroxy-beta-thujone","45096397","QCIUNUUHBWFYTD-QNSHHTMESA-N","InChI=1S/C10H16O2/c1-6(2)10-4-7(10)9(3,12)8(11)5-10/h6-7,12H,4-5H2,1-3H3/t7-,9-,10+/m1/s1","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","NULL","BMPWRVNLYWBHGK-ZNJAXHRXSA-N","InChI=1S/C16H24O8/c1-6(2)16-4-7(16)15(3,8(17)5-16)24-14-11(20)9(18)10(19)12(23-14)13(21)22/h6-7,9-12,14,18-20H,4-5H2,1-3H3,(H,21,22)/t7-,9+,10+,11-,12+,14?,15?,16+/m1/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01730","2-iodobenzyl bromide","11426472","GQFITODJWOIYPF-UHFFFAOYSA-N","InChI=1S/C7H6BrI/c8-5-6-3-1-2-4-7(6)9/h1-4H,5H2","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","TVXIENVEPKSGFZ-UHFFFAOYSA-N","InChI=1S/C17H22BrN3O6S/c18-7-10-3-1-2-4-13(10)28-9-12(16(25)20-8-15(23)24)21-14(22)6-5-11(19)17(26)27/h1-4,11-12H,5-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)","Dong, GQ. ET AL. (2014); Prediction of substrates for glutathione transferases by covalent docking; J Chem Inf Model. 2014 Jun 23;54(6):1687-99. DOI:10.1021/ci5001554"
"BIOTID01731","Hexafluoroisopropanol","13529","BYEAHWXPCBROCE-UHFFFAOYSA-N","InChI=1S/C3H2F6O/c4-2(5,6)1(10)3(7,8)9/h1,10H","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","NULL","UVZRKXDKGGDUGP-AQKNRBDQSA-N","InChI=1S/C9H10F6O7/c10-8(11,12)7(9(13,14)15)22-6-3(18)1(16)2(17)4(21-6)5(19)20/h1-4,6-7,16-18H,(H,19,20)/t1-,2-,3+,4-,6?/m0/s1","Acta Anaesthesiol Belg. 1996;47(1):7-14; Metabolism and toxicity of the new anesthetic agents."
"BIOTID01732","2,4-diene-VPA","14178878","UUILWXIBBZVJDU-ALCCZGGFSA-N","InChI=1S/C8H12O2/c1-3-5-7(6-4-2)8(9)10/h3,5H,1,4,6H2,2H3,(H,9,10)/b7-5-","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","NULL","SAZCFXWQTSLYCS-DYYLRZFVSA-N","InChI=1S/C14H20O8/c1-3-5-7(6-4-2)13(20)22-14-10(17)8(15)9(16)11(21-14)12(18)19/h3,5,8-11,14-17H,1,4,6H2,2H3,(H,18,19)/b7-5-/t8-,9-,10+,11-,14?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01733","3,7-Dihydroxyfavone","5393152","UWQJWDYDYIJWKY-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-6-7-11-12(8-10)19-15(14(18)13(11)17)9-4-2-1-3-5-9/h1-8,16,18H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","FAJWSFCXQJXRMW-WQUGZTNDSA-N","InChI=1S/C21H18O10/c22-13-11-7-6-10(29-21-17(26)14(23)16(25)19(31-21)20(27)28)8-12(11)30-18(15(13)24)9-4-2-1-3-5-9/h1-8,14,16-17,19,21,23-26H,(H,27,28)/t14-,16-,17+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01734","3,7-Dihydroxyfavone","5393152","UWQJWDYDYIJWKY-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-6-7-11-12(8-10)19-15(14(18)13(11)17)9-4-2-1-3-5-9/h1-8,16,18H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","ZRKSFDOQNORFAF-MBIBTLSJSA-N","InChI=1S/C21H18O10/c22-10-6-7-11-12(8-10)29-17(9-4-2-1-3-5-9)18(13(11)23)30-21-16(26)14(24)15(25)19(31-21)20(27)28/h1-8,14-16,19,21-22,24-26H,(H,27,28)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01735","Indole-3-acetic-acid","802","SEOVTRFCIGRIMH-UHFFFAOYSA-N","InChI=1S/C10H9NO2/c12-10(13)5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H,12,13)","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","124202110","BPTLUNCVRGWZSW-JHZZJYKESA-N","InChI=1S/C16H17NO8/c18-10(5-7-6-17-9-4-2-1-3-8(7)9)24-16-13(21)11(19)12(20)14(25-16)15(22)23/h1-4,6,11-14,16-17,19-21H,5H2,(H,22,23)/t11-,12-,13+,14-,16+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060001"
"BIOTID01736","Amrinone","3698","RNLQIBCLLYYYFJ-UHFFFAOYSA-N","InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)","UGT","Glucuronidation of primary aromatic amine","Human Phase II","Human","Inamrinone","3698","RNLQIBCLLYYYFJ-UHFFFAOYSA-N","InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)","https://www.drugbank.ca/drugs/DB01427"
"BIOTID01737","butanol","263","LRHPLDYGYMQRHN-UHFFFAOYSA-N","InChI=1S/C4H10O/c1-2-3-4-5/h5H,2-4H2,1H3","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","69607982","URUUTUFAIZAMFP-NMLRKWPISA-N","InChI=1S/C10H18O7/c1-2-3-4-16-10-7(13)5(11)6(12)8(17-10)9(14)15/h5-8,10-13H,2-4H2,1H3,(H,14,15)/t5-,6-,7+,8-,10?/m0/s1","Jurowich, S. et al. (2004); Glucuronidation of aliphatic alcohols in human liver microsomes in vitro; Alcohol 32 (2004) 187Ã¢â‚¬â€œ194"
"BIOTID01738","Paeonol","11092","UILPJVPSNHJFIK-UHFFFAOYSA-N","InChI=1S/C9H10O3/c1-6(10)8-4-3-7(12-2)5-9(8)11/h3-5,11H,1-2H3","SULT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","174699","RSQFVCRSJCQZST-UHFFFAOYSA-N","InChI=1S/C9H10O6S/c1-6(10)8-4-3-7(14-2)5-9(8)15-16(11,12)13/h3-5H,1-2H3,(H,11,12,13)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01739","8-Hydroxy-7-methoxyisoflavone","NULL","OEPCEMYLDJNBNH-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-11-7-12-15(18)13(10-5-3-2-4-6-10)9-20-16(12)14(17)8-11/h2-9,17H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","WTVMJVBGHPSYMJ-ICNUUSJMSA-N","InChI=1S/C22H20O10/c1-29-11-7-12-15(23)13(10-5-3-2-4-6-10)9-30-19(12)14(8-11)31-22-18(26)16(24)17(25)20(32-22)21(27)28/h2-9,16-18,20,22,24-26H,1H3,(H,27,28)/t16-,17-,18+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01740","8,14-diOH-efavirenz","16725849","WILFXLMJFSKQRP-ZDUSSCGKSA-N","InChI=1S/C14H9ClF3NO4/c15-7-5-8-10(9(20)6-7)19-11(21)23-13(8,14(16,17)18)4-3-12(22)1-2-12/h5-6,20,22H,1-2H2,(H,19,21)/t13-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","SUVBXWXDHXJMOP-XNSSWWKFSA-N","InChI=1S/C20H17ClF3NO10/c21-7-5-8-10(9(26)6-7)25-17(32)35-19(8,20(22,23)24)4-3-18(1-2-18)34-16-13(29)11(27)12(28)14(33-16)15(30)31/h5-6,11-14,16,26-29H,1-2H2,(H,25,32)(H,30,31)/t11-,12-,13+,14-,16?,19-/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01742","4p-hydroxy-2,3p,4-trichlorobiphenyl","53221454","IPQDZKABLRZERH-UHFFFAOYSA-N","InChI=1S/C12H7Cl3O/c13-8-2-3-9(10(14)6-8)7-1-4-12(16)11(15)5-7/h1-6,16H","SULT","4-OH sulfonation of phenolic compound","Human Phase II","Human","NULL","NULL","QAPKFUYZESKCHS-UHFFFAOYSA-N","InChI=1S/C12H7Cl3O4S/c13-8-2-3-9(10(14)6-8)7-1-4-12(11(15)5-7)19-20(16,17)18/h1-6H,(H,16,17,18)","http://www.brenda-enzymes.org/enzyme.php?ecno=2.8.2.15&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01743","Hydroxyoxid acid","NULL","DHFKAKCKGXSZQB-YRRINSJYSA-N","InChI=1S/C15H24O3/c1-13(2)9-4-6-14(3)11(8-9)10(12(16)17)5-7-15(13,14)18/h9-11,18H,4-8H2,1-3H3,(H,16,17)/t9-,10+,11+,14+,15-/m1/s1","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","NULL","LYYZJNLOBSHXDV-BNMQTBAUSA-N","InChI=1S/C21H32O9/c1-19(2)9-4-6-20(3)11(8-9)10(16(25)26)5-7-21(19,20)30-18-14(24)12(22)13(23)15(29-18)17(27)28/h9-15,18,22-24H,4-8H2,1-3H3,(H,25,26)(H,27,28)/t9-,10+,11+,12+,13+,14-,15+,18?,20+,21-/m1/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01744","N-Desmethyl-4-OH- atomoxetine","68400313","RDBXJTRXTFVOGY-MRXNPFEDSA-N","InChI=1S/C16H19NO2/c1-12-11-14(18)7-8-15(12)19-16(9-10-17)13-5-3-2-4-6-13/h2-8,11,16,18H,9-10,17H2,1H3/t16-/m1/s1","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","OCYYTTFFKJKWEH-PEAWXGHCSA-N","InChI=1S/C22H27NO8/c1-12-11-14(29-22-19(26)17(24)18(25)20(31-22)21(27)28)7-8-15(12)30-16(9-10-23)13-5-3-2-4-6-13/h2-8,11,16-20,22,24-26H,9-10,23H2,1H3,(H,27,28)/t16-,17+,18+,19-,20+,22?/m1/s1","https://www.pharmgkb.org/pathway/PA166160830"
"BIOTID01745","cis-6-(2-acetylvinylthio)purine","1560206","UTZQOKLQPPYAKV-IHWYPQMZSA-N","InChI=1S/C9H8N4OS/c1-6(14)2-3-15-9-7-8(11-4-10-7)12-5-13-9/h2-5H,1H3,(H,10,11,12,13)/b3-2-","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","FICKONRFBIVKSW-WTKPLQERSA-M","InChI=1S/C19H25N7O7S2/c1-9(27)4-14(35-18-15-16(23-7-22-15)24-8-25-18)34-6-11(17(31)21-5-13(29)30)26-12(28)3-2-10(20)19(32)33/h4,7-8,10-11,14,27H,2-3,5-6,20H2,1H3,(H,21,31)(H,26,28)(H,29,30)(H,32,33)(H,22,23,24,25)/p-1/b9-4-","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01746","benzoic acid","243","WPYMKLBDIGXBTP-UHFFFAOYSA-N","InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)","UGT","O-glucuronidation of aromatic acid","Human Phase II","Human","NULL","54117809","NLOPFVNXNMEEDI-XFVPOMSTSA-N","InChI=1S/C13H14O8/c14-7-8(15)10(11(17)18)20-13(9(7)16)21-12(19)6-4-2-1-3-5-6/h1-5,7-10,13-16H,(H,17,18)/t7-,8-,9+,10-,13?/m0/s1","Belsito, D. et al. (2012); A toxicological and dermatological assessment of aryl alkyl alcohol simple acid ester derivatives when used as fragrance ingredients; Food and Chemical Toxicology 50 (2012) S269Ã¢â‚¬â€œS313"
"BIOTID01747","N-Desmethyl p-hydroxyrosiglitazone","131769972","SVUUNTJZVPNZSL-UHFFFAOYSA-N","InChI=1S/C17H17N3O4S/c21-12-3-6-15(19-10-12)18-7-8-24-13-4-1-11(2-5-13)9-14-16(22)20-17(23)25-14/h1-6,10,14,21H,7-9H2,(H,18,19)(H,20,22,23)","SULT","O-sulfonation","Human Phase II","Human","NULL","131769973","ULPCBLHRDLQTTD-UHFFFAOYSA-N","InChI=1S/C17H17N3O7S2/c21-16-14(28-17(22)20-16)9-11-1-3-12(4-2-11)26-8-7-18-15-6-5-13(10-19-15)27-29(23,24)25/h1-6,10,14H,7-9H2,(H,18,19)(H,20,21,22)(H,23,24,25)","http://www.hmdb.ca/metabolites/HMDB0060839"
"BIOTID01748","Tizoxanide","394397","FDTZUTSGGSRHQF-UHFFFAOYSA-N","InChI=1S/C10H7N3O4S/c14-7-4-2-1-3-6(7)9(15)12-10-11-5-8(18-10)13(16)17/h1-5,14H,(H,11,12,15)","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","UJTOVSZPBVTOMC-VDQYPUQXSA-N","InChI=1S/C16H15N3O10S/c20-9-10(21)12(14(24)25)29-15(11(9)22)28-7-4-2-1-3-6(7)13(23)18-16-17-5-8(30-16)19(26)27/h1-5,9-12,15,20-22H,(H,24,25)(H,17,18,23)/t9-,10-,11+,12-,15?/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060643"
"BIOTID01749","epicatechin metabo5","3028409","VYWFHBSBNKNWSB-UHFFFAOYSA-N","InChI=1S/C11H12O3/c12-9-3-1-2-8(6-9)7-10-4-5-11(13)14-10/h1-3,6,10,12H,4-5,7H2","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","DPSUQBKEHXAIDY-CHCGNJSTSA-N","InChI=1S/C17H20O9/c18-11-5-4-10(24-11)7-8-2-1-3-9(6-8)25-17-14(21)12(19)13(20)15(26-17)16(22)23/h1-3,6,10,12-15,17,19-21H,4-5,7H2,(H,22,23)/t10?,12-,13-,14+,15-,17?/m0/s1","From Jarleips validations"
"BIOTID01750","carvone metabo6","66963260","YNTOEUGPNLOIEP-UHFFFAOYSA-N","InChI=1S/C10H14O2/c1-6(2)8-5-4-7(3)9(11)10(8)12/h4,8,10,12H,1,5H2,2-3H3","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","NULL","NBLRDPBCVGIEKU-WRRJTVRWSA-N","InChI=1S/C16H22O8/c1-6(2)8-5-4-7(3)9(17)13(8)23-16-12(20)10(18)11(19)14(24-16)15(21)22/h4,8,10-14,16,18-20H,1,5H2,2-3H3,(H,21,22)/t8?,10-,11-,12+,13?,14-,16?/m0/s1","From Jarleips validations"
"BIOTID01751","5,7,2p-Trihydroxyflavone","5322064","OFYPDAKTVZXXPC-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-8-5-11(18)15-12(19)7-13(20-14(15)6-8)9-3-1-2-4-10(9)17/h1-7,16-18H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","21309393","ZUWLOUKBEQEHEC-DAZJWRSOSA-N","InChI=1S/C21H18O11/c22-10-4-2-1-3-9(10)13-7-12(24)15-11(23)5-8(6-14(15)31-13)30-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21-23,25-27H,(H,28,29)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01752","Estradiol acetate","9818306","FHXBMXJMKMWVRG-SLHNCBLASA-N","InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1","UGT","17-OH glucuronidation of sterol","Human Phase II","Human","NULL","NULL","ODXJNPXZOZZOQQ-UHFFFAOYSA-N","InChI=1S/C26H34O9/c1-12(27)33-14-4-6-15-13(11-14)3-5-17-16(15)9-10-26(2)18(17)7-8-19(26)34-25-22(30)20(28)21(29)23(35-25)24(31)32/h4,6,11,16-23,25,28-30H,3,5,7-10H2,1-2H3,(H,31,32)","http://www.hmdb.ca/metabolites/HMDB0061687"
"BIOTID01753","N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine","104954","DCVWQAGUQFBCTF-UHFFFAOYSA-N","InChI=1S/C13H12N4O/c1-17-11-7-10(9-5-3-2-4-6-9)8-14-12(11)15-13(17)16-18/h2-8,18H,1H3,(H,14,15,16)","UGT1A1, 1A3, 1A6","Hydroxylamine O-glucuronidation","Human Phase II","Human","NULL","NULL","YZOJGZCDCRPMLU-ZBCYVVTKSA-N","InChI=1S/C19H20N4O7/c1-23-11-7-10(9-5-3-2-4-6-9)8-20-16(11)21-19(23)22-30-18-14(26)12(24)13(25)15(29-18)17(27)28/h2-8,12-15,18,24-26H,1H3,(H,27,28)(H,20,21,22)/t12-,13-,14+,15-,18?/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01754","N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine","104954","DCVWQAGUQFBCTF-UHFFFAOYSA-N","InChI=1S/C13H12N4O/c1-17-11-7-10(9-5-3-2-4-6-9)8-14-12(11)15-13(17)16-18/h2-8,18H,1H3,(H,14,15,16)","SULT1A1","Hydroxylamine O-sulfonation","Human Phase II","Human","NULL","71448983","LPVOGSWZCYNQGE-UHFFFAOYSA-N","InChI=1S/C13H12N4O4S/c1-17-11-7-10(9-5-3-2-4-6-9)8-14-12(11)15-13(17)16-21-22(18,19)20/h2-8H,1H3,(H,14,15,16)(H,18,19,20)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01755","Carboxy celecoxib","10047220","WTHNOVFEXONZMI-UHFFFAOYSA-N","InChI=1S/C17H12F3N3O4S/c18-17(19,20)15-9-14(10-1-3-11(4-2-10)16(24)25)23(22-15)12-5-7-13(8-6-12)28(21,26)27/h1-9H,(H,24,25)(H2,21,26,27)","UGT","O-glucuronidation of aromatic acid","Human Phase II","Human","NULL","118753620","ZSTBSABHKHAHNU-CTNWFZKLSA-N","InChI=1S/C23H20F3N3O10S/c24-23(25,26)15-9-14(29(28-15)12-5-7-13(8-6-12)40(27,36)37)10-1-3-11(4-2-10)21(35)39-22-18(32)16(30)17(31)19(38-22)20(33)34/h1-9,16-19,22,30-32H,(H,33,34)(H2,27,36,37)/t16-,17-,18+,19-,22?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01756","estrone","5870","DNXHEGUUPJUMQT-CBZIJGRNSA-N","InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1","UGT1A1, 1A3, 1A7,1A8, 1A10","3-OH glucuronidation of sterol","Human Phase II","Human","NULL","13783435","FJAZVHYPASAQKM-AYGAEXAVSA-N","InChI=1S/C24H30O8/c1-24-9-8-14-13-5-3-12(10-11(13)2-4-15(14)16(24)6-7-17(24)25)31-23-20(28)18(26)19(27)21(32-23)22(29)30/h3,5,10,14-16,18-21,23,26-28H,2,4,6-9H2,1H3,(H,29,30)/t14-,15-,16+,18+,19+,20-,21+,23?,24+/m1/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01757","Carvedilol","2585","OGHNVEJMJSYVRP-UHFFFAOYSA-N","InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","129627137","PUVQFGCELBOSRN-VWRHRJFVSA-N","InChI=1S/C30H34N2O10/c1-38-21-10-4-5-11-22(21)39-14-13-31-15-17(41-30-27(35)25(33)26(34)28(42-30)29(36)37)16-40-23-12-6-9-20-24(23)18-7-2-3-8-19(18)32-20/h2-12,17,25-28,30-35H,13-16H2,1H3,(H,36,37)/t17?,25-,26-,27+,28-,30?/m0/s1","Makoto Sekimoto et al (2016); In Vitro Enhancement of Carvedilol Glucuronidation by Amiodarone-Mediated Altered Protein Binding in Incubation Mixture of Human Liver Microsomes with Bovine Serum Albumin; Biological and Pharmaceutical Bulletin; Vol. 39 (2016) No. 8 p. 1359-1363"
"BIOTID01758","6-gingerol","90942","LPRPIMHDDACJHT-UHFFFAOYSA-N","InChI=1S/C17H26O4/c1-3-4-5-6-14(18)12-15(19)9-7-13-8-10-17(21-2)16(20)11-13/h8,10-11,14,18,20H,3-7,9,12H2,1-2H3","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","QWMJIWQZAQQMMV-NKLDDAGYSA-N","InChI=1S/C23H34O10/c1-3-4-5-6-14(24)12-15(25)9-7-13-8-10-16(31-2)17(11-13)32-23-20(28)18(26)19(27)21(33-23)22(29)30/h8,10-11,14,18-21,23-24,26-28H,3-7,9,12H2,1-2H3,(H,29,30)/t14?,18-,19-,20+,21-,23?/m0/s1","PMID:736680"
"BIOTID01759","6-gingerol","90942","LPRPIMHDDACJHT-UHFFFAOYSA-N","InChI=1S/C17H26O4/c1-3-4-5-6-14(18)12-15(19)9-7-13-8-10-17(21-2)16(20)11-13/h8,10-11,14,18,20H,3-7,9,12H2,1-2H3","UGT","3-OH-glucuronidation of a phenolic compound","Human Phase II","Human","NULL","NULL","QWMJIWQZAQQMMV-NKLDDAGYSA-N","InChI=1S/C23H34O10/c1-3-4-5-6-14(24)12-15(25)9-7-13-8-10-16(31-2)17(11-13)32-23-20(28)18(26)19(27)21(33-23)22(29)30/h8,10-11,14,18-21,23-24,26-28H,3-7,9,12H2,1-2H3,(H,29,30)/t14?,18-,19-,20+,21-,23?/m0/s1","PMID:736680"
"BIOTID01760","6-gingerol","90942","LPRPIMHDDACJHT-UHFFFAOYSA-N","InChI=1S/C17H26O4/c1-3-4-5-6-14(18)12-15(19)9-7-13-8-10-17(21-2)16(20)11-13/h8,10-11,14,18,20H,3-7,9,12H2,1-2H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","OBSNJYZNKOGIKD-DTSFXDEQSA-N","InChI=1S/C23H34O10/c1-3-4-5-6-15(32-23-20(28)18(26)19(27)21(33-23)22(29)30)12-14(24)9-7-13-8-10-17(31-2)16(25)11-13/h8,10-11,15,18-21,23,25-28H,3-7,9,12H2,1-2H3,(H,29,30)/t15?,18-,19-,20+,21-,23?/m0/s1","PMID:736680"
"BIOTID01761","O-Desmethylnaproxen","13393711","XWJUDDGELKXYNO-QMMMGPOBSA-N","InChI=1S/C13H12O3/c1-8(13(15)16)9-2-3-11-7-12(14)5-4-10(11)6-9/h2-8,14H,1H3,(H,15,16)/t8-/m0/s1","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","BFGOTVVWSNGSME-JSKICXPDSA-N","InChI=1S/C19H20O9/c1-8(17(23)24)9-2-3-11-7-12(5-4-10(11)6-9)27-19-15(22)13(20)14(21)16(28-19)18(25)26/h2-8,13-16,19-22H,1H3,(H,23,24)(H,25,26)/t8-,13-,14-,15+,16-,19?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01762","O-Desmethylnaproxen","13393711","XWJUDDGELKXYNO-QMMMGPOBSA-N","InChI=1S/C13H12O3/c1-8(13(15)16)9-2-3-11-7-12(14)5-4-10(11)6-9/h2-8,14H,1H3,(H,15,16)/t8-/m0/s1","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","NULL","WKYUVCYFVJKWHF-JSKICXPDSA-N","InChI=1S/C19H20O9/c1-8(9-2-3-11-7-12(20)5-4-10(11)6-9)18(26)28-19-15(23)13(21)14(22)16(27-19)17(24)25/h2-8,13-16,19-23H,1H3,(H,24,25)/t8-,13-,14-,15+,16-,19?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01763","O-Desmethylnaproxen","13393711","XWJUDDGELKXYNO-QMMMGPOBSA-N","InChI=1S/C13H12O3/c1-8(13(15)16)9-2-3-11-7-12(14)5-4-10(11)6-9/h2-8,14H,1H3,(H,15,16)/t8-/m0/s1","SULT1A1; SULT1B1; SULT1E1","O-sulfonation","Human Phase II","Human","NULL","184679","BNKMSCMOWGCUOF-QMMMGPOBSA-N","InChI=1S/C13H12O6S/c1-8(13(14)15)9-2-3-11-7-12(19-20(16,17)18)5-4-10(11)6-9/h2-8H,1H3,(H,14,15)(H,16,17,18)/t8-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01764","O-Desmethylnaproxen","13393711","XWJUDDGELKXYNO-QMMMGPOBSA-N","InChI=1S/C13H12O3/c1-8(13(15)16)9-2-3-11-7-12(14)5-4-10(11)6-9/h2-8,14H,1H3,(H,15,16)/t8-/m0/s1","SULT1A1; SULT1B1; SULT1E1","O-sulfonation","Human Phase II","Human","NULL","NULL","PWQKGXQZPPKRFB-QMMMGPOBSA-N","InChI=1S/C13H12O6S/c1-8(13(15)19-20(16,17)18)9-2-3-11-7-12(14)5-4-10(11)6-9/h2-8,14H,1H3,(H,16,17,18)/t8-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01765","4-hydroxycyclopenta[def]chrysene","119026","GESJVEUWYDSOMJ-UHFFFAOYSA-N","InChI=1S/C19H12O/c20-19-15-7-3-5-11-8-9-14-13-6-2-1-4-12(13)10-16(19)18(14)17(11)15/h1-10,19-20H","SULT1E1","Sulfation of secondary alcohol","Human Phase II","Human","NULL","NULL","YFIKGULYFBLKNU-UHFFFAOYSA-N","InChI=1S/C19H12O4S/c20-24(21,22)23-19-15-7-3-5-11-8-9-14-13-6-2-1-4-12(13)10-16(19)18(14)17(11)15/h1-10,19H,(H,20,21,22)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01766","Rhamnetin","5281691","JGUZGNYPMHHYRK-UHFFFAOYSA-N","InChI=1S/C16H12O7/c1-22-8-5-11(19)13-12(6-8)23-16(15(21)14(13)20)7-2-3-9(17)10(18)4-7/h2-6,17-19,21H,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","JKFUJEONKRJCFG-XTLXVGOWSA-N","InChI=1S/C22H20O13/c1-32-8-5-11(25)13-12(6-8)33-18(7-2-3-9(23)10(24)4-7)19(14(13)26)34-22-17(29)15(27)16(28)20(35-22)21(30)31/h2-6,15-17,20,22-25,27-29H,1H3,(H,30,31)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01767","4-Fluorophenol","9732","RHMPLDJJXGPMEX-UHFFFAOYSA-N","InChI=1S/C6H5FO/c7-5-1-3-6(8)4-2-5/h1-4,8H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","OCXWWSGTHKMASL-SDQGTYQYSA-N","InChI=1S/C12H13FO7/c13-5-1-3-6(4-2-5)19-12-9(16)7(14)8(15)10(20-12)11(17)18/h1-4,7-10,12,14-16H,(H,17,18)/t7-,8-,9+,10-,12?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01768","7,3p-Dihydroxyflavone","5391140","DYARIVMCYYQNNQ-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-3-1-2-9(6-10)14-8-13(18)12-5-4-11(17)7-15(12)19-14/h1-8,16-17H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","UWZXHFFBCSGPTI-DAZJWRSOSA-N","InChI=1S/C21H18O10/c22-10-3-1-2-9(6-10)14-8-13(23)12-5-4-11(7-15(12)30-14)29-21-18(26)16(24)17(25)19(31-21)20(27)28/h1-8,16-19,21-22,24-26H,(H,27,28)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01769","Methyl-4-hydroxybenzoate","8434","NUVBSKCKDOMJSU-UHFFFAOYSA-N","InChI=1S/C9H10O3/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6,10H,2H2,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","LZYNMJNOTCVYBQ-VDQYPUQXSA-N","InChI=1S/C15H18O9/c1-2-22-14(21)7-3-5-8(6-4-7)23-15-11(18)9(16)10(17)12(24-15)13(19)20/h3-6,9-12,15-18H,2H2,1H3,(H,19,20)/t9-,10-,11+,12-,15?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01770","13-hydroxyoctadecadienoic acid","6443013","HNICUWMFWZBIFP-IRQZEAMPSA-N","InChI=1S/C18H32O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h7,9,12,15,17,19H,2-6,8,10-11,13-14,16H2,1H3,(H,20,21)/b9-7-,15-12+/t17-/m0/s1","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","NULL","PARPHFPLQDJYGI-SGLWAERKSA-N","InChI=1S/C24H40O9/c1-2-3-11-14-17(15-12-9-7-5-4-6-8-10-13-16-18(25)26)32-24-21(29)19(27)20(28)22(33-24)23(30)31/h7,9,12,15,17,19-22,24,27-29H,2-6,8,10-11,13-14,16H2,1H3,(H,25,26)(H,30,31)/b9-7-,15-12+/t17-,19-,20-,21+,22-,24?/m0/s1","Jude, R.A. et al. (2001); Glucuronidation of Linoleic Acid Diols by Human Microsomal and Recombinant UDP-Glucuronosyltransferases: Identification of UGT2B7 as the Major Isoform Involved; Archives of Biochemistry and Biophysics; Vol. 389, No. 2, May 15, pp. 176Ã¢â‚¬â€œ186, 2001; doi:10.1006/abbi.2001.2344"
"BIOTID01771","13-hydroxyoctadecadienoic acid","6443013","HNICUWMFWZBIFP-IRQZEAMPSA-N","InChI=1S/C18H32O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h7,9,12,15,17,19H,2-6,8,10-11,13-14,16H2,1H3,(H,20,21)/b9-7-,15-12+/t17-/m0/s1","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","NULL","QPDWXTKZYWVOOP-SGLWAERKSA-N","InChI=1S/C24H40O9/c1-2-3-11-14-17(25)15-12-9-7-5-4-6-8-10-13-16-18(26)32-24-21(29)19(27)20(28)22(33-24)23(30)31/h7,9,12,15,17,19-22,24-25,27-29H,2-6,8,10-11,13-14,16H2,1H3,(H,30,31)/b9-7-,15-12+/t17-,19-,20-,21+,22-,24?/m0/s1","Jude, R.A. et al. (2001); Glucuronidation of Linoleic Acid Diols by Human Microsomal and Recombinant UDP-Glucuronosyltransferases: Identification of UGT2B7 as the Major Isoform Involved; Archives of Biochemistry and Biophysics; Vol. 389, No. 2, May 15, pp. 176Ã¢â‚¬â€œ186, 2001; doi:10.1006/abbi.2001.2344"
"BIOTID01772","Dihydrodaidzein","176907","JHYXBPPMXZIHKG-UHFFFAOYSA-N","InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-7,13,16-17H,8H2","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","122421244","SMUUTIXQVTUCJD-YKCLCNASSA-N","InChI=1S/C21H20O10/c22-10-3-1-9(2-4-10)13-8-29-14-7-11(5-6-12(14)15(13)23)30-21-18(26)16(24)17(25)19(31-21)20(27)28/h1-7,13,16-19,21-22,24-26H,8H2,(H,27,28)/t13?,16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01773","Aminoflavone M-VI","NULL","OLLJBHLSMFUULQ-UHFFFAOYSA-N","InChI=1S/C16H11F3N2O4/c1-5-10(18)12(21-24)9-13(22)14(23)15(25-16(9)11(5)19)6-2-3-8(20)7(17)4-6/h2-4,21,23-24H,20H2,1H3","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","LKOFLRBDUHBSMA-UIOIVBMKSA-N","InChI=1S/C22H19F3N2O10/c1-5-10(24)12(27-34)9-13(28)19(36-22-16(31)14(29)15(30)20(37-22)21(32)33)17(35-18(9)11(5)25)6-2-3-8(26)7(23)4-6/h2-4,14-16,20,22,27,29-31,34H,26H2,1H3,(H,32,33)/t14-,15-,16+,20-,22?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01774","Etodolac","3308","NNYBQONXHNTVIJ-UHFFFAOYSA-N","InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","131769991","XJZNMEMKZBFUIZ-JSXGDUDQSA-N","InChI=1S/C23H29NO9/c1-3-11-6-5-7-12-13-8-9-31-23(4-2,20(13)24-15(11)12)10-14(25)32-22-18(28)16(26)17(27)19(33-22)21(29)30/h5-7,16-19,22,24,26-28H,3-4,8-10H2,1-2H3,(H,29,30)/t16-,17-,18+,19-,22?,23?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01775","fenchone metabo3","14606066","RBJVDSYEMJHFOC-UHFFFAOYSA-N","InChI=1S/C10H16O2/c1-9(2)6-4-7(11)10(3,5-6)8(9)12/h6-7,11H,4-5H2,1-3H3","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","NULL","FBICJHRJXRZSLK-NJPGAIFGSA-N","InChI=1S/C16H24O8/c1-15(2)6-4-7(16(3,5-6)14(15)22)23-13-10(19)8(17)9(18)11(24-13)12(20)21/h6-11,13,17-19H,4-5H2,1-3H3,(H,20,21)/t6?,7?,8-,9-,10+,11-,13?,16?/m0/s1","From Jarleips validations"
"BIOTID01776","FYX-051","5288320","UBVZQGOVTLIHLH-UHFFFAOYSA-N","InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)","UGT1A9","N-glucuronidation of azole","Human Phase II","Human","NULL","NULL","PXFJUSGWRQLDOE-ZBCYVVTKSA-N","InChI=1S/C19H16N6O6/c20-8-11-7-10(3-6-22-11)16-23-17(9-1-4-21-5-2-9)25(24-16)18-14(28)12(26)13(27)15(31-18)19(29)30/h1-7,12-15,18,26-28H,(H,29,30)/t12-,13-,14+,15-,18?/m0/s1","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01777","FYX-051","5288320","UBVZQGOVTLIHLH-UHFFFAOYSA-N","InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)","UGT1A9","N-glucuronidation","Human Phase II","Human","NULL","NULL","JKWKMCHCIBXGTI-ZBCYVVTKSA-O","InChI=1S/C19H16N6O6/c20-8-11-7-10(3-6-22-11)17-23-16(9-1-4-21-5-2-9)24-25(17)18-14(28)12(26)13(27)15(31-18)19(29)30/h1-7,12-15,18,26-28H,(H,29,30)/p+1/t12-,13-,14+,15-,18?/m0/s1","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01778","pentanol","6276","AMQJEAYHLZJPGS-UHFFFAOYSA-N","InChI=1S/C5H12O/c1-2-3-4-5-6/h6H,2-5H2,1H3","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","66709879","WBOZHVZBNFRQEI-PKTFNFCYSA-N","InChI=1S/C11H20O7/c1-2-3-4-5-17-11-8(14)6(12)7(13)9(18-11)10(15)16/h6-9,11-14H,2-5H2,1H3,(H,15,16)/t6-,7-,8+,9-,11?/m0/s1","Jurowich, S. et al. (2004); Glucuronidation of aliphatic alcohols in human liver microsomes in vitro; Alcohol 32 (2004) 187Ã¢â‚¬â€œ194"
"BIOTID01779","2-propanol","3776","KFZMGEQAYNKOFK-UHFFFAOYSA-N","InChI=1S/C3H8O/c1-3(2)4/h3-4H,1-2H3","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","20717005","ZCIAYIYCMGRNQL-UBQDNYDRSA-N","InChI=1S/C9H16O7/c1-3(2)15-9-6(12)4(10)5(11)7(16-9)8(13)14/h3-7,9-12H,1-2H3,(H,13,14)/t4-,5-,6+,7-,9?/m0/s1","Jurowich, S. et al. (2004); Glucuronidation of aliphatic alcohols in human liver microsomes in vitro; Alcohol 32 (2004) 187Ã¢â‚¬â€œ194"
"BIOTID01780","3-Hydroxy-7,4p-dimethoxyflavone","265699","IFHXSMSQHPVVSF-UHFFFAOYSA-N","InChI=1S/C17H14O5/c1-20-11-5-3-10(4-6-11)17-16(19)15(18)13-8-7-12(21-2)9-14(13)22-17/h3-9,19H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","ZRRFQRHQGVMADR-GWQNJANKSA-N","InChI=1S/C23H22O11/c1-30-11-5-3-10(4-6-11)19-20(15(24)13-8-7-12(31-2)9-14(13)32-19)33-23-18(27)16(25)17(26)21(34-23)22(28)29/h3-9,16-18,21,23,25-27H,1-2H3,(H,28,29)/t16-,17-,18+,21-,23?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01781","10-hydroxycarbazepine","114709","BMPDWHIDQYTSHX-UHFFFAOYSA-N","InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","NULL","CMBFCYCIYDPVRG-UDDOEOBRSA-N","InChI=1S/C21H22N2O8/c22-21(29)23-12-7-3-1-5-10(12)9-14(11-6-2-4-8-13(11)23)30-20-17(26)15(24)16(25)18(31-20)19(27)28/h1-8,14-18,20,24-26H,9H2,(H2,22,29)(H,27,28)/t14?,15-,16-,17+,18-,20?/m0/s1","https://www.drugbank.ca/metabolites/DBMET01412"
"BIOTID01782","Norethindrone","71751192","CQOHDQNOAACQBL-LEUUCSQGSA-N","InChI=1S/C26H34O8/c1-3-26(34-24-21(30)19(28)20(29)22(33-24)23(31)32)11-9-18-17-6-4-13-12-14(27)5-7-15(13)16(17)8-10-25(18,26)2/h1,12,15-22,24,28-30H,4-11H2,2H3,(H,31,32)/t15-,16+,17+,18-,19+,20+,21-,22+,24+,25-,26-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","(2R,3R,4R,5S,6R)-6-{[(1S,2R,10R,11S,14R,15S)-14-ethynyl-15-methyl-5-oxotetracyclo[8.7.0.0Ã‚Â²,Ã¢ÂÂ·.0Ã‚Â¹Ã‚Â¹,Ã‚Â¹Ã¢ÂÂµ]heptadec-6-en-14-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid","71751192","CQOHDQNOAACQBL-LEUUCSQGSA-N","InChI=1S/C26H34O8/c1-3-26(34-24-21(30)19(28)20(29)22(33-24)23(31)32)11-9-18-17-6-4-13-12-14(27)5-7-15(13)16(17)8-10-25(18,26)2/h1,12,15-22,24,28-30H,4-11H2,2H3,(H,31,32)/t15-,16+,17+,18-,19+,20+,21-,22+,24+,25-,26-/m0/s1","https://pubchem.ncbi.nlm.nih.gov/compound/71751192"
"BIOTID01783","O-Desmethyl-2p-OH-Indomethacin phenethylamide","NULL","WTKXBAMDBPYRKN-UHFFFAOYSA-N","InChI=1S/C26H23ClN2O4/c1-16-21(14-25(32)28-15-24(31)17-5-3-2-4-6-17)22-13-20(30)11-12-23(22)29(16)26(33)18-7-9-19(27)10-8-18/h2-13,24,30-31H,14-15H2,1H3,(H,28,32)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KYGSWFWUYIVTSM-JJPTWMICSA-N","InChI=1S/C32H31ClN2O10/c1-16-21(22-13-20(36)11-12-23(22)35(16)30(41)18-7-9-19(33)10-8-18)14-25(37)34-15-24(17-5-3-2-4-6-17)44-32-28(40)26(38)27(39)29(45-32)31(42)43/h2-13,24,26-29,32,36,38-40H,14-15H2,1H3,(H,34,37)(H,42,43)/t24?,26-,27-,28+,29-,32?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01784","5-Hydroxyflavone","68112","IYBLVRRCNVHZQJ-UHFFFAOYSA-N","InChI=1S/C15H10O3/c16-11-7-4-8-13-15(11)12(17)9-14(18-13)10-5-2-1-3-6-10/h1-9,16H","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","YFZHQAJHLAMKEF-DAZJWRSOSA-N","InChI=1S/C21H18O9/c22-11-9-14(10-5-2-1-3-6-10)28-12-7-4-8-13(15(11)12)29-21-18(25)16(23)17(24)19(30-21)20(26)27/h1-9,16-19,21,23-25H,(H,26,27)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01785","Oroxylin A","5320315","LKOJGSWUMISDOF-UHFFFAOYSA-N","InChI=1S/C16H12O5/c1-20-16-11(18)8-13-14(15(16)19)10(17)7-12(21-13)9-5-3-2-4-6-9/h2-8,18-19H,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","QXIPXNZUEQYPLZ-ICNUUSJMSA-N","InChI=1S/C22H20O11/c1-30-19-13(32-22-18(27)16(25)17(26)20(33-22)21(28)29)8-12-14(15(19)24)10(23)7-11(31-12)9-5-3-2-4-6-9/h2-8,16-18,20,22,24-27H,1H3,(H,28,29)/t16-,17-,18+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01787","ketotifen","3827","ZCVMWBYGMWKGHF-UHFFFAOYSA-N","InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3","UGT","N-glucuronidation","Human Phase II","Human","NULL","NULL","WLTPAELNPGRIGG-ZHTAWDLNSA-O","InChI=1S/C25H27NO7S/c1-26(24-21(30)19(28)20(29)22(33-24)25(31)32)9-6-13(7-10-26)18-15-5-3-2-4-14(15)12-17(27)23-16(18)8-11-34-23/h2-5,8,11,19-22,24,28-30H,6-7,9-10,12H2,1H3/p+1/b18-13-/t19-,20-,21+,22-,24?,26?/m0/s1","Dalvie, D. et al (2009); Assessment of Three Human in Vitro Systems in the Generation of Major Human Excretory and Circulating Metabolites; Chem. Res. Toxicol. 2009, 22, 357Ã¢â‚¬â€œ36"
"BIOTID01788","7-ethyl-10-hydroxycamptothecin","4014291","FJHBVJOVLFPMQE-UHFFFAOYSA-N","InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","SSJQVDUAKDRWTA-VTOJQLKUSA-N","InChI=1S/C28H28N2O11/c1-3-12-13-7-11(40-26-22(33)20(31)21(32)23(41-26)25(35)36)5-6-17(13)29-19-14(12)9-30-18(19)8-16-15(24(30)34)10-39-27(37)28(16,38)4-2/h5-8,20-23,26,31-33,38H,3-4,9-10H2,1-2H3,(H,35,36)/t20-,21-,22+,23-,26?,28?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01789","Fenretinide","5288209","AKJHMTWEGVYYSE-FXILSDISSA-N","InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","UVITUJIIRZWOPU-QGIYCXAWSA-N","InChI=1S/C32H41NO8/c1-19(11-16-24-21(3)10-7-17-32(24,4)5)8-6-9-20(2)18-25(34)33-22-12-14-23(15-13-22)40-31-28(37)26(35)27(36)29(41-31)30(38)39/h6,8-9,11-16,18,26-29,31,35-37H,7,10,17H2,1-5H3,(H,33,34)(H,38,39)/b9-6+,16-11+,19-8+,20-18+/t26-,27-,28+,29-,31?/m0/s1","Wu et al. 2011; First-pass metabolism via UDP-glucuronosyltransferase- a barrier to oral bioavailability of phenolics"
"BIOTID01790","Fenretinide","5288209","AKJHMTWEGVYYSE-FXILSDISSA-N","InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+","UGT","4-OH sulfonation of phenolic compound","Human Phase II","Human","NULL","NULL","UVITUJIIRZWOPU-QGIYCXAWSA-N","InChI=1S/C32H41NO8/c1-19(11-16-24-21(3)10-7-17-32(24,4)5)8-6-9-20(2)18-25(34)33-22-12-14-23(15-13-22)40-31-28(37)26(35)27(36)29(41-31)30(38)39/h6,8-9,11-16,18,26-29,31,35-37H,7,10,17H2,1-5H3,(H,33,34)(H,38,39)/b9-6+,16-11+,19-8+,20-18+/t26-,27-,28+,29-,31?/m0/s1","Wu et al. 2011; First-pass metabolism via UDP-glucuronosyltransferase- a barrier to oral bioavailability of phenolics"
"BIOTID01791","3-Hydroxy-6-methyl-3p,4p-methylenedioxyflavone","15939984","KWAOBWWDFBQFGR-UHFFFAOYSA-N","InChI=1S/C17H12O5/c1-9-2-4-12-11(6-9)15(18)16(19)17(22-12)10-3-5-13-14(7-10)21-8-20-13/h2-7,19H,8H2,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","NKDPDGKGOPGXMS-GWQNJANKSA-N","InChI=1S/C23H20O11/c1-9-2-4-12-11(6-9)15(24)20(19(32-12)10-3-5-13-14(7-10)31-8-30-13)33-23-18(27)16(25)17(26)21(34-23)22(28)29/h2-7,16-18,21,23,25-27H,8H2,1H3,(H,28,29)/t16-,17-,18+,21-,23?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01792","6-Hydroxymelatonin","1864","OMYMRCXOJJZYKE-UHFFFAOYSA-N","InChI=1S/C13H16N2O3/c1-8(16)14-4-3-9-7-15-11-6-12(17)13(18-2)5-10(9)11/h5-7,15,17H,3-4H2,1-2H3,(H,14,16)","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","BIRHYNBRXCOXLU-UHFFFAOYSA-N","InChI=1S/C19H24N2O9/c1-8(22)20-4-3-9-7-21-11-6-13(12(28-2)5-10(9)11)29-19-16(25)14(23)15(24)17(30-19)18(26)27/h5-7,14-17,19,21,23-25H,3-4H2,1-2H3,(H,20,22)(H,26,27)","http://www.hmdb.ca/metabolites/HMDB0060786"
"BIOTID01794","Sinapinic acid","637775","PCMORTLOPMLEFB-ONEGZZNKSA-N","InChI=1S/C11H12O5/c1-15-8-5-7(3-4-10(12)13)6-9(16-2)11(8)14/h3-6,14H,1-2H3,(H,12,13)/b4-3+","UGT","O-glucuronidation","Human Phase II","Human","NULL","124202107","YAIVMBWMHPRYKU-VKAIBYOUSA-N","InChI=1S/C17H20O11/c1-25-8-5-7(6-9(26-2)11(8)19)3-4-10(18)27-17-14(22)12(20)13(21)15(28-17)16(23)24/h3-6,12-15,17,19-22H,1-2H3,(H,23,24)/b4-3+/t12-,13-,14+,15-,17+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060019"
"BIOTID01795","Tolmetin","5509","UPSPUYADGBWSHF-UHFFFAOYSA-N","InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","155656","MEFIGCPEYJZFFC-ZFORQUDYSA-N","InChI=1S/C21H23NO9/c1-10-3-5-11(6-4-10)15(24)13-8-7-12(22(13)2)9-14(23)30-21-18(27)16(25)17(26)19(31-21)20(28)29/h3-8,16-19,21,25-27H,9H2,1-2H3,(H,28,29)/t16-,17-,18+,19-,21+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0042044"
"BIOTID01796","Licofelone M2","NULL","QUCLYFKWRYCDCG-UHFFFAOYSA-N","InChI=1S/C23H22ClNO3/c1-23(2)12-18-21(14-6-4-3-5-7-14)22(15-8-9-16(24)19(26)10-15)17(11-20(27)28)25(18)13-23/h3-10,26H,11-13H2,1-2H3,(H,27,28)","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","NULL","OIPSDICMVLCYHY-TXZJZKILSA-N","InChI=1S/C29H30ClNO9/c1-29(2)12-18-21(14-6-4-3-5-7-14)22(15-8-9-16(30)19(32)10-15)17(31(18)13-29)11-20(33)39-28-25(36)23(34)24(35)26(40-28)27(37)38/h3-10,23-26,28,32,34-36H,11-13H2,1-2H3,(H,37,38)/t23-,24-,25+,26-,28?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675.|http://www.hmdb.ca/metabolites/HMDB0061130"
"BIOTID01797","O-methoxycatechol","18702042","CWDFAWQMQXOHPJ-UHFFFAOYSA-N","InChI=1S/C7H8O3/c1-9-10-7-5-3-2-4-6(7)8/h2-5,8H,1H3","SULT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","22473","AQTYXAPIHMXAAV-UHFFFAOYSA-N","InChI=1S/C7H8O5S/c1-11-6-4-2-3-5-7(6)12-13(8,9)10/h2-5H,1H3,(H,8,9,10)","http://www.hmdb.ca/metabolites/HMDB0060013"
"BIOTID01798","phenethyl isothiocyanate","16741","IZJDOKYDEWTZSO-UHFFFAOYSA-N","InChI=1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","CWQOXGNRTBQTID-KBPBESRZSA-N","InChI=1S/C19H25N4O6S2/c20-13(18(28)29)6-7-15(24)23-14(17(27)22-10-16(25)26)11-31-19(30)21-9-8-12-4-2-1-3-5-12/h1-5,13-14H,6-11,20H2,(H,22,27)(H,23,24)(H,25,26)(H,28,29)/t13-,14-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01799","6-hydroxymethylbenzo[a]pyrene","30544","FJQLVOHCPDYIFE-UHFFFAOYSA-N","InChI=1S/C21H14O/c22-12-19-16-7-2-1-6-15(16)17-10-8-13-4-3-5-14-9-11-18(19)21(17)20(13)14/h1-11,22H,12H2","SULT1B1; SULT1C3","O-sulfonation","Human Phase II","Human","NULL","50026","WPJPSIKNQCJUCP-UHFFFAOYSA-N","InChI=1S/C21H14O4S/c22-26(23,24)25-12-19-16-7-2-1-6-15(16)17-10-8-13-4-3-5-14-9-11-18(19)21(17)20(13)14/h1-11H,12H2,(H,22,23,24)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01800","isobutanol","6560","ZXEKIIBDNHEJCQ-UHFFFAOYSA-N","InChI=1S/C4H10O/c1-4(2)3-5/h4-5H,3H2,1-2H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","BBLDJTVYNSHUPK-NMLRKWPISA-N","InChI=1S/C10H18O7/c1-4(2)3-16-10-7(13)5(11)6(12)8(17-10)9(14)15/h4-8,10-13H,3H2,1-2H3,(H,14,15)/t5-,6-,7+,8-,10?/m0/s1","Jurowich, S. et al. (2004); Glucuronidation of aliphatic alcohols in human liver microsomes in vitro; Alcohol 32 (2004) 187Ã¢â‚¬â€œ194"
"BIOTID01801","Lonidamine","39562","WDRYRZXSPDWGEB-UHFFFAOYSA-N","InChI=1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21)","UGT","O-glucuronidation","Human Phase II","Human","NULL","16042756","NGXCZUKKEQMKRC-KHYATNAISA-N","InChI=1S/C21H18Cl2N2O8/c22-10-6-5-9(12(23)7-10)8-25-13-4-2-1-3-11(13)14(24-25)20(31)33-21-17(28)15(26)16(27)18(32-21)19(29)30/h1-7,15-18,21,26-28H,8H2,(H,29,30)/t15-,16-,17+,18-,21?/m0/s1",""
"BIOTID01802","2,2‐dichloro‐2‐fluoroethanol","164603","LJTFLXOWPJPVCJ-UHFFFAOYSA-N","InChI=1S/C2H3Cl2FO/c3-2(4,5)1-6/h6H,1H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","PLCGWGPQEGUNKG-OJGRKFFBSA-N","InChI=1S/C8H11Cl2FO7/c9-8(10,11)1-17-7-4(14)2(12)3(13)5(18-7)6(15)16/h2-5,7,12-14H,1H2,(H,15,16)/t2-,3-,4+,5-,7?/m0/s1","Tong Z et al; Drug Metabolism and Disposition 26 (7): 711-3 (1998)"
"BIOTID01803","Geraniol","637566","GLZPCOQZEFWAFX-JXMROGBWSA-N","InChI=1S/C10H18O/c1-9(2)5-4-6-10(3)7-8-11/h5,7,11H,4,6,8H2,1-3H3/b10-7+","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","OLJYZVCOHXCPAB-JXMROGBWSA-N","InChI=1S/C10H18O4S/c1-9(2)5-4-6-10(3)7-8-14-15(11,12)13/h5,7H,4,6,8H2,1-3H3,(H,11,12,13)/b10-7+","Kinetics and dosin"
"BIOTID01804","Buprenorphine","644073","RMRJXGBAOAMLHD-IHFGGWKQSA-N","InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","Buprenorphine glucuronide","131769995","CZULHKGIAJASAA-RONBUCGTSA-N","InChI=1S/C35H49NO10/c1-31(2,3)32(4,42)20-15-33-10-11-35(20,43-5)30-34(33)12-13-36(16-17-6-7-17)21(33)14-18-8-9-19(26(46-30)22(18)34)44-29-25(39)23(37)24(38)27(45-29)28(40)41/h8-9,17,20-21,23-25,27,29-30,37-39,42H,6-7,10-16H2,1-5H3,(H,40,41)/t20-,21-,23+,24+,25-,27+,29-,30-,32-,33-,34+,35-/m1/s1","https://www.drugbank.ca/metabolites/DBMET00176"
"BIOTID01805","Nateglinide","NULL","OELFLUMRDSZNSF-BRWVUGGUSA-N","InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","YTIRWNSTJVSCRW-IESJKZRYSA-N","InChI=1S/C25H35NO9/c1-13(2)15-8-10-16(11-9-15)22(30)26-17(12-14-6-4-3-5-7-14)24(33)35-25-20(29)18(27)19(28)21(34-25)23(31)32/h3-7,13,15-21,25,27-29H,8-12H2,1-2H3,(H,26,30)(H,31,32)/t15-,16-,17-,18+,19+,20-,21+,25?/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01806","trans-isoeugenol","853433","BJIOGJUNALELMI-ONEGZZNKSA-N","InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3-7,11H,1-2H3/b4-3+","UGT","O-glucuronidation","Human Phase II","Human","NULL","124202102","HBQGHTRBYUFZLV-MIJQFFSFSA-N","InChI=1S/C16H20O8/c1-3-4-8-5-6-9(10(7-8)22-2)23-16-13(19)11(17)12(18)14(24-16)15(20)21/h3-7,11-14,16-19H,1-2H3,(H,20,21)/b4-3+/t11-,12-,13+,14-,16?/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060021"
"BIOTID01807","Clofibric acid","2797","TXCGAZHTZHNUAI-UHFFFAOYSA-N","InChI=1S/C10H11ClO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)","UGT","O-glucuronidation","Human Phase II","Human","NULL","133401","LCJVUUVMVSSIGZ-ZAOAHOKWSA-N","InChI=1S/C16H19ClO9/c1-16(2,26-8-5-3-7(17)4-6-8)15(23)25-14-11(20)9(18)10(19)12(24-14)13(21)22/h3-6,9-12,14,18-20H,1-2H3,(H,21,22)/t9-,10-,11+,12-,14?/m0/s1","https://pubchem.ncbi.nlm.nih.gov/compound/155696#section=IUPAC-Name"
"BIOTID01808","N-Hydroxymexiletine","92288929","ABMUWCMGKRQAIK-SNVBAGLBSA-N","InChI=1S/C11H17NO2/c1-8-5-4-6-9(2)11(8)14-7-10(3)12-13/h4-6,10,12-13H,7H2,1-3H3/t10-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","XXMULGPNDWROEN-SRUJRSLGSA-N","InChI=1S/C17H25NO8/c1-8-5-4-6-9(2)14(8)24-7-10(3)18-26-17-13(21)11(19)12(20)15(25-17)16(22)23/h4-6,10-13,15,17-21H,7H2,1-3H3,(H,22,23)/t10-,11+,12+,13-,15+,17?/m1/s1","https://pubchem.ncbi.nlm.nih.gov/compound/197617#section=InChI"
"BIOTID01809","Dehydroisoandrosterone","5881","FMGSKLZLMKYGDP-USOAJAOKSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","53480448","GLONBVCUAVPJFV-CLIRWHJISA-N","InChI=1S/C25H36O8/c1-24-9-7-13(32-23-20(29)18(27)19(28)21(33-23)22(30)31)11-12(24)3-4-14-15-5-6-17(26)25(15,2)10-8-16(14)24/h3,13-16,18-21,23,27-29H,4-11H2,1-2H3,(H,30,31)/t13?,14?,15?,16?,18-,19-,20+,21?,23+,24?,25?/m0/s1","http://www.hmdb.ca/metabolites/HMDB0010327"
"BIOTID01810","4-hydroxymethyl ambrisentan","25183815","PDUAYPFMBRYSNN-LJQANCHMSA-N","InChI=1S/C22H22N2O5/c1-15-13-18(14-25)24-21(23-15)29-19(20(26)27)22(28-2,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-13,19,25H,14H2,1-2H3,(H,26,27)/t19-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","HYNPRXQATWYSER-KFXNSFBMSA-N","InChI=1S/C28H30N2O11/c1-15-13-18(14-31)30-27(29-15)40-23(25(37)41-26-21(34)19(32)20(33)22(39-26)24(35)36)28(38-2,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-13,19-23,26,31-34H,14H2,1-2H3,(H,35,36)/t19-,20-,21+,22-,23+,26?/m0/s1","https://www.drugbank.ca/metabolites/DBMET01406"
"BIOTID01811","4-Methoxyphenol","9015","NWVVVBRKAWDGAB-UHFFFAOYSA-N","InChI=1S/C7H8O2/c1-9-7-4-2-6(8)3-5-7/h2-5,8H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","18654381","OPHAIPSAIQWLKD-NJMOVEGISA-N","InChI=1S/C13H16O8/c1-19-6-2-4-7(5-3-6)20-13-10(16)8(14)9(15)11(21-13)12(17)18/h2-5,8-11,13-16H,1H3,(H,17,18)/t8-,9-,10+,11-,13?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01812","N-OH-ABA","24849078","WCPKDLWOWHLXNO-UHFFFAOYSA-N","InChI=1S/C17H11NO2/c19-17-12-5-2-1-4-10(12)11-8-9-15(18-20)13-6-3-7-14(17)16(11)13/h1-9,18,20H","SULT1A1, SULT1A2","O-sulfonation","Human Phase II","Human","NULL","NULL","MBBWEJFOKGQOKS-UHFFFAOYSA-N","InChI=1S/C17H11NO5S/c19-17-12-5-2-1-4-10(12)11-8-9-15(18-23-24(20,21)22)13-6-3-7-14(17)16(11)13/h1-9,18H,(H,20,21,22)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01813","3,5-Dihydroxyflavone","5393151","QHYWQIVTVQAKQF-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-7-4-8-11-12(10)13(17)14(18)15(19-11)9-5-2-1-3-6-9/h1-8,16,18H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","68735468","ZFBQQJUTYLABMS-MBIBTLSJSA-N","InChI=1S/C21H18O10/c22-10-7-4-8-11-12(10)13(23)18(17(29-11)9-5-2-1-3-6-9)30-21-16(26)14(24)15(25)19(31-21)20(27)28/h1-8,14-16,19,21-22,24-26H,(H,27,28)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01814","2-amino-6- methyldipyrido[1,2-a:3p,2p-d]- imidazole (Glu-P-1)","49971","AYLURHVFAYRSHT-UHFFFAOYSA-N","InChI=1S/C11H10N4/c1-7-3-2-6-15-10(7)13-8-4-5-9(12)14-11(8)15/h2-6H,1H3,(H2,12,14)","NAT1,NAT2","N-acetylation","Human Phase II","Human","NULL","128685","FZRWLIBASRVEFR-UHFFFAOYSA-N","InChI=1S/C13H12N4O/c1-8-4-3-7-17-12(8)15-10-5-6-11(14-9(2)18)16-13(10)17/h3-7H,1-2H3,(H,14,16,18)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01815","Thalifendine","72704","GLYPKDKODVRYGP-UHFFFAOYSA-O","InChI=1S/C19H15NO4/c1-22-16-3-2-11-6-15-13-8-18-17(23-10-24-18)7-12(13)4-5-20(15)9-14(11)19(16)21/h2-3,6-9H,4-5,10H2,1H3/p+1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","XGXIXPBJUUVSMI-VAZBFKODSA-O","InChI=1S/C25H23NO10/c1-32-16-3-2-11-6-15-13-8-18-17(33-10-34-18)7-12(13)4-5-26(15)9-14(11)22(16)35-25-21(29)19(27)20(28)23(36-25)24(30)31/h2-3,6-9,19-21,23,25,27-29H,4-5,10H2,1H3/p+1/t19-,20-,21+,23-,25?/m0/s1","Yang, G. et al. (2017); Glucuronidation: driving factors and their impact on glucuronide disposition;  Drug Metab Rev. 2017 May;49(2):105-138. DOI:10.1080/03602532.2017.1293682; PMID:28266877"
"BIOTID01816","1-iodoethane","6340","HVTICUPFWKNHNG-UHFFFAOYSA-N","InChI=1S/C2H5I/c1-2-3/h2H2,1H3","GST","GSH-conjugation","Human Phase II","Human","ethylglutathione","107650","HMFDVPSBWOHOAP-YUMQZZPRSA-N","InChI=1S/C12H21N3O6S/c1-2-22-6-8(11(19)14-5-10(17)18)15-9(16)4-3-7(13)12(20)21/h7-8H,2-6,13H2,1H3,(H,14,19)(H,15,16)(H,17,18)(H,20,21)/t7-,8-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01817","Dihydroferulic acid","14340","BOLQJTPHPSDZHR-UHFFFAOYSA-N","InChI=1S/C10H12O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2,4,6,11H,3,5H2,1H3,(H,12,13)","SULT","O-sulfonation","Human Phase II","Human","NULL","187489","UMCDODPBPQMWQP-UHFFFAOYSA-N","InChI=1S/C10H12O7S/c1-16-9-6-7(3-5-10(11)12)2-4-8(9)17-18(13,14)15/h2,4,6H,3,5H2,1H3,(H,11,12)(H,13,14,15)","http://www.hmdb.ca/metabolites/HMDB0041724"
"BIOTID01818","4-Propoxyphenol","29352","KIIIPQXXLVCCQP-UHFFFAOYSA-N","InChI=1S/C9H12O2/c1-2-7-11-9-5-3-8(10)4-6-9/h3-6,10H,2,7H2,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","21349584","KSNISIWYBBWYNC-HXMBFPRCSA-N","InChI=1S/C15H20O8/c1-2-7-21-8-3-5-9(6-4-8)22-15-12(18)10(16)11(17)13(23-15)14(19)20/h3-6,10-13,15-18H,2,7H2,1H3,(H,19,20)/t10-,11-,12+,13-,15?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01819","valproic acid","3121","NIJJYAXOARWZEE-UHFFFAOYSA-N","InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","101061009","XXKSYIHWRBBHIC-JLERCCTOSA-N","InChI=1S/C14H24O8/c1-3-5-7(6-4-2)13(20)22-14-10(17)8(15)9(16)11(21-14)12(18)19/h7-11,14-17H,3-6H2,1-2H3,(H,18,19)/t8-,9-,10+,11-,14?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01820","Diclofenac","3033","DCOPUUMXTXDBNB-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","90842887","JXIKYYSIYCILNG-BCHVZBRRSA-N","InChI=1S/C20H19Cl2NO8/c21-10-5-3-6-11(22)14(10)23-12-7-2-1-4-9(12)8-13(24)30-20-17(27)15(25)16(26)18(31-20)19(28)29/h1-7,15-18,20,23,25-27H,8H2,(H,28,29)/t15-,16-,17+,18-,20?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01821","Eugenol","3314","RRAFCDWBNXTKKO-UHFFFAOYSA-N","InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","54086604","MQXZRKSWEMEXCG-AKFOCJAPSA-N","InChI=1S/C16H20O8/c1-3-4-8-5-6-9(10(7-8)22-2)23-16-13(19)11(17)12(18)14(24-16)15(20)21/h3,5-7,11-14,16-19H,1,4H2,2H3,(H,20,21)/t11-,12-,13+,14-,16?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01822","3-ethylphenol","12101","HMNKTRSOROOSPP-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-2-7-4-3-5-8(9)6-7/h3-6,9H,2H2,1H3","SULT","3-OH sulfonation of phenolic compound","Human Phase II","Human","NULL","86290012","DMIBREBMNWKSQY-UHFFFAOYSA-N","InChI=1S/C8H10O4S/c1-2-7-4-3-5-8(6-7)12-13(9,10)11/h3-6H,2H2,1H3,(H,9,10,11)","http://www.hmdb.ca/metabolites/HMDB0062721"
"BIOTID01823","(R,R)-1-phenylpropylene oxide","123339","YVCOJTATJWDGEU-UHFFFAOYSA-N","InChI=1S/C9H10O/c1-7-9(10-7)8-5-3-2-4-6-8/h2-7,9H,1H3","GST","GSH-conjugation of epoxide","Human Phase II","Human","NULL","NULL","QYYOHGIHNQSSFZ-YRFCHQJDSA-N","InChI=1S/C19H25N3O7S/c20-12(19(27)28)6-7-15(23)22-13(18(26)21-8-16(24)25)9-30-10-14-17(29-14)11-4-2-1-3-5-11/h1-5,12-14,17H,6-10,20H2,(H,21,26)(H,22,23)(H,24,25)(H,27,28)/t12-,13-,14?,17?/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01824","Wogonin","5281703","XLTFNNCXVBYBSX-UHFFFAOYSA-N","InChI=1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","LNOHXHDWGCMVCO-XTLXVGOWSA-N","InChI=1S/C22H20O11/c1-30-18-13(32-22-17(27)15(25)16(26)20(33-22)21(28)29)8-11(24)14-10(23)7-12(31-19(14)18)9-5-3-2-4-6-9/h2-8,15-17,20,22,24-27H,1H3,(H,28,29)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01825","3,3p,4p-Trihydroxyflavone","145826","KPGMHZQXQVDYNT-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-10-6-5-8(7-11(10)17)15-14(19)13(18)9-3-1-2-4-12(9)20-15/h1-7,16-17,19H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","DQGGXJWEMYGIRL-MBIBTLSJSA-N","InChI=1S/C21H18O11/c22-10-6-5-8(7-11(10)23)17-18(13(24)9-3-1-2-4-12(9)30-17)31-21-16(27)14(25)15(26)19(32-21)20(28)29/h1-7,14-16,19,21-23,25-27H,(H,28,29)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01826","fenchone metabo4","86047059","QYPAZGZCYSBEOJ-UHFFFAOYSA-N","InChI=1S/C10H16O2/c1-9(2)6-4-10(3,8(9)12)5-7(6)11/h6-7,11H,4-5H2,1-3H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","OVBFDDZQQOCVTB-NJPGAIFGSA-N","InChI=1S/C16H24O8/c1-15(2)6-4-16(3,14(15)22)5-7(6)23-13-10(19)8(17)9(18)11(24-13)12(20)21/h6-11,13,17-19H,4-5H2,1-3H3,(H,20,21)/t6?,7?,8-,9-,10+,11-,13?,16?/m0/s1","From Jarleips validations"
"BIOTID01827","Sorafenib","216239","MLDQJTXFUGDVEO-UHFFFAOYSA-N","InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)","UGT","O-glucuronidation","Human Phase II","Human","NULL","71752221","HALZWBPBJOJUOZ-QMDPOKHVSA-N","InChI=1S/C27H24ClF3N4O9/c1-32-23(39)18-11-15(8-9-33-18)43-14-5-2-12(3-6-14)34-26(42)35(13-4-7-17(28)16(10-13)27(29,30)31)24-21(38)19(36)20(37)22(44-24)25(40)41/h2-11,19-22,24,36-38H,1H3,(H,32,39)(H,34,42)(H,40,41)/t19-,20-,21+,22-,24+/m0/s1","https://www.drugbank.ca/metabolites/DBMET01001"
"BIOTID01828","4-Iodophenol","10894","VSMDINRNYYEDRN-UHFFFAOYSA-N","InChI=1S/C6H5IO/c7-5-1-3-6(8)4-2-5/h1-4,8H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","JDROCSGCMQVIRT-SDQGTYQYSA-N","InChI=1S/C12H13IO7/c13-5-1-3-6(4-2-5)19-12-9(16)7(14)8(15)10(20-12)11(17)18/h1-4,7-10,12,14-16H,(H,17,18)/t7-,8-,9+,10-,12?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01829","4-Hydroxyacetophenone","7469","TXFPEBPIARQUIG-UHFFFAOYSA-N","InChI=1S/C8H8O2/c1-6(9)7-2-4-8(10)5-3-7/h2-5,10H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","CXEPHEQPBJSNGZ-ZAOAHOKWSA-N","InChI=1S/C14H16O8/c1-6(15)7-2-4-8(5-3-7)21-14-11(18)9(16)10(17)12(22-14)13(19)20/h2-5,9-12,14,16-18H,1H3,(H,19,20)/t9-,10-,11+,12-,14?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01830","Triclosan","5564","XEFQLINVKFYRCS-UHFFFAOYSA-N","InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","DNYVWBJVOYZRCX-PDHYLSHYSA-N","InChI=1S/C18H15Cl3O8/c19-7-1-3-10(9(21)5-7)27-11-4-2-8(20)6-12(11)28-18-15(24)13(22)14(23)16(29-18)17(25)26/h1-6,13-16,18,22-24H,(H,25,26)/t13-,14-,15+,16-,18?/m0/s1","Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation"
"BIOTID01831","Triclosan","5564","XEFQLINVKFYRCS-UHFFFAOYSA-N","InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H","SULT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","67606152","ZPFYUMPBKRRSTR-UHFFFAOYSA-N","InChI=1S/C12H7Cl3O5S/c13-7-1-3-10(9(15)5-7)19-11-4-2-8(14)6-12(11)20-21(16,17)18/h1-6H,(H,16,17,18)","Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation"
"BIOTID01832","Naltrexone","71750923","KCSKQJYZSCIQRR-ODTDCTFRSA-N","InChI=1S/C26H31NO10/c28-13-5-6-26(34)15-9-12-3-4-14(35-24-19(31)17(29)18(30)21(37-24)23(32)33)20-16(12)25(26,22(13)36-20)7-8-27(15)10-11-1-2-11/h3-4,11,15,17-19,21-22,24,29-31,34H,1-2,5-10H2,(H,32,33)/t15-,17+,18+,19-,21+,22+,24-,25+,26-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","(2S,3S,4S,5R,6S)-6-{[(1S,5R,13R,17S)-4-(cyclopropylmethyl)-17-hydroxy-14-oxo-12-oxa-4-azapentacyclo[9.6.1.0Ã‚Â¹,Ã‚Â¹Ã‚Â³.0Ã¢ÂÂµ,Ã‚Â¹Ã¢ÂÂ·.0Ã¢ÂÂ·,Ã‚Â¹Ã¢ÂÂ¸]octadeca-7(18),8,10-trien-10-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid","71750923","KCSKQJYZSCIQRR-ODTDCTFRSA-N","InChI=1S/C26H31NO10/c28-13-5-6-26(34)15-9-12-3-4-14(35-24-19(31)17(29)18(30)21(37-24)23(32)33)20-16(12)25(26,22(13)36-20)7-8-27(15)10-11-1-2-11/h3-4,11,15,17-19,21-22,24,29-31,34H,1-2,5-10H2,(H,32,33)/t15-,17+,18+,19-,21+,22+,24-,25+,26-/m1/s1",""
"BIOTID01833","Combretastatin A4","5351344","HVXBOLULGPECHP-WAYWQWQTSA-N","InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","DVUNNRSRNSOECT-NDFGWKAYSA-N","InChI=1S/C24H28O11/c1-30-14-8-7-12(5-6-13-10-16(31-2)21(33-4)17(11-13)32-3)9-15(14)34-24-20(27)18(25)19(26)22(35-24)23(28)29/h5-11,18-20,22,24-27H,1-4H3,(H,28,29)/b6-5-/t18-,19-,20+,22-,24?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01834","Ascorbic acid","54670067","CIWBSHSKHKDKBQ-JLAZNSOCSA-N","InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1","SULT","O-sulfonation","Human Phase II","Human","NULL","98048983","XDBMXUKHMOFBPJ-VVJJHMBFSA-N","InChI=1S/C6H8O9S/c7-1-2(8)4-3(9)5(6(10)14-4)15-16(11,12)13/h2,4,7-9H,1H2,(H,11,12,13)/t2-,4-/m1/s1","http://www.hmdb.ca/metabolites/HMDB0060649"
"BIOTID01835","testosterone","6013","MUMGGOZAMZWBJJ-DYKIIFRCSA-N","InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","SULT","O-sulfonation","Human Phase II","Human","NULL","119207","WAQBISPOEAOCOG-DYKIIFRCSA-N","InChI=1S/C19H28O5S/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(24-25(21,22)23)19(15,2)10-8-16(14)18/h11,14-17H,3-10H2,1-2H3,(H,21,22,23)/t14-,15-,16-,17-,18-,19-/m0/s1","http://www.hmdb.ca/metabolites/HMDB0002833"
"BIOTID01836","2-aminofluorene","1539","CFRFHWQYWJMEJN-UHFFFAOYSA-N","InChI=1S/C13H11N/c14-11-5-6-13-10(8-11)7-9-3-1-2-4-12(9)13/h1-6,8H,7,14H2","NAT","N-acetylation","Human Phase II","Human","NULL","5897","CZIHNRWJTSTCEX-UHFFFAOYSA-N","InChI=1S/C15H13NO/c1-10(17)16-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9H,8H2,1H3,(H,16,17)","Liu, L.  et al. (2007); Arylamine N-Acetyltransferases: Characterization of the Substrate Specificities and Molecular Interactions of Environmental Arylamines with Human NAT1 and NAT2"
"BIOTID01837","Droloxifene","3033767","ZQZFYGIXNQKOAV-OCEACIFDSA-N","InChI=1S/C26H29NO2/c1-4-25(20-9-6-5-7-10-20)26(22-11-8-12-23(28)19-22)21-13-15-24(16-14-21)29-18-17-27(2)3/h5-16,19,28H,4,17-18H2,1-3H3/b26-25+","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","LLJQVSGWCSTGGW-AITOGICDSA-N","InChI=1S/C32H37NO8/c1-4-25(20-9-6-5-7-10-20)26(21-13-15-23(16-14-21)39-18-17-33(2)3)22-11-8-12-24(19-22)40-32-29(36)27(34)28(35)30(41-32)31(37)38/h5-16,19,27-30,32,34-36H,4,17-18H2,1-3H3,(H,37,38)/b26-25+/t27-,28-,29+,30-,32?/m0/s1","John, BA et al. (2002); Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects.; Xenobiotica. 2002 Aug;32(8):699-713.; PMID:12296990; DOI:10.1080/00498250210143029"
"BIOTID01838","Berberrubine","3084288","OEGWOBMNQDATKP-UHFFFAOYSA-O","InChI=1S/C19H15NO4/c1-22-19-14-9-20-5-4-12-7-17-18(24-10-23-17)8-13(12)15(20)6-11(14)2-3-16(19)21/h2-3,6-9H,4-5,10H2,1H3/p+1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","JTACAMOIQSBONP-VAZBFKODSA-O","InChI=1S/C25H23NO10/c1-32-22-14-9-26-5-4-12-7-17-18(34-10-33-17)8-13(12)15(26)6-11(14)2-3-16(22)35-25-21(29)19(27)20(28)23(36-25)24(30)31/h2-3,6-9,19-21,23,25,27-29H,4-5,10H2,1H3/p+1/t19-,20-,21+,23-,25?/m0/s1","Yang, G. et al. (2017); Glucuronidation: driving factors and their impact on glucuronide disposition;  Drug Metab Rev. 2017 May;49(2):105-138. DOI:10.1080/03602532.2017.1293682; PMID:28266877"
"BIOTID01839","7-Hydroxy-3-methylflavone","5391151","SUNCCQBNDWHMPR-UHFFFAOYSA-N","InChI=1S/C16H12O3/c1-10-15(18)13-8-7-12(17)9-14(13)19-16(10)11-5-3-2-4-6-11/h2-9,17H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","WFAROJVCARSBGP-ICNUUSJMSA-N","InChI=1S/C22H20O9/c1-10-15(23)13-8-7-12(9-14(13)30-19(10)11-5-3-2-4-6-11)29-22-18(26)16(24)17(25)20(31-22)21(27)28/h2-9,16-18,20,22,24-26H,1H3,(H,27,28)/t16-,17-,18+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01840","4-aminoveratrole","22770","LGDHZCLREKIGKJ-UHFFFAOYSA-N","InChI=1S/C8H11NO2/c1-10-7-4-3-6(9)5-8(7)11-2/h3-5H,9H2,1-2H3","NAT","N-acetylation","Human Phase II","Human","NULL","244160","DZPYVOWPTBVRJR-UHFFFAOYSA-N","InChI=1S/C10H13NO3/c1-7(12)11-8-4-5-9(13-2)10(6-8)14-3/h4-6H,1-3H3,(H,11,12)","PMID:735860|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01841","phentolamine","5775","MRBDMNSDAVCSSF-UHFFFAOYSA-N","InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)","SULT1A3; SULT1A5","O-sulfonation","Human Phase II","Human","NULL","NULL","NJXRFXGANNWYRK-UHFFFAOYSA-N","InChI=1S/C17H19N3O4S/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(11-15)24-25(21,22)23/h2-8,11H,9-10,12H2,1H3,(H,18,19)(H,21,22,23)","PMID:645680"
"BIOTID01842","Fenofibric Acid","74603167","BHOJZVSZYFTIOZ-UHFFFAOYSA-N","InChI=1S/C23H23ClO10/c1-23(2,22(31)33-21-18(28)16(26)17(27)19(32-21)20(29)30)34-14-9-5-12(6-10-14)15(25)11-3-7-13(24)8-4-11/h3-10,16-19,21,26-28H,1-2H3,(H,29,30)","UGT","O-glucuronidation","Human Phase II","Human","6-({2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoyl}oxy)-3,4,5-trihydroxyoxane-2-carboxylic acid","74603167","BHOJZVSZYFTIOZ-UHFFFAOYSA-N","InChI=1S/C23H23ClO10/c1-23(2,22(31)33-21-18(28)16(26)17(27)19(32-21)20(29)30)34-14-9-5-12(6-10-14)15(25)11-3-7-13(24)8-4-11/h3-10,16-19,21,26-28H,1-2H3,(H,29,30)",""
"BIOTID01843","Resacetophenone","6990","SULYEHHGGXARJS-UHFFFAOYSA-N","InChI=1S/C8H8O3/c1-5(9)7-3-2-6(10)4-8(7)11/h2-4,10-11H,1H3","SULT","O-sulfonation","Human Phase II","Human","NULL","10657183","COXWPCPYWFBNJH-UHFFFAOYSA-N","InChI=1S/C8H8O6S/c1-5(9)7-3-2-6(10)4-8(7)14-15(11,12)13/h2-4,10H,1H3,(H,11,12,13)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01844","Epinephrine","5816","UCTWMZQNUQWSLP-VIFPVBQESA-N","InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1","SULT","O-sulfonation","Human Phase II","Human","NULL","3035453","AELFRHHZGTVYGJ-QMMMGPOBSA-N","InChI=1S/C9H13NO6S/c1-10-5-8(12)6-2-3-9(7(11)4-6)16-17(13,14)15/h2-4,8,10-12H,5H2,1H3,(H,13,14,15)/t8-/m0/s1","http://www.hmdb.ca/metabolites/HMDB0001876"
"BIOTID01845","Diallyl disulfide","16590","PFRGXCVKLLPLIP-UHFFFAOYSA-N","InChI=1S/C6H10S2/c1-3-5-7-8-6-4-2/h3-4H,1-2,5-6H2","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","RCLYCBNSJJJOKN-UEUCCFLYSA-N","InChI=1S/C16H25N3O6S3/c1-2-6-27-28-8-3-7-26-10-12(15(23)18-9-14(21)22)19-13(20)5-4-11(17)16(24)25/h2-3,7,11-12H,1,4-6,8-10,17H2,(H,18,23)(H,19,20)(H,21,22)(H,24,25)/b7-3+/t11-,12-/m0/s1","Kinetics and dosin"
"BIOTID01846","10-hydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene","159823","VEFFVGHBCVMXOT-UHFFFAOYSA-N","InChI=1S/C20H16O/c21-17-6-2-5-14-11-15-8-7-12-3-1-4-13-9-10-16(19(14)17)20(15)18(12)13/h1,3-4,7-11,17,21H,2,5-6H2","SULT1E1","O-sulfonation","Human Phase II","Human","NULL","NULL","FBIRPHVNSAZLJA-UHFFFAOYSA-N","InChI=1S/C20H16O4S/c21-25(22,23)24-17-6-2-5-14-11-15-8-7-12-3-1-4-13-9-10-16(19(14)17)20(15)18(12)13/h1,3-4,7-11,17H,2,5-6H2,(H,21,22,23)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01847","trovafloxacin","NULL","WVPSKSLAZQPAKQ-CDMJZVDBSA-N","InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16+","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","GTZVGNAECYGIIQ-FOOAVRCKSA-N","InChI=1S/C26H23F3N4O9/c27-8-1-2-15(13(28)3-8)33-7-12(25(40)42-26-20(37)18(35)19(36)21(41-26)24(38)39)17(34)9-4-14(29)23(31-22(9)33)32-5-10-11(6-32)16(10)30/h1-4,7,10-11,16,18-21,26,35-37H,5-6,30H2,(H,38,39)/t10-,11+,16+,18-,19-,20+,21-,26?/m0/s1","Dalvie, D. et al (2009); Assessment of Three Human in Vitro Systems in the Generation of Major Human Excretory and Circulating Metabolites; Chem. Res. Toxicol. 2009, 22, 357Ã¢â‚¬â€œ36"
"BIOTID01848","2-hydroxymethylpyrene","146932","XIKICBSLAFJTDZ-UHFFFAOYSA-N","InChI=1S/C17H12O/c18-10-11-8-14-6-4-12-2-1-3-13-5-7-15(9-11)17(14)16(12)13/h1-9,18H,10H2","SULT2A1","O-sulfonation","Human Phase II","Human","NULL","179886","BXQLMAIEVDQAEP-UHFFFAOYSA-N","InChI=1S/C17H12O4S/c18-22(19,20)21-10-11-8-14-6-4-12-2-1-3-13-5-7-15(9-11)17(14)16(12)13/h1-9H,10H2,(H,18,19,20)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01849","alpha-methyl benzyl alcohol","7409","WAPNOHKVXSQRPX-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-7(9)8-5-3-2-4-6-8/h2-7,9H,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","LLURZZQATGMQGS-NLNZTVMASA-N","InChI=1S/C14H18O7/c1-7(8-5-3-2-4-6-8)20-14-11(17)9(15)10(16)12(21-14)13(18)19/h2-7,9-12,14-17H,1H3,(H,18,19)/t7?,9-,10-,11+,12-,14?/m0/s1","Belsito, D. et al. (2012); A toxicological and dermatological assessment of aryl alkyl alcohol simple acid ester derivatives when used as fragrance ingredients; Food and Chemical Toxicology 50 (2012) S269Ã¢â‚¬â€œS313"
"BIOTID01850","Propofol","4943","OLBCVFGFOZPWHH-UHFFFAOYSA-N","InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3","UGT1A8, UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","101649830","JZSJIASBMOIIKI-ODEDACCXSA-N","InChI=1S/C18H26O7/c1-8(2)10-6-5-7-11(9(3)4)15(10)24-18-14(21)12(19)13(20)16(25-18)17(22)23/h5-9,12-14,16,18-21H,1-4H3,(H,22,23)/t12-,13-,14+,16-,18?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218|Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01851","Kaempferol","5280863","IYRMWMYZSQPJKC-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","HKMMHEQNCQNUNN-WQUGZTNDSA-N","InChI=1S/C21H18O12/c22-8-3-1-7(2-4-8)18-15(26)13(24)12-10(23)5-9(6-11(12)32-18)31-21-17(28)14(25)16(27)19(33-21)20(29)30/h1-6,14,16-17,19,21-23,25-28H,(H,29,30)/t14-,16-,17+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01852","Kaempferol","5280863","IYRMWMYZSQPJKC-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","22846027","FNTJVYCFNVUBOL-MBIBTLSJSA-N","InChI=1S/C21H18O12/c22-8-3-1-7(2-4-8)17-18(13(25)12-10(24)5-9(23)6-11(12)31-17)32-21-16(28)14(26)15(27)19(33-21)20(29)30/h1-6,14-16,19,21-24,26-28H,(H,29,30)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01853","2-ethylaniline","11357","MLPVBIWIRCKMJV-UHFFFAOYSA-N","InChI=1S/C8H11N/c1-2-7-5-3-4-6-8(7)9/h3-6H,2,9H2,1H3","NAT","N-acetylation","Human Phase II","Human","NULL","36332","ZXOVAGUQXNXKHF-UHFFFAOYSA-N","InChI=1S/C10H13NO/c1-3-9-6-4-5-7-10(9)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)","PMID:686074|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01854","N-hydroxy-2-amino-6-methyldipyrido[1,2-a:3p,2p-d]-imidazole","104998","XGRLYZZMBWLSNE-UHFFFAOYSA-N","InChI=1S/C11H10N4O/c1-7-3-2-6-15-10(7)12-8-4-5-9(14-16)13-11(8)15/h2-6,16H,1H3,(H,13,14)","SULT1A1","O-sulfonation","Human Phase II","Human","NULL","NULL","OIPHNBSYKGNFRJ-UHFFFAOYSA-N","InChI=1S/C11H10N4O4S/c1-7-3-2-6-15-10(7)12-8-4-5-9(13-11(8)15)14-19-20(16,17)18/h2-6H,1H3,(H,13,14)(H,16,17,18)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01855","4-nonylphenol","1752","IGFHQQFPSIBGKE-UHFFFAOYSA-N","InChI=1S/C15H24O/c1-2-3-4-5-6-7-8-9-14-10-12-15(16)13-11-14/h10-13,16H,2-9H2,1H3","SULT1C1; SULT1C2","O-sulfonation","Human Phase II","Human","NULL","18186063","CQGBQHVFCCEEPW-UHFFFAOYSA-N","InChI=1S/C15H24O4S/c1-2-3-4-5-6-7-8-9-14-10-12-15(13-11-14)19-20(16,17)18/h10-13H,2-9H2,1H3,(H,16,17,18)","PMID:645675"
"BIOTID01856","Tizanidine M6","NULL","COUBTDJHGNWOFR-UHFFFAOYSA-N","InChI=1S/C9H8ClN5OS/c10-4-3-5(16)7-8(15-17-14-7)6(4)13-9-11-1-2-12-9/h3,16H,1-2H2,(H2,11,12,13)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","IGBNEBKYFXFREK-ZAOAHOKWSA-N","InChI=1S/C15H16ClN5O7S/c16-4-3-5(27-14-11(24)9(22)10(23)12(28-14)13(25)26)7-8(21-29-20-7)6(4)19-15-17-1-2-18-15/h3,9-12,14,22-24H,1-2H2,(H,25,26)(H2,17,18,19)/t9-,10-,11+,12-,14?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01857","Tizanidine M6","NULL","COUBTDJHGNWOFR-UHFFFAOYSA-N","InChI=1S/C9H8ClN5OS/c10-4-3-5(16)7-8(15-17-14-7)6(4)13-9-11-1-2-12-9/h3,16H,1-2H2,(H2,11,12,13)","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","JPCZEGIHCYSSMV-UHFFFAOYSA-N","InChI=1S/C9H8ClN5O4S2/c10-4-3-5(19-21(16,17)18)7-8(15-20-14-7)6(4)13-9-11-1-2-12-9/h3H,1-2H2,(H2,11,12,13)(H,16,17,18)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01858","Dezocine","3033053","VTMVHDZWSFQSQP-VBNZEHGJSA-N","InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","195975","OGFASZKCOLUFAW-LCZVVBTCSA-N","InChI=1S/C22H31NO7/c1-22-8-4-2-3-5-12(19(22)23)9-11-6-7-13(10-14(11)22)29-21-17(26)15(24)16(25)18(30-21)20(27)28/h6-7,10,12,15-19,21,24-26H,2-5,8-9,23H2,1H3,(H,27,28)/t12-,15+,16+,17-,18-,19+,21-,22?/m1/s1",""
"BIOTID01859","Dulcin","9013","GGLIEWRLXDLBBF-UHFFFAOYSA-N","InChI=1S/C9H12N2O2/c1-2-13-8-5-3-7(4-6-8)11-9(10)12/h3-6H,2H2,1H3,(H3,10,11,12)","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","NXRTYUWUBFLGLO-GCFWVWJCSA-N","InChI=1S/C15H20N2O8/c1-2-24-8-5-3-7(4-6-8)16-15(23)17-13-11(20)9(18)10(19)12(25-13)14(21)22/h3-6,9-13,18-20H,2H2,1H3,(H,21,22)(H2,16,17,23)/t9-,10-,11+,12-,13?/m0/s1","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01860","S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid","12769847","DTOPKPBTCXKNFF-UHFFFAOYSA-N","InChI=1S/C14H14O2S/c1-9-7-8-17-13(9)12-5-3-11(4-6-12)10(2)14(15)16/h3-8,10H,1-2H3,(H,15,16)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","TZCRTEBIDCXWQB-UPPKGEOUSA-N","InChI=1S/C20H22O8S/c1-9-7-8-29-17(9)12-5-3-11(4-6-12)10(2)19(26)28-20-15(23)13(21)14(22)16(27-20)18(24)25/h3-8,10,13-16,20-23H,1-2H3,(H,24,25)/t10?,13-,14-,15+,16-,20?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01861","S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid","12769847","DTOPKPBTCXKNFF-UHFFFAOYSA-N","InChI=1S/C14H14O2S/c1-9-7-8-17-13(9)12-5-3-11(4-6-12)10(2)14(15)16/h3-8,10H,1-2H3,(H,15,16)","TAU","Taurine conjugation of aliphatic acid","Human Phase II","Human","NULL","NULL","SCEQSTKTVDFSQK-UHFFFAOYSA-N","InChI=1S/C16H19NO5S2/c1-11-7-9-23-15(11)14-5-3-13(4-6-14)12(2)16(18)22-17-8-10-24(19,20)21/h3-7,9,12,17H,8,10H2,1-2H3,(H,19,20,21)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01862","Jaceidin","5464461","XUWTZJRCCPNNJR-UHFFFAOYSA-N","InChI=1S/C18H16O8/c1-23-11-6-8(4-5-9(11)19)16-18(25-3)15(22)13-12(26-16)7-10(20)17(24-2)14(13)21/h4-7,19-21H,1-3H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","21722026","IXUDTZUOBGRRSD-NKUGBYDDSA-N","InChI=1S/C24H24O14/c1-33-11-6-8(4-5-10(11)37-24-18(30)16(28)17(29)22(38-24)23(31)32)19-21(35-3)15(27)13-12(36-19)7-9(25)20(34-2)14(13)26/h4-7,16-18,22,24-26,28-30H,1-3H3,(H,31,32)/t16-,17-,18+,22-,24+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0031656"
"BIOTID01863","menthol","16666","NOOLISFMXDJSKH-KXUCPTDWSA-N","InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","CLJGMBYGTHRUNF-WZCRPZMRSA-N","InChI=1S/C16H28O7/c1-7(2)9-5-4-8(3)6-10(9)22-16-13(19)11(17)12(18)14(23-16)15(20)21/h7-14,16-19H,4-6H2,1-3H3,(H,20,21)/t8-,9+,10-,11+,12+,13-,14+,16?/m1/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01864","5,6-O-DiDesmethyl Donepezil","49849820","UJEPFLUMZAEBIS-UHFFFAOYSA-N","InChI=1S/C22H25NO3/c24-20-12-17-11-18(22(26)19(17)13-21(20)25)10-15-6-8-23(9-7-15)14-16-4-2-1-3-5-16/h1-5,12-13,15,18,24-25H,6-11,14H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","ZPRHUWFRFRXVHF-XUCPCBLWSA-N","InChI=1S/C28H33NO9/c30-20-12-17-11-18(10-15-6-8-29(9-7-15)14-16-4-2-1-3-5-16)22(31)19(17)13-21(20)37-28-25(34)23(32)24(33)26(38-28)27(35)36/h1-5,12-13,15,18,23-26,28,30,32-34H,6-11,14H2,(H,35,36)/t18?,23-,24-,25+,26-,28?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01865","5,6-O-DiDesmethyl Donepezil","49849820","UJEPFLUMZAEBIS-UHFFFAOYSA-N","InChI=1S/C22H25NO3/c24-20-12-17-11-18(22(26)19(17)13-21(20)25)10-15-6-8-23(9-7-15)14-16-4-2-1-3-5-16/h1-5,12-13,15,18,24-25H,6-11,14H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","HJVSDNWYXFSKGL-XUCPCBLWSA-N","InChI=1S/C28H33NO9/c30-20-13-19-17(12-21(20)37-28-25(34)23(32)24(33)26(38-28)27(35)36)11-18(22(19)31)10-15-6-8-29(9-7-15)14-16-4-2-1-3-5-16/h1-5,12-13,15,18,23-26,28,30,32-34H,6-11,14H2,(H,35,36)/t18?,23-,24-,25+,26-,28?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01866","3,6,4p-Trihydroxyflavone","676308","QUPHEKFURGDWME-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)15-14(19)13(18)11-7-10(17)5-6-12(11)20-15/h1-7,16-17,19H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","YAMLHVHEXZXZKD-MBIBTLSJSA-N","InChI=1S/C21H18O11/c22-9-3-1-8(2-4-9)17-18(13(24)11-7-10(23)5-6-12(11)30-17)31-21-16(27)14(25)15(26)19(32-21)20(28)29/h1-7,14-16,19,21-23,25-27H,(H,28,29)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01867","4p-Carboxylumiracoxib","9904747","LUNFHOZKXHTOLG-UHFFFAOYSA-N","InChI=1S/C15H13ClFNO3/c1-8-2-3-13(9(4-8)5-14(20)21)18-15-11(16)6-10(19)7-12(15)17/h2-4,6-7,18-19H,5H2,1H3,(H,20,21)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","SEZLIFDZXOQYCW-DAZJWRSOSA-N","InChI=1S/C21H21ClFNO9/c1-8-2-3-13(24-15-11(22)6-10(25)7-12(15)23)9(4-8)5-14(26)32-21-18(29)16(27)17(28)19(33-21)20(30)31/h2-4,6-7,16-19,21,24-25,27-29H,5H2,1H3,(H,30,31)/t16-,17-,18+,19-,21?/m0/s1","https://www.drugbank.ca/metabolites/DBMET01281"
"BIOTID01868","Norbuprenorphine","114976","YOYLLRBMGQRFTN-IOMBULRVSA-N","InChI=1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","OOLGGESLZHGXGC-WHHIWHMYSA-N","InChI=1S/C31H43NO10/c1-27(2,3)28(4,38)16-13-29-8-9-31(16,39-5)26-30(29)10-11-32-17(29)12-14-6-7-15(22(42-26)18(14)30)40-25-21(35)19(33)20(34)23(41-25)24(36)37/h6-7,16-17,19-21,23,25-26,32-35,38H,8-13H2,1-5H3,(H,36,37)/t16-,17-,19+,20+,21-,23+,25?,26-,28+,29-,30+,31-/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01869","O-Desmethylvenlafaxine","9859500","BHCUWXACHAFFSK-UHFFFAOYSA-N","InChI=1S/C14H21NO2/c15-10-13(11-4-6-12(16)7-5-11)14(17)8-2-1-3-9-14/h4-7,13,16-17H,1-3,8-10,15H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","71316024","VNRFTNKWISCOMJ-KUIQUDTGSA-N","InChI=1S/C20H29NO8/c21-10-13(20(27)8-2-1-3-9-20)11-4-6-12(7-5-11)28-19-16(24)14(22)15(23)17(29-19)18(25)26/h4-7,13-17,19,22-24,27H,1-3,8-10,21H2,(H,25,26)/t13?,14-,15-,16+,17-,19+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0061172"
"BIOTID01870","2,8-Dihydroxyquinoline","97250","ZXZKYYHTWHJHFT-UHFFFAOYSA-N","InChI=1S/C9H7NO2/c11-7-3-1-2-6-4-5-8(12)10-9(6)7/h1-5,11H,(H,10,12)","UGT","O-glucuronidation","Human Phase II","Human","NULL","53481014","YQBCNQXCTHWJOK-DKBOKBLXSA-N","InChI=1S/C15H15NO8/c17-7-3-1-2-6-4-5-8(16-9(6)7)23-15-12(20)10(18)11(19)13(24-15)14(21)22/h1-5,10-13,15,17-20H,(H,21,22)/t10-,11-,12+,13-,15+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0011658"
"BIOTID01871","Hydroxyfarnesol","86583467","FLIKBVTXNBEPQQ-RDUMTQBOSA-N","InChI=1S/C15H26O2/c1-13(7-5-9-15(3)12-17)6-4-8-14(2)10-11-16/h6,9-10,16-17H,4-5,7-8,11-12H2,1-3H3/b13-6+,14-10+,15-9+","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","LJYACKYHFNLLNS-XNBWETQDSA-N","InChI=1S/C21H34O8/c1-13(6-4-8-14(2)10-11-22)7-5-9-15(3)12-28-21-18(25)16(23)17(24)19(29-21)20(26)27/h6,9-10,16-19,21-25H,4-5,7-8,11-12H2,1-3H3,(H,26,27)/b13-6+,14-10+,15-9+/t16-,17-,18+,19-,21?/m0/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01872","Dihydromorphine","5359421","IJVCSMSMFSCRME-KBQPJGBKSA-N","InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KCPRJVDBLLJBMF-QMGRMYLDSA-N","InChI=1S/C23H29NO9/c1-24-7-6-23-10-3-4-12(25)20(23)32-18-13(5-2-9(14(18)23)8-11(10)24)31-22-17(28)15(26)16(27)19(33-22)21(29)30/h2,5,10-12,15-17,19-20,22,25-28H,3-4,6-8H2,1H3,(H,29,30)/t10-,11+,12-,15-,16-,17+,19-,20-,22?,23-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01873","Ketoprofen","3825","DKYWVDODHFEZIM-UHFFFAOYSA-N","InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)","UGT","O-glucuronidation","Human Phase II","Human","NULL","131281","PBTXSZZKPHBHMA-LYFYOZKASA-N","InChI=1S/C22H22O9/c1-11(13-8-5-9-14(10-13)15(23)12-6-3-2-4-7-12)21(29)31-22-18(26)16(24)17(25)19(30-22)20(27)28/h2-11,16-19,22,24-26H,1H3,(H,27,28)/t11?,16-,17-,18+,19-,22-/m0/s1","http://www.hmdb.ca/metabolites/HMDB0010334"
"BIOTID01874","1-iodopropane","33643","PVWOIHVRPOBWPI-UHFFFAOYSA-N","InChI=1S/C3H7I/c1-2-3-4/h2-3H2,1H3","GST","O-glucuronidation","Human Phase II","Human","propyl-glutathione","98438","IJQSYVSEZCHJFD-IUCAKERBSA-N","InChI=1S/C13H23N3O6S/c1-2-5-23-7-9(12(20)15-6-11(18)19)16-10(17)4-3-8(14)13(21)22/h8-9H,2-7,14H2,1H3,(H,15,20)(H,16,17)(H,18,19)(H,21,22)/t8-,9-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01875","7-hydroxy-12-methylbenz[a]anthracene","NULL","DNSORFIUSTVMNQ-UHFFFAOYSA-N","InChI=1S/C19H14O/c1-12-14-7-4-5-9-16(14)19(20)17-11-10-13-6-2-3-8-15(13)18(12)17/h2-11,20H,1H3","SULT2A1","O-sulfonation","Human Phase II","Human","NULL","NULL","ZRZLRDIJEUDWRA-UHFFFAOYSA-N","InChI=1S/C19H14O4S/c1-12-14-7-4-5-9-16(14)19(23-24(20,21)22)17-11-10-13-6-2-3-8-15(13)18(12)17/h2-11H,1H3,(H,20,21,22)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01876","Lasofoxifene","216416","GXESHMAMLJKROZ-IAPPQJPRSA-N","InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","WBWCSRRUQKSEDJ-YYPWBVRDSA-N","InChI=1S/C34H39NO8/c36-29-30(37)32(33(39)40)43-34(31(29)38)42-25-13-15-27-23(20-25)10-14-26(21-6-2-1-3-7-21)28(27)22-8-11-24(12-9-22)41-19-18-35-16-4-5-17-35/h1-3,6-9,11-13,15,20,26,28-32,34,36-38H,4-5,10,14,16-19H2,(H,39,40)/t26-,28+,29+,30+,31-,32+,34?/m1/s1","https://pubchem.ncbi.nlm.nih.gov/compound/46782042"
"BIOTID01877","1-iodo-3-phenylpropane","138121","RGCKJSPKMTWLLX-UHFFFAOYSA-N","InChI=1S/C9H11I/c10-8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2","GST","GSH-conjugation","Human Phase II","Human","3-phenylpropyl-glutathione","68147343","XXFHHLLTANPROX-GJZGRUSLSA-N","InChI=1S/C19H27N3O6S/c20-14(19(27)28)8-9-16(23)22-15(18(26)21-11-17(24)25)12-29-10-4-7-13-5-2-1-3-6-13/h1-3,5-6,14-15H,4,7-12,20H2,(H,21,26)(H,22,23)(H,24,25)(H,27,28)/t14-,15-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01878","4p-OH-aceclofenac","9842299","BTDFYMBLEDMWOK-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO5/c17-11-6-10(20)7-12(18)16(11)19-13-4-2-1-3-9(13)5-15(23)24-8-14(21)22/h1-4,6-7,19-20H,5,8H2,(H,21,22)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","YDTXNQMKVXJXMQ-QAKXDBDYSA-N","InChI=1S/C22H21Cl2NO11/c23-11-6-10(35-22-19(31)17(29)18(30)20(36-22)21(32)33)7-12(24)16(11)25-13-4-2-1-3-9(13)5-15(28)34-8-14(26)27/h1-4,6-7,17-20,22,25,29-31H,5,8H2,(H,26,27)(H,32,33)/t17-,18-,19+,20-,22?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01879","4p-OH-aceclofenac","9842299","BTDFYMBLEDMWOK-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO5/c17-11-6-10(20)7-12(18)16(11)19-13-4-2-1-3-9(13)5-15(23)24-8-14(21)22/h1-4,6-7,19-20H,5,8H2,(H,21,22)","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","ZAQMXKOBGNZADV-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO8S/c17-11-6-10(27-28(23,24)25)7-12(18)16(11)19-13-4-2-1-3-9(13)5-15(22)26-8-14(20)21/h1-4,6-7,19H,5,8H2,(H,20,21)(H,23,24,25)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01880","4-Hydroxy-5-(3p,5p-dihydroxyphenyl)-valeric acid","52920333","QKRQBODPNMXFLS-UHFFFAOYSA-N","InChI=1S/C11H14O5/c12-8(1-2-11(15)16)3-7-4-9(13)6-10(14)5-7/h4-6,8,12-14H,1-3H2,(H,15,16)","UGT","O-glucuronidation","Human Phase II","Human","NULL","124202069","NLJOFAILECLFIF-UHFFFAOYSA-N","InChI=1S/C18H26O12/c19-9(3-8-4-10(20)6-11(21)5-8)1-2-12(22)28-7-29-18-15(25)13(23)14(24)16(30-18)17(26)27/h4-6,9,13-21,23-27H,1-3,7H2","http://www.hmdb.ca/metabolites/HMDB0059974"
"BIOTID01881","1-iodobutane","10962","KMGBZBJJOKUPIA-UHFFFAOYSA-N","InChI=1S/C4H9I/c1-2-3-4-5/h2-4H2,1H3","GST","GSH-conjugation","Human Phase II","Human","butyl-glutathione","14972243","YGCGHOZSELIPKD-UWVGGRQHSA-N","InChI=1S/C14H25N3O6S/c1-2-3-6-24-8-10(13(21)16-7-12(19)20)17-11(18)5-4-9(15)14(22)23/h9-10H,2-8,15H2,1H3,(H,16,21)(H,17,18)(H,19,20)(H,22,23)/t9-,10-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01882","4-hydroxyatomoxetine","9816910","PPXQPRLGNSJNJM-QGZVFWFLSA-N","InChI=1S/C17H21NO2/c1-13-12-15(19)8-9-16(13)20-17(10-11-18-2)14-6-4-3-5-7-14/h3-9,12,17-19H,10-11H2,1-2H3/t17-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","DJWNPJFKTPNTAE-RBEFBJKVSA-N","InChI=1S/C23H29NO8/c1-13-12-15(30-23-20(27)18(25)19(26)21(32-23)22(28)29)8-9-16(13)31-17(10-11-24-2)14-6-4-3-5-7-14/h3-9,12,17-21,23-27H,10-11H2,1-2H3,(H,28,29)/t17-,18+,19+,20-,21+,23?/m1/s1","https://www.pharmgkb.org/pathway/PA166160830"
"BIOTID01883","7-Hydoxy-5-methylflavone","5393156","QGHXBJKZPBTQQL-UHFFFAOYSA-N","InChI=1S/C16H12O3/c1-10-7-12(17)8-15-16(10)13(18)9-14(19-15)11-5-3-2-4-6-11/h2-9,17H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","DNCBXIVNAMCLMP-QAKXDBDYSA-N","InChI=1S/C22H20O9/c1-10-7-12(29-22-19(26)17(24)18(25)20(31-22)21(27)28)8-15-16(10)13(23)9-14(30-15)11-5-3-2-4-6-11/h2-9,17-20,22,24-26H,1H3,(H,27,28)/t17-,18-,19+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01884","6,7,3p-Trihydroxflavone","5393155","YLQLFNHURAYJDR-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-2-8(4-9)14-6-11(17)10-5-12(18)13(19)7-15(10)20-14/h1-7,16,18-19H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","OMHXBGBPZQHJEW-DAZJWRSOSA-N","InChI=1S/C21H18O11/c22-9-3-1-2-8(4-9)13-6-11(23)10-5-12(24)15(7-14(10)30-13)31-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21-22,24-27H,(H,28,29)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01885","N-hydroxy-2-acetylaminofluorene","5896","SOKUIEGXJHVFDV-UHFFFAOYSA-N","InChI=1S/C15H13NO2/c1-10(17)16(18)13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9,18H,8H2,1H3","UGT1A4, 1A6","O-glucuronidation","Human Phase II","Human","NULL","NULL","VPBPTHOOANATTD-DAZJWRSOSA-N","InChI=1S/C21H21NO8/c1-10(23)22(30-21-18(26)16(24)17(25)19(29-21)20(27)28)13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9,16-19,21,24-26H,8H2,1H3,(H,27,28)/t16-,17-,18+,19-,21?/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01886","N-hydroxy-2-acetylaminofluorene","5896","SOKUIEGXJHVFDV-UHFFFAOYSA-N","InChI=1S/C15H13NO2/c1-10(17)16(18)13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9,18H,8H2,1H3","SULT1A1","O-sulfonation","Human Phase II","Human","NULL","28091","VAQHXJKAFOKQTD-UHFFFAOYSA-N","InChI=1S/C15H13NO5S/c1-10(17)16(21-22(18,19)20)13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9H,8H2,1H3,(H,18,19,20)","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01887","7-Hydroxy-alpha-thujone","11041106","BWIMEHVFTVSHCC-BRDIYROLSA-N","InChI=1S/C10H16O2/c1-6-7-4-10(7,5-8(6)11)9(2,3)12/h6-7,12H,4-5H2,1-3H3/t6-,7-,10-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","WHRPFNIQYJHGRX-PWKOIPFUSA-N","InChI=1S/C16H24O8/c1-6-7-4-16(7,5-8(6)17)15(2,3)24-14-11(20)9(18)10(19)12(23-14)13(21)22/h6-7,9-12,14,18-20H,4-5H2,1-3H3,(H,21,22)/t6-,7-,9+,10+,11-,12+,14?,16-/m1/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01888","Pentaerythritol Dibromide","18692","CHUGKEQJSLOLHL-UHFFFAOYSA-N","InChI=1S/C5H10Br2O2/c6-1-5(2-7,3-8)4-9/h8-9H,1-4H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","71751501","JQFPAHSMEUXVKF-GBMPTNJUSA-N","InChI=1S/C11H18Br2O8/c12-1-11(2-13,3-14)4-20-10-7(17)5(15)6(16)8(21-10)9(18)19/h5-8,10,14-17H,1-4H2,(H,18,19)/t5-,6-,7+,8-,10+/m1/s1",""
"BIOTID01889","5-(3p,4p-Dihydroxyphenyl)-gamma-valerolactone-4p-O-methyl","44389510","CEZQHDADSGTTOP-UHFFFAOYSA-N","InChI=1S/C12H14O4/c1-15-11-4-2-8(7-10(11)13)6-9-3-5-12(14)16-9/h2,4,7,9,13H,3,5-6H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","124202064","VZGJAVFCUBLIJF-ZOQSEFCISA-N","InChI=1S/C18H22O10/c1-25-10-4-2-8(6-9-3-5-12(19)26-9)7-11(10)27-18-15(22)13(20)14(21)16(28-18)17(23)24/h2,4,7,9,13-16,18,20-22H,3,5-6H2,1H3,(H,23,24)/t9?,13-,14-,15+,16-,18+/m1/s1","http://www.hmdb.ca/metabolites/HMDB0059990"
"BIOTID01890","2-Methoxyestrone","440624","WHEUWNKSCXYKBU-QPWUGHHJSA-N","InChI=1S/C19H24O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,20H,3-8H2,1-2H3/t12-,13+,15-,19-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","22833612","CLTGLDLWQUZPJU-OOJOVCNMSA-N","InChI=1S/C24H32O8/c1-24-8-7-12-13(15(24)5-6-18(24)25)4-3-11-9-17(16(30-2)10-14(11)12)31-23-21(28)19(26)20(27)22(29)32-23/h9-10,12-13,15,19-23,26-29H,3-8H2,1-2H3/t12-,13+,15-,19-,20-,21+,22-,23+,24-/m0/s1","https://www.drugbank.ca/metabolites/DBMET00568"
"BIOTID01891","Carveol","7438","BAVONGHXFVOKBV-UHFFFAOYSA-N","InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h4,9-11H,1,5-6H2,2-3H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","BVXOWZPSSZQRID-FVMLSKNMSA-N","InChI=1S/C16H24O7/c1-7(2)9-5-4-8(3)10(6-9)22-16-13(19)11(17)12(18)14(23-16)15(20)21/h4,9-14,16-19H,1,5-6H2,2-3H3,(H,20,21)/t9?,10?,11-,12-,13+,14-,16?/m0/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01892","7-Hydroxyflavone","5281894","MQGPSCMMNJKMHQ-UHFFFAOYSA-N","InChI=1S/C15H10O3/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-9,16H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","GJYJIIZMSBDMGT-DAZJWRSOSA-N","InChI=1S/C21H18O9/c22-13-9-14(10-4-2-1-3-5-10)29-15-8-11(6-7-12(13)15)28-21-18(25)16(23)17(24)19(30-21)20(26)27/h1-9,16-19,21,23-25H,(H,26,27)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01893","Bisphenol A","6623","IISBACLAFKSPIT-UHFFFAOYSA-N","InChI=1S/C15H16O2/c1-15(2,11-3-7-13(16)8-4-11)12-5-9-14(17)10-6-12/h3-10,16-17H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","KHZOXXYQSBJDHB-BCHVZBRRSA-N","InChI=1S/C21H24O8/c1-21(2,11-3-7-13(22)8-4-11)12-5-9-14(10-6-12)28-20-17(25)15(23)16(24)18(29-20)19(26)27/h3-10,15-18,20,22-25H,1-2H3,(H,26,27)/t15-,16-,17+,18-,20?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01894","25-Hydroxyvitamin D2","45073667","KJKIIUAXZGLUND-YOSVZNIJSA-N","InChI=1S/C28H44O2/c1-19-10-14-24(29)18-23(19)13-12-22-8-7-17-28(6)25(15-16-26(22)28)20(2)9-11-21(3)27(4,5)30/h9,11-13,20-21,24-26,29-30H,1,7-8,10,14-18H2,2-6H3/b11-9+,22-12+,23-13-/t20-,21+,24+,25-,26?,28-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","6444033","MWEHQOJAQKGFMP-JJVXHKTJSA-N","InChI=1S/C34H52O8/c1-19-10-14-24(35)18-23(19)13-12-22-8-7-17-34(6)25(15-16-26(22)34)20(2)9-11-21(3)33(4,5)42-32-29(38)27(36)28(37)30(41-32)31(39)40/h9,11-13,20-21,24-30,32,35-38H,1,7-8,10,14-18H2,2-6H3,(H,39,40)/b11-9+,22-12+,23-13-/t20-,21+,24?,25-,26?,27+,28+,29-,30+,32+,34-/m1/s1","http://www.hmdb.ca/metabolites/HMDB0010342"
"BIOTID01895","Edaravone","NULL","PLVBQEFRONZLHO-UHFFFAOYSA-N","InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-7,13H,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KZSVPEVBRMCCMG-AKFOCJAPSA-N","InChI=1S/C16H18N2O7/c1-8-7-10(18(17-8)9-5-3-2-4-6-9)24-16-13(21)11(19)12(20)14(25-16)15(22)23/h2-7,11-14,16,19-21H,1H3,(H,22,23)/t11-,12-,13+,14-,16?/m0/s1",""
"BIOTID01896","6,7-Dihydroxyflavone","5353357","GSAOUZGPXSGVRS-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-11-7-14(9-4-2-1-3-5-9)19-15-8-13(18)12(17)6-10(11)15/h1-8,17-18H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","ZCWAJKNETUOVNC-DAZJWRSOSA-N","InChI=1S/C21H18O10/c22-11-7-13(9-4-2-1-3-5-9)29-14-8-15(12(23)6-10(11)14)30-21-18(26)16(24)17(25)19(31-21)20(27)28/h1-8,16-19,21,23-26H,(H,27,28)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01897","Flurbiprofen","92337","SYTBZMRGLBWNTM-SNVBAGLBSA-N","InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1","UGT2B7, UGT1A1, UGT1A3, UGT1A9, UGT2B4","O-glucuronidation","Human Phase II","Human","NULL","NULL","PLPQBSOCUVSKTP-WZDVMJGVSA-N","InChI=1S/C21H21FO8/c1-10(12-7-8-13(14(22)9-12)11-5-3-2-4-6-11)20(28)30-21-17(25)15(23)16(24)18(29-21)19(26)27/h2-10,15-18,21,23-25H,1H3,(H,26,27)/t10-,15+,16+,17-,18+,21?/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01898","Codeine","5284371","OROGSEYTTFOCAN-DNJOTXNNSA-N","InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","21309489","CRWVOYRJXPDBPM-CJXISONYSA-N","InChI=1S/C24H29NO9/c1-25-8-7-24-11-4-6-14(32-23-18(28)16(26)17(27)20(34-23)22(29)30)21(24)33-19-13(31-2)5-3-10(15(19)24)9-12(11)25/h3-6,11-12,14,16-18,20-21,23,26-28H,7-9H2,1-2H3,(H,29,30)/t11-,12+,14-,16-,17-,18+,20-,21-,23?,24-/m0/s1","Wu et al. 2011; First-pass metabolism via UDP-glucuronosyltransferase- a barrier to oral bioavailability of phenolics"
"BIOTID01899","Losartan","3961","PSIFNNKUMBGKDQ-UHFFFAOYSA-N","InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)","UGT1A1, UGT1A3, UGT1A10. UGT2B7, UGT2B17","O-glucuronidation","Human Phase II","Human","NULL","NULL","SRIGUAVCZXEAHJ-UHFFFAOYSA-O","InChI=1S/C28H35ClN6O7/c1-2-3-8-20-30-25(29)19(14-36)34(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)26-31-33-35(32-26)27-23(39)21(37)22(38)24(42-27)28(40)41/h4-7,9-12,21-24,26-28,32,36-41H,2-3,8,13-14H2,1H3/p+1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01900","N-hydroxy-2-acetylamino-3-methyl-5-phenylpyridine","177823","ZKYZEPGTJXOSGF-UHFFFAOYSA-N","InChI=1S/C14H14N2O2/c1-10-8-13(12-6-4-3-5-7-12)9-15-14(10)16(18)11(2)17/h3-9,18H,1-2H3","SULT1A1","O-sulfonation","Human Phase II","Human","NULL","NULL","VGBLERPZXYBDLR-YEBSBHECSA-N","InChI=1S/C20H22N2O8/c1-10-8-13(12-6-4-3-5-7-12)9-21-18(10)22(11(2)23)30-20-16(26)14(24)15(25)17(29-20)19(27)28/h3-9,14-17,20,24-26H,1-2H3,(H,27,28)/t14-,15-,16+,17-,20?/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01901","5-OH-paeonol","12543919","TXBDGLVJCSOBLF-UHFFFAOYSA-N","InChI=1S/C9H10O4/c1-5(10)6-3-8(12)9(13-2)4-7(6)11/h3-4,11-12H,1-2H3","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","APWOIKVWJRZADY-UHFFFAOYSA-N","InChI=1S/C9H10O7S/c1-5(10)6-3-7(11)9(15-2)4-8(6)16-17(12,13)14/h3-4,11H,1-2H3,(H,12,13,14)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01902","1-iodooctane","12380","UWLHSHAHTBJTBA-UHFFFAOYSA-N","InChI=1S/C8H17I/c1-2-3-4-5-6-7-8-9/h2-8H2,1H3","GST","GSH-conjugation","Human Phase II","Human","octyl-glutathione","443115","MJWCZWAVSJZQNL-KBPBESRZSA-N","InChI=1S/C18H33N3O6S/c1-2-3-4-5-6-7-10-28-12-14(17(25)20-11-16(23)24)21-15(22)9-8-13(19)18(26)27/h13-14H,2-12,19H2,1H3,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t13-,14-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01903","4-phenoxyaniline","8764","WOYZXEVUWXQVNV-UHFFFAOYSA-N","InChI=1S/C12H11NO/c13-10-6-8-12(9-7-10)14-11-4-2-1-3-5-11/h1-9H,13H2","NAT","N-acetylation","Human Phase II","Human","NULL","80579","JIHOMPVYRSEHKW-UHFFFAOYSA-N","InChI=1S/C14H13NO2/c1-11(16)15-12-7-9-14(10-8-12)17-13-5-3-2-4-6-13/h2-10H,1H3,(H,15,16)","PMID:735860|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01904","N-hydroxy-2-aminobenzanthrone","NULL","BYBSBXPRYXNOPV-UHFFFAOYSA-N","InChI=1S/C18H13NO2/c20-16-6-4-12-9-17-13(7-14(12)8-16)2-1-11-3-5-15(19-21)10-18(11)17/h1-5,7-10,19,21H,6H2","SULT1A1","O-sulfonation","Human Phase II","Human","NULL","NULL","RHYNZJFHPJNMNG-VDPKEQMDSA-N","InChI=1S/C24H21NO8/c26-16-6-4-12-9-17-13(7-14(12)8-16)2-1-11-3-5-15(10-18(11)17)25-33-24-21(29)19(27)20(28)22(32-24)23(30)31/h1-5,7-10,19-22,24-25,27-29H,6H2,(H,30,31)/t19-,20-,21+,22-,24?/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01905","xanthurenic acid","5699","FBZONXHGGPHHIY-UHFFFAOYSA-N","InChI=1S/C10H7NO4/c12-7-3-1-2-5-8(13)4-6(10(14)15)11-9(5)7/h1-4,12H,(H,11,13)(H,14,15)","SULT","O-sulfonation","Human Phase II","Human","NULL","11522049","FNGKEPQCRRMUOC-UHFFFAOYSA-N","InChI=1S/C10H7NO7S/c12-7-4-6(10(13)14)11-9-5(7)2-1-3-8(9)18-19(15,16)17/h1-4H,(H,11,12)(H,13,14)(H,15,16,17)","http://www.hmdb.ca/metabolites/HMDB0059741"
"BIOTID01906","Pyridine N-oxide","3877978","DEINLRGVTJVCOS-UHFFFAOYSA-N","InChI=1S/C5H6NO/c7-6-4-2-1-3-5-6/h1-5,7H/q+1","UGT","O-glucuronidation","Human Phase II","Human","NULL","131770061","KITHDEVLYXWSPB-ZBGLXGBJSA-O","InChI=1S/C11H13NO7/c13-6-7(14)9(10(16)17)18-11(8(6)15)19-12-4-2-1-3-5-12/h1-9,11,13-15H/p+1/t6-,7-,8+,9-,11-/m1/s1","https://www.drugbank.ca/metabolites/DBMET00994"
"BIOTID01907","N-nitrosodimethylamine","6124","UMFJAHHVKNCGLG-UHFFFAOYSA-N","InChI=1S/C2H6N2O/c1-4(2)3-5/h1-2H3","SULT1A1","O-sulfonation oxidation","Human Phase II","Human","NULL","NULL","PSGCJVUPNYGRQA-UHFFFAOYSA-N","InChI=1S/C4H10N2O2/c1-4(7)6(8)5(2)3/h6H,1-3H3","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01908","Acetaminophen","1983","RZVAJINKPMORJF-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)","SULT","O-sulfonation","Human Phase II","Human","NULL","83939","IGTYILLPRJOVFY-UHFFFAOYSA-N","InChI=1S/C8H9NO5S/c1-6(10)9-7-2-4-8(5-3-7)14-15(11,12)13/h2-5H,1H3,(H,9,10)(H,11,12,13)","http://www.hmdb.ca/metabolites/HMDB0059911"
"BIOTID01909","Acetaminophen","1983","RZVAJINKPMORJF-UHFFFAOYSA-N","InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)","UGT","O-glucuronidation","Human Phase II","Human","NULL","10404153","IPROLSVTVHAQLE-ZAOAHOKWSA-N","InChI=1S/C14H17NO8/c1-6(16)15-7-2-4-8(5-3-7)22-14-11(19)9(17)10(18)12(23-14)13(20)21/h2-5,9-12,14,17-19H,1H3,(H,15,16)(H,20,21)/t9-,10-,11+,12-,14?/m0/s1","Wu et al. 2011; First-pass metabolism via UDP-glucuronosyltransferase- a barrier to oral bioavailability of phenolics"
"BIOTID01910","serotonin","5202","QZAYGJVTTNCVMB-UHFFFAOYSA-N","InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","73707588","QALKNDMLQRCLGT-AKFOCJAPSA-N","InChI=1S/C16H20N2O7/c17-4-3-7-6-18-10-2-1-8(5-9(7)10)24-16-13(21)11(19)12(20)14(25-16)15(22)23/h1-2,5-6,11-14,16,18-21H,3-4,17H2,(H,22,23)/t11-,12-,13+,14-,16?/m0/s1","PMID:673033"
"BIOTID01911","Misonidazole","26105","OBBCSXFCDPPXOL-UHFFFAOYSA-N","InChI=1S/C7H11N3O4/c1-14-5-6(11)4-9-3-2-8-7(9)10(12)13/h2-3,6,11H,4-5H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","AGTMQQNYEJNPKI-HHSHATBTSA-N","InChI=1S/C13H19N3O10/c1-24-5-6(4-15-3-2-14-13(15)16(22)23)25-12-9(19)7(17)8(18)10(26-12)11(20)21/h2-3,6-10,12,17-19H,4-5H2,1H3,(H,20,21)/t6?,7-,8-,9+,10-,12?/m0/s1","IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: http://monographs.iarc.fr/ENG/Classification/index.php p. V71 886 (1999)"
"BIOTID01912","Etiocholanolone","5880","QGXBDMJGAMFCBF-BNSUEQOYSA-N","InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14+,15+,16+,18+,19+/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","443078","VFUIRAVTUVCQTF-SDHZCXLISA-N","InChI=1S/C25H38O8/c1-24-9-7-13(32-23-20(29)18(27)19(28)21(33-23)22(30)31)11-12(24)3-4-14-15-5-6-17(26)25(15,2)10-8-16(14)24/h12-16,18-21,23,27-29H,3-11H2,1-2H3,(H,30,31)/t12-,13-,14+,15+,16+,18+,19+,20-,21+,23-,24+,25+/m1/s1","http://www.hmdb.ca/metabolites/HMDB0004484"
"BIOTID01913","3-alpha-hydroxydesogestrel","29981456","ZMLDTNLDYRJTAZ-JASYKLOUSA-N","InChI=1S/C22H30O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,16-20,23-24H,3-4,6-11,13H2,1H3/t16-,17+,18+,19+,20-,21+,22+/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KTJQPBFLZZUVHY-KUZWSSKFSA-N","InChI=1S/C28H38O8/c1-4-27-13-14(3)20-17-9-7-16(35-26-23(31)21(29)22(30)24(36-26)25(32)33)12-15(17)6-8-18(20)19(27)10-11-28(27,34)5-2/h2,12,16-24,26,29-31,34H,3-4,6-11,13H2,1H3,(H,32,33)/t16?,17-,18-,19-,20+,21-,22-,23+,24-,26?,27-,28-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01914","3-alpha-hydroxydesogestrel","29981456","ZMLDTNLDYRJTAZ-JASYKLOUSA-N","InChI=1S/C22H30O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,16-20,23-24H,3-4,6-11,13H2,1H3/t16-,17+,18+,19+,20-,21+,22+/m1/s1","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","SFLFQWSDLZNFPJ-JASYKLOUSA-N","InChI=1S/C22H30O5S/c1-4-21-13-14(3)20-17-9-7-16(27-28(24,25)26)12-15(17)6-8-18(20)19(21)10-11-22(21,23)5-2/h2,12,16-20,23H,3-4,6-11,13H2,1H3,(H,24,25,26)/t16-,17+,18+,19+,20-,21+,22+/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01915","B[a]P 7,8-epoxide","37455","OLLMQFHYRYHKTD-UHFFFAOYSA-N","InChI=1S/C20H12O/c1-2-11-4-5-13-10-16-14(8-9-17-20(16)21-17)15-7-6-12(3-1)18(11)19(13)15/h1-10,17,20H","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","FDOKFDNZZDFSTR-QMIJOYDGSA-N","InChI=1S/C30H29N3O8S/c31-21(30(39)40)9-11-24(35)33-22(29(38)32-13-25(36)37)14-42-41-28-20-12-17-5-4-15-2-1-3-16-6-7-19(27(17)26(15)16)18(20)8-10-23(28)34/h1-8,10,12,21-23,28,34H,9,11,13-14,31H2,(H,32,38)(H,33,35)(H,36,37)(H,39,40)/t21-,22-,23?,28?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01916","4-Chlorophenol","4684","WXNZTHHGJRFXKQ-UHFFFAOYSA-N","InChI=1S/C6H5ClO/c7-5-1-3-6(8)4-2-5/h1-4,8H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","22827811","PFUGOKWIRNXFOW-SDQGTYQYSA-N","InChI=1S/C12H13ClO7/c13-5-1-3-6(4-2-5)19-12-9(16)7(14)8(15)10(20-12)11(17)18/h1-4,7-10,12,14-16H,(H,17,18)/t7-,8-,9+,10-,12?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01917","Tyramine","5610","DZGWFCGJZKJUFP-UHFFFAOYSA-N","InChI=1S/C8H11NO/c9-6-5-7-1-3-8(10)4-2-7/h1-4,10H,5-6,9H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","193088","AQKVISOBVPVACA-BYNIDDHOSA-N","InChI=1S/C14H19NO7/c15-6-5-7-1-3-8(4-2-7)21-14-11(18)9(16)10(17)12(22-14)13(19)20/h1-4,9-12,14,16-18H,5-6,15H2,(H,19,20)/t9-,10-,11+,12-,14+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0010328"
"BIOTID01918","Minoxidil","4201","ZIMGGGWCDYVHOY-UHFFFAOYSA-N","InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2","SULT","O-sulfonation","Human Phase II","Human","NULL","4219798","DHVJQUFZGZOFFY-UHFFFAOYSA-N","InChI=1S/C9H15N5O4S/c10-7-6-8(13-4-2-1-3-5-13)12-9(11)14(7)18-19(15,16)17/h6,11H,1-5,10H2,(H,15,16,17)","Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation"
"BIOTID01919","3p-Oxohexobarbital","160461","JLDHHLBFGIBRGN-UHFFFAOYSA-N","InChI=1S/C12H14N2O4/c1-12(7-4-3-5-8(15)6-7)9(16)13-11(18)14(2)10(12)17/h6H,3-5H2,1-2H3,(H,13,16,18)","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","KOIDTVHMKHPOSM-CVXASFDDSA-N","InChI=1S/C22H31N5O10S/c1-21(18(35)26-20(37)27(2)19(21)36)22(7-3-4-11(28)8-22)38-10-13(16(32)24-9-15(30)31)25-14(29)6-5-12(23)17(33)34/h12-13H,3-10,23H2,1-2H3,(H,24,32)(H,25,29)(H,30,31)(H,33,34)(H,26,35,37)/t12-,13-,21?,22?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01920","Fluoxetine","3386","RTHCYVBBDHJXIQ-UHFFFAOYSA-N","InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","ROQAUFRWFXOLOE-GDBUUVARSA-N","InChI=1S/C23H26F3NO7/c1-27(21-19(30)17(28)18(29)20(34-21)22(31)32)12-11-16(13-5-3-2-4-6-13)33-15-9-7-14(8-10-15)23(24,25)26/h2-10,16-21,28-30H,11-12H2,1H3,(H,31,32)/t16?,17-,18-,19+,20-,21?/m0/s1","https://www.drugbank.ca/metabolites/DBMET00857"
"BIOTID01921","Vitamin D2","5280793","MECHNRXZTMCUDQ-RKHKHRCZSA-N","InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","6443809","NLCXHIGBBJLZMX-HLQYQDSBSA-N","InChI=1S/C34H52O7/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-34(26,27)6)12-13-24-18-25(14-11-21(24)4)40-33-30(37)28(35)29(36)31(41-33)32(38)39/h9-10,12-13,19-20,22,25-31,33,35-37H,4,7-8,11,14-18H2,1-3,5-6H3,(H,38,39)/b10-9+,23-12+,24-13+/t20-,22+,25?,26+,27?,28-,29-,30+,31-,33+,34+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0010344"
"BIOTID01922","5-O-Desmethyl Donepezil","11503234","DSMISVLYMKJMLP-UHFFFAOYSA-N","InChI=1S/C23H27NO3/c1-27-22-14-20-18(13-21(22)25)12-19(23(20)26)11-16-7-9-24(10-8-16)15-17-5-3-2-4-6-17/h2-6,13-14,16,19,25H,7-12,15H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","UBLKQFQMHFDJGO-OWECDQGASA-N","InChI=1S/C29H35NO9/c1-37-21-14-20-18(13-22(21)38-29-26(34)24(32)25(33)27(39-29)28(35)36)12-19(23(20)31)11-16-7-9-30(10-8-16)15-17-5-3-2-4-6-17/h2-6,13-14,16,19,24-27,29,32-34H,7-12,15H2,1H3,(H,35,36)/t19?,24-,25-,26+,27-,29?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01923","6-Hydroxyflavone","72279","GPZYYYGYCRFPBU-UHFFFAOYSA-N","InChI=1S/C15H10O3/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-9,16H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","HNDAUHKJBIZLCM-DAZJWRSOSA-N","InChI=1S/C21H18O9/c22-13-9-15(10-4-2-1-3-5-10)29-14-7-6-11(8-12(13)14)28-21-18(25)16(23)17(24)19(30-21)20(26)27/h1-9,16-19,21,23-25H,(H,26,27)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01924","Dihydrocurcumin","NULL","DAYJNOVOURUJSU-YEMCPHRMSA-N","InChI=1S/C21H22O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3,5-7,9-13,23-25H,4,8H2,1-2H3/b7-3+,17-13-","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KVELFAOSGXWONI-AIJAMMBCSA-N","InChI=1S/C27H30O12/c1-36-20-11-14(5-9-18(20)30)3-7-16(28)13-17(29)8-4-15-6-10-19(21(12-15)37-2)38-27-24(33)22(31)23(32)25(39-27)26(34)35/h4-6,8-13,22-25,27-28,30-33H,3,7H2,1-2H3,(H,34,35)/b8-4+,16-13-/t22-,23-,24+,25-,27?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01925","4-OH-2,6-dimethylaniline","76543","GCWYXRHXGLFVFE-UHFFFAOYSA-N","InChI=1S/C8H11NO/c1-5-3-7(10)4-6(2)8(5)9/h3-4,10H,9H2,1-2H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","AWRXPBKJZCAGIZ-ZAOAHOKWSA-N","InChI=1S/C14H19NO7/c1-5-3-7(4-6(2)8(5)15)21-14-11(18)9(16)10(17)12(22-14)13(19)20/h3-4,9-12,14,16-18H,15H2,1-2H3,(H,19,20)/t9-,10-,11+,12-,14?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01926","3-Hydroxy-6-methylflavone","227445","KLGALCMPMFKGDQ-UHFFFAOYSA-N","InChI=1S/C16H12O3/c1-10-7-8-13-12(9-10)14(17)15(18)16(19-13)11-5-3-2-4-6-11/h2-9,18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","HQLXUDIGPIDYSU-XTLXVGOWSA-N","InChI=1S/C22H20O9/c1-10-7-8-13-12(9-10)14(23)19(18(29-13)11-5-3-2-4-6-11)30-22-17(26)15(24)16(25)20(31-22)21(27)28/h2-9,15-17,20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01927","1-iodoheptane","20274","LMHCYRULPLGEEZ-UHFFFAOYSA-N","InChI=1S/C7H15I/c1-2-3-4-5-6-7-8/h2-7H2,1H3","GST","GSH-conjugation","Human Phase II","Human","heptyl-glutathione","57458810","CKHDGVXSRMQISO-STQMWFEESA-N","InChI=1S/C17H31N3O6S/c1-2-3-4-5-6-9-27-11-13(16(24)19-10-15(22)23)20-14(21)8-7-12(18)17(25)26/h12-13H,2-11,18H2,1H3,(H,19,24)(H,20,21)(H,22,23)(H,25,26)/t12-,13-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01928","Tolcapone","4659569","MIQPIUSUKVNLNT-UHFFFAOYSA-N","InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","GPCPARWMTQPHCE-VKODVYPMSA-N","InChI=1S/C20H19NO11/c1-8-2-4-9(5-3-8)13(23)10-6-11(21(29)30)17(12(22)7-10)31-20-16(26)14(24)15(25)18(32-20)19(27)28/h2-7,14-16,18,20,22,24-26H,1H3,(H,27,28)/t14-,15-,16+,18-,20?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01929","4-Nitrophenol","980","BTJIUGUIPKRLHP-UHFFFAOYSA-N","InChI=1S/C6H5NO3/c8-6-3-1-5(2-4-6)7(9)10/h1-4,8H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","22788341","QSUILVWOWLUOEU-SDQGTYQYSA-N","InChI=1S/C12H13NO9/c14-7-8(15)10(11(17)18)22-12(9(7)16)21-6-3-1-5(2-4-6)13(19)20/h1-4,7-10,12,14-16H,(H,17,18)/t7-,8-,9+,10-,12?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01930","3-Indole carboxylic acid","69867","KMAKOBLIOCQGJP-UHFFFAOYSA-N","InChI=1S/C9H7NO2/c11-9(12)7-5-10-8-4-2-1-3-6(7)8/h1-5,10H,(H,11,12)","UGT","O-glucuronidation","Human Phase II","Human","NULL","53481645","BDNWJTRKUBXAGH-DOVARBIBSA-N","InChI=1S/C15H15NO8/c17-9-10(18)12(13(20)21)23-15(11(9)19)24-14(22)7-5-16-8-4-2-1-3-6(7)8/h1-5,9-12,15-19H,(H,20,21)/t9-,10-,11+,12?,15-/m0/s1","http://www.hmdb.ca/metabolites/HMDB0013189"
"BIOTID01931","Fisetin","5281614","XHEFDIBZLJXQHF-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","VPQMCNFLPZDUNL-MBIBTLSJSA-N","InChI=1S/C21H18O12/c22-8-2-3-9-12(6-8)31-17(7-1-4-10(23)11(24)5-7)18(13(9)25)32-21-16(28)14(26)15(27)19(33-21)20(29)30/h1-6,14-16,19,21-24,26-28H,(H,29,30)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01932","Ornidazole","28061","IPWKIXLWTCNBKN-UHFFFAOYSA-N","InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KBQRFMVIJNGKLT-RBQCFVEXSA-N","InChI=1S/C13H18ClN3O9/c1-5-15-3-7(17(23)24)16(5)4-6(2-14)25-13-10(20)8(18)9(19)11(26-13)12(21)22/h3,6,8-11,13,18-20H,2,4H2,1H3,(H,21,22)/t6?,8-,9-,10+,11-,13?/m0/s1","Yang, G. et al. (2017); Glucuronidation: driving factors and their impact on glucuronide disposition;  Drug Metab Rev. 2017 May;49(2):105-138. DOI:10.1080/03602532.2017.1293682; PMID:28266877"
"BIOTID01933","3-Hydroxy-6,4p-dimethoxyflavone","688858","RIRAMOVDGJDPRU-UHFFFAOYSA-N","InChI=1S/C17H14O5/c1-20-11-5-3-10(4-6-11)17-16(19)15(18)13-9-12(21-2)7-8-14(13)22-17/h3-9,19H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","IWDGVDFFCRPYDE-GWQNJANKSA-N","InChI=1S/C23H22O11/c1-30-11-5-3-10(4-6-11)19-20(15(24)13-9-12(31-2)7-8-14(13)32-19)33-23-18(27)16(25)17(26)21(34-23)22(28)29/h3-9,16-18,21,23,25-27H,1-2H3,(H,28,29)/t16-,17-,18+,21-,23?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01934","Lumiracoxib M25","NULL","RVWXBXJNQUDTIJ-UHFFFAOYSA-N","InChI=1S/C15H11ClFNO2/c1-8-2-3-13-9(4-8)5-14(20)18(13)15-11(16)6-10(19)7-12(15)17/h2-4,6-7,19H,5H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","SETAFJOLASRPRK-DAZJWRSOSA-N","InChI=1S/C21H19ClFNO8/c1-8-2-3-13-9(4-8)5-14(25)24(13)15-11(22)6-10(7-12(15)23)31-21-18(28)16(26)17(27)19(32-21)20(29)30/h2-4,6-7,16-19,21,26-28H,5H2,1H3,(H,29,30)/t16-,17-,18+,19-,21?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01935","3p-Amino-3p-deoxythimidine","359310","ADVCGXWUUOVPPB-UHFFFAOYSA-N","InChI=1S/C10H15N3O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4,11H2,1H3,(H,12,15,16)","UGT","O-glucuronidation","Human Phase II","Human","NULL","131769941","RDVUSEMLHAXQRK-SMNQMHOSSA-N","InChI=1S/C16H23N3O10/c1-5-3-19(16(26)18-13(5)22)8-2-6(17)7(28-8)4-27-11-9(20)12(14(23)24)29-15(25)10(11)21/h3,6-12,15,20-21,25H,2,4,17H2,1H3,(H,23,24)(H,18,22,26)/t6?,7?,8?,9-,10+,11-,12-,15?/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060751"
"BIOTID01936","4-Ethylphenol","31242","HXDOZKJGKXYMEW-UHFFFAOYSA-N","InChI=1S/C8H10O/c1-2-7-3-5-8(9)6-4-7/h3-6,9H,2H2,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","VCVXAAYLLIDUGA-ZAOAHOKWSA-N","InChI=1S/C14H18O7/c1-2-7-3-5-8(6-4-7)20-14-11(17)9(15)10(16)12(21-14)13(18)19/h3-6,9-12,14-17H,2H2,1H3,(H,18,19)/t9-,10-,11+,12-,14?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01937","3,3p-Dihydroxyflavone","676295","QZESEGHSLFKZIV-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-5-3-4-9(8-10)15-14(18)13(17)11-6-1-2-7-12(11)19-15/h1-8,16,18H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","DNTVZTPUZAAJTG-MBIBTLSJSA-N","InChI=1S/C21H18O10/c22-10-5-3-4-9(8-10)17-18(13(23)11-6-1-2-7-12(11)29-17)30-21-16(26)14(24)15(25)19(31-21)20(27)28/h1-8,14-16,19,21-22,24-26H,(H,27,28)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01938","MaxiPost","9885204","ULYONBAOIMCNEH-UHFFFAOYSA-N","InChI=1S/C16H10ClF4NO2/c1-24-13-5-3-9(17)7-11(13)15(18)10-4-2-8(16(19,20)21)6-12(10)22-14(15)23/h2-7H,1H3,(H,22,23)","UGT2B7","O-glucuronidation","Human Phase II","Human","NULL","NULL","LHGCJCWQABXCEH-DFPMCGAKSA-N","InChI=1S/C22H18ClF4NO8/c1-35-13-5-3-9(23)7-11(13)21(24)10-4-2-8(22(25,26)27)6-12(10)28(20(21)34)18-16(31)14(29)15(30)17(36-18)19(32)33/h2-7,14-18,29-31H,1H3,(H,32,33)/t14-,15-,16+,17-,18?,21?/m0/s1","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01939","3-Methoxy-4-hydroxyphenylglycol","10805","FBWPWWWZWKPJFL-UHFFFAOYSA-N","InChI=1S/C9H12O4/c1-13-9-4-6(8(12)5-10)2-3-7(9)11/h2-4,8,10-12H,5H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","22833525","VMWCOZPKGQMCRO-UICVJNQZSA-N","InChI=1S/C15H20O10/c1-23-9-4-6(7(17)5-16)2-3-8(9)24-15-12(20)10(18)11(19)13(25-15)14(21)22/h2-4,7,10-13,15-20H,5H2,1H3,(H,21,22)/t7?,10-,11-,12+,13-,15+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0000496"
"BIOTID01940","4p-OH-diclofenac","116545","KGVXVPRLBMWZLG-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c15-10-6-9(18)7-11(16)14(10)17-12-4-2-1-3-8(12)5-13(19)20/h1-4,6-7,17-18H,5H2,(H,19,20)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","AYKUFPDRLGDHLA-BCHVZBRRSA-N","InChI=1S/C20H19Cl2NO9/c21-10-6-9(31-20-17(28)15(26)16(27)18(32-20)19(29)30)7-11(22)14(10)23-12-4-2-1-3-8(12)5-13(24)25/h1-4,6-7,15-18,20,23,26-28H,5H2,(H,24,25)(H,29,30)/t15-,16-,17+,18-,20?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01941","4p-OH-diclofenac","116545","KGVXVPRLBMWZLG-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c15-10-6-9(18)7-11(16)14(10)17-12-4-2-1-3-8(12)5-13(19)20/h1-4,6-7,17-18H,5H2,(H,19,20)","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","VMRXAZSKKNZVAC-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO6S/c15-10-6-9(23-24(20,21)22)7-11(16)14(10)17-12-4-2-1-3-8(12)5-13(18)19/h1-4,6-7,17H,5H2,(H,18,19)(H,20,21,22)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01942","Farnesol","3327","CRDAMVZIKSXKFV-UHFFFAOYSA-N","InChI=1S/C15H26O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16H,5-6,8,10,12H2,1-4H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","GNEHABOQLSVVFN-DAZJWRSOSA-N","InChI=1S/C21H34O7/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-27-21-18(24)16(22)17(23)19(28-21)20(25)26/h7,9,11,16-19,21-24H,5-6,8,10,12H2,1-4H3,(H,25,26)/t16-,17-,18+,19-,21?/m0/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01943","4-n-Butylphenol","15420","CYYZDBDROVLTJU-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-2-3-4-9-5-7-10(11)8-6-9/h5-8,11H,2-4H2,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","GERIAFADWKOZEM-AKFOCJAPSA-N","InChI=1S/C16H22O7/c1-2-3-4-9-5-7-10(8-6-9)22-16-13(19)11(17)12(18)14(23-16)15(20)21/h5-8,11-14,16-19H,2-4H2,1H3,(H,20,21)/t11-,12-,13+,14-,16?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01944","Arbidol","131411","KCFYEAOKVJSACF-UHFFFAOYSA-N","InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","YWNDZUQXXCRSIJ-ZIWOYPDPSA-N","InChI=1S/C28H33BrN2O9S/c1-5-38-27(37)20-18(13-41-14-9-7-6-8-10-14)31(4)17-11-16(29)24(15(19(17)20)12-30(2)3)39-28-23(34)21(32)22(33)25(40-28)26(35)36/h6-11,21-23,25,28,32-34H,5,12-13H2,1-4H3,(H,35,36)/t21-,22-,23+,25-,28?/m0/s1","Yang, G. et al. (2017); Glucuronidation: driving factors and their impact on glucuronide disposition;  Drug Metab Rev. 2017 May;49(2):105-138. DOI:10.1080/03602532.2017.1293682; PMID:28266877"
"BIOTID01945","2,3-Dihydroxynaphthalene","7091","JRNGUTKWMSBIBF-UHFFFAOYSA-N","InChI=1S/C10H8O2/c11-9-5-7-3-1-2-4-8(7)6-10(9)12/h1-6,11-12H","COMT","O-methylation","Human Phase II","Human","NULL","599943","SJTNTIRIRIPZDV-UHFFFAOYSA-N","InChI=1S/C11H10O2/c1-13-11-7-9-5-3-2-4-8(9)6-10(11)12/h2-7,12H,1H3","Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation"
"BIOTID01946","3-Hydroxy-4-aminopyridine","2762419","DBDKLFOUWUHPDW-UHFFFAOYSA-N","InChI=1S/C5H6N2O/c6-4-1-2-7-3-5(4)8/h1-3,8H,(H2,6,7)","SULT","O-sulfonation","Human Phase II","Human","NULL","92043695","UHYGMFPQJLJNNE-UHFFFAOYSA-N","InChI=1S/C5H6N2O4S/c6-4-1-2-7-3-5(4)11-12(8,9)10/h1-3H,(H2,6,7)(H,8,9,10)","http://www.hmdb.ca/metabolites/HMDB0061120"
"BIOTID01947","Lorazepam","3958","DIWRORZWFLOCLC-UHFFFAOYSA-N","InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)","UGT","O-glucuronidation","Human Phase II","Human","NULL","62966","IWOJSSFCRQKNKN-IFBJMGMISA-N","InChI=1S/C21H18Cl2N2O8/c22-8-5-6-12-10(7-8)13(9-3-1-2-4-11(9)23)25-19(18(29)24-12)33-21-16(28)14(26)15(27)17(32-21)20(30)31/h1-7,14-17,19,21,26-28H,(H,24,29)(H,30,31)/t14-,15-,16+,17-,19?,21-/m0/s1","http://www.hmdb.ca/metabolites/HMDB0041917"
"BIOTID01948","Thyroxine","853","XUIIKFGFIJCVMT-UHFFFAOYSA-N","InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)","UGT","O-glucuronidation","Human Phase II","Human","NULL","152424","RGHRJBIKIYUHEV-SGPDEFQSSA-N","InChI=1S/C21H19I4NO10/c22-8-1-6(3-12(26)19(30)31)2-9(23)16(8)34-7-4-10(24)17(11(25)5-7)35-21-15(29)13(27)14(28)18(36-21)20(32)33/h1-2,4-5,12-15,18,21,27-29H,3,26H2,(H,30,31)(H,32,33)/t12-,13-,14-,15+,18-,21?/m0/s1","http://www.hmdb.ca/metabolites/HMDB0010326"
"BIOTID01949","fenchone metabo2","72544043","VTLIGYFZUGDYFX-UHFFFAOYSA-N","InChI=1S/C10H16O2/c1-9(2)6-4-5-10(3,7(6)11)8(9)12/h6-7,11H,4-5H2,1-3H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","HQALKTAKXYTNKL-BTARYMNBSA-N","InChI=1S/C16H24O8/c1-15(2)6-4-5-16(3,14(15)22)11(6)24-13-9(19)7(17)8(18)10(23-13)12(20)21/h6-11,13,17-19H,4-5H2,1-3H3,(H,20,21)/t6?,7-,8-,9+,10-,11?,13?,16?/m0/s1","From Jarleips validations"
"BIOTID01950","4-Phenylphenol","7103","YXVFYQXJAXKLAK-UHFFFAOYSA-N","InChI=1S/C12H10O/c13-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9,13H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","54264794","RFZQPUBFBMWPMZ-PDHYLSHYSA-N","InChI=1S/C18H18O7/c19-13-14(20)16(17(22)23)25-18(15(13)21)24-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9,13-16,18-21H,(H,22,23)/t13-,14-,15+,16-,18?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z||  http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/4/1/17.html"
"BIOTID01951","3p-OH-diclofenac","112230","HYPJZSYXUWYJDG-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c15-9-5-6-11(18)13(16)14(9)17-10-4-2-1-3-8(10)7-12(19)20/h1-6,17-18H,7H2,(H,19,20)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","ARGURFYRBZGESR-BCHVZBRRSA-N","InChI=1S/C20H19Cl2NO9/c21-9-5-6-11(31-20-17(28)15(26)16(27)18(32-20)19(29)30)13(22)14(9)23-10-4-2-1-3-8(10)7-12(24)25/h1-6,15-18,20,23,26-28H,7H2,(H,24,25)(H,29,30)/t15-,16-,17+,18-,20?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01952","3p-OH-diclofenac","112230","HYPJZSYXUWYJDG-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c15-9-5-6-11(18)13(16)14(9)17-10-4-2-1-3-8(10)7-12(19)20/h1-6,17-18H,7H2,(H,19,20)","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","OJTDRDPBNNTVRJ-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO6S/c15-9-5-6-11(23-24(20,21)22)13(16)14(9)17-10-4-2-1-3-8(10)7-12(18)19/h1-6,17H,7H2,(H,18,19)(H,20,21,22)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01953","Irinotecan","60838","UWKQSNNFCGGAFS-XIFFEERXSA-N","InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","APOPWJAIJPVPBQ-YJMKPTCOSA-N","InChI=1S/C39H46N4O12/c1-3-22-23-16-21(53-38(51)42-14-10-20(11-15-42)41-12-6-5-7-13-41)8-9-27(23)40-29-24(22)18-43-28(29)17-26-25(34(43)47)19-52-37(50)39(26,4-2)55-36-32(46)30(44)31(45)33(54-36)35(48)49/h8-9,16-17,20,30-33,36,44-46H,3-7,10-15,18-19H2,1-2H3,(H,48,49)/t30-,31-,32+,33-,36?,39-/m0/s1","Wu et al. 2011; First-pass metabolism via UDP-glucuronosyltransferase- a barrier to oral bioavailability of phenolics"
"BIOTID01954","Syringetin","5281953","UZMAPBJVXOGOFT-UHFFFAOYSA-N","InChI=1S/C17H14O8/c1-23-11-3-7(4-12(24-2)14(11)20)17-16(22)15(21)13-9(19)5-8(18)6-10(13)25-17/h3-6,18-20,22H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","CQWKAELUUGWHJF-FRMANSKWSA-N","InChI=1S/C23H22O14/c1-33-11-3-7(4-12(34-2)14(11)25)20-17(28)15(26)13-9(24)5-8(6-10(13)36-20)35-23-19(30)16(27)18(29)21(37-23)22(31)32/h3-6,16,18-19,21,23-25,27-30H,1-2H3,(H,31,32)/t16-,18-,19+,21-,23?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01955","Syringetin","5281953","UZMAPBJVXOGOFT-UHFFFAOYSA-N","InChI=1S/C17H14O8/c1-23-11-3-7(4-12(24-2)14(11)20)17-16(22)15(21)13-9(19)5-8(18)6-10(13)25-17/h3-6,18-20,22H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","DIWWVZPWHQBEMJ-GWQNJANKSA-N","InChI=1S/C23H22O14/c1-33-11-3-7(4-12(34-2)14(11)26)19-20(15(27)13-9(25)5-8(24)6-10(13)35-19)36-23-18(30)16(28)17(29)21(37-23)22(31)32/h3-6,16-18,21,23-26,28-30H,1-2H3,(H,31,32)/t16-,17-,18+,21-,23?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01956","6-Methoxyluteolin","5317284","FHHSEFRSDKWJKJ-UHFFFAOYSA-N","InChI=1S/C16H12O7/c1-22-16-11(20)6-13-14(15(16)21)10(19)5-12(23-13)7-2-3-8(17)9(18)4-7/h2-6,17-18,20-21H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","54375297","UWBKEKWTUMGDCN-ICNUUSJMSA-N","InChI=1S/C22H20O13/c1-32-19-13(34-22-18(29)16(27)17(28)20(35-22)21(30)31)6-12-14(15(19)26)10(25)5-11(33-12)7-2-3-8(23)9(24)4-7/h2-6,16-18,20,22-24,26-29H,1H3,(H,30,31)/t16-,17-,18+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01957","morphine","5288826","BQJCRHHNABKAKU-KBQPJGBKSA-N","InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","9847115","GNJCUHZOSOYIEC-FJUCOFCUSA-N","InChI=1S/C23H27NO9/c1-24-7-6-23-10-3-5-13(31-22-17(28)15(26)16(27)19(33-22)21(29)30)20(23)32-18-12(25)4-2-9(14(18)23)8-11(10)24/h2-5,10-11,13,15-17,19-20,22,25-28H,6-8H2,1H3,(H,29,30)/t10-,11+,13-,15-,16-,17+,19-,20-,22?,23-/m0/s1","Wu et al. 2011; First-pass metabolism via UDP-glucuronosyltransferase- a barrier to oral bioavailability of phenolics"
"BIOTID01958","morphine","5288826","BQJCRHHNABKAKU-KBQPJGBKSA-N","InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","18595497","WAEXKFONHRHFBZ-QMGRMYLDSA-N","InChI=1S/C23H27NO9/c1-24-7-6-23-10-3-4-12(25)20(23)32-18-13(5-2-9(14(18)23)8-11(10)24)31-22-17(28)15(26)16(27)19(33-22)21(29)30/h2-5,10-12,15-17,19-20,22,25-28H,6-8H2,1H3,(H,29,30)/t10-,11+,12-,15-,16-,17+,19-,20-,22?,23-/m0/s1","Wu et al. 2011; First-pass metabolism via UDP-glucuronosyltransferase- a barrier to oral bioavailability of phenolics"
"BIOTID01959","Chrysin","5281607","RTIXKCRFFJGDFG-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-8,16-17H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","IDRSJGHHZXBATQ-DAZJWRSOSA-N","InChI=1S/C21H18O10/c22-11-6-10(29-21-18(26)16(24)17(25)19(31-21)20(27)28)7-14-15(11)12(23)8-13(30-14)9-4-2-1-3-5-9/h1-8,16-19,21-22,24-26H,(H,27,28)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01960","Quinagolide","3086401","GDFGTRDCCWFXTG-ZIFCJYIRSA-N","InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","VJFXVUZYQUBQJM-UWCLXBPASA-N","InChI=1S/C26H41N3O9S/c1-4-10-28-14-17(27-39(35,36)29(5-2)6-3)11-16-12-18-15(13-19(16)28)8-7-9-20(18)37-26-23(32)21(30)22(31)24(38-26)25(33)34/h7-9,16-17,19,21-24,26-27,30-32H,4-6,10-14H2,1-3H3,(H,33,34)/t16-,17+,19-,21+,22+,23-,24+,26?/m1/s1","https://www.drugbank.ca/drugs/DB09097"
"BIOTID01961","4,5-Dihydrodrospirenone","NULL","QRLGYRXUXCWMCE-AAQOLUSRSA-N","InChI=1S/C24H34O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h12-18,20-21,25H,3-11H2,1-2H3/t12?,13-,14+,15-,16?,17?,18+,20?,21?,22-,23+,24?/m1/s1","SULT","O-sulfonation","Human Phase II","Human","NULL","131770037","ZHIWICDXDMTIEM-AAQOLUSRSA-N","InChI=1S/C24H34O5S/c1-22-6-3-12(30(26,27)28)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(25)29-24/h12-18,20-21H,3-11H2,1-2H3,(H,26,27,28)/t12?,13-,14+,15-,16?,17?,18+,20?,21?,22-,23+,24?/m1/s1","http://www.hmdb.ca/metabolites/HMDB0061126"
"BIOTID01962","fenchone metabo1","14080459","HUCDGRHTEUBMQF-UHFFFAOYSA-N","InChI=1S/C10H16O2/c1-9-4-3-7(5-9)10(2,6-11)8(9)12/h7,11H,3-6H2,1-2H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","WUUFOFXDXHAZSG-ZNYBNKCLSA-N","InChI=1S/C16H24O8/c1-15-4-3-7(5-15)16(2,14(15)22)6-23-13-10(19)8(17)9(18)11(24-13)12(20)21/h7-11,13,17-19H,3-6H2,1-2H3,(H,20,21)/t7?,8-,9-,10+,11-,13?,15?,16?/m0/s1","From Jarleips validations"
"BIOTID01963","7,3p,4p-Trihydroxyflavone","5322065","PVFGJHYLIHMCQD-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-2-3-10-12(18)7-14(20-15(10)6-9)8-1-4-11(17)13(19)5-8/h1-7,16-17,19H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","MSNBYHUUQKCKLR-DAZJWRSOSA-N","InChI=1S/C21H18O11/c22-11-4-1-8(5-13(11)24)14-7-12(23)10-3-2-9(6-15(10)31-14)30-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21-22,24-27H,(H,28,29)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01964","Caffeic Acid","689043","QAIPRVGONGVQAS-DUXPYHPUSA-N","InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","LTGOIJNQWZWJRF-DXCVSUPFSA-N","InChI=1S/C15H16O10/c16-7-5-6(2-4-9(17)18)1-3-8(7)24-15-12(21)10(19)11(20)13(25-15)14(22)23/h1-5,10-13,15-16,19-21H,(H,17,18)(H,22,23)/b4-2+/t10-,11-,12+,13-,15?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01965","Caffeic Acid","689043","QAIPRVGONGVQAS-DUXPYHPUSA-N","InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","BSOMSDFTZKNUHY-DXCVSUPFSA-N","InChI=1S/C15H16O10/c16-7-3-1-6(2-4-9(17)18)5-8(7)24-15-12(21)10(19)11(20)13(25-15)14(22)23/h1-5,10-13,15-16,19-21H,(H,17,18)(H,22,23)/b4-2+/t10-,11-,12+,13-,15?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01966","Daidzein","5281708","ZQSIJRDFPHDXIC-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","91117088","MMIBOZXVZLENRZ-DAZJWRSOSA-N","InChI=1S/C21H18O10/c22-10-3-1-9(2-4-10)13-8-29-14-7-11(5-6-12(14)15(13)23)30-21-18(26)16(24)17(25)19(31-21)20(27)28/h1-8,16-19,21-22,24-26H,(H,27,28)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01967","Lumiracoxib M23","9904747","LUNFHOZKXHTOLG-UHFFFAOYSA-N","InChI=1S/C15H13ClFNO3/c1-8-2-3-13(9(4-8)5-14(20)21)18-15-11(16)6-10(19)7-12(15)17/h2-4,6-7,18-19H,5H2,1H3,(H,20,21)","UGT","O-glucuronidation","Human Phase II","Human","Lumiracoxib M22","NULL","SEZLIFDZXOQYCW-DAZJWRSOSA-N","InChI=1S/C21H21ClFNO9/c1-8-2-3-13(24-15-11(22)6-10(25)7-12(15)23)9(4-8)5-14(26)32-21-18(29)16(27)17(28)19(33-21)20(30)31/h2-4,6-7,16-19,21,24-25,27-29H,5H2,1H3,(H,30,31)/t16-,17-,18+,19-,21?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01968","sulfamerazine","5325","QPPBRPIAZZHUNT-UHFFFAOYSA-N","InChI=1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)","NAT","N-acetylation","Human Phase II","Human","NULL","67181","PHFJZKMLXDFUNB-UHFFFAOYSA-N","InChI=1S/C13H14N4O3S/c1-9-7-8-14-13(15-9)17-21(19,20)12-5-3-11(4-6-12)16-10(2)18/h3-8H,1-2H3,(H,16,18)(H,14,15,17)","PMID:487121|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID01969","Dihyroxy-1H-indole","114683","SGNZYJXNUURYCH-UHFFFAOYSA-N","InChI=1S/C8H7NO2/c10-7-3-5-1-2-9-6(5)4-8(7)11/h1-4,9-11H","UGT","O-glucuronidation","Human Phase II","Human","NULL","124202061","IAHCDPVIVIKDFJ-DIACKHNESA-N","InChI=1S/C14H15NO8/c16-7-3-5-1-2-15-6(5)4-8(7)22-14-11(19)9(17)10(18)12(23-14)13(20)21/h1-4,9-12,14-19H,(H,20,21)/t9-,10-,11+,12-,14+/m1/s1","http://www.hmdb.ca/metabolites/HMDB0059997"
"BIOTID01970","5-OH-diclofenac","3052566","VNQURRWYKFZKJZ-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c15-10-2-1-3-11(16)14(10)17-12-5-4-9(18)6-8(12)7-13(19)20/h1-6,17-18H,7H2,(H,19,20)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","IDADOEOUYMZXRJ-BCHVZBRRSA-N","InChI=1S/C20H19Cl2NO9/c21-10-2-1-3-11(22)14(10)23-12-5-4-9(6-8(12)7-13(24)25)31-20-17(28)15(26)16(27)18(32-20)19(29)30/h1-6,15-18,20,23,26-28H,7H2,(H,24,25)(H,29,30)/t15-,16-,17+,18-,20?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01971","5-OH-diclofenac","3052566","VNQURRWYKFZKJZ-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO3/c15-10-2-1-3-11(16)14(10)17-12-5-4-9(18)6-8(12)7-13(19)20/h1-6,17-18H,7H2,(H,19,20)","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","INWWIJJNGBIMAN-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO6S/c15-10-2-1-3-11(16)14(10)17-12-5-4-9(23-24(20,21)22)6-8(12)7-13(18)19/h1-6,17H,7H2,(H,18,19)(H,20,21,22)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID01972","M23OH","130019492","VKRWZFFYDXRJLG-UHFFFAOYSA-N","InChI=1S/C10H14N4O/c1-2-3-4-7-5-9(11)14-10(13-7)8(15)6-12-14/h5-6,15H,2-4,11H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","NAPXVXNTXNDHFC-PACLMXLRSA-N","InChI=1S/C16H22N4O7/c1-2-3-4-7-5-9(17)20-14(19-7)8(6-18-20)26-16-12(23)10(21)11(22)13(27-16)15(24)25/h5-6,10-13,16,21-23H,2-4,17H2,1H3,(H,24,25)/t10-,11-,12+,13-,16?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01973","M23OH","130019492","VKRWZFFYDXRJLG-UHFFFAOYSA-N","InChI=1S/C10H14N4O/c1-2-3-4-7-5-9(11)14-10(13-7)8(15)6-12-14/h5-6,15H,2-4,11H2,1H3","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","LQIGRWPKNKBXFP-UHFFFAOYSA-N","InChI=1S/C10H14N4O4S/c1-2-3-4-7-5-9(11)14-10(13-7)8(6-12-14)18-19(15,16)17/h5-6H,2-4,11H2,1H3,(H,15,16,17)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01974","Fraxetin","5273569","HAVWRBANWNTOJX-UHFFFAOYSA-N","InChI=1S/C10H8O5/c1-14-6-4-5-2-3-7(11)15-10(5)9(13)8(6)12/h2-4,12-13H,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","ZHKAJLJMDJPZQR-JGHOESPPSA-N","InChI=1S/C16H16O11/c1-24-6-4-5-2-3-7(17)25-12(5)11(21)13(6)26-16-10(20)8(18)9(19)14(27-16)15(22)23/h2-4,8-10,14,16,18-21H,1H3,(H,22,23)/t8-,9-,10+,14-,16?/m0/s1","Yang, G. et al. (2017); Glucuronidation: driving factors and their impact on glucuronide disposition;  Drug Metab Rev. 2017 May;49(2):105-138. DOI:10.1080/03602532.2017.1293682; PMID:28266877"
"BIOTID01975","17-beta estradiol","5757","VOXZDWNPVJITMN-ZBRFXRBCSA-N","InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1","UGT1A1, UGT1A3","O-glucuronidation","Human Phase II","Human","NULL","13783824","MUOHJTRCBBDUOW-BFXFFQJBSA-N","InChI=1S/C24H32O8/c1-24-9-8-14-13-5-3-12(10-11(13)2-4-15(14)16(24)6-7-17(24)25)31-23-20(28)18(26)19(27)21(32-23)22(29)30/h3,5,10,14-21,23,25-28H,2,4,6-9H2,1H3,(H,29,30)/t14-,15-,16+,17+,18+,19+,20-,21+,23?,24+/m1/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID01976","3,2p-Dihydroxyflavone","455313","VECGDSZOFMYGAF-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-11-7-3-1-5-9(11)15-14(18)13(17)10-6-2-4-8-12(10)19-15/h1-8,16,18H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","XCANWUALMZNLCE-MBIBTLSJSA-N","InChI=1S/C21H18O10/c22-11-7-3-1-5-9(11)17-18(13(23)10-6-2-4-8-12(10)29-17)30-21-16(26)14(24)15(25)19(31-21)20(27)28/h1-8,14-16,19,21-22,24-26H,(H,27,28)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01977","Dexmedetomidine","5311068","CUHVIMMYOGQXCV-NSHDSACASA-N","InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1","UGT2B20; UGT1A4","O-glucuronidation","Human Phase II","Human","NULL","NULL","FREYOLUEFLYXMW-FJMDGSOVSA-O","InChI=1S/C19H24N2O6/c1-9-5-4-6-12(10(9)2)11(3)13-7-21(8-20-13)18-16(24)14(22)15(23)17(27-18)19(25)26/h4-8,11,14-18,22-24H,1-3H3,(H,25,26)/p+1/t11-,14-,15-,16+,17-,18?/m0/s1","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01978","Dexmedetomidine","5311068","CUHVIMMYOGQXCV-NSHDSACASA-N","InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1","UGT2B20; UGT1A4","O-glucuronidation","Human Phase II","Human","NULL","NULL","WITSQVDDNFJZMV-FJMDGSOVSA-N","InChI=1S/C19H24N2O6/c1-9-5-4-6-12(10(9)2)11(3)13-7-20-8-21(13)18-16(24)14(22)15(23)17(27-18)19(25)26/h4-8,11,14-18,22-24H,1-3H3,(H,25,26)/t11-,14-,15-,16+,17-,18?/m0/s1","Kaivosaari, S. et al. (2011); N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.; Xenobiotica. 2011 Aug;41(8):652-69. DOI:10.3109/00498254.2011.563327"
"BIOTID01979","4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol","104856","OGRXKBUCZFFSTL-UHFFFAOYSA-N","InChI=1S/C10H15N3O2/c1-13(12-15)7-3-5-10(14)9-4-2-6-11-8-9/h2,4,6,8,10,14H,3,5,7H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","53297451","VSVYJUYJFLYYSI-UKOUFMKDSA-O","InChI=1S/C16H23N3O8/c1-18(17-26)6-3-5-10(20)9-4-2-7-19(8-9)15-13(23)11(21)12(22)14(27-15)16(24)25/h2,4,7-8,10-15,20-23H,3,5-6H2,1H3/p+1/t10?,11-,12-,13+,14-,15+/m0/s1","PMID:11408353;  PMID:17638922;  PMID:14709623;  http://www.hmdb.ca/metabolites/HMDB0060498"
"BIOTID01980","Ferulic Acid","445858","KSEBMYQBYZTDHS-HWKANZROSA-N","InChI=1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","TWSIWBHKRJLZCF-AURBXFGWSA-N","InChI=1S/C16H18O10/c1-24-9-6-7(3-5-10(17)18)2-4-8(9)25-16-13(21)11(19)12(20)14(26-16)15(22)23/h2-6,11-14,16,19-21H,1H3,(H,17,18)(H,22,23)/b5-3+/t11-,12-,13+,14-,16?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01981","Ethyl-4-hydroxybenzoate","8434","NUVBSKCKDOMJSU-UHFFFAOYSA-N","InChI=1S/C9H10O3/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6,10H,2H2,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","LZYNMJNOTCVYBQ-VDQYPUQXSA-N","InChI=1S/C15H18O9/c1-2-22-14(21)7-3-5-8(6-4-7)23-15-11(18)9(16)10(17)12(24-15)13(19)20/h3-6,9-12,15-18H,2H2,1H3,(H,19,20)/t9-,10-,11+,12-,15?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01983","3-Hydroxy-5-methoxyflavone","688675","WHLQVYWQNZFUPW-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-11-8-5-9-12-13(11)14(17)15(18)16(20-12)10-6-3-2-4-7-10/h2-9,18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","UQTKNLNNVVKVSC-XTLXVGOWSA-N","InChI=1S/C22H20O10/c1-29-11-8-5-9-12-13(11)14(23)19(18(30-12)10-6-3-2-4-7-10)31-22-17(26)15(24)16(25)20(32-22)21(27)28/h2-9,15-17,20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01984","3-Hydroxy-4p-methoxyflavone","97141","IIBBFGMVMNZMGA-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-11-8-6-10(7-9-11)16-15(18)14(17)12-4-2-3-5-13(12)20-16/h2-9,18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","PPCBELYSDXAMFR-XTLXVGOWSA-N","InChI=1S/C22H20O10/c1-29-11-8-6-10(7-9-11)18-19(14(23)12-4-2-3-5-13(12)30-18)31-22-17(26)15(24)16(25)20(32-22)21(27)28/h2-9,15-17,20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01985","4-OH-propofol","3014064","UFWIJKBKROBWTG-UHFFFAOYSA-N","InChI=1S/C12H18O2/c1-7(2)10-5-9(13)6-11(8(3)4)12(10)14/h5-8,13-14H,1-4H3","UGT1A8, UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","101649831","OCSNDZGMSQTRGL-ODEDACCXSA-N","InChI=1S/C18H26O8/c1-7(2)10-5-9(19)6-11(8(3)4)15(10)25-18-14(22)12(20)13(21)16(26-18)17(23)24/h5-8,12-14,16,18-22H,1-4H3,(H,23,24)/t12-,13-,14+,16-,18?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01986","4-OH-propofol","3014064","UFWIJKBKROBWTG-UHFFFAOYSA-N","InChI=1S/C12H18O2/c1-7(2)10-5-9(13)6-11(8(3)4)12(10)14/h5-8,13-14H,1-4H3","SULT","O-sulfonation","Human Phase II","Human","NULL","10446031","RKAQPQOYAJQIAA-UHFFFAOYSA-N","InChI=1S/C12H18O5S/c1-7(2)10-5-9(17-18(14,15)16)6-11(8(3)4)12(10)13/h5-8,13H,1-4H3,(H,14,15,16)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01987","Aflatoxin B1 exo 8,9-epoxide","14189358","KHBXRZGALJGBPA-UHFFFAOYSA-N","InChI=1S/C17H12O7/c1-20-7-4-8-11(12-14-17(23-14)24-16(12)21-8)13-10(7)5-2-3-6(18)9(5)15(19)22-13/h4,12,14,16-17H,2-3H2,1H3","GST1A1; GST1A2; GSTM1; GSTM3; GSTP1","GSH-conjugation","Human Phase II","Human","NULL","NULL","LYDBAPNRLUDIAS-YFCNOFAQSA-N","InChI=1S/C27H29N3O13S/c1-40-13-6-14-19(22-18(13)9-2-4-12(31)17(9)25(39)42-22)20-21(35)27(43-26(20)41-14)44-8-11(23(36)29-7-16(33)34)30-15(32)5-3-10(28)24(37)38/h6,10-11,20-21,26-27,35H,2-5,7-8,28H2,1H3,(H,29,36)(H,30,32)(H,33,34)(H,37,38)/t10-,11-,20?,21?,26?,27?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID01988","Gypsogenin","4483446","QMHCWDVPABYZMC-UHFFFAOYSA-N","InChI=1S/C30H46O4/c1-25(2)13-15-30(24(33)34)16-14-28(5)19(20(30)17-25)7-8-22-26(3)11-10-23(32)27(4,18-31)21(26)9-12-29(22,28)6/h7,18,20-23,32H,8-17H2,1-6H3,(H,33,34)","UGT","O-glucuronidation","Human Phase II","Human","NULL","13919536","NUSHOJSYOLRGAX-UHFFFAOYSA-N","InChI=1S/C36H54O10/c1-31(2)13-15-36(30(43)44)16-14-34(5)19(20(36)17-31)7-8-22-32(3)11-10-23(33(4,18-37)21(32)9-12-35(22,34)6)45-29-26(40)24(38)25(39)27(46-29)28(41)42/h7,18,20-27,29,38-40H,8-17H2,1-6H3,(H,41,42)(H,43,44)","http://www.hmdb.ca/metabolites/HMDB0034520"
"BIOTID01989","p-Toluidine","7813","RZXMPPFPUUCRFN-UHFFFAOYSA-N","InChI=1S/C7H9N/c1-6-2-4-7(8)5-3-6/h2-5H,8H2,1H3","NAT","N-acetylation","Human Phase II","Human","NULL","7684","YICAMJWHIUMFDI-UHFFFAOYSA-N","InChI=1S/C9H11NO/c1-7-3-5-9(6-4-7)10-8(2)11/h3-6H,1-2H3,(H,10,11)","Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation"
"BIOTID01990","Geraldol","5482101","WRFQRUBJBPLPAM-UHFFFAOYSA-N","InChI=1S/C16H12O6/c1-21-13-6-8(2-5-11(13)18)16-15(20)14(19)10-4-3-9(17)7-12(10)22-16/h2-7,17-18,20H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","IEYYAUPNGATRNW-XTLXVGOWSA-N","InChI=1S/C22H20O12/c1-31-13-6-8(2-5-11(13)24)18-19(14(25)10-4-3-9(23)7-12(10)32-18)33-22-17(28)15(26)16(27)20(34-22)21(29)30/h2-7,15-17,20,22-24,26-28H,1H3,(H,29,30)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01991","3-Hydroxyflavone","11349","HVQAJTFOCKOKIN-UHFFFAOYSA-N","InChI=1S/C15H10O3/c16-13-11-8-4-5-9-12(11)18-15(14(13)17)10-6-2-1-3-7-10/h1-9,17H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","66808570","VEKBKNOLQIUOFC-MBIBTLSJSA-N","InChI=1S/C21H18O9/c22-13-11-8-4-5-9-12(11)28-17(10-6-2-1-3-7-10)18(13)29-21-16(25)14(23)15(24)19(30-21)20(26)27/h1-9,14-16,19,21,23-25H,(H,26,27)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z|Yang, G. et al. (2017); Glucuronidation: driving factors and their impact on glucuronide disposition;  Drug Metab Rev. 2017 May;49(2):105-138. DOI:10.1080/03602532.2017.1293682; PMID:28266877"
"BIOTID01992","Myricetin","5281672","IKMDFBPHZNJCSN-UHFFFAOYSA-N","InChI=1S/C15H10O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,16-20,22H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","14058645","MBWOCQLTCWTIJE-MBIBTLSJSA-N","InChI=1S/C21H18O14/c22-6-3-7(23)11-10(4-6)33-17(5-1-8(24)12(26)9(25)2-5)18(13(11)27)34-21-16(30)14(28)15(29)19(35-21)20(31)32/h1-4,14-16,19,21-26,28-30H,(H,31,32)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01993","4-Methylphenol","2879","IWDCLRJOBJJRNH-UHFFFAOYSA-N","InChI=1S/C7H8O/c1-6-2-4-7(8)5-3-6/h2-5,8H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","66849195","JPAUCQAJHLSMQW-NJMOVEGISA-N","InChI=1S/C13H16O7/c1-6-2-4-7(5-3-6)19-13-10(16)8(14)9(15)11(20-13)12(17)18/h2-5,8-11,13-16H,1H3,(H,17,18)/t8-,9-,10+,11-,13?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01994","abiraterone","132971","GZOSMCIZMLWJML-VJLLXTKPSA-N","InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1","SULT","O-sulfonation","Human Phase II","Human","abiraterone sulfate","71312701","LUQSJWRTYLGZJB-ZHVNYGEGSA-N","InChI=1S/C24H31NO4S/c1-23-11-9-18(29-30(26,27)28)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22H,6,8-12,14H2,1-2H3,(H,26,27,28)/t18?,19-,21-,22-,23-,24+/m0/s1","https://www.drugbank.ca/metabolites/DBMET00788"
"BIOTID01995","Biochanin A","52941012","CQQVMFDJEHVCOW-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-13-8-7-11-14(17)12(9-20-16(11)15(13)18)10-5-3-2-4-6-10/h2-9,18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","FELLBQGDKVLDHZ-XTLXVGOWSA-N","InChI=1S/C22H20O10/c1-29-13-8-7-11-14(23)12(10-5-3-2-4-6-10)9-30-18(11)19(13)31-22-17(26)15(24)16(25)20(32-22)21(27)28/h2-9,15-17,20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01996","Datiscetin","5281610","WCNLFPKXBGWWDS-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-7-5-10(18)12-11(6-7)21-15(14(20)13(12)19)8-3-1-2-4-9(8)17/h1-6,16-18,20H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","ZMPNWZBVVZGGOK-MBIBTLSJSA-N","InChI=1S/C21H18O12/c22-7-5-10(24)12-11(6-7)31-17(8-3-1-2-4-9(8)23)18(13(12)25)32-21-16(28)14(26)15(27)19(33-21)20(29)30/h1-6,14-16,19,21-24,26-28H,(H,29,30)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01997","3,7,3p-Trihydroxyflavone","5393165","PSGKFXVPVUNGDT-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-2-8(6-9)15-14(19)13(18)11-5-4-10(17)7-12(11)20-15/h1-7,16-17,19H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","ISGQTBOKFBDQPU-MBIBTLSJSA-N","InChI=1S/C21H18O11/c22-9-3-1-2-8(6-9)17-18(13(24)11-5-4-10(23)7-12(11)30-17)31-21-16(27)14(25)15(26)19(32-21)20(28)29/h1-7,14-16,19,21-23,25-27H,(H,28,29)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID01998","Limonen-10-ol","10819","NDTYTMIUWGWIMO-UHFFFAOYSA-N","InChI=1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","USSVDYQHMLZFBY-SHIOMWLHSA-N","InChI=1S/C16H24O7/c1-8(2)10-5-3-9(4-6-10)7-22-16-13(19)11(17)12(18)14(23-16)15(20)21/h3,10-14,16-19H,1,4-7H2,2H3,(H,20,21)/t10?,11-,12-,13+,14-,16?/m0/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID01999","Nirvanol (N-demethylmephenytoin","173835","LZFIVJCLUUNXKT-UHFFFAOYSA-N","InChI=1S/C11H12N2O3/c1-2-11(9(15)12-10(16)13-11)7-3-5-8(14)6-4-7/h3-6,14H,2H2,1H3,(H2,12,13,15,16)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","UXNQYGATIZUCQK-NSOBYCPISA-N","InChI=1S/C17H20N2O9/c1-2-17(7-3-5-8(20)6-4-7)15(26)19(16(27)18-17)13-11(23)9(21)10(22)12(28-13)14(24)25/h3-6,9-13,20-23H,2H2,1H3,(H,18,27)(H,24,25)/t9-,10-,11+,12-,13?,17?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02000","Galangin","5281616","VCCRNZQBSJXYJD-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","RNIDRAZXQJUZTQ-WQUGZTNDSA-N","InChI=1S/C21H18O11/c22-10-6-9(30-21-17(27)14(24)16(26)19(32-21)20(28)29)7-11-12(10)13(23)15(25)18(31-11)8-4-2-1-3-5-8/h1-7,14,16-17,19,21-22,24-27H,(H,28,29)/t14-,16-,17+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02001","Galangin","5281616","VCCRNZQBSJXYJD-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","AHSXTKYJDFBHFC-MBIBTLSJSA-N","InChI=1S/C21H18O11/c22-9-6-10(23)12-11(7-9)30-17(8-4-2-1-3-5-8)18(13(12)24)31-21-16(27)14(25)15(26)19(32-21)20(28)29/h1-7,14-16,19,21-23,25-27H,(H,28,29)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02002","7-Hydroxy-4p-methoxyflavone","5320693","SQVXWIUVAILQRH-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)15-9-14(18)13-7-4-11(17)8-16(13)20-15/h2-9,17H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","KDULJPKZESDTFK-QAKXDBDYSA-N","InChI=1S/C22H20O10/c1-29-11-4-2-10(3-5-11)15-9-14(23)13-7-6-12(8-16(13)31-15)30-22-19(26)17(24)18(25)20(32-22)21(27)28/h2-9,17-20,22,24-26H,1H3,(H,27,28)/t17-,18-,19+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02003","3-Hydroxy-3p-methoxyflavone","676296","GYLGASXCHFNKHD-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-11-6-4-5-10(9-11)16-15(18)14(17)12-7-2-3-8-13(12)20-16/h2-9,18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","PPNVNENSEFLUSY-XTLXVGOWSA-N","InChI=1S/C22H20O10/c1-29-11-6-4-5-10(9-11)18-19(14(23)12-7-2-3-8-13(12)30-18)31-22-17(26)15(24)16(25)20(32-22)21(27)28/h2-9,15-17,20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02004","1-iodomethane","6328","INQOMBQAUSQDDS-UHFFFAOYSA-N","InChI=1S/CH3I/c1-2/h1H3","GST","GSH-conjugation of organohalide","Human Phase II","Human","methylglutathione","134692079","QTQDDTSVRVWHMO-BQBZGAKWSA-N","InChI=1S/C11H19N3O6S/c1-21-5-7(10(18)13-4-9(16)17)14-8(15)3-2-6(12)11(19)20/h6-7H,2-5,12H2,1H3,(H,13,18)(H,14,15)(H,16,17)(H,19,20)/t6-,7-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID02005","Zileuton","60490","MWLSOWXNZPKENC-UHFFFAOYSA-N","InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)","UDP-glucuronosyltransferase 1-9","N-hydroxy glucuronidation","Human Phase II","Human","Zileuton O-glucuronide","71752997","CYYKQHWQVGZJRJ-UPZRFPAJSA-N","InChI=1S/C17H20N2O8S/c1-7(10-6-8-4-2-3-5-9(8)28-10)19(17(18)25)27-16-13(22)11(20)12(21)14(26-16)15(23)24/h2-7,11-14,16,20-22H,1H3,(H2,18,25)(H,23,24)/t7?,11-,12-,13+,14-,16-/m0/s1","https://www.drugbank.ca/metabolites/DBMET00141"
"BIOTID02006","cis-Dibromochrysanthemic acid","181248","MDIQXIJPQWLFSD-UHFFFAOYSA-N","InChI=1S/C8H10Br2O2/c1-8(2)4(3-5(9)10)6(8)7(11)12/h3-4,6H,1-2H3,(H,11,12)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","STYWOSKAMYSBSP-VVRSNZIZSA-N","InChI=1S/C14H18Br2O8/c1-14(2)4(3-5(15)16)6(14)12(22)24-13-9(19)7(17)8(18)10(23-13)11(20)21/h3-4,6-10,13,17-19H,1-2H3,(H,20,21)/t4?,6?,7-,8-,9+,10-,13?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02007","N-Acetyl-5-HT","903","MVAWJSIDNICKHF-UHFFFAOYSA-N","InChI=1S/C12H14N2O2/c1-8(15)13-5-4-9-7-14-12-3-2-10(16)6-11(9)12/h2-3,6-7,14,16H,4-5H2,1H3,(H,13,15)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","DRKQFNYKSNWOTC-PDHYLSHYSA-N","InChI=1S/C18H22N2O8/c1-8(21)19-5-4-9-7-20-12-3-2-10(6-11(9)12)27-18-15(24)13(22)14(23)16(28-18)17(25)26/h2-3,6-7,13-16,18,20,22-24H,4-5H2,1H3,(H,19,21)(H,25,26)/t13-,14-,15+,16-,18?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02008","N-Acetyl-5-HT","903","MVAWJSIDNICKHF-UHFFFAOYSA-N","InChI=1S/C12H14N2O2/c1-8(15)13-5-4-9-7-14-12-3-2-10(16)6-11(9)12/h2-3,6-7,14,16H,4-5H2,1H3,(H,13,15)","SULT","O-sulfonation","Human Phase II","Human","NULL","45479248","UCAJZNVFRVLULS-UHFFFAOYSA-N","InChI=1S/C12H14N2O5S/c1-8(15)13-5-4-9-7-14-12-3-2-10(6-11(9)12)19-20(16,17)18/h2-3,6-7,14H,4-5H2,1H3,(H,13,15)(H,16,17,18)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02009","4-Cyclopentylphenol","15202","SNBKPVVDUBFDEJ-UHFFFAOYSA-N","InChI=1S/C11H14O/c12-11-7-5-10(6-8-11)9-3-1-2-4-9/h5-9,12H,1-4H2","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","FJPKOQCTXQDVAM-JSMXJDTGSA-N","InChI=1S/C17H22O7/c18-12-13(19)15(16(21)22)24-17(14(12)20)23-11-7-5-10(6-8-11)9-3-1-2-4-9/h5-9,12-15,17-20H,1-4H2,(H,21,22)/t12-,13-,14+,15-,17?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02010","2-Methoxy-estradiol-17beta","66414","CQOQDQWUFQDJMK-SSTWWWIQSA-N","InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","443076","LLCPFVIBUZJITJ-GVEMAFOVSA-N","InChI=1S/C25H34O9/c1-25-8-7-12-13(15(25)5-6-18(25)26)4-3-11-9-17(16(32-2)10-14(11)12)33-24-21(29)19(27)20(28)22(34-24)23(30)31/h9-10,12-13,15,18-22,24,26-29H,3-8H2,1-2H3,(H,30,31)/t12-,13+,15-,18-,19-,20-,21+,22-,24+,25-/m0/s1","http://www.hmdb.ca/metabolites/HMDB0006765"
"BIOTID02011","5-Hydroxy, 6-methoxy duloxetine","NULL","DVRXANQWPAEONA-UHFFFAOYSA-N","InChI=1S/C19H21NO4/c1-20-11-10-17(16-7-4-12-23-16)24-15-6-3-5-14-13(15)8-9-18(22-2)19(14)21/h3-9,12,17,20-21H,10-11H2,1-2H3","SULT","O-sulfonation","Human Phase II","Human","NULL","131770039","BIOIJFFUDCEYJH-UHFFFAOYSA-N","InChI=1S/C19H21NO7S/c1-20-11-10-17(16-7-4-12-25-16)26-15-6-3-5-14-13(15)8-9-18(24-2)19(14)27-28(21,22)23/h3-9,12,17,20H,10-11H2,1-2H3,(H,21,22,23)","http://www.hmdb.ca/metabolites/HMDB0061128"
"BIOTID02012","4-Bromophenol","7808","GZFGOTFRPZRKDS-UHFFFAOYSA-N","InChI=1S/C6H5BrO/c7-5-1-3-6(8)4-2-5/h1-4,8H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","JXGQMTXMLLENJP-SDQGTYQYSA-N","InChI=1S/C12H13BrO7/c13-5-1-3-6(4-2-5)19-12-9(16)7(14)8(15)10(20-12)11(17)18/h1-4,7-10,12,14-16H,(H,17,18)/t7-,8-,9+,10-,12?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02013","Hydromorphone","5284570","WVLOADHCBXTIJK-YNHQPCIGSA-N","InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1","UGT","Aromatic -OH glucuronidation","Human Phase II","Human","Hydromorphone 3-beta-O-glucuronide","131769997","VLSHIBYUEOPPRX-BITROGNRSA-N","InChI=1S/C23H27NO9/c1-24-7-6-23-10-3-4-12(25)20(23)32-18-13(5-2-9(14(18)23)8-11(10)24)31-22-17(28)15(26)16(27)19(33-22)21(29)30/h2,5,10-11,15-17,19-20,22,26-28H,3-4,6-8H2,1H3,(H,29,30)/t10-,11+,15+,16+,17-,19+,20-,22+,23-/m1/s1","https://www.drugbank.ca/metabolites/DBMET00180"
"BIOTID02014","Hydromorphone","5284570","WVLOADHCBXTIJK-YNHQPCIGSA-N","InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1","SULT","O-sulfonation","Human Phase II","Human","Hydromorphone 3-sulfate","46781713","XXRHORKOBJFKDL-YNHQPCIGSA-N","InChI=1S/C17H19NO6S/c1-18-7-6-17-10-3-4-12(19)16(17)23-15-13(24-25(20,21)22)5-2-9(14(15)17)8-11(10)18/h2,5,10-11,16H,3-4,6-8H2,1H3,(H,20,21,22)/t10-,11+,16-,17-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02015","Licofelone","133021","UAWXGRJVZSAUSZ-UHFFFAOYSA-N","InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","WHKFJCYVPLCOGR-TXZJZKILSA-N","InChI=1S/C29H30ClNO8/c1-29(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(30)11-9-16)18(31(19)14-29)12-20(32)38-28-25(35)23(33)24(34)26(39-28)27(36)37/h3-11,23-26,28,33-35H,12-14H2,1-2H3,(H,36,37)/t23-,24-,25+,26-,28?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675.|http://www.hmdb.ca/metabolites/HMDB0061130"
"BIOTID02016","4-Phenylazophenol","15529","BEYOBVMPDRKTNR-BUHFOSPRSA-N","InChI=1S/C12H10N2O/c15-12-8-6-11(7-9-12)14-13-10-4-2-1-3-5-10/h1-9,15H/b14-13+","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","XDYRXDLTQRIZHD-WUYLDYEISA-N","InChI=1S/C18H18N2O7/c21-13-14(22)16(17(24)25)27-18(15(13)23)26-12-8-6-11(7-9-12)20-19-10-4-2-1-3-5-10/h1-9,13-16,18,21-23H,(H,24,25)/b20-19+/t13-,14-,15+,16-,18?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02017","4-Nitrososulfamethoxazole","125483","GHNQGDUYHCZZPT-UHFFFAOYSA-N","InChI=1S/C10H9N3O4S/c1-7-6-10(12-17-7)13-18(15,16)9-4-2-8(11-14)3-5-9/h2-6H,1H3,(H,12,13)","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","LKYJVYRLFKCEQX-GJZGRUSLSA-N","InChI=1S/C20H26N6O10S2/c1-11-8-16(24-36-11)25-38(34,35)13-4-2-12(3-5-13)26(33)37-10-15(19(30)22-9-18(28)29)23-17(27)7-6-14(21)20(31)32/h2-5,8,14-15,26H,6-7,9-10,21H2,1H3,(H,22,30)(H,23,27)(H,24,25)(H,28,29)(H,31,32)/t14-,15-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02018","2-Hydroxymethyatomoxetine","9881925","FYSYNTKLUNOCQR-QGZVFWFLSA-N","InChI=1S/C17H21NO2/c1-18-12-11-17(14-7-3-2-4-8-14)20-16-10-6-5-9-15(16)13-19/h2-10,17-19H,11-13H2,1H3/t17-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","JTFZJNBQBJLYRG-RBEFBJKVSA-N","InChI=1S/C23H29NO8/c1-24-12-11-17(14-7-3-2-4-8-14)31-16-10-6-5-9-15(16)13-30-23-20(27)18(25)19(26)21(32-23)22(28)29/h2-10,17-21,23-27H,11-13H2,1H3,(H,28,29)/t17-,18+,19+,20-,21+,23?/m1/s1","https://www.pharmgkb.org/pathway/PA166160830"
"BIOTID02019","1-iodopentane","12335","BLXSFCHWMBESKV-UHFFFAOYSA-N","InChI=1S/C5H11I/c1-2-3-4-5-6/h2-5H2,1H3","GST","GSH-conjugation","Human Phase II","Human","pentyl-glutathione","57376159","AIOKZAFWWVBSMY-QWRGUYRKSA-N","InChI=1S/C15H27N3O6S/c1-2-3-4-7-25-9-11(14(22)17-8-13(20)21)18-12(19)6-5-10(16)15(23)24/h10-11H,2-9,16H2,1H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)/t10-,11-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID02020","O-Desmethyl-tramado","130829","UWJUQVWARXYRCG-UHFFFAOYSA-N","InChI=1S/C15H23NO2/c1-16(2)11-13-6-3-4-9-15(13,18)12-7-5-8-14(17)10-12/h5,7-8,10,13,17-18H,3-4,6,9,11H2,1-2H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","29919005","DSBGQRZOJXSECT-VZFNFROLSA-N","InChI=1S/C21H31NO8/c1-22(2)11-13-6-3-4-9-21(13,28)12-7-5-8-14(10-12)29-20-17(25)15(23)16(24)18(30-20)19(26)27/h5,7-8,10,13,15-18,20,23-25,28H,3-4,6,9,11H2,1-2H3,(H,26,27)/t13-,15+,16+,17-,18+,20-,21+/m1/s1","http://www.hmdb.ca/metabolites/HMDB0060856"
"BIOTID02021","4-Hydroxyandrostenedione","44287448","OSVMTWJCGUFAOD-FWMAMRLESA-N","InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11?,12?,13?,18-,19+/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","128210","JIKFCHILHFFTSH-NRIFOQJISA-N","InChI=1S/C25H34O9/c1-24-10-8-15(26)20(33-23-19(30)17(28)18(29)21(34-23)22(31)32)14(24)4-3-11-12-5-6-16(27)25(12,2)9-7-13(11)24/h11-13,17-19,21,23,28-30H,3-10H2,1-2H3,(H,31,32)/t11?,12?,13?,17-,18-,19+,21-,23+,24+,25-/m0/s1","http://www.hmdb.ca/metabolites/HMDB0010315"
"BIOTID02022","7-Hydroxy-6-methoxyisoflavone","21676187","GQVNHXNTSMARSK-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-15-7-11-14(8-13(15)17)20-9-12(16(11)18)10-5-3-2-4-6-10/h2-9,17H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","OCPRWOGVEWQIOO-QAKXDBDYSA-N","InChI=1S/C22H20O10/c1-29-14-7-11-13(30-9-12(16(11)23)10-5-3-2-4-6-10)8-15(14)31-22-19(26)17(24)18(25)20(32-22)21(27)28/h2-9,17-20,22,24-26H,1H3,(H,27,28)/t17-,18-,19+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02023","OT-7100 M5","19709702","WMLBPFXDYDINND-UHFFFAOYSA-N","InChI=1S/C10H14N4/c1-2-3-4-8-7-9(11)14-10(13-8)5-6-12-14/h5-7H,2-4,11H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","XXAPJWZTOWUCJN-OFBDQPAMSA-N","InChI=1S/C16H22N4O6/c1-2-3-4-8-7-10(20-9(18-8)5-6-17-20)19-15-13(23)11(21)12(22)14(26-15)16(24)25/h5-7,11-15,19,21-23H,2-4H2,1H3,(H,24,25)/t11-,12-,13+,14-,15?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02024","OT-7100 M5","19709702","WMLBPFXDYDINND-UHFFFAOYSA-N","InChI=1S/C10H14N4/c1-2-3-4-8-7-9(11)14-10(13-8)5-6-12-14/h5-7H,2-4,11H2,1H3","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","YCEGAALFECPYAS-UHFFFAOYSA-N","InChI=1S/C10H14N4O3S/c1-2-3-4-8-7-10(13-18(15,16)17)14-9(12-8)5-6-11-14/h5-7,13H,2-4H2,1H3,(H,15,16,17)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02025","Erlotinib M18","18925065","PKUSDEYOSFKCTN-UHFFFAOYSA-N","InChI=1S/C19H17N3O3/c1-3-13-5-4-6-14(9-13)22-19-15-10-17(23)18(25-8-7-24-2)11-16(15)20-12-21-19/h1,4-6,9-12,23H,7-8H2,2H3,(H,20,21,22)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","ZJUVNHXXORUWLK-PZYOUWLLSA-N","InChI=1S/C25H25N3O9/c1-3-13-5-4-6-14(9-13)28-23-15-10-18(17(35-8-7-34-2)11-16(15)26-12-27-23)36-25-21(31)19(29)20(30)22(37-25)24(32)33/h1,4-6,9-12,19-22,25,29-31H,7-8H2,2H3,(H,32,33)(H,26,27,28)/t19-,20-,21+,22-,25?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02026","zaltoprofen","5720","MUXFZBHBYYYLTH-UHFFFAOYSA-N","InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","NHCMHNHENGNTQQ-XZOWDJSYSA-N","InChI=1S/C23H22O9S/c1-10(22(30)32-23-19(27)17(25)18(26)20(31-23)21(28)29)11-6-7-15-12(8-11)9-14(24)13-4-2-3-5-16(13)33-15/h2-8,10,17-20,23,25-27H,9H2,1H3,(H,28,29)/t10?,17-,18-,19+,20-,23?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02027","4p-OH-triamterene","71046","QNJVMSASTUDLGC-UHFFFAOYSA-N","InChI=1S/C12H11N7O/c13-9-7(5-1-3-6(20)4-2-5)16-8-10(14)18-12(15)19-11(8)17-9/h1-4,20H,(H6,13,14,15,17,18,19)","SULT","O-sulfonation","Human Phase II","Human","NULL","162951","UGLZTFAGJYBEIZ-UHFFFAOYSA-N","InChI=1S/C12H11N7O4S/c13-9-7(5-1-3-6(4-2-5)23-24(20,21)22)16-8-10(14)18-12(15)19-11(8)17-9/h1-4H,(H,20,21,22)(H6,13,14,15,17,18,19)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02028","4-Ethoxyphenol","12150","LKVFCSWBKOVHAH-UHFFFAOYSA-N","InChI=1S/C8H10O2/c1-2-10-8-5-3-7(9)4-6-8/h3-6,9H,2H2,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","PHYRKQMERRGUEK-ZAOAHOKWSA-N","InChI=1S/C14H18O8/c1-2-20-7-3-5-8(6-4-7)21-14-11(17)9(15)10(16)12(22-14)13(18)19/h3-6,9-12,14-17H,2H2,1H3,(H,18,19)/t9-,10-,11+,12-,14?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02029","4-Hydroxyduloxetine","29981497","DRRXQCXSBONKPD-KRWDZBQOSA-N","InChI=1S/C18H19NO2S/c1-19-11-10-17(18-7-4-12-22-18)21-16-9-8-15(20)13-5-2-3-6-14(13)16/h2-9,12,17,19-20H,10-11H2,1H3/t17-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","29981513","OBIZFSZXDHWUJZ-ANUWOGMRSA-N","InChI=1S/C24H27NO8S/c1-25-11-10-17(18-7-4-12-34-18)31-15-8-9-16(14-6-3-2-5-13(14)15)32-24-21(28)19(26)20(27)22(33-24)23(29)30/h2-9,12,17,19-22,24-28H,10-11H2,1H3,(H,29,30)/t17-,19-,20-,21+,22-,24+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060763"
"BIOTID02030","Pterostilbene","5281727","VLEUZFDZJKSGMX-ONEGZZNKSA-N","InChI=1S/C16H16O3/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11,17H,1-2H3/b4-3+","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","QMAWHLGOYBNGRJ-GWOGNAIMSA-N","InChI=1S/C22H24O9/c1-28-15-9-13(10-16(11-15)29-2)4-3-12-5-7-14(8-6-12)30-22-19(25)17(23)18(24)20(31-22)21(26)27/h3-11,17-20,22-25H,1-2H3,(H,26,27)/b4-3+/t17-,18-,19+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02031","6-OH-harmaline","5280952","SATMZMMKDDTOSQ-UHFFFAOYSA-N","InChI=1S/C12H10N2O/c1-7-12-10(4-5-13-7)9-3-2-8(15)6-11(9)14-12/h2-6,14-15H,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","5488285","CDBONOOLMKZYJF-PDHYLSHYSA-N","InChI=1S/C18H18N2O7/c1-7-12-10(4-5-19-7)9-3-2-8(6-11(9)20-12)26-18-15(23)13(21)14(22)16(27-18)17(24)25/h2-6,13-16,18,20-23H,1H3,(H,24,25)/t13-,14-,15+,16-,18?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02032","6-OH-harmaline","5280952","SATMZMMKDDTOSQ-UHFFFAOYSA-N","InChI=1S/C12H10N2O/c1-7-12-10(4-5-13-7)9-3-2-8(15)6-11(9)14-12/h2-6,14-15H,1H3","SULT","O-sulfonation","Human Phase II","Human","NULL","5488302","XOPVDDSGVTVABP-UHFFFAOYSA-N","InChI=1S/C12H10N2O4S/c1-7-12-10(4-5-13-7)9-3-2-8(6-11(9)14-12)18-19(15,16)17/h2-6,14H,1H3,(H,15,16,17)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02033","Magnolol","72300","VVOAZFWZEDHOOU-UHFFFAOYSA-N","InChI=1S/C18H18O2/c1-3-5-13-7-9-17(19)15(11-13)16-12-14(6-4-2)8-10-18(16)20/h3-4,7-12,19-20H,1-2,5-6H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","HNZWDCABYFRGNV-VDPKEQMDSA-N","InChI=1S/C24H26O8/c1-3-5-13-7-9-17(25)15(11-13)16-12-14(6-4-2)8-10-18(16)31-24-21(28)19(26)20(27)22(32-24)23(29)30/h3-4,7-12,19-22,24-28H,1-2,5-6H2,(H,29,30)/t19-,20-,21+,22-,24?/m0/s1","Yang, G. et al. (2017); Glucuronidation: driving factors and their impact on glucuronide disposition;  Drug Metab Rev. 2017 May;49(2):105-138. DOI:10.1080/03602532.2017.1293682; PMID:28266877"
"BIOTID02034","7-OH-efavirenz","40621976","GZMDZAYFVCXHFM-ZDUSSCGKSA-N","InChI=1S/C14H9ClF3NO3/c15-9-5-8-10(6-11(9)20)19-12(21)22-13(8,14(16,17)18)4-3-7-1-2-7/h5-7,20H,1-2H2,(H,19,21)/t13-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","BQLVNDDLDQZWTI-YZOXJGBRSA-N","InChI=1S/C20H17ClF3NO9/c21-9-5-8-10(25-18(31)34-19(8,20(22,23)24)4-3-7-1-2-7)6-11(9)32-17-14(28)12(26)13(27)15(33-17)16(29)30/h5-7,12-15,17,26-28H,1-2H2,(H,25,31)(H,29,30)/t12-,13-,14+,15-,17?,19-/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02035","6-O-Desmethyl Donepezil","14553555","DJRBBQJREIMIEU-UHFFFAOYSA-N","InChI=1S/C23H27NO3/c1-27-22-13-18-12-19(23(26)20(18)14-21(22)25)11-16-7-9-24(10-8-16)15-17-5-3-2-4-6-17/h2-6,13-14,16,19,25H,7-12,15H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","GUJDLRRGLWFUSI-OWECDQGASA-N","InChI=1S/C29H35NO9/c1-37-21-13-18-12-19(11-16-7-9-30(10-8-16)15-17-5-3-2-4-6-17)23(31)20(18)14-22(21)38-29-26(34)24(32)25(33)27(39-29)28(35)36/h2-6,13-14,16,19,24-27,29,32-34H,7-12,15H2,1H3,(H,35,36)/t19?,24-,25-,26+,27-,29?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02036","Morin","5281670","YXOLAZRVSSWPPT-UHFFFAOYSA-N","InChI=1S/C15H10O7/c16-6-1-2-8(9(18)3-6)15-14(21)13(20)12-10(19)4-7(17)5-11(12)22-15/h1-5,16-19,21H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","HDKCICJCZJMUET-MBIBTLSJSA-N","InChI=1S/C21H18O13/c22-6-1-2-8(9(24)3-6)17-18(13(26)12-10(25)4-7(23)5-11(12)32-17)33-21-16(29)14(27)15(28)19(34-21)20(30)31/h1-5,14-16,19,21-25,27-29H,(H,30,31)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02037","6-OH-MXAA","53951284","JEPCGWROBIUIMK-UHFFFAOYSA-N","InChI=1S/C17H14O5/c1-9-11(8-18)5-6-13-15(21)12-4-2-3-10(7-14(19)20)17(12)22-16(9)13/h2-6,18H,7-8H2,1H3,(H,19,20)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","OQSVSSLJNHMAPI-GWQNJANKSA-N","InChI=1S/C23H22O11/c1-9-11(8-32-23-18(29)16(27)17(28)21(34-23)22(30)31)5-6-13-15(26)12-4-2-3-10(7-14(24)25)20(12)33-19(9)13/h2-6,16-18,21,23,27-29H,7-8H2,1H3,(H,24,25)(H,30,31)/t16-,17-,18+,21-,23?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02038","Procainamide","4913","REQCZEXYDRLIBE-UHFFFAOYSA-N","InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)","NAT","N-acetylation of arylamine","Human Phase II","Human","NULL","4342","KEECCEWTUVWFCV-UHFFFAOYSA-N","InChI=1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)","Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation"
"BIOTID02039","3,4p-Dihydroxyfavone","688715","GPGOCTLAUAHUQO-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-7-5-9(6-8-10)15-14(18)13(17)11-3-1-2-4-12(11)19-15/h1-8,16,18H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","SJDCPSVIXJWGOE-MBIBTLSJSA-N","InChI=1S/C21H18O10/c22-10-7-5-9(6-8-10)17-18(13(23)11-3-1-2-4-12(11)29-17)30-21-16(26)14(24)15(25)19(31-21)20(27)28/h1-8,14-16,19,21-22,24-26H,(H,27,28)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02040","3-OH-nevirapine","10978907","DANIONWINZEYME-UHFFFAOYSA-N","InChI=1S/C15H14N4O2/c1-8-11(20)7-17-14-12(8)18-15(21)10-3-2-6-16-13(10)19(14)9-4-5-9/h2-3,6-7,9,20H,4-5H2,1H3,(H,18,21)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","NDHKVQJGORCCLP-IQSUWLOCSA-N","InChI=1S/C21H22N4O8/c1-8-11(32-21-15(28)13(26)14(27)16(33-21)20(30)31)7-23-18-12(8)24-19(29)10-3-2-6-22-17(10)25(18)9-4-5-9/h2-3,6-7,9,13-16,21,26-28H,4-5H2,1H3,(H,24,29)(H,30,31)/t13-,14-,15+,16-,21?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02041","Neomenthol","1254","NOOLISFMXDJSKH-UHFFFAOYSA-N","InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3","UGT","Alkyl-OH glucuronidation","Human Phase II","Human","NULL","183838","CLJGMBYGTHRUNF-SHLVDPONSA-N","InChI=1S/C16H28O7/c1-7(2)9-5-4-8(3)6-10(9)22-16-13(19)11(17)12(18)14(23-16)15(20)21/h7-14,16-19H,4-6H2,1-3H3,(H,20,21)/t8?,9?,10?,11-,12-,13+,14-,16+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060012"
"BIOTID02042","Glycitein","5317750","DXYUAIFZCFRPTH-UHFFFAOYSA-N","InChI=1S/C16H12O5/c1-20-15-6-11-14(7-13(15)18)21-8-12(16(11)19)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3","UGT1A9","7-O-glucuronidation of isoflavone","Human Phase II","Human","NULL","NULL","HVZUFDAWJOXFQU-QAKXDBDYSA-N","InChI=1S/C22H20O11/c1-30-14-6-11-13(31-8-12(16(11)24)9-2-4-10(23)5-3-9)7-15(14)32-22-19(27)17(25)18(26)20(33-22)21(28)29/h2-8,17-20,22-23,25-27H,1H3,(H,28,29)/t17-,18-,19+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02043","N-Desmethyl o-hydroxyrosiglitazone","86278298","GWVBGLUFILBNNY-UHFFFAOYSA-N","InChI=1S/C17H17N3O4S/c21-13-2-1-7-18-15(13)19-8-9-24-12-5-3-11(4-6-12)10-14-16(22)20-17(23)25-14/h1-7,14,21H,8-10H2,(H,18,19)(H,20,22,23)","SULT","O-sulfonation","Human Phase II","Human","NULL","131769971","HOMPAUSQZJYDFA-UHFFFAOYSA-N","InChI=1S/C17H17N3O7S2/c21-16-14(28-17(22)20-16)10-11-3-5-12(6-4-11)26-9-8-19-15-13(2-1-7-18-15)27-29(23,24)25/h1-7,14H,8-10H2,(H,18,19)(H,20,21,22)(H,23,24,25)","http://www.hmdb.ca/metabolites/HMDB0060837"
"BIOTID02044","cumene hydroperoxide","6629","YQHLDYVWEZKEOX-UHFFFAOYSA-N","InChI=1S/C9H12O2/c1-9(2,11-10)8-6-4-3-5-7-8/h3-7,10H,1-2H3","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","UNOPQFXKZSVJFM-KBPBESRZSA-N","InChI=1S/C19H27N3O8S/c1-19(2,12-6-4-3-5-7-12)29-30-31-11-14(17(26)21-10-16(24)25)22-15(23)9-8-13(20)18(27)28/h3-7,13-14H,8-11,20H2,1-2H3,(H,21,26)(H,22,23)(H,24,25)(H,27,28)/t13-,14-/m0/s1","Dong, GQ. ET AL. (2014); Prediction of substrates for glutathione transferases by covalent docking; J Chem Inf Model. 2014 Jun 23;54(6):1687-99. DOI:10.1021/ci5001554"
"BIOTID02045","(11S)-11-hydroperoxylinoleic acid","5281026","PLWDMWAXENHPLY-PDBSFCERSA-N","InChI=1S/C18H32O4/c1-2-3-4-8-11-14-17(22-21)15-12-9-6-5-7-10-13-16-18(19)20/h11-12,14-15,17,21H,2-10,13,16H2,1H3,(H,19,20)/b14-11-,15-12-/t17-/m0/s1","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","VQJMATDSMKWHGW-CBSAECKWSA-N","InChI=1S/C28H47N3O10S/c1-2-3-4-8-11-14-21(15-12-9-6-5-7-10-13-16-25(33)34)40-41-42-20-23(27(37)30-19-26(35)36)31-24(32)18-17-22(29)28(38)39/h11-12,14-15,21-23H,2-10,13,16-20,29H2,1H3,(H,30,37)(H,31,32)(H,33,34)(H,35,36)(H,38,39)/b14-11-,15-12-/t21-,22-,23-/m0/s1","Dong, GQ. ET AL. (2014); Prediction of substrates for glutathione transferases by covalent docking; J Chem Inf Model. 2014 Jun 23;54(6):1687-99. DOI:10.1021/ci5001554"
"BIOTID02046","Naproxen","156391","CMWTZPSULFXXJA-VIFPVBQESA-N","InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1","UGT","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","54484412","XRHIELLXTVJOKM-WDZACEAPSA-N","InChI=1S/C20H22O9/c1-9(10-3-4-12-8-13(27-2)6-5-11(12)7-10)19(26)29-20-16(23)14(21)15(22)17(28-20)18(24)25/h3-9,14-17,20-23H,1-2H3,(H,24,25)/t9-,14-,15-,16+,17-,20?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02047","Flavopiridol","5287969","BIIVYFLTOXDAOV-YVEFUNNKSA-N","InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","SYNNBRRQNWDVQW-CAZZKBMBSA-N","InChI=1S/C27H28ClNO11/c1-29-7-6-12(16(32)10-29)19-18(39-27-23(35)21(33)22(34)25(40-27)26(36)37)9-15(31)20-14(30)8-17(38-24(19)20)11-4-2-3-5-13(11)28/h2-5,8-9,12,16,21-23,25,27,31-35H,6-7,10H2,1H3,(H,36,37)/t12-,16+,21-,22-,23+,25-,27?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02048","5-OH-resacetophenone","74559","WCJLAYDOJJYRHF-UHFFFAOYSA-N","InChI=1S/C8H8O4/c1-4(9)5-2-7(11)8(12)3-6(5)10/h2-3,10-12H,1H3","SULT","O-sulfonation","Human Phase II","Human","NULL","10848131","CYVRFZMFCIXKPO-UHFFFAOYSA-N","InChI=1S/C8H8O7S/c1-4(9)5-2-8(15-16(12,13)14)7(11)3-6(5)10/h2-3,10-11H,1H3,(H,12,13,14)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02049","15-alpha-hydroxydesogestrel","NULL","RWVQLLLACWCLQR-XITVERIXSA-N","InChI=1S/C22H30O2/c1-4-21-12-14(3)19-16-9-7-6-8-15(16)10-11-17(19)20(21)18(23)13-22(21,24)5-2/h2,8,16-20,23-24H,3-4,6-7,9-13H2,1H3/t16-,17+,18-,19+,20+,21-,22-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","JBEHDKDCZHVUAQ-BRKKTWJOSA-N","InChI=1S/C28H38O8/c1-4-27-12-14(3)19-16-9-7-6-8-15(16)10-11-17(19)20(27)18(29)13-28(27,5-2)36-26-23(32)21(30)22(31)24(35-26)25(33)34/h2,8,16-24,26,29-32H,3-4,6-7,9-13H2,1H3,(H,33,34)/t16-,17+,18-,19+,20+,21-,22-,23+,24-,26?,27-,28-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02050","cyclic N-Acetylserotonin","NULL","WJJVDJLKISXDQN-UHFFFAOYSA-N","InChI=1S/C12H12N2O2/c1-7(15)14-5-4-9-10-6-8(16)2-3-11(10)13-12(9)14/h2-3,6,13,16H,4-5H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","131769960","DHEUSGDHJNTOLK-UHFFFAOYSA-N","InChI=1S/C18H20N2O8/c1-7(21)20-5-4-9-10-6-8(2-3-11(10)19-16(9)20)27-18-14(24)12(22)13(23)15(28-18)17(25)26/h2-3,6,12-15,18-19,22-24H,4-5H2,1H3,(H,25,26)","http://www.hmdb.ca/metabolites/HMDB0060812"
"BIOTID02051","7-Hydroxy-2p-methoxyflavone","5391150","PFEQKIBOPJQNBI-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-14-5-3-2-4-12(14)16-9-13(18)11-7-6-10(17)8-15(11)20-16/h2-9,17H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","GIBGBAIGIFSNRL-QAKXDBDYSA-N","InChI=1S/C22H20O10/c1-29-14-5-3-2-4-12(14)16-9-13(23)11-7-6-10(8-15(11)31-16)30-22-19(26)17(24)18(25)20(32-22)21(27)28/h2-9,17-20,22,24-26H,1H3,(H,27,28)/t17-,18-,19+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02052","8-OH efivarenz","487643","OOVOMPCQLMFEDT-ZDUSSCGKSA-N","InChI=1S/C14H9ClF3NO3/c15-8-5-9-11(10(20)6-8)19-12(21)22-13(9,14(16,17)18)4-3-7-1-2-7/h5-7,20H,1-2H2,(H,19,21)/t13-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","OURIKXWHMJZDHE-YZOXJGBRSA-N","InChI=1S/C20H17ClF3NO9/c21-8-5-9-11(25-18(31)34-19(9,20(22,23)24)4-3-7-1-2-7)10(6-8)32-17-14(28)12(26)13(27)15(33-17)16(29)30/h5-7,12-15,17,26-28H,1-2H2,(H,25,31)(H,29,30)/t12-,13-,14+,15-,17?,19-/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02053","fenchone metabo5","129636129","XYQIHUFLAHGMEY-UHFFFAOYSA-N","InChI=1S/C10H16O2/c1-8(2)7(11)9(3)4-5-10(8,12)6-9/h12H,4-6H2,1-3H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","VVWUPIMWCSAYJM-IVSAUMCASA-N","InChI=1S/C16H24O8/c1-14(2)13(22)15(3)4-5-16(14,6-15)24-12-9(19)7(17)8(18)10(23-12)11(20)21/h7-10,12,17-19H,4-6H2,1-3H3,(H,20,21)/t7-,8-,9+,10-,12?,15?,16?/m0/s1","From Jarleips validations"
"BIOTID02054","Genistein","5280961","TZBJGXHYKVUXJN-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","68980674","JIVINIISUDEORF-DAZJWRSOSA-N","InChI=1S/C21H18O11/c22-9-3-1-8(2-4-9)11-7-30-13-6-10(5-12(23)14(13)15(11)24)31-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21-23,25-27H,(H,28,29)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02055","Maackiain","91510","HUKSJTUUSUGIDC-ZBEGNZNMSA-N","InChI=1S/C16H12O5/c17-8-1-2-9-12(3-8)18-6-11-10-4-14-15(20-7-19-14)5-13(10)21-16(9)11/h1-5,11,16-17H,6-7H2/t11-,16-/m0/s1","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","PCJUMVMSWWTDAT-ONOLNTSHSA-N","InChI=1S/C22H20O11/c23-16-17(24)20(21(26)27)33-22(18(16)25)31-8-1-2-9-12(3-8)28-6-11-10-4-14-15(30-7-29-14)5-13(10)32-19(9)11/h1-5,11,16-20,22-25H,6-7H2,(H,26,27)/t11-,16-,17-,18+,19-,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02056","O-Desmethylgalantamine","443722","OYSGWKOGUVOGFQ-RBOXIYTFSA-N","InChI=1S/C16H19NO3/c1-17-7-6-16-5-4-11(18)8-13(16)20-15-12(19)3-2-10(9-17)14(15)16/h2-5,11,13,18-19H,6-9H2,1H3/t11-,13-,16-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","XDVUICJRQISSRL-PBTKJLNWSA-N","InChI=1S/C22H27NO9/c1-23-7-6-22-5-4-11(24)8-13(22)31-18-12(3-2-10(9-23)14(18)22)30-21-17(27)15(25)16(26)19(32-21)20(28)29/h2-5,11,13,15-17,19,21,24-27H,6-9H2,1H3,(H,28,29)/t11-,13-,15-,16-,17+,19-,21?,22-/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02057","O-Desmethylgalantamine","443722","OYSGWKOGUVOGFQ-RBOXIYTFSA-N","InChI=1S/C16H19NO3/c1-17-7-6-16-5-4-11(18)8-13(16)20-15-12(19)3-2-10(9-17)14(15)16/h2-5,11,13,18-19H,6-9H2,1H3/t11-,13-,16-/m0/s1","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","AVISFYJLJIUZGB-RBOXIYTFSA-N","InChI=1S/C16H19NO6S/c1-17-7-6-16-5-4-11(18)8-13(16)22-15-12(23-24(19,20)21)3-2-10(9-17)14(15)16/h2-5,11,13,18H,6-9H2,1H3,(H,19,20,21)/t11-,13-,16-/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02058","Diosmetin","5281612","MBNGWHIJMBWFHU-UHFFFAOYSA-N","InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3","UGT1A9","Aromatic O-glucuronidation","Human Phase II","Human","NULL","68852783","XCKMDTYMOHXUHG-QAKXDBDYSA-N","InChI=1S/C22H20O12/c1-31-13-3-2-8(4-10(13)23)14-7-12(25)16-11(24)5-9(6-15(16)33-14)32-22-19(28)17(26)18(27)20(34-22)21(29)30/h2-7,17-20,22-24,26-28H,1H3,(H,29,30)/t17-,18-,19+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02059","5-(3p,4p,5p-Trihydroxyphenyl)-gamma-valerolactone","44389277","CZVAQLJEUUFQCH-UHFFFAOYSA-N","InChI=1S/C11H12O5/c12-8-4-6(5-9(13)11(8)15)3-7-1-2-10(14)16-7/h4-5,7,12-13,15H,1-3H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","124202080","VQHXMQYHVVQQFP-CXWHQSFFSA-N","InChI=1S/C17H20O11/c18-8-4-6(3-7-1-2-10(19)26-7)5-9(11(8)20)27-17-14(23)12(21)13(22)15(28-17)16(24)25/h4-5,7,12-15,17-18,20-23H,1-3H2,(H,24,25)/t7?,12-,13-,14+,15-,17?/m0/s1","http://www.hmdb.ca/metabolites/HMDB0059984"
"BIOTID02060","carvacrol","10364","RECUKUPTGUEGMW-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","TZRSIUKJGIWYEN-AKFOCJAPSA-N","InChI=1S/C16H22O7/c1-7(2)9-5-4-8(3)10(6-9)22-16-13(19)11(17)12(18)14(23-16)15(20)21/h4-7,11-14,16-19H,1-3H3,(H,20,21)/t11-,12-,13+,14-,16?/m0/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID02061","carvacrol","10364","RECUKUPTGUEGMW-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H3","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","STFQFVOYWIOQOT-UHFFFAOYSA-N","InChI=1S/C10H14O4S/c1-7(2)9-5-4-8(3)10(6-9)14-15(11,12)13/h4-7H,1-3H3,(H,11,12,13)","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID02062","11-Hydroxyprogesterone","92750","BFZHCUBIASXHPK-AYHYENMDSA-N","InChI=1S/C21H30O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h10,15-19,24H,4-9,11H2,1-3H3/t15-,16+,17-,18?,19+,20-,21+/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","42621273","WVTMNZAPPOMZST-UCMXSJKRSA-N","InChI=1S/C27H38O9/c1-12(28)16-6-7-17-15-5-4-13-10-14(29)8-9-26(13,2)19(15)18(11-27(16,17)3)35-25-22(32)20(30)21(31)23(36-25)24(33)34/h10,15-23,25,30-32H,4-9,11H2,1-3H3,(H,33,34)/t15?,16-,17?,18?,19?,20+,21+,22-,23+,25-,26+,27-/m1/s1","http://www.hmdb.ca/metabolites/HMDB0010364"
"BIOTID02063","2-Hydroxydoxepin","59023617","GRQPGTWGEQWMMM-CAOOACKPSA-N","InChI=1S/C19H21NO2/c1-20(2)11-5-8-17-16-7-4-3-6-14(16)13-22-19-10-9-15(21)12-18(17)19/h3-4,6-10,12,21H,5,11,13H2,1-2H3/b17-8+","UGT","O-glucuronidation","Human Phase II","Human","NULL","131769921","RECOUBTVNVWWDB-CAOOACKPSA-N","InChI=1S/C25H29NO8/c1-26(2)11-5-8-17-16-7-4-3-6-14(16)13-32-19-10-9-15(12-18(17)19)33-25-22(29)20(27)21(28)23(34-25)24(30)31/h3-4,6-10,12,20-23,25,27-29H,5,11,13H2,1-2H3,(H,30,31)/b17-8+","http://www.hmdb.ca/metabolites/HMDB0060700"
"BIOTID02064","N-Oxide abiraterone","NULL","CZKQCNRNNUYEPR-UHFFFAOYSA-N","InChI=1S/C24H31NO2/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25(27)15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3","SULT","O-sulfonation","Human Phase II","Human","NULL","131769975","AEEMBGRHVQPUBV-UHFFFAOYSA-N","InChI=1S/C24H31NO5S/c1-23-11-9-18(30-31(27,28)29)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25(26)15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22H,6,8-12,14H2,1-2H3,(H,27,28,29)","http://www.hmdb.ca/metabolites/HMDB0060848"
"BIOTID02065","N-Carbamoyllorcaserin","NULL","IBYCTQTUVCNSJC-UHFFFAOYSA-N","InChI=1S/C12H14ClNO2/c1-8-7-14(12(15)16)5-4-9-2-3-10(13)6-11(8)9/h2-3,6,8H,4-5,7H2,1H3,(H,15,16)","UGT","O-glucuronidation","Human Phase II","Human","NULL","131770057","DGFKLWZCLRDMAF-IJQUCLSUSA-N","InChI=1S/C21H28ClNO5/c1-11-10-23(8-7-15-5-6-16(22)9-17(11)15)21(26)28-20-14(4)12(2)13(3)18(27-20)19(24)25/h5-6,9,11-14,18,20H,7-8,10H2,1-4H3,(H,24,25)/t11?,12-,13-,14+,18-,20?/m1/s1","http://www.hmdb.ca/metabolites/HMDB0061159"
"BIOTID02066","Suprofen","5359","MDKGKXOCJGEUJW-UHFFFAOYSA-N","InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KXXLFSMVJNYZFS-GTWUMVILSA-N","InChI=1S/C20H20O9S/c1-9(10-4-6-11(7-5-10)13(21)12-3-2-8-30-12)19(27)29-20-16(24)14(22)15(23)17(28-20)18(25)26/h2-9,14-17,20,22-24H,1H3,(H,25,26)/t9?,14-,15-,16+,17-,20?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02067","Indomethacin","3715","CGIGDMFJXJATDK-UHFFFAOYSA-N","InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","QCBWEVBGELGABM-PZYOUWLLSA-N","InChI=1S/C25H24ClNO10/c1-11-15(10-18(28)36-25-21(31)19(29)20(30)22(37-25)24(33)34)16-9-14(35-2)7-8-17(16)27(11)23(32)12-3-5-13(26)6-4-12/h3-9,19-22,25,29-31H,10H2,1-2H3,(H,33,34)/t19-,20-,21+,22-,25?/m0/s1","Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation|https://www.drugbank.ca/metabolites/DBMET00157"
"BIOTID02068","Norpatchoulenol","11830601","OSQSDJNIURJARY-MHDGFBEUSA-N","InChI=1S/C14H22O/c1-12(2)10-6-8-13(3)11(9-10)5-4-7-14(12,13)15/h4-5,10-11,15H,6-9H2,1-3H3/t10-,11-,13+,14-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","OJKXFVCQUKJUAU-MUXJQBHZSA-N","InChI=1S/C20H30O7/c1-18(2)10-6-8-19(3)11(9-10)5-4-7-20(18,19)27-17-14(23)12(21)13(22)15(26-17)16(24)25/h4-5,10-15,17,21-23H,6-9H2,1-3H3,(H,24,25)/t10-,11-,12+,13+,14-,15+,17?,19+,20-/m1/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID02069","5-OH-aceclofenac","101998321","IUSFDHLZHGPYRJ-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO5/c17-11-2-1-3-12(18)16(11)19-13-5-4-10(20)6-9(13)7-15(23)24-8-14(21)22/h1-6,19-20H,7-8H2,(H,21,22)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KIMYHIOPHVHXGR-QAKXDBDYSA-N","InChI=1S/C22H21Cl2NO11/c23-11-2-1-3-12(24)16(11)25-13-5-4-10(6-9(13)7-15(28)34-8-14(26)27)35-22-19(31)17(29)18(30)20(36-22)21(32)33/h1-6,17-20,22,25,29-31H,7-8H2,(H,26,27)(H,32,33)/t17-,18-,19+,20-,22?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02070","5-OH-aceclofenac","101998321","IUSFDHLZHGPYRJ-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO5/c17-11-2-1-3-12(18)16(11)19-13-5-4-10(20)6-9(13)7-15(23)24-8-14(21)22/h1-6,19-20H,7-8H2,(H,21,22)","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","LUTJZJPNYASPOY-UHFFFAOYSA-N","InChI=1S/C16H13Cl2NO8S/c17-11-2-1-3-12(18)16(11)19-13-5-4-10(27-28(23,24)25)6-9(13)7-15(22)26-8-14(20)21/h1-6,19H,7-8H2,(H,20,21)(H,23,24,25)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02071","3-Hydroxy-2p-methoxyflavone","578729","NOPCFBOJEWSFKO-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-12-8-4-3-7-11(12)16-15(18)14(17)10-6-2-5-9-13(10)20-16/h2-9,18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","ZFLCKQJYDYZRPD-XTLXVGOWSA-N","InChI=1S/C22H20O10/c1-29-12-8-4-3-7-11(12)18-19(14(23)10-6-2-5-9-13(10)30-18)31-22-17(26)15(24)16(25)20(32-22)21(27)28/h2-9,15-17,20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02072","Licofelone M4","22500686","OCECVTMNVSFNIW-UHFFFAOYSA-N","InChI=1S/C23H22ClNO3/c1-23(2)12-19-22(15-5-9-17(26)10-6-15)21(14-3-7-16(24)8-4-14)18(11-20(27)28)25(19)13-23/h3-10,26H,11-13H2,1-2H3,(H,27,28)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","LXLRVOZCAXHOTL-TXZJZKILSA-N","InChI=1S/C29H30ClNO9/c1-29(2)12-19-22(15-5-9-17(32)10-6-15)21(14-3-7-16(30)8-4-14)18(31(19)13-29)11-20(33)39-28-25(36)23(34)24(35)26(40-28)27(37)38/h3-10,23-26,28,32,34-36H,11-13H2,1-2H3,(H,37,38)/t23-,24-,25+,26-,28?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675.|http://www.hmdb.ca/metabolites/HMDB0061130"
"BIOTID02073","Chrysoeriol","5280666","SCZVLDHREVKTSH-UHFFFAOYSA-N","InChI=1S/C16H12O6/c1-21-14-4-8(2-3-10(14)18)13-7-12(20)16-11(19)5-9(17)6-15(16)22-13/h2-7,17-19H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","VLYLVFHVHHGXHX-QAKXDBDYSA-N","InChI=1S/C22H20O12/c1-31-14-4-8(2-3-10(14)23)13-7-12(25)16-11(24)5-9(6-15(16)33-13)32-22-19(28)17(26)18(27)20(34-22)21(29)30/h2-7,17-20,22-24,26-28H,1H3,(H,29,30)/t17-,18-,19+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02074","Nitroso-dapsone","132146770","UAQFAHXMXOCEAD-UHFFFAOYSA-N","InChI=1S/C12H10N2O3S/c13-9-1-5-11(6-2-9)18(16,17)12-7-3-10(14-15)4-8-12/h1-8H,13H2","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","QVAUUWUVKOENDA-ROUUACIJSA-N","InChI=1S/C22H27N5O9S2/c23-13-1-5-15(6-2-13)38(35,36)16-7-3-14(4-8-16)27(34)37-12-18(21(31)25-11-20(29)30)26-19(28)10-9-17(24)22(32)33/h1-8,17-18,27H,9-12,23-24H2,(H,25,31)(H,26,28)(H,29,30)(H,32,33)/t17-,18-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02075","(1-methyl-5-piperazin-1-yl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-(5-methyl-pyridin-2-yl)-amine","46926354","XEETWKYVVQVUPU-UHFFFAOYSA-N","InChI=1S/C19H26N8/c1-4-5-14-16-17(26(3)25-14)18(22-15-7-6-13(2)12-21-15)24-19(23-16)27-10-8-20-9-11-27/h6-7,12,20H,4-5,8-11H2,1-3H3,(H,21,22,23,24)","NAT","N-acetylation","Human Phase II","Human","NULL","NULL","IEINBJNPVKYPFR-UHFFFAOYSA-N","InChI=1S/C21H28N8O/c1-5-6-16-18-19(27(4)26-16)20(23-17-8-7-14(2)13-22-17)25-21(24-18)29-11-9-28(10-12-29)15(3)30/h7-8,13H,5-6,9-12H2,1-4H3,(H,22,23,24,25)","PMID:706918|http://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.5&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID02076","S-MTPPA","NULL","QVRAPMOKLOZAAU-UHFFFAOYSA-N","InChI=1S/C15H16O2S/c1-10-8-9-18-13(10)11-4-6-12(7-5-11)15(2,3)14(16)17/h4-9H,1-3H3,(H,16,17)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","MWJGLEGMDVXLIO-JKPQCYAASA-N","InChI=1S/C21H24O8S/c1-10-8-9-30-17(10)11-4-6-12(7-5-11)21(2,3)20(27)29-19-15(24)13(22)14(23)16(28-19)18(25)26/h4-9,13-16,19,22-24H,1-3H3,(H,25,26)/t13-,14-,15+,16-,19?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02077","brostallicin","6918408","RXOVOXFAAGIKDQ-UHFFFAOYSA-N","InChI=1S/C30H35BrN12O5/c1-16(31)25(44)36-17-9-22(41(3)12-17)27(46)38-19-11-24(43(5)14-19)29(48)39-20-10-23(42(4)15-20)28(47)37-18-8-21(40(2)13-18)26(45)34-6-7-35-30(32)33/h8-15H,1,6-7H2,2-5H3,(H,34,45)(H,36,44)(H,37,47)(H,38,46)(H,39,48)(H4,32,33,35)","GST","GSH-conjugation","Human Phase II","Human","glutathionyl-brostallicin","NULL","RMLABMNJFBPRJW-WIXBZOCESA-N","InChI=1S/C40H52BrN15O11S/c1-53-15-21(9-27(53)35(62)45-7-8-46-40(43)44)49-37(64)29-11-23(17-55(29)3)51-38(65)30-12-22(16-56(30)4)50-36(63)28-10-20(14-54(28)2)48-33(60)24(41)18-68-19-26(34(61)47-13-32(58)59)52-31(57)6-5-25(42)39(66)67/h9-12,14-17,24-26H,5-8,13,18-19,42H2,1-4H3,(H,45,62)(H,47,61)(H,48,60)(H,49,64)(H,50,63)(H,51,65)(H,52,57)(H,58,59)(H,66,67)(H4,43,44,46)/t24?,25-,26-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID02078","8-OH-2,3,7-TriCDD","119141","PMDIZNYHSROIKW-UHFFFAOYSA-N","InChI=1S/C12H5Cl3O3/c13-5-1-9-10(2-6(5)14)18-12-4-8(16)7(15)3-11(12)17-9/h1-4,16H","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KAHALRUUUAHVDH-PDHYLSHYSA-N","InChI=1S/C18H13Cl3O9/c19-5-1-9-10(2-6(5)20)28-12-4-8(7(21)3-11(12)27-9)29-18-15(24)13(22)14(23)16(30-18)17(25)26/h1-4,13-16,18,22-24H,(H,25,26)/t13-,14-,15+,16-,18?/m0/s1","Kasai, N. et al. (2004); Sequential metabolism of 2,3,7-trichlorodibenzo-p-dioxin (2,3,7-triCDD) by cytochrome P450 and UDP-glucuronosyltransferase in human liver microsomes.; Drug Metab Dispos. 2004 Aug;32(8):870-5."
"BIOTID02079","Oxazepam","4616","ADIMAYPTOBDMTL-UHFFFAOYSA-N","InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)","UGT","O-glucuronidation","Human Phase II","Human","NULL","160870","FIKQKGFUBZQEBL-IFBJMGMISA-N","InChI=1S/C21H19ClN2O8/c22-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)24-19(18(28)23-12)32-21-16(27)14(25)15(26)17(31-21)20(29)30/h1-8,14-17,19,21,25-27H,(H,23,28)(H,29,30)/t14-,15-,16+,17-,19?,21-/m0/s1","http://www.hmdb.ca/metabolites/HMDB0041969"
"BIOTID02080","3p-OH-hexobarbital","160460","YHCGILGEMWNROZ-UHFFFAOYSA-N","InChI=1S/C12H16N2O4/c1-12(7-4-3-5-8(15)6-7)9(16)13-11(18)14(2)10(12)17/h6,8,15H,3-5H2,1-2H3,(H,13,16,18)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KJVMQZNJQDWAMS-RXEJOWTBSA-N","InChI=1S/C18H24N2O10/c1-18(15(26)19-17(28)20(2)16(18)27)7-4-3-5-8(6-7)29-14-11(23)9(21)10(22)12(30-14)13(24)25/h6,8-12,14,21-23H,3-5H2,1-2H3,(H,24,25)(H,19,26,28)/t8?,9-,10-,11+,12-,14?,18?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02081","p-Hydroxyphenobarbital","9785","IEPXMKJNWPXDBP-UHFFFAOYSA-N","InChI=1S/C12H12N2O4/c1-2-12(7-3-5-8(15)6-4-7)9(16)13-11(18)14-10(12)17/h3-6,15H,2H2,1H3,(H2,13,14,16,17,18)","UGT (primary)","O-glucuronidation","Human Phase II","Human","NULL","NULL","RQTUXVFRLKPUJG-ZAOAHOKWSA-N","InChI=1S/C18H20N2O10/c1-2-18(15(26)19-17(28)20-16(18)27)7-3-5-8(6-4-7)29-14-11(23)9(21)10(22)12(30-14)13(24)25/h3-6,9-12,14,21-23H,2H2,1H3,(H,24,25)(H2,19,20,26,27,28)/t9-,10-,11+,12-,14?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02082","p-Hydroxyphenobarbital","9785","IEPXMKJNWPXDBP-UHFFFAOYSA-N","InChI=1S/C12H12N2O4/c1-2-12(7-3-5-8(15)6-4-7)9(16)13-11(18)14-10(12)17/h3-6,15H,2H2,1H3,(H2,13,14,16,17,18)","SULT","O-sulfonation","Human Phase II","Human","NULL","71371485","SBVMQBDFNZJWGL-UHFFFAOYSA-N","InChI=1S/C12H12N2O7S/c1-2-12(9(15)13-11(17)14-10(12)16)7-3-5-8(6-4-7)21-22(18,19)20/h3-6H,2H2,1H3,(H,18,19,20)(H2,13,14,15,16,17)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02083","Sulfamethoxazole","5329","JLKIGFTWXXRPMT-UHFFFAOYSA-N","InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","MZRHXWAVHGYGKI-OFBDQPAMSA-N","InChI=1S/C16H19N3O9S/c1-7-6-10(18-28-7)19-29(25,26)9-4-2-8(3-5-9)17-15-13(22)11(20)12(21)14(27-15)16(23)24/h2-6,11-15,17,20-22H,1H3,(H,18,19)(H,23,24)/t11-,12-,13+,14-,15?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02084","Sulfamethoxazole","5329","JLKIGFTWXXRPMT-UHFFFAOYSA-N","InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)","NAT1, NAT2","N-acetylation of arylamine","Human Phase II","Human","NULL","65280","GXPIUNZCALHVBA-UHFFFAOYSA-N","InChI=1S/C12H13N3O4S/c1-8-7-12(14-19-8)15-20(17,18)11-5-3-10(4-6-11)13-9(2)16/h3-7H,1-2H3,(H,13,16)(H,14,15)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02085","4-n-Propylphenol","12580","KLSLBUSXWBJMEC-UHFFFAOYSA-N","InChI=1S/C9H12O/c1-2-3-8-4-6-9(10)7-5-8/h4-7,10H,2-3H2,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","LZQQIZJNVCGDPN-HXMBFPRCSA-N","InChI=1S/C15H20O7/c1-2-3-8-4-6-9(7-5-8)21-15-12(18)10(16)11(17)13(22-15)14(19)20/h4-7,10-13,15-18H,2-3H2,1H3,(H,19,20)/t10-,11-,12+,13-,15?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02086","Butyl-4-hydroxybenzoate","7184","QFOHBWFCKVYLES-UHFFFAOYSA-N","InChI=1S/C11H14O3/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7,12H,2-3,8H2,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","GZCNKLAIZRKKTB-CLDVFSPQSA-N","InChI=1S/C17H22O9/c1-2-3-8-24-16(23)9-4-6-10(7-5-9)25-17-13(20)11(18)12(19)14(26-17)15(21)22/h4-7,11-14,17-20H,2-3,8H2,1H3,(H,21,22)/t11-,12-,13+,14-,17?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02087","Quercetin","5280343","REFJWTPEDVJJIY-UHFFFAOYSA-N","InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","13258914","DUBCCGAQYVUYEU-MBIBTLSJSA-N","InChI=1S/C21H18O13/c22-7-4-10(25)12-11(5-7)32-17(6-1-2-8(23)9(24)3-6)18(13(12)26)33-21-16(29)14(27)15(28)19(34-21)20(30)31/h1-5,14-16,19,21-25,27-29H,(H,30,31)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02088","Taurocholic acid","6675","WBWWGRHZICKQGZ-HZAMXZRMSA-N","InChI=1S/C26H45NO7S/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34)/t15-,16+,17-,18-,19+,20+,21-,22+,24+,25+,26-/m1/s1","SULT","O-sulfonation","Human Phase II","Human","NULL","53477754","LKTXOQJJFLAZRW-XVBIMYNNSA-N","InChI=1S/C26H45NO10S2/c1-15(4-7-23(30)27-10-11-38(31,32)33)18-5-6-19-24-20(14-22(29)26(18,19)3)25(2)9-8-17(37-39(34,35)36)12-16(25)13-21(24)28/h15-22,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32,33)(H,34,35,36)/t15-,16+,17-,18?,19?,20?,21-,22+,24?,25+,26-/m1/s1","http://www.hmdb.ca/metabolites/HMDB0002581"
"BIOTID02089","Propranolol","4946","AQHHHDLHHXJYJD-UHFFFAOYSA-N","InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","10048595","PCALHJGQCKATMK-QVKBUXFFSA-N","InChI=1S/C22H29NO8/c1-12(2)23-10-14(11-29-16-9-5-7-13-6-3-4-8-15(13)16)30-22-19(26)17(24)18(25)20(31-22)21(27)28/h3-9,12,14,17-20,22-26H,10-11H2,1-2H3,(H,27,28)/t14?,17-,18-,19+,20-,22?/m0/s1","Yang, G. et al. (2017); Glucuronidation: driving factors and their impact on glucuronide disposition;  Drug Metab Rev. 2017 May;49(2):105-138. DOI:10.1080/03602532.2017.1293682; PMID:28266877"
"BIOTID02090","3,7-Dihydroxy-3p,4p-dimethoxyflavone","5378832","LTSJJOKAWSCMBC-UHFFFAOYSA-N","InChI=1S/C17H14O6/c1-21-12-6-3-9(7-14(12)22-2)17-16(20)15(19)11-5-4-10(18)8-13(11)23-17/h3-8,18,20H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","STGBANHLMLBDFU-FRMANSKWSA-N","InChI=1S/C23H22O12/c1-31-12-6-3-9(7-14(12)32-2)20-17(26)15(24)11-5-4-10(8-13(11)34-20)33-23-19(28)16(25)18(27)21(35-23)22(29)30/h3-8,16,18-19,21,23,25-28H,1-2H3,(H,29,30)/t16-,18-,19+,21-,23?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02091","3,7-Dihydroxy-3p,4p-dimethoxyflavone","5378832","LTSJJOKAWSCMBC-UHFFFAOYSA-N","InChI=1S/C17H14O6/c1-21-12-6-3-9(7-14(12)22-2)17-16(20)15(19)11-5-4-10(18)8-13(11)23-17/h3-8,18,20H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","JRFRKYIWFYUIBM-GWQNJANKSA-N","InChI=1S/C23H22O12/c1-31-12-6-3-9(7-14(12)32-2)19-20(15(25)11-5-4-10(24)8-13(11)33-19)34-23-18(28)16(26)17(27)21(35-23)22(29)30/h3-8,16-18,21,23-24,26-28H,1-2H3,(H,29,30)/t16-,17-,18+,21-,23?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02092","Erlotinib M16","74963268","NEEHJGWAKAIBAR-UHFFFAOYSA-N","InChI=1S/C22H23N3O5/c1-4-15-11-16(5-6-19(15)26)25-22-17-12-20(29-9-7-27-2)21(30-10-8-28-3)13-18(17)23-14-24-22/h1,5-6,11-14,26H,7-10H2,2-3H3,(H,23,24,25)","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","WBMXSWDFNCZNQR-UHFFFAOYSA-N","InChI=1S/C22H23N3O8S/c1-4-15-11-16(5-6-19(15)33-34(26,27)28)25-22-17-12-20(31-9-7-29-2)21(32-10-8-30-3)13-18(17)23-14-24-22/h1,5-6,11-14H,7-10H2,2-3H3,(H,23,24,25)(H,26,27,28)","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02093","Equol","382975","ADFCQWZHKCXPAJ-UHFFFAOYSA-N","InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","XDPLKWRSVXUQBN-SHXVRUDWSA-N","InChI=1S/C21H22O9/c22-13-4-1-10(2-5-13)12-7-11-3-6-14(8-15(11)28-9-12)29-21-18(25)16(23)17(24)19(30-21)20(26)27/h1-6,8,12,16-19,21-25H,7,9H2,(H,26,27)/t12?,16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02094","4-Hydroxybenzophenone","14347","NPFYZDNDJHZQKY-UHFFFAOYSA-N","InChI=1S/C13H10O2/c14-12-8-6-11(7-9-12)13(15)10-4-2-1-3-5-10/h1-9,14H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","70500973","FZCXIQKUSIIMMV-OOHXRKOZSA-N","InChI=1S/C19H18O8/c20-13(10-4-2-1-3-5-10)11-6-8-12(9-7-11)26-19-16(23)14(21)15(22)17(27-19)18(24)25/h1-9,14-17,19,21-23H,(H,24,25)/t14-,15-,16+,17-,19?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02095","4p-Hydroxyfenoprofen","10106551","RIGQDHFDPVTTEV-UHFFFAOYSA-N","InChI=1S/C15H14O4/c1-10(15(17)18)11-3-2-4-14(9-11)19-13-7-5-12(16)6-8-13/h2-10,16H,1H3,(H,17,18)","UGT","O-glucuronidation","Human Phase II","Human","NULL","131769945","FPPVBAMKHUAIOP-OYQCQVHHSA-N","InChI=1S/C21H22O10/c1-10(19(24)25)11-3-2-4-14(9-11)29-12-5-7-13(8-6-12)30-17-15(22)18(20(26)27)31-21(28)16(17)23/h2-10,15-18,21-23,28H,1H3,(H,24,25)(H,26,27)/t10?,15-,16+,17-,18-,21?/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060772"
"BIOTID02096","4-Hydroxyifosfamide","308171","JHUJMHKRHQPBRG-UHFFFAOYSA-N","InChI=1S/C7H15Cl2N2O3P/c8-2-4-10-15(13)11(5-3-9)7(12)1-6-14-15/h7,12H,1-6H2,(H,10,13)","GST","GSH-conjugation","Human Phase II","Human","NULL","NULL","DSLZNGNGALUIJI-LGUIJYROSA-N","InChI=1S/C17H30Cl2N5O9PS/c18-4-6-22-34(31)24(7-5-19)14(3-8-32-34)33-35-10-12(16(28)21-9-15(26)27)23-13(25)2-1-11(20)17(29)30/h11-12,14H,1-10,20H2,(H,21,28)(H,22,31)(H,23,25)(H,26,27)(H,29,30)/t11-,12-,14?,34?/m0/s1",""
"BIOTID02097","4p,5-diOH-diclofenac","3052567","DRZFITWJHHNHAD-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO4/c15-10-5-9(19)6-11(16)14(10)17-12-2-1-8(18)3-7(12)4-13(20)21/h1-3,5-6,17-19H,4H2,(H,20,21)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","LCMVCHAFCNHEIV-BCHVZBRRSA-N","InChI=1S/C20H19Cl2NO10/c21-10-5-9(32-20-17(29)15(27)16(28)18(33-20)19(30)31)6-11(22)14(10)23-12-2-1-8(24)3-7(12)4-13(25)26/h1-3,5-6,15-18,20,23-24,27-29H,4H2,(H,25,26)(H,30,31)/t15-,16-,17+,18-,20?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02098","4p,5-diOH-diclofenac","3052567","DRZFITWJHHNHAD-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO4/c15-10-5-9(19)6-11(16)14(10)17-12-2-1-8(18)3-7(12)4-13(20)21/h1-3,5-6,17-19H,4H2,(H,20,21)","SULT","O-sulfonation","Human Phase II","Human","NULL","NULL","SEUWKZLWRGWUAC-UHFFFAOYSA-N","InChI=1S/C14H11Cl2NO7S/c15-10-5-9(24-25(21,22)23)6-11(16)14(10)17-12-2-1-8(18)3-7(12)4-13(19)20/h1-3,5-6,17-18H,4H2,(H,19,20)(H,21,22,23)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02099","15-Hydroxypatchoulol","NULL","RTSORXBIZDRAMP-RKEKIRQTSA-N","InChI=1S/C15H26O2/c1-13(2)11-5-6-14(3)12(8-11)10(9-16)4-7-15(13,14)17/h10-12,16-17H,4-9H2,1-3H3/t10-,11-,12+,14+,15-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","SOAWPLUCMRWYQW-WFOPRKHUSA-N","InChI=1S/C21H34O8/c1-19(2)11-5-6-20(3)12(8-11)10(4-7-21(19,20)27)9-28-18-15(24)13(22)14(23)16(29-18)17(25)26/h10-16,18,22-24,27H,4-9H2,1-3H3,(H,25,26)/t10-,11-,12+,13+,14+,15-,16+,18?,20+,21-/m1/s1","JaÃŒË†ger, W. and HoÃŒË†ferl,M. (2016); Metabolism of Terpenoids in Animal Models and Humans"
"BIOTID02100","3-Methoxy-4-hydroxyphenylethyleneglycol","10805","FBWPWWWZWKPJFL-UHFFFAOYSA-N","InChI=1S/C9H12O4/c1-13-9-4-6(8(12)5-10)2-3-7(9)11/h2-4,8,10-12H,5H2,1H3","SULT","4-OH sulfonation of phenolic compound","Human Phase II","Human","NULL","4183","WUFPNASKMLJSND-UHFFFAOYSA-N","InChI=1S/C9H12O7S/c1-15-9-4-6(7(11)5-10)2-3-8(9)16-17(12,13)14/h2-4,7,10-11H,5H2,1H3,(H,12,13,14)","http://www.hmdb.ca/metabolites/HMDB0000559"
"BIOTID02101","Seratrodast","2449","ZBVKEHDGYSLCCC-UHFFFAOYSA-N","InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","ZQJLOFNRURZAIC-XUCPCBLWSA-N","InChI=1S/C28H34O10/c1-14-15(2)22(31)20(16(3)21(14)30)18(17-10-6-4-7-11-17)12-8-5-9-13-19(29)37-28-25(34)23(32)24(33)26(38-28)27(35)36/h4,6-7,10-11,18,23-26,28,32-34H,5,8-9,12-13H2,1-3H3,(H,35,36)/t18?,23-,24-,25+,26-,28?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02102","Isorhamnetin","5281654","IZQSVPBOUDKVDZ-UHFFFAOYSA-N","InChI=1S/C16H12O7/c1-22-11-4-7(2-3-9(11)18)16-15(21)14(20)13-10(19)5-8(17)6-12(13)23-16/h2-6,17-19,21H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","89646653","VVZWHOMBDMMRSC-XTLXVGOWSA-N","InChI=1S/C22H20O13/c1-32-11-4-7(2-3-9(11)24)18-19(14(26)13-10(25)5-8(23)6-12(13)33-18)34-22-17(29)15(27)16(28)20(35-22)21(30)31/h2-6,15-17,20,22-25,27-29H,1H3,(H,30,31)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02103","3-Hydroxy-7-methoxyflavone","344546","IPRIGHIBTRMTDP-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-11-7-8-12-13(9-11)20-16(15(18)14(12)17)10-5-3-2-4-6-10/h2-9,18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","BRQDNQXQNQAPGY-XTLXVGOWSA-N","InChI=1S/C22H20O10/c1-29-11-7-8-12-13(9-11)30-18(10-5-3-2-4-6-10)19(14(12)23)31-22-17(26)15(24)16(25)20(32-22)21(27)28/h2-9,15-17,20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02104","Thienorphine","102212421","WTGSHWLSWVFVAH-HRHGHGIZSA-N","InChI=1S/C31H39NO4S/c1-28(34,10-9-21-4-3-15-37-21)23-17-29-11-12-31(23,35-2)27-30(29)13-14-32(18-19-5-6-19)24(29)16-20-7-8-22(33)26(36-27)25(20)30/h3-4,7-8,15,19,23-24,27,33-34H,5-6,9-14,16-18H2,1-2H3/t23?,24-,27?,28-,29+,30+,31-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","ZYHGUKWCAIYINU-PRLQKGFMSA-N","InChI=1S/C37H47NO10S/c1-34(44,10-9-21-4-3-15-49-21)23-17-35-11-12-37(23,45-2)33-36(35)13-14-38(18-19-5-6-19)24(35)16-20-7-8-22(29(48-33)25(20)36)46-32-28(41)26(39)27(40)30(47-32)31(42)43/h3-4,7-8,15,19,23-24,26-28,30,32-33,39-41,44H,5-6,9-14,16-18H2,1-2H3,(H,42,43)/t23?,24-,26+,27+,28-,30+,32?,33?,34-,35+,36+,37-/m1/s1","J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Nov 1;859(1):52-61; PMID:17933594; DOI:10.1016/j.jchromb.2007.09.028"
"BIOTID02105","Mexiletine alcohol","10397396","QFOWJPBDGSGFEJ-UHFFFAOYSA-N","InChI=1S/C11H16O2/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10,12H,7H2,1-3H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","RWJCSHWLXABCAS-RNQPHIEHSA-N","InChI=1S/C17H24O8/c1-8-5-4-6-9(2)14(8)23-7-10(3)24-17-13(20)11(18)12(19)15(25-17)16(21)22/h4-6,10-13,15,17-20H,7H2,1-3H3,(H,21,22)/t10?,11-,12-,13+,15-,17?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02106","Luteolin","5280445","IQPNAANSBPBGFQ-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","5488307","VSUOKLTVXQRUSG-DAZJWRSOSA-N","InChI=1S/C21H18O12/c22-9-2-1-7(3-10(9)23)13-6-12(25)15-11(24)4-8(5-14(15)32-13)31-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-24,26-28H,(H,29,30)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02107","Luteolin","5280445","IQPNAANSBPBGFQ-UHFFFAOYSA-N","InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","15372481","JDOFZOKGCYYUER-DAZJWRSOSA-N","InChI=1S/C21H18O12/c22-8-4-10(24)15-11(25)6-12(31-14(15)5-8)7-1-2-9(23)13(3-7)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-24,26-28H,(H,29,30)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02108","4-OH-S-flurbiprofen","40579112","GTSMMBJBNJDFRA-SECBINFHSA-N","InChI=1S/C15H13FO3/c1-9(15(18)19)11-4-7-13(14(16)8-11)10-2-5-12(17)6-3-10/h2-9,17H,1H3,(H,18,19)/t9-/m1/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","GKKZUATWZHUXDX-CPZYBKRKSA-N","InChI=1S/C21H21FO9/c1-9(19(26)27)11-4-7-13(14(22)8-11)10-2-5-12(6-3-10)30-21-17(25)15(23)16(24)18(31-21)20(28)29/h2-9,15-18,21,23-25H,1H3,(H,26,27)(H,28,29)/t9-,15+,16+,17-,18+,21?/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02110","3-Hydroxy-6-methoxyflavone","688676","OGURJSOPVFCIOO-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-11-7-8-13-12(9-11)14(17)15(18)16(20-13)10-5-3-2-4-6-10/h2-9,18H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","JBVKRKSXSQNJOP-XTLXVGOWSA-N","InChI=1S/C22H20O10/c1-29-11-7-8-13-12(9-11)14(23)19(18(30-13)10-5-3-2-4-6-10)31-22-17(26)15(24)16(25)20(32-22)21(27)28/h2-9,15-17,20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02111","7,2p-Dihydroxyflavone","5391149","NUGPQONICGTVNA-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-9-5-6-11-13(18)8-15(19-14(11)7-9)10-3-1-2-4-12(10)17/h1-8,16-17H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","YFWMDHIZJVDNSB-DAZJWRSOSA-N","InChI=1S/C21H18O10/c22-12-4-2-1-3-10(12)15-8-13(23)11-6-5-9(7-14(11)30-15)29-21-18(26)16(24)17(25)19(31-21)20(27)28/h1-8,16-19,21-22,24-26H,(H,27,28)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02112","4-Hydroxyphenytoin","17732","XEEDURHPFVXALT-UHFFFAOYSA-N","InChI=1S/C15H12N2O3/c18-12-8-6-11(7-9-12)15(10-4-2-1-3-5-10)13(19)16-14(20)17-15/h1-9,18H,(H2,16,17,19,20)","UGT","O-glucuronidation","Human Phase II","Human","NULL","135250","RCYKZSJKDMUDIE-MXYJCWFVSA-N","InChI=1S/C21H20N2O9/c24-13-14(25)16(17(27)28)32-18(15(13)26)31-12-8-6-11(7-9-12)21(10-4-2-1-3-5-10)19(29)22-20(30)23-21/h1-9,13-16,18,24-26H,(H,27,28)(H2,22,23,29,30)/t13-,14-,15+,16-,18?,21?/m0/s1","http://www.hmdb.ca/metabolites/HMDB0060769"
"BIOTID02113","Candesartan","2541","HTQMVQVXFRQIKW-UHFFFAOYSA-N","InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)","UGT1A3","O-glucuronidation","Human Phase II","Human","NULL","131769984","IQMPSFXZXNRDMY-GPKAUORGSA-N","InChI=1S/C30H28N6O9/c1-2-43-30-31-20-9-5-8-19(28(42)45-29-24(39)22(37)23(38)25(44-29)27(40)41)21(20)36(30)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)26-32-34-35-33-26/h3-13,22-25,29,37-39H,2,14H2,1H3,(H,40,41)(H,32,33,34,35)/t22-,23-,24+,25-,29?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02114","Candesartan","2541","HTQMVQVXFRQIKW-UHFFFAOYSA-N","InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)","UGT1A3","O-glucuronidation","Human Phase II","Human","NULL","NULL","LYKDYQVBGWTPMW-XOEMIVIESA-O","InChI=1S/C30H28N6O9/c1-2-44-30-31-20-9-5-8-19(28(40)41)21(20)35(30)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)26-32-34-36(33-26)27-24(39)22(37)23(38)25(45-27)29(42)43/h3-13,22-25,27,37-39H,2,14H2,1H3,(H,40,41)(H,42,43)/p+1/t22-,23-,24+,25-,27?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02115","Formononetin","5280378","HKQYGTCOTHHOMP-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","UMBVLOHYPOQARY-QAKXDBDYSA-N","InChI=1S/C22H20O10/c1-29-11-4-2-10(3-5-11)14-9-30-15-8-12(6-7-13(15)16(14)23)31-22-19(26)17(24)18(25)20(32-22)21(27)28/h2-9,17-20,22,24-26H,1H3,(H,27,28)/t17-,18-,19+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02116","Phenytoin","1775","CXOFVDLJLONNDW-UHFFFAOYSA-N","InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","MFWASOUYXGTTLJ-CLYSKQOPSA-N","InChI=1S/C21H20N2O8/c24-13-14(25)16(18(27)28)31-17(15(13)26)23-19(29)21(22-20(23)30,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13-17,24-26H,(H,22,30)(H,27,28)/t13-,14-,15+,16-,17?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02117","Haloperidol","3559","LNEPOXFFQSENCJ-UHFFFAOYSA-N","InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2","UGT","O-glucuronidation","Human Phase II","Human","NULL","92131856","ZFNLYKVTHNLKNZ-BFZHNPFYSA-N","InChI=1S/C27H31ClFNO8/c28-18-7-5-17(6-8-18)27(38-26-23(34)21(32)22(33)24(37-26)25(35)36)11-14-30(15-12-27)13-1-2-20(31)16-3-9-19(29)10-4-16/h3-10,21-24,26,32-34H,1-2,11-15H2,(H,35,36)/t21-,22-,23+,24-,26?/m0/s1","https://www.drugbank.ca/metabolites/DBMET00105"
"BIOTID02118","benzo[a]pyrene-7,8-diol","42267","FWKXMJCJEOUXDE-UHFFFAOYSA-N","InChI=1S/C20H12O2/c21-17-9-8-14-15-7-6-12-3-1-2-11-4-5-13(19(15)18(11)12)10-16(14)20(17)22/h1-10,21-22H","UGT1A1","O-glucuronidation","Human Phase II","Human","NULL","NULL","QOTFDLQHFBVWMK-QKBZUBFZSA-N","InChI=1S/C26H20O8/c27-17-9-8-14-15-7-6-12-3-1-2-11-4-5-13(19(15)18(11)12)10-16(14)23(17)33-26-22(30)20(28)21(29)24(34-26)25(31)32/h1-10,20-22,24,26-30H,(H,31,32)/t20-,21-,22+,24-,26?/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID02119","N-OH-mexiletine","154368","ABMUWCMGKRQAIK-UHFFFAOYSA-N","InChI=1S/C11H17NO2/c1-8-5-4-6-9(2)11(8)14-7-10(3)12-13/h4-6,10,12-13H,7H2,1-3H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","XXMULGPNDWROEN-RNQPHIEHSA-N","InChI=1S/C17H25NO8/c1-8-5-4-6-9(2)14(8)24-7-10(3)18-26-17-13(21)11(19)12(20)15(25-17)16(22)23/h4-6,10-13,15,17-21H,7H2,1-3H3,(H,22,23)/t10?,11-,12-,13+,15-,17?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02120","(R)-(-)-Ibuprofen","114864","HEFNNWSXXWATRW-SNVBAGLBSA-N","InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m1/s1","UGT1A1, UGT1A3, UGTA9, UGT2B4, UGT2B7","O-glucuronidation of aliphatic acid","Human Phase II","Human","NULL","NULL","ABOLXXZAJIAUGR-DQFMJPLQSA-N","InChI=1S/C19H26O8/c1-9(2)8-11-4-6-12(7-5-11)10(3)18(25)27-19-15(22)13(20)14(21)16(26-19)17(23)24/h4-7,9-10,13-16,19-22H,8H2,1-3H3,(H,23,24)/t10-,13+,14+,15-,16+,19?/m1/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02121","6-Hydroxymethyletoricoxib","44266438","SCVWZQQMIZJGJY-UHFFFAOYSA-N","InChI=1S/C18H15ClN2O3S/c1-25(23,24)16-6-3-12(4-7-16)17-8-14(19)10-21-18(17)13-2-5-15(11-22)20-9-13/h2-10,22H,11H2,1H3","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","UJWKCNOGFMSHNK-VDPKEQMDSA-N","InChI=1S/C24H23ClN2O9S/c1-37(33,34)16-6-3-12(4-7-16)17-8-14(25)10-27-18(17)13-2-5-15(26-9-13)11-35-24-21(30)19(28)20(29)22(36-24)23(31)32/h2-10,19-22,24,28-30H,11H2,1H3,(H,31,32)/t19-,20-,21+,22-,24?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02122","N-hydroxy-2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline","115104","FVNCCTJGBOTWTM-UHFFFAOYSA-N","InChI=1S/C11H11N5O/c1-6-5-12-7-3-4-8-10(9(7)13-6)14-11(15-17)16(8)2/h3-5,17H,1-2H3,(H,14,15)","UGT1A1","O-glucuronidation","Human Phase II","Human","NULL","NULL","WGRHCMQDFHKVDC-AKFOCJAPSA-N","InChI=1S/C17H19N5O7/c1-6-5-18-7-3-4-8-10(9(7)19-6)20-17(22(8)2)21-29-16-13(25)11(23)12(24)14(28-16)15(26)27/h3-5,11-14,16,23-25H,1-2H3,(H,20,21)(H,26,27)/t11-,12-,13+,14-,16?/m0/s1","Rendic, S. et al. 2012; Contributions of Human Enzymes in Carcinogen Metabolism Slobodan Rendic1,* and F. Peter Guengerich; Chem Res Toxicol. 2012 July 16; 25(7): 1316Ã¢â‚¬â€œ1383. doi:10.1021/tx300132k"
"BIOTID02123","(11R)-11-hydroperoxylinoleic acid","102518369","PLWDMWAXENHPLY-LILDEJAOSA-N","InChI=1S/C18H32O4/c1-2-3-4-8-11-14-17(22-21)15-12-9-6-5-7-10-13-16-18(19)20/h11-12,14-15,17,21H,2-10,13,16H2,1H3,(H,19,20)/b14-11-,15-12-/t17-/m1/s1","GST","GSH-conjugatoon","Human Phase II","Human","NULL","NULL","VQJMATDSMKWHGW-JCQSMXKYSA-N","InChI=1S/C28H47N3O10S/c1-2-3-4-8-11-14-21(15-12-9-6-5-7-10-13-16-25(33)34)40-41-42-20-23(27(37)30-19-26(35)36)31-24(32)18-17-22(29)28(38)39/h11-12,14-15,21-23H,2-10,13,16-20,29H2,1H3,(H,30,37)(H,31,32)(H,33,34)(H,35,36)(H,38,39)/b14-11-,15-12-/t21-,22+,23+/m1/s1","Dong, GQ. ET AL. (2014); Prediction of substrates for glutathione transferases by covalent docking; J Chem Inf Model. 2014 Jun 23;54(6):1687-99. DOI:10.1021/ci5001554"
"BIOTID02124","Galantamine","9651","ASUTZQLVASHGKV-JDFRZJQESA-N","InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","AVISFYJLJIUZGB-RBOXIYTFSA-N","InChI=1S/C16H19NO6S/c1-17-7-6-16-5-4-11(18)8-13(16)22-15-12(23-24(19,20)21)3-2-10(9-17)14(15)16/h2-5,11,13,18H,6-9H2,1H3,(H,19,20,21)/t11-,13-,16-/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02125","Gemfibrozil","3463","HEMJJKBWTPKOJG-UHFFFAOYSA-N","InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","CJMNXSKEVNPQOK-OOHXRKOZSA-N","InChI=1S/C21H30O9/c1-11-6-7-12(2)13(10-11)28-9-5-8-21(3,4)20(27)30-19-16(24)14(22)15(23)17(29-19)18(25)26/h6-7,10,14-17,19,22-24H,5,8-9H2,1-4H3,(H,25,26)/t14-,15-,16+,17-,19?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02126","4-Isopropylphenol","7465","YQUQWHNMBPIWGK-UHFFFAOYSA-N","InChI=1S/C9H12O/c1-7(2)8-3-5-9(10)6-4-8/h3-7,10H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","SNKJPAACBYGQFK-HXMBFPRCSA-N","InChI=1S/C15H20O7/c1-7(2)8-3-5-9(6-4-8)21-15-12(18)10(16)11(17)13(22-15)14(19)20/h3-7,10-13,15-18H,1-2H3,(H,19,20)/t10-,11-,12+,13-,15?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02127","Troglitazone","5591","GXPHKUHSUJUWKP-UHFFFAOYSA-N","InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","NUTWTXPQUHCSIQ-JROBZXJDSA-N","InChI=1S/C30H35NO11S/c1-13-14(2)24-18(15(3)23(13)40-28-22(34)20(32)21(33)25(41-28)27(36)37)9-10-30(4,42-24)12-39-17-7-5-16(6-8-17)11-19-26(35)31-29(38)43-19/h5-8,19-22,25,28,32-34H,9-12H2,1-4H3,(H,36,37)(H,31,35,38)/t19?,20-,21-,22+,25-,28?,30?/m0/s1","Yang, G. et al. (2017); Glucuronidation: driving factors and their impact on glucuronide disposition;  Drug Metab Rev. 2017 May;49(2):105-138. DOI:10.1080/03602532.2017.1293682; PMID:28266877"
"BIOTID02128","3,6-Dihydroxyfavone","688659","XHLOLFKZCUCROE-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-6-7-12-11(8-10)13(17)14(18)15(19-12)9-4-2-1-3-5-9/h1-8,16,18H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","XXGVDEMWFANIBW-MBIBTLSJSA-N","InChI=1S/C21H18O10/c22-10-6-7-12-11(8-10)13(23)18(17(29-12)9-4-2-1-3-5-9)30-21-16(26)14(24)15(25)19(31-21)20(27)28/h1-8,14-16,19,21-22,24-26H,(H,27,28)/t14-,15-,16+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02129","4-Oxo-9-cis-retinoic acid","9948768","YOFBBAJVETYSCH-RGCKQYDYSA-N","InChI=1S/C20H26O3/c1-14(7-6-8-15(2)13-19(22)23)9-11-17-16(3)10-12-18(21)20(17,4)5/h6-9,11,13H,10,12H2,1-5H3,(H,22,23)/b8-6+,11-9+,14-7-,15-13+","UGT","O-glucuronidation","Human Phase II","Human","NULL","131769834","XEIKLAKHCVSUMR-CAHRZYSUSA-N","InChI=1S/C26H34O9/c1-14(9-11-17-16(3)10-12-18(27)26(17,4)5)7-6-8-15(2)13-19(28)34-25-22(31)20(29)21(30)23(35-25)24(32)33/h6-9,11,13,20-23,25,29-31H,10,12H2,1-5H3,(H,32,33)/b8-6+,11-9+,14-7-,15-13+/t20-,21+,22-,23-,25-/m1/s1","http://www.hmdb.ca/metabolites/HMDB0060122"
"BIOTID02130","Tetrahydrocurcumin","11895692","PNTMRHGYQCMNCZ-SSZFMOIBSA-N","InChI=1S/C21H24O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h5-6,9-13,22,24-25H,3-4,7-8H2,1-2H3/b16-13-","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","NJXVQZJOUDIWTN-YDZKFMFESA-N","InChI=1S/C27H32O12/c1-36-20-11-14(5-9-18(20)30)3-7-16(28)13-17(29)8-4-15-6-10-19(21(12-15)37-2)38-27-24(33)22(31)23(32)25(39-27)26(34)35/h5-6,9-13,22-25,27-28,30-33H,3-4,7-8H2,1-2H3,(H,34,35)/b16-13-/t22-,23-,24+,25-,27?/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02131","7-Hydroxy-3p-methoxyflavone","5377778","IDNRUSTZBHNIHZ-UHFFFAOYSA-N","InChI=1S/C16H12O4/c1-19-16-14(18)12-8-7-11(17)9-13(12)20-15(16)10-5-3-2-4-6-10/h2-9,17H,1H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","MMUVUCUKPSVYIS-XTLXVGOWSA-N","InChI=1S/C22H20O10/c1-29-19-14(23)12-8-7-11(9-13(12)31-18(19)10-5-3-2-4-6-10)30-22-17(26)15(24)16(25)20(32-22)21(27)28/h2-9,15-17,20,22,24-26H,1H3,(H,27,28)/t15-,16-,17+,20-,22?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02132","3-Hydroxy-5,7-dimethoxyflavone","14606540","CPYJUQBXJXCLAY-UHFFFAOYSA-N","InChI=1S/C17H14O5/c1-20-11-8-12(21-2)14-13(9-11)22-17(16(19)15(14)18)10-6-4-3-5-7-10/h3-9,19H,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","NYIQKNFWTDFRBQ-GWQNJANKSA-N","InChI=1S/C23H22O11/c1-30-11-8-12(31-2)14-13(9-11)32-19(10-6-4-3-5-7-10)20(15(14)24)33-23-18(27)16(25)17(26)21(34-23)22(28)29/h3-9,16-18,21,23,25-27H,1-2H3,(H,28,29)/t16-,17-,18+,21-,23?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02133","Psilocin","4980","SPCIYGNTAMCTRO-UHFFFAOYSA-N","InChI=1S/C12H16N2O/c1-14(2)7-6-9-8-13-10-4-3-5-11(15)12(9)10/h3-5,8,13,15H,6-7H2,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","QPZFVYCQQOLROG-PDHYLSHYSA-N","InChI=1S/C18H24N2O7/c1-20(2)7-6-9-8-19-10-4-3-5-11(12(9)10)26-18-15(23)13(21)14(22)16(27-18)17(24)25/h3-5,8,13-16,18-19,21-23H,6-7H2,1-2H3,(H,24,25)/t13-,14-,15+,16-,18?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02134","Apigenin","5280443","KZNIFHPLKGYRTM-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","12912213","JBFOLLJCGUCDQP-DAZJWRSOSA-N","InChI=1S/C21H18O11/c22-9-3-1-8(2-4-9)13-7-12(24)15-11(23)5-10(6-14(15)31-13)30-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21-23,25-27H,(H,28,29)/t16-,17-,18+,19-,21?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02135","4-sec-Butylphenol","7453","ZUTYZAFDFLLILI-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-3-8(2)9-4-6-10(11)7-5-9/h4-8,11H,3H2,1-2H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","WBBFDIVHFXZWBL-NECYTEFCSA-N","InChI=1S/C16H22O7/c1-3-8(2)9-4-6-10(7-5-9)22-16-13(19)11(17)12(18)14(23-16)15(20)21/h4-8,11-14,16-19H,3H2,1-2H3,(H,20,21)/t8?,11-,12-,13+,14-,16?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02136","Isoferulic Acid","736186","QURCVMIEKCOAJU-HWKANZROSA-N","InChI=1S/C10H10O4/c1-14-9-4-2-7(6-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","SHJZLGVIOYFHCB-AURBXFGWSA-N","InChI=1S/C16H18O10/c1-24-8-4-2-7(3-5-10(17)18)6-9(8)25-16-13(21)11(19)12(20)14(26-16)15(22)23/h2-6,11-14,16,19-21H,1H3,(H,17,18)(H,22,23)/b5-3+/t11-,12-,13+,14-,16?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02137","DMXAA","123964","CC1=C(OC(C(CC(O)=O)=CC=C3)=C3C2=O)C2=CC=C1C","InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)","UGT1A9, UGT2B7","O-glucuronidation","Human Phase II","Human","NULL","NULL","CUPVOBUYMCVRQB-GWQNJANKSA-N","InChI=1S/C23H22O10/c1-9-6-7-13-15(25)12-5-3-4-11(20(12)32-19(13)10(9)2)8-14(24)31-23-18(28)16(26)17(27)21(33-23)22(29)30/h3-7,16-18,21,23,26-28H,8H2,1-2H3,(H,29,30)/t16-,17-,18+,21-,23?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02138","3,7-Dihydroxy-3p,4p,5p-trimethoxyflavone","6250403","NJNGYVOYOVPWBB-UHFFFAOYSA-N","InChI=1S/C18H16O7/c1-22-13-6-9(7-14(23-2)18(13)24-3)17-16(21)15(20)11-5-4-10(19)8-12(11)25-17/h4-8,19,21H,1-3H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","YYBBCDHBDWPAKT-ZTCBVEBZSA-N","InChI=1S/C24H24O13/c1-32-13-6-9(7-14(33-2)21(13)34-3)20-17(27)15(25)11-5-4-10(8-12(11)36-20)35-24-19(29)16(26)18(28)22(37-24)23(30)31/h4-8,16,18-19,22,24,26-29H,1-3H3,(H,30,31)/t16-,18-,19+,22-,24?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02139","3,7-Dihydroxy-3p,4p,5p-trimethoxyflavone","6250403","NJNGYVOYOVPWBB-UHFFFAOYSA-N","InChI=1S/C18H16O7/c1-22-13-6-9(7-14(23-2)18(13)24-3)17-16(21)15(20)11-5-4-10(19)8-12(11)25-17/h4-8,19,21H,1-3H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","MGPJRQXFVAPOKA-HKBOJXCQSA-N","InChI=1S/C24H24O13/c1-32-13-6-9(7-14(33-2)20(13)34-3)19-21(15(26)11-5-4-10(25)8-12(11)35-19)36-24-18(29)16(27)17(28)22(37-24)23(30)31/h4-8,16-18,22,24-25,27-29H,1-3H3,(H,30,31)/t16-,17-,18+,22-,24?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02140","4-nitrophenethyl bromide","79266","NTURQZFFJDCTMZ-UHFFFAOYSA-N","InChI=1S/C8H8BrNO2/c9-6-5-7-1-3-8(4-2-7)10(11)12/h1-4H,5-6H2","GST","GSH-conjugation of organohalide","Human Phase II","Human","4-nitrophenethyl-glutathione","NULL","FWZNSHPWXZCIRD-KBPBESRZSA-N","InChI=1S/C18H24N4O8S/c19-13(18(27)28)5-6-15(23)21-14(17(26)20-9-16(24)25)10-31-8-7-11-1-3-12(4-2-11)22(29)30/h1-4,13-14H,5-10,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t13-,14-/m0/s1","http://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID02141","Erlotinib M14","16045730","MTLKTHNRZJKPRP-UHFFFAOYSA-N","InChI=1S/C21H21N3O4/c1-3-15-5-4-6-16(11-15)24-21-17-12-19(28-10-9-26-2)20(27-8-7-25)13-18(17)22-14-23-21/h1,4-6,11-14,25H,7-10H2,2H3,(H,22,23,24)","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","XIXVMGWVZKBHGH-JNKBPBDDSA-N","InChI=1S/C27H29N3O10/c1-3-15-5-4-6-16(11-15)30-25-17-12-19(37-8-7-36-2)20(13-18(17)28-14-29-25)38-9-10-39-27-23(33)21(31)22(32)24(40-27)26(34)35/h1,4-6,11-14,21-24,27,31-33H,7-10H2,2H3,(H,34,35)(H,28,29,30)/t21-,22-,23+,24-,27?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02142","Dapsone","2955","MQJKPEGWNLWLTK-UHFFFAOYSA-N","InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2","NAT2","N-acetylation of arylamine","Human Phase II","Human","NULL","11257","WDOCBIHNYYQINH-UHFFFAOYSA-N","InChI=1S/C14H14N2O3S/c1-10(17)16-12-4-8-14(9-5-12)20(18,19)13-6-2-11(15)3-7-13/h2-9H,15H2,1H3,(H,16,17)","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02143","Phenylephrine","6041","SONNWYBIRXJNDC-VIFPVBQESA-N","InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","DMVJUYDQYGHJIC-MLFYPQLQSA-N","InChI=1S/C15H21NO8/c1-16-6-9(17)7-3-2-4-8(5-7)23-15-12(20)10(18)11(19)13(24-15)14(21)22/h2-5,9-13,15-20H,6H2,1H3,(H,21,22)/t9-,10-,11-,12+,13-,15?/m0/s1","Wu et al. 2011; First-pass metabolism via UDP-glucuronosyltransferase- a barrier to oral bioavailability of phenolics"
"BIOTID02144","AFB1exo 8,9-epoxide","5287635","GACWFTLPANAFAK-GVLSTKRJSA-N","InChI=1S/C17H14O7/c1-21-9-4-10-14(13-8(19)5-22-17(13)23-10)15-12(9)6-2-3-7(18)11(6)16(20)24-15/h4,8,13,17,19H,2-3,5H2,1H3/t8-,13-,17+/m0/s1","GSTA1/A2, GSTM1/M3, GSTP1","GSH-conjugatoon","Human Phase II","Human","NULL","NULL","LYDBAPNRLUDIAS-QTRMHHBKSA-N","InChI=1S/C27H29N3O13S/c1-40-13-6-14-19(22-18(13)9-2-4-12(31)17(9)25(39)42-22)20-21(35)27(43-26(20)41-14)44-8-11(23(36)29-7-16(33)34)30-15(32)5-3-10(28)24(37)38/h6,10-11,20-21,26-27,35H,2-5,7-8,28H2,1H3,(H,29,36)(H,30,32)(H,33,34)(H,37,38)/t10-,11-,20+,21+,26-,27?/m0/s1","Wang, and Zhou (2009); Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 4066-4218"
"BIOTID02145","Pregnenolone","8955","ORNBQBCIOKFOEO-QGVNFLHTSA-N","InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1","SULT","3-OH-sulfation of sterol","Human Phase II","Human","NULL","20845972","DIJBBUIOWGGQOP-OZIWPBGVSA-N","InChI=1S/C21H32O5S/c1-13(22)17-6-7-18-16-5-4-14-12-15(26-27(23,24)25)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19H,5-12H2,1-3H3,(H,23,24,25)/t15?,16-,17+,18-,19-,20-,21+/m0/s1","http://www.hmdb.ca/metabolites/HMDB0000774"
"BIOTID02146","4-tert-Butylphenol","7393","QHPQWRBYOIRBIT-UHFFFAOYSA-N","InChI=1S/C10H14O/c1-10(2,3)8-4-6-9(11)7-5-8/h4-7,11H,1-3H3","UGT1A9","O-glucuronidation","Human Phase II","Human","NULL","NULL","GOIPNXCDBCWGIA-HXMBFPRCSA-N","InChI=1S/C16H22O7/c1-16(2,3)8-4-6-9(7-5-8)22-15-12(19)10(17)11(18)13(23-15)14(20)21/h4-7,10-13,15,17-19H,1-3H3,(H,20,21)/t10-,11-,12+,13-,15?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02147","Melatonin","896","DRLFMBDRBRZALE-UHFFFAOYSA-N","InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)","UGT","O-glucuronidation","Human Phase II","Human","NULL","131769970","GXNGLFUTEZJKRQ-UHFFFAOYSA-N","InChI=1S/C19H24N2O8/c1-9(22)20-6-5-10-8-21(13-4-3-11(28-2)7-12(10)13)18-16(25)14(23)15(24)17(29-18)19(26)27/h3-4,7-8,14-18,23-25H,5-6H2,1-2H3,(H,20,22)(H,26,27)","http://www.hmdb.ca/metabolites/HMDB0060830"
"BIOTID02148","Dihydroisomorphine","44721143","IJVCSMSMFSCRME-QWPSNIKLSA-N","InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13?,16-,17-/m0/s1","UGT","O-glucuronidation","Human Phase II","Human","NULL","NULL","KCPRJVDBLLJBMF-GONAIESISA-N","InChI=1S/C23H29NO9/c1-24-7-6-23-10-3-4-12(25)20(23)32-18-13(5-2-9(14(18)23)8-11(10)24)31-22-17(28)15(26)16(27)19(33-22)21(29)30/h2,5,10-12,15-17,19-20,22,25-28H,3-4,6-8H2,1H3,(H,29,30)/t10-,11+,12?,15-,16-,17+,19-,20-,22?,23-/m0/s1","Zhou, S.F. et al. (2009); Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development; Current Medicinal Chemistry, 2009, 16, 3480-3675."
"BIOTID02149","Propyl-4-hydroxybenzoate","7175","QELSKZZBTMNZEB-UHFFFAOYSA-N","InChI=1S/C10H12O3/c1-2-7-13-10(12)8-3-5-9(11)6-4-8/h3-6,11H,2,7H2,1H3","UGT1A9","Aromatic -OH glucuronidation","Human Phase II","Human","NULL","NULL","HVFINIMQRFKIPD-PACLMXLRSA-N","InChI=1S/C16H20O9/c1-2-7-23-15(22)8-3-5-9(6-4-8)24-16-12(19)10(17)11(18)13(25-16)14(20)21/h3-6,10-13,16-19H,2,7H2,1H3,(H,20,21)/t10-,11-,12+,13-,16?/m0/s1","Wu et al. 2011; Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches; Pharm Res (2012) 29:1544Ã¢â‚¬â€œ1561; DOI 10.1007/s11095-012-0666-z"
"BIOTID02150","rac-4-hydroxynonenal","1693","JVJFIQYAHPMBBX-UHFFFAOYSA-N","InChI=1S/C9H16O2/c1-2-3-4-6-9(11)7-5-8-10/h5,7-9,11H,2-4,6H2,1H3","GST","GSH-conjugation of apha,beta-unsaturated carbonyl","Human Phase II","Human","S-(4-hydroxy-1-oxononan-3-yl)glutathione","134820111","NOKRNJLENDLSKM-HESLUPGFSA-N","InChI=1S/C19H33N3O8S/c1-2-3-4-5-14(24)15(8-9-23)31-11-13(18(28)21-10-17(26)27)22-16(25)7-6-12(20)19(29)30/h9,12-15,24H,2-8,10-11,20H2,1H3,(H,21,28)(H,22,25)(H,26,27)(H,29,30)/t12-,13-,14?,15?/m0/s1","https://www.brenda-enzymes.org/enzyme.php?ecno=2.5.1.18&Suchword=&reference=&UniProtAcc=&organism%5B%5D=Homo+sapiens&show_tm=0"
"BIOTID02151","Epicatechin","72276","PFTAWBLQPZVEMU-UKRRQHHQSA-N","InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15-/m1/s1","Unspecified gut bacterial enzyme","Flavan-3-ol C-ring fission","Human Gut Microbial","Gut microbial environment","5-(3',4'-dihydroxyphenyl)-gamma-valerolactone","152432","ZNXXWTPQHVLMQT-UHFFFAOYSA-N","InChI=1S/C11H12O4/c12-9-3-1-7(6-10(9)13)5-8-2-4-11(14)15-8/h1,3,6,8,12-13H,2,4-5H2",""
"BIOTID02152","Epicatechin","72276","PFTAWBLQPZVEMU-UKRRQHHQSA-N","InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15-/m1/s1","Unspecified gut bacterial enzyme","Flavan-3-ol C-ring fission","Human Gut Microbial","Gut microbial environment","Phloroglucinol","359","QCDYQQDYXPDABM-UHFFFAOYSA-N","InChI=1S/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9H",""
"BIOTID02153","Daidzein","5281708","ZQSIJRDFPHDXIC-UHFFFAOYSA-N","InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H","Unspecified bacterial dehydroxylase","4'-Deydroxylation of substitued benzene","Human Gut Microbial","Gut microbial environment","Dihydrodazein","176907","JHYXBPPMXZIHKG-UHFFFAOYSA-N","InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-7,13,16-17H,8H2","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02154","Dihydrodazein","176907","JHYXBPPMXZIHKG-UHFFFAOYSA-N","InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-7,13,16-17H,8H2","Unspecified gut bacterial enzyme","Dehydration of isoflavanone","Human Gut Microbial","Gut microbial environment","Tetrahydrodaidzein","6430026","YOSDNAMJVOLJKI-UHFFFAOYSA-N","InChI=1S/C15H14O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-7,13,15-18H,8H2","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02155","Tetrahydrodaidzein","6430026","YOSDNAMJVOLJKI-UHFFFAOYSA-N","InChI=1S/C15H14O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-7,13,15-18H,8H2","Unspecified gut bacterial enzyme","Isoflavan-4-ol dehydroxylation","Human Gut Microbial","Gut microbial environment","Equol","382975","ADFCQWZHKCXPAJ-UHFFFAOYSA-N","InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02156","Quercitrin","5280459","OXGUCUVFOIWWQJ-HQBVPOQASA-N","InChI=1S/C21H20O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-18,21-26,28-29H,1H3/t7-,15-,17+,18+,21-/m0/s1","EC 3.2.1.X","Glycoside hydrolysis","Human Gut Microbial","Gut microbial environment","L-Rhamnose","25310","SHZGCJCMOBCMKK-JFNONXLTSA-N","InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3-,4+,5+,6?/m0/s1","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02157","Quercitrin","5280459","OXGUCUVFOIWWQJ-HQBVPOQASA-N","InChI=1S/C21H20O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-18,21-26,28-29H,1H3/t7-,15-,17+,18+,21-/m0/s1","EC 3.2.1.X","Glycoside hydrolysis","Human Gut Microbial","Gut microbial environment","Quercetin","5280343","REFJWTPEDVJJIY-UHFFFAOYSA-N","InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02158","Quercitrin","5280459","OXGUCUVFOIWWQJ-HQBVPOQASA-N","InChI=1S/C21H20O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-18,21-26,28-29H,1H3/t7-,15-,17+,18+,21-/m0/s1","EC 3.2.1.40","Rhamnohydrolysis of alpha-L-rhamnoside","Human Gut Microbial","Gut microbial environment","alpha-L-Rhamnose","439710","SHZGCJCMOBCMKK-HGVZOGFYSA-N","InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3-,4+,5+,6+/m0/s1","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02159","Quercetin","5280343","REFJWTPEDVJJIY-UHFFFAOYSA-N","InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H","Unspecified gut bacterial enzyme","Flavonoid C-ring reduction","Human Gut Microbial","Gut microbial environment","Dihydroquercetin","471","CXQWRCVTCMQVQX-UHFFFAOYSA-N","InChI=1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H",""
"BIOTID02160","3-hydroxyphenylacetic acid","12122","FVMDYYGIDFPZAX-UHFFFAOYSA-N","InChI=1S/C8H8O3/c9-7-3-1-2-6(4-7)5-8(10)11/h1-4,9H,5H2,(H,10,11)","Unspecified bacterial dehydroxylase","3'-Deydroxylation of substitued benzene","Human Gut Microbial","Gut microbial environment","2-Phenylacetic acid","999","WLJVXDMOQOGPHL-UHFFFAOYSA-N","InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02161","4-hydroxyphenylacetic acid","127","XQXPVVBIMDBYFF-UHFFFAOYSA-N","InChI=1S/C8H8O3/c9-7-3-1-6(2-4-7)5-8(10)11/h1-4,9H,5H2,(H,10,11)","Unspecified bacterial dehydroxylase","4'-Deydroxylation of substitued benzene","Human Gut Microbial","Gut microbial environment","2-Phenylacetic acid","999","WLJVXDMOQOGPHL-UHFFFAOYSA-N","InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02162","3,4-dihydroxyphenylacetic acid","547","CFFZDZCDUFSOFZ-UHFFFAOYSA-N","InChI=1S/C8H8O4/c9-6-2-1-5(3-7(6)10)4-8(11)12/h1-3,9-10H,4H2,(H,11,12)","Unspecified bacterial dehydroxylase","Dehydroxylation of catechol","Human Gut Microbial","Gut microbial environment","3-hydroxyphenylacetic acid","12122","FVMDYYGIDFPZAX-UHFFFAOYSA-N","InChI=1S/C8H8O3/c9-7-3-1-2-6(4-7)5-8(10)11/h1-4,9H,5H2,(H,10,11)","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02163","3,4-dihydroxyphenylacetic acid","547","CFFZDZCDUFSOFZ-UHFFFAOYSA-N","InChI=1S/C8H8O4/c9-6-2-1-5(3-7(6)10)4-8(11)12/h1-3,9-10H,4H2,(H,11,12)","Unspecified bacterial dehydroxylase","Dehydroxylation of catechol","Human Gut Microbial","Gut microbial environment","4-hydroxyphenylacetic acid","127","XQXPVVBIMDBYFF-UHFFFAOYSA-N","InChI=1S/C8H8O3/c9-7-3-1-6(2-4-7)5-8(10)11/h1-4,9H,5H2,(H,10,11)","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02164","3,4-dihydroxyphenylacetic acid","547","CFFZDZCDUFSOFZ-UHFFFAOYSA-N","InChI=1S/C8H8O4/c9-6-2-1-5(3-7(6)10)4-8(11)12/h1-3,9-10H,4H2,(H,11,12)","Unspecified gut bacterial enzyme","Alpha-oxidation of carboxylic acid","Human Gut Microbial","Gut microbial environment","Protocatehuic acid","72","YQUVCSBJEUQKSH-UHFFFAOYSA-N","InChI=1S/C7H6O4/c8-5-2-1-4(7(10)11)3-6(5)9/h1-3,8-9H,(H,10,11)","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02165","3,4-dihydroxyphenylpropionic acid","348154","DZAUWHJDUNRCTF-UHFFFAOYSA-N","InChI=1S/C9H10O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1,3,5,10-11H,2,4H2,(H,12,13)","Unspecified bacterial dehydroxylase","Dehydroxylation of catechol","Human Gut Microbial","Gut microbial environment","3-(3-hydroxyphenyl)propanoic acid","91","QVWAEZJXDYOKEH-UHFFFAOYSA-N","InChI=1S/C9H10O3/c10-8-3-1-2-7(6-8)4-5-9(11)12/h1-3,6,10H,4-5H2,(H,11,12)","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02166","3,4-dihydroxyphenylpropionic acid","348154","DZAUWHJDUNRCTF-UHFFFAOYSA-N","InChI=1S/C9H10O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1,3,5,10-11H,2,4H2,(H,12,13)","Unspecified bacterial dehydroxylase","Dehydroxylation of catechol","Human Gut Microbial","Gut microbial environment","4-hydroxy- 4-Hydroxyphenylpropionic acid","10394","NMHMNPHRMNGLLB-UHFFFAOYSA-N","InChI=1S/C9H10O3/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-2,4-5,10H,3,6H2,(H,11,12)","Duda-Chodak, A. et al. (2015); Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review; Eur J Nutr (2015) 54:325-341; DOI 10.1007/s00394-015-0852-y"
"BIOTID02167","Cyanidin","128861","VEVZSMAEJFVWIL-UHFFFAOYSA-O","InChI=1S/C15H10O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-6H,(H4-,16,17,18,19,20)/p+1","Unspecified gut bacterial enzyme","Anthocyanidin C-ring fission","Human Gut Microbial","Gut microbial environment","2,4,6-Trihydroxybenzaldehyde","68099","BTQAJGSMXCDDAJ-UHFFFAOYSA-N","InChI=1S/C7H6O4/c8-3-5-6(10)1-4(9)2-7(5)11/h1-3,9-11H","Aura, A.-M. et al., Eur. J. Nutr., 44, 133Ã¢â‚¬â€œ142, 2005|Fleschhut, J. et al., Eur. J. Nutr., 45, 7Ã¢â‚¬â€œ15, 2006"
"BIOTID02168","Cyanidin","128861","VEVZSMAEJFVWIL-UHFFFAOYSA-O","InChI=1S/C15H10O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-6H,(H4-,16,17,18,19,20)/p+1","Unspecified gut bacterial enzyme","Anthocyanidin C-ring fission","Human Gut Microbial","Gut microbial environment","3,4-Dihydroxyphenylacetic acid","547","CFFZDZCDUFSOFZ-UHFFFAOYSA-N","InChI=1S/C8H8O4/c9-6-2-1-5(3-7(6)10)4-8(11)12/h1-3,9-10H,4H2,(H,11,12)","Aura, A.-M. et al., Eur. J. Nutr., 44, 133Ã¢â‚¬â€œ142, 2005|Fleschhut, J. et al., Eur. J. Nutr., 45, 7Ã¢â‚¬â€œ15, 2006"
"BIOTID02169","Genistein","5280961","TZBJGXHYKVUXJN-UHFFFAOYSA-N","InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H","Unspecified bacterial isoflavone reductase","Reduction of isoflavone to isoflavanone","Human Gut Microbial","Gut microbial environment","Dihydrogenistein","9838356","UQGVUYNHDKMLSE-UHFFFAOYSA-N","InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-6,11,16-18H,7H2",""
"BIOTID02170","Dihydrogenistein","9838356","UQGVUYNHDKMLSE-UHFFFAOYSA-N","InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-6,11,16-18H,7H2","Unspecified gut bacterial enzyme","Isoflavanone C-ring fission","Human Gut Microbial","Gut microbial environment","NULL","59846969","YQJWBMJVIIHDFM-UHFFFAOYSA-N","InChI=1S/C15H12O5/c1-8(9-2-4-10(16)5-3-9)15(20)14-12(18)6-11(17)7-13(14)19/h2-7,16-19H,1H2","Joannou, G.E. et al., J. Steroid Biochem. Mol. Biol., 54, 167Ã¢â‚¬â€œ184, 1995|Coldham, N.G. et al., Xenobiotica, 32, 45Ã¢â‚¬â€œ62, 2002."
"BIOTID02171","NULL","59846969","YQJWBMJVIIHDFM-UHFFFAOYSA-N","InChI=1S/C15H12O5/c1-8(9-2-4-10(16)5-3-9)15(20)14-12(18)6-11(17)7-13(14)19/h2-7,16-19H,1H2","EC 1.6.99.1","Reduction of alpha,beta unsaturated carbon-carbon double bond adjacent to an electron withdrawing group","Human Gut Microbial","Gut microbial environment","6'-Hydroxy-O-desmethylangolensin","20601635","IEFUAUZFJJOQMC-UHFFFAOYSA-N","InChI=1S/C15H14O5/c1-8(9-2-4-10(16)5-3-9)15(20)14-12(18)6-11(17)7-13(14)19/h2-8,16-19H,1H3","Joannou, G.E. et al., J. Steroid Biochem. Mol. Biol., 54, 167Ã¢â‚¬â€œ184, 1995|Coldham, N.G. et al., Xenobiotica, 32, 45Ã¢â‚¬â€œ62, 2002."
"BIOTID02172","NULL","59846969","YQJWBMJVIIHDFM-UHFFFAOYSA-N","InChI=1S/C15H12O5/c1-8(9-2-4-10(16)5-3-9)15(20)14-12(18)6-11(17)7-13(14)19/h2-7,16-19H,1H2","Unspecified gut bacterial enzyme","Keto hydrolysis","Human Gut Microbial","Gut microbial environment","4-hydroxyphenyl-2-propenoic acid","19424742","SVTBKBTZCWQLGX-UHFFFAOYSA-N","InChI=1S/C9H8O3/c1-6(9(11)12)7-2-4-8(10)5-3-7/h2-5,10H,1H2,(H,11,12)","Joannou, G.E. et al., J. Steroid Biochem. Mol. Biol., 54, 167Ã¢â‚¬â€œ184, 1995|Coldham, N.G. et al., Xenobiotica, 32, 45Ã¢â‚¬â€œ62, 2002."
"BIOTID02173","NULL","59846969","YQJWBMJVIIHDFM-UHFFFAOYSA-N","InChI=1S/C15H12O5/c1-8(9-2-4-10(16)5-3-9)15(20)14-12(18)6-11(17)7-13(14)19/h2-7,16-19H,1H2","Unspecified gut bacterial enzyme","Keto hydrolysis","Human Gut Microbial","Gut microbial environment","Phloroglucinol","359","QCDYQQDYXPDABM-UHFFFAOYSA-N","InChI=1S/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9H","Joannou, G.E. et al., J. Steroid Biochem. Mol. Biol., 54, 167Ã¢â‚¬â€œ184, 1995|Coldham, N.G. et al., Xenobiotica, 32, 45Ã¢â‚¬â€œ62, 2002."
"BIOTID02174","4-hydroxyphenyl-2-propenoic acid","102526","ZHMMPVANGNPCBW-UHFFFAOYSA-N","InChI=1S/C9H10O3/c1-6(9(11)12)7-2-4-8(10)5-3-7/h2-6,10H,1H3,(H,11,12)","EC 1.6.99.1","Reduction of alpha,beta unsaturated carbon-carbon double bond adjacent to an electron withdrawing group","Human Gut Microbial","Gut microbial environment","NULL","102526","ZHMMPVANGNPCBW-UHFFFAOYSA-N","InChI=1S/C9H10O3/c1-6(9(11)12)7-2-4-8(10)5-3-7/h2-6,10H,1H3,(H,11,12)","Joannou, G.E. et al., J. Steroid Biochem. Mol. Biol., 54, 167Ã¢â‚¬â€œ184, 1995|Coldham, N.G. et al., Xenobiotica, 32, 45Ã¢â‚¬â€œ62, 2002."
"BIOTID02175","Sudan I","NULL","MRQIXHXHHPWVIL-ISLYRVAYSA-N","InChI=1S/C16H12N2O/c19-15-11-10-12-6-4-5-9-14(12)16(15)18-17-13-7-2-1-3-8-13/h1-11,19H/b18-17+","EC 1.7.1.6","Reduction of azobenzene","Human Gut Microbial","Gut microbial environment","1-Amino-2-naphthol","14535","FHMMQQXRSYSWCM-UHFFFAOYSA-N","InChI=1S/C10H9NO/c11-10-8-4-2-1-3-7(8)5-6-9(10)12/h1-6,12H,11H2","Claus, SP et al. (2016); npj Biofilms and Microbiomes, 2, 16003; doi:10.1038/npjbiofilms.2016.3"
"BIOTID02176","Sudan I","NULL","MRQIXHXHHPWVIL-ISLYRVAYSA-N","InChI=1S/C16H12N2O/c19-15-11-10-12-6-4-5-9-14(12)16(15)18-17-13-7-2-1-3-8-13/h1-11,19H/b18-17+","EC 1.7.1.6","Reduction of azobenzene","Human Gut Microbial","Gut microbial environment","Aniline","6115","PAYRUJLWNCNPSJ-UHFFFAOYSA-N","InChI=1S/C6H7N/c7-6-4-2-1-3-5-6/h1-5H,7H2","Claus, SP et al. (2016); npj Biofilms and Microbiomes, 2, 16003; doi:10.1038/npjbiofilms.2016.3"
"BIOTID02177","Choline","305","OEYIOHPDSNJKLS-UHFFFAOYSA-N","InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1","EC 4.3.99.4","Lysis of choline to trimethylamine","Human Gut Microbial","Gut microbial environment","Trimethylazanium","3782034","GETQZCLCWQTVFV-UHFFFAOYSA-O","InChI=1S/C3H9N/c1-4(2)3/h1-3H3/p+1","Spanogiannopoulos, P. et al. (2016); Nat Rev Microbiol. 2016 Apr;14(5):273-87. DOI:10.1038/nrmicro.2016.17"
"BIOTID02178","Choline","305","OEYIOHPDSNJKLS-UHFFFAOYSA-N","InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1","EC 4.3.99.4","Lysis of choline to trimethylamine","Human Gut Microbial","Gut microbial environment","Acetaldehyde","177","IKHGUXGNUITLKF-UHFFFAOYSA-N","InChI=1S/C2H4O/c1-2-3/h2H,1H3","Spanogiannopoulos, P. et al. (2016); Nat Rev Microbiol. 2016 Apr;14(5):273-87. DOI:10.1038/nrmicro.2016.17"
